StreetAccount

Healthcare sector summaries (^HEALTH) Full SA coverage

Sector: Healthcare Industry: Biotechnology & Drugs

Description

The Healthcare Sector Summaries are three daily recaps including sector-specific corporate news, sell-side research calls, media reports, what to expect for the day, etc. The comments are delivered daily, pre-market, midday, and post-market.

Portfolios Manage

^HEALTH does not appear in any portfolios.

Upcoming Events

Category News Date Range: 100 Days

Filtered by: All

Records Returned: 351
Related Company News

30-Oct-2026 23:56	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished widely mixed yet higher overall on Friday. Breadth expanded on the session and decliners beat advancers by more than 2:1 on the XLV. Healthcare +0.43% vs the S&P 500 (1.82%). Most major health groups ended lower amidst the market sell-off and risk rotation. Pharma group amongst the primary beneficiaries and key outlier in Health, the DRG closed up +2.03%, while declines in MedTech (and gains in Pharma) were amplified by earnings updates. REGN +13.3% and ILMN (18.6%) bracketed the XLV wire to wire on their respective prints. SYK (6.4%) Q3 miss was foretold, the Q4 guide and slowdown in hips and knees was not, patients' insurance rearing up at the device manufacturer. More moderate declines in payers and providers, mostly red but relatively firm, seeing some support from the rotation. Macro Stocks ended week on a down note as AI/tech faced renewed selling pressure. AMZN lower post-earnings. While AI takeaways mostly upbeat, sentiment weighed down by slowing advertising growth, plan to ramp capex meaningfully next year. INTC the other big focus as solid Data Center/AI results overshadowed by guidance cut on PC market headwinds driven by memory shortages, component costs, and its own FY27 capex ramp. Deepening tech drawdown has amplified broader AI financing scrutiny ahead of Anthropic's coming IPO (Blackstone also told investors Anthropic may not receive IG rating after going public, according to FT report). Treasuries rallied on flight-to-safety dynamic, while select groups (defensives, energy) were better as stocks continued to reflect internal rotation rather than wholesale de-risking (nine of 11 S&P sectors higher for the week). Oil also firmer ahead of expected escalation in kinetic activity in Iran following midterms, skepticism around diplomatic offramp. Other areas of focus include resilient AI fundamentals (consumption, backlogs), mixed consumer takeaways, some modest dovish Fed rate path pricing following less-hawkish policy assessment. Notable Gainers on Friday: +22.2% CDNA (CareDx): earnings; best performer on XBI +13.3% REGN (Regeneron): earnings; 52-week high; best performer on XLV +11.1% BTSG (BrightSpring Health Services): earnings +7.0% AZN (AstraZeneca): earnings +6.0% BBIO (BridgeBio Pharma): earnings +5.3% TGTX (TG Therapeutics): unusual options volume; shares +13% for the week +5.0% ATR (AptarGroup): earnings +4.8% EXEL (Exelixis): earnings; 52-week high +4.5% PGEN (Precigen): shares were +9% yesterday +3.5% VRTX (Vertex Pharmaceuticals): 52-week high +3.2% LLY (Eli Lilly): follow-through, pharma sympathy; 52-week high +3.1% INCY (Incyte): upgraded at Oppenheimer +3.1% GILD (Gilead Sciences): earnings; 52-week high +3.0% DXCM (Dexcom): earnings Notable Decliners on Friday: -90.8% ABOS (Acumen Pharmaceuticals): trial results in Alzheimer's disease; downgrades -38.1% ATEC (Alphatec Holdings): earnings; downgraded at BMO Capital Markets -18.6% ILMN (Illumina): earnings; worst performer on XLV -17.9% AGIO (Agios Pharmaceuticals): FDA extends PDUFA date by three months; worst performer on XBI -14.9% BFLY (Butterfly Network): follow-through; market rotation -14.7% NRXP (NRX Pharmaceuticals): small-cap biotech; updates on Ketamine program -14.4% MLYS (Mineralys Therapeutics): on nearly 3X average volume -14.0% TXG (10X Genomics): sympathy to AI trade -11.9% TWST (Twist Bioscience): sympathy to AI trade -11.3% IOVA (Iovance Biotherapeutics): follow-through, shares were (35%) yesterday -9.8% ALHC (Alignment Healthcare): earnings; downgraded at KeyBanc -9.7% GRAL (GRAIL, Inc.): market rotation; stock closed higher 8 of last 9 days (+35% over the same) -9.1% RMD (ResMed): earnings -8.0% ABSI (Absci Corp.): shares remain higher +21% for the week -8.0% FTRE (Fortrea Holdings): follow-through; market rotation -8.0% BRKR (Bruker): sympathy to ILMN; market rotation -7.2% TEM (Tempus AI): sympathy to AI trade -6.7% HIMS (Hims & Hers Health): stock back to even WTD (peptides) -6.5% BHVN (Biohaven): earnings -6.4% SYK (Stryker): earnings; downgraded at Canaccord -6.3% BBTX (Bambusa Therapeutics, Inc.): day one IPO (biotech) -6.2% RGEN (Repligen Corp.): private $1B convertible notes -6.2% BCAX (Bicara Therapeutics, Inc.): follow-through, downgraded at Goldman Sachs -5.3% RVTY (Revvity): risk-off / market rotation -5.2% ALNY (Alnylam Pharmaceuticals): follow-through, downgraded at Raymond James -5.0% NTRA (Natera): on above average volume -5.0% RXRX (Recursion Pharmaceuticals): sympathy to AI trade Week in Review: Earnings scorecard: According to FactSet Scorecard, with 34.55% of companies (57 of 165) having reported, 85.96% of the S&P 1500 Health Care (SP567-SPX) have beaten consensus EPS expectations, vs 86.50% last year (Q3 2025), with an average beat of +13.72% vs +13.27% last year. On the topline, 89.47% have beaten sales expectations, vs 82.82% last year (Q3 2025), with an average beat of +2.84% vs +2.22% last year. Healthcare equities outperformed for the week. The S&P 500 Healthcare Index up +3.14% vs the S&P 500 Index down (0.57%). Outperformers: Pharma, Biotech, Services, MedTech Underperformers: Managed Care Major health groups were mostly higher by mid-single digits for the week. It was the fourth straight week of broad gains for the XLV, which concluded the best month since April 2020, when markets bounced back from the pandemic declaration the previous month. Healthcare again a significant beneficiary of market rotation, combined with strong earnings results from large-cap drug manufacturers. The DRG climbed +6.02% to conclude October +11.77%, for its best month in 27 years. MedTech earnings were more mixed, in both LifeSci and Devices subgroups, and the group lagged overall for the week. Hospitals also saw widely mixed returns, but again benefitted from market rotation, and a private equity deal for Surgery Partners. Year-to-date, Healthcare +19.35% vs the S&P 500 +10.73%. Healthcare up one spot to second out of eleven major sectors in CY26. Energy +56.62% and Telecom (11.85%) bracket them all. Notable movers for the week: Gainers: REPL +53.7% - earnings; best performer on XBI SGRY +47.4% - acquired by PE for $5.7B GKOS +32.8% - earnings GMAB +30.3% - trial results in Head and Neck cancer (HNSCC); downgrades BHC +27.3% - earnings ORKA +20.9% - trial results in psoriasis INSM +20.5% - earnings KNSA +20.2% - earnings BLCO +14.5% - earnings ICLR +14.1% - earnings TGTX +12.9% - closed higher six straight days; shares +105% YTD LLY +11.3% - earnings BTSG +11.3% - earnings MRNA +10.8% - follow-through, shares +652% YTD LH +9.9% - earnings EHC +9.5% - earnings GILD +9.4% - earnings Decliners: IOVA (39.8%) - trial results in NSCLC ALNY (26.3%) - earnings; multiple downgrades CYH (17.8%) - earnings ILMN (12.4%) - earnings; worst performer on XLV ALHC (9.8%) - earnings; downgraded at KeyBanc BAX (9.1%) - earnings RMD (9.1%) - earnings BSX (8.1%) - earnings; multiple downgrades AVTR (7.2%) - earnings BBTX (6.3%) - IPO (biotech #29 in CY26) UHS (5.8%) - earnings SYK (5.0%) - earnings; downgraded at Canaccord Genuity GSK (2.4%) - earnings; downgraded at Jefferies Week Ahead (Sat - Sun): Oct 31 - Nov 8 Overview: ELECTION DAY (US markets are open on Tuesday 3-Nov) Earnings calendar Mon 2-Nov: before IDXX, TEM, KRYS, AXSM after VRTX, NBIX, JAZZ, BMRN, MSA, HNGE, WAY, TVTX Tue 3-Nov: before BAYN.GR, PFE, TEVA, WAT, BNTX, RVTY, FMS, MDGL, HSIC, ALKS, AMRX, RYTM, SHC after AMGN, CORT, PACS, MIRM, ATRC Wed 4-Nov: before NVO, CVS, COR, MDLN, FRE.GR, RPRX, UTHR, ZBH, CRL, SNN, PODD, BRKR, OPCH, LIVN after MCK, EW, RVMD, QGEN, BIO, CAI, CYTK, GRAL, BLLN, ADPT, ARQT, RLAY, VCYT, NVST, ACAD Thu 5-Nov: before CI, CAH, BDX, ONC, ZTS, STE, VTRS, OSCR, IOVA, TFX, HAE, LFST intraday GMAB after MTD, GH, SOLV, HALO, GMED, TXG, CON, ICUI, IRTC, PLSE Fri 6-Nov: before MRNA, HUM, ELAN Corporate calendar Mon 2-Nov: INO to discuss FDA approval of Voceryq (8:00ET), EW Analyst Meeting at TCT (20:00ET) Wed 4-Nov: WVE R&D Day (9:30ET) Conference calendar Tue 3-Nov: Abstracts for SITC 2026 released online (9:00ET) Wed 4-Nov: Abstracts for Triple Meeting 2026 (AACR-NCI-EORTC) released online (3:00ET); Abstracts for ASH 2026 released online (9:00ET) Thu 5-Nov: AASLD 2026 (Nov 5-9) Fri 6-Nov: ACR Convergence (Nov 6-11); AHA Scientific Session (Nov 6-9) Regulatory calendar n/a Syndicate calendar / potential IPO pricing n/a Related: ABOS, ABSI, ACAD, ADPT, AGIO, ALHC, ALKS, ALNY, AMGN, AMRX, ARQT, ATEC, ATR, ATRC, AVTR, AXSM, AZN, BAX, BAYN.GR, BBIO, BBTX, BCAX, BDX, BFLY, BHC, BHVN, BIO, BLCO, BLLN, BMRN, BNTX, BRKR, BSX, BTSG, CAH, CAI, CDNA, CI, CON, COR, CORT, CRL, CVS, CYH, CYTK, DXCM, EHC, ELAN, EW, EXEL, FMS, FRE.GR, FTRE, GH, GILD, GKOS, GMAB, GMED, GRAL, GSK, HAE, HALO, HIMS, HNGE, HSIC, HUM, ICLR, ICUI, IDXX, ILMN, INCY, INO, INSM, IOVA, IRTC, JAZZ, KNSA, KRYS, LFST, LH, LIVN, LLY, MCK, MDGL, MDLN, MIRM, MLYS, MRNA, MSA, MTD, NBIX, NRXP, NTRA, NVO, NVST, ONC, OPCH, ORKA, OSCR, PACS, PFE, PGEN, PLSE, PODD, QGEN, REGN, REPL, RGEN, RLAY, RMD, RPRX, RVMD, RVTY, RXRX, RYTM, SGRY, SHC, SNN, SOLV, STE, SYK, TEM, TEVA, TFX, TGTX, TVTX, TWST, TXG, UHS, UTHR, VCYT, VRTX, VTRS, WAT, WAY, WVE, ZBH, ZTS...(more)	show story hide story
30-Oct-2026 14:48	StreetAccount Summary: Notable Drug Events expected for the week of 1-Nov Mon 2-Nov Industry meeting with clinical data: CGA-IGC Annual Meeting (Nov 2-4) (RXRX) Tue 3-Nov Investor event: ANNX virtual investor meeting (11:00ET) Abstracts release: SITC 2026 abstracts (9:00ET) Wed 4-Nov Industry meeting with clinical data: The Society for Immunotherapy of Cancer (SITC) Meeting (Nov 4-8) (OBX, HOWL, CADL, IMCR, ELTX, CATX) Investor event: WVE R&D Day (9:30ET) Abstracts release: ASH 2026 abstracts (9:00ET) Triple Meeting 2026 (AACR-NCI-EORTC) abstracts (3:00ET) Thu 5-Nov Industry meeting with clinical data: The Liver Meeting (AASLD) (Nov 5-9) (KLRA, GILD, GSK.LN, MDGL, IONS, MIRM, VIR, ALT, ASMB, ALGS) Fri 6-Nov Industry meetings with clinical data: American College of Rheumatology (ACR) Convergence Conference (Nov 6-11) (ZBIO, CABA, ARTV, CGEM, IMM.AU, ARGX, KYMR) AHA Scientific Session (Nov 6-9) (BRVE, ALNY) later during November 2026 Regulatory decisions: FDA PDUFAs: TEVA (IGALMI sNDA, 14-Nov), SMMT/9926.HK (Ivonescimab BLA, 14-Nov), CYTX (MYQORZO sNDA, 14-Nov), ROP.SW/BIIB (Gazyva sBLA, 15-Nov), Mandos LLC (Adrabetadex NDA, 17-Nov), BAYN.GR (Asundexian NDA, 19-Nov), SVRA (MOLBREEVI BLA, 22-Nov), CAPR (deramiocel BLA, 22-Nov), SAN.FP (venglustat NDA, 25-Nov), BBIO (ribitol NDA, 27-Nov), GSK.LN (neladalkib NDA, 27-Nov), 532321.IN (Lipaglyn NDA, 27-Nov), PYPD/Azurity Pharmaceuticals (D-PLEX NDA, 28-Nov), COGT (Bezuclastinib NDA, 30-Nov), ROP.SW (Giredestrant NDA, 30-Nov), VRTX (Povetacicept BLA, 30-Nov), REGN/ALNY (cemdisiran NDA); EMA CHMP opinions on MAA (13-Nov) Industry meetings with clinical data: Society for Neuro-Oncology Annual Meeting (Nov 12-15), Clinical Trials on Alzheimer's Disease (CTAD) Conference (Nov 16-19) Regulatory meeting: EMA CHMP monthly meeting (Nov 9-12) Trial results: NEU.AU/ACAD (Ph3 Rett syndrome), HELP (Ph3 MDD), SLGL (Ph3 basal cell carcinomas), PEPG (Ph2 DM1), PHARM.NA (Ph2 CVID), RADX (Ph2 PET imaging), DWTX (Ph2 CINP), IBRX (Ph2 NMIBC), BIOV.SW/GSK.LN (Ph2 TB Pneumonia), SXTP (Ph2 babesiosis), ZBIO/XNCR (Ph2 SLE), IPH.FP (Ph1 solid tumors), VANI (Ph1 obesity) expected imminently Trial results: CGON (Ph3 INT-NMIBC) Related: 532321.IN, 9926.HK, ACAD, ALGS, ALNY, ALT, ANNX, ARGX, ARTV, ASMB, BAYN.GR, BBIO, BIIB, BIOV.SW, BRVE, CABA, CADL, CAPR, CATX, CGEM, CGON, COGT, CYTX, DWTX, ELTX, GILD, GSK.LN, HELP, HOWL, IBRX, IMCR, IMM.AU, IONS, IPH.FP, KLRA, KYMR, MDGL, MIRM, NEU.AU, OBX, PEPG, PHARM.NA, PYPD, RADX, REGN, ROP.SW, RXRX, SAN.FP, SLGL, SMMT, SVRA, SXTP, TEVA, VANI, VIR, VRTX, WVE, XNCR, ZBIO...(more)	show story hide story
30-Oct-2026 11:13	CDC reports 264 new cases of measles this week, PA decelerating, NY and more states accelerating Year-to-date, CDC has reported 4,852 cases of measles, roughly 1,000 in the past weeks alone. Weekly cases of 264 not a new high, but ~18% above the five-week rolling average. Pennsylvania rises to 1,411 (+84) yet a slight deceleration in weekly trend. Meanwhile New York (+46), Wisconsin (+45), Minnesota (+38) and Ohio (+30) are all accelerating week over week. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
30-Oct-2026 11:04	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +1.02% vs the S&P 500 (1.38%). Most major health groups are lower amid the market sell-off and risk rotation, Pharma the outlier and beneficiary, DRG +2.06%, while declines in MedTech (and gains in Pharma) are amplified by earnings updates. REGN +12% and ILMN (15%) bracket the XLV on respective prints. SYK (5%) Q3 miss was foretold, the Q4 guide and slowdown in hips and knees was not, patients' insurance rearing up at the device manufacturer. More moderate declines in payers and providers, mostly red but relatively firm, seeing some support from the rotation. Gainers +24.7% CDNA (CareDx): earnings; best performer on XBI +11.7% REGN (Regeneron): earnings; 52-week high; best performer on XLV +11.4% BTSG (BrightSpring Health Services): earnings +7.5% EXEL (Exelixis): earnings; 52-week high +6.3% AZN (AstraZeneca): earnings +5.5% DXCM (Dexcom): earnings +4.1% GILD (Gilead Sciences): earnings; 52-week high +4.0% LLY (Eli Lilly): follow-through, pharma sympathy; 52-week high +4.0% INCY (Incyte): upgraded at Oppenheimer +3.6% SNY (Sanofi): earnings +3.5% VRTX (Vertex Pharmaceuticals): 52-week high +2.1% AMGN (Amgen): follow-through, pharma sympathy; 52-week high +1.5% ABBV (AbbVie): earnings +1.4% MRK (Merck): follow-through, pharma sympathy Decliners -87.8% ABOS (Acumen Pharmaceuticals): trial results in Alzheimer's disease; downgrades -35.9% ATEC (Alphatec Holdings): earnings; downgraded at BMO Capital Markets -18.7% AGIO (Agios Pharmaceuticals): FDA extends PDUFA date by three months; worst performer on XBI -15.3% ILMN (Illumina): earnings; worst performer on XLV -14.7% NRXP (NRX Pharmaceuticals): small-cap biotech; updates on Ketamine program -12.7% TXG (10X Genomics): sympathy to AI trade -11.0% BCAX (Bicara Therapeutics, Inc.): follow-through, downgraded at Goldman Sachs -10.7% TWST (Twist Bioscience): sympathy to AI trade -10.0% ALHC (Alignment Healthcare): earnings; downgraded at KeyBanc -9.2% ABSI (Absci Corp.): shares remain +20% WTD -7.6% RMD (ResMed): earnings -7.4% RXRX (Recursion Pharmaceuticals): sympathy to AI trade -7.3% IOVA (Iovance Biotherapeutics): follow-through -6.9% DVA (DaVita): earnings -5.7% TEM (Tempus AI): sympathy to AI trade -5.4% HIMS (Hims & Hers Health): stock back to even WTD (peptides) -5.2% SYK (Stryker): earnings; downgraded at Canaccord -5.2% BHVN (Biohaven): earnings -4.9% RVTY (Revvity): risk-off / market rotation -3.3% RARE (Ultragenyx Pharmaceutical): on light volume -3.3% CRL (Charles River Laboratories): risk-off / market rotation -2.1% ALNY (Alnylam Pharmaceuticals): follow-through, downgraded at Raymond James -0.1% BSX (Boston Scientific): follow-through, downgraded at TD Cowen	show story hide story
30-Oct-2026 09:01	SYK Stryker Q3 print complicated by the previously disclosed and newly disclosed headwinds ($311.75) Shares of Stryker (10%) in the pre-market following last night's Q3 print which missed on the top and bottom lines. Company also reduced FY outlook for both EPS and revenue growth. More color commentary on the call regarding the ongoing disruptions and normalization of inventory, plus a call out for slow down of the ortho market more broadly. Disclosures at the Wells Fargo conference in September had analysts prepared for some measure of Q3 shortfall, but the call commentary on knee and hip deceleration was unexpected. Bulls cite management's long track record for navigating the cycles past, while some believe company can defend and even take share, but the slowdown nevertheless putting pressure on estimates and targets, and at least one downgrade on the tape so far. FactSet showing 73% of analysts (24 of 33) maintain buy-equivalent ratings. See Related StreetAccount comments: 10/29/2026 4:12:50 PM - StreetAccount Metrics Recap - Stryker Q3 Earnings 10/29/2026 4:10:06 PM - Stryker reports Q3 EPS $3.52 ex-items vs FactSet $3.55 [26 est, $3.44-3.78]; increases share repurchase authorization by $3.0B 9/8/2026 10:55:04 AM - Stryker trades lower amid presentation at Wells Fargo Conference Related: JNJ	show story hide story
30-Oct-2026 08:30	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar again front and center for the sector, headlined by MedTech overnight and Pharma on Friday morning. Many more reports sprinkled throughout the sector. Pharma continues the strong showing in Q3 with beats from Astra, Sanofi, and AbbVie. MedTech troubles also continue with recent spate of cybersecurity incidents continuing to impact. Stryker noted disruption ongoing. Shares of SYK (11%) in the pre-market. Illumina reported topline light, and guided Q4 topline below. Shares of ILMN (13%) in the pre-market. Two more biotech IPOs priced overnight: Aspen Neuroscience and Bambusa Therapeutics. Yesterday, Healthcare equities finished broadly higher. All major health groups ended higher for the session, including a squeaker for the XBI +0.18% with two outsized decliners. Pharma was the clear leader all day on the back of big earnings beats from several large-cap drugmakers, and fresh 52-week highs for multiple non-reporting drug names across the DRG +3.44%. Week-to-date, most groups on track for +3% to +5% gains, with Managed Care an exception, tracking lower by (3%) on the averages. Macro S&P futures are down (1.1%) on Friday morning, and Nasdaq futures down (2.4%). Tech under pressure following latest high-profile earnings disappointments. AI takeaways from AMZN largely upbeat, though expectations elevated and FCF headwinds from outsized capex still an overhang. Slowdown in non-AI segments another key area of scrutiny (similar to GOOGL). INTC results also play into the positive AI compute/capex demand narrative, though margin pressure (and PC headwinds) from memory cost surge and supply constraints have received the bulk of the attention. Several other tech names under significant post-earnings pressure, including RDDT, TWLO and RBLX. Equal-weight S&P holding up much better with the continued divergence between the AI/momentum and broadening out trades (rotation > broad risk off). Oil the other big area of focus with no signs of any meaningful traction behind recent diplomacy hints. However, rates lower, seemingly more focused on tech weakness. Pre-market trading update Trading higher +14.3% NRXP small-cap biotech; updates on Ketamine program; call at 830ET +10.5% CDNA earnings +8.2% REGN earnings +7.9% BTSG earnings +7.3% RARE on light volume +5.7% AZN earnings +5.0% GILD earnings +3.6% SNY earnings +3.1% AMGN follow-through, pharma sympathy +3.1% LLY follow-through, pharma sympathy +2.9% DXCM earnings +2.4% MRK follow-through, pharma sympathy +2.3% INCY upgraded at Oppenheimer Trading lower -32.2% ATEC earnings; downgraded at BMO Capital Markets -13.3% ILMN earnings -10.7% ALHC earnings; downgraded at KeyBanc -10.5% SYK earnings; downgraded at Canaccord -7.0% TWST sympathy to AI trade -6.3% TEM sympathy to AI trade -6.1% TXG sympathy to AI trade -5.4% BHVN earnings -4.7% RXRX sympathy to AI trade -4.6% HIMS on 88K shares; stock +7% WTD (peptides) -3.8% BCAX follow-through, downgraded at Goldman Sachs -3.6% IOVA follow-through -0.7% ABBV earnings -0.6% ALNY follow-through, downgraded at Raymond James -0.5% BSX follow-through, downgraded at TD Cowen Pharma Earnings: ABBV reports Q3 EPS $3.82 ex-items vs FactSet $3.73 on revenue $17.40B vs FS $17.32B. Raises FY EPS outlook by $0.11 at the midpoints. Conf. call at 9:00ET; typically provides additional guidance on the call AZN.LN (AZN) reports Q3 Core EPS $2.79 vs consensus $2.59 on revenue $16.21B vs consensus $15.94B. Confirms FY guidance. Conf. call at 10:30ET Quick take: Analysts point out good cost control added to operational beat. Of note, group also announced a restructuring program with total costs of $2B from now through 2029. Group confirmed FY26 guidance which analysts note was as expected; however, a few remark, given solid core EPS beat, it could be a bit disappointing. Limited changes to consensus EPS expected. SAN.FP (SNY) reports Q3 Business EPS €3.55 vs consensus €2.81 on net sales €14.44B vs consensus €13.25B. Raises FY sales growth outlook to low-teens from prior around 10%. Conf. call at 8:30ET Biotech Earnings: REGN reports Q3 EPS $20.07 ex-items vs FactSet $16.42 on revenue $5.12B vs FactSet $4.56B. Notes that the Sanofi Development Balance was fully repaid as of the end of Q2 of 2026 and no longer reduced Sanofi collaboration revenue beginning in Q3 of 2026. Conf. call at 8:30ET EXEL reported Q3 EPS $0.94 ex-items vs FactSet $0.89 on revenue $658.7M vs FS $646.5M. Reaffirms FY outlook. Now expects STELLAR-304 trial readout with zanzalintinib in Q1 of 2027 vs prior H2 of 2026. BHVN reported Q3 results including cash & equivalents $164.0M at 30-Sep. Several near-term catalysts, but obesity readout is not one - phase 2 readout with taldefgrobep alfa slipped to H2 of 2027 vs prior H2 of 2026. Research: ALNY downgraded to outperform from strong buy Raymond James (Martin Auster), target cut to $315 from $420 or approx. 81% upside. BCAX downgraded to sell at Goldman Sachs (Richard Law), target is $8 or approx. 18% downside. INCY upgraded to outperform from perform at Oppenheimer (Jay Olson), target increased to $144 from $120 or approx. 23% upside. KZIA initiated buy at Needham (Gil Blum), target is $27 or approx. 210% upside. NSRX initiated buy at Maxim Group (Naz Rahman), target is $7 or approx. 119% upside. Life Science & MedTech Earnings: SYK reported Q3 EPS $3.52 ex-items vs FactSet $3.55 on revenue $6.52B vs FS $6.62B. Lowers FY26 EPS outlook by $0.075 at the midpoints. Lowers FY26 revenue growth to +6.5-7.0% vs prior +8.3-9.3% and FactSet +8.2%. On the call: With respect to Peripheral Vascular manufacturing impact and "ongoing" supply disruption: "Our teams made meaningful progress restoring supply throughout the quarter, and we now expect inventory levels and product availability to continue normalizing through the end of the year." ILMN reported Q3 EPS $1.44 ex-items vs FactSet $1.36 on revenue $1.13B vs FS $1.15B. Raises FY26 EPS outlook by $0.075, and raises revenue outlook by $30M, at the midpoints. Quick take: Share declines are widely attributed to results that failed to clear a high bar following the stock's +121% YTD rally. Commentary also points to limited NovaSeq X contribution to instrument revenue and another q/q slowdown in consumables. Views on the company's HSD% revenue growth outlook for 2027 remain divided. Bears point to ongoing instrument weakness, heightened competition, and reimbursement headwinds in Europe, while bulls see support from AI and multiomics adoption, resilient US clinical growth, and continued confidence in long-term margin targets. RMD reported Q1 EPS $2.91 ex-items vs FactSet $2.69 on revenue $1.42B vs FS $1.39B. DXCM reported Q3 EPS $0.73 vs FactSet $0.67 on revenue $1.34B vs FS $1.33B. Raises lower-end of FY revenue guide, midpoint by $10M. MMSI reports Q3 EPS $1.12 ex-items vs FactSet $1.04 on revenue $416.2M vs FS $410.6M. Company acquires Solo Pace for ~$45M. Raises FY EPS guidance by $0.05, raises revenue outlook by $48M, at the midpoints. CDNA reported Q3 EPS $0.74 ex-items, unclear if comparable to FactSet $0.25, on revenue $139M vs FS $122.0M. Adj EBITDA $30M vs FS $14.3M. Raises FY revenue outlook by $30M, adj EBITDA by $23M, at the midpoints. ATEC reported Q3 adj EBITDA $38.3M vs FactSet $36.3M on revenue $221.2M vs FS $225.2M. Lower FY guidance for adj EBITDA, and revenue. Research: ATEC downgraded to market perform from outperform at BMO Capital Markets (Vik Chopra), target cut to $8 from $12 or approx. 30% downside. BSX downgraded to hold from buy at TD Cowen (Joshua Jennings), target cut to $46 from $56 or approx. 8% upside. SYK downgraded to hold from buy at Canaccord Genuity (Caitlin Roberts), target cut to $300 from $385 or approx. 4% downside. Services & Hospitals Earnings: DVA reported Q3 EPS $3.82 ex-items vs FactSet $3.57 on revenue $3.58B vs FS $3.52B. Raises low-end of FY EPS outlook by $0.20. BTSG reports Q3 adj EBITDA $228M vs FactSet $214.5M on revenue $4.21B vs FactSet $3.88B. Raises FY26 adj EBITDA outlook by $22.5M, and revenue by $750M, at the midpoints. Conf. call at 8:30ET Managed Care Earnings: ALHC reported Q3 EPS ($0.04) vs FactSet ($0.04) on revenue $1.36B vs FS $1.31B, adj EBITDA $21.8M vs FS $22.7M. Guides Q4 revenue floor $1.316B vs FactSet consensus $1.33B, adj EBITDA floor ($28M) vs FactSet consensus $19.8M. For FY, now expects adj EBITDA floor $100M vs prior guidance $145-163M and FS $148.4M. Research: ALHC downgraded to sector weight from overweight at KeyBanc (Matthew Gilmor), following Q3 results. On Deck: Conference (cont.): ESGCT Congress 2026 (Oct 27-30) Regulatory FDA Adcom: Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to review Sydnexis' (private) NDA for atropine sulfate for slowing myopia progression in children 3 years and older. (8:30-15:00ET) (LGND) FDA PDUFA for Inovio (INO) BLA for INO-3107 in recurrent respiratory papillomatosis (RRP) on Sun 1-Nov: FDA PDUFA for Agios Pharma. (AGIO) sNDA for PYRUKYND in sickle cell disease This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, AGIO, ALHC, ALNY, AMGN, ATEC, AZN, AZN.LN, BCAX, BHVN, BSX, BTSG, CDNA, DVA, DXCM, EXEL, GILD, HIMS, ILMN, INCY, INO, IOVA, KZIA, LGND, LLY, MMSI, MRK, NRXP, NSRX, RARE, REGN, RMD, RXRX, SAN.FP, SNY, SYK, TEM, TWST, TXG, +ASPE, +BBTX...(more)	show story hide story
30-Oct-2026 08:26	ILMN Illumina falls on mixed Q3 results despite raised FY26 guidance and reaffirmed 2027 growth target ($290.06) ILMN shares (13.7%) premarket after reporting Q3 adjusted EPS ahead of FactSet but revenue below. Raised FY26 EPS and revenue outlook. On the call, reaffirmed its 2027 HSD% growth target. Share declines are widely attributed to results that failed to clear a high bar following the stock's +121% YTD rally. Commentary also points to limited NovaSeq X contribution to instrument revenue and another q/q slowdown in consumables. Views on the company's HSD% revenue growth outlook for 2027 remain divided. Bears point to ongoing instrument weakness, heightened competition, and reimbursement headwinds in Europe, while bulls see support from AI and multiomics adoption, resilient US clinical growth, and continued confidence in long-term margin targets. See Related StreetAccount comments: 10/29/2026 4:43:55 PM - Illumina guides Q4 EPS $1.51-1.56 vs FactSet $1.54 - slide presentation 10/29/2026 4:12:39 PM - StreetAccount Metrics Recap - Illumina Q3 Earnings 10/29/2026 4:10:33 PM - Illumina reports Q3 EPS $1.44 ex-items vs FactSet $1.36 [19 est, $1.33-1.38]	show story hide story
29-Oct-2026 17:06	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly higher on Thursday. Advancers beat decliners by nearly 11:1 on the XLV. Healthcare +2.50% vs S&P 500 (0.30%). All major health groups ended higher for the session, including a squeaker for the XBI +0.18% with two outsized decliners. Pharma was the clear leader all day on the back of big earnings beats from several large-cap drugmakers, and fresh 52-week highs for multiple non-reporting drug names across the DRG +3.44%. LLY +6.6% and BAX (7.7%) bracketed the XLV, both on earnings. Earnings calendar the primary source of direction today, not only the plus-sized beats for LLY, MRK +3.8% and BMY +1.4%, but for Hospitals with some notable earnings, THC +0.8% and CYH (9.4%) with divergent Q3 reports. BSX +0.6% saw two more downgrades overnight, and a first downgrade for GSK (0.1%) post-earnings. Dialysis names notably higher following an improved final rate for ESRD in CY2027. Yesterday, Healthcare equities finished moderately higher and inline overall. Most major health groups held onto gains for the session. Advancers were led by Biotech, MedTech and the Services groups. Value widely underperformed growth before and after the FOMC decision. Earnings calendar a primary driver of stock performance, report volume ramped overnight with large-cap prints all across the Healthcare sector. Big headline in Biotech is the phase readout for GMAB +28.3% in head-and-neck cancer, combo with Keytruda besting the blockbuster alone, and bar raised for future challengers. Macro Big earnings burst today. Several threads in today's narrative. AI trade came under pressure after a strong week despite what seemed to be positive earnings takeaways for the compute/capex theme. But GOOGL was a big decliner on concerns about Search deceleration and MSFT was unable to hang on to early gains helped by Azure momentum (and its $25B bonding plan coming under scrutiny); CAT another big decliner on the AI power/infrastructure front. But the weak AI trade masked very positive breadth: S&P gainers outnumbered decliners by four to one while the equal-weight RSP notably outperformed after lagging the prior four sessions; strength extended well beyond defensives to some cyclical pockets as well as small caps. Came alongside lower rates (though Treasury yields still mostly higher WTD) and lower oil. WTI crude has been choppy this week, with latest headlines about Mideast diplomacy contrasting with broadening market expectations for a resumption of kinetic activity following the midterms. Plenty of positive takes from today's economic data, with Q3 GDP strong, jobless claims still near multi-decade lows, and core PCE largely in line. Notable Gainers +33.6% GKOS (Glaukos): earnings +28.8% BHC (Bausch Health Cos.): earnings +26.9% TDOC (Teladoc Health): earnings +17.0% MESO (Mesoblast): earnings +15.1% INSM (Insmed): earnings; best performing biotech on XBI +8.3% REPL (Replimune Group): follow-through, shares +52% WTD; 52-week high +7.7% EHC (Encompass Health): earnings +7.6% RAPP (Rapport Therapeutics): shares were (18%) yesterday +6.6% LLY (Eli Lilly): earnings; 52-week high; best performer on XLV +5.9% VKTX (Viking Therapeutics): earnings +5.1% DVA (DaVita): CMS finalizes CY2027 rule for ESRD PPS +4.0% GILD (Gilead Sciences): on average volume; pharma sympathy; 52-week high +3.8% MRK (Merck): earnings +3.2% WST (West Pharmaceutical Services): earnings; 52-week high +3.2% NVS (Novartis): on average volume; pharma sympathy Notable Decliners -35.4% IOVA (Iovance Biotherapeutics): trial results in NSCLC; worst performer on XBI -25.1% ALNY (Alnylam Pharmaceuticals): earnings; 52-week low -10.6% FTRE (Fortrea Holdings): earnings; shares were +6% yesterday (ICLR sympathy) -9.4% CYH (Community Health Systems): earnings -7.7% BAX (Baxter International): earnings; worst performer on XLV -7.5% NVCR (Novocure): earnings Earnings in Pharma LLY reports Q3 EPS $7.48 ex-items vs FactSet $5.68 on revenue $24.40B vs FS $22.58B. Jardiance milestones boost the topline in Q3. Sales outperformance by Mounjaro and Zepbound; Foundayo sales ($184M vs SA $229M) were below consensus. Verzenio inline to slightly ahead. Updates FY EPS guidance for IPR&D, narrows outlook and reduces midpoint by $0.50. Raises FY revenue outlook by $5.5B at the midpoints. Quick take: Sentiment broadly positive around the update, outsized strength from Incretin products commonly highlighted - with both Mounjaro and Zepbound sales ahead of consensus (+7% and +6% respectively). Broad based strength across diabetes and obesity overshadowed some slight concern around weakness in early trends for Foundayo sales ($184M vs SA $229.1M). Discussion around outlook also largely bullish, noting the FY revenue raise was the third of the year - with demand trends in obesity continuing to support upside. On the 10:00 call, focus likely to be on Foundayo's launch cadence and pricing trends, Incretin demand outlook and expectations around the 07-Dec R&D day. MRK reports Q3 EPS $2.49 ex-items vs FactSet $2.09 on revenue $18.09B vs FS $17.33B. Wide beat by Keytruda, Gardasil and Welireg. A few sales misses also of note. Raises FY EPS outlook by $0.085, and FY revenue outlook by $250M, at the midpoints. BMY reports Q3 EPS $1.35 ex-items vs FactSet $1.10 on revenue $13.07B vs FS $12.72B. Opdivo a little light to StreetAccount consensus, but other key products make up the difference and more. Earnings in Life Sci & MedTech WST reports Q3 EPS $2.66 ex-items vs FactSet $2.20 on revenue $874.5M vs FS $827.1M. Raise FY EPS outlook by $0.48 at the midpoints. Raises FY organic growth outlook, and revenue outlook for FY. BAX reports Q3 EPS $0.58 ex-items vs FactSet $0.52 on revenue $2.98B vs FS $2.91B. Raises FY revenue growth outlook by 100bps to +4-5%, similar for organic growth +3-4%, and raises EPS outlook by $0.05 at the midpoints. ALGN reported Q3 EPS $2.80 ex-items vs FactSet $2.77 on revenue $1.02B vs FS $1.00B. Guides Q4 revenue below consensus, and FY aligner volume up LSD y/y. Also announced CEO succession plan, effective year-end 2026. Jennifer L. Davis joins from PG, where she was CEO of their Global Healthcare business. GKOS reported Q3 EPS $0.47 ex-items, unclear if comparable to FactSet ($0.10), on revenue $211.0M vs FS $168.0M. Raises FY26 revenue guidance by $90M at the midpoints. Guides FY27 topline growth +28%, or an even $1.00B vs FS $852.4M. Quick Take: Strong Q3 results surpassed even elevated buy-side expectations, prompting several firms to materially raise price targets and alleviating concerns around Epioxa competition and potential iDose disruption from LCDs in 2027. The beat was primarily driven by Epioxa, which helped drive a positive inflection in profitability, with commentary broadly constructive on its growth trajectory. Despite the increased guidance, the outlook is viewed as attainable, with further upside potential and the company's pipeline remaining largely underappreciated. Earnings in Hospitals THC reports Q3 adjusted EBITDA $1.36B, including $147M favorable impact, vs FactSet $1.17B. Revenue $5.63B vs FS $5.49B. EPS $6.64 ex-items vs FS $4.68. Raises FY guidance for adj EBITDA by $195M at the midpoints. EHC reported Q3 adjusted EBITDA $346.6M vs FactSet $325.3M on revenue $1.61B vs FS $1.60B. Raises FY26 outlook top to bottom. CYH reports Q3 adj EBITDA $280M vs FactSet $319.3M, revenue $2.76B vs FS $2.80B. Lowers FY26 adj EBITDA outlook by $87.5M at the midpoints, lowers revenue by $100M at the midpoints; also reduced FY EPS (loss). Earnings in SMID-cap Biotech ALNY reports Q3 EPS $15.72, unclear if comparable to FactSet $1.66, on revenue $1.46B vs FS $1.43B. Reaffirms FY net product revenues. Quick Take: Concerns remain around the long-term outlook, particularly the pending 340B reform, which could significantly constrain Amvuttra's growth if enacted. Topline upside is attributed primarily to collaboration/royalty revenue, while Amvuttra is in line with expectations, with a modest U.S. beat. However, commentary notes underlying U.S. growth likely decelerated after adjusting for the extra shipping week in Q3. Discussion is constructive on the TRITON-CM update, with study enrichment viewed as increasing nucresiran's PoS. INCY reports Q3 EPS ($3.60) ex-items vs FactSet ($3.93) on revenue $1.56B vs FS $1.46B. Raises FY net sales guidance by $60M at the midpoints. INSM reports Q3 EPS ($0.46) vs FactSet ($0.38) on revenue $524.4M vs FS $500.4M. Brinsupri revenue $400.1M or +29% q/q. Raises low-end of FY Brinsupri guidance and Arikayce guidance. Reiterates LT peak sales guidance for Brinsupri and other key products. Quick Take: Takeaways note that expectations for Brinsupri, which drove the beat and raise, had moderated ahead of the print, but results confirm that strong launch momentum remains intact. Commentary is also positive on Arikayce's commercial performance, though elevated R&D expenses tied to TPIP limited the earnings upside. Analysts seek additional details on Q3 new patient starts, which were not disclosed in the press release. CDC ACIP seeking nominations for new members; due by 31-Dec Federal Register notice today showing signs of life for the sidelined vaccine advisory panel. Nominations for ACIP are open until 31-Dec-2026. The CDC ACIP has not met since 5-Dec-2025 when they voted on Hepatitis B birth dose. Meetings in February, March, June and October 2026 have been cancelled or stayed in response to the ongoing litigation (AAP v Kennedy). Per today's FR notice: ACIP consists of up to "19 experts that that collectively represent a balanced range of scientific, clinical, and public health expertise relevant to the Committee's mission, including person(s) knowledgeable about consumer perspectives and/or social and community aspects of immunization programs." Notable research in Healthcare today Pharma: GSK.LN (GSK) downgraded to hold from buy at Jefferies (Michael Leuchten), target cut to 2100p from 2500p or approx. 16% upside. Biotech: ALNY downgraded to hold from buy at Stifel (Paul Matteis), target cut to $225 from $318 or approx. 13% upside. ARTV downgraded to hold from buy at Jefferies (Roger Song), target cut to $4 from $23 or approx. 7% downside. BIIB upgraded to buy at Argus Research GMAB downgraded to hold from buy at DNB Carnegie (Rune Majlund Dahl), target increased to DKK4100 from DKK3100 or approx. 6% upside. ABSI initiated buy at Jefferies (Andrew Tsai), target is $14 or approx. 18% upside. AGIO assumed buy at HC Wainwright (Douglas Tsao), target remains $55 or approx. 44% upside. CSTL initiated outperform at Mizuho (Bradley Bowers), target is $60 or approx. 64% upside. CHRS assumed buy at HC Wainwright (Swayampakula Ramakanth), target remains $7 or approx. 503% upside. KARD initiated overweight at Cantor Fitzgerald (Kristen Kluska), target is $50 or approx. 264% upside. MedTech: BSX downgraded to hold from buy at Jefferies (Matthew Taylor), target cut to $46 from $60 or approx. 8% upside. BSX downgraded to perform from outperform at Oppenheimer (Suraj Kalia) Services: AIRS initiated buy at Lake Street (Ben Haynor), target is $3 or approx. 108% upside. Post-close news Earnings: GILD reports Q3 EPS $2.55 ex-items vs FactSet $2.19 on revenue $8.30B vs FS $7.81B. Yeztugo (US/WW) $294M / $305M. FS consensus $283.2M. Raises FY by $900M at the midpoints. Updates FY EPS for IPR&D charges. Conf. call at 16:30ET Shares trading +2.6% in the after-hours SYK reports Q3 EPS $3.52 ex-items vs FactSet $3.55 on revenue $6.52B vs FS $6.62B. Lowers FY26 EPS outlook by $0.075 at the midpoints. Lowers FY26 revenue growth to +6.5-7.0% vs prior +8.3-9.3% and FactSet +8.2%. Conf. call at 16:30ET On the call: With respect to Peripheral Vascular manufacturing impact and "ongoing" supply disruption: "Our teams made meaningful progress restoring supply throughout the quarter, and we now expect inventory levels and product availability to continue normalizing through the end of the year." Shares trading (10.9%) in the after-hours ILMN reports Q3 EPS $1.44 ex-items vs FactSet $1.36 on revenue $1.13B vs FS $1.15B. Raises FY26 EPS outlook by $0.075, and raises revenue outlook by $30M, at the midpoints. Conf. call at 16:30ET Shares trading (13.8%) in the after-hours RMD reports Q1 EPS $2.91 ex-items vs FactSet $2.69 on revenue $1.42B vs FS $1.39B. Conf. call at 16:30ET ADRs trading +3.6% in the after-hours DXCM reports Q3 EPS $0.73 vs FactSet $0.67 on revenue $1.34B vs FS $1.33B. Raises lower-end of FY revenue guide, midpoint by $10M. Conf. call at 16:30ET Shares trading +0.1% in the after-hours EXEL reports Q3 EPS $0.94 ex-items vs FactSet $0.89 on revenue $658.7M vs FS $646.5M. Reaffirms FY outlook. Now expects STELLAR-304 trial readout with zanzalintinib in Q1 of 2027 vs prior H2 of 2026. Conf. call at 17:00ET Shares trading (0.3%) in the after-hours DVA reports Q3 EPS $3.82 ex-items vs FactSet $3.57 on revenue $3.58B vs FS $3.52B. Raises low-end of FY EPS outlook by $0.20. Conf. call at 17:00ET Shares trading (9.9%) in the after-hours MMSI reports Q3 EPS $1.12 ex-items vs FactSet $1.04 on revenue $416.2M vs FS $410.6M. Company acquires Solo Pace for ~$45M. Raises FY EPS guidance by $0.05, raises revenue outlook by $48M, at the midpoints. Conf. call at 16:30ET Shares trading UNCH in the after-hours On Deck: Conference (cont.): ESGCT Congress 2026 (Oct 27-30) Earnings tomorrow morning ABBV (call at 9:00ET), AZN (call at 10:30ET), SNY (call at 8:30ET), REGN (call at 8:30ET), BTSG (call at 8:30ET) Syndicate calendar / potential IPO pricing tonight +ASPE Aspen Neuroscience - S-1/A - stem-cell therapies for Parkinson's +BBTX Bambusa Therapeutics - S-1A - bispecific mAbs for I&I diseases (BNTX, Adimab) Regulatory FDA Adcom on Friday: Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to review Sydnexis' (private) NDA for atropine sulfate for slowing myopia progression in children 3 years and older. (8:30-15:00ET) (LGND) FDA PDUFA on Friday for Inovio (INO) BLA for INO-3107 in recurrent respiratory papillomatosis (RRP) on Sun 1-Nov: FDA PDUFA for Agios Pharma. (AGIO) sNDA for PYRUKYND in sickle cell disease StreetAccount Healthcare Reads Kennedy's closing arguments for the 2026 midterms: Fraud, vaccines, and MAHA (29-Oct) STAT News Senate candidate El-Sayed wants to 'grill' RFK Jr., calls him the 'most incompetent HHS secretary ever' (28-Oct) STAT News The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion ... Not the Finish Line (28-Oct) fdalawblog FDA scientists opposed the Trump administration's effort to ease peptides access (28-Oct) AP Ebola Sequencing Links Kenya, Nigeria Cases to Congo Chain (28-Oct) Bloomberg CDC's deputy director to leave Trump administration after brief stint (27-Oct) WaPo Healthcare Stocks Become Anti-AI Bet as Investors Turn Defensive (27-Oct) Bloomberg Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own (27-Oct) STAT News Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94% (27-Oct) Reuters Moderna CEO on what's next after success in cancer vaccine (26-Oct) STAT News Obesity drug developer Corxel to go public via SPAC deal (26-Oct) Reuters The Cost of Healthcare Is Hitting America Where It Hurts: The Wallet (26-Oct) KFF Health News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ABSI, AGIO, AIRS, ALGN, ALNY, ARTV, AZN, BAX, BHC, BIIB, BMY, BNTX, BSX, BTSG, CHRS, CSTL, CYH, DVA, DXCM, EHC, EXEL, FTRE, GILD, GKOS, GMAB, GSK.LN, ILMN, INCY, INO, INSM, IOVA, KARD, LGND, LLY, MESO, MMSI, MRK, NVCR, NVS, PG, RAPP, REGN, REPL, RMD, SNY, SYK, TDOC, THC, VKTX, WST, +ASPE, +BBTX...(more)	show story hide story
29-Oct-2026 11:05	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +2.02% vs the S&P 500 (0.32%). All major health groups higher on the session, with Pharma the clear leader on the back of big earnings beats from several large-cap drugmakers, and fresh 52-week highs for multiple non-reporting drug names across the DRG +3.33% and XBI +0.65%. LLY +7% and BAX (4%) bracket the XLV. Earnings calendar the primary source of direction today, not only the plus-sized beats for LLY +7%, MRK +5% and BMY (flat), but Hospitals also out with notable earnings, THC modestly higher and CYH (13%) on divergent Q3 reports. BSX (1%) saw two more downgrades overnight, and a first for GSK (1%) post-earnings. Dialysis names higher following an improved final rate for ESRD in CY2027. Gainers +29.7% GKOS (Glaukos): earnings +23.8% TDOC (Teladoc Health): earnings +23.1% BHC (Bausch Health Cos.): earnings +16.4% MESO (Mesoblast): earnings +16.1% INSM (Insmed): earnings; best performer on XBI +9.8% RAPP (Rapport Therapeutics): shares were (18%) yesterday +7.7% REPL (Replimune Group): 52-week high; shares +52% WTD +6.8% LLY (Eli Lilly): earnings; 52-week high; best performer on XLV +6.3% VKTX (Viking Therapeutics): earnings +6.1% EHC (Encompass Health): earnings +5.1% MRK (Merck): earnings +4.8% WST (West Pharmaceutical Services): earnings; 52-week high +3.1% BIIB (Biogen): upgraded at Argus Research; announces CTAD presentations +2.7% AZN (AstraZeneca): on average volume; pharma sympathy +2.6% NVS (Novartis): on average volume; pharma sympathy +2.6% INDV (Indivior Pharmaceuticals): earnings +2.2% VRTX (Vertex Pharmaceuticals): on average volume; pharma sympathy +2.2% AMGN (Amgen): pharma sympathy; 52-week high +1.5% ABBV (AbbVie): on average volume; pharma sympathy; 52-week high +1.4% GILD (Gilead Sciences): on average volume; pharma sympathy; 52-week high +0.1% THC (Tenet Healthcare): earnings Decliners -33.1% IOVA (Iovance Biotherapeutics): trial results in NSCLC; worst performer on XBI -19.1% ALNY (Alnylam Pharmaceuticals): earnings; 52-week low -12.8% CYH (Community Health Systems): earnings -12.1% FTRE (Fortrea Holdings): earnings; shares were +6% yesterday (ICLR sympathy) -6.8% NVCR (Novocure): earnings -5.9% NEO (NeoGenomics): earnings -4.0% BAX (Baxter International): earnings; worst performer on XLV -1.9% INCY (Incyte): earnings -1.3% TAK (Takeda Pharmaceutical): earnings -1.0% GSK (GSK Plc): follow-through; downgraded at Jefferies -0.5% BMY (Bristol Myers Squibb): earnings	show story hide story
29-Oct-2026 10:09	ALNY Alnylam Pharmaceuticals falls as 340B concerns weigh on outlook; TRITON-CM enrollment expands ($196.00 -$36.40) ALNY shares (15.7%) after reporting Q3 EPS of $15.72, with revenue modestly ahead of FactSet consensus. Reaffirmed FY net product revenue guidance. The company also announced an update to TRITON-CM, including an expansion of target enrollment from 1,750 to ~2,250 patients. Concerns remain around the long-term outlook, particularly the pending 340B reform, which could significantly constrain Amvuttra's growth if enacted. Topline upside is attributed primarily to collaboration/royalty revenue, while Amvuttra is in line with expectations, with a modest U.S. beat. However, commentary notes underlying U.S. growth likely decelerated after adjusting for the extra shipping week in Q3. Discussion is constructive on the TRITON-CM update, with study enrichment viewed as increasing nucresiran's PoS. See Related StreetAccount comments: 10/29/2026 8:09:02 AM - StreetAccount Metrics Recap - Alnylam Pharmaceuticals Q3 Earnings 10/29/2026 8:08:22 AM - Alnylam Pharmaceuticals reports Q3 EPS $15.72	show story hide story
29-Oct-2026 09:13	CDC ACIP seeking nominations for new members; due by 31-Dec Federal Register notice today showing signs of life for the sidelined vaccine advisory panel. Nominations for ACIP are open until 31-Dec-2026. The CDC ACIP has not met since 5-Dec-2025 when they voted on Hepatitis B birth dose. Meetings in February, March, June and October 2026 have been cancelled or stayed in response to the ongoing litigation (AAP v Kennedy). Per today's FR notice: ACIP consists of up to "19 experts that that collectively represent a balanced range of scientific, clinical, and public health expertise relevant to the Committee's mission, including person(s) knowledgeable about consumer perspectives and/or social and community aspects of immunization programs." For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: AZN, BNTX, GSK, MRNA, NVAX, PCVX, PFE...(more)	show story hide story
29-Oct-2026 09:00	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar heavy with large-cap reports in Pharma headlining the sector, but notable reports throughout. Plus sized topline beats for Lilly, Merck and Bristol. Shares of LLY up nearly +5% in the pre-market. LSD gains for other reporting and non-reporting pharma names. Hospitals also with notable earnings, THC (2%) and CYH (14%) on divergent Q3 reports. Boston Scientific saw two more downgrades overnight, and a first for GSK post-earnings. Post-close on Wednesday, CMS finalized the ESRD payment rules for CY2027, improving the final rate by 160bps more than the June proposal (+2.7% vs +1.1%). Yesterday, Healthcare equities finished moderately higher and inline overall. Most major health groups held onto gains for the session. Advancers were led by Biotech, MedTech and the Services groups. Value widely underperformed growth before and after the FOMC decision. Earnings calendar a primary driver of stock performance, report volume ramped overnight with large-cap prints all across the Healthcare sector. Big headline in Biotech is the phase readout for GMAB +28.3% in head-and-neck cancer, combo with Keytruda besting the blockbuster alone, and bar raised for future challengers. Macro S&P futures are down (0.5%) on Thursday morning. AI/momentum trade under some pressure following big bounce over the last few days. Disappointing Q3 results from GOOGL the big headwind with the bulk of the focus on the softer Search performance. However, Google Cloud a standout, while MSFT a post-earnings outperformer on the back of better Azure growth/guidance. Memory under some scrutiny after Samsung pushed capital return announcement to January (following 100T won package recently outlined by SK Hynix). Software also under pressure with NOW guiding for cRPO deceleration (and bar high). Oil pullback the other big story today with latest wave of diplomacy headlines surrounding US-Iran conflict. Rates also lower following yesterday's upward pressure on long-term yields. Nothing particularly incremental in the FOMC meeting takeaways. Combination of AI/momentum pullback, lower oil and lower rates seems to be providing some support for the broadening out trade. Little impact from today's economic releases, with core PCE largely in line with expectations. Pre-market trading update Trading higher +18.2% MESO earnings +16.8% INSM earnings +15.8% GKOS earnings +12.2% TDOC earnings +11.7% BHC earnings +5.7% AMLX on 7K shares +5.0% INDV earnings +4.6% LLY earnings +4.4% NEO earnings +4.1% WST earnings +3.7% BAX earnings +3.6% AMGN on 10K shares +3.4% VRTX on light volume +3.3% GILD on 18K shares +3.2% NVS on 31K ADRs +2.8% BIIB upgraded at Argus Research; announces CTAD presentations +2.5% MRK earnings +2.2% AZN on 30K ADRs +1.9% ABBV on 10K shares Trading lower -25.5% IOVA trial results in NSCLC; call at 830ET -8.4% ALNY earnings -13.6% CYH earnings -7.7% NVCR earnings -3.1% VKTX earnings -0.8% KYMR earnings; phase 1 trial results; call at 830ET (low volume) Pharma Earnings: LLY reports Q3 EPS $7.48 ex-items vs FactSet $5.68 on revenue $24.40B vs FS $22.58B. Jardiance milestones boost the topline in Q3. Sales outperformance by Mounjaro and Zepbound; Foundayo sales ($184M vs SA $229M) were below consensus. Verzenio inline to slightly ahead. Updates FY EPS guidance for IPR&D, narrows outlook and reduces midpoint by $0.50. Raises FY revenue outlook by $5.5B at the midpoints. Conf. call at 10:00ET MRK reports Q3 EPS $2.49 ex-items vs FactSet $2.09 on revenue $18.09B vs FS $17.33B. Wide beat by Keytruda, Gardasil and Welireg. A few sales misses also of note. Raises FY EPS outlook by $0.085, and FY revenue outlook by $250M, at the midpoints. Conf. call at 9:00ET BMY reports Q3 EPS $1.35 ex-items vs FactSet $1.10 on revenue $13.07B vs FS $12.72B. Opdivo a little light to StreetAccount consensus, but other key products make up the difference and more. Conf. call at 8:00ET Research: GSK.LN (GSK) downgraded to hold from buy at Jefferies (Michael Leuchten), target cut to 2100p from 2500p or approx. 16% upside. Biotech Earnings: ALNY reports Q3 EPS $15.72, unclear if comparable to FactSet $1.66, on revenue $1.46B vs FS $1.43B. Reaffirms FY net product revenues. Conf. call at 8:30ET INCY reports Q3 EPS ($3.60) ex-items vs FactSet ($3.93) on revenue $1.56B vs FS $1.46B. Raises FY net sales guidance by $60M at the midpoints. Conf. call at 8:00ET INSM reports Q3 EPS ($0.46) vs FactSet ($0.38) on revenue $524.4M vs FS $500.4M. Brinsupri revenue $400.1M or +29% q/q. Raises low-end of FY Brinsupri guidance and Arikayce guidance. Reiterates LT peak sales guidance for Brinsupri and other key products. Conf. call at 8:00ET Research: ARTV downgraded to hold from buy at Jefferies (Roger Song), target cut to $4 from $23 or approx. 7% downside. BIIB upgraded to buy at Argus Research GMAB downgraded to hold from buy at DNB Carnegie (Rune Majlund Dahl), target increased to DKK4100 from DKK3100 or approx. 6% upside. ABSI initiated buy at Jefferies (Andrew Tsai), target is $14 or approx. 18% upside. AGIO assumed buy at HC Wainwright (Douglas Tsao), target remains $55 or approx. 44% upside. CSTL initiated outperform at Mizuho (Bradley Bowers), target is $60 or approx. 64% upside. CHRS assumed buy at HC Wainwright (Swayampakula Ramakanth), target remains $7 or approx. 503% upside. KARD initiated overweight at Cantor Fitzgerald (Kristen Kluska), target is $50 or approx. 264% upside. Life Science & MedTech Earnings: WST reports Q3 EPS $2.66 ex-items vs FactSet $2.20 on revenue $874.5M vs FS $827.1M. Raise FY EPS outlook by $0.48 at the midpoints. Raises FY organic growth outlook, and revenue outlook for FY. Conf. call at 8:00ET BAX reports Q3 EPS $0.58 ex-items vs FactSet $0.52 on revenue $2.98B vs FS $2.91B. Raises FY revenue growth outlook by 100bps to +4-5%, similar for organic growth +3-4%, and raises EPS outlook by $0.05 at the midpoints. Conf. call at 8:30ET ALGN reported Q3 EPS $2.80 ex-items vs FactSet $2.77 on revenue $1.02B vs FS $1.00B. Guides Q4 revenue below consensus, and FY aligner volume up LSD y/y. Also announced CEO succession plan, effective year-end 2026. Jennifer L. Davis joins from PG, where she was CEO of their Global Healthcare business. GKOS reported Q3 EPS $0.47 ex-items, unclear if comparable to FactSet ($0.10), on revenue $211.0M vs FS $168.0M. Raises FY26 revenue guidance by $90M at the midpoints. Guides FY27 topline growth +28%, or an even $1.00B vs FS $852.4M. Quick Take: Strong Q3 results surpassed even elevated buy-side expectations, prompting several firms to materially raise price targets and alleviating concerns around Epioxa competition and potential iDose disruption from LCDs in 2027. The beat was primarily driven by Epioxa, which helped drive a positive inflection in profitability, with commentary broadly constructive on its growth trajectory. Despite the increased guidance, the outlook is viewed as attainable, with further upside potential and the company's pipeline remaining largely underappreciated. Research: BSX downgraded to hold from buy at Jefferies (Matthew Taylor), target cut to $46 from $60 or approx. 8% upside. BSX downgraded to perform from outperform at Oppenheimer (Suraj Kalia) Services & Hospitals Earnings: THC reports Q3 adjusted EBITDA $1.36B, including $147M favorable impact, vs FactSet $1.17B. Revenue $5.63B vs FS $5.49B. EPS $6.64 ex-items vs FS $4.68. Raises FY guidance for adj EBITDA by $195M at the midpoints. Conf. call at 10:00ET EHC reported Q3 adjusted EBITDA $346.6M vs FactSet $325.3M on revenue $1.61B vs FS $1.60B. Raises FY26 outlook top to bottom. Conf. call at 10:00ET CYH reports Q3 adj EBITDA $280M vs FactSet $319.3M, revenue $2.76B vs FS $2.80B. Lowers FY26 adj EBITDA outlook by $87.5M at the midpoints, lowers revenue by $100M at the midpoints; also reduced FY EPS (loss). Conf. call at 11:00ET Regulatory: CMS finalized CY2027 rule for ESRD PPS, an increase to payment rates by +2.7% y/y and 160bps improvement from the June proposal. (DVA, FMS) On Deck: Oct 24 - Nov 1 Conference calendar (cont.): ESGCT Congress 2026 (Oct 27-30) Corporate calendar Thu 29-Oct: XFOR Investor Day (10:00ET) EVAX trial results (10:30ET) Earnings calendar Thu 29-Oct: after GILD (call at 16:30ET), SYK (call at 16:30ET), ILMN (call at 16:30ET), RMD (call at 16:30ET), DXCM (call at 16:30ET), EXEL (call at 17:00ET), DVA (call at 17:00ET), MMSI (call at 16:30ET) Fri 30-Oct: before ABBV (call at 9:00ET), AZN (call at 10:30ET), SNY (call at 8:30ET), REGN (call at 8:30ET), BTSG (call at 8:30ET) Syndicate calendar / potential IPO pricing Thu 29-Oct (post-market): +ASPE Aspen Neuroscience - S-1/A - stem-cell therapies for Parkinson's +BBTX Bambusa Therapeutics - S-1A - bispecific mAbs for I&I diseases (BNTX, Adimab) Regulatory calendar Fri 30-Oct: FDA Adcom: Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to review Sydnexis' (private) NDA for atropine sulfate for slowing myopia progression in children 3 years and older. (8:30-15:00ET) (LGND) FDA PDUFA for Inovio (INO) BLA for INO-3107 in recurrent respiratory papillomatosis (RRP) Sun 1-Nov: FDA PDUFA for Agio Pharma (AGIO) sNDA for PYRUKYND in sickle cell disease This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ABSI, AGIO, ALGN, ALNY, AMGN, AMLX, ARTV, AZN, BAX, BHC, BIIB, BMY, BSX, CHRS, CSTL, CYH, DVA, EHC, FMS, GILD, GKOS, GMAB, GSK.LN, INCY, INDV, INSM, IOVA, KARD, KYMR, LLY, MESO, MRK, NEO, NVCR, NVS, PG, TDOC, THC, VKTX, VRTX, WST...(more)	show story hide story
29-Oct-2026 08:57	LLY Eli Lilly trading higher on Q3 results - Mounjaro and Zepbound strength highlighted ($1288.30) LLY shares ~+4% in early reaction to the Q3 top and bottom line beat, reporting EPS of $7.48 ex-items meaningfully ahead of FactSet $5.68 on revenue revenue $24.40B vs FactSet $22.58B. Company also updated full year guidance targets, EPS now at $35.00-36.00 ex-items vs prior guidance $35.50-36.50 and FactSet $33.76 (including acquired IPR&D charges), with revenue expected in a range $91.0-92.0B vs prior guidance $85-87B and FactSet $88.82B. Sentiment broadly positive around the update, outsized strength from Incretin products commonly highlighted - with both Mounjaro and Zepbound sales ahead of consensus (+7% and +6% respectively). Broad based strength across diabetes and obesity overshadowed some slight concern around weakness in early trends for Foundayo sales ($184M vs SA $229.1M). Discussion around outlook also largely bullish, noting the FY revenue raise was the third of the year - with demand trends in obesity continuing to support upside. On the 10:00 call, focus likely to be on Foundayo's launch cadence and pricing trends, Incretin demand outlook and expectations around the 07-Dec R&D day. See Related StreetAccount comments: 10/29/2026 6:48:58 AM - Eli Lilly reports Q3 EPS $7.48 ex-items vs FactSet $5.68 [17 est, $4.65-7.27]	show story hide story
29-Oct-2026 08:52	INSM Insmed beats Q3 estimates on strong Brinsupri growth, raises product guidance ($96.98) INSM shares +16.5% premarket after reporting Q3 revenue ahead of FactSet expectations, including Brinsupri +29% q/q. Raised low-end of FY Brinsupri guidance and Arikayce guidance. Reiterated LT peak sales guidance for Brinsupri and other key products. Takeaways note that expectations for Brinsupri, which drove the beat and raise, had moderated ahead of the print, but results confirm that strong launch momentum remains intact. Commentary is also positive on Arikayce's commercial performance, though elevated R&D expenses tied to TPIP limited the earnings upside. Analysts seek additional details on Q3 new patient starts, which were not disclosed in the press release. See Related StreetAccount comments: 10/29/2026 7:09:32 AM - StreetAccount Metrics Recap - Insmed Q3 Earnings 10/29/2026 7:06:00 AM - Insmed reports Q3 EPS ($0.46) vs FactSet ($0.38) [23 est, ($0.84)-(0.09)]	show story hide story
29-Oct-2026 07:55	GKOS Glaukos surges on strong Q3 beat-and-raise, driven by Epioxa strength ($181.43) GKOS shares +15.8% premarket after reporting Q3 adjusted EPS of $0.47, with revenue ahead of expectations. Raised FY26 revenue guidance and guided to 28% topline growth in FY27. Strong Q3 results surpassed even elevated buy-side expectations, prompting several firms to materially raise price targets and alleviating concerns around Epioxa competition and potential iDose disruption from LCDs in 2027. The beat was primarily driven by Epioxa, which helped drive a positive inflection in profitability, with commentary broadly constructive on its growth trajectory. Despite the increased guidance, the outlook is viewed as attainable, with further upside potential and the company's pipeline remaining largely underappreciated. See Related StreetAccount comments: 10/28/2026 4:10:28 PM - Glaukos reports Q3 EPS $0.47 ex-items	show story hide story
29-Oct-2026 07:32	CMS finalizes CY2027 rule for ESRD Prospective Payment System (PPS); +2.7% increase vs +1.1% proposal (post-close 28-Oct) The Centers for Medicare & Medicaid Services (CMS) issued a final rule updating payment rates and policies under the end-stage renal disease (ESRD) Prospective Payment System (PPS) for renal dialysis services furnished to Medicare beneficiaries on or after January 1, 2027. For CY 2027, CMS will increase the ESRD PPS base rate to $297.52, which CMS expects will increase total payments to all ESRD facilities, both freestanding and hospital-based, by approximately +2.7%. StreetAccount notes the proposed increase in June was +1.1%. See Related StreetAccount comments: 6/25/2026 9:32:36 AM - Street Takeaways - CMS 2026 ESRD rate proposal; implications for FME.GR and DVA 6/25/2026 8:30:28 AM - CMS publishes rate proposal for end stage renal disease bundle payment (24-Jun, timing uncertain) Related: CDNA, DMAC, DVA, FMS Reference Link: Fact Sheet Reference Link: CMS-1846-F	show story hide story
28-Oct-2026 17:02	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished moderately higher and inline overall on Wednesday. Advancers beat decliners by more than 2:1 on the XLV, although breadth was far from midday highs. Healthcare +0.25% vs S&P 500 +0.28%. Most major health groups held onto gains for the session. Advancers were led by Biotech, MedTech and the Services groups. Value widely underperformed growth before and after the FOMC decision. Earnings calendar a primary driver of stock performance, report volume ramped overnight with large-cap prints all across the Healthcare sector. LH +8.8% and BSX (5.8%) bracketed the XLV from wire to wire on their respective prints (and outlooks). Boston Scientific delivered a penny beat in Q3 but topline was mixed, and the light Q4 guide is today's focus. CEO says expect trough year in 2027; return to growth in '28. ICLR +17.0% reported signs of bookings strength on a solid Q3 beat. GSK (4.3%) a Q3 beat-and-reaffirm unable to excite investors. BIIB (3.4%) reported core MS sales below consensus, but highlights include growth products in the Q3 beat-and-raise. Apart from earnings, AI trade attention turns back to drug development with Anthropic update in the field last night. LDD gains in several AI-focused biotech and LST names. Big headline in Biotech is the phase readout for GMAB +28.3% in head-and-neck cancer, combo with Keytruda besting the blockbuster alone, and bar raised for future challengers. Yesterday, Healthcare equities finished mixed to little changed overall. Major health groups ended widely split for the session, between the XBI +2.90% and Services ~(2%) on the average. Biopharma stocks broadly higher; payers and providers broadly lower. MedTech group was inline overall with the tape, though Diagnostics fared well and Devices dragged. Earnings calendar returned to play a role today, and Hospitals were the big outlier after HCA (3.3%) management offered up preliminary thoughts on 2027 on this morning's earnings call. Uninsured charges of $400M hit during Q3 and are expected to remain a headwind looking forward. Macro AI/momentum trade outperformance was the big story again today. Initial catalyst revolved around SKHY earnings, particularly in terms of extended demand visibility. Broader earnings calendar largely supportive of the fundamental AI narrative as well, though high bar dynamic influenced some of the price action. Additional support this afternoon from the ORCL analyst day update, where company guided for much stronger FCF in FY30, while also seemingly providing some reprieve on the capex/funding intensity front. AI trade outperformance accompanied by weaker breadth, as was the case on Tuesday. Fed left policy unchanged and Warsh did not provide any forward guidance, both of which were widely expected. Big backup in long-term rates/curve steepening today despite the lack of surprises from the Fed (and Warsh acknowledged financial conditions have tightened). Recent AI trade bounce (and related easing of growth worries) and oil among the possible drivers. When it comes to oil, there were more reports about a likely resumption of kinetic activities following the midterms, though diplomacy efforts remained in play. Hyperscaler earnings the key area of focus over the next couple of days. Market particularly focused on cloud revenue/backlog growth given capex and monetization debates. Notable Gainers +31.5% AXGN (AxoGen): earnings +29.3% KIDS (OrthoPediatrics): earnings +28.3% GMAB (Genmab): trial results with Peto. in HNSCC +23.2% PRME (Prime Medicine): best performer on XBI; follow-through, shares +46% WTD +23.1% REPL (Replimune Group): earnings +18.2% DNA (Ginkgo Bioworks Holdings): sympathy to Anthropic update on drug development +17.0% ICLR (ICON plc): earnings +16.4% GENB (Generate Biomedicines): Anthropic mentions research +15.8% BLCO (Bausch + Lomb): earnings +15.6% BEAM (Beam Therapeutics): follow-through, shares +20% WTD +15.5% SDGR (Schrödinger): sympathy to Anthropic update on drug development +15.5% PACB (Pacific Biosciences): sympathy to Anthropic update on drug development +12.7% NGNE (Neurogene): follow-through, shares +29% WTD +8.8% LH (Labcorp Holdings): earnings; best performer on XLV +8.5% TWST (Twist Bioscience): sympathy to Anthropic update on drug development +7.4% RXRX (Recursion Pharmaceuticals): sympathy to Anthropic update on drug development +7.2% TXG (10X Genomics): sympathy to Anthropic update on drug development +6.6% GEHC (GE HealthCare Technologies): earnings +6.2% TEM (Tempus AI): sympathy to Anthropic update on drug development +5.9% FTRE (Fortrea Holdings): sympathy to ICLR +5.3% CAI (Caris Life Sciences): sympathy to Anthropic update on drug development +4.8% GRAL (GRAIL, Inc.): sympathy to Anthropic update on drug development +4.8% CHE (Chemed): earnings; upgraded at Jefferies +4.2% CRL (Charles River Laboratories): sympathy to ICLR +3.5% CLOV (Clover Health): initiation +3.0% MRNA (Moderna): on below average volume; shares +7% WTD Notable Decliners -44.2% BCAX (Bicara Therapeutics, Inc.): sympathy to GMAB (HNSCC); worst performer on XBI -23.4% INBX (Inhibrx Biosciences): sympathy to GMAB (HNSCC) -18.3% RAPP (Rapport Therapeutics): secondary offering, priced -16.5% BBNX (Beta Bionics, Inc.): earnings -15.8% GERN (Geron): discontinues imetelstat in r/r MF -5.8% BSX (Boston Scientific): earnings; downgraded at JPMorgan; worst performer on XLV -4.3% GSK (GSK Plc): earnings -3.4% BIIB (Biogen): earnings; hit 52-week high (intraday) -2.9% UHS (Universal Health Services): earnings -2.6% AVTR (Avantor): earnings Genmab added nearly $8B on Head and Neck cancer readout Trading update (market close): GMAB +28.3%, CRBP +2.4%, MRK (0.7%), INBX (23.4%), BCAX (44.2%) Genmab ADRs added nearly $8B in market cap on today's readout. Company announced topline results from the global Phase 3 LiGeR-HN1 trial evaluating bispecific antibody petosemtamab in combo with Keytruda versus Merck's Keytruda alone in 1L metastatic head and neck squamous cell carcinoma (HNSCC). Small-cap biotech Bicara Therapeutics anticipates phase 3 interim analysis of BCA101 in HPV-negative patients by the middle of 2027; Inhibrx Biosciences' phase 2 results were presented at ESMO; Corbus Pharma's phase 1/2 readout in Q1 of 2027. Boston Scientific trades lower amid earnings call, CEO calls out trough year in 2027 Shares of BSX (9.0%) in the pre-market - but coming off worst levels ~(12%) - the majority of the pressure occurring minutes into today's Q3 earnings call after CEO delivered prepared remarks peppered with challenges - from EP and PFA market share declines, cybersecurity incident impacts, marketplace headwinds, and internally shifting strategies. WATCHMAN outlook maintained for Q4 - no improvement in the US y/y, continued deceleration, and with International similar to Q3 - resulting in flat to LSD decline w/w in Q4. Looking ahead, Mahoney said 2027 will be the trough in the cycle, but expects investments to over the next three years to support return to growth in 2028 and more for 2029. Earnings in Life Science & MedTech BSX reports Q3 EPS $0.73 ex-items vs FactSet $0.72 on revenue $5.14B vs FS $5.06B. Upside from Neuromod and Interventional Cardio; misses include Endo and EP. Guides Q4 EPS below consensus, a Q4 revenue decline vs consensus for growth. Lowers FY EPS outlook by $0.13 at the midpoints, and revenue growth lower by more than one point. Stock downgraded in reaction GEHC reports Q3 EPS $1.34 ex-items vs FactSet $1.20 on revenue $5.50B vs FS $5.35B. Raises FY outlook by $0.10 at the midpoints, and now expects organic revenue growth ~4% vs prior +3-4%. ICLR reports Q3 adj EPS $2.66 vs FactSet $2.62 on revenue $2.02B vs FS $2.01B, and adj EBITDA $336.9M vs FS $332.5M. Narrows FY EPS outlook, midpoint unchanged, raises FY revenue outlook by $150M at the midpoint. AVTR reports Q3 EPS $0.22 ex-items vs FactSet $0.21 on revenue $1.70B vs FS $1.64B. Raises low-end of FY EPS outlook by $0.01. Upgrades organic growth outlook by 100bps at the midpoints. Cooper Companies makes the CEO change COO announces that CEO Al White is stepping down effective immediately. The search for a permanent CEO is underway. Company also announced several concurrent Board changes, and reaffirmed FY26 guidance as provided on 9-Sep-2026. Earnings in Services & Hospitals LH reports Q3EPS $4.78 ex-items vs FactSet $4.64 on revenue $3.81B vs FS $3.76B. Organic growth +5.5% vs StreetAccount +3.7%. Raises FY EPS outlook by 17.5 cents, and raises FY revenue outlook by $65M, at the midpoints. ENSG reported Q3 $2.03 ex-items vs FactSet $1.97 on revenue $1.48B vs FS $1.51B, adj EBITDA $190.7M vs FS $186.2M. Raises FY26 EPS guidance by 18c at the midpoints, and revenue by $10M at the midpoints. UHS reported Q3 EPS $5.22 including items vs FactSet $5.19, on revenue $4.73B vs FS $4.71B, and adj EBITDA $640.4M vs StreetAccount $634.0M. CHE reported Q3 EPS $6.75 ex-items vs FactSet $6.44 on revenue $690.9M vs FS $685.0M, adj EBITDA $133.8M vs FS $130.9M. Now expects FY EPS 'at or slightly above the high-end of prior range'. Stock upgraded in reaction GSK lower on Q3 beat-and-reaffirm GSK reports Q3 core EPS 54.6p vs consensus 50.4p on revenue £8.89B vs consensus £8.84B. Reaffirmed FY outlook top to bottom. Recent acquisitions, growth products fuel Biogen Q3 and sales outlook BIIB reports Q3 EPS $2.62 ex-items vs FactSet $1.99 on revenue $2.80B vs FS $2.63B. MS franchise sales broadly missed, upside came from rare diseases, Syfovre and Zurzuvae. Raises low-end of FY EPS outlook by $0.20, citing ongoing business strength and Apellis dilution favorability. CEO comments on strength of growth portfolio, including from Apellis products. FDA publishes briefing materials ahead of Friday Adcom for RYJUNEA As previously announced, the FDA's DODAC will meet on Friday 30-Oct to review the NDA for atropine sulfate ophthalmic solution 0.01% (RYJUNEA), submitted by Sydnexis. Inc (0HJL1B-E). The proposed indication (use) is for slowing of myopia progression in children 3 years of age or older. (LGND recently acquired financial interest) Today, the FDA has published briefing materials for the meeting. DODAC will discuss four questions - no voting questions. Agency highlights statistical uncertainty caused by missing data, inconsistencies in the efficacy profile, and seeks panel input on whether the application meets standard for Substantial Evidence of Effectiveness. Notable research in Healthcare today Biotech: DYN downgraded to perform from outperform at Oppenheimer (Kostas Biliouris) LABT initiated buy at HC Wainwright (Matthew Keller), target is $3 or approx. 934% upside. SPRO initiated overweight at Cantor Fitzgerald (Kristen Kluska), target is $6 or approx. 426% upside. MedTech: BSX downgraded to neutral from overweight at JPMorgan (Robbie Marcus) MMSI initiated hold at Freedom Capital (Keith Hinton), target is $90 or approx. 4% downside. Services: CHE upgraded to buy from hold at Jefferies (Brian Tanquilut), follows Q3 print. Target increased to $620 from $520 or approx. 22% upside. Managed Care: ALHC initiated hold at Needham (Matthew Shea) CLOV initiated buy at Needham (Matthew Shea), target is $6 or approx. 30% upside. (FactSet average PT $5.50; range $5-6) Post-close news Earnings: ALGN reports Q3 EPS $2.80 ex-items vs FactSet $2.77 on revenue $1.02B vs FS $1.00B. Guides Q4 revenue below consensus, and FY aligner volume up LSD y/y. Also announced CEO succession plan, effective year-end 2026. Jennifer L. Davis joins from PG, where she was CEO of their Global Healthcare business. Conf. call at 16:30ET Shares trading (3.4%) in the after-hours GKOS reports Q3 EPS $0.47 ex-items, unclear if comparable to FactSet ($0.10), on revenue $211.0M vs FS $168.0M. Raises FY26 revenue guidance by $90M at the midpoints. Guides FY27 topline growth +28%, or an even $1.00B vs FS $852.4M. Conf. call at 16:30ET Shares trading +12.4% in the after-hours EHC reports Q3 adjusted EBITDA $346.6M vs FactSet $325.3M on revenue $1.61B vs FS $1.60B. Raises FY26 outlook top to bottom. Conf. call tomorrow at 10:00ET Shares trading (5.8%) in the after-hours CYH reports Q3 adj EBITDA $280M vs FactSet $319.3M, revenue $2.76B vs FS $2.80B. Lowers FY26 adj EBITDA outlook by $87.5M at the midpoints, lowers revenue by $100M at the midpoints; also reduced FY EPS (loss). Conf. call tomorrow at 11:00ET Shares trading (13.2%) in the after-hours Week Ahead (Sat - Sun) Oct 24 - Nov 1 Conference calendar (cont.): ESGCT Congress 2026 (Oct 27-30) Corporate calendar Wed 28-Oct: CHRS interim trial results with tagmokitug in solid tumors (16:30ET) Thu 29-Oct: XFOR Investor Day (10:00ET) EVAX trial results (10:30ET) Earnings calendar Wed 28-Oct: after EHC (call Thu at 10:00ET), ALGN (call at 16:30ET), GKOS (call at 16:30ET) Thu 29-Oct: before LLY(call at 10:00ET), MRK (call at 9:00ET), BMY (call at 8:00ET), ALNY (call at 8:30ET), WST (call at 8:00ET), INCY (call at 8:00ET), THC (call at 10:00ET), INSM (call at 8:00ET), BAX (call at 8:30ET), LGND (call at 8:30ET), INDV after GILD(call at 16:30ET), SYK (call at 16:30ET), ILMN (call at 16:30ET), RMD (call at 16:30ET), DXCM (call at 16:30ET), EXEL (call at 17:00ET), DVA (call at 17:00ET), MMSI (call at 16:30ET) Fri 30-Oct: before ABBV(call at 9:00ET), AZN (call at 10:30ET), SNY (call at 8:30ET), REGN (call at 8:30ET), BTSG (call at 8:30ET) Syndicate calendar / potential IPO pricing Thu 29-Oct (post-market): +ASPE Aspen Neuroscience - S-1/A - stem-cell therapies for Parkinson's +BBTX Bambusa Therapeutics - S-1A - bispecific mAbs for I&I diseases (BNTX, Adimab) Regulatory calendar Fri 30-Oct: FDA Adcom: Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to review Sydnexis' (private) NDA for atropine sulfate for slowing myopia progression in children 3 years and older. (8:30-15:00ET) (LGND) FDA PDUFA for Inovio (INO) BLA for INO-3107 in recurrent respiratory papillomatosis (RRP) Sun 1-Nov: FDA PDUFA for Agio Pharma (AGIO) sNDA for PYRUKYND in sickle cell disease StreetAccount Healthcare Reads The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion ... Not the Finish Line (28-Oct) fdalawblog FDA scientists opposed the Trump administration's effort to ease peptides access (28-Oct) AP Senate candidate El-Sayed wants to 'grill' RFK Jr., calls him the 'most incompetent HHS secretary ever' (28-Oct) STAT News Ebola Sequencing Links Kenya, Nigeria Cases to Congo Chain (28-Oct) Bloomberg CDC's deputy director to leave Trump administration after brief stint (27-Oct) WaPo Healthcare Stocks Become Anti-AI Bet as Investors Turn Defensive (27-Oct) Bloomberg Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own (27-Oct) STAT News Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94% (27-Oct) Reuters Moderna CEO on what's next after success in cancer vaccine (26-Oct) STAT News Obesity drug developer Corxel to go public via SPAC deal (26-Oct) Reuters The Cost of Healthcare Is Hitting America Where It Hurts: The Wallet (26-Oct) KFF Health News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALGN, ALHC, AVTR, AXGN, BBNX, BCAX, BEAM, BIIB, BLCO, BSX, CAI, CHE, CLOV, COO, CRBP, CRL, CYH, DNA, DYN, EHC, ENSG, FTRE, GEHC, GENB, GERN, GKOS, GMAB, GRAL, GSK, ICLR, INBX, KIDS, LABT, LGND, LH, MMSI, MRK, MRNA, NGNE, PACB, PG, PRME, RAPP, REPL, RXRX, SDGR, SPRO, TEM, TWST, TXG, UHS...(more)	show story hide story
28-Oct-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Health Index +0.98% vs the S&P 500 +0.08%. All major health groups are higher on the session, led by MedTech, Services and Biotech groups, but mostly growth is outperforming value. Earnings calendar ramped overnight with large-cap reports in most corners of the Health sector. LH +10% and BSX (7%) bracket the XLV on their respective prints (and outlook). Boston Scientific delivered a penny beat in Q3 but topline was mixed, and the light Q4 guide is today's focus. CEO says expect trough year in 2027; return to growth in '28. ICLR +13% reported signs of bookings strength on a solid Q3 beat. GSK (3%) a Q3 beat-and-reaffirm unable to excite investors. BIIB +2% reported core MS sales below consensus, but highlights include growth products in the Q3 beat-and-raise. Apart from earnings, AI trade attention turns back to drug development with Anthropic update in the field last night. LDD gains in several AI-focused biotech and LST names. Gainers +24.6% AXGN (AxoGen): earnings +22.1% GMAB (Genmab): trial results with Peto. in HNSCC +14.5% DNA (Ginkgo Bioworks Holdings): sympathy to Anthropic update on drug development +13.9% PRME (Prime Medicine): best performer on XBI; follow-through, shares +34% WTD +13.6% SDGR (Schrödinger): sympathy to Anthropic update on drug development +12.9% GENB (Generate Biomedicines): Anthropic mentions research +12.8% ICLR (ICON plc): earnings +10.0% TXG (10X Genomics): sympathy to Anthropic update on drug development +10.0% LH (Labcorp Holdings): earnings; best performer on XLV +9.1% CHE (Chemed): earnings; upgraded at Jefferies +8.7% TWST (Twist Bioscience): sympathy to Anthropic update on drug development +7.8% GEHC (GE HealthCare Technologies): earnings +7.5% BLCO (Bausch + Lomb): earnings +7.1% RXRX (Recursion Pharmaceuticals): sympathy to Anthropic update on drug development +3.9% CLOV (Clover Health): initiation +3.8% MRNA (Moderna): on average volume; shares +8% WTD +2.1% UHS (Universal Health Services): earnings +2.0% BIIB (Biogen): earnings +1.2% ALHC (Alignment Healthcare): initiation Decliners -38.5% BCAX (Bicara Therapeutics, Inc.): sympathy to GMAB; worst performer on XBI -19.7% GERN (Geron): discontinues imetelstat in r/r MF -18.6% RAPP (Rapport Therapeutics): secondary offering, priced -7.8% BSX (Boston Scientific): earnings; worst performer on XLV -3.4% GSK (GSK Plc): earnings -2.5% AVTR (Avantor): earnings -0.5% DYN (Dyne Therapeutics): downgraded at Oppenheimer	show story hide story
28-Oct-2026 11:02	Genmab higher on head and neck cancer readout; investor call at 12:00ET Trading update (intraday): GMAB +24.6%, MRK +0.1%, BCAX (40.5%) Genmab ADRs adding nearly $7B in market cap on today's readout. Company will be hosting an investor update call at 12:00ET today to discuss topline results from the global Phase 3 LiGeR-HN1 trial evaluating bispecific antibody petosemtamab in combo with Keytruda versus Keytruda alone in 1L metastatic head and neck squamous cell carcinoma (HNSCC). Small-cap biotech Bicara Therapeutics anticipates phase 3 interim analysis of BCA101 in HPV-negative patients by the middle of next year. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. See Related StreetAccount comments: 10/28/2026 9:42:06 AM - Genmab announces statistically significant, clinically meaningful improvement in overall survival and objective response with Petosemtamab combination at first interim analysis in first-line R/M patients with PD-L1+ head and neck cancer Related: BCAX, GMAB, MRK	show story hide story
28-Oct-2026 09:25	FDA publishes briefing materials ahead of Friday Adcom for RYJUNEA As previously announced, the FDA's DODAC will meet on Friday 30-Oct to review the NDA for atropine sulfate ophthalmic solution 0.01% (RYJUNEA), submitted by Sydnexis. Inc (0HJL1B-E). The proposed indication (use) is for slowing of myopia progression in children 3 years of age or older. Today, the FDA has published briefing materials for the meeting. Excerpts: While the primary endpoint was met for 0.01% atropine, the result is statistically borderline, and its interpretation depends critically on the validity of the assumptions underlying the primary analysis. A key assumption concerns the handling of missing data. Beyond the statistical uncertainty caused by missing data, the clinical review identified several inconsistencies in the efficacy profile that complicate the assessment of substantial evidence of effectiveness. The agency seeks the committee's input on whether the current application meets this standard [Substantial Evidence of Effectiveness (SEE)], given that Study SYD-101-001 is not highly persuasive on its own and the relevant literature for the US population does not provide robust confirmatory evidence. Questions for the panel - four discussion questions, no voting questions 1. DISCUSSION: The robustness of the primary efficacy results from Study SYD-101-001, considering the borderline statistical significance and the impact of missing data on the reliability of the findings. 2. DISCUSSION: The clinical meaningfulness of the observed efficacy profile, taking into account the magnitude of the treatment effect on spherical equivalent, the declining treatment trajectory over time, and the lack of a significant effect on axial length. 3. DISCUSSION: How the descriptive and exploratory subgroup analyses (e.g., children aged 3 to ≤12 years and fast progressors) contribute to a determination of effectiveness. 4. DISCUSSION: Whether the published literature provides sufficient corroboration to satisfy the substantial evidence standard for approval. See Related StreetAccount comments: 9/24/2026 8:54:58 AM - FDA panel to meet on 30-Oct to review NDA for RYJUNEA / SYD-101 9/22/2026 7:03:32 AM - Ligand Pharmaceuticals acquires royalty and milestone interest in Santen's Ryjunea from Sydnexis for $23M 7/13/2026 9:24:50 AM - Sydnexis (private) announces FDA Adcom to review NDA for SYD-101; date to be determined Related: 4536.JP, LGND, 0HJL1B-E Reference Link: FDA briefing document	show story hide story
28-Oct-2026 09:08	BSX Boston Scientific trades lower amid earnings call, CEO calls out trough year in 2027 Shares of BSX (9.0%) in the pre-market - but coming off worst levels ~(12%) - the majority of the pressure occurring minutes into today's Q3 earnings call after CEO delivered prepared remarks peppered with challenges - from EP and PFA market share declines, cybersecurity incident impacts, marketplace headwinds, and internally shifting strategies. WATCHMAN outlook maintained for Q4 - no improvement in the US y/y, continued deceleration, and with International similar to Q3 - resulting in flat to LSD decline w/w in Q4. Looking ahead, Mahoney said 2027 will be the trough in the cycle, but expects investments to over the next three years to support return to growth in 2028 and more for 2029. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
28-Oct-2026 08:37	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar ramped overnight with large-cap reports in most corners of the Health sector. Boston Scientific delivered a penny beat in Q3 but topline was mixed, and the light Q4 guide is today's focus. Shares of BSX (13%) in the pre-market. ICON Plc reported signs of bookings strength on a solid Q3 beat. Shares of ICLR +7% in the pre-market. GSK a Q3 beat-and-reaffirm; ADRs are down (5%) in the pre-market. Biogen reported core MS sales below consensus, but highlights include growth products in the Q3 beat-and-raise. Shares of BIIB +1% in the pre-market. Additionally, Cooper Companies reported a CEO change, not unexpected following the recent outcome of strategic review and shares (27%) YTD. Shares of COO little changed early. Yesterday, Healthcare equities finished mixed to little changed overall. Major health groups ended widely split for the session, between the XBI +2.90% and Services ~(2%) on the average. Biopharma stocks broadly higher; payers and providers broadly lower. MedTech group was inline overall with the tape, though Diagnostics fared well and Devices dragged. Earnings calendar returned to play a role today, and Hospitals were the big outlier after HCA (3.3%) management offered up preliminary thoughts on 2027 on this morning's earnings call. Uninsured charges of $400M hit during Q3 and are expected to remain a headwind looking forward. Macro S&P futures are up +0.15% on Wednesday morning. AI trade outperforming again with a heightened focus on the favorable fundamental backdrop highlighted by earnings. SKHY in focus following a big beat and comments about LTAs with 14 major customers covering 50%+ of its production capacity for 2027 and 2028, along with expectations for memory demand to outpace supply through 2030 (and $75B capital return). While AI earnings read-throughs were upbeat elsewhere in tech, some focus on a high bar. Renewed divergence between AI trade and breadth another area of scrutiny. Oil strength the other big story today with report White House has told Gulf allies to prepare for a possible short-but-intense military campaign against Iran after the midterms. However, this has already been the consensus view (and oil has repriced for kinetic risk in recent weeks). FOMC meeting this afternoon increasingly framed as a likely non-event for stocks, while market much more interested in earnings from MSFT and GOOGL after the close (and AMZN the next day). Cloud revenue/backlog growth the key area of focus amid the myriad moving pieces surrounding capex and monetization dynamics. Pre-market trading update Trading higher +14.8% AXGN earnings +8.6% GEHC earnings +7.1% ICLR earnings +3.8% GENB Anthropic mentions research +3.8% CHE earnings; upgraded at Jefferies +3.7% BLCO earnings +1.9% ALHC initiation +1.9% CLOV initiation +1.1% BIIB earnings Trading lower -23.4% RAPP secondary offering, priced -12.9% BSX earnings -5.8% UHS earnings -5.4% GSK earnings -3.5% DYN downgraded at Oppenheimer -3.4% AVTR earnings -2.0% TEVA on 40K ADRs -1.7% MRNA on 142K shares Pharma Earnings: GSK reports Q3 core EPS 54.6p vs consensus 50.4p on revenue £8.89B vs consensus £8.84B. Reaffirmed FY outlook top to bottom. Conf. call at 8:00ET Biotech Earnings: BIIB reports Q3 EPS $2.62 ex-items vs FactSet $1.99 on revenue $2.80B vs FS $2.63B. MS franchise sales broadly missed, upside came from rare diseases, Syfovre and Zurzuvae. Raises low-end of FY EPS outlook by $0.20, citing ongoing business strength and Apellis dilution favorability. CEO comments on strength of growth portfolio, including from Apellis products. Conf. call at 8:30ET Research: DYN downgraded to perform from outperform at Oppenheimer (Kostas Biliouris) LABT initiated buy at HC Wainwright (Matthew Keller), target is $3 or approx. 934% upside. SPRO initiated overweight at Cantor Fitzgerald (Kristen Kluska), target is $6 or approx. 426% upside. Life Science & MedTech Corporate: COO announces that CEO Al White is stepping down effective immediately. The search for a permanent CEO is underway. Company also announced several concurrent Board changes, and reaffirmed FY26 guidance as provided on 9-Sep-2026. Earnings: BSX reports Q3 EPS $0.73 ex-items vs FactSet $0.72 on revenue $5.14B vs FS $5.06B. Upside from Neuromod and Interventional Cardio; misses include Endo and EP. Guides Q4 EPS below consensus, a Q4 revenue decline vs consensus for growth. Lowers FY EPS outlook by $0.13 at the midpoints, and revenue growth lower by more than one point. Conf. call at 8:00ET GEHC reports Q3 EPS $1.34 ex-items vs FactSet $1.20 on revenue $5.50B vs FS $5.35B. Raises FY outlook by $0.10 at the midpoints, and now expects organic revenue growth ~4% vs prior +3-4%. Conf. call at 8:30ET ICLR reports Q3 adj EPS $2.66 vs FactSet $2.62 on revenue $2.02B vs FS $2.01B, and adj EBITDA $336.9M vs FS $332.5M. Narrows FY EPS outlook, midpoint unchanged, raises FY revenue outlook by $150M at the midpoint. Conf. call at 8:00ET AVTR reports Q3 EPS $0.22 ex-items vs FactSet $0.21 on revenue $1.70B vs FS $1.64B. Raises low-end of FY EPS outlook by $0.01. Upgrades organic growth outlook by 100bps at the midpoints. Conf. call at 8:00ET Research: MMSI initiated hold at Freedom Capital (Keith Hinton), target is $90 or approx. 4% downside. Services & Hospitals Earnings: LH reports Q3EPS $4.78 ex-items vs FactSet $4.64 on revenue $3.81B vs FS $3.76B. Organic growth +5.5% vs StreetAccount +3.7%. Raises FY EPS outlook by 17.5 cents, and raises FY revenue outlook by $65M, at the midpoints. Conf. call at 8:00ET ENSG reported Q3 $2.03 ex-items vs FactSet $1.97 on revenue $1.48B vs FS $1.51B, adj EBITDA $190.7M vs FS $186.2M. Raises FY26 EPS guidance by 18c at the midpoints, and revenue by $10M at the midpoints. Conf. call at 13:00ET UHS reported Q3 EPS $5.22 including items vs FactSet $5.19, on revenue $4.73B vs FS $4.71B, and adj EBITDA $640.4M vs StreetAccount $634.0M. Conf. call at 8:00ET CHE reported Q3 EPS $6.75 ex-items vs FactSet $6.44 on revenue $690.9M vs FS $685.0M, adj EBITDA $133.8M vs FS $130.9M. Now expects FY EPS 'at or slightly above the high-end of prior range'. Stock upgraded in reaction Conf. call at 10:00ET Research: CHE upgraded to buy from hold at Jefferies (Brian Tanquilut), follows Q3 print. Target increased to $620 from $520 or approx. 22% upside. Managed Care Research: ALHC initiated hold at Needham (Matthew Shea) CLOV initiated buy at Needham (Matthew Shea), target is $6 or approx. 30% upside. (FactSet average PT $5.50; range $5-6) On Deck: Conference (cont.): ESGCT Congress 2026 (Oct 27-30) Corporate CHRS interim trial results with tagmokitug in solid tumors (16:30ET) on Thu 29-Oct: XFOR Investor Day (10:00ET), EVAX trial results (10:30ET) Earnings after the close today EHC (call Thu at 10:00ET), ALGN (call at 16:30ET), GKOS (call at 16:30ET) Earnings on Thu 29-Oct: before LLY (call at 10:00ET), MRK (call at 9:00ET), BMY (call at 8:00ET), ALNY (call at 8:30ET), WST (call at 8:00ET), INCY (call at 8:00ET), THC (call at 10:00ET), INSM (call at 8:00ET), BAX (call at 8:30ET), LGND (call at 8:30ET), INDV after GILD (call at 16:30ET), SYK (call at 16:30ET), ILMN (call at 16:30ET), RMD (call at 16:30ET), DXCM (call at 16:30ET), EXEL (call at 17:00ET), DVA (call at 17:00ET), MMSI (call at 16:30ET) Syndicate calendar / potential IPO pricing Thu 29-Oct (post-market): +ASPE Aspen Neuroscience - S-1/A - stem-cell therapies for Parkinson's +BBTX Bambusa Therapeutics - S-1A - bispecific mAbs for I&I diseases (BNTX, Adimab) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALGN, ALHC, ALNY, AVTR, AXGN, BAX, BIIB, BLCO, BMY, BNTX, BSX, CHE, CHRS, CLOV, COO, DVA, DXCM, DYN, EHC, ENSG, EVAX, EXEL, GEHC, GENB, GILD, GKOS, GSK, ICLR, ILMN, INCY, INDV, INSM, LABT, LGND, LH, LLY, MMSI, MRK, MRNA, RAPP, RMD, SPRO, SYK, TEVA, THC, UHS, WST, XFOR, +ASPE, +BBTX...(more)	show story hide story
27-Oct-2026 19:52	Anthropic provides update on drug development, life sciences team, and the acquisition of Mithril Medicine Anthropic: ... we've begun to run some research programs ourselves. We've acquired Mithril Medicine, a one-person company that has been developing treatments for two rare forms of muscular dystrophy. Its founder, Cody Tranbarger, used Claude to organize contracts, logistics, and experiments with 11 external labs, and delegated many other aspects of Mithril's operations to Claude. As a result, Mithril took a possible treatment for one form of muscular dystrophy from an idea to promising results in mice in less than 18 months. Now at Anthropic, Cody is continuing this research, and plans to start several new programs. If his drug candidates continue to hold up, we expect a drug to be ready to start clinical trials in humans as soon as late 2028. Read more and see our technical report (linked below) StreetAccount notes that Tranbarger today revealed his identity as @Prof_Oak_ on X.com (see reference link below) Editor's Note: This comment was revised to include distribution for GENB which was also mentioned and is trading +4.1% in the pre-market (28-Oct-2026, 08:16 ET) Reference Link: Press release See Related StreetAccount comments: 4/18/2023 10:32:56 PM - "CARTITUDE-4 details released in EHA abstracts. HR of 0.26, ahead of expectations and well ahead of 0.49 HR in KarMMa-3 (not perfectly comparable) CARVYKTI remains one hell of a drug $LEGN $TSVT" - Tweet by @Prof_Oak_ Related: GENB, +ANT Reference Link: Reveal post by @Prof_Oak_ Reference Link: Technical report	show story hide story
27-Oct-2026 17:18	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to little changed overall on Tuesday. Decliners outnumbered the advancers on the XLV. Healthcare (0.04%) vs S&P 500 +0.60%. Major health groups ended widely split for the session, between the XBI +2.90% and Services ~(2%) on the average. Biopharma stocks broadly higher; payers and providers broadly lower. MedTech group was inline overall with the tape, though Diagnostics fared well and Devices dragged. MRNA +4.6%, which caught a bid despite early pressure for the first downgrade post-ESMO, and UHS (4.5%) bracketed the XLV. Earnings calendar returned to play a role today, and Hospitals were the big outlier after HCA (3.3%) management offered up preliminary thoughts on 2027 on this morning's earnings call. Uninsured charges of $400M hit during Q3 and are expected to remain a headwind looking forward. CNC +1.0% following today's Q3 print, a beat-and-raise with MLR 20bps better than consensus, and outlier among MCOs today. MOH (2.6%) lead the rest of the payers into the red. Moderna hit with first downgrade since the ESMO data leak, presentation, and ongoing debate over the valuation with stock +605% YTD. William Blair to the sidelines awaiting next tumor readouts. Yesterday, Healthcare equities finished mixed to essentially flat overall. After a busy weekend of ESMO presentations, even the higher profile biopharma stocks were little changed on Monday. Most major health groups ended with modest gains for the session. One small subgroup of outperformance, the providers traded higher early only on the back of SGRY +47%, acquired by HealthSpan Partners for transaction value around $5.7B. Macro Another day of outperformance for the AI trade. More positive recent sentiment has been attributed to removal of some high-profile funding overhangs and renewed focus on the strong compute/capex demand narrative (expected to be a feature of this week's hyperscaler earnings). Also some support from today's AI-related earnings reporters and positive takes on ORCL announcements. Nothing really new in terms of the high-profile themes out of the latest flurry of earnings (AI infrastructure/data center/non-res demand, pricing power, input price pressures, pricing/cost-savings/productivity offsets, resilient but bifurcated consumer, solid freight backdrop, limited spillover from higher rates). Some help from lower oil amid hopes for ongoing diplomacy, though no real incremental development and still concerns about a near-term return to kinetic activity. Latest consumer confidence report also supportive, featuring improved labor-market perceptions. Big event tomorrow is the October FOMC meeting, expected to leave rates on hold and offer little guidance for December. Notable Gainers +22.2% KNSA (Kiniksa Pharmaceuticals): earnings +20.5% PRME (Prime Medicine): on 2X average volume; best performer on XBI +13.5% FTH (Faeth Therapeutics): presentations at ESMO +12.1% QURE (uniQure NV): on light volume +11.9% ABSI (Absci Corp.): on above average volume +10.5% IBRX (ImmunityBio): on light volume; shares were (5%) yesterday +10.1% TWST (Twist Bioscience): on light volume +8.6% CLYM (Climb Bio): on 3X average volume; shares were (14%) yesterday +7.6% GRAL (GRAIL, Inc.): on heavy volume +7.5% WVE (Wave Life Sciences): earnings +7.4% TEM (Tempus AI): on light volume +6.9% TXG (10X Genomics): on light volume +6.0% VERA (Vera Therapeutics): on light volume +5.8% IOVA (Iovance Biotherapeutics): on light volume +5.3% ELVN (Enliven Therapeutics): on 2X average volume +4.6% MRNA (Moderna): best performer on XLV; on average volume; despite downgrade at William Blair +4.4% TRAX (First Tracks Biotherapeutics Inc): on light volume; in sympathy to ARGX +4.3% VCYT (Veracyte): on above average volume +3.1% ILMN (Illumina): on light volume; second-best on XLV Notable Decliners -30.7% ARTV (Artiva Biotherapeutics): grade 5 neurotoxicity, discontinues AlloNK, RIF, strategic alternatives; downgrades -9.0% EYE (National Vision Holdings): on heavy volume -4.8% SPRY (ARS Pharmaceuticals): worst performer on XBI -4.6% ACHC (Acadia Healthcare): sympathy to HCA -4.5% UHS (Universal Health Services): sympathy to HCA; worst performer on XLV -3.4% ZTS (Zoetis): on light volume -3.3% SOLV (Solventum Corp.): on heavy volume -3.3% HCA (HCA Healthcare): earnings; preliminary comments on 2027 -3.1% ZLAB (ZAI Lab): on heavy volume -2.9% ARDT (Ardent Health): sympathy to HCA -2.6% MOH (Molina Healthcare): sympathy to CNC -2.6% THC (Tenet Healthcare): sympathy to HCA -2.4% RGEN (Repligen Corp.): earnings Post-close news Corporate: COO announces that CEO Al White is stepping down effective immediately. The search for a permanent CEO is underway. Company also announced several concurrent Board changes, and reaffirmed FY26 guidance as provided on 9-Sep-2026. Shares trading +0.2% in the after-hours Earnings: ICLR reports Q3 adj EPS $2.66 vs FactSet $2.62 on revenue $2.02B vs FS $2.01B, and adj EBITDA $336.9M vs FS $332.5M. Narrows FY EPS outlook, midpoint unchanged, raises FY revenue outlook by $150M at the midpoint. Conf. call tomorrow at 8:00ET Shares trading +6.5% in the after-hours ENSG reports Q3 $2.03 ex-items vs FactSet $1.97 on revenue $1.48B vs FS $1.51B, adj EBITDA $190.7M vs FS $186.2M. Raises FY26 EPS guidance by 18c at the midpoints, and revenue by $10M at the midpoints. Conf. call tomorrow at 13:00ET Shares trading +5.2% in the after-hours UHS reports Q3 EPS $5.22 including items vs FactSet $5.19, on revenue $4.73B vs FS $4.71B, and adj EBITDA $640.4M vs StreetAccount $634.0M. Conf. call tomorrow at 8:00ET Shares trading (4.9%) in the after-hours CHE reports Q3 EPS $6.75 ex-items vs FactSet $6.44 on revenue $690.9M vs FS $685.0M, adj EBITDA $133.8M vs FS $130.9M. Now expects FY EPS 'at or slightly above the high-end of prior range'. Conf. call tomorrow at 10:00ET Shares trading (1.3%) in the after-hours Hospitals sharply lower following preliminary view on 2027 from HCA Trading update with XLV (0.14%): UHS (5.4%), HCA (4.6%), THC (3.3%), ARDT (3.3%) Stocks took a steep drop just minutes into the HCA prepared remarks, when CEO Sam Hazen offered his preliminary view on 2027, full guidance will be given in January. HCA expects earnings to be 'generally consistent' with 2026 -- FactSet consensus for 2027 EPS implies +8.8% growth next year - before growth returns to performance more inline with LT targets. HCA initially higher on Q3 beat, improved FY outlook; call upcoming HCA reports Q3 adj EBITDA $3.92B vs FactSet $3.73B on revenue $19.85B vs FS $19.33B. Q3 admissions metrics well ahead of consensus. For FY guidance now expects results will be in the upper half of its prior guide (mid-July). Quick Take: Results were better than feared, with most anticipating an SDP-driven beat, but underlying business performance also seen as improving, with strong volume growth, disciplined cost management, and a favorable demand backdrop cited as key contributors. However, surgical volumes remain a soft spot, with lower case volumes attributed primarily to ACA coverage losses and softer elective demand. Conf. call at 10:00ET Centene higher on solid Q3 print; 2027 uncertainty remains CNC reports Q3 EPS $0.58 ex-items vs FactSet $0.10 on revenue $50.65B vs FS $47.12B. MLR 20bp better than StreetAccount consensus, 92.7% vs 92.9%. Raises FY EPS guide to greater than $5.20 vs prior greater than $4.80. FY MLR guide down 15bps at the midpoints. Quick Take: Results are viewed as solid, though uncertainty around 2027 policy remains a concern, with raised guidance still implying Q4 EPS below consensus. Q3 upside is primarily attributed to strong topline growth and cost controls, alongside Medicare outperformance. Key questions for the call include Q3 Medicaid rate and cost trends, the Jan. 1, 2027 rate outlook, acuity shifts, Marketplace trajectory, Part D performance drivers, and 2027 growth and margin expectations. IQVIA Holdings higher on Q3 beat-and-raise IQV reports Q3 EPS $3.34 ex-items vs FactSet $3.26 on revenue $4.43B vs FS $4.37B, adj EBITDA $1.03B vs FS $1.01B. Book to bill ratio 1.2x vs StreetAccount 1.17x. Raises bottom-end of FY EPS guidance by $0.10, midpoint by $0.05. Eli Lilly trades higher following court ruling against Novo LLY Reuters reported on Monday that court ruled for Eli Lilly in suit brought by Novo (NVO) over obesity drug ads. Novo filed suit in July arguing that Lilly ads were false and materially misleading. Novartis higher on Q3 beat, with topline mixed NOVN.SW (NVS) reports Q3 core EPS $2.46 vs consensus $2.29 on revenue $14.52B vs FactSet $14.45B. Raised FY guidance for core operating income, with growth LSD vs prior decline LSD. Quick take: Beat driven primarily by operational efficiency gains rather than top-line outperformance; strength in Cosentyx, Ilaris, and Zolgensma offsetting weakness in Pluvicto and Scemblix. Analysts also flagged that the company raised its FY26 core operating profit guidance implying approx 2-3% upside to consensus, supported by notably lower SG&A and R&D costs. Additionally, analysts point out that key pipeline catalysts remain on track, including remibrutinib HS Phase 3 readout expected before year-end and Leqvio ORION-4 now expected in Q4. Repligen lower on Q3 beat-and-raise RGEN reports Q3 EPS $0.53 ex-items vs FactSet $0.46 on revenue $209.3M vs FS $206.7M. Raises low-end of FY EPS outlook by $0.02, midpoint by $0.01. Raises FY revenue outlook by $24M at the midpoints, narrows organic growth outlook to +12-13% vs prior +10.5-13.5%. RadNet higher following acquisition of ONRAD RDNT announced the acquisition of ONRAD Inc in a cash and stock deal. Acquisition expected to add $190-200M in revenue, $60-65M adj EBITDA, in the its first full year. Radnet will pay $350M in cash plus 5M shares, and earnout up to $210M. Aclaris Therapeutics lower on proof-of-concept, secondary offering ACRS announced primary analysis results from the phase 1b POC trials of ATI-052 in atopic dermatitis and asthma. Both trials demonstrated strong proof-of-concept with rapid and broad responses. Company prioritize phase 2B development in Eosinophilic Esophagitis (EoE) - with additional indications disclosed near-term. Company also announced $50M secondary offering, priced. Notable research in Healthcare today Biotech: MRNA downgraded to market perform from outperform at William Blair (Myles Minter) ARTV downgraded to hold from buy at TD Cowen (Tyler Van Buren). Follows clinical discontinuation and announced strategic alternatives. ARTV downgraded to hold from buy at Needham (Gil Blum). Follows discontinuation of AlloNK. ARTV downgraded to neutral from outperform at Wedbush Securities (Martin Fan), target cut to $4 from $40 or approx. 2% downside. (FactSet average PT $36; range $23-41) ARTV maintained overweight at Cantor Fitzgerald (Josh Schimmer), removes price target. Firm is not giving up on rest of the CAR-T field. DNTH initiated buy at Roth Capital (Adam Walsh), target is $113 or approx. 42% upside. PYPD initiated outperform at Oppenheimer (Les Sulewski), target is $10 or approx. 89% upside. MedTech: ABT downgraded to hold from buy at Argus Research. DRIO initiated buy at BTIG (David Larsen), target is $6 or approx. 76% upside. HYPR initiated buy at Lucid Capital Markets (Alex Nowak), target is $2 or approx. 178% upside. On Deck: Conference (cont.): ESGCT Congress 2026 (Oct 27-30) Corporate CHRS interim trial results with tagmokitug in solid tumors (16:30ET) on Thu 29-Oct: XFOR Investor Day (10:00ET); EVAX trial results (10:30ET) Earnings tomorrow: before GSK (call at 8:00ET), BSX (call at 8:00ET), BIIB (call at 8:30ET), GEHC (call at 8:30ET), LH (call at 9:00ET), AVTR (call at 8:00ET), BLCO (call at 8:00ET) after EHC (call Thu at 10:00ET), ALGN (call at 16:30ET), GKOS (call at 16:30ET) Earnings on Thu 29-Oct: before LLY (call at 10:00ET), MRK (call at 9:00ET), BMY (call at 8:00ET), ALNY (call at 8:30ET), WST (call at 8:00ET), INCY (call at 8:00ET), THC (call at 10:00ET), INSM (call at 8:00ET), BAX (call at 8:30ET), LGND (call at 8:30ET), INDV after GILD (call at 16:30ET), SYK (call at 16:30ET), ILMN (call at 16:30ET), RMD (call at 16:30ET), DXCM (call at 16:30ET), EXEL (call at 17:00ET), DVA (call at 17:00ET), MMSI (call at 16:30ET) Earnings on Fri 30-Oct: before ABBV (call at 9:00ET), AZN (call at 10:30ET), SNY (call at 8:30ET), REGN (call at 8:30ET), BTSG (call at 8:30ET) Syndicate calendar / potential IPO pricing on Thu 29-Oct (post-market): +ASPE Aspen Neuroscience - S-1/A - stem-cell therapies for Parkinson's +BBTX Bambusa Therapeutics - S-1A - bispecific mAbs for I&I diseases (BNTX, Adimab) StreetAccount Healthcare Reads CDC's deputy director to leave Trump administration after brief stint (27-Oct) WaPo Healthcare Stocks Become Anti-AI Bet as Investors Turn Defensive (27-Oct) Bloomberg Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own (27-Oct) STAT News Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94% (27-Oct) Reuters Moderna CEO on what's next after success in cancer vaccine (26-Oct) STAT News Obesity drug developer Corxel to go public via SPAC deal (26-Oct) Reuters The Cost of Healthcare Is Hitting America Where It Hurts: The Wallet (26-Oct) KFF Health News ADA Admits Mistakes and Issues a Partial Apology (24-Oct) ConscienHealth This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ABSI, ABT, ACHC, ACRS, ALGN, ALNY, ARDT, ARTV, AVTR, AZN, BAX, BIIB, BLCO, BMY, BNTX, BSX, BTSG, CHE, CHRS, CLYM, CNC, COO, DNTH, DRIO, DVA, DXCM, EHC, ELVN, ENSG, EVAX, EXEL, EYE, FTH, GEHC, GILD, GKOS, GRAL, GSK, HCA, HYPR, IBRX, ICLR, ILMN, INCY, INDV, INSM, IOVA, IQV, KNSA, LGND, LH, LLY, MMSI, MOH, MRK, MRNA, NOVN.SW, NVO, PRME, PYPD, QURE, RDNT, REGN, RGEN, RMD, SNY, SOLV, SPRY, SYK, TEM, THC, TRAX, TWST, TXG, UHS, VCYT, VERA, WST, WVE, XFOR, ZLAB, ZTS, +ASPE, +BBTX...(more)	show story hide story
27-Oct-2026 11:03	Hospitals sharply lower following preliminary view on 2027 from HCA Trading update with XLV (0.14%): UHS (5.4%), HCA (4.6%), THC (3.3%), ARDT (3.3%) Stocks took a steep drop just minutes into the HCA prepared remarks, when CEO Sam Hazen offered his preliminary view on 2027, full guidance will be given in January. HCA expects earnings to be 'generally consistent' with 2026 -- FactSet consensus for 2027 EPS implies +8.8% growth next year - before growth returns to performance more inline with LT targets. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ARDT, HCA, THC, UHS	show story hide story
27-Oct-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index +0.02% vs the S&P 500 +0.51%. Most major health groups have found positive territory for the session after red open. Hospitals the outlier after preliminary thoughts on 2027 from HCA management. Earnings call ongoing. HCA (5%) and peers fell similarly. CNC +5% and UHS (5%) bracket the XLV. Former up on today's Q3 print, a beat-and-raise with MLR 20bps better than consensus; payers performing well on the HCA commentary too. Rest of todays earnings movers are quite modest. MRNA (3%) saw the first downgrade hit following ESMO. Gainers +19.1% KNSA (Kiniksa Pharmaceuticals): earnings +9.5% FTH (Faeth Therapeutics): best performer on XBI; presentations at ESMO +8.6% PRME (Prime Medicine): on average volume +7.4% TWST (Twist Bioscience): on average volume +6.5% IBRX (ImmunityBio): shares were (5%) yesterday +4.7% WVE (Wave Life Sciences): earnings +4.5% CNC (Centene): earnings; best performer on XLV +3.1% TRAX (First Tracks Biotherapeutics Inc): sympathy to ARGX (Celiac disease) Decliners -31.7% ARTV (Artiva Biotherapeutics): grade 5 neurotoxicity, discontinues AlloNK, RIF, strategic alternatives; downgrades -5.4% UHS (Universal Health Services): sympathy to HCA; worst performer on XLV -4.9% ZLAB (ZAI Lab): on moderate volume -4.8% HCA (HCA Healthcare): earnings; early comments on 2027 during prepared remarks -4.5% ACRS (Aclaris Therapeutics): trial results in atopic dermatitis -3.4% THC (Tenet Healthcare): sympathy to HCA -3.0% MRNA (Moderna): downgraded at Wm Blair; worst performer on XBI -3.0% ARDT (Ardent Health): sympathy to HCA -1.7% RGEN (Repligen Corp.): earnings -1.4% ABT (Abbott Labs): downgraded at Argus	show story hide story
27-Oct-2026 09:46	HCA HCA Healthcare beats expectations on strong admissions, raises FY outlook ($477.60 +$12.34) HCA shares +2.5% after reporting Q3 adjusted EBITDA and revenue ahead of FactSet consensus, with Q3 admissions metrics also well ahead of expectations. For FY26, the company now expects results to land in the upper half of its prior guidance range (issued in mid-July). Results were better than feared, with most anticipating an SDP-driven beat, but underlying business performance also seen as improving, with strong volume growth, disciplined cost management, and a favorable demand backdrop cited as key contributors. However, surgical volumes remain a soft spot, with lower case volumes attributed primarily to ACA coverage losses and softer elective demand. See Related StreetAccount comments: 10/27/2026 7:06:01 AM - StreetAccount Metrics Recap - HCA Healthcare Q3 Earnings 10/27/2026 7:03:20 AM - HCA Healthcare reports Q3 adjusted EBITDA $3.92B vs FactSet $3.73B [22 est, $3.54-3.96B]	show story hide story
27-Oct-2026 08:31	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar picks up again today with a handful of large-cap reports from across the sector. HCA leading gainers with a Q3 beat providing incremental confidence in FY guide. Shares of HCA +2% in the pre-market. Novartis slightly higher on Q3 beat-and-raise. ADRs +1% in the pre-market. Centene Q3 beat-and-raise, with MLR 20bps better than consensus. Shares of CNC flat ahead of the call. IQV with Q3 beat and mild raise. Book-to-bill ahead of consensus. Shares of IQV flat in the pre-market. Moderna hit with first downgrade since the ESMO data leak, presentation, and ongoing debate over the valuation with stock +574% YTD. William Blair to the sidelines awaiting next tumor readouts. Yesterday, Healthcare equities finished mixed to essentially flat overall. After a busy weekend of ESMO presentations, even the higher profile biopharma stocks were little changed on Monday. Most major health groups ended with modest gains for the session. One small subgroup of outperformance, the providers traded higher early only on the back of SGRY +47%, acquired by HealthSpan Partners for transaction value around $5.7B. Macro S&P futures are up +0.3% on Tuesday morning. No big directional drivers in play ahead of next round of hyperscaler earnings, FOMC and next week's midterm elections. AI continues to get the bulk of the attention, particularly in terms of capital intensity. However, removal of some near-term funding overhangs, renewed focus on positive compute/capex demand fundamental narrative and recent wave of hedge fund de-risking seemed to help sentiment on Monday. Rates and energy the key areas of focus outside of AI. Fed widely expected to leave rates unchanged at this week's meeting, though December tightening expectations remain elevated. Oil helped on Monday by no kinetic escalation over the weekend and diplomacy headlines, though expectations for a resumption of hostilities remain elevated. Pre-market trading update Trading higher +18.2% KNSA earnings +6.3% WVE earnings +1.0% HCA earnings; call at 10ET +1.0% NVS earnings; call at 8ET +0.4% GH on 17K shares +0.0% IQV earnings; call at 9ET Trading lower -31.3% ARTV grade 5 neurotoxicity, discontinues AlloNK, RIF, strategic alternatives -7.7% ACRS trial results in atopic dermatitis; call at 8ET -5.3% ZLAB on 17K shares -3.1% MRNA downgraded at Wm Blair -2.9% GILD on 4K shares -0.7% RGEN earnings; call at 8ET (low volume) -0.3% CNC earnings; call at 830ET Pharma Earnings: NOVN.SW (NVS) reports Q3 core EPS $2.46 vs consensus $2.29 on revenue $14.52B vs FactSet $14.45B. Raised FY guidance for core operating income, with growth LSD vs prior decline LSD. Conf. call at 8:00ET Quick take: Beat driven primarily by operational efficiency gains rather than top-line outperformance; strength in Cosentyx, Ilaris, and Zolgensma offsetting weakness in Pluvicto and Scemblix. Analysts also flagged that the company raised its FY26 core operating profit guidance implying approx 2-3% upside to consensus, supported by notably lower SG&A and R&D costs. Additionally, analysts point out that key pipeline catalysts remain on track, including remibrutinib HS Phase 3 readout expected before year-end and Leqvio ORION-4 now expected in Q4. Litigation: LLY Reuters reported on Monday that court ruled for Eli Lilly in suit brought by Novo (NVO) over obesity drug ads. Novo filed suit in July arguing that Lilly ads were false and materially misleading. Biotech Trial results: ACRS announced primary analysis results from the phase 1b POC trials of ATI-052 in atopic dermatitis and asthma. Both trials demonstrated strong proof-of-concept with rapid and broad responses. Company prioritize phase 2B development in Eosinophilic Esophagitis (EoE) - with additional indications disclosed near-term. Company also announced $50M secondary offering, priced. Conf. call at 8:00ET Research: MRNA downgraded to market perform from outperform at William Blair (Myles Minter) DNTH initiated buy at Roth Capital (Adam Walsh), target is $113 or approx. 42% upside. PYPD initiated outperform at Oppenheimer (Les Sulewski), target is $10 or approx. 89% upside. Life Science & MedTech Earnings: IQV reports Q3 EPS $3.34 ex-items vs FactSet $3.26 on revenue $4.43B vs FS $4.37B, adj EBITDA $1.03B vs FS $1.01B. Book to bill ratio 1.2x vs StreetAccount 1.17x. Raises bottom-end of FY EPS guidance by $0.10, midpoint by $0.05. Conf. call at 9:00ET RGEN reports Q3 EPS $0.53 ex-items vs FactSet $0.46 on revenue $209.3M vs FS $206.7M. Raises low-end of FY EPS outlook by $0.02, midpoint by $0.01. Raises FY revenue outlook by $24M at the midpoints, narrows organic growth outlook to +12-13% vs prior +10.5-13.5%. Conf. call at 8:00ET Research: ABT downgraded to hold from buy at Argus Research. DRIO initiated buy at BTIG (David Larsen), target is $6 or approx. 76% upside. HYPR initiated buy at Lucid Capital Markets (Alex Nowak), target is $2 or approx. 178% upside. Services & Hospitals Earnings: HCA reports Q3 adj EBITDA $3.92B vs FactSet $3.73B on revenue $19.85B vs FS $19.33B. Q3 admissions metrics well ahead of consensus. For FY guidance now expects results will be in the upper half of its prior guide (mid-July). Conf. call at 10:00ET M&A: RDNT announced the acquisition of ONRAD Inc in a cash and stock deal. Acquisition expected to add $190-200M in revenue, $60-65M adj EBITDA, in the its first full year. Radnet will pay $350M in cash plus 5M shares, and earnout up to $210M. Conf. call at 8:00ET Managed Care Earnings: CNC reports Q3 EPS $0.58 ex-items vs FactSet $0.10 on revenue $50.65B vs FS $47.12B. MLR 20bp better than StreetAccount consensus, 92.7% vs 92.9%. Raises FY EPS guide to greater than $5.20 vs prior greater than $4.80. FY MLR guide down 15bps at the midpoints. Quick Take: Results are viewed as solid, though uncertainty around 2027 policy remains a concern, with raised guidance still implying Q4 EPS below consensus. Q3 upside is primarily attributed to strong topline growth and cost controls, alongside Medicare outperformance. Key questions for the call include Q3 Medicaid rate and cost trends, the Jan. 1, 2027 rate outlook, acuity shifts, Marketplace trajectory, Part D performance drivers, and 2027 growth and margin expectations. Conf. call at 8:30ET On Deck: Conference ESGCT Congress 2026 (Oct 27-30) Corporate LBRX R&D Day (14:00ET) on Wed 28-Oct: CHRS interim trial results with tagmokitug in solid tumors (16:30ET) Earnings after the close today ICLR (call Wed at 8:00ET), UHS (call Wed at 8:00ET), CHE (call at 10:00ET) Earnings tomorrow Wed 28-Oct: before GSK (call at 8:00ET), BSX (call at 8:00ET), BIIB (call at 8:30ET), GEHC (call at 8:30ET), LH (call at 9:00ET), AVTR (call at 8:00ET), BLCO (call at 8:00ET) after EHC (call Thu at 10:00ET), ALGN (call at 16:30ET), GKOS (call at 16:30ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ACRS, ALGN, ARTV, AVTR, BIIB, BLCO, BSX, CHE, CHRS, CNC, DNTH, DRIO, EHC, GEHC, GH, GILD, GKOS, GSK, HCA, HYPR, ICLR, IQV, KNSA, LBRX, LH, LLY, MRNA, NOVN.SW, NVO, NVS, PYPD, RDNT, RGEN, UHS, WVE, ZLAB...(more)	show story hide story
27-Oct-2026 08:00	CNC Centene reports a Q3 beat and raise; Medicare strength offset by 2027 policy uncertainty ($68.03) CNC reported Q3 EPS ex-items beating FactSet with revenue also above. MLR 92.7% beat StreetAccount 92.9%. Raised FY26 EPS and revenue guidance and lowered MLR. Results are viewed as solid, though uncertainty around 2027 policy remains a concern, with raised guidance still implying Q4 EPS below consensus. Q3 upside is primarily attributed to strong topline growth and cost controls, alongside Medicare outperformance. Key questions for the call include Q3 Medicaid rate and cost trends, the Jan. 1, 2027 rate outlook, acuity shifts, Marketplace trajectory, Part D performance drivers, and 2027 growth and margin expectations. See Related StreetAccount comments: 10/27/2026 6:07:54 AM - StreetAccount Metrics Recap - Centene Q3 Earnings 10/27/2026 6:07:44 AM - Centene reports Q3 EPS $0.58 ex-items vs FactSet $0.10 [20 est, $0.00-0.33]	show story hide story
26-Oct-2026 16:59	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to essentially flat overall on Monday. Advancers equaled by decliners on the XLV after breadth swung both positive and negative on the session. Healthcare (0.01%) vs S&P 500 +0.70%. Most major health groups ended with modest gains for the session. Managed Care after an intraday reversal traded lower with Medicaid names pacing broad declines by as much as (3%). MCOs with HIX exposure also closed lower, following the proposed tightening of rules for enrollment. Small subgroup of outperformance, the providers traded higher early only on the back of SGRY +47%, acquired by HealthSpan Partners; Bain Capital to retain its ownership stake. Peers walked back early gains however, including THC +0.2%. Orthopedic medical device manufacturers remained soft on the session, though ZBH (1.1%) and SYK (0.3%) were no longer among today's top decliners on the XLV. CRL +3.5% and MRK (3.2%) bracketed the XLV. A very busy weekend of ESMO 2026 highlights, including standing ovations for AMGN's +1.2% Imdelltra in 1L SCLC, and the Moderna-Merck INTerpath study in melanoma. MRNA (0.6%), and MRK lower despite positive sac-TMT results in lung cancer. GMAB +2.0% also viewed as having a strong weekend with multiple readouts for peto and Rina-S, and walking away with the JPMorgan upgrade in response. M&A in the health services group with HealthSpan Partners acquiring Surgery Partners for transaction value around $5.7B. Bain Capital will continue to hold its stake. Macro AI trade had a solid day backed by positive sentiment around multiple headlines, including META $95B equity raise and SPCX $40B debt raise (helping support the elevated-capex narrative which received some scrutiny last week). Also attention on Anthropic's S-1 filing ahead of this month's planned IPO. Developments come ahead of a big week of hyperscaler earnings (GOOGL and MSFT post-close Wednesday, AMZN post-close Thursday) expected to highlight favorable monetization dynamics. Also focus this week on Wednesday's FOMC decision. Fed expected to hold rates steady; meeting unlikely to generate guidance to shift market expectations for a December hike. Likely some broad market help today from lower oil prices following weekend headlines about Mideast diplomatic efforts, though these have not yielded any fruit and a resumption of kinetic activity is still expected. Other factors in the narrative today included recent hedge-fund derisking (and setup for a potential momentum bounce), CTA short covering, ongoing French riots, post-election market slide in Brazil, and potential for relief rally following US midterms next week. Notable Gainers +47.6% SGRY (Surgery Partners): acquired by BSMH/Bain remains holder +15.9% XNCR (Xencor): trial results for XmAb819 in ccRCC; best performer on XBI +12.7% ORKA (Oruka Therapeutics): trial results in psoriasis +9.1% WGS (GeneDx Holdings): shares were (16%) on Friday +8.8% REPL (Replimune Group): on average volume +5.7% PRAX (Praxis Precision Medicines): on light volume +5.6% GRAL (GRAIL, Inc.): follow-through, shares were +13% last week +4.2% ERAS (Erasca): presentations at ESMO +3.8% TWST (Twist Bioscience): on light volume +3.4% CRL (Charles River Laboratories): best performer on XLV; shares were +13% last week Notable Decliners -32.0% ORIC (Oric Pharma.): presentations at ESMO; worst performer on XBI -26.9% AVBP (Arrivent Biopharma): trial results for ARR-217 at ESMO -13.5% CLYM (Climb Bio): presentations at Kidney Week; on heavy volume -6.3% SMMT (Summit Therapeutics): partner Akeso presented at ESMO -5.3% IDYA (IDEAYA Biosciences): presentations at ESMO -5.0% IBRX (ImmunityBio): on below average volume -3.2% MRK (Merck): trial results for INT at ESMO w MRNA; trial results for sac-TMT at ESMO w Kelun; worst performer on XLV -3.0% CNC (Centene): CMS proposed rule on exchanges; ahead of earnings tomorrow Surgery Partners Inc acquired in $5.7B deal SGRY acquired by HealthSpan Partners, an affiliate of Bon Secours Mercy Health, in an all-cash transaction valued at around $5.7B. Monday announcement confirmed a report by the FT on Sunday. Holder Bain Capital will roll over equity interest into the acquiring entity. Notable presentations for biopharma at ESMO AMGN presented landmark interim Phase 3 results showing that IMDELLTRA plus IMFINZI (AZN) as 1L treatment of ES-SCLC reduced the risk of death by 58% (HR 0.42). The phase 3 DeLLphi-305 study extended median OS by 8.4 months (21.1 vs 12.7). Data simultaneously published in NEJM. AVBP announced initial phase 1 results for ARR-217 at ESMO, a potential treatment for GI cancers. Drug has advanced into phase 1B dose optimization study with further data expected in 2027. GMAB announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab in mCRC. Also announced updated results from a Phase 2 trial evaluating peto in 1L HNSCC. Four phase 3 trials with peto are ongoing: in HNSCC and in CRC. Next up phase 3 results in 1L HNSCC later this year. Stock upgraded at JPMorgan. MRK and Kelun presented results of the Phase III OptiTROP-Lung06 study of sac-TMT (SKB264/MK-2870) at ESMO. Results were simultaneously published in NEJM. Median PFS 15.0 months vs control 5.7 months, and responses more durable (13.6 mos vs 6.8 mos). OS trending favorably but not yet mature. ORKA announced week 16 results from its EVERLAST-B Phase 2b trial of ORKA-001 (HALO) in in moderate-to-severe psoriasis. 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A. Company to meet with regulatory authorities about phase 3 plans. Obesity drug developer Corxel Pharma going public via SPAC, $300M PIPE Corxel Pharmaceuticals to go public with agreement to combine with Amanat Acquisition Corp (AMAN). New ticker symbol to be disclosed later. The transaction includes $300M in PIPE financing. Corxel is developing the phase 3 ready, oral GLP-1 candidate CX11, and a preclinical oral amylin agonist CX12, for obesity. Notable research in Healthcare today Biotech: AARD downgraded to perform from outperform at Oppenheimer (Leland Gershell), cites lack of visibility into ARD-101 path forward. CATX downgraded to sector perform from outperform at RBC Capital Markets (Leonid Timashev), follows results with GEP-NET. Target cut to $4 from $14 or approx. 148% upside. (FactSet average PT $12; range $5-18) GMAB.DC (GMAB) upgraded to overweight from neutral at JPMorgan (Zain Ebrahim), target increased to DKK3500 from DKK2050 or approx. 32% upside. (FactSet average PT DKK3156; range DKK2348-4003) ASND initiated hold at Canaccord Genuity (Gary Nachman), target is $268 or approx. 10% upside. DARE initiated buy at Ladenburg Thalmann (Jeffrey Cohen), target is $2 or approx. 208% upside. ETRA initiated buy at HC Wainwright (Raghuram Selvaraju), target is $30 or approx. 244% upside. PRE initiated buy at Maxim Group (Tom Forte), target is $41 or approx. 136% upside. TNXP initiated buy at Canaccord Genuity (Gary Nachman), target is $118 or approx. 248% upside. MedTech: A (Agilent) initiated buy at Deutsche Bank (Justin Bowers), target is $190 or approx. 10% upside. (FactSet average PT $184; range $155-200) Services: NUTX initiated buy at Ladenburg Thalmann (Jeffrey Cohen), target is $336 or approx. 60% upside. Post-close news M&A: RDNT announced the acquisition of ONRAD Inc in a cash and stock deal. Acquisition expected to add $190-200M in revenue, $60-65M adj EBITDA, in the its first full year. Radnet will pay $350M in cash plus 5M shares, and earnout up to $210M. Conf. call tomorrow at 8:00ET Shares of RDNT trading (1.8%) in the after-hours Litigation: LLY Court rules for Eli Lilly in Novo (NVO) suit over obesity drug ads - Reuters Novo Nordisk filed suit in July arguing that Eli Lilly ads were false and materially misleading. Research: DNTH initiated buy at Roth Capital, target is $113 or approx. 42% upside. On Deck: Conference ESGCT Congress 2026 (Oct 27-30) Corporate ZBIO R&D Day (8:00ET) ZYME portfolio update (8:30ET) LBRX R&D Day (14:00ET) on Wed 28-Oct: CHRS interim trial results with tagmokitug in solid tumors (16:30ET) Regulatory FDA PDUFA today for Sun Pharma (524715.IN) sBLA for ILUMYA in psoriatic arthritis Earnings tomorrow before NVS (call at 8:00ET), HCA (call at 10:00ET), IQV (call at 9:00ET), CNC (call at 8:30ET), RGEN (call at 8:00ET) after ICLR (call Wed at 8:00ET), UHS (call Wed at 8:00ET), CHE (call at 10:00ET) Earnings on Wed 28-Oct: before GSK, BSX, BIIB, GEHC, LH, AVTR, BLCO after EHC, ALGN, GKOS StreetAccount Healthcare Reads Moderna CEO on what's next after success in cancer vaccine (26-Oct) STAT News Obesity drug developer Corxel to go public via SPAC deal (26-Oct) Reuters The Cost of Healthcare Is Hitting America Where It Hurts: The Wallet (26-Oct) KFF Health News ADA Admits Mistakes and Issues a Partial Apology (24-Oct) ConscienHealth This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 524715.IN, A, AARD, ALGN, AMAN, AMGN, ASND, AVBP, AVTR, AZN, BIIB, BLCO, BSX, CATX, CHE, CHRS, CLYM, CNC, CRL, DARE, DNTH, EHC, ERAS, ETRA, GEHC, GKOS, GMAB, GMAB.DC, GRAL, GSK, HALO, HCA, IBRX, ICLR, IDYA, IQV, LBRX, LH, LLY, MRK, MRNA, NUTX, NVO, NVS, ORIC, ORKA, PRAX, PRE, RDNT, REPL, RGEN, SGRY, SMMT, TNXP, TWST, UHS, WGS, XNCR, ZBIO, ZYME...(more)	show story hide story
26-Oct-2026 11:06	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index +0.17% vs the S&P 500 +0.94%. Most major health groups in positive territory, however moves are quite modest apart from the providers subgroup of Services. SGRY +46% acquired by Healthspan Partners; Bain Capital to retain its ownership stake. Moderate gains for peers, most notable THC +2%. Orthopedic medical device manufacturers are softer, though stocks lightly mixed on the day. ZBH (2%) and SYK (1%) among top decliners on the XLV. CRL +2% and MRNA (3%) bracket the XLV. Very busy weekend of ESMO 2026 highlights, including standing ovations for AMGN's +1% Imdelltra in 1L SCLC, and the Moderna-Merck INTerpath study in melanoma. MRK (2%) despite positive sac-TMT results in lung cancer. GMAB +1% also viewed as having a strong weekend with multiple readouts for peto and Rina-S, and walking away with the JPMorgan upgrade in response. Gainers +46.3% SGRY (Surgery Partners): acquired by BSMH/Bain remains holder +24.7% XNCR (Xencor): trial results for XmAb819 in ccRCC; best performer on XBI +10.3% WGS (GeneDx Holdings): shares were (16%) on Friday +10.1% ORKA (Oruka Therapeutics): trial results in psoriasis +5.7% ERAS (Erasca): presentations at ESMO +4.5% GRAL (GRAIL, Inc.): follow-through, shares were +13% last week +2.4% CRL (Charles River Laboratories): best performer on XLV; shares were +13% last week +2.0% DVA (DaVita): on average volume +1.9% GMAB (Genmab): trial results for peto. at ESMO; upgraded at JPMorgan +1.2% JNJ (Johnson & Johnson): presentations at ESMO +0.9% AMGN (Amgen): trial results for IMDELLTRA at ESMO Decliners -26.8% AVBP (Arrivent Biopharma): trial results for ARR-217 at ESMO; worst performer on XBI -22.2% ORIC (Oric Pharmaceuticals): presentations at ESMO -10.8% CLYM (Climb Bio): presentations at Kidney Week; on light volume -5.8% SMMT (Summit Therapeutics): partner Akeso presented at ESMO -4.8% IDYA (IDEAYA Biosciences): presentations at ESMO -4.4% VSTM (Verastem): presentations at ESMO -2.8% MRNA (Moderna): presentation of intismeran at ESMO w MRK; worst performer on XLV -2.0% MRK (Merck): trial results for INT at ESMO w MRNA; trial results for sac-TMT at ESMO w Kelun; second-worst on XLV -1.9% ZBH (Zimmer Biomet Holdings): on average volume; ortho devices soft on SGRY -1.6% INCY (Incyte): presentations at ESMO	show story hide story
26-Oct-2026 08:39	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis A busy weekend of ESMO 2026 highlights, including standing ovations for Amgen's Imdelltra in 1L SCLC and the Moderna-Merck INTerpath study in melanoma. Stocks not reflecting the same sentiment early Monday. Shares of AMGN flat, shares of MRNA down another 8% in the pre-market; MRK flat despite sac-TMT results in lung cancer. Genmab also viewed as having a strong weekend with multiple readouts for petosemtamab and Rina-S, and walking away with the JPMorgan upgrade in response. ADRs for GMAB +3% in the pre-market. Macro S&P futures are up +0.4% on Monday morning, near pre-market highs. Busy near-term catalyst path with peak week of Q3 earnings, including three big hyperscalers (MSFT, GOOGL and AMZN), FOMC on Wednesday and midterm elections the following Tuesday. META equity raise the big story this morning following the latest ramp in AI capex and funding scrutiny last week. Hedge fund risk reduction a big theme in the sell-side research over the last few days. Also more discussion about how capital cost and availability have increasingly come to dominate AI debate. Monetization another area of focus going into this week's cloud revenue/backlog updates. On the macro front, Fed widely expected to leave policy unchanged this week, leaving the bulk of the scrutiny for the Warsh press conference. No kinetic escalation in the Middle East over the weekend seems to be hitting oil (along with some regional talks), though headlines continue to point to a near-term resumption of hostilities. While no meaningful spillover effects for US, a couple of international developments have received attention. French riots were better controlled this weekend and Moody's held France's credit rating steady, while Lula unexpectedly prevailed in Brazil's election (expected to drive selloff in Brazilian assets). Pre-market trading update: Trading higher +32.0% XNCR trial results for XmAb819 in ccRCC; call at 700ET +23.8% SGRY shares halted; FT reported Sunday that Bon Secours nears takeover +4.6% TNXP initiation +4.5% AVBP trial results for ARR-217 at ESMO; call at 800ET +4.4% IONS on 24K shares +2.6% GMAB trial results for petosemtamab at ESMO; upgraded at JPMorgan +0.9% ORKA trial results in psoriasis; call at 800ET +0.7% AMGN trial results for IMDELLTRA at ESMO Trading lower -8.1% MRNA presentation of intismeran at ESMO w MRK -2.9% BNTX trial results for pumitamig at ESMO w BMY -0.5% MRK trial results for INT at ESMO w MRNA; trial results for sac-TMT at ESMO w Kelun Pharma Trial results (ESMO) MRK and Kelun presented results of the Phase III OptiTROP-Lung06 study of sac-TMT (SKB264/MK-2870) at ESMO. Results were simultaneously published in NEJM. Median PFS 15.0 months vs control 5.7 months, and responses more durable (13.6 mos vs 6.8 mos). OS trending favorably but not yet mature. Biotech Trial results (ESMO) AMGN presented landmark interim Phase 3 results showing that IMDELLTRA plus IMFINZI (AZN) as 1L treatment of ES-SCLC reduced the risk of death by 58% (HR 0.42). The phase 3 DeLLphi-305 study extended median OS by 8.4 months (21.1 vs 12.7). Data simultaneously published in NEJM. AVBP announced initial phase 1 results for ARR-217 at ESMO, a potential treatment for GI cancers. Drug has advanced into phase 1B dose optimization study with further data expected in 2027. Conf. call at 8:00ET GMAB announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab in mCRC. Also announced updated results from a Phase 2 trial evaluating peto in 1L HNSCC. Four phase 3 trials with peto are ongoing: in HNSCC and in CRC. Next up phase 3 results in 1L HNSCC later this year. Stock upgraded at JPMorgan. ORKA announced week 16 results from its EVERLAST-B Phase 2b trial of ORKA-001 (HALO) in in moderate-to-severe psoriasis. 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A. Company to meet with regulatory authorities about phase 3 plans. Conf. call at 8:00ET Research: GMAB.DC (GMAB) upgraded to overweight from neutral at JPMorgan (Zain Ebrahim), target increased to DKK3500 from DKK2050 or approx. 32% upside. (FactSet average PT DKK3156; range DKK2348-4003) ASND initiated hold at Canaccord Genuity (Gary Nachman), target is $268 or approx. 10% upside. DARE initiated buy at Ladenburg Thalmann (Jeffrey Cohen), target is $2 or approx. 208% upside. ETRA initiated buy at HC Wainwright (Raghuram Selvaraju), target is $30 or approx. 244% upside. TNXP initiated buy at Canaccord Genuity (Gary Nachman), target is $118 or approx. 248% upside. IPO filing: +WWB (Windward Bio) files for Nasdaq IPO of indeterminate amount (F-1) Clinical-stage biotech with focus on anti-TLSP treatment of COPD, asthma Novo Holdings A/S is top shareholder, and owns 14.5% before this offering Services & Hospitals Media report / M&A: SGRY Bon Secours Mercy Health in late-stage talks to acquire Surgery Partners for about $20/share ($6B), reported the FT on Sunday. Shares are halted on Monday morning up +23.8% in the pre-market Research: NUTX initiated buy at Ladenburg Thalmann (Jeffrey Cohen), target is $336 or approx. 60% upside. Managed Care Regulatory: Post-close on Friday, CMS proposed Pre-Eligibility Verification rule for OE28. The proposed rule would require Exchanges to verify the following criteria before providing financial assistance (PTC or CSR): household income and family size status as a citizen, U.S. national, or eligible noncitizen (including lawfully present) eligibility for or enrollment in other qualifying coverage place of residence The rule also creates a verification period beginning 1-Aug before the start of Open Enrollment (mid-December historically). Comment period open for 30 days Fact Sheet; Rule CMS-9873-P (203pp) On Deck: Conferences (cont.) ESMO 2026 (Oct 23-27) on Tue 27-Oct: ESGCT Congress 2026 (Oct 27-30) Corporate BOLT to discuss merger with Prana Therapies (8:30ET) MRK Investor webcast at ESMO (14:30ET) CPIX webcast on ifetroban for CM associated with DMD (16:30ET) on Tue 27-Oct: ZBIO R&D Day (8:00ET); ZYME portfolio update (8:30ET); LBRX R&D Day (14:00ET) Regulatory FDA PDUFA on Monday for Sun Pharma (524715.IN) sBLA for ILUMYA in psoriatic arthritis Earnings on Tue 27-Oct: before NVS, HCA, IQV, CNC, RGEN after ICLR, UHS, CHE Syndicate calendar / potential IPO pricing n/a This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 524715.IN, AMGN, ASND, AVBP, AZN, BNTX, BOLT, CHE, CNC, CPIX, DARE, ETRA, GMAB, GMAB.DC, HALO, HCA, ICLR, IONS, IQV, LBRX, MRK, MRNA, NUTX, NVO, NVS, ORKA, RGEN, SGRY, TNXP, UHS, XNCR, ZBIO, ZYME, +WWB...(more)	show story hide story
23-Oct-2026 19:33	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished broadly lower on Friday. Decliners beating advancers by nearly 4:1 on the XLV. Healthcare (1.12%) vs S&P 500 (0.52%). Nearly all major health groups ended lower for the session; only MedTech found positive territory before the market close. The rest trimmed weekly gains to LSD. Managed Care and Pharma were today's leading decliners, followed closely by Biotech. Pharma group underpinned by disclosures of serious adverse events, including BMY (2.4%) and NVS (3.3%). Moderna and Merck were relatively stable on Friday, loosely inline with their respective benchmarks. ISRG +1.9% and CI (2.8%) bracketed the XLV, the former secured solid 6% weekly gain on Tuesday's Q3 print, despite early hand-wringing around procedure volume deceleration. A temporary lull in the earnings calendar Friday put an outsized focus on biopharma, and ESMO data specifically. TNGX (16.4%) was in focus on day one ESMO. Despite the reaction, initial sell-side takeaways seemed constructive on the data updates in PDAC; a sell-the-news crowd has camped in Madrid. Moderna addresses the room on Saturday, while Merck has an important SAC-TMT presentation Sunday before their investor event on Monday. Macro Oil strength was the big story today with WTI settling back above $100 a barrel. Nothing really incremental on the US-Iran conflict though elevated expectations for a nearer-term resumption of kinetic activity. Oil was an outsized headwind on the consumer groups today. Hot inflation dynamic also evident in the October flash PMIs out this morning. Oil likely contributed to higher rates after a big rally on Thursday (AI trade stabilization another factor) and the combination seems to be weighing on the broadening trade. However, AI trade stabilized today, coming amid a flurry of cautious-leaning headlines in the financial press; however, this has not applied to the latest batch of reporters (particularly data center) despite the largely upbeat fundamental takeaways. Mag 7 earnings and FOMC the highlights next week. Midterms the following week. Historical post-midterm performance a bullish talking point. Notable Gainers on Friday: +66.7% LYCA (Lycia Therapeutics, Inc.): day one IPO (biotech) +49.6% BOLT (Bolt Biotherapeutics): reverse merger with Prana Therapies +25.4% LUCD (Lucid Diagnostics): Medicare reimbursement for EsoGuard; private placement $15M +9.5% GMAB (Genmab): trial results in ovarian cancer +9.4% AVBP (Arrivent Biopharma): best performer on XBI; sympathy to ORIC; on 2X average volume; shares +26% for the week +9.0% ZLAB (ZAI Lab): private placement $250M; presentations at ESMO +6.0% TEM (Tempus AI): expanded license agreement with BMY +4.3% GRAL (GRAIL, Inc.): second-best on XBI; light volume; shares +12.5% for the week +1.9% ISRG (Intuitive Surgical): best performer on XLV; shares +6% for the week Notable Decliners on Friday: -64.8% AARD (Aardvark Therapeutics): FDA lifts clinical hold; updated data in PWS, path forward in PWS -29.0% CATX (Perspective Therapeutics): trial results in NETs -20.1% CORT (Corcept Therapeutics): sympathy to GMAB -16.4% TNGX (Tango Therapeutics): updates from ESMO; strategic reprioritization and RIF; worst performer on XBI -16.4% WGS (GeneDx Holdings): unusual options volume -15.0% FTH (Faeth Therapeutics): small-cap biotech; ESMO presentations in breast cancer -9.2% PBLS (Parabilis Medicines, Inc.): on heavy volume; shares remain +7% for the week -8.9% FDMT (4D Molecular Therapeutics): on average volume -8.9% OVID (Ovid Therapeutics): small-cap biotech; on average volume -8.7% OLMA (Olema Pharmaceuticals): small-cap biotech; ESMO presentations in breast cancer; 52-week low -7.1% AXSM (Axsome Therapeutics): on 2X average daily volume -7.0% OSCR (Oscar Health): on average volume -7.0% AVTX (Avalo Therapeutics): follow-through, downgrades -6.7% BBOT (BridgeBio Oncology Therapeutics): small-cap biotech; on average volume -4.9% HIMS (Hims & Hers Health): on average volume; shares (1%) for the week -3.4% ORIC (Oric Pharmaceuticals): ESMO presentation -3.3% NVS (Novartis): trial results in RMS -2.8% CI (Cigna Group): worst performer on XLV; on average volume Week in Review: Earnings scorecard: According to FactSet Scorecard, with 9.12% of companies (12 of 165) having reported, 91.67% of the S&P 1500 Health Care (SP567-SPX) have beaten consensus EPS expectations, vs 86.50% last year (Q3 2025), with an average beat of +9.12% vs +13.27% last year. On the topline, 100.00% have beaten sales expectations, vs 82.82% last year (Q3 2025), with an average beat of +1.39% vs +2.22% last year. Healthcare equities outperformed for the week. The S&P 500 Healthcare Index gained +1.45% vs the S&P 500 Index (0.47%). Outperformers: MedTech, Biotech, Managed Care, Services, Pharma Underperformers: none Major health groups were all higher against the red tape this week. Low to mid-single digit gains on the averages. All except Pharma (DRG +15.34%) are up +20% or more YTD vs the S&P +11%. Sector remains a top beneficiary of the recent market rotation with the AI trade dominant. Earnings calendar provided a few more datapoints, mostly in MedTech, and almost exclusively positive. Thermo Fisher (2%) delivered a Q3 beat, however FY guidance tweak suggests a muted Q4, and Abbott (1%) a Q3 print inline with medical devices broadly light to consensus. Intuitive Surgical +6% delivered another Q3 beat, with enough positives for bulls and decelerating procedures to keep bears entertained. XBI traded +3.6% on Tuesday (the other four days were net flat). Shares of Moderna were up +700% YTD with the most anticipated data of Q4 ahead: detailed data from INT scheduled for the ESMO main event Saturday - until the data leaked on Thursday. Achievement of the Hazard Ratio bogey not enough to overcome the broken embargo, and renewed investor concerns that the stock had just come too far too fast. Shares of MRNA fell as much as (24%). Bull and bears further entrenched by the abstracts, slides, and press releases. Live presentation (and investor event) still on tap for this weekend. All eyes still seeking signs of validation (or invalidation) beyond the first tumor type. Year-to-date, Healthcare up +15.71% vs the S&P 500 +11.37%. Healthcare third out of eleven major sectors in CY26. Energy +55.06% and Telecom (3.67%) bracket them all. Notable movers for the week: Gainers: SLN +126.6% - acquired by MRK.GR for $1.3B MYGN +46.2% - divests Prenatal business to LH for $210M; best performer on XBI IRON +31.1% - trial results in EPP; secondary raise BHVN +28.8% - FDA accepts NDA resubmission, plans Adcom MANE +27.5% - trial results in male pattern hair loss LQDA +24.2% - follows +26% last week GMAB +18.4% - trial results in ovarian cancer HTFL +17.4% - Piper Sandler comments, raises PT; shares +95% YTD CRL +15.1% - sympathy to LST earnings; 52W high; best performer on XLV SYRE +13.1% - presentations at UEGW / sympathy ABBV GRAL +12.5% - sympathy to LST earnings; follows (16%) last week HNGE +12.5% - 52-week high; shares +140% YTD ORKA +11.4% - sell-side comments ahead of EVERLAST readouts QGEN +9.2% - acquired for PE for $12.1B ROIV +8.8% - trial results in NIU MEDP +8.2% - earnings SRT3.GR +8.0% - earnings BIIB +7.8% - Wells Fargo comments, raises PT to $310 (street-high); Needham comments; 52W high ISRG +6.0% - earnings, guidance Decliners: EYPT (86.5%) - trial results in wet AMD; restructuring AVTX (38.5%) - sympathy to ABBV (trial results in hidradenitis suppurativa); worst performer on XBI CORT (22.1%) - sympathy to GMAB (trial results in ovarian cancer) IBRX (10.5%) - follows (13%) last week DXCM (9.4%) - sympathy to ABT / CVS Caremark; worst performer on XLV MRNA (8.2%) - INTerpath-001 data leak and release by ESMO; stock remains +579% YTD AXSM (7.7%) - stock closed lower 23 of last 26 days; shares (43%) off June highs ELAN (4.4%) - downgraded at Jefferies Week Ahead (Sat - Sun): Oct 24 - Nov 1 Conference calendar (cont.) NAMS 2026 (Oct 20-24), ASN 2026 (Kidney Week) (Oct 21-25), EHDN Congress (Oct 22-24), ESMO 2026 (Oct 23-27) Tue 27-Oct: ESGCT Congress 2026 (Oct 27-30) Corporate calendar Sat 24-Oct: PFE presentation of PCV25 infant at IDWeek (11:00ET) (PCVX); MRNA Investor webcast at ESMO (13:00ET) (MRK) Sun 25-Oct: MRK presentation of SAC-TMT at ESMO (03:15ET) Mon 26-Oct: BOLT to discuss merger with Prana Therapies (8:30ET); MRK Investor webcast at ESMO (14:30ET); CPIX webcast on ifetroban for CM associated with DMD (16:30ET) Tue 27-Oct: ZBIO R&D Day (8:00ET); ZYME portfolio update (8:30ET); LBRX R&D Day (14:00ET) Wed 28-Oct: CHRS interim trial results with tagmokitug in solid tumors (16:30ET) Thu 29-Oct: XFOR Investor Day (10:00ET); EVAX trial results (10:30ET) Regulatory calendar Mon 26-Oct: FDA PDUFA for Sun Pharma (524715.IN) sBLA for ILUMYA in psoriatic arthritis Fri 30-Oct: FDA PDUFA for Inovio (INO) BLA for INO-3107 in recurrent respiratory papillomatosis (RRP) Sun 1-Nov: FDA PDUFA for Agio Pharma (AGIO) sNDA for PYRUKYND in sickle cell disease Earnings calendar Tue 27-Oct: before NVS, HCA, IQV, CNC, RGEN after ICLR, UHS, CHE Wed 28-Oct: before GSK, BSX, BIIB, GEHC, LH, AVTR, BLCO after EHC, ALGN, GKOS Thu 29-Oct: before LLY, MRK, BMY, ALNY, WST, INCY, THC, INSM, BAX, LGND, INDV after GILD, SYK, ILMN, RMD, DXCM, EXEL, DVA, MMSI Fri 30-Oct: before ABBV, AZN, SNY, REGN, BTSG Syndicate calendar / potential IPO pricing n/a Related: 524715.IN, ABBV, ABT, AGIO, ALGN, ALNY, AVTR, AVTX, AXSM, AZN, BAX, BHVN, BIIB, BLCO, BMY, BOLT, BSX, BTSG, CHE, CHRS, CNC, CORT, CPIX, CRL, CVS, DVA, DXCM, EHC, ELAN, EVAX, EXEL, EYPT, GEHC, GILD, GKOS, GMAB, GRAL, GSK, HCA, HNGE, HTFL, IBRX, ICLR, ILMN, INCY, INDV, INO, INSM, IQV, IRON, ISRG, LBRX, LGND, LH, LLY, LQDA, MANE, MEDP, MMSI, MRK, MRK.GR, MRNA, MYGN, NVS, ORKA, PCVX, PFE, QGEN, REGN, RGEN, RMD, ROIV, SLN, SNY, SRT3.GR, SYK, SYRE, THC, UHS, WST, XFOR, ZBIO, ZYME...(more)	show story hide story
23-Oct-2026 16:35	CMS proposes Pre-Eligibility Verification rule for OE28 The proposed rule would require Exchanges to verify the following criteria before providing financial assistance (PTC or CSR): household income and family size status as a citizen, U.S. national, or eligible noncitizen (including lawfully present) eligibility for or enrollment in other qualifying coverage place of residence The rule also creates a verification period beginning 1-Aug before the start of Open Enrollment (mid-December historically). Comment period open for 30 days Fact Sheet; Rule CMS-9873-P (203pp) For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: CI, CNC, CVS, ELV, HCA, HUM, UHS, UNH...(more)	show story hide story
23-Oct-2026 14:39	StreetAccount Summary: Notable Drug Events expected for the week of 25-Oct (cont.) Industry meetings with clinical data: ESMO Congress 2026 (Oct 23-27) (INCY, IMTX, XNCR, CMPX, 6996.HK, INBX, GSK.LN, BNTX, MRNA, OSE.FP, 4502.JP, PFE, NBP, AVBP, 2157.HK, AMGN, SMMT, FARN.LN, PRTC.LN, LLY, EVAX) ASN 2026 (Kidney Week) (Oct 21-25) Sun 25-Oct Trial results: SMMT to present Ph3 results for Ivonescimab in advanced biliary tract cancer at ESMO LLY to present Ph 1/2 first-line data for olomorasib in NSCLC at ESMO MRK to present Ph3 LITESPARK-011 final analysis and LITESPARK-012 results in advanced RCC at ESMO Mon 26-Oct Trial results: LLY to present updated results from the Ph 3 study of selpercatinib vs cabozantinib or vandetanib (C/V) in medullary thyroid cancer (MTC) at ESMO Investor events: MRK Investor webcast at ESMO (14:30ET) CPIX webcast on ifetroban for CM associated with DMD (16:30ET) Tue 27-Oct Industry meetings with clinical data: ESGCT Annual Congress (Oct 27-30) (BNTC, BEAM) Investor events: ZBIO R&D Day (8:00ET) ZYME portfolio update (8:30ET) LBRX R&D Day (14:00ET) Wed 28-Oct Trial results: CHRS to present Ph1/2 data for tagmokitug in solid tumors (16:30ET) Thu 29-Oct Regulatory decisions: 524715.IN (Sun Pharma) FDA PDUFA for ILUMYA sBLA in psoriatic arthritis XBRANE.SS FDA BsUFA for Xlucane BLA in retinal disorders Investor event: EVAX to discuss ph 2 trial of EVX-01 in patients with advanced melanoma (10:30ET) Fri 30-Oct Regulatory decision: INO FDA PDUFA FOR INO-3107 BLA in recurrent respiratory papillomatosis later during October 2026 Trial results: RAPP (Ph3 FOS), TLSA (Ph2 na-SPMS), PBLS (Ph1/2 Desmoid Tumors), TRDA (Ph1/2 DMD), EIKN (Ph1/2 solid tumors) expected imminently Trial results: CGON (Ph3 INT-NMIBC) Related: 2157.HK, 4502.JP, 524715.IN, 6996.HK, AMGN, AVBP, BEAM, BNTC, BNTX, CGON, CHRS, CMPX, CPIX, EIKN, EVAX, FARN.LN, GSK.LN, IMTX, INBX, INCY, INO, LBRX, LLY, MRK, MRNA, NBP, OSE.FP, PBLS, PFE, PRTC.LN, RAPP, SMMT, TLSA, TRDA, XBRANE.SS, XNCR, ZBIO, ZYME...(more)	show story hide story
23-Oct-2026 11:13	BMY Bristol Myers lower following disclosure of patient death in MS study BMY (2.3%) on Friday morning vs the DRG (1.42%). Company presented interim safety and efficacy data from the phase 1 study of zola-cel in patients with highly active relapsing Multiple Sclerosis. Company says after the data cutoff, one patient experienced a fatal event of septic pneumonia. Study included 66 patients. Company says no additional grade 5 AEs have been reported across all autoimmune studies of the CAR-T therapy, which include 190 patients treated in phase 1. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
23-Oct-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.96%) vs the S&P 500 (0.15%). All major health groups are red for the session, declines (1%) to (2%) on the averages, trimming nice weekly gains in every group. Biotech and Pharma are leading the declines, XBI (2.29%) and DRG (1.74%). MRNA and MRK each lower again, but inline with their respective benchmarks. ISRG +2% and VTRS (3%) bracket the XLV, the former on track for a solid MSD gain this week. Temporary lull in the earnings calendar puts focus on biopharma and ESMO specifically. TNGX (17%) in focus on day one ESMO. Initial takeaways seem constructive on the data updates in PDAC; sell-the-news crowd camped in Madrid. Moderna addresses the room on Saturday, while Merck has other important presentations before their investor event on Monday. Gainers +30.9% LUCD (Lucid Diagnostics): Medicare reimbursement for EsoGuard; private placement $15M +6.0% ZLAB (ZAI Lab): private placement $250M; presentations at ESMO +2.3% GRAL (GRAIL, Inc.): best performer on XBI; light volume; shares +10% WTD +1.9% ISRG (Intuitive Surgical): best performer on XLV; shares +5% WTD +0.0% CATX (Perspective Therapeutics): shares halted for news Decliners -47.6% AARD (Aardvark Therapeutics): FDA lifts clinical hold; updated data in PWS, path forward in PWS -17.2% TNGX (Tango Therapeutics): updates from ESMO; strategic reprioritization and RIF; worst performer on XBI -8.4% PRME (Prime Medicine): on average volume -8.1% FDMT (4D Molecular Therapeutics): on average volume -7.9% AVTX (Avalo Therapeutics): follow-through, downgrades -7.8% PBLS (Parabilis Medicines, Inc.): shares remain +9% WTD -4.8% HIMS (Hims & Hers Health): on average volume -3.4% ZYME (Zymeworks): out-license agreement with ROP.SW -3.1% VTRS (Viatris): worst performer on XLV; shares (4%) WTD -2.7% BIIB (Biogen): second-worst performer on XLV; average volume; shares +6% WTD -2.4% MRK (Merck): follow-through; shares (2%) WTD -1.5% MRNA (Moderna): follow-through; shares (8%) WTD	show story hide story
23-Oct-2026 08:34	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis ESMO 2026 officially underway in Madrid, after the leak and embargo break one day ago. Pancreatic cancer and Tango Therapeutics with impactful updates on Day One. After encouraging interim data with PRMT5i candidates, company shelving novel target discovery. Shares of TNGX (9%) in the pre-market. Yesterday, Healthcare equities were mostly higher. Biotech soft all day, and grew weaker with the leak of MRNA (17.6%) melanoma data ahead of ESMO. Shares retraced some of the autumn runup for the cancer vaccine. MRK (1.8%) also volatile, as were many other INT-adjacent equities. Services group, followed by Pharma, were the top gainers. For the week-to-date, all major health groups higher by +3% to +5%. Earning calendar ramps significantly beginning next Tuesday. Macro S&P futures down (0.3%) on Friday morning, Nasdaq futures are down (0.1%). AI bounce attempt in focus this morning, though not providing meaningful support at the index level. Nothing specific behind the move (however, Asia/South Korea held up much better than expected overnight). Stabilization coming despite a flurry of headlines surrounding funding concerns/spread widening, trimmed OpenAI valuation target, deal delays, monetization scrutiny, cybersecurity risks, and the broader inability to take advantage of the favorable compute and capex demand narratives out of earnings. Rotation>risk off, Treasuries as an AI hedge (and breakdown in yield/oil correlation), better Middle East oil flows, ramp in expectations for renewed kinetic activity/extended standoiff in the region, French contagion debate, and hedge fund and retail P&L pain some other recent areas of focus. Pre-market trading update Trading higher +25.2% LUCD Medicare reimbursement for EsoGuard; private placement $15M +7.2% ZLAB private placement $250M; presentations at ESMO +1.3% CATX shares halted for news +1.0% ZYME out-license agreement with ROP.SW Trading lower -20.3% AARD FDA lifts clinical hold; call at 800ET to discuss path forward -8.8% TNGX updates from ESMO; strategic reprioritization and RIF; call at 730ET -4.2% MRVI on 7K shares -3.9% GRAL on 10K shares -3.8% MRNA follow-through -2.7% AVTX follow-through, downgrades -1.1% MRK follow-through Pharma Research: ROP.SW upgraded to buy from hold at Deutsche Bank (Emmanuel Papadakis), target increased to CHF500 from CHF340 or approx. 26% upside. New Street-high PT. Biotech Corporate: TNGX disclosed via 8-K that it will deprioritize novel target discovery in a strategic reprioritization, and focus efforts instead on PRMT5-targeted therapies including lead asset vopimetostat (TNG462) and TNG456. Company plans to reduce workforce by 14%, primarily in research. Investor call from ESMO at 7:30ET; slides M&A: GILD announced the acquisition of an oral IL-23R inhibitor program from PepStar Therapeutics (private) for $1.275B in upfront cash. IL-23R is a clinically validated target in immune-mediated inflammatory diseases, including Inflammatory Bowel Diseases (IBD), with potential applications in psoriasis. Regulatory: AARD announced that FDA has lifted the clinical hold on ARD-101 for Prader-Willi Syndrome (PWS). Also updated on exploratory data from terminated HERO trial, and OLE trial, plans to discuss path forward with FDA. Conf. call at 8:00ET. IPO priced: LYCA Lycia Therapeutics upsized IPO priced at the top-end of anticipated range ($16-18/shr) and raised $317.5M in gross proceeds (before the shoe). Lycia is the 28th Biotech IPO of CY2026, 33rd overall in Healthcare. Research: AVTX downgraded to neutral from buy at HC Wainwright (Mitchell Kapoor) AVTX *downgraded* to neutral from buy at Guggenheim Securities (Yatin Suneja) TTRX upgraded to hold from sell at WBB Securities (Steve Brozak), citing valuation. Target is $10 or approx. 2% downside. BNTC initiated outperform at Raymond James (Tiago Fauth), target is $14 or approx. 59% upside. CAMP initiated strong buy at Raymond James (Tiago Fauth), target is $10 or approx. 195% upside. IMUX initiated overweight at Cantor Fitzgerald (Yanni Soutoutzidis) Life Science & MedTech M&A / media report: SNN Talks to combine with JNJ ortho unit collapse, reports the FT. Research: SRT3.GR upgraded to outperform from sector perform at RBC Capital Markets (Charles Weston), target increased to €330 from €220 or approx. 21% upside. GH initiated buy at Roth Capital (Max Masucci), target is $200 or approx. 23% upside. MBOT initiated market outperform at Citizens (Daniel Stauder), target is $2.50 or approx. 166% upside. NTRA initiated buy at Roth Capital (Max Masucci), target is $475 or approx. 18% upside. OSUR initiated buy at Craig-Hallum Capital (Bill Bonello), target is $7 or approx. 84% upside. QTI initiated buy at D. Boral Capital (Patrick McCann), target is $9 or approx. 281% upside. On Deck: Conferences (cont.) NAMS 2026 (Oct 20-24) (cont.) ASN 2026 (Kidney Week) (Oct 21-25) (cont.) EHDN Congress (Oct 22-24) ESMO 2026 (Oct 23-27) Note: LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) Corporate on Sat 24-Oct: PFE presentation of PCV25 infant at IDWeek (11:00ET) (PCVX) MRNA Investor webcast at ESMO (13:00ET) Note: MRK event is on Monday afternoon Peek Ahead to next week Oct 26 - Nov 1 Corporate calendar: Mon 26-Oct: MRK Investor webcast at ESMO (14:30ET) Regulatory calendar: Mon 26-Oct: FDA PDUFA for Sun Pharma (524715.IN) sBLA for ILUMYA in psoriatic arthritis Fri 30-Oct: FDA PDUFA for Inovio (INO) BLA for INO-3107 in recurrent respiratory papillomatosis (RRP) Sun 1-Nov: FDA PDUFA for Agio Pharma (AGIO) sNDA for PYRUKYND in sickle cell disease Earnings calendar: Tue 27-Oct: before NVS, HCA, IQV, CNC, RGEN after ICLR, UHS, CHE Wed 28-Oct: before GSK, BSX, BIIB, GEHC, LH, AVTR, BLCO after EHC, ALGN, GKOS Thu 29-Oct: before LLY, MRK, BMY, ALNY, WST, INCY, THC, INSM, BAX, LGND, INDV after GILD, SYK, ILMN, RMD, DXCM, EXEL, DVA, MMSI Fri 30-Oct: before ABBV, AZN, SNY, REGN, BTSG This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 524715.IN, AARD, AGIO, AVTX, BNTC, CAMP, CATX, CHE, CNC, GH, GILD, GRAL, HCA, ICLR, IMUX, INO, IQV, JNJ, LUCD, LYCA, MBOT, MRK, MRNA, MRVI, NTRA, NVS, OSUR, PCVX, PFE, QTI, RGEN, ROP.SW, SNN, SRT3.GR, TNGX, TTRX, UHS, ZLAB, ZYME...(more)	show story hide story
22-Oct-2026 17:16	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly higher on Thursday. Advancers beat decliners by nearly 4:1 on the XLV. Healthcare +1.33% vs S&P 500 (1.21%). Most major health groups ended higher by +1% to +3% on the average. Biotech soft all day, and grew weaker with the leak of MRNA (17.6%) melanoma data ahead of ESMO. Shares retraced some of the autumn runup for the cancer vaccine. MRK (1.8%) also volatile, as were many other INT-adjacent equities. Services group, followed by Pharma, were the top gainers. The DRG +1.91% higher including the slip by MRK; most drugmakers were higher +1% to +4% each. ABBV +0.1% another outlier following its phase 3 readout in Hidradenitis Suppurativa; results moved certain biotech competitors more - AVTX (39.2%) and MLTX +15.9%. BIIB +5.3% and MRNA bracketed the XLV. Shares of Moderna were in focus ahead of the details on the melanoma cancer vaccine at ESMO (presentation is Saturday). Data circulated showed an encouraging Hazard Ratio = 0.58. Several sell-side analysts said if true, the details supported intismeran in broader settings. Once confirmed, more bearish analysts came out for the debate. Earnings calendar ramped but was not a major factor today. A handful of reports overnight including first CRO and third MCO. MOH +0.8% unable to extend the MLR beat by the group, a narrow miss on consolidated MLR. European prints include Sartorius and Roche, both beat-and-affirmed, though stocks telling a different story today: SRT3.GR +4.8% and ROP.SW (flat). Diagnostic firm Qiagen confirmed earlier media reports that reached acquisition agreement with a group of investors led by EQT. Valuation as predicted, around €10.8B ($12.1B at current exchange rate). Yesterday, Healthcare equities were mixed to lower overall. Most major health groups ended lower for the session, all were between +/- 1% on the averages. Payers, providers and Pharma were the leading decliners; only MedTech beat the wider tape. Earnings calendar snapped back to the forefront with several MedTech prints on the tape. Macro AI saw another round of sharp pressure with funding concerns seemingly back in play (more focus on CDS widening). While META came under scrutiny today, expectations that it would tap markets (potentially both equity and credit) to fund its capex ramp have been in play for a while. But today's dynamics also come against the positive fundamental AI compute/capex demand backdrop (some of today's other positive earnings themes include cyclical/industrial recovery, pricing power, solid consumer demand, though also more focus on input price pressure). However, tone today is more rotation than risk-off, with S&P breadth positive and equal-weight RSP outperforming by largest single-day margin since July 2024; defensives, rate-sensitive plays among the big beneficiaries. Reflexivity dynamic a key tailwind for Treasuries, with support also chalked up to CTA short covering and flight-to-quality from another big backup in French bond yields. Oil strength was the other big story today amid latest batch of headlines highlighting expectations for a renewed ramp in kinetic activity in the Middle East. Notable Gainers +25.0% BHVN (Biohaven): FDA accepts NDA resubmission with Q1 PDUFA +15.9% MLTX (MoonLake Immunotherapeutics): sympathy to ABBV +14.2% HCSG (Healthcare Services Group): follow-through, shares +17% WTD +13.0% NBTX (Nanobiotix): shares were +7% yesterday and +37% WTD +9.2% VSTM (Verastem): best performer on XBI; shares +16% WTD +6.5% CELC (Celcuity): initiation +5.3% BIIB (Biogen): best performer on XLV; shares +9% WTD; 52-week high +5.3% DVA (DaVita): second-best performer on XLV; shares remain (1%) WTD +4.8% STE (STERIS): on above average volume +4.7% SRT3.GR (Sartorius): earnings +4.5% COO (The Cooper Cos.): on below average volume +4.4% PODD (Insulet): on below average volume; shares +5% WTD +4.2% ZBH (Zimmer Biomet Holdings): on average daily volume +3.8% MDT (Medtronic): on very light volume +3.8% JNJ (Johnson & Johnson): on above average volume +3.8% CI (Cigna Group): on average volume; 52-week high +3.1% BMY (Bristol Myers Squibb): on above average volume Notable Decliners -39.2% AVTX (Avalo Therapeutics): sympathy to ABBV; worst performer on XBI -17.6% MRNA (Moderna): Embargo leak and lifted for INTerpath-001 data ahead of ESMO presentation on Saturday; worst performer on XLV, second-worst on XBI -9.3% NVAX (Novavax, Inc.): shares (11%) WTD -9.2% TWST (Twist Bioscience): sympathy to MRNA; shares remain +2% WTD -8.9% ZLAB (ZAI Lab): on heavy volume; Endpoints News report on Treasury and China biotech deals -8.7% AAPG (Ascentage Pharma): on heavy volume; Endpoints News report on Treasury and China biotech deals -7.7% TXG (10X Genomics): shares back to even WTD -5.8% TEM (Tempus AI): sympathy to MRNA -5.5% ALMR (Alamar Biosciences): shares remain +18% WTD -4.8% ILMN (Illumina): on below average volume; shares remain +3% WTD -3.1% ARCT (Arcturus Therapeutics): sympathy to MRNA -1.8% MRK (Merck): Embargo leak and lifted for INTerpath-001 data ahead of ESMO presentation on Saturday What to expect from the Moderna-Merck cancer vaccine data reveal - STAT News Topline results for intismeran (MRNA, MRK) in melanoma were announced in August 2026. STAT News' Adam Feuerstein discusses the main event Saturday at ESMO, 16:30 local / 10:30ET, when detailed results of the INTerpath-001 trial will be presented. Hazard ratio of 0.60, meaning a risk reduction of the RFS endpoint by 40%, is the focus for investors. The hazard ratio expected to foretell the opportunity in tumors beyond melanoma. Trading update following possible data leak of Moderna-Merck Unwind in Moderna also being seen across those leveraged to individualized neoantigen therapies. ESMO lifts embargo, releases data for INTerpath-001 In short, the actual data now being reported by ESMO and Merck (MRK) are the same data circulated earlier today from the Oncology Central website. STAT News released their formerly embargoed story, and stated: "The data were not bad - in fact, the outcome was better than many analysts had predicted. The problem was Moderna's fat valuation, which even a groundbreaking cancer treatment couldn't fully support. " Thu afternoon trading update: MRNA (22.5%), MRK (0.6%) Avalo Therapeutics trading lower in reaction to competitor readout AVTX trading (41.1%) on Thursday morning, in reaction to AbbVie (ABBV) phase 3 results (INTREPID) with lutikizumab in Hidradenitis Suppurativa. The study met its primary endpoint and 8 ranked secondary endpoints. See linked comment. Avalo's lead candidate abdakibart (AVTX-009) is planned to enter phase 3 in HS early next year. Sartorius AG higher following Q3 beat-and-affirm SRT3.GR reports Q3 EBITDA €279.9M vs consensus €268.9M on revenue €926.3M vs consensus €899.3M, and confirmed FY26 guidance for the group and the bioprocessing segment. Growth in the LP&S segment now expected around the upper end of its +4-6% guide. Molina Healthcare lower despite Q3 beat as guidance implies weaker Q4 MOH reported Q3 EPS $0.89 ex-items vs FactSet $0.79 on revenue $11.08B vs FS $10.86B. Consolidated MLR narrowly missed, 92.9% vs StreetAccount consensus 92.8%. Reaffirms FY EPS outlook and all metrics. Quick Take: Takeaways suggest Q3 EPS upside is not reflected in guidance, implying a weaker Q4 outlook than prior commentary and limited cushion for Medicaid MLR deterioration from Florida CMS impact. Q3 upside was also viewed as underwhelming, with the EPS beat attributed to lower-than-expected G&A. On the call, some seek color on elevated Medicaid cost trends, 1/1/27 rates, and the Florida CMS rollout. Medpace shares lag despite Q3 beat-and-raise MEDP reported Q3 EPS $4.84 vs FactSet $4.44 on revenue $716.0M vs FS $714.5M, EBITDA $172.1M vs FS $160.5M. Backlog $3.17B vs FS $3.13B. Broadly raises FY guidance. Shares of Roche lag; analysts point to low quality beat ROP.SW reported Q3 revenue CHF16.13B vs consensus CHF15.75B. Pharma segment mostly ahead of consensus, including Vabysmo narrow beat, while Tecentriq and Kadcyla fell short. Diagnostic segment sales slightly ahead. Quick take: Analysts were positive following the print, noting that revenue beat expectations, driven mainly by the Pharmaceuticals segment, while Diagnostics came in slightly ahead of consensus. Analysts note that the Pharma beat was attributable to timing effects from Japan's ERP system implementation, and Diagnostics was in line to slightly ahead of consensus despite continued China pricing reform headwinds. Analysts also flag that the company confirmed its outlook for the year, implying no material change to consensus and offering limited upside from the shares today, though some see the 7% constant currency growth acceleration and positioning toward the upper end of guidance ranges as warranting a modest positive reaction. However, analysts remain concerned about the phasing benefit and weakness in key franchises, suggesting limited visibility into top-line growth momentum through 2027. Quest Diagnostics latest victim of cybersecurity incident; Q3 print ahead of consensus DGX reported Q3 EPS $3.00 ex-items vs FactSet $2.87 on revenue $3.10B vs FS $3.05B. Raised FY EPS outlook by 10 cents, and revenue outlook by $85M at the midpoints. Company also disclosed via 8-K an October cybersecurity incident. Company does not see any material disruption to its operations. Quick take: Initial takeaways suggest expectations were high heading into the print, but commentary remains constructive on continued momentum, with upside attributed to sustained volume strength. Leerink notes the stock's direction may largely depend on PAMA commentary and its potential impact on FY27 estimates. Another IPO filing in biotech +RZRA (Rezera Inc.) files for Nasdaq IPO of indeterminate amount. Clinical-stage biotech focused on oral inhibitors of NLRP3. S-1 StreetAccount notes that LLY paid $1.2B in January 2026 for Ventyx Biosciences and its NLRP3 portfolio. Qiagen takeout confirmed as expected QGEN confirmed recent press reports, and announced an agreement to be acquired by Crown NL Bidco B.V. - a private equity led group of investors - for €46.50 per share in cash, or EV €10.8B ($12.1B at exchange rates). Supervisory and Managing Boards approved the Business Combination Agreement and support the transaction. Notable research in Healthcare today Biotech: IONS upgraded to outperform from market perform at BMO Capital Markets (David Lebowitz), target increased to $66 from $54 or approx. 49% upside. CADL initiated buy at Jefferies (Maury Raycroft), target is $25 or approx. 199% upside. CELC initiated overweight at Cantor Fitzgerald (Li Watsek), target is $140 or approx. 127% upside. ETRA initiated overweight at JPMorgan (Anupam Rama), target is $36 or approx. 298% upside. KARD initiated outperform at Baird (Jack Allen), target is $43 or approx. 235% upside. PBLS initiated buy at HC Wainwright (Robert Burns), target is $40 or approx. 44% upside. RNA initiated buy at Roth Capital (Boobalan Pachaiyappan), target is $15 or approx. 88% upside. Post-close news M&A: GILD announces the acquisition of an oral IL-23R inhibitor program from PepStar Therapeutics (private) for $1.275B in upfront cash. IL-23R is a clinically validated target in immune-mediated inflammatory diseases, including Inflammatory Bowel Diseases (IBD), with potential applications in psoriasis. Shares of GILD trading unchanged in the after-hours Regulatory: AARD announces that FDA has lifted the clinical hold on ARD-101 for Prader-Willi Syndrome (PWS). Company to host conference call tomorrow at 8:00ET. Shares are halted for news Research: GH initiated buy at Roth Capital (Max Masucci), target is $200 or approx. 23% upside. NTRA initiated buy at Roth Capital (Max Masucci), target is $475 or approx. 18% upside. On Deck: Conferences (cont.) NAMS 2026 (Oct 20-24) (cont.) ASN 2026 (Kidney Week) (Oct 21-25) (cont.) EHDN Congress (Oct 22-24) LBAs for ESMO tonight at 18:05ET ESMO 2026 (Oct 23-27) Note: LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) Syndicate / IPO pricing tonight +LYCA Lycia Therapeutics - looking to raise $250M Corporate TNGX Investor webcast at ESMO (7:30ET) on Sat 24-Oct: PFE presentation of PCV25 infant at IDWeek (11:00ET) (PCVX); MRNA Investor webcast at ESMO (13:00ET) (MRK) Peek Ahead to next week Oct 26 - Nov 1 Earnings calendar: Tue 27-Oct: before NVS, HCA, IQV, CNC, RGEN after ICLR, UHS, CHE Wed 28-Oct: before GSK, BSX, BIIB, GEHC, LH, AVTR, BLCO after EHC, ALGN, GKOS Thu 29-Oct: before LLY, MRK, BMY, ALNY, WST, INCY, THC, INSM, BAX, LGND, INDV after GILD, SYK, ILMN, RMD, DXCM, EXEL, DVA, MMSI Fri 30-Oct: before ABBV, AZN, SNY, REGN, BTSG Regulatory calendar: Mon 26-Oct: FDA PDUFA for Sun Pharma (524715.IN) sBLA for ILUMYA in psoriatic arthritis Fri 30-Oct: FDA PDUFA for Inovio (INO) BLA for INO-3107 in recurrent respiratory papillomatosis (RRP) Sun 1-Nov: FDA PDUFA for Agio Pharma (AGIO) sNDA for PYRUKYND in sickle cell disease StreetAccount Healthcare Reads HHS Was Caught With Erroneous Legal Citations (22-Oct) Washington Sun Top RFK Jr Adviser Calley Means Resigns in Blow to MAHA (22-Oct) Bloomberg Job-Based Health Plan Costs Rise, With Little Relief in Sight (22-Oct) KFF Health News Workers are paying 9% more for family health coverage this year, a higher jump than in the recent past (22-Oct) STAT News All-or-Nothing Biotech Bets Dented by Rising Treasury Yields (22-Oct) Bloomberg 'Go to Canada': Trump Touted Americans' Access to Cheaper Drugs. A New Rule Threatens It. (22-Oct) KFF Health News Mark Cuban wants to crack open the market for rare disease treatments (21-Oct) STAT News Nigeria reports Ebola case as outbreak reaches West Africa (21-Oct) Reuters This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AAPG, AARD, ABBV, ALMR, ARCT, AVTX, BHVN, BIIB, BMY, BNTX, CADL, CELC, CI, COO, DGX, DVA, ETRA, GH, GILD, HCSG, ILMN, IONS, JNJ, KARD, LLY, MDT, MEDP, MLTX, MOH, MRK, MRNA, NBTX, NTRA, NVAX, PBLS, PCVX, PFE, PODD, QGEN, RNA, ROP.SW, SRT3.GR, STE, TEM, TNGX, TWST, TXG, VSTM, ZBH, ZLAB, +LYCA...(more)	show story hide story
22-Oct-2026 13:28	Trading update following possible data leak of Moderna-Merck Still no confirmation on the veracity of the data circulating today, and the ESMO data embargo remains intact. Unwind in Moderna also being seen across those leveraged to individualized neoantigen therapies. Thursday afternoon trading update, with XLV +0.84% and XBI (1.66%): MRNA (24.0%), TWST (10.8%), TEM (9.1%), ARCT (5.2%), MRK (2.6%), BNTX (2.0%) For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ARCT, BNTX, MRK, MRNA, TEM, TWST...(more)	show story hide story
22-Oct-2026 11:24	What to expect from the Moderna-Merck cancer vaccine data reveal - STAT News Topline results for intismeran (MRNA, MRK) in melanoma were announced in August 2026. STAT News' Adam Feuerstein discusses the main event Saturday at ESMO, 16:30 local / 10:30ET, when detailed results of the INTerpath-001 trial will be presented. Hazard ratio of 0.60, meaning a risk reduction of the RFS endpoint by 40%, is the focus for investors. The hazard ratio expected to foretell the opportunity in tumors beyond melanoma. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: MRK, MRNA	show story hide story
22-Oct-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Health Index +1.42% vs the S&P 500 (1.31%). Most major health groups higher by 1% or more for the session, and only Biotech leaking lower with the XBI (0.24%). Biotech newsflow relatively quiet, but signs of more regulatory flexibility in the rare disease space after FDA accepts NDA resubmission in SCA from BHVN +30%. Fairly short review timeline expected to include an Adcom review. Pharma group today's big gainer, the DRG +1.91% with most drugmakers up +1% to +3%. ABBV (flat) despite phase 3 readout in Hidradenitis Suppurativa; moving biotech competitors more (AVTX, MLTX). PODD +3% and MRNA (4%) bracket the XLV. Shares of Moderna remain in focus ahead of the details on the melanoma cancer vaccine at ESMO (presentation is Saturday). Earnings calendar ramps but not a major factor today. A handful of reports overnight including first CRO and third MCO. MOH (flat) unable to extend the MLR beat by the group, a narrow miss on consolidated MLR. European prints include Sartorius and Roche, both beat-and-affirmed, though stocks telling a different story today: SRT3.GR +5% and ROP.SW (flat). Gainers +30.2% BHVN (Biohaven): FDA accepts NDA resubmission with Q1 PDUFA +13.2% MLTX (MoonLake Immunotherapeutics): sympathy to ABBV (trial results in HS) +11.1% NBTX (Nanobiotix): shares were +7% yesterday and +21% WTD +8.9% HCSG (Healthcare Services Group): follow-through, shares +12% WTD +6.5% CELC (Celcuity): initiation; best performer on XBI +5.0% SRT3.GR (Sartorius): earnings +4.7% QURE (uniQure NV): sympathy to BHVN +3.3% ROIV (Roivant Sciences): follow-through, shares +14% WTD +3.1% PODD (Insulet): best performer on XLV; shares +3% WTD +2.8% LLY (Eli Lilly): second-best performer on XLV +0.6% QGEN (Qiagen): acquired by EQT.SS for €10.8B ($12.1B) +0.4% MOH (Molina Healthcare): earnings +0.3% MEDP (Medpace Holdings): earnings Decliners -40.3% AVTX (Avalo Therapeutics): sympathy to ABBV (trial results in HS) -8.3% ALMR (Alamar Biosciences): shares remain +13% WTD -7.6% AAPG (Ascentage Pharma): on strong volume -6.9% TXG (10X Genomics): shares now (1%) WTD -6.8% ZLAB (ZAI Lab): on above average volume -4.4% MRNA (Moderna): worst performer on XLV; shares +9% WTD ahead of ESMO -3.9% TWST (Twist Bioscience): shares remain +7% WTD -3.8% ILMN (Illumina): shares remain +3% WTD -2.9% SMMT (Summit Therapeutics): issues PR on ESMO presentations -0.9% DGX (Quest Diagnostics): earnings -0.7% RCUS (Arcus Biosciences): secondary offering -0.2% ROP.SW (Roche Holding): earnings	show story hide story
22-Oct-2026 08:24	DGX Quest Diagnostics Q3 pressured by a high bar, but momentum still seen as intact ($238.93) DGX (5.2%) premarket after reporting Q3 EPS ahead of FactSet with revenue also ahead. Raised FY EPS and revenue outlook at the midpoints. The company also disclosed an October cybersecurity incident in an 8-K, noting no material operational impact. Initial takeaways suggest expectations were high heading into the print, but commentary remains constructive on continued momentum, with upside attributed to sustained volume strength. Leerink notes the stock's direction may largely depend on PAMA commentary and its potential impact on FY27 estimates. See Related StreetAccount comments: 10/22/2026 6:55:51 AM - Quest Diagnostics discloses cybersecurity incident - 8-K 10/22/2026 6:51:56 AM - StreetAccount Metrics Recap - Quest Diagnostics Q3 Earnings 10/22/2026 6:50:27 AM - Quest Diagnostics reports Q3 EPS $3.00 ex-items vs FactSet $2.87 [13 est, $2.82-2.94]	show story hide story
22-Oct-2026 08:23	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings reports continue to ramp, a handful of reports overnight including first CRO and third MCO. Molina Healthcare unable to extend the MLR beat by the group, a narrow miss on consolidated MLR. Shares of MOH (3%) in the pre-market. European prints include Sartorius AG and Roche, both beat-and-affirmed, though stocks telling a different story today: SRT3.GR +2% and ROP.SW (1%). Diagnostic firm Qiagen confirmed earlier media reports that reached acquisition agreement with a group of investors led by EQT. Valuation as predicted, around €10.8B ($12.1B at current exchange rate). ADRs for QGEN +1% in the pre-market. Biotech newsflow relatively quiet, but signs of more regulatory flexibility in the rare disease space after FDA accepts NDA resubmission in SCA from Biohaven. Fairly short review timeline expected to include an Adcom review. Shares of BHVN +38% in the pre-market. QURE +6% in sympathy. Yesterday, Healthcare equities were mixed to lower overall. Most major health groups ended lower for the session, all were between +/- 1% on the averages. Payers, providers and Pharma were the leading decliners; only MedTech beat the wider tape. Earnings calendar snapped back to the forefront with several MedTech prints on the tape. Macro S&P futures are down (1.0%) on Thursday morning, and Nasdaq down (1.7%). Risk off with AI trade under pressure and no meaningful cushion from rotation. Big selloff in Asia overnight. Nothing in the latest batch of results to really disrupt the broader compute/capex demand narrative. However, TSLA capex guidance cut disappointed given the outsized focus on new products/initiatives, META takeaways largely positive but still some scrutiny surrounding big capex needs and Muse monetization waiting game, and LRCX guide underwhelmed against a high bar. Treasuries a beneficiary of the AI trade stumble (and likely flight-to-quality from another jump in French yields). Geopolitics the other big story today with oil boosted by latest batch of headlines highlighting expectations for a renewed ramp in kinetic activity in the Middle East. This has also been flagged as a headwind for the historical post-election outperformance narrative. Pre-market trading update Trading higher +37.7% BHVN FDA accepts NDA resubmission with Q1 PDUFA +8.5% NBTX shares were +7% yesterday and +21% WTD +6.0% QURE sympathy to BHVN +2.1% SRT3.GR in European trading; earnings +0.9% QGEN acquired by EQT.SS for €10.8B ($12.1B) Trading lower -9.3% RCUS secondary offering -6.7% AAPG on 5K shares -4.9% MEDP earnings (low volume) -4.8% TWST on 13K shares -4.2% DGX earnings (low volume) -4.1% ZLAB on 43K ADRs -3.0% RXRX risk-off trade with AI -2.9% SMMT issues PR on ESMO presentations -2.5% MOH earnings (low volume) -0.9% ROP.SW in European trading; earnings Pharma Earnings: ROP.SW reports Q3 revenue CHF16.13B vs consensus CHF15.75B. Pharma segment mostly ahead of consensus, including Vabysmo narrow beat, while Tecentriq and Kadcyla fell short. Diagnostic segment sales slightly ahead. Quick take: Analysts were positive following the print, noting that revenue beat expectations, driven mainly by the Pharmaceuticals segment, while Diagnostics came in slightly ahead of consensus. Analysts note that the Pharma beat was attributable to timing effects from Japan's ERP system implementation, and Diagnostics was in line to slightly ahead of consensus despite continued China pricing reform headwinds. Analysts also flag that the company confirmed its outlook for the year, implying no material change to consensus and offering limited upside from the shares today, though some see the 7% constant currency growth acceleration and positioning toward the upper end of guidance ranges as warranting a modest positive reaction. However, analysts remain concerned about the phasing benefit and weakness in key franchises, suggesting limited visibility into top-line growth momentum through 2027. Conf. call at 8:00ET Biotech Regulatory: BHVN announced that FDA has accepted the NDA resubmission for troriluzole (Vyglxia) in Spinocerebellar ataxia (SCA), following the November 2025 CRL. FDA plans to convene an Advisory Committee meeting (to be announced), and expects to take action on PDUFA date during Q1 of 2027. Research: IONS upgraded to outperform from market perform at BMO Capital Markets (David Lebowitz), target increased to $66 from $54 or approx. 49% upside. CADL initiated buy at Jefferies (Maury Raycroft), target is $25 or approx. 199% upside. CELC initiated overweight at Cantor Fitzgerald (Li Watsek), target is $140 or approx. 127% upside. ETRA initiated overweight at JPMorgan (Anupam Rama), target is $36 or approx. 298% upside. KARD initiated outperform at Baird (Jack Allen), target is $43 or approx. 235% upside. PBLS initiated buy at HC Wainwright (Robert Burns), target is $40 or approx. 44% upside. IPO filing: +RZRA (Rezera Inc.) files for Nasdaq IPO of indeterminate amount. Clinical-stage biotech focused on oral inhibitors of NLRP3. S-1 StreetAccount notes that LLY paid $1.2B in January 2026 for Ventyx Biosciences and its NLRP3 portfolio. Life Science & MedTech M&A: QGEN confirmed recent press reports, and announced an agreement to be acquired by Crown NL Bidco B.V. - a private equity led group of investors - for €46.50 per share in cash, or EV €10.8B ($12.1B at exchange rates). Supervisory and Managing Boards approved the Business Combination Agreement and support the transaction. Earnings: SRT3.GR reports Q3 EBITDA €279.9M vs consensus €268.9M on revenue €926.3M vs consensus €899.3M, and confirmed FY26 guidance for the group and the bioprocessing segment. Growth in the LP&S segment now expected around the upper end of its +4-6% guide. Conf. call at 7:00ET MEDP reported Q3 EPS $4.84 vs FactSet $4.44 on revenue $716.0M vs FS $714.5M, EBITDA $172.1M vs FS $160.5M. Backlog $3.17B vs FS $3.13B. Broadly raises FY guidance. Conf. call at 9:00ET Services & Hospitals Earnings: DGX reports Q3 EPS $3.00 ex-items vs FactSet $2.87 on revenue $3.10B vs FS $3.05B. Raises FY EPS outlook by 10 cents, and revenue outlook by $85M at the midpoints. Company also disclosed via 8-K an October cybersecurity incident. Company does not see any material disruption to its operations. Conf. call at 8:30ET Managed Care Earnings: MOH reported Q3 EPS $0.89 ex-items vs FactSet $0.79 on revenue $11.08B vs FS $10.86B. Consolidated MLR narrowly missed, 92.9% vs StreetAccount consensus 92.8%. Reaffirms FY EPS outlook and all metrics. Quick Take: Takeaways suggest Q3 EPS upside is not reflected in guidance, implying a weaker Q4 outlook than prior commentary and limited cushion for Medicaid MLR deterioration from Florida CMS impact. Q3 upside was also viewed as underwhelming, with the EPS beat attributed to lower-than-expected G&A. On the call, some seek color on elevated Medicaid cost trends, 1/1/27 rates, and the Florida CMS rollout. Conf. call at 8:00ET On Deck: Conferences (cont.) NAMS 2026 (Oct 20-24) (cont.) ASN 2026 (Kidney Week) (Oct 21-25) EHDN Congress (Oct 22-24) Craig-Hallum Biotech Catalyst Conference (Oct 22) on Fri 23-Oct: ESMO 2026 (Oct 23-27) Note: LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) Syndicate / IPO pricing tonight +LYCA Lycia Therapeutics - looking to raise $250M Corporate on Fri 23-Oct: TNGX Investor webcast at ESMO (7:30ET) on Sat 24-Oct: PFE presentation of PCV25 infant at IDWeek (11:00ET) (PCVX); MRNA Investor webcast at ESMO (13:00ET) (MRK) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AAPG, BHVN, CADL, CELC, DGX, ETRA, IONS, KARD, LLY, MEDP, MOH, MRK, MRNA, NBTX, PBLS, PCVX, PFE, QGEN, QURE, RCUS, ROP.SW, RXRX, SMMT, SRT3.GR, TNGX, TWST, ZLAB, +LYCA, +RZRA...(more)	show story hide story
22-Oct-2026 07:49	MOH Molina Healthcare falls despite Q3 beat as guidance implies weaker Q4 ($214.90) MOH is (4.2%) premarket after reporting Q3 EPS beating FactSet on revenue also ahead. Consolidated MLR narrowly missed, 92.9% vs StreetAccount consensus 92.8%. Reaffirmed FY EPS outlook and all metrics. Takeaways suggest Q3 EPS upside is not reflected in guidance, implying a weaker Q4 outlook than prior commentary and limited cushion for Medicaid MLR deterioration from Florida CMS impact. Q3 upside was also viewed as underwhelming, with the EPS beat attributed to lower-than-expected G&A. On the call, some seek color on elevated Medicaid cost trends, 1/1/27 rates, and the Florida CMS rollout. See Related StreetAccount comments: 10/21/2026 4:39:29 PM - StreetAccount Metrics Recap - Molina Healthcare Q3 Earnings 10/21/2026 4:19:38 PM - Molina Healthcare reports Q3 EPS $0.89 ex-items vs FactSet $0.79 [19 est, $0.69-1.68]	show story hide story
21-Oct-2026 17:03	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed and lower overall on Wednesday. Decliners outnumbered advancers on the XLV. Healthcare (0.45%) vs S&P 500 +0.58%. Most major health groups ended lower for the session, all were between +/- 1% on the averages. Payers, providers and Pharma were the leading decliners; only MedTech beat the wider tape. CRL +9.3% and DXCM (6.4%) bracketed the XLV, in sympathy to their MedTech peer reporters. Earnings calendar snapped back to the forefront with several MedTech prints on the tape. ISRG (2.3%) reported a Q3 beat, however focus on the slowing growth in daVinci procedures. TMO +1.0% delivered a Q3 beat, however FY guidance tweak suggests a muted Q4. ABT (1.9%) on a Q3 print inline with medical devices broadly light to consensus. DHR +4.3% on a Q3 beat and raise (by less than the outperformance). Flattening diagnostics segment and FX impacts updated outlook. For the second day, Bloomberg reported that a takeout deal was near for QGEN +2.2%. Yesterday, Healthcare equities were broadly higher. All major health groups ended higher by 2% or more on the averages, with Biotech, Managed Care, and Pharma leading. XBI +3.64%, DRG +2.81%. Dialysis names pressured by new HHS kidney care plan announcement. Sector news was still very quiet between conferences and ahead of the anticipated ramp in the earnings calendar. Macro AI trade the big focus following blowout results from SPCX and a positive SMCI preannouncement; also some focus on NVDA supply chain agreements. Still-robust compute demand and expansive capex plans among the big talking points, but competitive challenges and funding dynamics also remain in the narrative. Some attention pulled ahead to META results after the bell; GOOGL faced some pressure into the print (boutique research firm call flagged). Earnings takeaways mixed with the usual moving pieces and nothing particularly incremental for the market narrative. Middle East updated leaned cautious, including late afternoon report US preparing order to evacuate some embassy staff from Gulf, which some officials said could suggest possible resumption of hostilities. Notable Gainers +10.7% ABSI (Absci Corp.): best performer on XBI; shares +22% WTD +9.3% CRL (Charles River Laboratories): sympathy to Tools earnings; best performer on XLV +7.0% NBTX (Nanobiotix): shares +21% WTD and (17%) MTD +6.9% TNGX (Tango Therapeutics): second-best on XBI; on heavy volume, shares +22% WTD ahead of ESMO +6.4% GRAL (GRAIL, Inc.): on below average volume; shares +13% WTD +6.3% ICLR (ICON plc): sympathy to Tools earnings +5.8% TXG (10X Genomics): on average volume +5.6% ILMN (Illumina): sympathy to Tools earnings; second-best on XLV +5.4% ROIV (Roivant Sciences): trial results in non-infectious uveitis +4.7% OVID (Ovid Therapeutics): on 3X average volume; shares +15% WTD +4.5% TWST (Twist Bioscience): sympathy to Tools earnings +4.3% DHR (Danaher): earnings +4.2% DMRA (Damora Therapeutics): on average volume; shares +17% WTD +3.3% WAT (Waters): sympathy to Tools earnings +3.3% IQV (IQVIA Holdings): sympathy to Tools earnings +2.2% QGEN (Qiagen): Bloomberg reports that deal with EQT is near Notable Decliners -19.6% RCUS (Arcus Biosciences): follow-through; worst performer on XBI -14.7% RAPP (Rapport Therapeutics): follow-through -14.2% ACH (Accendra Health): despite upgrade at CFRA -11.2% IART (Integra LifeSciences Holdings): earnings -11.0% CAPR (Capricor Therapeutics): on average volume -6.4% DXCM (Dexcom): worst performer on XLV; sympathy to ABT -3.7% NVAX (Novavax, Inc.): shares (2%) WTD -2.4% BSX (Boston Scientific): sympathy to ABT -2.3% ISRG (Intuitive Surgical): earnings, guidance; upgraded at Erste Group Earnings in MedTech TMO reports Q3 EPS $6.69 ex-items vs FactSet $6.40 on revenue $12.14B vs FS $11.95B. Organic growth +6% vs FS +4.3% and guidance approx. 4%. On the call: Reaffirms Q4 organic growth +4% vs FS +4.5%. Raises FY26 revenue outlook by $200M at the midpoints, or roughly the Q3 outperformance. Along the same lines, EPS outlook raised by just 15c at the midpoints, or less than the Q3 beat. Quick take: Initial sentiment largely upbeat, discussion noted the high bar into the print but commonly highlighted outperformance in both Lab Products and Biopharma Services (LSS underperformed) - signaling increased funding across both pharma and biotech. Management noted on the call Q3 upside was aided by Pharma Services, with some activity shifted into Q3 from Q4 - despite the shift - raised its second-half organic growth outlook and tweaked FY26 guidance higher on strong underlying momentum. ABT reports Q3 EPS $1.42 ex-items vs FactSet $1.42 on revenue $13.01B vs FS $12.99B. Most segments inline, partially offset by medical devices light -- EP, HF, NM, Diabetes were all just below consensus. Guides Q4 EPS bracketing FS consensus. Narrow FY26 EPS outlook, midpoint maintained. Expects FY26 comp sales growth around +6.0% vs prior guidance around +5.0% to +7.5%. Announces intent to separate nutrition business into a standalone public company. DHR reports Q3 EPS $2.11 ex-items vs FactSet $1.92 on revenue $6.55B vs FS $6.56B. Raises FY26 EPS guidance by $0.07 at the midpoints, lowers outlook for core sales growth to around +2.5% vs prior +3.0-4.0% amid flattening diagnostics segment and greater FX impact. ISRG reported Q3 EPS $3.00 ex-items vs FactSet $2.65 on revenue $3.05B vs FS $2.91B. W/W procedures (DV and Ion) grew ~15% y/y (DV grew ~14% y/y vs StreetAccount +13.5%; Ion grew ~31% y/y). Narrowed FY outlook for W/W DV growth to +14-15% vs prior +13.5-15.5%; expects to be closer to the midpoint of this range Quick take: Initial takeaways on the print highlighted Q3 revenue outperformance, new placements (both US and OUS), expanding margins, and dynamic growth initiatives. Plenty of positives for the bulls. Bears remain hyper focused on daVinci procedure volumes, especially the US growth rate which slipped to +10.3%, and w/w guidance narrowed to +14-15%, and expected near the midpoint. Elevance Health Q3 beat and raise driven by one-time benefit ELV reports Q3 adjusted EPS $6.99, including net non-operating benefit $1.85/shr, unclear if comparable to FactSet $4.71. Q3 MLR 90.6% vs StreetAccount 91.2%. Raises FY EPS outlook to at least $29.00 vs prior at least $27.00. Reaffirms long-term targets in slides. Cencora raises the stake in American Oncology Network COR announced it will pay $1.7B to raise its ownership from 4% to 75% in the oncology services provider AONC. The companies previously had a supplier arrangement and strategic relationship. Cencora also updated its FY2026 financial guidance, now expects EPS at least $17.90, which is at the high-end of the prior range $17.75-17.95. SMID-cap biotech headlines ROIV announced results from the Phase 3 CLARITY program evaluating brepocitinib (LISRAYA) in non-infectious uveitis (NIU). Both the CLARITY-1 and CLARITY-2 studies met the primary endpoint, and brepo was stat-sig on all key secondary endpoints. Company intends to file sNDA in H1 of 2027. IBRX announced database lock for Cohort A of its registrational trial evaluating ANKTIVA in BCG-naive NMIBC. Company expects readout in November 2026, and is on-track for sBLA submission during Q4 of 2026. UNCY announced that FDA accepted its resubmitted NDA with a six-month review cycle. PDUFA for oxylanthanum carbonate (OLC) for hyperphosphatemia in CKD is 25-Mar-2027. As previously announced, the NDA resubmission includes CMC data from a new third-party drug product manufacturing vendor. Notable research in Healthcare today Pharma: JNJ downgraded to hold from buy at Erste Group (Hans Engel) Biotech: KZIA initiated buy at Guggenheim Securities (Paul Jeng), target is $35 or approx. 344% upside. VOR initiated outperform at William Blair (Myles Minter) XLO initiated outperform at Raymond James (Sean McCutcheon), target is $16 or approx. 87% upside. MedTech: ISRG upgraded to buy from hold at Erste Group (Hans Engel) CTSO initiated speculative buy at WBB Securities (Steve Brozak), target is $9.50 or approx. 79% upside. Services: ACH upgraded to strong buy from buy at CFRA Post-close news Earnings: MEDP reports Q3 EPS $4.84 vs FactSet $4.44 on revenue $716.0M vs FS $714.5M, EBITDA $172.1M vs FS $160.5M. Backlog $3.17B vs FS $3.13B. Broadly raises FY guidance. First CRO to report in Q3, IQV, ICLR, FTRE report next week Conf. call tomorrow at 9:00ET Shares trading (1.3%) in the after-hours MOH reports Q3 EPS $0.89 ex-items vs FactSet $0.79 on revenue $11.08B vs FS $10.86B. Consolidated MLR narrowly missed, 92.9% vs StreetAccount consensus 92.8%. Reaffirms FY EPS outlook and all metrics. Third MCO report in Q3, both UNH and ELV have beaten MLR Conf. call tomorrow at 8:00ET Shares trading (4.1%) in the after-hours Research: IONS upgraded to outperform from market perform at BMO Capital Markets (David Lebowitz), target increased to $66 from $54 or approx. 49% upside. Initiated 18-Aug-2026 Shares trading +1.7% in the after-hours IPO filing: +RZRA (Rezera Inc.) files for Nasdaq IPO of indeterminate amount. Clinical-stage biotech focused on oral inhibitors of NLRP3. S-1 StreetAccount notes that LLY paid $1.2B in January 2026 for Ventyx Biosciences and its NLRP3 portfolio. On Deck: Conferences (cont.) NAMS 2026 (Oct 20-24) (cont.) ASN 2026 (Kidney Week) (Oct 21-25) EHDN Congress (Oct 22-24) Craig-Hallum Biotech Catalyst Conference (Oct 22) on Fri 23-Oct: ESMO 2026 (Oct 23-27) Note: LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) Earnings tomorrow morning: DGX (8:30ET), ROP.SW (8:00ET), SRT3.GR (7:00ET) Corporate on Fri 23-Oct: TNGX Investor webcast at ESMO (7:30ET) on Sat 24-Oct: PFE presentation of PCV25 infant at IDWeek (11:00ET) (PCVX); MRNA Investor webcast at ESMO (13:00ET) Syndicate / IPO pricing Thu 22-Oct (post-close) +LYCA Lycia Therapeutics - looking to raise $250M StreetAccount Healthcare Reads Mark Cuban wants to crack open the market for rare disease treatments (21-Oct) STAT News Nigeria reports Ebola case as outbreak reaches West Africa (21-Oct) Reuters Daily Pill to keep Breast Cancer Away is Roche's Next Frontier Drug (20-Oct) Bloomberg Exclusive: HHS releases new kidney care plan (20-Oct) Axios Trump puts fraudsters on notice with $25M whistleblower program offering cash for tips that deliver (20-Oct) Fox News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABSI, ABT, ACH, AONC, BSX, CAPR, COR, CRL, CTSO, DGX, DHR, DMRA, DXCM, ELV, GRAL, IART, IBRX, ICLR, ILMN, IONS, IQV, ISRG, JNJ, KZIA, LLY, MEDP, MOH, MRK, MRNA, NBTX, NVAX, OVID, PCVX, PFE, QGEN, RAPP, RCUS, ROIV, ROP.SW, SRT3.GR, TMO, TNGX, TWST, TXG, UNCY, VOR, WAT, XLO, +LYCA, +RZRA...(more)	show story hide story
21-Oct-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.81%) vs the S&P 500 +0.30%. Major health groups are trading mixed on the averages, between (1%) and +1%. Only Services group relatively firm. Dialysis names faring better, up +1%, although offset by Hospitals down (1%). Distributors inline, including COR (1%) expanding via M&A in the oncology services space. Pharma and Managed Care groups are leading declines; MedTech and Biotech the advancers. CRL +5% and ISRG (3%) bracket the XLV. Earnings calendar back to the forefront with several MedTech prints on the tape. ISRG reported a Q3 beat, however focus on the slowing growth in daVinci procedures. TMO +1% delivered a Q3 beat, however FY guidance tweak suggests a muted Q4. ABT (3%) on a Q3 print inline with medical devices broadly light to consensus. DHR +3% on a Q3 beat and raise (by less than the outperformance). Flattening diagnostics segment and FX impacts updated outlook. Gainers +8.7% OVID (Ovid Therapeutics): best performer on XBI; on strong volume +7.1% ABSI (Absci Corp.): second-best on XBI +6.5% ROIV (Roivant Sciences): trial results for brepo in non-infectious uveitis +5.8% DMRA (Damora Therapeutics): on average volume +5.5% TNGX (Tango Therapeutics): on strong volume +5.3% CRL (Charles River Laboratories): sympathy to Tools earnings; best performer on XLV +4.1% UNCY (Unicycive Therapeutics): FDA accepts Class 2 NDA resubmission +3.7% TWST (Twist Bioscience): sympathy to Tools earnings +3.6% ILMN (Illumina): sympathy to Tools earnings; second-best on XLV +2.7% DHR (Danaher): earnings +2.4% VOR (Vor Biopharma): initiation +1.0% BBIO (BridgeBio Pharma): downgraded at CFRA +0.9% TMO (Thermo Fisher Scientific): earnings Decliners -8.8% ACH (Accendra Health): despite upgrade at CFRA -5.5% CAPR (Capricor Therapeutics): worst performer on XBI; on average volume -3.4% ISRG (Intuitive Surgical): earnings, guidance; upgraded at Erste Group; worst performer on XLV -2.8% ABT (Abbott Labs): earnings; announces plan to separate Nutrition business -2.7% IBRX (ImmunityBio): trial update in NMIBC -2.2% NVAX (Novavax, Inc.): shares even WTD -1.4% JNJ (Johnson & Johnson): downgraded at Erste Group -1.3% IART (Integra LifeSciences Holdings): earnings -1.2% ELV (Elevance Health): earnings, guidance	show story hide story
21-Oct-2026 10:34	TMO Thermo Fisher Scientific beat and raise Q3 on +6% organic growth, Lab Products and Biopharma strength ($700.13 +$12.76) TMO trading approximately +1.0% following the Q3 top and bottom line beat; organic growth ahead, +6% vs. consensus +4.3% and guidance of ~+4%. FY26 guidance moved higher - revenue now expected at $47.7-48.2B vs prior $47.4-48.1B and FS $47.9B and adjusted EPS $25.13-25.43 vs prior $24.93-25.33 and FS $25.14. Initial sentiment largely upbeat, discussion noted the high bar into the print but commonly highlighted outperformance in both Lab Products and Biopharma Services (LSS underperformed) - signaling increased funding across both pharma and biotech. Management noted on the call Q3 upside was aided by Pharma Services, with some activity shifted into Q3 from Q4 - despite the shift - raised its second-half organic growth outlook and tweaked FY26 guidance higher on strong underlying momentum. See Related StreetAccount comments: 10/21/2026 6:04:40 AM - StreetAccount Metrics Recap - Thermo Fisher Scientific Q3 Earnings 10/21/2026 6:03:10 AM - Thermo Fisher Scientific reports Q3 EPS $6.69 ex-items vs FactSet $6.40 [21 est, $6.33-6.47]	show story hide story
21-Oct-2026 09:12	ISRG Intuitive Surgical lower amid deceleration of daVinci procedure growth ($438.00) Shares of ISRG down (8.0%) in the pre-market. Company reported Q3 results after the close on Tuesday, both EPS and revenue well ahead of consensus. Worldwide procedure growth (daVinci and Ion combined) grew +15%, though investor focus on the reported DV growth around 14% vs StreetAccount +13.5%. Initial takeaways on the print highlighted Q3 revenue outperformance, new placements (both US and OUS), expanding margins, and dynamic growth initiatives. Plenty of positives for the bulls. Bears remain hyper focused on daVinci procedure volumes, especially the US growth rate which slipped to +10.3%, and w/w guidance narrowed to +14-15%, and expected near the midpoint. See Related StreetAccount comments: 10/20/2026 4:10:20 PM - StreetAccount Metrics Recap - Intuitive Surgical Q3 Earnings 10/20/2026 4:08:54 PM - Intuitive Surgical reports Q3 EPS $3.00 ex-items vs FactSet $2.65 [26 est, $2.53-2.76]	show story hide story
21-Oct-2026 08:40	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar back to the forefront with several MedTech prints on the tape. All four reports are trading lower early. Post-close on Tuesday Intuitive Surgical reported a Q3 beat, however focus on the slowing growth in daVinci procedures. Shares of ISRG (7%) in the pre-market. Thermo Fisher started the Wednesday morning reports with a Q3 beat, however FY guidance tweak suggests a muted Q4. Shares of TMO (3%) in the pre-market. Abbott Labs Q3 print inline with medical devices broadly light to consensus. Shares of ABT (4%) in the pre-market. Danaher Q3 beat and raise (by less than the outperformance). Flattening diagnostics segment and FX impacts updated outlook. Shares of DHR (5%) in the pre-market. Yesterday, Healthcare equities were broadly higher. All major health groups ended higher by 2% or more on the averages, with Biotech, Managed Care, and Pharma leading. XBI +3.64%, DRG +2.81%. Dialysis names pressured by new HHS kidney care plan announcement. Sector news was still very quiet between conferences and ahead of the anticipated ramp in the earnings calendar. Macro S&P futures are up +0.2% on Wednesday morning. AI trade underpinned by positive compute and capex demand takeaways from blowout SPCX earnings/guidance and positive SMCI preannouncement. (Kospi also bounced ~3.3% overnight as Elice recovered a good chunk of its IPO selloff). However, also keeps the broader AI funding scrutiny theme in play (and circularity dynamic back in the headlines with report NVDA could provide additional support for Finmus). Treasuries fairly stable despite upward pressure on European yields (French 10-year yields hit 5% for first time since 2002). Oil higher as latest upbeat flow headlines (Middle East exports above pre-war levels) seemingly overshadowed by lack of traction behind recent headlines about progress in US-Iran talks, along with continued concerns about another ramp in kinetic activity following the midterm elections. Pre-market trading update Trading higher +8.9% ROIV trial results for brepo in non-infectious uveitis; call at 800ET +6.3% UNCY FDA accepts Class 2 NDA resubmission +1.1% IBRX trial update in NMIBC +0.9% ELV earnings Trading lower -6.6% ISRG earnings; upgraded at Erste Group -4.8% DHR earnings -4.3% TWST on 15K shares -3.9% ABT earnings; announces plan to separate Nutrition business -2.7% TMO earnings -0.8% JNJ downgraded at Erste Group Pharma M&A: ALC announced the acquisition of Neurotech Pharmaceuticals (private, 05TR1G-E), and their FDA-approved drug Encelto (rev-cel) for Macular Telangiectasia Type 2 (MacTel). Research: JNJ downgraded to hold from buy at Erste Group (Hans Engel) Biotech Trial results: ROIV announced results from the Phase 3 CLARITY program evaluating brepocitinib (LISRAYA) in non-infectious uveitis (NIU). Both the CLARITY-1 and CLARITY-2 studies met the primary endpoint, and brepo was stat-sig on all key secondary endpoints. Company intends to file sNDA in H1 of 2027. Conf. call at 8:00ET Trial update: IBRX announced database lock for Cohort A of its registrational trial evaluating ANKTIVA in BCG-naive NMIBC. Company expects readout in November 2026, and is on-track for sBLA submission during Q4 of 2026. Regulatory: UNCY announced that FDA accepted its resubmitted NDA with a six-month review cycle. PDUFA for oxylanthanum carbonate (OLC) for hyperphosphatemia in CKD is 25-Mar-2027. As previously announced, the NDA resubmission includes CMC data from a new third-party drug product manufacturing vendor. Research: KZIA initiated buy at Guggenheim Securities (Paul Jeng), target is $35 or approx. 344% upside. VOR initiated outperform at William Blair (Myles Minter) XLO initiated outperform at Raymond James (Sean McCutcheon), target is $16 or approx. 87% upside. Life Science & MedTech Earnings: TMO reports Q3 EPS $6.69 ex-items vs FactSet $6.40 on revenue $12.14B vs FS $11.95B. Organic growth +6% vs FS +4.3% and guidance approx. 4%. Conf. call at 7:00ET; guides on call ABT reports Q3 EPS $1.42 ex-items vs FactSet $1.42 on revenue $13.01B vs FS $12.99B. Most segments inline, partially offset by medical devices light -- EP, HF, NM, Diabetes were all just below consensus. Guides Q4 EPS bracketing FS consensus. Narrow FY26 EPS outlook, midpoint maintained. Expects FY26 comp sales growth around +6.0% vs prior guidance around +5.0% to +7.5%. Announces intent to separate nutrition business into a standalone public company. Conf. call at 9:00ET DHR reports Q3 EPS $2.11 ex-items vs FactSet $1.92 on revenue $6.55B vs FS $6.56B. Raises FY26 EPS guidance by $0.07 at the midpoints, lowers outlook for core sales growth to around +2.5% vs prior +3.0-4.0% amid flattening diagnostics segment and greater FX impact. Conf. call at 8:00ET ISRG reported Q3 EPS $3.00 ex-items vs FactSet $2.65 on revenue $3.05B vs FS $2.91B. W/W procedures (DV and Ion) grew ~15% y/y (DV grew ~14% y/y vs StreetAccount +13.5%; Ion grew ~31% y/y) Narrowed FY outlook for W/W DV growth to +14-15% vs prior +13.5-15.5%; expects to be closer to the midpoint of this range Research ISRG upgraded to buy from hold at Erste Group (Hans Engel) CTSO initiated speculative buy at WBB Securities (Steve Brozak), target is $9.50 or approx. 79% upside. Services & Hospitals Regulatory: FME.GR (FMS) FDA disclosed the approval of two NDAs - one for Cienby, another for Calrezdy, used in regional citrate anticoagulation (RCA) with the multiFiltrate PRO System. Managed Care Earnings: ELV reports Q3 adjusted EPS $6.99, including net non-operating benefit $1.85/shr, unclear if comparable to FactSet $4.71. Q3 MLR 90.6% vs StreetAccount 91.2%. Raises FY EPS outlook to at least $29.00 vs prior at least $27.00. Reaffirms long-term targets in slides. Conf. call at 8:30ET On Deck: Conferences (cont.) NAMS 2026 (Oct 20-24) ASN 2026 (Kidney Week) (Oct 21-25) on Thu 22-Oct: EHDN Congress (Oct 22-24); Craig-Hallum Biotech Catalyst Conference on Fri 23-Oct: ESMO 2026 (Oct 23-27) Note: LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) Earnings today after the close MEDP (Thu at 9:00ET), MOH (Thu at 8:00ET) Earnings on Thu 22-Oct: before DGX (8:30ET), ROP.SW (8:00ET), SRT3.GR (7:00ET) Corporate FDMT Investor Day NYC (10:30ET) on Fri 23-Oct: TNGX Investor webcast at ESMO (7:30ET) on Sat 24-Oct: MRNA Investor webcast at ESMO (MRK) (13:00ET) Syndicate / IPO pricing Thu 22-Oct (post-close) +LYCA Lycia Therapeutics - looking to raise $250M This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ALC, CTSO, DGX, DHR, ELV, FDMT, FME.GR, IBRX, ISRG, JNJ, KZIA, MEDP, MOH, MRK, MRNA, ROIV, ROP.SW, SRT3.GR, TMO, TNGX, TWST, UNCY, VOR, XLO, +LYCA...(more)	show story hide story
20-Oct-2026 17:32	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly higher on Tuesday. Advancers beat decliners by 11:1 on the XLV (just five decliners). Healthcare +2.33% vs S&P 500 +0.28%. All major health groups ended higher by 2% or more on the averages, with Biotech, Managed Care, and Pharma leading. XBI +3.64%, DRG +2.81%. MRNA +6.7% and DVA (6.2%) bracketed the XLV; dialysis names pressured by media report that HHS will take steps to cultivate competition in the kidney care market. Major drug stocks were broadly higher +2% to +5% each; Animal Health names were the outliers following the Jefferies downgrades of ELAN (3.4%) and ZTS +0.6%. Sector news was still very quiet between conferences and ahead of the anticipated ramp in the earnings calendar. ISRG +1.1% reports tonight post-close; a much larger slate tomorrow including ABT (1.6%). Shares of RAPP +2.7% on today's bipolar data and ensuing debate around marginal benefit and treatment AEs. Call out for the ESMO names faring better after digestion of abstracts. MYGN +31.6% topped all gainers on the XBI with the certainty of cash for its prenatal business, sold to LH +1.4% for $210M. Clinical trial updates today highlighted by a novel mechanism for the treatment of acute bipolar mania. Rapport Therapeutics' mid-stage trial met its primary endpoint, and treatment-emergent adverse events reported to be mild or moderate. Yesterday, Healthcare equities were mixed yet lower overall. Biotech, MedTech and Managed Care were all gainers; Pharma leading decliner with the DRG (1.02%) and Services down similar. MRNA +4.1% and HSIC (2.8%) bracketed the XLV. XBI +2.45% also saw a boost from today's premium M&A deal in biopharma. Sector gearing up for busier week of earnings, beginning with Intuitive Surgical on Tuesday post-close. Macro Several moving pieces today. Some stabilization in the AI trade following earlier pullback partly chalked up to poor debut of Korean neocloud provider Elice, which fell more than 30%. Breadth strong with a mix of defensive and select cyclicals faring well. Lower rate backdrop (long end) another area of focus multiple drivers, including positioning, seemingly in play. Oil weaker with reports of traction behind US-Iran talks, though off lows on headline pushing back against an imminent deal. Mixed takeaways from the higher-profile reporters today with seemingly little impact on broader market narratives ahead of upcoming hyperscaler and semi earnings (and NVDA GTC Berlin). Software M&A and soft housing market data some of the other highlights today. Notable Gainers +31.6% MYGN (Myriad Genetics): to divest prenatal testing business; upgraded at Piper Sandler; best performer on XBI +13.7% TRAX (First Tracks Biotherapeutics Inc): on average volume +12.8% KLRA (Kailera Therapeutics, Inc.): on above average volume +11.0% CLYM (Climb Bio): initiation +8.1% SRPT (Sarepta Therapeutics): on average volume +7.9% SYRE (Spyre Therapeutics): shares +14% WTD +7.3% RCUS (Arcus Biosciences): trial results in ccRCC +6.7% MRNA (Moderna): best performer on XLV; shares +11% WTD +5.5% ZBIO (Zenas BioPharma): on below average volume +5.1% CRL (Charles River Laboratories): on above average volume +5.0% QGEN (Qiagen): Bloomberg report - EQT.SS in talks to acquire for more than $50/shr +4.8% BMY (Bristol Myers Squibb): on average volume +4.1% BIIB (Biogen): on above average volume +3.5% LLY (Eli Lilly): on above average volume +3.4% RVTY (Revvity): on below average volume +3.3% MRK (Merck): sympathy to RCUS; on average volume +3.0% OBIO (Orchestra Biomed): on 3X average daily volume; confusion with OpenAI acquisition target (Orchestra Bio Inc.) Notable Decliners -7.7% ANAB (AnaptysBio): litigation headlines (with GSK); worst performer on XBI -6.2% DVA (DaVita): Axios report on HHS plan for kidney care; worst performer on XLV -3.4% ELAN (Elanco Animal Health): downgraded at Jefferies -2.4% FMS (Fresenius Medical Care): Axios report on HHS plans for kidney care -1.9% BAX (Baxter International): FDA warning letter Dialysis providers trading sharply lower following media report Axios reporting that HHS Secretary RFK Jr will announce today steps to increase competition in the highly concentrated dialysis marketplace. Shares of DaVita and Fresenius Medical trading down (6%) and (2%) respectively. Myriad Genetics higher on prenatal divestiture MYGN and Labcorp (LH) announced that Myriad will sell its Prenatal Health testing business for $210M in cash plus adjustments. Labcorp expects to add $160M in revenue in year one. Upgraded at Piper Sandler in reaction Trial results in SMID-cap biotech RAPP announced topline results from the phase 2 trial of RAP-219 in adults with acute bipolar mania. The trial met its primary endpoint. Company to meet FDA during Q1 of 2027. Plans to initiate two phase 3 trial in H2 of 2027. Reported $436M in cash as of 30-Jun. Quick take: Wells Fargo says efficacy looks good, but the firm has questions on safety and TEAEs. RCUS announced updated data from its Ph1/2 trials of casdatifan in ccRCC. Quick take: Leerink Partners says that while 1L uncertainty remains, firm is encouraged by the updated data, expects positive stock reaction. ODTX presented at UEGW results from its phase 2a trial evaluating OD-001 in ulcerative colitis (UC). Company plans to advance a phase 2b monotherapy trial and a phase 2b trial adding vedolizumab. Results from both expected H2 of 2027. US CDC acknowledges third death from measles in CY2026 Without providing any details (ie. location), the CDC website tracking measles now displays 3* deaths in CY2026. CDC continues to note () that this number is subject to change, and it will "update its reporting as additional information becomes available and relevant reviews are completed". Pennsylvania reported its sixth (6) death from measles on 12-Oct-2026. Notable research in Healthcare today* Pharma: ELAN downgraded to hold from buy at Jefferies (Keith Devas), target cut to $24 from $31 or approx. 2% upside. ZTS downgraded to hold from buy at Jefferies (Keith Devas), target cut to $83 from $103 or approx. 4% upside. Biotech: EYPT downgraded to underweight from neutral at JPMorgan (Tessa Romero), follows LUCIA readout. EYPT downgraded to neutral from outperform at Mizuho Securities (Graig Suvannavejh), follows LUCIA readout. Target cut to $0.50 from $39 or approx. 14% upside. ADRX seeing initial sell-side coverage following IPO on 25-Sep. Shares have traded +4% since pricing at $17.00. All buy-equivalent ratings so far (JPMorgan, LifeSci Capital, Morgan Stanley, TD Cowen, UBS) with an average PT $34, range $32-38, or approx. 94% upside. ABVX assumed overweight at Morgan Stanley (Michael Ulz), target is $180 or approx. 106% upside. AGMB assumed overweight at Morgan Stanley (Michael Ulz), target is $28 or approx. 240% upside. ARQT assumed overweight at Morgan Stanley (Michael Ulz), target is $38 or approx. 19% upside. ATTO assumed overweight at Morgan Stanley (Michael Ulz), target is $39 or approx. 181% upside. CLDX assumed overweight at Morgan Stanley (Michael Ulz), target is $57 or approx. 92% upside. CLYM initiated buy at Deutsche Bank (David Hoang), target is $28 or approx. 188% upside. ENSC initiated overweight at Cantor Fitzgerald (Olivia Saunders), target is $2 or approx. 300% upside. EVMN assumed overweight at Morgan Stanley (Chris Yu), targets is $26 or approx. 393% upside. INCY assumed equal-weight at Morgan Stanley (Chris Yu), targets is $119 or approx. 5% upside. KYMR assumed overweight at Morgan Stanley (Michael Ulz), target is $135 or approx. 25% upside. KZIA initiated outperform at Leerink Partners (Andrew Berens), target is $30 or approx. 282% upside. LKFT assumed equal-weight at Morgan Stanley (Chris Yu), targets is $26 or approx. 13% downside. QTTB assumed overweight at Morgan Stanley (Michael Ulz), target is $34 or approx. 336% upside. TVRD initiated buy at Chardan Capital (Gautam Chukka), target is $8 or approx. 725% upside. ZBIO assumed equal-weight at Morgan Stanley (Chris Yu), targets is $32 or approx. 20% upside. MedTech: MYGN upgraded to neutral from underweight at Piper Sandler (David Westenberg), target increased to $5 from $2 or approx. 13% downside. AORT initiated buy at Jefferies (Michael Sarcone), target is $31 or approx. 39% upside. KMTS initiated outperform at Evercore ISI (Vijay Kumar), target is $34 or approx. 16% upside. Services: CON initiated overweight at Stephens (Raj Kumar), target is $45 or approx. 18% upside. Post-close news Earnings: ISRG reports Q3 EPS $3.00 ex-items vs FactSet $2.65 on revenue $3.05B vs FS $2.91B. W/W procedures (DV and Ion) grew ~15% y/y (DV grew ~14% y/y vs StreetAccount +13.5%; Ion grew ~31% y/y) Narrowed FY outlook for W/W DV growth to +14-15% vs prior +13.5-15.5%; expects to be closer to the midpoint of this range Shares trading (7.0%) in the after-hours / post-call M&A: ALC announced the acquisition of Neurotech Pharmaceuticals (private, 05TR1G-E), and their FDA-approved drug Encelto (rev-cel) for Macular Telangiectasia Type 2 (MacTel). ADRs trading unchanged in the after-hours Regulatory: FMS FDA disclosed the approval of two NDAs - one for Cienby, another for Calrezdy, used in regional citrate anticoagulation (RCA). ADRs trading +1.2% in the after-hours On Deck: Conference (cont.) NAMS 2026 (Oct 20-24) ASN 2026 (Kidney Week) (Oct 21-25) on Thu 22-Oct: EHDN Congress (Oct 22-24); Craig-Hallum Biotech Catalyst Conference Earnings tomorrow before ABT (9:00ET), DHR (8:00ET), ELV (8:30ET), TMO (7:00ET) after MEDP (Thu at 9:00ET), MOH (Thu at 8:00ET) Earnings on Thu 22-Oct: before DGX (8:30ET), ROP.SW (8:00ET), SRT3.GR (7:00ET) Corporate calendar FDMT Investor Day NYC (10:30ET) Syndicate / IPO pricing on Thu 22-Oct (post-close) +LYCA Lycia Therapeutics - looking to raise $250M This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ABVX, ADRX, AGMB, ALC, ANAB, AORT, ARQT, ATTO, BAX, BIIB, BMY, CLDX, CLYM, CON, CRL, DGX, DHR, DVA, ELAN, ELV, ENSC, EVMN, EYPT, FDMT, FMS, INCY, ISRG, KLRA, KMTS, KYMR, KZIA, LH, LKFT, LLY, MEDP, MOH, MRK, MRNA, MYGN, OBIO, ODTX, QGEN, QTTB, RAPP, RCUS, ROP.SW, RVTY, SRPT, SRT3.GR, SYRE, TMO, TRAX, TVRD, ZBIO, ZTS, +LYCA...(more)	show story hide story
20-Oct-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +2.28% vs the S&P 500 +0.65%. All major health groups are broadly higher by 1% or more on the averages, led by Pharma and Biotech, DRG +3.06% and XBI +3.20%. LLY +5% and BAX (3%) bracket the XLV. All major drugmakers are up LSD on the session; Animal Health names are outliers following the Jefferies downgrades; ELAN (3%). Sector news still very quiet between conferences and ahead of the anticipated ramp in the earnings calendar. ISRG (flat) reports after the close today; bigger slate tomorrow including ABT (flat). Breadth even more positive on the XBI. Shares of RAPP +6%, though have come off their early highs following today's bipolar data. Call out for the ESMO names faring better after digestion of abstracts. MYGN +32% tops however on the certainty of cash for its prenatal business, sold to LH +1% for $210M. Gainers +32.4% MYGN (Myriad Genetics): to divest prenatal testing business; best performer on XBI +9.3% RCUS (Arcus Biosciences): trial results in ccRCC +9.3% CLYM (Climb Bio): initiation +8.5% SYRE (Spyre Therapeutics): shares +12% WTD +5.8% RAPP (Rapport Therapeutics): trial results in acute bipolar mania +4.7% LLY (Eli Lilly): best performer on XLV +4.1% BIIB (Biogen): on average volume; second-best on XLV +3.8% BMY (Bristol Myers Squibb): on average volume +3.2% MRK (Merck): sympathy to RCUS; on average volume +2.6% ALVO (Alvotech): FDA approves new manufacturing process for bHumira Decliners -5.1% RTSN : recent biotech IPO -4.5% CTY : recent biotech IPO -3.8% EBS (Emergent BioSolutions): worst performer on XBI -3.3% BAX (Baxter International): FDA warning letter; worst performer on XLV -3.0% ELAN (Elanco Animal Health): downgraded at Jefferies -2.1% TRXB : recent biotech IPO -2.0% ADRX (ADARx Pharmaceuticals, Inc.): recent biotech IPO; initiations -0.7% CRSP (CRISPR Therapeutics): CFO departure	show story hide story
20-Oct-2026 08:28	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Sector news very quiet between conferences and ahead of the anticipated ramp in the earnings calendar. Intuitive Surgical reports after the close today; bigger slate tomorrow including Abbott Labs. Clinical trial updates today highlighted by a novel mechanism for the treatment of acute bipolar mania. Rapport Therapeutics' mid-stage trial met its primary endpoint, and treatment-emergent adverse events reported to be mild or moderate. Shares of RAPP +24% in the pre-market. Yesterday, Healthcare equities were mixed yet lower overall. Biotech, MedTech and Managed Care were all gainers; Pharma leading decliner with the DRG (1.02%) and Services down similar. MRNA +4.1% and HSIC (2.8%) bracketed the XLV. XBI +2.45% also saw a boost from today's premium M&A deal in biopharma. Sector gearing up for busier week of earnings, beginning with Intuitive Surgical on Tuesday post-close. Macro S&P futures are down (0.2%) on Tuesday morning, while Nasdaq futures are down (0.35%). AI trade under renewed pressure with focus on poor debut of Korean neocloud provider Elice, which fell more than 30%. Also some scrutiny surrounding a Monday bounce that was flagged as largely technical and saw CRWV fail to sustain earlier gains despite positive sell-side commentary. The other big AI headline has revolved around OpenAI reportedly accelerating a ~$30B fundraising round ahead of Anthropic IPO. Compute demand dynamic also in focus with report Nscale in talks for another $45B deal with Anthropic. Fairly quiet outside of AI, including when it comes to geopolitics. Not much from the earnings calendar overnight, though activity set to pick up with outsized focus over the next few days on hyperscalers and semis. Pre-market trading update Trading higher +23.8% RAPP trial results in acute bipolar mania; call at 800ET +7.8% ALVO FDA approves new manufacturing process for bHumira +1.8% RCUS ahead of trial results in ccRCC; call at 830ET Trading lower -2.4% TWST on light volume (6K shares) -1.7% CRSP CFO departure -1.6% ZTS downgraded at Jefferies -1.2% ODTX trial results in UC; call at 800ET -1.1% EYPT follow-through, downgrades -0.0% ELAN downgraded at Jefferies Pharma Research: ELAN downgraded to hold from buy at Jefferies (Keith Devas), target cut to $24 from $31 or approx. 2% upside. ZTS downgraded to hold from buy at Jefferies (Keith Devas), target cut to $83 from $103 or approx. 4% upside. Biotech Trial results: RAPP announced topline results from the phase 2 trial of RAP-219 in adults with acute bipolar mania. The trial met its primary endpoint. Company to meet FDA during Q1 of 2027. Plans to initiate two phase 3 trial in H2 of 2027. Reported $436M in cash as of 30-Jun. Conf. call at 8:00ET Quick take: Wells Fargo says efficacy looks good, but the firm has questions on safety and TEAEs. ODTX presented at UEGW results from its phase 2a trial evaluating OD-001 in ulcerative colitis (UC). Company plans to advance a phase 2b monotherapy trial and a phase 2b trial adding vedolizumab. Results from both expected H2 of 2027. Conf. call at 8:00ET RCUS is expected to present data from its Ph1/2 trials of casdatifan in ccRCC Conf. call at 8:30ET Research: EYPT downgraded to underweight from neutral at JPMorgan (Tessa Romero), follows LUCIA readout. EYPT downgraded to neutral from outperform at Mizuho Securities (Graig Suvannavejh), follows LUCIA readout. Target cut to $0.50 from $39 or approx. 14% upside. ADRX seeing initial sell-side coverage following IPO on 25-Sep. Shares have traded +4% since pricing at $17.00. All buy-equivalent ratings so far (JPMorgan, LifeSci Capital, Morgan Stanley, TD Cowen, UBS) with an average PT $34, range $32-38, or approx. 94% upside. ABVX assumed overweight at Morgan Stanley (Michael Ulz), target is $180 or approx. 106% upside. AGMB assumed overweight at Morgan Stanley (Michael Ulz), target is $28 or approx. 240% upside. ARQT assumed overweight at Morgan Stanley (Michael Ulz), target is $38 or approx. 19% upside. ATTO assumed overweight at Morgan Stanley (Michael Ulz), target is $39 or approx. 181% upside. CLDX assumed overweight at Morgan Stanley (Michael Ulz), target is $57 or approx. 92% upside. CLYM initiated buy at Deutsche Bank (David Hoang), target is $28 or approx. 188% upside. ENSC initiated overweight at Cantor Fitzgerald (Olivia Saunders), target is $2 or approx. 300% upside. EVMN assumed overweight at Morgan Stanley (Chris Yu), targets is $26 or approx. 393% upside. INCY assumed equal-weight at Morgan Stanley (Chris Yu), targets is $119 or approx. 5% upside. KYMR assumed overweight at Morgan Stanley (Michael Ulz), target is $135 or approx. 25% upside. KZIA initiated outperform at Leerink Partners (Andrew Berens), target is $30 or approx. 282% upside. LKFT assumed equal-weight at Morgan Stanley (Chris Yu), targets is $26 or approx. 13% downside. QTTB assumed overweight at Morgan Stanley (Michael Ulz), target is $34 or approx. 336% upside. TVRD initiated buy at Chardan Capital (Gautam Chukka), target is $8 or approx. 725% upside. ZBIO assumed equal-weight at Morgan Stanley (Chris Yu), targets is $32 or approx. 20% upside. Life Science & MedTech Research: AORT initiated buy at Jefferies (Michael Sarcone), target is $31 or approx. 39% upside. KMTS initiated outperform at Evercore ISI (Vijay Kumar), target is $34 or approx. 16% upside. Services & Hospitals Research: CON initiated overweight at Stephens (Raj Kumar), target is $45 or approx. 18% upside. On Deck: Conferences (cont.) UEGW 2026 (Oct 17-20) NAMS 2026 (Oct 20-24) on Wed 21-Oct: ASN 2026 (Kidney Week) (Oct 21-25) Corporate RCUS trial results in ccRCC (8:30ET) RGNX to review sur-vec program in wet AMD (13:00ET) on Wed 21-Oct: FDMT Investor Day NYC (10:30ET) Earnings after the close today ISRG (16:30ET) Earnings on Wed 21-Oct: before ABT (9:00ET), DHR (8:00ET), ELV (8:30ET), TMO (7:00ET) after MEDP (Thu at 9:00ET), MOH (Thu at 8:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ABVX, ADRX, AGMB, ALVO, AORT, ARQT, ATTO, CLDX, CLYM, CON, CRSP, DHR, ELAN, ELV, ENSC, EVMN, EYPT, FDMT, INCY, ISRG, KMTS, KYMR, KZIA, LKFT, MEDP, MOH, ODTX, QTTB, RAPP, RCUS, RGNX, TMO, TVRD, TWST, ZBIO, ZTS...(more)	show story hide story
19-Oct-2026 16:25	StreetAccount Sector Summary - Healthcare Post-Market Macro AI trade bounce the big story today. Largely chalked up to oversold conditions/cleaner positioning. In addition, several firms defended CRWV (though rally has not held), while SemiAnalysis was out with a largely upbeat report on the data center buildout. Also some thoughts that hyperscaler earnings, which kick off this week, could help shift the AI narrative back towards compute/capex demand. AI trade bounce a headwind for some of last week's rotational beneficiaries (equal-weight S&P underperforming today) Treasuries also weaker after renewed safe-haven interest (and positioning) helped offset hotter inflation data last week. Bond yield backup coming despite oil pullback. Some reported traction in US-Iran talks, though still myriad moving pieces when it comes to geopolitics. Synopsis Healthcare equities finish mixed yet lower overall on Monday. Decliners beat advancers by nearly 2:1 on the XLV. Healthcare (0.61%) vs S&P 500 +0.41%. Major health groups ended split on the session. Biotech, MedTech and Managed Care were all gainers; Pharma leading decliner with the DRG (1.02%) and Services down similar. MRNA +4.1% and HSIC (2.8%) bracketed the XLV. XBI +2.45% also saw a boost from today's premium M&A deal in biopharma. MRK.GR (0.0%) to acquire SLN +125.6% for approximately $1.3B in cash. Roche won Accelerated Approval for a label expansion of Jemperli, notably reviewed under the CNPV program founded by Dr Makary. Weekend news flow was fairly quiet despite Sunday's release of abstracts ahead of ESMO next weekend, and a few clinical readouts in biopharma this morning. Sector gearing up for busier week of earnings, beginning with Intuitive Surgical on Tuesday post-close. Healthcare gearing up for first ramp of the earnings calendar after the two bellwethers last week. Perhaps a dozen large-cap reports this week. ESMO 2026 abstracts were published Sunday night, although key late breakers are during the meeting which begins Friday. Last week, Healthcare widely outperformed the broader market, beneficiaries of the big market rotation and the AI selloff. The earnings reports from JNJ and UNH were overshadowed by macro drivers, with the hotter-than-expected CPI print, and AI-driven rotation. Notable Gainers +125.6% SLN (Silence Therapeutics): acquired by MRK.GR for $20/ADS +38.9% IRON (Disc Medicine): trial results in EPP; best performer on XBI +17.6% ANNX (Annexon): on 2X average daily volume; second-best on XBI +12.5% MANE (VeraDermics, Inc.): trial results in male pattern hair loss +11.4% AGIO (Agios Pharmaceuticals): on 2X average daily volume +11.4% PBLS (Parabilis Medicines, Inc.): ESMO abstract; shares (17%) last week and (45%) since mid-September +10.7% ARQT (Arcutis Biotherapeutics): near 52-week high +10.5% SGMT (Sagimet Biosciences): on above average volume +10.4% PRME (Prime Medicine): shares down (13%) last week +9.4% GLUE (Monte Rosa Therapeutics): on above average volume +9.3% VRDN (Viridian Therapeutics): on above average volume +8.1% OLMA (Olema Pharmaceuticals): shares remain (72%) YTD +7.6% PRAX (Praxis Precision Medicines): on above average volume +6.4% SMMT (Summit Therapeutics): trial results in ccRCC with Akeso +6.0% SYRE (Spyre Therapeutics): presented at UEGW +5.8% MBX (MBX Biosciences, Inc.): shares (8%) last week +5.6% ANAB (AnaptysBio): FDA approval of Jemperli sBLA with GSK +5.3% TWST (Twist Bioscience): on average volume +4.8% CDNA (CareDx): shares +256% YTD +4.1% MRNA (Moderna): best performer on XLV; hit multi-year high Thursday Notable Decliners -85.3% EYPT (EyePoint Pharmaceuticals): trial results in wet AMD; restructuring / RIF -11.3% MDXH (MDxHealth): follow-through; downgraded at BTIG -10.0% MESO (Mesoblast): 52-week low -8.4% OCUL (Ocular Therapeutix): sympathy to EYPT -8.3% IBRX (ImmunityBio): worst performer on XBI; shares (13%) last week -3.9% NVAX (Novavax, Inc.): second-worst on XBI; shares (12%) last week -2.8% HSIC (Henry Schein): on average volume; worst performer on XLV M&A Monday in biopharma SLN and MRK.GR announced an agreement under which Merck will acquire Silence at an equity value of around $1.3B. $20/ADS in cash; the price represents 130% premium to Friday's close of the ADS. Lead siRNA candidate divesiran (SLN124) recently announced best-in-class phase 2 data for polycythemia vera. FDA approves GSK's Jemperli under CNPV review FDA confirmed that the Jemperli (GSK, ANAB) sBLA for rectal cancer was approved as part of the Commissioner's National Priority Review (CNPV) pilot program -- the program started by former FDA Commissioner Marty Makary. Accelerated Approval came four months ahead of the PDUFA goal date. Roche signs a new ADC deal with Hansoh Pharma worth up to $15B Roche (ROP.SW) and Hansoh Pharma (3692.HK) announced their second major collaboration in the last year. In October 2025 Roche licensed an investigational ADC for colorectal cancer, worth over $1.5B. Today's ADC deal valued more than 10X the first. Hansoh receives $400M upfront, a first-anniversary payment $110M, and potentially upd to $15B in milestone payments. Separately, Oddo double-upgraded shares of Roche. Trial results and ESMO abstracts in SMID-cap biotech EYPT announced topline results from LUCIA, the second pivotal phase 3 trial of DURAVYU for the treatment of wet AMD. Study did not achieve the primary endpoint despite demonstrating visual improvement. Key secondary endpoints were met. DME program remains on track for readouts in Q4 of next year. GILD presented as a Late Breaker at UEGW results from SWIFT, the Phase 2 dose-ranging study evaluating emvistegrast (GS-1427) in adults with moderately to severely active ulcerative colitis (UC). Company plans phase 3 monotherapy study for 2027. (ABVX) IRON announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). The trial met all its primary and secondary endpoints. MANE announced topline results from Part A of its registration-directed Phase 3 Study '304' evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. Study met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01. ESMO regular abstracts were published on Sunday evening. (ABBV, BCAX, BNTX, CATX, CELC, GMAB, IDYA, INCY, JNJ, MGNX, ORIC, PFE, RCUS, RVMD, TNGX, XNCR, ZLAB, ZNTL) Notable research in Healthcare today Pharma: NOVO.B.DC (NVO) downgraded to underperform from neutral at Oddo (Florent Cespedes), target cut to DKK221 from DKK305. ROP.SW upgraded to outperform from underperform at Oddo (Florent Cespedes), target increased to CHF440 from CHF300. Oddo tean pharma also revised price targets for ARGX.BB, AZN.LN, BNTX, GSK.LN, IPN.FP, MRNA, SDZ.SW, and UCB.BB Biotech: MAZE initiated buy at Canaccord Genuity (Whitney Ijem), target is $75 of approx. 172% upside. MNKD initiated buy at Chardan Capital (Andreas Argyrides), target is $10 or approx. 229% upside. QNRX initiated buy at Canaccord Genuity (Whitney Ijem), target is $18 of approx. 362% upside MedTech: MDXH downgraded to neutral from buy at BTIG (Mark Massaro), follows the recent preannouncement. Post-close news Secondary: IRON announces $350M equity offering Market cap at Monday close $3.03B following +39% rise Shares trading (0.9%) in the after-hours Week Ahead (Sat - Sun) Conference (cont.) UEGW 2026 (Oct 17-20) NAMS 2026 (Oct 20-24) on Wed 21-Oct: ASN 2026 (Kidney Week) (Oct 21-25) Corporate calendar RCUS trial results in ccRCC (8:30ET) RGNX to review sur-vec program in wet AMD (13:00ET) on Wed 21-Oct: FDMT Investor Day NYC (10:30ET) Earnings tomorrow after the close ISRG (16:30ET) Earnings on Wed 21-Oct: before ABT (9:00ET), DHR (8:00ET), ELV (8:30ET), TMO (7:00ET) after MEDP (Thu at 9:00ET), MOH (Thu at 8:00ET) StreetAccount Healthcare Reads Jalen Hurts to miss rest of Eagles' season due to blood clots in lungs (19-Oct) NY Times I was a Theranos whistleblower. In 'You Can See Everything,' Elizabeth Holmes is still lying (19-Oct) STAT News (Opinion) Roche puts future German investments 'on hold' (19-Oct) Reuters Trump signs order creating NIH division, task force for women's health (19-Oct) Reuters Trump's chief of staff almost skipped screening that detected aggressive cancer (18-Oct) Fox News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 3692.HK, ABBV, ABT, ABVX, AGIO, ANAB, ANNX, ARGX.BB, ARQT, AZN.LN, BCAX, BNTX, CATX, CDNA, CELC, DHR, ELV, EYPT, FDMT, GILD, GLUE, GMAB, GSK, GSK.LN, HSIC, IBRX, IDYA, INCY, IPN.FP, IRON, ISRG, JNJ, MANE, MAZE, MBX, MDXH, MEDP, MESO, MGNX, MNKD, MOH, MRK.GR, MRNA, NOVO.B.DC, NVAX, OCUL, OLMA, ORIC, PBLS, PFE, PRAX, PRME, QNRX, RCUS, RGNX, ROP.SW, RVMD, SDZ.SW, SGMT, SLN, SMMT, SYRE, TMO, TNGX, TWST, UCB.BB, VRDN, XNCR, ZLAB, ZNTL...(more)	show story hide story
19-Oct-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.58%) vs the S&P 500 +0.64%. Major health groups are all loosely mixed to begin the week. Biotech are leading gainers; others are little changed on the averages. MRNA +3% and MDT (2%) bracket the XLV movers. XBI +1.60% also getting a lift from high premium Monday M&A. Merck KGaA to acquire Silence Therapeutics for approximately $1.3B in cash; SLN +125%. Weekend news flow was fairly quiet despite Sunday's release of abstracts ahead of ESMO next weekend, and a few clinical readouts in biopharma this morning. Sector gearing up for busier week of earnings, beginning on Wednesday. Gainers +125.4% SLN (Silence Therapeutics): acquired by MRK.GR for $20/ADS +38.9% IRON (Disc Medicine): trial results in EPP; best performer on XBI +12.9% PBLS (Parabilis Medicines, Inc.): ESMO abstract; shares (17%) last week and (45%) since mid-September +8.7% OLMA (Olema Pharmaceuticals): shares remain (72%) YTD +8.1% PRME (Prime Medicine): shares down (13%) last week +7.4% ARQT (Arcutis Biotherapeutics): near 52-week high +6.8% MANE (VeraDermics, Inc.): trial results in male pattern hair loss +6.4% SMMT (Summit Therapeutics): trial results in ccRCC with Akeso +4.7% ABSI (Absci Corp.): shares down (19%) last week +4.0% GRAL (GRAIL, Inc.): shares down (16%) last week +3.8% SYRE (Spyre Therapeutics): presented at UEGW +3.6% MRNA (Moderna): best performer on XLV; hit multi-year high Thursday +3.4% CDNA (CareDx): shares +251% YTD +3.4% MBX (MBX Biosciences, Inc.): shares (8%) last week Decliners -84.6% EYPT (EyePoint Pharmaceuticals): trial results in wet AMD; restructuring / RIF -10.0% MDXH (MDxHealth): follow-through; downgraded at BTIG -9.3% MESO (Mesoblast): 52-week low -8.3% IBRX (ImmunityBio): worst performer on XBI; shares (13%) last week -6.5% OCUL (Ocular Therapeutix): sympathy to EYPT -1.9% MDT (Medtronic): worst performer on XLV -1.8% VTRS (Viatris): second-worst on XLV	show story hide story
19-Oct-2026 08:29	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis A fairly quiet weekend for sector news flow. A few clinical readouts on Monday morning , plus the return of M&A in biopharma. Merck KGaA to acquire Silence Therapeutics for approximately $1.3B in cash. Healthcare gearing up for first ramp of the earnings calendar after the two bellwethers last week. Just a half dozen large-cap reports this week, starting on Wednesday pre-open with Abbott Labs. ESMO 2026 abstracts were published overnight, although key late breakers are during the meeting which begins Friday. Last week, Healthcare widely outperformed the broader market, beneficiaries of the big market rotation and the AI selloff. The earnings reports from JNJ and UNH were overshadowed by macro drivers, with the hotter-than-expected CPI print, and AI-driven rotation. Macro S&P futures are up +0.4% on Monday morning, and Nasdaq futures up +1.1%. Bounce attempt largely chalked up to technical dynamics. Flurry of drawdown superlatives from the Street and in the financial press. Also some hope that first batch of big tech earnings this week can help shift the AI narrative back toward the compute and capex demand pieces of the narrative following the recent ramp in funding scrutiny (SemiAnalysis also out positive today on the AI data center buildout). Outside of AI, weekend headlines revolved around return of safe-haven status for Treasuries, Trump's framing of Russia deals as necessary to keep peace talks alive, Houthi advances in Yemen, inflation pressure (food, travel), rate surge impact on CRE, US fiscal imbalances, and French protests. Pre-market trading update Trading higher +50.6% IRON trial results in EPP; call at 800ET +6.6% CATX ESMO abstract (on low volume) +5.4% OCUL sympathy to EYPT +4.8% SLN (halted for news); acquired by MRK.GR for $20/ADS +1.1% MANE trial results in male pattern hair loss; call at 800ET Trading lower -83.5% EYPT trial results in wet AMD; restructuring / RIF -5.8% MDXH follow-through; downgraded at BTIG -4.8% ABVX on 96K ADRs -1.2% MRNA on 179K shares Biotech M&A: SLN and MRK.GR announced an agreement under which Merck will acquire Silence at an equity value of around $1.3B. $20/ADS in cash; the price represents 130% premium to Friday's close of the ADS. Lead siRNA candidate divesiran (SLN124) recently announced best-in-class phase 2 data for polycythemia vera. Trial results: EYPT announced topline results from LUCIA, the second pivotal phase 3 trial of DURAVYU for the treatment of wet AMD. Study did not achieve the primary endpoint despite demonstrating visual improvement. Key secondary endpoints were met. DME program remains on track for readouts in Q4 of next year. Conf. call at 8:00ET IRON announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). The trial met all its primary and secondary endpoints. Conf. call at 8:00ET MANE announced topline results from Part A of its registration-directed Phase 3 Study '304' evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. Study met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01. Conf. call at 8:00ET Abstracts published: ESMO regular abstracts were published on Sunday evening. (ABBV, BCAX, BNTX, CATX, CELC, GMAB, IDYA, INCY, JNJ, MGNX, ORIC, PFE, RCUS, RVMD, TNGX, XNCR, ZLAB, ZNTL, more) Research: MAZE initiated buy at Canaccord Genuity (Whitney Ijem), target is $75 of approx. 172% upside. MNKD initiated buy at Chardan Capital (Andreas Argyrides), target is $10 or approx. 229% upside. QNRX initiated buy at Canaccord Genuity (Whitney Ijem), target is $18 of approx. 362% upside. Managed Care Regulatory: Post-close on Friday, CMS proposed rule changes for Medicare Advantage and Part D for CY2028. Press release; Fact Sheet CMS proposed rule (CMS-4214-P) The proposed rule for CY 2028 will be open for public comment for 60 days following publication in the Federal Register. CMS anticipates releasing another proposed rule consisting of policy and technical changes for Part C and Part D later this fall. On Deck: Conference (cont.) UEGW 2026 (Oct 17-20) on Tue 20-Oct: NAMS 2026 (Oct 20-24) on Wed 21-Oct: ASN 2026 (Kidney Week) (Oct 21-25) on Thu 22-Oct: EHDN Congress (Oct 22-24); Craig-Hallum Biotech Catalyst on Fri 23-Oct: ESMO 2026 (Oct 23-27) Note: LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) Corporate on Tue 20-Oct: RCUS trial results in ccRCC (8:30ET), RGNX to review sur-vec program in wet AMD (13:00ET) on Wed 21-Oct: FDMT Investor Day NYC (10:30ET) on Fri 23-Oct: TNGX Investor webcast at ESMO (7:30ET) on Sat 24-Oct: MRNA Investor webcast at ESMO (13:00ET) Earnings on Wed 21-Oct: before ABT (9:00ET), DHR (8:00ET), ELV (8:30ET), TMO (7:00ET) after MEDP (Thu at 9:00ET), MOH (Thu at 8:00ET) on Thu 22-Oct: before DGX (8:30ET), ROP.SW (8:00ET), SRT3.GR (7:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ABT, ABVX, BCAX, BNTX, CATX, CELC, CI, CVS, DHR, ELV, EYPT, FDMT, GMAB, IDYA, INCY, IRON, JNJ, MANE, MAZE, MDXH, MEDP, MGNX, MNKD, MOH, MRK.GR, MRNA, OCUL, ORIC, PFE, QNRX, RCUS, RGNX, RVMD, SLN, TMO, TNGX, UNH, XNCR, ZLAB, ZNTL...(more)	show story hide story
16-Oct-2026 20:27	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished mixed to slightly lower overall on Friday. Decliners beat advancers by 2:1 on the XLV, a reversal from the morning and versus even at midday. Healthcare (0.26%) vs S&P 500 (1.09%). Nearly all major health groups ended lower for the session, only Pharma held onto modest gains. DRG +0.41% to end a solid week up +3.15%. Biotech extended its recent pullback, the XBI (3.65%) on Friday and (6.15%) on the week. Highly negative breadth on the biotech ETF, just six modest gainers. IDXX +2.4%, on the Goldman Sachs initiation, and MRNA (7.8%) bracketed the XLV. NVAX (12.2%) also lower. Shares of Moderna turned red for the week. ESMO abstracts due out Sunday evening, and the meeting is still one week away - Merck +0.5% and Moderna present next Saturday. Corporate newsflow fairly quiet on the session. Earnings calendar resumes next Wednesday with ABT, DHR, ELV, SRT3.GR and TMO; followed by ESMO Congress. Macro Market ended the week on a down note amid continued pressure on the AI trade. Eight-session SOX drop now representing a 15%+ drawdown (and now off more than 23% from June's record high). Ongoing weakness seems to be more a sign of further deterioration in sentiment rather than new AI headline flow, though past few days have seen the narrative cover a lot of familiar topics including debt/funding dynamics (neocloud CRWV has been a focus), elevated positioning, competitive landscape, capacity issues, compute demand growth, token prices, enterprise spending dynamics, and IPO delays. Big non-AI news today the firming expectations for an October Fed hold helped by Warsh's noncommittal comments Thursday night; but event merely confirmed consensus and did not provide much support (though Treasuries were a bit volatile today). Fairly quiet on the geopolitical front, though no help from higher oil (WTI back near $100/barrel, Brent briefly hit its highest since May). Trump ramped up criticism on Ukraine's Zelensky while deal for Russian diesel increasingly seen as a longshot. Notable Gainers on Friday: +25.9% IAM (Iambic Therapeutics): day two IPO (biotech) +24.4% CTY (City Therapeutics, Inc.): day one IPO (biotech) +4.6% AAPG (Ascentage Pharma): initiation +2.8% ALKS (Alkermes): reinstated buy at Truist; best performer on XBI +2.4% IDXX (IDEXX Laboratories): initiation at Goldman; best performer on XLV +2.4% VTRS (Viatris): FDA approves RYZUMVI sNDA; 52-week high Notable Decliners on Friday: -65.8% MDXH (MDxHealth): preannounce; downgraded at Craig-Hallum Capital -62.7% GUTS (Fractyl Health): trial results in weight maintenance -16.7% RXRX (Recursion Pharmaceuticals): AI weakness; worst performer on XBI -13.8% OMER (Omeros): EMA CHMP re-examination negative -13.0% GRAL (GRAIL, Inc.): follow-through -12.2% NVAX (Novavax, Inc.): vaccine weakness; on above average volume -12.0% SLS (SELLAS Life Sciences Group, Inc.): on heavy volume -11.1% EBS (Emergent BioSolutions): CFO retirement at end of year -10.0% ERAS (Erasca): COO departure effective 2-Nov -9.0% TEM (Tempus AI): AI weakness -7.8% MRNA (Moderna): vaccine weakness; on above average volume; worst performer on XLV -5.2% IRD (Opus Genetics): FDA approves RYZUMVI sNDA -5.0% OPK (Opko Health): follow-through; upgraded at Barrington -4.4% HUM (Humana): on average volume; shares down (4%) for the week -4.4% TRAX (First Tracks Biotherapeutics Inc): Leerink comments, raises price target Week in Review: Healthcare equities outperformed for the week. The S&P 500 Healthcare Index gained +3.37% vs the S&P 500 Index down (1.95%). Outperformers: Managed Care, Services, Pharma, MedTech Underperformers: Biotech Major health groups were mostly higher on the week as beneficiaries of the big market rotation and the AI selloff. The earnings calendar also kicked off for Healthcare with two bellwether names, JNJ and UNH, but results were overshadowed by macro drivers, with the hotter-than-expected CPI print, and AI-driven rotation. As for the prints themselves, results were mixed at best. UHC delivered a lead-off hit with MLR beat by 150bps. At JNJ, IM segment cleared investors hurdle with better than 7%+ sales growth, while MT sales offset. Guidance raised by just the quarterly outperformance. Large-cap drugmakers, which again includes Moderna at $87B, volatile on the week, with an eye on ESMO around the corner. Merck and Moderna will be presenting details of their melanoma vaccine next Saturday the 24th. Executives from both jointly sat down with STAT Summit this week, and MRNA President Hoge told investors that "we have a lot of exploring to do" with the cancer vaccine. Despite the pullback this week by the XBI (6.15%), two new IPO offerings successfully debuted on the Nasdaq. Twenty-seven Biotech IPOs YTD have raised more than $7.4B. Year-to-date, Healthcare +14.06% vs the S&P 500 +11.89%. Healthcare third out of eleven major sectors in CY26. Energy +52.71% and Consumer Discretionary (4.06%) bracket them all. Notable movers for the week: Gainers: LQDA +25.5% - settlement with UTHR; upgraded at LifeSci HALO +10.3% - sympathy to Takeda Ig trial results; best performer on XBI ARQT +8.4% - initiation at Cantor Fitzgerald IDXX +8.2% - initiation at Goldman Sachs; best performer on XLV CVS +7.2% - sympathy to UNH; market rotation; shares +19% YTD MDT +7.1% - completed MMED exchange; best week since May 2025 CI +7.0% - sympathy to UNH; best week since Nov 2025 MCK +7.0% - market rotation; best week since Feb 2026; shares +23% YTD CAH +6.9% - market rotation; shares +25% YTD UNH +5.8% - earnings, MLR driven beat and raise Decliners: RXRX (20.5%) - AI sell-off; largest one-week pullback since May 2025 PLSE (17.4%) - stock closed lower all five days; sympathy to JNJ; shares +224% YTD MANE (16.9%) - follows +12% prior week; shares +188% YTD SMMT (16.8%) - read-across from Akeso HK$2B offering; sell-side previews ESMO ERAS (16.5%) - COO departure; shares +260% YTD GRAL (16.2%) - AI sell-off; shares +38% YTD KOD (14.1%) - B Riley comments on FDMT relative valuation MMED (11.3%) - MDT completes exchange offer PTGX (10.4%) - sympathy to JNJ; largest one-week pullback since Oct 2025 BNTX (9.5%) - trial results in HNSCC TEM (8.8%) - AI sell-off; shares +10% YTD ILMN (5.6%) - worst performer on XLV; largest one-week pullback since Aug 2026; shares +100% YTD JNJ (2.2%) - earnings mixed, MedTech results light Week Ahead (Sat - Sun): Oct 17 - 25 Conference calendar Sat 17-Oct: UEGW 2026 (Oct 17-20) Sun 18-Oct: regular abstracts for ESMO 2026 published online (18:05ET) Tue 20-Oct: NAMS 2026 (Oct 20-24) Wed 21-Oct: ASN 2026 (Kidney Week) (Oct 21-25) Thu 22-Oct: EHDN Congress (Oct 22-24); Craig-Hallum Biotech Catalyst Fri 23-Oct: ESMO 2026 (Oct 23-27) Note: LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) Corporate calendar Tue 20-Oct: RCUS trial results in ccRCC (8:30ET), RGNX to review sur-vec program in wet AMD (13:00ET) Wed 21-Oct: FDMT Investor Day NYC (10:30ET) Fri 23-Oct: TNGX Investor webcast at ESMO (7:30ET) Sat 24-Oct: MRNA Investor webcast at ESMO (13:00ET) Earnings calendar Wed 21-Oct: before ABT (9:00ET), DHR (8:00ET), ELV (8:30ET), TMO (7:00ET) after MEDP (Thu at 9:00ET), MOH (Thu at 8:00ET) Thu 22-Oct: before DGX (8:30ET), ROP.SW (8:00ET), SRT3.GR (7:00ET) Regulatory calendar n/a Syndicate / IPO pricing n/a Related: AAPG, ABT, ALKS, ARQT, BNTX, CAH, CI, CTY, CVS, DGX, DHR, EBS, ELV, ERAS, FDMT, GRAL, GUTS, HALO, HUM, IAM, IDXX, ILMN, IRD, JNJ, KOD, LQDA, MANE, MCK, MDT, MDXH, MEDP, MMED, MOH, MRK, MRNA, NVAX, OMER, OPK, PLSE, PTGX, RCUS, RGNX, ROP.SW, RXRX, SLS, SMMT, SRT3.GR, TEM, TMO, TNGX, TRAX, UNH, UTHR, VTRS...(more)	show story hide story
16-Oct-2026 16:38	CMS proposes rule changes for Medicare Advantage and Part D for CY2028 CMS proposed rule (CMS-4214-P) to implement key sections of the Consolidated Appropriations Act of 2026 including section 6220 (REAL Health Providers Act) and section 6224 (Modernizing and Ensuring Pharmacy Benefit Manager Accountability). This rule also proposes a conforming change mandated by section 6219 of the CAA (Adjustments to Medicare Part D Cost-Sharing Reductions for Low-Income Individuals) that would reduce the generic drug copayment from $1 to $0 for full-benefit dual eligible individuals. CMS is also proposing transparency and reporting requirements for PBMs aimed at curbing practices that drive up drug costs. PBMs would have to report their compensation and cost performance to plan sponsors and CMS on an annual basis. The rule would also require PBM payments to reflect fair market value for services provided, rather than drug costs. The proposed rule for CY 2028 will be open for public comment for 60 days following publication in the Federal Register. CMS anticipates releasing another proposed rule consisting of policy and technical changes for Part C and Part D later this fall. Related: CI, CVS, UNH Reference Link Reference Link: Fact Sheet	show story hide story
16-Oct-2026 15:04	StreetAccount Summary: Notable Drug Events expected for the week of 18-Oct Sun 18-Oct Abstracts release: ESMO regular abstracts published online (18:05ET) Tue 20-Oct Trial results: RCUS to present data from its Ph1/2 trials of casdatifan in ccRCC (webcast 8:30ET) Investor event: RGNX investor meeting to review the surabgene lomparvovec clinical program in wet AMD (webcast 13:00ET) Wed 21-Oct Industry meeting with clinical data: American Society of Nephrology (ASN) Kidney Week (Oct 21-25) (PYC.AU, VRTX) Trial results: KYTX to present Ph2 data in stiff person syndrome and Ph1 data in multiple sclerosis at MSToronto 2026 Thu 22-Oct Industry meeting with clinical data: European Huntington's Disease Network (EHDN) Congress (Oct 22-24) (ALNY) Corporate: ROP.SW earnings call (7:00ET) Fri 23-Oct Trial results: DMAC to present early safety and trial findings from its Ph2 study of rinvecalinase alfa in early-onset fetal growth restriction Industry meeting with clinical data: ESMO Congress 2026 (Oct 23-27) (INCY, ZNTL, IMTX, XNCR, TNGX, 7630.HK, CMPX, 6996.HK, INBX, GSK.LN, BNTX, MRNA, MGNX, OSE.FP, 4502.JP, PFE, NBP, AVBP, 2157.HK, 1801.HK, AMGN) Investor event: TNGX to discuss Ph1/2 study of vopimetostat + daraxonrasib or zoldonrasib in MTAPdel/RASmut mPDAC & mNSCLC (webcast 7:30ET) Sat 24-Oct Trial results: PFE to present Ph2 data from its trial of PCV25 pneumococcal conjugate vaccine for infants at IDWeek Investor event: MRNA to discuss Ph3 data for intismeran autogene + pembrolizumab vs pembrolizumab in melanoma (webcast 13:00ET) later during October 2026 Regulatory decisions: FDA PDUFAs: GSK.LN/IONS (Hibsago NDA, 26-Oct), 524715.IN/MRK (ILUMYA sBLA, 29-Oct), INO (INO-3107 BLA, 30-Oct); FDA BsUFA XBRANE.SS (Xlucane BLA, 29-Oct) Industry meetings with clinical data: ESGCT Annual Congress (Oct 27-30) Trial results: RAPP (Ph3 FOS, Ph2 Bipolar I disorder), TLSA (Ph2 na-SPMS), PBLS (Ph1/2 Desmoid Tumors), BNTC (Ph1/2 OPMD), TRDA (Ph1/2 DMD), EIKN (Ph1/2 solid tumors), BEAM (Ph1/2 GSDIa), CATX (Ph1/2 NETs), CHRS (Ph1 cancer) expected imminently Trial results: PFE (Ph3 mCRPC), AARD (Ph3 PwS), CGON (Ph3 INT-NMIBC) Related: 1801.HK, 2157.HK, 4502.JP, 524715.IN, 6996.HK, 7630.HK, AARD, ALNY, AMGN, AVBP, BEAM, BNTC, BNTX, CATX, CGON, CHRS, CMPX, DMAC, EIKN, GSK.LN, IMTX, INBX, INCY, INO, IONS, KYTX, MGNX, MRK, MRNA, NBP, OSE.FP, PBLS, PFE, PYC.AU, RAPP, RCUS, RGNX, ROP.SW, TLSA, TNGX, TRDA, VRTX, XBRANE.SS, XNCR, ZNTL...(more)	show story hide story
16-Oct-2026 11:05	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.30% vs the S&P 500 (0.13%). Most major health groups have turned lower on the session; only Pharma holding onto gains. DRG +0.87% extending strong week, approaching +4% WTD. Biotech is adding to its weekly pullback, the XBI (2.09%) on the session and (4.63%) on the week. Highly negative breadth on the biotech ETF to start, but narrowing by mid-morning. IDXX +2%, on upbeat initiation, and MRNA (9%) bracket the XLV. NVAX also (11%). Shares of Moderna turned red for the week. ESMO abstracts out Sunday evening, and the meeting is still one week away. MRK +1% higher and inline with the DRG Index. Corporate newsflow is fairly quiet. Earnings calendar resumes next Wednesday with ABT, DHR, ELV, SRT3.GR and TMO. Gainers +2.9% AAPG (Ascentage Pharma): initiation +2.2% IDXX (IDEXX Laboratories): initiation; best performer on XLV +1.9% OPK (Opko Health): follow-through; upgraded at Barrington +1.8% AVBP (Arrivent Biopharma): best performer on XBI; shares (44%) MTD +1.8% PODD (Insulet): second-best performer on XLV; shares +4% WTD +1.4% ALKS (Alkermes): reinstated buy at Truist +1.1% TRAX (First Tracks Biotherapeutics Inc): Leerink comments, raises price target Decliners -55.3% MDXH (MDxHealth): preannounce; downgraded at Craig-Hallum Capital -48.5% GUTS (Fractyl Health): trial results in weight maintenance -12.6% EBS (Emergent BioSolutions): CFO retirement at EOY; worst performer on XBI -11.5% OMER (Omeros): EMA CHMP re-examination -10.6% NVAX (Novavax, Inc.): vaccine weakness; on strong volume; second-worst on XBI -10.3% SLS (SELLAS Life Sciences Group, Inc.): shares (13%) WTD -9.2% MRNA (Moderna): vaccine weakness; on strong volume; worst performer on XLV -2.9% HUM (Humana): shares down (3%) WTD -1.9% UNH (UnitedHealth Group): shares remain +5% WTD	show story hide story
16-Oct-2026 08:32	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Fairly quiet in terms of corporate newsflow overnight. Earnings calendar resumes next Wednesday with ABT, DHR, ELV, TMO. EMA CHMP published opinions on MAA from the October 2026 meeting. Eli Lilly wins a positive recommendation for its oral drug Foundayo; Revolution Medicines was out yesterday with their positive recommendation for Rasonque. Yesterday, Healthcare equities were broadly higher, with just four very modest decliners on the XLV. MedTech and Biotech led the moves, catalyst more sector rotation than anything Healthcare specific. XBI +2.05% took a large bite out of its weekly decline. Macro S&P futures are up +0.1% on Friday morning. AI trade still looking a bit weaker in the premarket though following a pause in the KOSPI's sharp downslide. Not a lot of AI headline flow though some focus on Anthropic's IPO plans after Reuters report some investors considering a lower valuation. A lot of attention on Fed Chair Warsh's comments overnight; while no specific guidance was expected, his noncommittal remarks helping to further solidify expectations for an FOMC hold this month (FedWatch hike odds now only ~15%). Fairly quiet on the geopolitical front. Trump ramped up criticism on Ukraine's Zelensky for continuing to target Russian energy infrastructure, said Zelensky more difficult to deal with than Putin. Pre-market trading update Trading higher +8.9% RGC shares are +30% WTD +4.0% OPK follow-through; upgraded at Barrington +3.1% AAPG initiation +2.8% EIKN initiation +2.0% ACRS on 14K shares Trading lower -48.1% GUTS trial results in weight maintenance; call at 800ET -33.7% MDXH preannounce; downgraded at Craig-Hallum Capital -4.6% EBS CFO retirement at EOY -4.3% OMER EMA CHMP re-examination EMA CHMP publishes summary of opinions for October 2026 meeting Summary here. EMA recommends six (6) new medicines for approval (including two biosimilars and one hybrid medicine), and extension of therapeutic indication for another five (5). Positive opinions for MAA include: Revolution Medicines (RVMD) Rasonque (daraxonrasib) opinion was previously announced by the company on 15-Oct Eli Lilly (LLY) Foundayo (orforglipron) Ascendis Pharma (ASND) Yuviwel (navepegritide) Orphelia Pharma (private) Kizfizo (temozolomide) - a new hybrid medicine Plus two biosimilars. Extensions of indication were recommended for: Pandemic influenza vaccine H5N1 AstraZeneca (AZN), Kyinsu (NOVO.B.DC), Talvey (JNJ), Tryngolza (SOBI.SS, IONS), and Tukysa (PFE) Outcome of re-examination: Omeros (OMER) Yartemlea (narsoplimab) - confirmed refusal of MAA Withdrawal of application: PFE Ibrance (palbociclib) - extension for maintenance treatment of mBC AZN Truqap (capivasertib) - extension for PTEN-deficient metastatic prostate cancer RX to OTC switch: Mundipharma Corp. (private) Nyxoid (naloxone) now available without a medical prescription Pharma Regulatory: ROP.SW On the PDUFA goal date, the FDA approved sBLA for Enspryng for the treatment of adults with Thyroid Eye Disease. Third medicine approved by FDA for TED, first subcutaneous formulation. (AMGN, VRDN) Research: ELAN initiated buy at Goldman Sachs (Matt Dellatorre), target is $32 or approx. 36% upside. ZTS initiated neutral at Goldman Sachs (Matt Dellatorre), target is $74 or approx. 6% downside. Biotech IPO priced: CTY City Therapeutics raised $200M when 11.1M share IPO (upsized) priced at the midpoint of the anticipated range ($17-19). Shares to begin trading on the Nasdaq today. Research: AAPG initiated outperform at William Blair (Alethia Young), target is $31 or approx. 111% upside. ALKS reinstated buy at Truist (Alex Nackenoff), target is $55 or approx. 37% upside. CYTK initiated outperform at William Blair (Alethia Young), target is $101 or approx. 58% upside. EIKN initiated buy at HC Wainwright (Sara Nik), target is $23 or approx. 205% upside. EWTX initiated outperform at William Blair (Alethia Young), target is $53 or approx. 39% upside. FTH initiated outperform at William Blair (Alethia Young), target is $66 or approx. 220% upside. IDYA initiated outperform at William Blair (Alethia Young), target is $51 or approx. 51% upside. IMNM initiated outperform at William Blair (Alethia Young), target is $35 or approx. 101% upside. KARD initiated outperform at William Blair (Alethia Young), target is $38 or approx. 174% upside. PRAX initiated overweight at JPMorgan (Tessa Romero), target is $700 or approx. 182% upside. PTCT reinstated hold at Truist (Alex Nackenoff), target is $62 or approx. 2% upside. PVLA initiated outperform at William Blair (Alethia Young), target is $266 or approx. 109% upside. RCUS initiated in initiated outperform at William Blair (Alethia Young), target is $50 or approx. 119% upside. RVMD initiated outperform at William Blair (Alethia Young), target is $226 or approx. 19% upside. RYTM initiated outperform at William Blair (Alethia Young), target is $206 or approx. 134% upside. TNGX initiated initiated outperform at William Blair (Alethia Young), target is $42 or approx. 85% upside. WVE initiated outperform at William Blair (Alethia Young), target is $8.37 or approx. 162% upside. Life Science & MedTech Regulatory: EW published an 'early alert' on the recall of SAPIEN M3 Commander delivery system. Company sent customers a letter on 5-Oct-2026. Company has reported one death and one serious injury associated with this issue. Quick take: Leerink Partners (outperform rated) says the death and injury are concerning, however the recall is limited to four lots of product - not with the product design - thus expects limited financial impact. Privately-held Sequel Med Tech (0Z0LZT-E) announced that FDA has cleared twiist for adults with Type 2 Diabetes. Compatible with CGMs from ABT and SENS. Follows launch in T1D in March 2026. Research: IDXX initiated buy at Goldman Sachs (Matt Dellatorre), target is $740 or approx. 35% upside. IRTC initiated overweight at Piper Sandler (Adam Maeder), target is $160 or approx. 46% upside. PRCT transferred overweight, rating unchanged, at Piper Sandler (Adam Maeder), target is $25 or approx. 38% upside. Services & Hospitals Research: OPK upgraded to outperform from market perform at Barrington Research (Michael Petusky), sees upside to the BioReference divestment announced yesterday. Target is $2.25 or approx. 40% upside. (FactSet average PT $5; range $3-9) CON initiated buy at Jefferies (Jack Slevin), target is $47 or approx. 20% upside. On Deck: Regulatory on Sat 17-Oct: IRD / VTRS FDA PDUFA for Ryzumvi sNDA for presbyopia Conference on Sat 17-Oct: UEGW 2026 (Oct 17-20) on Sun 18-Oct: ESMO 2026 regular abstracts published online (18:05ET) Peek Ahead to next week Oct 19 - 25 Earnings: ABT, DGX, DHR, ELV, MEDP, MOH, SRT3.GR, TMO Investor event: RCUS (Oct 20, 8:30ET), RGNX (Oct 20, 13:00ET), FDMT (Oct 21, 10:30ET) Conference: NAMS 2026 (Oct 20-24), Craig-Hallum Biotech Catalyst Conference (Oct 22), ESMO 2026 (Oct 23-27) LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AAPG, ABT, ACRS, ALKS, AMGN, ASND, AZN, CON, CTY, CYTK, DGX, DHR, EBS, EIKN, ELAN, ELV, EW, EWTX, FDMT, FTH, GUTS, IDXX, IDYA, IMNM, IONS, IRD, IRTC, JNJ, KARD, LLY, MDXH, MEDP, MOH, NOVO.B.DC, OMER, OPK, PFE, PRAX, PRCT, PTCT, PVLA, RCUS, RGC, RGNX, ROP.SW, RVMD, RYTM, SENS, SOBI.SS, SRT3.GR, TMO, TNGX, VRDN, VTRS, WVE, ZTS, 0Z0LZT-E...(more)	show story hide story
16-Oct-2026 07:20	EMA CHMP publishes summary of opinions for October 2026 meeting Summary here. EMA recommends six (6) new medicines for approval (including two biosimilars and one hybrid medicine), and extension of therapeutic indication for another five (5). Positive opinions for MAA include: Revolution Medicines (RVMD) Rasonque (daraxonrasib) opinion was previously announced by the company on 15-Oct Eli Lilly (LLY) Foundayo (orforglipron) Ascendis Pharma (ASND) Yuviwel (navepegritide) Orphelia Pharma (private) Kizfizo (temozolomide) - a new hybrid medicine Plus two biosimilars. Extensions of indication were recommended for: Pandemic influenza vaccine H5N1 AstraZeneca (AZN), Kyinsu (NOVO.B.DC), Talvey (JNJ), Tryngolza (SOBI.SS, IONS), and Tukysa (PFE) Outcome of re-examination: Omeros (OMER) Yartemlea (narsoplimab) - confirmed refusal of MAA Withdrawal of application: PFE Ibrance (palbociclib) - extension for maintenance treatment of mBC AZN Truqap (capivasertib) - extension for PTEN-deficient metastatic prostate cancer RX to OTC switch: Mundipharma Corp. (private) Nyxoid (naloxone) now available without a medical prescription For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ASND, AZN, IONS, JNJ, LLY, NOVO.B.DC, OMER, PFE, RVMD, SOBI.SS...(more)	show story hide story
15-Oct-2026 16:51	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly higher on Thursday. Just four very modest decliners on the XLV. VEEV +5.3% and MRK (1.5%) bracketed the XLV. Healthcare +1.84% vs S&P 500 +0.33%. All major health groups higher by around +2% on the averages. MedTech and Biotech led the moves, catalyst more sector rotation than anything Healthcare specific. XBI +2.05% took a large bite out of its weekly decline. MRNA +4.5% and MRK shared the stage at the STAT Summit on Thursday, and talked about the personalized cancer vaccine. Diabetes Tech group fared much better today; DXCM +5.1% saw the NEJM publish landmark trial data for non-insulin treated T2D patients. Analysts see clearing pathway to broader uptake and reimbursement. Elsewhere fairly quiet in terms of sector news. LH +2.4% plucked BioReference Labs, and blood test for prostate cancer, from OPK +17.5% in a deal valued at up to $875M including earnouts. One small pocket of weakness: startup MCOs down around (2%) each, with large-cap peers all green and about 350 bps better on the average. Day One of Open Enrollment for Medicare plans. Another biotech IPO successfully priced. NVDIA-backed Iambic Therapeutics raised $150M ahead of its Nasdaq debut. Shares of IAM (3%) on the debut. Yesterday, Healthcare equities were broadly higher. UNH +4.8% and PODD (3.0%) bracketed the XLV. Most major health groups ended higher on the averages; Biotech and MedTech essentially flat. XBI (0.02%) still looking for a catalyst to climb out of the >(4%) WTD hole. Defensive groups outperformed on the macro drivers and rotation. Macro Rotation again the major theme. Big Treasury rally today in a safe-haven trade; note consensus still for an October Fed hold despite today's hotter core PPI reading. More defensive pockets including staples and healthcare also saw big gains today. Came alongside continued weakness in the AI trade though some BTD cushion for select semi/memory names. Today's AI headlines largely continued the ongoing narrative of concern around growth durability and debt/ROI dynamics; TSM earnings saw strong AI demand trends but investors were seemingly looking for bigger guidance bump. Today's round of super-regional bank earnings better received than the moneycenters', though broad financial sector pared losses from earlier in the week. Not a lot of focus on geopolitics though oil was stronger after Ukraine's Zelenskyy said strikes on Russian refineries would resume; attacks on ships in Strait of Hormuz also continuing at elevated levels. Notable Gainers +19.7% VSTM (Verastem): best performer on XBI; trial results by China partner +18.2% IAM (Iambic Therapeutics): day one IPO (biotech) +17.5% OPK (Opko Health): agreement to sell BioReference Labs to Labcorp +17.4% RGC (Regencell Bioscience Holdings): on unusual volume; shares +43% WTD +15.3% PRME (Prime Medicine): second-best on XBI; shares remain (10%) WTD +11.2% RXRX (Recursion Pharma.): secondary offering priced; clinical and partnership updates +11.1% ANL (Adlai Nortye): announces clinical collaborations with MRK and LLY +10.2% ARQT (Arcutis Biotherapeutics): initiation +8.6% COAG (Hemab Therapeutics): initiation +7.5% VKTX (Viking Therapeutics): initiation +7.1% MMED (MiniMed Group): sympathy to DXCM; shares were (9%) yesterday +6.6% FTRE (Fortrea Holdings): upgraded at Deutsche Bank +5.3% VEEV (Veeva Systems): best performer on XLV +5.1% DXCM (Dexcom): publication of data in NEJM; second-best on XLV +4.7% DVA (DaVita): on average volume +4.6% COO (The Cooper Cos.): on below average volume +4.5% MRNA (Moderna): panel at STAT Summit with MRK; shares were +5% yesterday +4.5% VTRS (Viatris): on average volume +4.4% ELAN (Elanco Animal Health): on above average volume +4.2% ZTS (Zoetis): on average volume +4.1% SYK (Stryker): on average volume +3.6% PODD (Insulet): sympathy to DXCM; shares were (3%) yesterday +3.5% LLY (Eli Lilly): on above average volume; shares were +4% yesterday +3.4% ALGN (Align Technology): downgraded at Baird +3.0% NVST (Envista Holdings): downgraded at Baird +2.9% AZN (AstraZeneca): discovery collaboration with insitro an AI therapeutics company Notable Decliners -4.5% SLS (SELLAS Life Sciences Group, Inc.): shares remain +201% YTD -4.3% CABA (Cabaletta Bio): worst performer on XBI; stock lower for eighth straight day; six straight weeks; shares (20%) WTD -3.7% ORKA (Oruka Therapeutics): shares lower 8 of last 9 days; still +144% YTD -3.4% PCVX (Vaxcyte): shares remain +15% MTD -3.0% GRAL (GRAIL, Inc.): shares remain +58% YTD -2.5% TWST (Twist Bioscience): on above avg volume; shares (10%) WTD -1.6% PLSE (Pulse Biosciences): follow-through, shares (15%) WTD -1.5% MRK (Merck): worst performer on XLV; panel at STAT Summit with MRNA -1.4% ILMN (Illumina): on average volume; one of four decliners on XLV Diabetes Tech stocks rebound with CGM data published in NEJM DXCM announced that NEJM published results from the landmark CONNECT trial in non-insulin treated Type 2 Diabetes (T2 NIT). Observed benefits include those taking GLP-1s. Quick take: Wells Fargo sees this boosting CGM usage for T2 NIT patients and probability of CMS coverage by mid-2027. OPKO Health higher on deal with Labcorp OPK and LH announced an agreement for Labcorp to acquire select assets of BioReference Health LLC from Opko Health for $722M in cash at closing, plus up to $150M in earnouts. Transaction includes the laboratory testing business and the proprietary 4Kscore Test, an FDA-approved blood test for detecting prostate cancer. Nvidia-backed Iambic Therapeutics IPO priced IAM Iambic Therapeutics raised $150M when 9.4M share IPO priced at the midpoint of the anticipated range ($15-17). Shares to begin trading on the Nasdaq today. FDA decision near for Roche's Enspryng sBLA in Thyroid Eye Disease Enspryng sBLA under priority review at FDA; PDUFA is 15-Oct-2026. Enspryng (ROP.SW) could become the third FDA approved treatment for TED, after Tepezza (AMGN) and Lumvoa (VRDN), and the first subcutaneous treatment for TED. Amgen are still developing subcutaneous Tepezza; topline ph3 results were announced in April 2026. Viridian expects to submit an FDA application for elegrobart (SC) in TED early next year. Notable research in Healthcare today Biotech: ALNY assumed buy at UBS (Joon Lee), target is $354 or approx. 58% upside. ARWR assumed buy at UBS (Joon Lee), target is $109 or approx. 87% upside. ARQT initiated overweight at Cantor Fitzgerald (Steve Seedhouse), target is $48 or approx. 82% upside. ASND assumed buy at UBS (Joon Lee), target is $269 or approx. 19% upside. BBIO assumed buy at UBS (Joon Lee), target is $92 or approx. 42% upside. BMRN assumed buy at UBS (Joon Lee), target is $88 or approx. 60% upside. COAG initiated overweight at JPMorgan (Joyce Zhou), target is $70 or approx. 134% upside. CRSP initiated neutral at UBS (Joon Lee), target is $52 or approx. 4% upside. DRUG initiated outperform at Wolfe Research (Rudy Li), target is $150 or approx. 196% upside. ELOX initiated overweight at Cantor Fitzgerald (Yanni Souroutzidis) FTH initiated outperform at LifeSci Capital (Oliver McCammon), target is $40 or approx. 100% upside. HRMY initiated buy at Ladenburg Thalmann, target is $55 or approx. 47% upside. IONS assumed buy, vs prior neutral (upgrade), at UBS (Joon Lee), target is $88 or approx. 106% upside. OVID initiated outperform at Wolfe Research (Rudy Li), target is $5 or approx. 128% upside. PRAX initiated buy at UBS (Joon Lee), target is $706 or approx. 195% upside. PTCT assumed buy at UBS (Joon Lee), target is $90 or approx. 51% upside. QURE assumed buy at UBS (Joon Lee), target is $48 or approx. 129% upside. RAPP initiated outperform at Wolfe Research (Rudy Li), target is $50 or approx. 76% upside. RAPP initiated buy at UBS (Joon Lee), target is $71 or approx. 151% upside. RARE initiated neutral at UBS (Joon Lee), target is $16 or approx. 7% upside. REGN assumed buy, vs prior neutral (upgrade), at UBS (Joon Lee), target is $978 or approx. 26% upside. SLDB initiated buy at UBS (Joon Lee), target is $20 or approx. 266% upside. VKTX initiated buy at UBS (Joon Lee), target is $94 or approx. 269% upside. WVE initiated buy at UBS (Joon Lee), target is $11 or approx. 256% upside. MedTech: ALGN downgraded to neutral from outperform at Baird (Jeff Johnson), target cut to $162 from $218 or approx. 12% upside. (FactSet average PT $194; range $155-235) FTRE upgraded to buy from hold at Deutsche Bank (Justin Bowers), target increased to $25 from $20 or approx. 17% upside. (FactSet average PT $22; range $16-26) NVST downgraded to neutral from outperform at Baird (Jeff Johnson), target cut to $26 from $34 or approx. 14% upside. (FactSet average PT $29; range $23-34) ESTA initiated buy at Stifel (Joseph Federico), target is $85 or approx. 47% upside. (FactSet average PT $102; range $92-117) SGHT initiated buy at HC Wainwright (Yi Chen), target is $14 or approx. 70% upside. (FactSet average PT $9; range $8-12) TMO initiated buy at Guggenheim Securities (Subbu Nambi), target is $740 or approx. 10% upside. (FactSet average PT $694; range $575-800) On Deck: Regulatory ROP.SW FDA PDUFA today for Enspryng sBLA for TED on Fri 16-Oct: EMA CHMP opinions for MAA (October 2026) on Sat 17-Oct: IRD / VTRS FDA PDUFA for Ryzumvi sNDA for presbyopia Syndicate / potential IPO pricing Thu 15-Oct (post-close): +CTY City Therapeutics Conference on Sat 17-Oct: UEGW 2026 (Oct 17-20) on Sun 18-Oct: ESMO 2026 regular abstracts published online (18:05ET) Peek Ahead to next week Oct 19 - 25 Earnings: ABT, DGX, DHR, ELV, MEDP, MOH, SRT3.GR, TMO Investor event: RCUS (Oct 20, 8:30ET), RGNX (Oct 20, 13:00ET), FDMT (Oct 21, 10:30ET) Conference: NAMS 2026 (Oct 20-24), ESMO 2026 (Oct 23-27) LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) StreetAccount Healthcare Reads Merck and Moderna have 'lot of exploring to do' after initial cancer vaccine success (15-Oct) STAT News What It Means for RFK Jr.'s Vaccine Panel to Be MIA During a Measles Outbreak (15-Oct) Washington Sun Individual Market Enrollment Continues to Fall Through Mid-2026 (14-Oct) KFF.org FDA Director of OGD Steps Down Amid 'Political Pressure,' Admin Burden (14-Oct) Pink Sheet Helen Branswell, whose reporting on infectious diseases and public health drew acclaim, dies at 69 (13-Oct) STAT News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ALGN, ALNY, AMGN, ANL, ARQT, ARWR, ASND, AZN, BBIO, BMRN, CABA, COAG, COO, CRSP, DGX, DHR, DRUG, DVA, DXCM, ELAN, ELOX, ELV, ESTA, FDMT, FTH, FTRE, GRAL, HALO, HRMY, IAM, ILMN, IONS, IRD, LH, LLY, MEDP, MMED, MOH, MRK, MRNA, NVST, OPK, ORKA, OVID, PCVX, PLSE, PODD, PRAX, PRME, PTCT, QURE, RAPP, RARE, RCUS, REGN, RGC, RGNX, ROP.SW, RXRX, SGHT, SLDB, SLS, SRT3.GR, SYK, TMO, TWST, VEEV, VKTX, VRDN, VSTM, VTRS, WVE, ZTS, +CTY...(more)	show story hide story
15-Oct-2026 14:28	FDA decision near for Roche's Enspryng sBLA in Thyroid Eye Disease Enspryng sBLA under priority review at FDA; PDUFA is 15-Oct-2026. Enspryng (ROP.SW) could become the third FDA approved treatment for TED, after Tepezza (AMGN) and Lumvoa (VRDN), and the first subcutaneous treatment for TED. Amgen are still developing a subcutaneous version of Tepezza; topline ph3 results were announced in April 2026. Viridian expects to submit an FDA application for elegrobart (SC) in TED early next year. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Editor's Note: This comment was revised to remove HALO from the comment, as Amgen cancelled the Horizon-Halozyme license agreement for ENHANZE. The sub Q version of Tepezza being advanced by Amgen does not utilize ENHANZE technology. (15-Oct-2026, 15:07 ET) Related: AMGN, ROP.SW, VRDN	show story hide story
15-Oct-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +2.55% vs the S&P 500 +0.03%. All major health groups higher by at least +1%, and as much as +3%. Pharma and Biotech groups quietly leading; the DRG +3.00% and XBI +2.29%. MRNA +6% and ILMN (2%) bracket the XLV. Diabetes Tech group also faring much better today; DexCom saw the NEJM publish landmark trial data for non-insulin treated T2D patients. Analysts see clearing pathway to broader uptake and reimbursement. Elsewhere fairly quiet in terms of sector news. LH +1% plucked BioReference Labs, and blood test for prostate cancer, from OPK +19% in a deal valued at up to $875M including earnouts. One small pocket of weakness: startup MCOs down (2%) to (3%) each, with large-cap peers all green. Gainers +19.0% OPK (Opko Health): agreement to sell BioReference Labs to Labcorp +8.5% PRME (Prime Medicine): best performer on XBI; shares remain (14%) WTD +7.8% ARQT (Arcutis Biotherapeutics): initiation; second-best on XBI +6.8% RXRX (Recursion Pharmaceuticals): secondary offering priced; clinical and partnership updates +6.0% MRNA (Moderna): best performer on XLV; shares were +5% yesterday +5.0% COAG (Hemab Therapeutics): initiation +4.6% LLY (Eli Lilly): second-best on XLV; shares were +4% yesterday +4.1% AZN (AstraZeneca): discovery collaboration with insitro an AI therapeutics company +3.6% DXCM (Dexcom): publication of data in NEJM +3.5% BMY (Bristol Myers Squibb): shares were +5% yesterday +2.9% FTRE (Fortrea Holdings): upgraded at Deutsche Bank +2.9% PODD (Insulet): sympathy to DXCM; shares were (3%) yesterday +2.6% NVST (Envista Holdings): downgraded at Baird +2.5% REGN (Regeneron): assumed/upgraded at UBS +1.9% IBRX (ImmunityBio): follow-through on FDA approval +1.8% MMED (MiniMed Group): sympathy to DXCM; shares were (9%) yesterday +1.7% ALGN (Align Technology): downgraded at Baird +1.5% BBNX (Beta Bionics, Inc.): sympathy to DXCM; shares were (5%) yesterday Decliners -5.7% TWST (Twist Bioscience): worst performer on XBI; on strong volume; shares (14%) WTD -2.3% TXG (10X Genomics): shares (12%) WTD -2.1% ILMN (Illumina): on average volume; worst performer on XLV -1.7% GRAL (GRAIL, Inc.): on average volume -0.9% EW (Edwards Lifesciences): one of four decliners on XLV	show story hide story
15-Oct-2026 08:43	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Fairly quiet in terms of sector news overnight. Labcorp plucks BioReference Labs, and blood test for prostate cancer, from Opko Health in a deal valued at up to $875M including earnouts. Shares of OPK +24% in the pre-market. Another biotech IPO successfully priced. NVDIA-backed Iambic Therapeutics raised $150M ahead of its Nasdaq debut. Yesterday, Healthcare equities were broadly higher. UNH +4.8% and PODD (3.0%) bracketed the XLV. Most major health groups ended higher on the averages; Biotech and MedTech essentially flat. XBI (0.02%) still looking for a catalyst to climb out of the >(4%) WTD hole. Defensive groups outperformed on the macro drivers and rotation. Macro S&P futures are down (0.3%) on Thursday morning, and Nasdaq down (1.2%). Tech selloff again the big story as semis, memory, neoclouds, and AI infrastructure pacing for another sharp decline, following steep selloff across South Korea's memory-linked names overnight. Anthropic told investors its Q3 revenue hit $16.8B, and is cash flow positive, though added to concerns that hockey-stick growth trends may be flattening out. Similar to Wednesday's ASML update, TSM earnings also weighing on sentiment. AI demand trends remain strong, but investors seemingly looking for bigger guidance bump, while AI-linked buildout pressuring margins. Treasuries rallying again as a safe haven trade; 10Y yield down another ~10 bp to lowest level in over three weeks. Market pricing 28 bp of hikes through year-end, now only ~3 bp above level before yesterday's hotter September core CPI print. Elsewhere, oil erased earlier declines as Ukraine's Zelenskyy said strikes on Russian refineries would resume, while attacks on ships in Strait of Hormuz continue at elevated levels. Pre-market trading update Trading higher +24.1% OPK agreement to sell BioReference Labs to Labcorp +4.0% FTRE upgraded at Deutsche Bank +2.9% AZN discovery collaboration with insitro an AI therapeutics company +2.4% DXCM publication of data in NEJM +2.3% IBRX follow-through on FDA approval +1.4% REGN assumed/upgraded at UBS Trading lowr -9.1% RXRX secondary offering priced -5.3% TEM on 158K shares -4.8% TWST on 21K shares -4.3% TXG on 25K shares -1.2% ALGN downgraded at Baird -1.1% NVST downgraded at Baird Biotech Regulatory: IBRX issued a press release on the previously reported FDA approval of Anktiva sBLA in NMIBC. IPO priced IAM Iambic Therapeutics raised $150M when 9.4M share IPO priced at the midpoint of the anticipated range ($15-17). Shares to begin trading on the Nasdaq today. Research: ALNY assumed buy at UBS (Joon Lee), target is $354 or approx. 58% upside. ARWR assumed buy at UBS (Joon Lee), target is $109 or approx. 87% upside. ARQT initiated overweight at Cantor Fitzgerald (Steve Seedhouse), target is $48 or approx. 82% upside. ASND assumed buy at UBS (Joon Lee), target is $269 or approx. 19% upside. BBIO assumed buy at UBS (Joon Lee), target is $92 or approx. 42% upside. BMRN assumed buy at UBS (Joon Lee), target is $88 or approx. 60% upside. COAG initiated overweight at JPMorgan (Joyce Zhou), target is $70 or approx. 134% upside. CRSP initiated neutral at UBS (Joon Lee), target is $52 or approx. 4% upside. DRUG initiated outperform at Wolfe Research (Rudy Li), target is $150 or approx. 196% upside. ELOX initiated overweight at Cantor Fitzgerald (Yanni Souroutzidis) OVID initiated outperform at Wolfe Research (Rudy Li), target is $5 or approx. 128% upside. IONS assumed buy, vs prior neutral (upgrade), at UBS (Joon Lee), target is $88 or approx. 106% upside. PRAX initiated buy at UBS (Joon Lee), target is $706 or approx. 195% upside. PTCT assumed buy at UBS (Joon Lee), target is $90 or approx. 51% upside. QURE assumed buy at UBS (Joon Lee), target is $48 or approx. 129% upside. RAPP initiated outperform at Wolfe Research (Rudy Li), target is $50 or approx. 76% upside. RAPP initiated buy at UBS (Joon Lee), target is $71 or approx. 151% upside. RARE initiated neutral at UBS (Joon Lee), target is $16 or approx. 7% upside. REGN assumed buy, vs prior neutral (upgrade), at UBS (Joon Lee), target is $978 or approx. 26% upside. SLDB initiated buy at UBS (Joon Lee), target is $20 or approx. 266% upside. VKTX initiated buy at UBS (Joon Lee), target is $94 or approx. 269% upside. WVE initiated buy at UBS (Joon Lee), target is $11 or approx. 256% upside. Life Science & MedTech Publication: DXCM announced that NEJM published results from the landmark CONNECT trial in non-insulin treated Type 2 Diabetes (T2 NIT). Observed benefits include those taking GLP-1s. Quick take: Wells Fargo sees this boosting CGM usage for T2 NIT patients and probability of CMS coverage by mid-2027. Research: ALGN downgraded to neutral from outperform at Baird (Jeff Johnson), target cut to $162 from $218 or approx. 12% upside. (FactSet average PT $194; range $155-235) FTRE upgraded to buy from hold at Deutsche Bank (Justin Bowers), target increased to $25 from $20 or approx. 17% upside. (FactSet average PT $22; range $16-26) NVST downgraded to neutral from outperform at Baird (Jeff Johnson), target cut to $26 from $34 or approx. 14% upside. (FactSet average PT $29; range $23-34) ESTA initiated buy at Stifel (Joseph Federico), target is $85 or approx. 47% upside. (FactSet average PT $102; range $92-117) SGHT initiated buy at HC Wainwright (Yi Chen), target is $14 or approx. 70% upside. (FactSet average PT $9; range $8-12) TMO initiated buy at Guggenheim Securities (Subbu Nambi), target is $740 or approx. 10% upside. (FactSet average PT $694; range $575-800) Services & Hospitals M&A: OPK and LH announced an agreement for Labcorp to acquire select assets of BioReference Health LLC from Opko Health for $722M in cash at closing, plus up to $150M in earnouts. Transaction includes the laboratory testing business and the proprietary 4Kscore Test, an FDA-approved blood test for detecting prostate cancer. On Deck: Regulatory (cont.): EMA CHMP monthly meeting (Oct 12-15); opinions for MAA on Friday ROP.SW FDA PDUFA today for Enspryng sBLA for TED on Sat 17-Oct: IRD / VTRS FDA PDUFA for Ryzumvi sNDA for presbyopia Conference on Sat 17-Oct: UEGW 2026 (Oct 17-20) on Sun 18-Oct: ESMO 2026 regular abstracts published online (18:05ET) Syndicate calendar / potential IPO pricing Thu 15-Oct (post-close): +CTY City Therapeutics Peek Ahead to next week Oct 19 - 25 Earnings: ABT, DGX, DHR, ELV, MEDP, MOH, SRT3.GR, TMO Investor event: RCUS (Oct 20, 8:30ET), RGNX (Oct 20, 13:00ET), FDMT (Oct 21, 10:30ET) Conference: NAMS 2026 (Oct 20-24), ESMO 2026 (Oct 23-27) LBAs for ESMO published at 18:05ET on Oct 22-25, and at 19:05ET on Oct 26 (clock change CEST->CET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ALGN, ALNY, ARQT, ARWR, ASND, AZN, BBIO, BMRN, COAG, CRSP, DGX, DRUG, DXCM, ELOX, ELV, ESTA, FDMT, FTRE, IAM, IBRX, IONS, IRD, LH, MEDP, MOH, NVST, OPK, OVID, PRAX, PTCT, QURE, RAPP, RARE, RCUS, REGN, RGNX, ROP.SW, RXRX, SGHT, SLDB, SRT3.GR, TEM, TMO, TWST, TXG, VKTX, VTRS, WVE, +CTY, +IAM...(more)	show story hide story
14-Oct-2026 16:35	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly higher on Wednesday. Advancers topped decliners by nearly 4:1 on the XLV, breadth at best levels of the session. UNH +4.8% and PODD (3.0%) bracketed the XLV. Healthcare +2.44% vs S&P 500 (1.11%). Most major health groups ended higher on the averages; Biotech and MedTech essentially flat. XBI (0.02%) still looking for a catalyst to climb out of the >(4%) WTD hole. MedTech group mixed, with Diabetes Tech space leading decline for the Device subgroup. Pharma, Managed Care and Services were the leading gainers; defensive groups outperformed on the macro drivers and rotation. Most large-cap drugmakers saw daily gains topping +3%, including a $40B market-cap ride for LLY +3.6%. RBC Capital Markets upgraded the Healthcare sector to overweight from market weight, swapping ratings with both the Tech and Materials sectors - call came well before the CPI print. Sector specific newsflow fairly light, company-specific, headlined by a significant patent infringement settlement in SMID-cap biotech: LQDA +26.6%. Global settlement agreement reached between Liquidia and United Therapeutics, resolving all litigation between the SMID-cap biotechs. Liquidia will pay nearly $400M to United across the next six months. Liquidia also preannounced Q3 net product sales. Yesterday, Healthcare equities were mixed yet lower overall. CNC +2.7% and JNJ (5.7%) bracketed the XLV. Most major health groups ended lower on the session. Biotech group the leading decliner for a second day, the XBI (3.04%) and now (4.53%) WTD. Pharma followed close behind, the DRG (2.21%). Macro Stocks spent the afternoon near session lows despite rates erasing big backup following morning's hotter-than-expected September core CPI print. Not much behind big shift throughout session (2Y was down more than 15 bp from morning peak), though may be a function of flight-to-safety shift amid sharp selloff across AI trade and Big Tech (and rotation toward defensive healthcare, staples). Hawkish Fed rate path bets also came off since the morning's CPI report, with 32% chance of October hike (was above 50%) and 30 bp of hikes through year-end (was above 35 bp earlier). A couple moving pieces around AI story, including underwhelming ASML guidance, latest scrutiny around debt/ROI dynamics (particularly around neoclouds like CRWV), some cautious sell-side commentary around extended valuations, enterprise spending backdrop. Fairly quiet elsewhere. Oil was higher on latest Middle East hostilities (Houthis claimed 42 strikes over past 24 hours). Banks were (again) a drag with poorly received earnings as rates hit FICC trading, though highlighted ongoing AI financing tailwind. Notable Gainers +26.6% LQDA (Liquidia): reached global settlement with UTHR; reports preliminary Q3 sales and cash; upgrades +7.9% ALMR (Alamar Biosciences): shares even WTD; lockup expiry tomorrow +7.7% TRAX (First Tracks Biotherapeutics Inc): best performer on XBI; shares +7% WTD +6.6% HALO (Halozyme Therapeutics): takeaways from JNJ print; 52-week high +5.9% EVO (Evotec): preliminary 9M results and unchanged FY guidance +4.8% UNH (UnitedHealth Group): best performer on XLV; follow-through, shares +4% WTD +4.8% ACHC (Acadia Healthcare): on below average volume; shares +9% WTD +4.6% MRNA (Moderna): shares +1% WTD +4.6% BMY (Bristol Myers Squibb): broad pharma strength on rotation +3.8% UHS (Universal Health Services): on average volume +3.8% LLY (Eli Lilly): broad pharma strength on rotation +3.8% MRK (Merck): broad pharma strength on rotation +3.8% AXSM (Axsome Therapeutics): on above average volume +3.5% VSTM (Verastem): updated clinical data in KRAS G12D-mutated solid tumors +3.4% ABBV (AbbVie): broad pharma strength on rotation; 52-week high +3.4% LONN.SW (Lonza Group): updated L-T outlook at CMD, reiterates FY26 outlook +3.4% REGN (Regeneron): broad pharma strength on rotation +3.2% AMGN (Amgen): broad pharma strength on rotation +3.0% PFE (Pfizer): broad pharma strength on rotation; 52-week high +1.1% IBRX (ImmunityBio): FDA expands Anktiva label in NMIBC Notable Decliners -33.8% BMEA (Biomea Fusion): trial results with oral GLP1 in obesity -11.5% KOD (Kodiak Sciences): B Riley comments on FDMT; worst performer on XBI -8.6% MMED (MiniMed Group): MDT concludes exchange; Diabetes Tech weakness -7.0% FTH (Faeth Therapeutics): follow-through, shares (23%) WTD -6.8% HIMS (Hims & Hers Health): Hers launches hair-loss care in UK; shares (10%) WTD -5.7% PRME (Prime Medicine): follow-through, shares (22%) WTD -5.0% OCGN (Ocugen): out-licensed MENA rights -4.6% BBNX (Beta Bionics, Inc.): Diabetes Tech weakness -4.6% PLSE (Pulse Biosciences): follow-through, shares (14%) WTD -4.4% VKTX (Viking Therapeutics): initiates phase 3 oral study; shares (12%) WTD -4.3% BHVN (Biohaven): on light volume; shares (10%) WTD -4.1% CABA (Cabaletta Bio): follow-through, shares (16%) WTD; 52-week low -3.8% TNDM (Tandem Diabetes Care): Diabetes Tech weakness -3.0% PODD (Insulet): Diabetes Tech weakness; worst performer on XLV -2.6% SHC (Sotera Health): downgraded at JPMorgan Liquidia higher on settlement with United Therapeutics LQDA and UTHR announced they have reached a global settlement agreement, resolving all litigation covering Yutrepia and treprostinil. Terms maintain uninterrupted patient access to Yutrepia for treatment of PAH. Liquidia reports $396.1M in cash as of 30-Sep, and will pay $393.1M across the next six months to United Therapeutics. Liquidia also reported preliminary Q3 net product sales of $222.7M. Upgrades in reaction Summit Therapeutics firmer on Wednesday; analysts looking ahead to ESMO SMMT partner Akeso (9926.HK) traded lower (9.6%) in Hong Kong on Wednesday after pricing a 20M share offering (HK$2B). StreetAccount notes that shares of Summit were lower by more than (9%) on Tuesday vs XBI (3%). Jefferies views ESMO as more incremental in nature than WCLC for Summit's ivonescimab, however Merck (MRK) /Kelun (6990.HK) Sac-TMT data risk direct read-across in lung. HC Wainwright shares that view, noting that Lung06 data may establish a pembro-containing regimen over ivo. Pure play CDMO Lonza charts course at newly acquired US facility LONN.SW reiterated FY26 guidance and updated its medium-term outlook ahead of today's Capital Markets Day at Vacaville (9:00ET). Slides here. Trial results in SMID-cap biotech VSTM announced initial multi-tumor clinical data update from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375. Treatment demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers. FDA alignment reached on Phase 3 trial design in 1L mPDAC; plan to open trial by year-end. BMEA announced phase 1 trail results for BMF-650, an oral GLP-1 agonist for weight reduction. GLP-131 study evaluated safety and tolerability measures as co-primary endpoints and pharmacokinetics, pharmacodynamics and weight reduction in overweight or obese, otherwise healthy adults as key secondary endpoints. Notable research in Healthcare today Pharma: JNJ reiterated outperform at RBC Capital Markets (Trung Huynh), views sell-off as buying opportunity ahead of 8-Dec EBR. Target cut to $280 from $290. Biotech: LQDA upgraded to buy from neutral at BTIG (Julian Harrison), notes better than expected settlement terms. Target is $70 or approx. 161% upside. (FactSet average PT $52; range $33-72) LQDA upgraded to outperform from market perform at LifeSci Capital (Gaurav Maini), citing removed overhang on the stock. Target is $59 or approx. 120% upside. JSPR resumed outperform (upgraded) at William Blair (Matt Phipps), prior rating was market perform. IMTX initiated buy at Stifel (Laura Prendergast), target is $15 or approx. 120% upside. IDYA resumed buy at Stifel (Laura Prendergast), target is $48 or approx. 40% upside. AAPG initiated buy at Citi (Yigal Nochomovitz), target is $46 or approx. 205% upside. RCUS initiated overweight at JPMorgan (Priyanka Grover), target is $41 or approx. 82% upside. SLGL initiated overweight at Cantor Fitzgerald (Imogen Mansfield) SPTX initiated buy at Canaccord Genuity (Sumant Kulkarni), target is $28 or approx. 74% upside. MedTech: BRKR downgraded to neutral from overweight at JPMorgan (Casey Woodring), target remains $60 or approx. 7% upside. (FactSet average PT $64; range $50-80) HSTM initiated hold at Freedom Capital (Gene Mannheimer), target is $36 or approx. 7% upside. Services: SHC downgraded to underweight from neutral at JPMorgan (Casey Woodring), target cut to $17 from $18 or approx. 7% downside. (FactSet average PT $23; range $18-25) Post-close news Regulatory: IBRX issued a press release on the previously reported FDA approval of Anktiva. Shares trading +0.4% in the after-hours; shares closed up +1.1% on Wednesday. Research: ESTA initiated buy at Stifel (Joseph Federico), target is $85 or approx. 47% upside. (FactSet average PT $102; range $92-117) On Deck: Regulatory (cont.): EMA CHMP monthly meeting (Oct 12-15) ROP.SW FDA PDUFA on Thursday for Enspryng sBLA for TED Syndicate calendar / potential IPO pricing Wed 14-Oct (post-close): +IAM Iambic Therapeutics Thu 15-Oct (post-close): +CTY City Therapeutics StreetAccount Healthcare Reads Individual Market Enrollment Continues to Fall Through Mid-2026 (14-Oct) KFF.org FDA Director of OGD Steps Down Amid 'Political Pressure,' Admin Burden (14-Oct) Pink Sheet Helen Branswell, whose reporting on infectious diseases and public health drew acclaim, dies at 69 (13-Oct) STAT News FTC demands Martin Shkreli divest his pharma stocks (13-Oct) STAT News Shkreli Faces Contempt for Breaking Pharma Industry Ban (13-Oct) Bloomberg This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 6990.HK, 9926.HK, AAPG, ABBV, ACHC, ALMR, AMGN, AXSM, BBNX, BHVN, BMEA, BMY, BRKR, CABA, ESTA, EVO, FTH, HALO, HIMS, HSTM, IBRX, IDYA, IMTX, JNJ, JSPR, KOD, LLY, LONN.SW, LQDA, MMED, MRK, MRNA, OCGN, PFE, PLSE, PODD, PRME, RCUS, REGN, ROP.SW, SHC, SLGL, SMMT, SPTX, TNDM, TRAX, UHS, UNH, UTHR, VKTX, VSTM, +CTY, +IAM...(more)	show story hide story
14-Oct-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +1.58% vs the S&P 500 (0.75%). All major health groups are higher on the averages, including early laggard Biotech, XBI +0.26% seeking to climb out of the (4%) WTD hole. LLY +3% and BSX (2%) bracket the XLV. Defensive groups outperforming on the macro drivers and rotation. RBC Capital Markets upgraded the Healthcare sector to overweight from market weight, swapping ratings with both the Tech and Materials sectors - call came well before the CPI print. Pharma and Managed Care are leading gainers today. Sector specific newsflow fairly light, company-specific, headlined by a significant patent infringement settlement in SMID-cap biotech: LQDA +25%. Gainers +24.7% LQDA (Liquidia): reached global settlement with UTHR; reports preliminary Q3 sales and cash; upgrades +19.1% VSTM (Verastem): updated clinical data in KRAS G12D-mutated solid tumors; best performer on XBI +8.0% ALMR (Alamar Biosciences): shares +1% WTD; lockup expiry tomorrow +7.2% HALO (Halozyme Therapeutics): takeaways from JNJ print; 52-week high +7.1% EVO (Evotec): preliminary 9M results and unchanged FY guidance +6.8% ATRA (Atara Biotherapeutics): FDA accepts BLA for tab-cel; PDUFA is 31-Mar-2027 +5.0% CAI (Caris Life Sciences): on average volume +3.4% LLY (Eli Lilly): on strong volume; best performer on XLV +3.3% LONN.SW (Lonza Group): updated L-T outlook at CMD, reiterates FY26 outlook +3.0% AXSM (Axsome Therapeutics): on average volume +3.0% AMGN (Amgen): shares +3% WTD +2.9% IMTX (Immatics): initiation +2.7% UNH (UnitedHealth Group): follow-through +1.6% ARWR (Arrowhead Pharmaceuticals): interim results in phase 1/2 in Alzheimer's disease; webinar 1430ET +0.3% GENB (Generate Biomedicines): AI-fueled R&D agreement in obesity with ZEAL.DC, deal worth up to $1.2B Decliners -33.3% BMEA (Biomea Fusion): trial results with oral GLP1 in obesity -6.0% MMED (MiniMed Group): MDT concludes exchange -5.6% CABA (Cabaletta Bio): worst performer on XBI; 52-week low -5.2% PRME (Prime Medicine): follow-through, shares (21%) WTD -3.8% KOD (Kodiak Sciences): B Riley comments on FDMT (relative valuation) -1.6% BSX (Boston Scientific): worst performer on XLV -1.5% SHC (Sotera Health): downgraded at JPMorgan	show story hide story
14-Oct-2026 08:41	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Global settlement agreement reached between Liquidia and United Therapeutics, resolving all litigation between the SMID-cap biotechs. Liquidia will pay nearly $400M to United across the next six months. Liquidia also preannounced Q3 net product sales. Shares of LQDA +38% in the pre-market; UTHR little changed. RBC Capital Markets upgraded the Healthcare sector to overweight from market weight, swapping ratings with both the Tech and Materials sectors. Yesterday, Healthcare equities were mixed yet lower overall. CNC +2.7% and JNJ (5.7%) bracketed the XLV. Most major health groups ended lower on the session. Biotech group the leading decliner for a second day, the XBI (3.04%) and now (4.53%) WTD. Pharma followed close behind, the DRG (2.21%). Macro S&P futures are up +0.2% on Wednesday morning, while Nasdaq futures are down (0.1%). Premarket trading pointing to another day of weakness for the AI trade, with underwhelming ASML guidance seemingly outweighing commentary on strong AI-driven demand; SOX down for past five sessions and has not seen a six-day decline since May 2025. Will be a lot of attention today on September CPI and implications for 28-Oct FOMC (market currently expecting a hold with higher probability of a December hike). Comes after some dovish Fedspeak Tuesday from Waller and Williams. More bank earnings on the calendar today after Tuesday's reports seemed to underwhelm despite some constructive elements. Not much impact from geopolitics; Houthis launched broad strikes against Saudi targets including Aramco's HQ. Pre-market trading update Trading higher +37.9% LQDA reached global settlement with UTHR; reports preliminary Q3 sales and cash; upgraded at BTIG +9.3% EVO preliminary 9M results and unchanged FY guidance +6.3% VSTM updated clinical data in KRAS G12D-mutated solid tumors; call at 8ET +5.4% ARWR interim results in phase 1/2 in Alzheimer's disease; webinar 1430ET +3.9% PODD on 14K shares +3.5% LONN.SW updated L-T outlook at CMD, reiterates FY26 outlook +3.4% GENB AI-fueled R&D agreement in obesity with ZEAL.DC, deal worth up to $1.2B +2.5% IMTX initiation (low volume) +2.1% RARE agrees to sell PRV for $203M (low volume) Trading lower -18.3% BMEA trial results with oral GLP1 in obesity -2.8% SHC downgraded at JPMorgan -1.0% BRKR downgraded at JPMorgan Pharma Research: JNJ reiterated outperform at RBC Capital Markets (Trung Huynh), views sell-off as buying opportunity ahead of 8-Dec EBR. Target cut to $280 from $290. Biotech Litigation / settlement: LQDA and UTHR announced they have reached a global settlement agreement, resolving all litigation covering Yutrepia and treprostinil. Terms maintain uninterrupted patient access to Yutrepia for treatment of PAH. Liquidia reports $396.1M in cash as of 30-Sep, and will pay $393.1M across the next six months to United Therapeutics. Liquidia also reported preliminary Q3 net product sales of $222.7M. Upgrades in reaction Trial results: VSTM announced initial multi-tumor clinical data update from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375. Treatment demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers. FDA alignment reached on Phase 3 trial design in 1L mPDAC; plan to open trial by year-end. Conf. call at 8:00ET BMEA announced phase 1 trail results for BMF-650, an oral GLP-1 agonist for weight reduction. GLP-131 study evaluated safety and tolerability measures as co-primary endpoints and pharmacokinetics, pharmacodynamics and weight reduction in overweight or obese, otherwise healthy adults as key secondary endpoints. Collaboration: GENB and ZEAL.DC announced a collaboration and license agreement to develop multispecific protein therapeutics for obesity and other metabolic disease. GENB receives $65M in upfront and early milestones, deal worth up to $1.2B in total development milestones, plus royalties. Corporate: SMMT partner Akeso (9926.HK) traded lower (9.6%) in Hong Kong on Wednesday after pricing a 20M share offering (HK$2B). StreetAccount notes that shares of Summit were lower by more than (9%) on Tuesday vs XBI (3%). Research: LQDA upgraded to buy from neutral at BTIG (Julian Harrison), notes better than expected settlement terms. Target is $70 or approx. 161% upside. (FactSet average PT $52; range $33-72) LQDA upgraded to outperform from market perform at LifeSci Capital (Gaurav Maini), citing removed overhang on the stock. Target is $59 or approx. 120% upside. JSPR resumed outperform (upgraded) at William Blair (Matt Phipps), prior rating was market perform. IMTX initiated buy at Stifel (Laura Prendergast), target is $15 or approx. 120% upside. IDYA resumed buy at Stifel (Laura Prendergast), target is $48 or approx. 40% upside. AAPG initiated buy at Citi (Yigal Nochomovitz), target is $46 or approx. 205% upside. RCUS initiated overweight at JPMorgan (Priyanka Grover), target is $41 or approx. 82% upside. SLGL initiated overweight at Cantor Fitzgerald (Imogen Mansfield) SPTX initiated buy at Canaccord Genuity (Sumant Kulkarni), target is $28 or approx. 74% upside. Life Science & MedTech Corporate: LONN.SW reiterated FY26 guidance and updated its medium-term outlook ahead of today's Capital Markets Day at Vacaville (9:00ET). Slides here. Research: BRKR downgraded to neutral from overweight at JPMorgan (Casey Woodring), target remains $60 or approx. 7% upside. (FactSet average PT $64; range $50-80) HSTM initiated hold at Freedom Capital (Gene Mannheimer), target is $36 or approx. 7% upside. Services & Hospitals Research: SHC downgraded to underweight from neutral at JPMorgan (Casey Woodring), target cut to $17 from $18 or approx. 7% downside. (FactSet average PT $23; range $18-25) On Deck: Conference (cont.): ACG 2026 (Oct 9-14) Regulatory (cont.): EMA CHMP monthly meeting (Oct 12-15) on Thu 15-Oct: ROP.SW FDA PDUFA for Enspryng sBLA for TED Syndicate calendar / potential IPO pricing Wed 14-Oct (post-close): +IAM Iambic Therapeutics Thu 15-Oct (post-close): +CTY City Therapeutics This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 9926.HK, AAPG, ARWR, BMEA, BRKR, EVO, GENB, HSTM, IDYA, IMTX, JNJ, JSPR, LONN.SW, LQDA, PODD, RARE, RCUS, ROP.SW, SHC, SLGL, SMMT, SPTX, UTHR, VSTM, ZEAL.DC, +AIM, +CTY...(more)	show story hide story
13-Oct-2026 16:56	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed yet lower overall on Tuesday. Decliners topped advancers by nearly 2:1 on the XLV, after breadth improved throughout the day. CNC +2.7% and JNJ (5.7%) bracketed the XLV. Healthcare (1.33%) vs S&P 500 (0.02%). Most major health groups ended lower on the session. Biotech group the leading decliner for a second day, the XBI (3.04%) and now (4.53%) WTD. Pharma followed close behind, the DRG (2.21%). Despite solid results from IM segment, JNJ was joined by every major drugmaker; declines ranged from (1%) to (2%) each. Managed Care and Services groups were the relative performers, despite hospitals lightly mixed. Earnings season in Healthcare kicked off today with two bellwether prints. JNJ reported a Q3 beat and raise, topline mixed and just inline overall with guidance tweaked just slightly higher. Pharma carried MedTech. Medical devices mostly soft in reaction; company and investors focused on further slimming of the business. UNH (0.2%) reported a Q3 beat and raise with Q3 MLR ahead of StreetAccount consensus by 150bps. Segment revenues mixed however, Healthcare beat offset by Optum light. Another setback in the mRNA cancer vaccine space, after BNTX (7.1%) reported that adding BNT113 to Keytruda did not extend PFS in HNSCC. Yesterday, Healthcare equities were mixed yet moderately higher overall. Providers and Payers groups were the top advancers with average gains above 1%; Biotech group was the lone decliner, the XBI (1.43%) to begin the week. Macro Several moving parts were in view though market saw another rangebound day for the S&P (28pt range vs Monday's 25). More broad pressure across the AI complex, particularly on semicaps and memory. Not much in terms of new headlines but sentiment remains fragile; some analyst comment focused on debt/equity issuance though other longstanding worries (IPO delays, China competition, monetization challenges, etc.) remain in the narrative. Today's big-bank reporters were weaker with some headline misses overshadowing more constructive elements (JPM guidance, GS IB strength). Market also processed some dovish Fedspeak from Waller (who said higher Treasury yields doing some of the tightening work) and Williams (said at this point, he sees no need for 2027 hikes). Not a lot on the geopolitical front though Saudi/Houthi tensions remain very high. Big focus today on the unofficial start to Q3 earnings season, led by the big banks. Notable Gainers +4.0% SLS (SELLAS Life Sciences): best performer on XBI; on average volume +3.7% CDNA (CareDx): second-best on XBI; on average volume +2.7% CNC (Centene): best performer on XLV; sympathy to UNH; reports in two weeks (27-Oct) +2.5% MOH (Molina Healthcare): sympathy to UNH; reports next week (21-Oct) Notable Decliners -16.3% OMDA (Omada Health, Inc.): sympathy to Google AI Health announcement -15.7% SNDX (Syndax Pharmaceuticals): trial results in IPF; worst performer on XBI -13.5% TSHA (Taysha Gene Therapies): on above average volume -13.3% SLDB (Solid Biosciences): on >2X average volume -9.6% KARD (Kardigan): on light volume -9.4% SMMT (Summit Therapeutics): on avg volume; shares (11%) WTD and YTD -7.6% ETRA (Electra Therapeutics, Inc.): initiations -7.5% PLSE (Pulse Biosciences): sympathy to JNJ -7.4% BMEA (Biomea Fusion): schedules investor call for Tuesday PM (obesity results) -7.1% BNTX (BioNTech): trial results in HNSCC -7.0% TRAX (First Tracks Biotherapeutics Inc): shares were +7% yesterday -5.7% JNJ (Johnson & Johnson): earnings, guidance; worst performer on XLV -4.4% NBIX (Neurocrine Biosciences): STAT News article -4.4% PTGX (Protagonist Therapeutics): sympathy to JNJ -4.3% VRTX (Vertex Pharmaceuticals): on below average volume -3.0% HUM (Humana): changes in VBC / JV with BlackRock JNJ lower following marginal Q3 beat JNJ reported Q3 EPS $2.59 ex-items vs FactSet $2.52 on revenue $25.40B vs FactSet $25.38B. Innovative Medicine sales outperformed consensus, up +7.7% y/y while MedTech sales lagged, up only +2.5% y/y. FY26 EPS guidance bumped 6.5c or roughly the quarterly outperformance, similar on the topline with revenue outlook raised just $100M at the midpoints. Quick take: Initial takeaways are less than constructive in the name despite the topline outperformance by IM that analysts were looking for above the 7% hurdle. MedTech results seen as lackluster with Cardio and Surgery facing ongoing challenges. Ortho growth acceleration a highlight for MT segment. Bottom line beat chalked up to lower tax rate, and the guidance raised solely for demonstrated operational performance in Q3. CFO comments to CNBC on knee and hip separation getting some attention ahead of the call. UnitedHealth Group higher following a Q3 beat and raise UNH reported Q3 EPS $4.69 ex-items vs FactSet $4.14 on revenue $112.69B vs FactSet $111.31B. Q3 MLR 88.4% vs StreetAccount 89.9%. Raises FY EPS outlook to at least $20.50 vs prior $19.50-20.00 and FactSet $19.80 Quick Take: Initial takeaways are broadly constructive on the results, with upside attributed primarily to outperformance at UHC and Optum Health, alongside $610M in net favorable prior-period development related to 2026 services; however, the company is still estimated to have beaten expectations excluding this benefit. Guidance is viewed as attainable against a low Q4 bar, with 2027 cost tailwinds expected as SG&A declines and prior investments begin to bear fruit. Trial results in SMID-cap biotech BNTX announced topline results from the AHEAD-MERIT Phase 2/3 clinical trial evaluating BNT113 (tenu-ra) in 1L HNSCC. Study did not meet its first primary endpoint of PFS in combo with Keytruda compared with Keytruda alone. Trial will continue towards the second primary endpoint of OS. SNDX announced topline results from the phase 2 trial MAXPIRe evaluating axatilimab (INCY, UCB.BB) in adults with IPF. Study did not meet the primary endpoint. Company will not advance for IPF; results do not affect other indications. BMEA scheduled an investor call for Tuesday post-market (16:30ET, 13-Oct) to review topline results of phase 1 trial for oral GLP-1 agonist BMF-650 in obesity. Notable research in Healthcare today Pharma: AZN.LN (AZN) upgraded to buy from sell at Nordea (Mattias Haggblom), target SEK1900 Biotech: ACAD downgraded to neutral from buy at UBS (Ashwani Verma), notes lower probability of success for remifanserin. Target cut to $23 from $49 or approx. 18% upside. CTNM downgraded to neutral from outperform at Baird (Charles Moore), target cut to $14 from $19 or approx. 63% upside. (FactSet average PT $21; range $14-28) NRSN downgraded to neutral from buy at Roth Capital (Boobalan Pachaiyappan), cites PARAGON delay. Target cut to $3.50 from $60 or approx. 1% upside. FHTX downgraded to in line from outperform at Evercore ISI (Gavin Clark-Gartner), target cut to $3 from $14 or approx. 54% upside. ETRA seeing initial sell-side coverage following IPO on 18-Sep. Shares have traded (38%) since pricing at $15/shr. All buy equivalent ratings so far (Cantor Fitzgerald, Evercore ISI, Jefferies, TD Cowen) AAPG initiated outperform at Citizens (Silvan Turkcan), target is $35 or approx. 129% upside. GOSS initiated buy at Chardan Capital (Andreas Argyrides), target is $160 or approx. 1624% upside. IKT initiated neutral at Chardan Capital (Andreas Argyrides), target is $1.50 or approx. 19% downside. KYNB initiated buy at Maxim Group (Michael Okunewitch), target is $35 or approx. 472% upside. MedTech: MMED initiated buy at Rothschild & Co Redburn (Issie Kirby), target is $30 or approx. 60% upside. (FactSet average PT $26; range $21-30) Post-close news Collaboration: GENB and ZEAL.DC announced a collaboration and license agreement to develop multispecific protein therapeutics for obesity and other metabolic disease. GENB receives $65M in upfront and early milestones, deal worth up to $1.2B in total development milestones, plus royalties. Shares of GENB +3.7% in the after-hours Trial results: BMEA announced phase 1 trail results for BMF-650, an oral GLP-1 agonist for weight reduction. GLP-131 study evaluated safety and tolerability measures as co-primary endpoints and pharmacokinetics, pharmacodynamics and weight reduction in overweight or obese, otherwise healthy adults as key secondary endpoints. Conf. call at 16:30ET Shares trading (20.3%) in the after-hours Research: HSTM initiated hold at Freedom Capital (Gene Mannheimer), target is $36 or approx. 7% upside. IMTX initiated buy at Stifel (Laura Prendergast), target is $15 or approx. 120% upside. IDYA resumed buy at Stifel (Laura Prendergast), target is $48 or approx. 40% upside. JNJ reiterated outperform at RBC Capital Markets (Trung Huynh), views sell-off as buying opportunity ahead of 8-Dec EBR. Target cut to $280 from $290. On Deck: Conference (cont.): ACG 2026 (Oct 9-14) Regulatory (cont.): EMA CHMP monthly meeting (Oct 12-15) on Thu 15-Oct: ROP.SW FDA PDUFA for Enspryng sBLA for TED Syndicate calendar / potential IPO pricing on Wed 14-Oct (post-close): +IAM Iambic Therapeutics on Thu 15-Oct (post-close): +CTY City Therapeutics StreetAccount Healthcare Reads Helen Branswell, whose reporting on infectious diseases and public health drew acclaim, dies at 69 (13-Oct) STAT News FTC demands Martin Shkreli divest his pharma stocks (13-Oct) STAT News Shkreli Faces Contempt for Breaking Pharma Industry Ban (13-Oct) Bloomberg Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug (13-Oct) STAT News Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics (13-Oct) Reuters This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AAPG, ACAD, AZN.LN, BMEA, BNTX, CDNA, CNC, CTNM, ETRA, FHTX, GENB, GOSS, HSTM, HUM, IDYA, IKT, IMTX, INCY, JNJ, KARD, KYNB, MMED, MOH, NBIX, NRSN, OMDA, PLSE, PTGX, ROP.SW, SLDB, SLS, SMMT, SNDX, TRAX, TSHA, UCB.BB, UNH, VRTX, ZEAL.DC, +CTY, +IAM...(more)	show story hide story
13-Oct-2026 11:12	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (1.05%) vs the S&P 500 (0.17%). Most major health groups are lower on the averages, led by Biotech for a second day, the XBI (1.60%). Services group the relative performer, firm with providers lightly mixed. Earnings season kicks off today in Healthcare with two bellwether prints. JNJ (5%) reported a Q3 beat and raise, topline mixed and just inline overall with guidance tweaked just slightly higher. Pharma beat nearly offset by MedTech light. Medical devices lower in reaction. Focus on further slimming of the business. UNH (flat) reported a Q3 beat and raise with Q3 MLR ahead of StreetAccount consensus by 150bps. Segment revenues mixed however, Healthcare beat offset by Optum light. Another setback in the mRNA cancer vaccine space, after BNTX (6%) reported that adding BNT113 to Keytruda did not extend PFS in HNSCC. Gainers +2.7% VEEV (Veeva Systems): best performer on XLV; expands partnership with IQV +2.5% ETRA (Electra Therapeutics, Inc.): initiations +2.1% NRIX (Nurix Therapeutics): best performer on XBI; earnings +1.7% MMED (MiniMed Group): initiation Decliners -17.3% SNDX (Syndax Pharmaceuticals): trial results in IPF; worst performer on XBI -6.7% SMMT (Summit Therapeutics): on heavy volume; shares (9%) WTD and YTD -5.7% BNTX (BioNTech): trial results in HNSCC -5.5% BMEA (Biomea Fusion): schedules investor call for Tuesday PM (obesity results) -5.2% PLSE (Pulse Biosciences): sympathy to JNJ -4.9% JNJ (Johnson & Johnson): earnings; worst performer on XLV -3.5% NBIX (Neurocrine Biosciences): STAT News article -3.0% HUM (Humana): JV with BlackRock -2.8% BSX (Boston Scientific): sympathy to JNJ -1.9% PTGX (Protagonist Therapeutics): sympathy to JNJ -1.3% GMAB (Genmab): sympathy to JNJ -0.8% MRNA (Moderna): early sympathy to BNTX -0.4% LEGN (Legend Biotech): sympathy to JNJ -0.3% UNH (UnitedHealth Group): earnings, MLR beat -0.1% AZN (AstraZeneca): double upgrade at Nordea	show story hide story
13-Oct-2026 08:51	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings season kicks off today in Healthcare with two bellwether prints. JNJ reported a Q3 beat and raise, topline mixed and just inline overall with guidance tweaked just slightly higher. Pharma beat nearly offset by MedTech light. Focus on further slimming of the business. Shares of JNJ down (2%) in the pre-market. UNH reported a Q3 beat and raise with Q3 MLR ahead of StreetAccount consensus by 150bps. Segment revenues mixed however, Healthcare beat offset by Optum light. Shares of UNH +4% in the pre-market. Another setback in the mRNA cancer vaccine space, after BioNTech reported that adding BNT113 to Keytruda did not extend PFS in HNSCC. Shares of BNTX (5%), and MRNA (3%) in sympathy. Yesterday, Healthcare equities were mixed yet moderately higher overall. Providers and Payers groups were the top advancers with average gains above 1%; Biotech group was the lone decliner, the XBI (1.43%) to begin the week. Macro S&P futures are down (0.1%) on Tuesday morning, Nasdaq futures down (0.8%) however. Another session of weakness from the AI trade with memory again coming under stiffer pressure. Not much in terms of new headline flow but sentiment remains fragile with a lot of recent analyst comment about market pushback on debt/equity issuance. And still focus on other longstanding worries including elevated expectations, crowded positioning, China competition, IPO delays, monetization challenges, and constant parade of frontier releases. Market outside AI space holding up better (consistent with recent indications of better breadth). Big-bank earnings fairly well received (JPM guidance, GS IB strength) opening a Q3 season expected to be very robust. Fairly quiet on the geopolitical front. Notable comments this morning from Fed's Waller who said rising Treasury yields doing some of the work of tighter monetary policy. Pre-market trading update Trading higher +4.7% UNH earnings, MLR beat; call at 800ET +4.4% BMEA schedules investor call for Tuesday PM (obesity results) +1.8% AZN on 73K ADRs Trading lower -12.1% SNDX trial results in IPF -5.1% BNTX trial results in HNSCC -2.6% MRNA sympathy to BNTX -2.3% JNJ earnings; call at 830ET -1.9% SMMT on 42K shares Pharma Earnings: JNJ reports Q3 EPS $2.59 ex-items vs FactSet $2.52 on revenue $25.40B vs FactSet $25.38B. Innovative Medicine sales outperformed consensus, up +7.7% y/y while MedTech sales lagged, up only +2.5% y/y. FY26 EPS guidance bumped 6.5c or roughly the quarterly outperformance, similar on the topline with revenue outlook raised just $100M at the midpoints. Quick take: Initial takeaways are less than constructive in the name despite the topline outperformance by IM that analysts were looking for above the 7% hurdle. MedTech results seen as lackluster with Cardio and Surgery facing ongoing challenges. Ortho growth acceleration a highlight for MT segment. Bottom line beat chalked up to lower tax rate, and the guidance raised solely for demonstrated operational performance in Q3. CFO comments to CNBC on knee and hip separation getting some attention ahead of the call. Conf. call at 8:30ET Biotech Trial results: BNTX announced topline results from the AHEAD-MERIT Phase 2/3 clinical trial evaluating BNT113 (tenu-ra) in 1L HNSCC. Study did not meet its first primary endpoint of PFS in combo with Keytruda compared with Keytruda alone. Trial will continue towards the second primary endpoint of OS. SNDX announced topline results from the phase 2 trial MAXPIRe evaluating axatilimab (INCY, UCB.BB) in adults with IPF. Study did not meet the primary endpoint. Company will not advance for IPF; results do not affect other indications. BMEA scheduled an investor call for Tuesday post-market (16:30ET, 13-Oct) to review topline results of phase 1 trial for oral GLP-1 agonist BMF-650 in obesity. Research: ACAD downgraded to neutral from buy at UBS (Ashwani Verma), notes lower probability of success for remifanserin. Target cut to $23 from $49 or approx. 18% upside. NRSN downgraded to neutral from buy at Roth Capital (Boobalan Pachaiyappan), cites PARAGON delay. Target cut to $3.50 from $60 or approx. 1% upside. FHTX downgraded to in line from outperform at Evercore ISI (Gavin Clark-Gartner), target cut to $3 from $14 or approx. 54% upside. ETRA seeing initial sell-side coverage following IPO on 18-Sep. Shares have traded (38%) since pricing at $15/shr. All buy equivalent ratings so far (Cantor Fitzgerald, Evercore ISI, Jefferies, TD Cowen) AAPG initiated outperform at Citizens (Silvan Turkcan), target is $35 or approx. 129% upside. GOSS initiated buy at Chardan Capital (Andreas Argyrides), target is $160 or approx. 1624% upside. IKT initiated neutral at Chardan Capital (Andreas Argyrides), target is $1.50 or approx. 19% downside. KYNB initiated buy at Maxim Group (Michael Okunewitch), target is $35 or approx. 472% upside. Life Science & MedTech Research: MMED initiated buy at Rothschild & Co Redburn (Issie Kirby), target is $30 or approx. 60% upside. (FactSet average PT $26; range $21-30) Managed Care Earnings: UNH reports Q3 EPS $4.69 ex-items vs FactSet $4.14 on revenue $112.69B vs FactSet $111.31B. Q3 MLR 88.4% vs StreetAccount 89.9%. Raises FY EPS outlook to at least $20.50 vs prior $19.50-20.00 and FactSet $19.80 Quick Take: Initial takeaways are broadly constructive on the results, with upside attributed primarily to outperformance at UHC and Optum Health, alongside $610M in net favorable prior-period development related to 2026 services; however, the company is still estimated to have beaten expectations excluding this benefit. Guidance is viewed as attainable against a low Q4 bar, with 2027 cost tailwinds expected as SG&A declines and prior investments begin to bear fruit. Conf. call at 8:00ET On Deck: Conference (cont.): ACG 2026 (Oct 9-14) Regulatory (cont.): EMA CHMP monthly meeting (Oct 12-15) Corporate ALEC R&D Day / ABC-enabled pipeline (11:00ET) (ROP.SW) BMEA to discuss phase 1 results in obesity (16:30ET) Syndicate calendar / potential IPO pricing on Wed 14-Oct (post-close): +IAM Iambic Therapeutics on Thu 15-Oct (post-close): +CTY City Therapeutics This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AAPG, ACAD, ALEC, AZN, BMEA, BNTX, ETRA, FHTX, GOSS, IKT, INCY, JNJ, KYNB, MMED, MRNA, NRSN, ROP.SW, SMMT, SNDX, UCB.BB, UNH, +CTY, +IAM...(more)	show story hide story
13-Oct-2026 08:40	JNJ Johnson & Johnson lower following marginal Q3 beat ($263.73) JNJ shares (2%) premarket after reporting Q3 EPS $2.59 ex-items vs FactSet $2.52 on revenue $25.40B vs FactSet $25.38B. Innovative Medicine sales outperformed consensus, up +7.7% y/y while MedTech sales lagged, up only +2.5% y/y. FY26 EPS guidance bumped 6.5c or roughly the quarterly outperformance, similar on the topline with revenue outlook raised just $100M at the midpoints. Initial takeaways are less than constructive in the name despite the topline outperformance by IM that analysts were looking for above the 7% hurdle. MedTech results seen as lackluster with Cardio and Surgery facing ongoing challenges. Ortho growth acceleration a highlight for MT segment. Bottom line beat chalked up to lower tax rate, and the guidance raised solely for demonstrated operational performance in Q3. CFO comments to CNBC on knee and hip separation getting some attention ahead of the call. See Related StreetAccount comments: 10/13/2026 6:39:15 AM - Johnson & Johnson CFO Joseph Wolk says company "leaning" towards spinning off hips-and-knees business -- wires, CNBC 10/13/2026 6:36:51 AM - Johnson & Johnson provides additional FY26 guidance - Earnings Slides 10/13/2026 6:28:00 AM - StreetAccount Metrics Recap - Johnson & Johnson Q3 Earnings 10/13/2026 6:23:41 AM - Johnson & Johnson reports Q3 EPS $2.59 ex-items vs FactSet $2.52 [15 est, $2.31-2.81] Related: GMAB, LEGN	show story hide story
13-Oct-2026 08:01	UNH UnitedHealth Group higher following a Q3 beat & raise ($378.52) UNH shares +2.2% premarket after reporting Q3 EPS and revenue ahead of FactSet, with MLR 88.4% beating StreetAccount 89.9%. Raised FY EPS guidance. Initial takeaways are broadly constructive on the results, with upside attributed primarily to outperformance at UHC and Optum Health, alongside $610M in net favorable prior-period development related to 2026 services; however, the company is still estimated to have beaten expectations excluding this benefit. Guidance is viewed as attainable against a low Q4 bar, with 2027 cost tailwinds expected as SG&A declines and prior investments begin to bear fruit. See Related StreetAccount comments: 10/13/2026 6:08:54 AM - StreetAccount Metrics Recap - UnitedHealth Group Q3 Earnings 10/13/2026 5:58:25 AM - UnitedHealth Group reports Q3 EPS $4.69 ex-items vs FactSet $4.14 [25 est, $3.90-4.56]	show story hide story
12-Oct-2026 16:59	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed yet moderately higher overall on Monday. Advancers beat decliners by 4:1 on the XLV. Healthcare +0.68% vs S&P 500 (0.06%). Major health groups ended loosely mixed for the session. Providers and Payers groups were the top advancers with average gains above 1%; Biotech group was the lone decliner, the XBI (1.43%). Aside from the typical flow of clinical readouts in biopharma, sector newsflow remained fairly quiet ahead of the kickoff to Q3 earnings season - JNJ and UNH report on Tuesday morning. MDT +3.9% and MRNA (5.0%) bracketed the XLV, after passing Monday morning leaders BIIB +1.6% / BMY (2.6%). Biogen hit fresh highs after today's bullish upgrade at JPMorgan, which sees opportunity beyond Leqembi; Bristol Myers weak despite two clinical readouts, market focusing on IPF, but has questions on dose response - and a patient death reportedly seen as unrelated to treatment. Small-cap biotech CTNM (36.0%) was highly volatile in read-across from BMY. Additionally, we saw clinical results in Celiac disease, plus new readouts in cholestatic pruritus and GEP-NETs. Robotic surgery headlines today with SYK +1.9% making its move - a strategic alliance with CMR Surgical. Other notable headlines around the sector: Long-time specialty pharma exec Brent Saunders exits BLCO (7.1%); and STE +2.1% will acquire privately-held Xodus Medical Inc for $2.1B. Sector focus squarely on the two bellwether prints coming up tomorrow morning. Macro AI trade came under pressure with memory an outsized laggard after headlines about density progress highlighted by China's CXMT. Other AI headlines have revolved around M&A, new models/competition (frontier, open-weight), scramble for compute capacity, favorable compute economics, and financing constraints. However, AI weakness again accompanied by some better breadth dynamics amid continued attention on recent weak breadth from financial press and sell-side commentary. Oil was higher following ramp in Middle East hostilities over the weekend along with skepticism surrounding Trump's diesel deal with Russia and Russia-Ukraine energy ceasefire claim. Pretty quiet elsewhere ahead of a number of potential high-profile catalysts, including big bank earnings, semi earnings (ASML, TSM), inflation data (CPI, PPI) and Fed Chair Warsh remarks. Latest batch of strategist commentary largely focused on expectations for another strong earnings season. Also some focus on depressed positioning outside of tech/Mag 7. Notable Gainers +7.2% ALHC (Alignment Healthcare): shares were (13%) on Friday +6.9% TRAX (First Tracks Biotherapeutics Inc): trial results in Celiac disease; best performer on XBI +6.4% PRCT (PROCEPT BioRobotics): sympathy to SYK headlines +3.9% MDT (Medtronic): best performer on XLV; exits MMED via exchange offer +3.4% ZBH (Zimmer Biomet Holdings): ahead of JNJ report tomorrow +3.0% GEHC (GE HealthCare Technologies): second-best on XLV; unusual options volume +1.9% SYK (Stryker): enters strategic alliance with CMR Surgical +1.6% BIIB (Biogen): upgraded at JPMorgan; 52-week high Notable Decliners -36.0% CTNM (Contineum Therapeutics): sympathy to BMY (IPF trial) -10.7% FTH (Faeth Therapeutics): worst performer on XBI; on below average volume; shares (43%) since 4-Sep -9.5% PRME (Prime Medicine): shares were +34% last week -8.0% RXRX (Recursion Pharmaceuticals): above average volume -7.1% BLCO (Bausch + Lomb): CEO Saunders departing company; comments on FY guidance -6.8% TXG (10X Genomics): shares were (14%) last week -5.1% HRMY (Harmony Biosciences): CEO steps down, appoints CEO, reiterates Wakix guidance -5.0% MRNA (Moderna): worst performer on XLV; shares +625% YTD -5.0% TWST (Twist Bioscience): shares were (15%) last week -4.6% MMED (MiniMed Group): MDT exits stake via exchange offer -3.2% IMVT (Immunovant): shares (38%) since 19-Aug-2026 -2.6% BMY (Bristol Myers Squibb): trial results in IPF; trial results in GEP-NETs -2.5% PLSE (Pulse Biosciences): on below avg volume; shares were +8% on Friday -2.4% ROIV (Roivant Sciences): downgraded at Wolfe Earnings previews Detailed ley metrics previews posted on StreetAccount for both JNJ and UNH UNH focus points Looking for preliminary FY27 EPS commentary, color around Medicare Advantage trends and discussion around Optum Health earnings. Bulls argue that Q2's stronger-than-expected Optum Health profit and a tighter medical-cost ratio signal a rebound that could offset attrition, whereas bears warn that losing roughly a million MA lives and any slip in the FY 88.1% cost-ratio guidance would pressure earnings and margins. JNJ focus points Can Innovative Medicine's new-drug ramp lift pharma revenue growth back above the 7% y/y target and offsets modest MedTech deceleration. Bulls cite accelerating Tremfya and pipeline launches, bears warn that lingering cardio weakness and procedure-volume uncertainty could blunt both pharma momentum and the guide. Bristol Myers trades lower following dual clinical read-outs BMY announced topline results from the phase 3 ALOFT-IPF trial evaluating admilparant in adults with IPF. Trial met its primary endpoint, and demonstrated a favorable safety and tolerability profile. Company to engage regulatory authorities and will present detailed results at a future medical meeting. StreetAccount notes that CTNM is developing a LPA1 receptor antagonist for IPF called PIPE-791. Bristol Myers Squibb tells Bloomberg that patient death likely unrelated to drug Shares of BMY near session lows, currently (3.4%), following today's update on the phase 3 ALOFT-IPF trial with admilparant. Shares of competitor CTNM (33%) also around session lows. Bloomberg has updated their pre-market article on the clinical results reported today, to include a line that a patient death in the study was likely unrelated to the drug treatment, according to company spokesperson. Investors have been waiting for more detailed safety results after recent report of liver tox risks. BMY announced topline results from a planned interim of the phase 3 ACTION-1 trial evaluating RYZ101 in patients with GEP-NETs. Study met the primary endpoint (PFS). Participants will be followed for OS. Brent Saunders leaving Bausch + Lomb after three and a half years BHC and BLCO jointly announced that both companies expect to raise FY guidance for adj EBITDA. Update comes alongside disclosure that B+L CEO Brent Saunders will depart the company which he noted was "stronger, more focused, and better positioned" than when he arrived in 2023. Earnings scheduled for 28-Oct-2026. Bausch Health CEO, and Chairman of B+L, has also been named interim CEO at B+L. Shares of BLCO were $16.98 on the morning of 15-Feb-2023; currently trading down (9%) to $15.76/shr. Trial results in SMID-cap biotech TRAX announced topline results from Cohort 1 of the phase 1B trial evaluating ANB033 in Celiac disease. Study achieved three key histologic efficacy endpoints, and demonstrated a consistent, favorable safety and tolerability profile. Company to engage FDA and seek alignment on the development pathway. MIRM announced topline results from the phase 3 EXPAND trial evaluating LIVMARLI (maralixibat) in cholestatic pruritus. study met its primary endpoint and all five prespecified secondary endpoints. Company plans to file sNDA in H1 of 2027. STERIS trades flat following acquisition STE announced the acquisition of Xodus Medical Inc (private) foe $2.1B, and expects cash tax benefits of ($300M) for a net purchase price around $1.8B. Company will update guidance after closing (around year-end). Notable research in Healthcare today Biotech: BIIB upgraded to overweight from neutral at JPMorgan (Chris Schott), target increased to $300 from $210 or approx. 33% upside. (FactSet average PT $244; range $175-300) BMRN upgraded to strong buy from outperform at Raymond James (Christopher Raymond), target is $109 or approx. 99% upside. (FactSet average PT $92; range $60-124) INSM downgraded to peer perform from outperform at Wolfe Research (Andy Chen) ROIV downgraded to peer perform from outperform at Wolfe Research (Andy Chen) ABCL initiated buy at UBS (Alice Nettleton), target is $18 or approx. 43% upside. BIOA initiated neutral at UBS (Alice Nettleton), target is $8 or approx. 26% upside. CNTB assumed outperform at Leerink Partners (Will Soghikian), target is $4 or approx. 360% upside. COAG initiated buy at Rodman & Renshaw (Michael King), target is $56 or approx. 77% upside. EQ initiated outperform at Leerink Partners (Will Soghikian), target is $6 or approx. 326% upside. EVMN initiated neutral at UBS (Alice Nettleton), target is $8 or approx. 28% upside. GLUE assumed buy at UBS (Alice Nettleton), target is $19 or approx. 84% upside. KARD initiated buy at UBS (Alice Nettleton), target is $25 or approx. 70% upside. OCUL initiated buy at UBS (Alice Nettleton), target is $14 or approx. 86% upside. ODTX initiated buy at UBS (Alice Nettleton), target is $27 or approx. 42% upside. MLYS initiated neutral at UBS (Alice Nettleton), target is $29 or approx. 24% upside. NKTR initiated neutral at UBS (Alice Nettleton), target is $53 or approx. 29% upside. NKTR initiated outperform at Leerink Partners (Will Soghikian), target is $130 or approx. 216% upside. PRE initiated buy at Lucid Capital Markets (Alex Nowak), target is $54 or approx. 147% upside. PTGX initiated buy at UBS (Alice Nettleton), target is $184 or approx. 28% upside. QNRX initiated buy at BTIG (Jeet Mukjerjee), target is $14 or approx. 211% upside. QTTB initiated outperform at Leerink Partners (Will Soghikian), target is $40 or approx. 380% upside. STTK initiated buy at UBS (Alice Nettleton), target is $17 or approx. 185% upside. SYRE initiated buy at UBS (Alice Nettleton), target is $120 or approx. 40% upside. TECX initiated neutral at UBS (Alice Nettleton), target is $26 or approx. 11% upside. VERA initiated market perform at Leerink Partners (Will Soghikian), target is $34 or approx. 14% upside. VKTX Cantor Fitzgerald comments briefly on the recent COO departure (hired 9 mos ago), not concerned in the short term. MedTech: BBNX initiated buy at Jefferies (Matthew Taylor), target is $30 or approx. 70% upside. BFLY initiated buy at Canaccord Genuity (William Plovanic), target is $10 or approx. 21% upside. IDXX initiated sector weight at KeyBanc (Steve Dechert) MMED initiated hold at Jefferies (Michael Toomey), target is $22 or approx. 12% upside. Managed Care: HUM upgraded to outperform from market perform at Raymond James (Parker Snure), target is $520 or approx. 20% upside. (FactSet average PT $459; range $280-596) Post-close news Trial results: SNDX announced topline results from the phase 2 trial MAXPIRe evaluating axatilimab (INCY, UCB.BB) in adults with IPF. Study did not meet the primary endpoint. Company will not advance for IPF; results do not affect other indications. Shares trading (15.4%) in the after-hours; shares of INCY (1.8%) BMEA schedules investor call for tomorrow post-market (16:30ET, 13-Oct) to review topline results of phase 1 trial for oral GLP-1 agonist BMF-650 in obesity. Shares trading +15.4% in the after-hours On Deck: Conference (cont.): ACG 2026 (Oct 9-14) Regulatory (cont.): EMA CHMP monthly meeting (Oct 12-15) Earnings tomorrow morning: JNJ (call at 8:30ET) UNH (call at 8:00ET) Corporate ALEC R&D Day / ABC-enabled pipeline (11:00ET) (ROP.SW) BMEA to discuss phase 1 results in obesity (16:30ET) Syndicate calendar / potential IPO pricing on Wed 14-Oct (post-close): +IAM Iambic Therapeutics on Thu 15-Oct (post-close): +CTY City Therapeutics This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABCL, ALEC, ALHC, BBNX, BFLY, BHC, BIIB, BIOA, BLCO, BMEA, BMRN, BMY, CNTB, COAG, CTNM, EQ, EVMN, FTH, GEHC, GLUE, HRMY, HUM, IDXX, IMVT, INCY, INSM, JNJ, KARD, MDT, MIRM, MLYS, MMED, MRNA, NKTR, OCUL, ODTX, PLSE, PRCT, PRE, PRME, PTGX, QNRX, QTTB, ROIV, ROP.SW, RXRX, SNDX, STE, STTK, SYK, SYRE, TECX, TRAX, TWST, TXG, UCB.BB, UNH, VERA, VKTX, ZBH, +CTY, +IAM...(more)	show story hide story
12-Oct-2026 14:00	BMY Bristol Myers Squibb tells Bloomberg that patient death likely unrelated to drug ($57.01 -$2.11) Shares of BMY near session lows, currently (3.4%), following today's update on the phase 3 ALOFT-IPF trial with admilparant. Shares of competitor CTNM (33%) also around session lows. Bloomberg has updated their pre-market article on the clinical results reported today, to include a line that a patient death in the study was likely unrelated to the drug treatment, according to company spokesperson. Investors have been waiting for more detailed safety results after recent report of liver tox risks. See Related StreetAccount comments: 10/12/2026 6:52:51 AM - Bristol Myers Squibb announces Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis met primary endpoint 9/29/2026 4:10:17 PM - Bristol Myers Squibb trading lower; Wells Fargo comments on liver safety disclosures with LPA1 Related: CTNM Reference Link: Bloomberg	show story hide story
12-Oct-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.28% vs the S&P 500 (0.04%). Major health groups are lightly mixed to start the week. Services group leading the advancers, Biotech group lone decliner. XBI (1.07%). Aside from the typical flow of clinical readouts in biopharma, sector newsflow remains fairly quiet ahead of the kickoff to Q3 earnings season - JNJ and UNH report on Tuesday morning. BIIB +3% and BMY (3%) bracket the XLV. Former hitting fresh highs after today's bullish upgrade at JPMorgan, which sees opportunity beyond Leqembi; the latter is weak despite two clinical readouts, market focusing on IPF, but has questions on dose response. Small-cap biotech CTNM (29%) highly volatile in read-across. More clinical results in Celiac disease, plus new readouts in cholestatic pruritus and GEP-NETs. Robotic surgery headlines today with SYK +1% making its move - a strategic alliance with CMR Surgical. Other notable headlines around the sector: Long-time specialty pharma exec Brent Saunders exits BLCO (8%); and STE +2% will acquire privately-held Xodus Medical Inc for $2.1B. Gainers +6.1% TRAX (First Tracks Biotherapeutics Inc): trial results in Celiac disease; best performer on XBI +6.1% ALHC (Alignment Healthcare): shares were (13%) on Friday +5.3% PRCT (PROCEPT BioRobotics): sympathy to SYK headlines +3.5% BIIB (Biogen): best performer on XLV; upgraded at JPMorgan; 52-week high +3.0% MDT (Medtronic): exits MMED via exchange offer; second-best on XLV +2.7% ABCL (AbCellera Biologics): initiation +1.3% BMRN (Biomarin Pharmaceutical): upgraded at Raymond James +0.9% LQDA (Liquidia): Friday court filing +0.4% SYK (Stryker): enters strategic alliance with CMR Surgical Decliners -33.0% CTNM (Contineum Therapeutics): sympathy to BMY (IPF trial) -9.1% BLCO (Bausch + Lomb): CEO Saunders departing company; comments on FY guidance -7.8% RXRX (Recursion Pharma.): worst performer on XBI; above average volume -5.2% TXG (10X Genomics): shares were (14%) last week -4.4% PLSE (Pulse Biosciences): on light volume -3.8% BHC (Bausch Health Cos.): sympathy to BLCO / comments on FY guidance -3.7% MIRM (Mirum Pharma.): trial results in cholestatic pruritus -3.2% HRMY (Harmony Biosciences): CEO steps down, appoints CEO, reiterates Wakix guidance -3.1% BMY (Bristol Myers Squibb): worst performer on XLV; trial results in IPF; trial results in GEP-NETs -3.1% MMED (MiniMed Group): MDT exits stake via exchange offer -1.8% SOLV (Solventum Corp.): media report (seeking bids for HIS business) -1.7% HUM (Humana): upgraded at Raymond James -1.6% INSM (Insmed): downgraded at Wolfe -1.3% ROIV (Roivant Sciences): downgraded at Wolfe	show story hide story
12-Oct-2026 08:36	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis One last quiet weekend although earnings season kicks off on Tuesday with JNJ and UNH. Monday morning brings several clinical readouts to the biopharma field, headlined by Bristol Myers Squibb late-stage results in IPF. Shares of BMY +4% in the pre-market. Same news also hitting small-cap biotech CTNM (26%) in read-across. More clinical results in Celiac disease, plus new readouts in cholestatic pruritus and GEP-NETs. M&A announcements limited to the Services group, where STERIS will acquire privately-held Xodus Medical Inc for $2.1B. Macro S&P futures are up +0.1% on Monday morning. Market holding up despite ramp in Middle East hostilities over the weekend and tech weakness overnight. When it comes to the energy, some focus on continued flow normalization and Trump's claim of an energy ceasefire between Russia and Ukraine (though neither side has confirmed). Overnight tech weakness largely confined to Korea/memory, with new architecture from China's CXMT mentioned as a competitive headwind. However, also some focus on AI M&A with both NVDA and AMZN reportedly pursuing high-profile deals. Earnings still the big bullish talking point for equities heading into the start of the Q3 reporting season this week. Third straight Q of 25%+ growth expected. Also some positive spin surrounding the extent of the de-rating that has already taken place, depressed positioning outside of Mag 7/tech and the near-term reopening of corporate buyback windows. Pre-market trading update Trading higher +14.3% TRAX trial results in Celiac disease; call at 830ET +7.0% MIRM trial results in cholestatic pruritus; call at 830ET +5.0% LQDA court filing +4.0% BMY trial results in IPF; trial results in GEP-NETs +3.5% BIIB upgraded at JPMorgan +1.9% BMRN upgraded at Raymond James +1.2% HUM upgraded at Raymond James Trading lower -26.2% CTNM sympathy to BMY (IPF) -2.4% BHVN on light volume -2.3% HRMY CEO steps down, appoints CEO, reiterates Wakix guidance -2.3% ALHC shares were (13%) on Friday -1.4% ROIV downgraded at Wolfe -1.1% TXG shares were (14%) last week -1.0% INSM downgraded at Wolfe Pharma Trial results: BMY announced topline results from the phase 3 ALOFT-IPF trial evaluating admilparant in adults with IPF. Trial met its primary endpoint, and demonstrated a favorable safety and tolerability profile. Company to engage regulatory authorities and will present detailed results at a future medical meeting. StreetAccount notes that CTNM is developing a LPA1 receptor antagonist for IPF called PIPE-791. BMY announced topline results from a planned interim of the phase 3 ACTION-1 trial evaluating RYZ101 in patients with GEP-NETs. Study met the primary endpoint (PFS). Participants will be followed for OS. Biotech Trial results: TRAX announced topline results from Cohort 1 of the phase 1B trial evaluating ANB033 in Celiac disease. Study achieved three key histologic efficacy endpoints, and demonstrated a consistent, favorable safety and tolerability profile. Company to engage FDA and seek alignment on the development pathway. Conf. call at 8:30ET MIRM announced topline results from the phase 3 EXPAND trial evaluating LIVMARLI (maralixibat) in cholestatic pruritus. study met its primary endpoint and all five prespecified secondary endpoints. Company plans to file sNDA in H1 of 2027. Conf. call at 8:30ET Research: BIIB upgraded to overweight from neutral at JPMorgan (Chris Schott), target increased to $300 from $210 or approx. 33% upside. (FactSet average PT $244; range $175-300) BMRN upgraded to strong buy from outperform at Raymond James (Christopher Raymond), target is $109 or approx. 99% upside. (FactSet average PT $92; range $60-124) INSM downgraded to peer perform from outperform at Wolfe Research (Andy Chen) ROIV downgraded to peer perform from outperform at Wolfe Research (Andy Chen) ABCL initiated buy at UBS (Alice Nettleton), target is $18 or approx. 43% upside. BIOA initiated neutral at UBS (Alice Nettleton), target is $8 or approx. 26% upside. CNTB assumed outperform at Leerink Partners (Will Soghikian), target is $4 or approx. 360% upside. COAG initiated buy at Rodman & Renshaw (Michael King), target is $56 or approx. 77% upside. EQ initiated outperform at Leerink Partners (Will Soghikian), target is $6 or approx. 326% upside. EVMN initiated neutral at UBS (Alice Nettleton), target is $8 or approx. 28% upside. GLUE assumed buy at UBS (Alice Nettleton), target is $19 or approx. 84% upside. KARD initiated buy at UBS (Alice Nettleton), target is $25 or approx. 70% upside. OCUL initiated buy at UBS (Alice Nettleton), target is $14 or approx. 86% upside. ODTX initiated buy at UBS (Alice Nettleton), target is $27 or approx. 42% upside. MLYS initiated neutral at UBS (Alice Nettleton), target is $29 or approx. 24% upside. NKTR initiated neutral at UBS (Alice Nettleton), target is $53 or approx. 29% upside. NKTR initiated outperform at Leerink Partners (Will Soghikian), target is $130 or approx. 216% upside. PRE initiated buy at Lucid Capital Markets (Alex Nowak), target is $54 or approx. 147% upside. PTGX initiated buy at UBS (Alice Nettleton), target is $184 or approx. 28% upside. QNRX initiated buy at BTIG (Jeet Mukjerjee), target is $14 or approx. 211% upside. QTTB initiated outperform at Leerink Partners (Will Soghikian), target is $40 or approx. 380% upside. STTK initiated buy at UBS (Alice Nettleton), target is $17 or approx. 185% upside. SYRE initiated buy at UBS (Alice Nettleton), target is $120 or approx. 40% upside. TECX initiated neutral at UBS (Alice Nettleton), target is $26 or approx. 11% upside. VERA initiated market perform at Leerink Partners (Will Soghikian), target is $34 or approx. 14% upside. Life Science & MedTech Research: BBNX initiated buy at Jefferies (Matthew Taylor), target is $30 or approx. 70% upside. BFLY initiated buy at Canaccord Genuity (William Plovanic), target is $10 or approx. 21% upside. IDXX initiated sector weight at KeyBanc (Steve Dechert) MMED initiated hold at Jefferies (Michael Toomey), target is $22 or approx. 12% upside. Services & Hospitals M&A: STE announced the acquisition of Xodus Medical Inc (private) foe $2.1B, and expects cash tax benefits of ($300M) for a net purchase price around $1.8B. Company will update guidance after closing (around year-end). Managed Care Research: HUM upgraded to outperform from market perform at Raymond James (Parker Snure), target is $520 or approx. 20% upside. (FactSet average PT $459; range $280-596) On Deck: Conferences (cont.): ACG 2026 (Oct 9-14); AAO 2026 (Oct 9-12) Regulatory EMA CHMP monthly meeting (Oct 12-15) Earnings tomorrow morning JNJ (call at 8:30ET), UNH (call at 8:00ET) Corporate on Tue 13-Oct: ALEC R&D Day / ABC-enabled pipeline (11:00ET) (ROP.SW) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABCL, ALEC, ALHC, BBNX, BFLY, BHVN, BIIB, BIOA, BMRN, BMY, CNTB, COAG, CTNM, EQ, EVMN, GLUE, HRMY, HUM, IDXX, INSM, JNJ, KARD, LQDA, MIRM, MLYS, MMED, NKTR, OCUL, ODTX, PRE, PTGX, QNRX, QTTB, ROIV, ROP.SW, STE, STTK, SYRE, TECX, TRAX, TXG, UNH, VERA...(more)	show story hide story
09-Oct-2026 19:48	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished broadly higher on Friday. Advancers beat decliners by nearly 9:1 on the XLV. Healthcare +1.58% vs S&P 500 +0.59%. All major health groups ended higher for the session. This included the Services group, an early laggard with BKD (7.1%) skewing the average. Some distribution names also soft ahead of Isaias landfall as CAT3, first Atlantic hurricane to hit the US since 2024. Friday's pre-open story in the NY Times on cancer vaccines added to the bull-story for MRNA +14.2% and others. Moderna shares rallied to the highest level since early January 2022. NVAX +15.8% also squeezed higher. Big earnings catalyst however remained the Star ratings for Medicare Advantage plans. Managed Care group top performer overall, followed by Biotech with the XBI +3.00%. HUM +12% topped the XLV, while CVS (1.9%) topped a short list of decliners. Medicare Advantage star ratings the catalyst that many were anticipating. Looking ahead, earnings kickoff is just around the corner; both JNJ and UNH report on Tuesday morning. Macro Breadth better again to cap off up week for stocks. AI trade mixed with chips down again despite positive LITE update (optical components sold out through 2029), while widening AI-linked CDS spreads, positioning remain overhangs. AAPL iPhone demand also in focus after company instructed suppliers to trim builds on surging memory/input costs. Oil choppy, with weakness tabbed to Trump comments downplaying pre-midterm strikes on Iran, though physical flow risks remain elevated as Strait of Hormuz vessel strikes escalate. Surging energy costs as a corporate margin headwind also in focus following DAL Q3 results (>60% jet fuel jump overshadowing resilient consumer demand). Not much behind today's modest Treasury weakness. Followed this week's stabilization with Fed rate path pricing little changed (~25 bp of hikes through year-end). Little reaction to secondary Friday macro updates (weaker preliminary Michigan consumer sentiment miss, Fed Governor Cook investigation). Notable Gainers on Friday: +16.1% KLRA (Kailera Therapeutics, Inc.): on nearly 2X avg daily volume; best performer on XBI +15.8% NVAX (Novavax, Inc.): NY Times story on cancer vaccines; second-best on XLV +14.2% MRNA (Moderna): NY Times story on cancer vaccines; shares +663% YTD +11.3% HUM (Humana): 2027 MA Star ratings; upgraded at Baird; best performer on XLV +10.2% HIMS (Hims & Hers Health): on strong volume; shares +7% for the week +8.0% DFTX (Definium Therapeutics): initiation +6.8% ARCT (Arcturus Therapeutics): NY Times story on cancer vaccines +5.3% BNTX (BioNTech): NY Times story on cancer vaccines +4.6% TEVA (Teva Pharma.): FDA approves Weltruza for adults with schizophrenia Notable Decliners on Friday: -13.4% ALHC (Alignment Healthcare): 2027 MA Star ratings; downgraded at William Blair and BofA -7.2% SPRY (ARS Pharma.): worst performer on XBI; shares +4% for the week -7.1% BKD (Brookdale Senior Living): September occupancy data -1.9% CVS (CVS Health): worst performer on XLV; 2027 MA Star ratings Week in Review: Healthcare equities outperformed for the week. The S&P 500 Healthcare Index gained +2.84% vs the S&P 500 Index +1.15%. Outperformers: Managed Care, Pharma Underperformers: Biotech, Services, MedTech Major health groups were mostly higher on the week, despite an up and down pathway. Biotech group the outlier, and despite a strong squeeze higher on Friday the group could not make much of the first high-premium biopharma M&A in months. The debate over AI impact on Life Sciences continued to fuel volatility in that subgroup. HC Wainwright argued the case that computer labs need wet labs, and AI will fuel demand note extinguish it. The annual reveal of Star ratings for Medicare Advantage plans was the catalyst that investors had been waiting for. Humana delivered improvements that will help boost '28 earnings, and Alignment Healthcare saw results that ensured litigation and appeals remain a part of the game. Earnings season kicks off next week with two bellwether names only - JNJ and UNH. Year-to-date, Healthcare +10.34% vs the S&P 500 +14.11%. Healthcare third out of eleven major sectors in CY26. Energy +45.44% and Utilities (3.06%) bracket them all. Notable movers for the week: Gainers: PCRX +44.0% - acquired by VTRS for $1.65B in cash OPCH +37.2% - acquired by private equity and MCK for $5.8B total EV PCVX +26.4% - trial results with pneumococcal vaccine; secondary offering, priced NVAX +21.9% - plague headlines; NYT story on cancer vaccines MRNA +18.4% - plague headlines; NYT story on cancer vaccines; best performer on XLV HAE +13.4% - CSL update on US rollout of HAE plasmapheresis HUM +11.2% - MA Star ratings for 2027; upgraded at Baird ERAS +8.8% - sympathy to RVMD ISRG +8.2% - best week in nearly a year GMAB +6.7% - trial results in DLBCL for Epkinly (ABBV) HIMS +6.6% - speculation around peptides / WaPo article Decliners: AVBP (40.8%) - trial results in NSCLC; worst performer on XBI TWST (15.3%) - ends four week streak TXG (13.7%) - ends five week streak ARGX (10.2%) - trial results in Sjogren's; trial results in celiac disease SRRK (9.9%) - resubmits MAA to EMA INSM (9.5%) - CFO steps down; reaffirms guidance RVMD (8.2%) - FDA posts review document for Rasonque SYRE (8.0%) - secondary offering, priced FMS (5.3%) - CEO steps down ALHC (5.0%) - MA Star ratings for 2027; California plan 3.5 star rating; downgraded at Wm Blair and BofA COO (4.5%) - follow-through; initiation; worst performer on XLV BMY (3.3%) - downgraded at Leerink Partners Week Ahead (Sat - Sun): Oct 10 - 18 Conference calendar (cont.): ISFTD 2026 (Oct 8-11); ACG 2026 (Oct 9-14); AAO 2026 (Oct 9-12) Sat 17-Oct: UEGW 2026 (Oct 17-20) Regulatory calendar Mon 12-Oct: EMA CHMP monthly meeting (Oct 12-15) Thu 15-Oct: FDA PDUFA for ROP.SW Enspryng sBLA for TED Fri 16-Oct: EMA CHMP opinions for MAA (October 2026) Sat 17-Oct: FDA PDUFA for IRD / VTRS Ryzumvi sNDA for presbyopia Earnings calendar Tue 13-Oct: before JNJ (call at 8:30ET), UNH (call at 8:00ET) Corporate calendar Tue 13-Oct: ALEC R&D Day / ABC-enabled pipeline (11:00ET) (ROP.SW) Syndicate calendar / potential IPO pricing (post-close) Wed 14-Oct: +IAM Iambic Therapeutics Thu 15-Oct: +CTY City Therapeutics Related: ABBV, ALEC, ALHC, ARCT, ARGX, AVBP, BKD, BMY, BNTX, COO, CSL.AU, CVS, DFTX, ERAS, FMS, GMAB, HAE, HIMS, HUM, INSM, IRD, ISRG, JNJ, KLRA, MRNA, NVAX, OPCH, PCRX, PCVX, ROP.SW, RVMD, SPRY, SRRK, SYRE, TEVA, TWST, TXG, UNH, VTRS, +AIM, +CTY...(more)	show story hide story
09-Oct-2026 15:02	CDC cancels the third straight ACIP meeting of 2026 - website Citing again the ongoing litigation over RFK's reconstitution of the ACIP, the meeting planned for Oct 21-23 has been cancelled, same outcome as the March and June meetings. CDC.gov shows the next upcoming meetings in February, June, and October 2027. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: GSK, MRNA, NVAX, PCVX, PFE	show story hide story
09-Oct-2026 14:15	StreetAccount Summary: Notable Drug Events expected for the week of 11-Oct (cont.) Industry meetings with clinical data: American Academy of Ophthalmology (AAO) Annual Meeting (Oct 9-12) (MRK) American College of Gastroenterology (ACG) Scientific Meeting (Oct 9-14) (JNJ) Mon 12-Oct Regulatory meeting: EMA CHMP monthly meeting (Oct 12-15) Tue 13-Oct Investor events: ALEC R&D day (webcast 11:00ET) KURA (Caspian Therapeutics) to discuss KO-7246 data following EASD (16:30ET) Corporate update: JNJ earnings call (8:30ET) Wed 14-Oct Trial results: VSTM to present data for VS-7375 Ph 2 trials in PDAC, NSCLC, and CRC and Ph 1/2 in solid tumors (8:00ET) ARWR to present interim clinical data from its Ph1/2 study of ARO-MAPT in Alzheimer's (14:30ET) Industry meeting with clinical data: The European Society for Immunodeficiencies (ESID) Meeting (Oct 14-17) (PHAR) Thu 15-Oct Regulatory decision: ROP.SW FDA PDUFA for Enspryng sBLA in TED Fri 16-Oct Regulatory decision: EMA CHMP opinions on MAA (16-Oct) Sat 17-Oct Regulatory decision: IRD / VTRS FDA PDUFA for Ryzumvi sNDA in presbyopia Investor meeting with clinical data: United European Gastroenterology (UEG) Week (Oct 17-20) (GILD, ABVX, PALI, EPRX, ODTX, ABBV) later during October 2026 Regulatory decisions: FDA PDUFAs: GSK.LN/IONS (Hibsago NDA, 26-Oct), 524715.IN/MRK (ILUMYA sBLA, 29-Oct), INO (INO-3107 BLA, 30-Oct); FDA BsUFA XBRANE.SS (Xlucane BLA, 29-Oct) Industry meetings with clinical data: European Huntington's Disease Network (EHDN) Congress (Oct 22-24); ESMO Congress 2026 (Oct 23-27); ESGCT Annual Congress (Oct 27-30) Trial results: MRNA (Ph3 melanoma), RAPP (Ph3 FOS, Ph2 Bipolar I disorder), BMY (Ph3 IPF), 4502.JP (Ph3 gastric cancer), CMPX (Ph2/3 biliary tract cancer), 6996.HK (Ph2 G/GEJ cancer, Ph1/2 melanoma), 7630.HK (Ph2 NSCLC and Ph1/2 mCRC), GSK.LN (Ph2 rectal cancer), DMAC (Ph2 fetal growth restriction), PFE (Ph2 NSCLC, Ph2 MBC), TLSA (Ph2 na-SPMS), INBX (Ph1/2 HNSCC), PBLS (Ph1/2 Desmoid Tumors), TNGX (Ph1/2 pancreatic cancer), BNTC (Ph1/2 OPMD), TRDA (Ph1/2 DMD), EIKN (Ph1/2 solid tumors), CATX (Ph1/2 NETs), RCUS (Ph1/2 ccRCC), BMEA (Ph1 obesity), ALNY (Ph1 Huntington's disease), INCY (Ph1 PDAC and Ph1 MSS CRC), IMTX (Ph1 cancer), XNCR (Ph1 ccRCC), CHRS (Ph1 HNSCC), ZNTL (Ph1 PROC), MGNX (Ph1 solid tumors) expected imminently Trial results: AARD (Ph3 PwS), CGON (Ph3 INT-NMIBC) Related: 4502.JP, 524715.IN, 6996.HK, 7630.HK, AARD, ABBV, ABVX, ALEC, ALNY, ARWR, BMEA, BMY, BNTC, CATX, CGON, CHRS, CMPX, DMAC, EIKN, EPRX, GILD, GSK.LN, IMTX, INBX, INCY, INO, IONS, IRD, JNJ, KURA, MGNX, MRK, MRNA, ODTX, PALI, PBLS, PFE, PHAR, RAPP, RCUS, ROP.SW, TLSA, TNGX, TRDA, VSTM, VTRS, XBRANE.SS, XNCR, ZNTL...(more)	show story hide story
09-Oct-2026 13:03	Cancer Vaccines Are the NIH's Next 'Big Bet' - NY Times Pre-open story by the NY Times discusses a public-private initiative by the NCI and industry to rapidly develop cancer vaccines, similar to the effort given to COVID-19. Program expected to begin in December and focus first on pancreatic, liver, and colorectal cancers. Trading update: NVAX +13.9%, MRNA +11.4%, ARCT +6.8%, BNTX +5.3%, MRK +2.4% For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ARCT, BNTX, MRK, MRNA, NVAX	show story hide story
09-Oct-2026 12:52	3407.JP FDA approves Hovilpri (pritelivir) for HSV infection (¥1585.5) FDA has approved Hovilpri (pritelivir) tablets for adults with weakened immune systems (i.e., immunocompromised patients) who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection and have not responded to other therapies (acyclovir, valacyclovir, or famciclovir). Mucocutaneous lesions occur on skin or mucosal surfaces, such as lips, nostrils, eyes and genitals. StreetAccount notes that Asahi Kasei recently acquire Aicuris, which developed pritelivir. See Related StreetAccount comments: 9/29/2026 8:42:14 AM - Asahi Kasei to integrate Asahi Kasei Therapeutics, Veloxis Pharmaceuticals, Calliditas Therapeutics and AiCuris Anti-infective Cures under Asahi Kasei Therapeutics 4/20/2026 8:02:44 AM - Asahi Kasei completes acquisition of Aicuris Anti-infective Cures 4/16/2026 9:45:45 AM - Aicuris (private, pending acquisition) announces that FDA grants priority review for pritelivir NDA in HSV infection (05:00ET) 2/26/2026 6:51:28 PM - Asahi Kasei signs definitive agreement to acquire Aicuris Anti-infective Cures for €780M (¥143.1B) Reference Link	show story hide story
09-Oct-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.60% vs the S&P 500 +0.41%. Most major health groups are higher on the averages. Services lag with BKD (7%) skewing the average. Managed Care group leading with HUM +12% atop the XLV, whereas CVS (2%) leads the short list of declines. Medicare Advantage star ratings the catalyst that many were anticipating. MRNA +5% rallying to its highest since January 2022. NVAX +7% also squeezing higher on no apparent news. XBI +1.61% volatile, attempting to trim the weekly decline or even break out. Gainers +11.7% HUM (Humana): 2027 MA Star ratings; upgraded at Baird; best performer on XLV +8.7% ABSI (Absci Corp.): best performer on XBI +7.5% DFTX (Definium Therapeutics): initiation +7.4% NVAX (Novavax, Inc.): on heavy volume; see also MRNA +5.7% TXG (10X Genomics): on moderate volume; shares (13%) WTD +5.1% TEVA (Teva Pharma.): FDA approves Weltruza for adults with schizophrenia +4.8% TWST (Twist Bioscience): on moderate volume; shares (15%) WTD +4.4% MRNA (Moderna): on strong volume; second-best on XLV +3.5% HIMS (Hims & Hers Health): on moderate volume +3.4% GRAL (GRAIL, Inc.): on moderate volume +2.8% CLOV (Clover Health): 2027 MA Star ratings +2.2% ELV (Elevance Health): 2027 MA Star ratings +1.7% CNC (Centene): 2027 MA Star ratings +1.1% UNH (UnitedHealth Group): 2027 MA Star ratings +0.4% ICLR (ICON plc): upgraded at BofA Decliners -17.3% ALHC (Alignment Healthcare): 2027 MA Star ratings; downgraded at Wm Blair and BofA -8.3% BKD (Brookdale Senior Living): September occupancy data -5.5% SPRY (ARS Pharmaceuticals): worst performer on XBI -2.8% JAZZ (Jazz Pharmaceuticals): departure of Chief Commercial Officer -1.7% CVS (CVS Health): worst performer on XLV; 2027 MA Star ratings; shares flat WTD -0.8% MOH (Molina Healthcare): 2027 MA Star ratings -0.5% OSCR (Oscar Health): 2027 MA Star ratings	show story hide story
09-Oct-2026 08:39	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Major headline was the long-awaited reveal of 2027 Star ratings in Medicare Advantage, announced on Thursday post-close. Humana delivered the most significant y/y improvement in the bonus-driving Stars. Shares of HUM +16% in the pre-market. Alignment Healthcare the largest deterioration y/y in Stars, and stated that it will pursue remedies for its California plan specifically. Shares of ALHC down (20%) in the pre-market. Other MCOs with varying levels of results; CLOV down (10%). Yesterday, Healthcare equities finished mixed to inline overall. Nearly all major health groups ended lower on the session, though each narrowed these declines to less than (1%) on the averages. Services group an outlier, drug distributors and hospitals benefitted from the intra-sector rotation. Shares of the MA-leveraged provider remained volatile into the CMS reveal of 2027 Star ratings tonight. Thursday brought the long-awaited return of high-premium M&A to biopharma, but it wasn't helpful to the XBI (0.63%); PCRX +44% was not in the XBI. Weakness persisted throughout the Life Science Tools group, continuation of the week's roller coaster. Macro S&P futures are up +0.4% on Friday morning. AI trade set for a bounce as yesterday's OpenAI revenue scare has been spun as more of an accounting adjustment than any meaningful reset in the demand narrative. Shift helped by Bloomberg report that OpenAI itself is guiding to ~$70B (net basis) by year-end. Infrastructure funding the other big AI story once again with more scrutiny on CDS spread widening. Also some focus on spillover effects from memory cost surge with report of AAPL telling suppliers to cut iPhone orders as high prices weigh on demand. Pretty quiet elsewhere. Oil on the defensive after Trump comments about not attacking Iran before midterms/productive discussions failed to dampen yesterday's rally on concerns about ramp in hostilities. Oil pullback not helping Treasuries, though rate stabilization has been one of the bigger themes this week. Pre-market trading update Trading higher +16.0% HUM 2027 MA Star ratings; upgraded at Baird +10.2% CLOV 2027 MA Star ratings +4.0% TEVA FDA approves Weltruza for adults with schizophrenia; call at 8ET +1.8% ICLR upgraded at BofA (low volume) +0.9% UNH 2027 MA Star ratings +0.7% OSCR 2027 MA Star ratings Trading lower -19.5% ALHC 2027 MA Star ratings; downgraded at Wm Blair and BofA -4.8% BKD September occupancy data -2.7% CVS 2027 MA Star ratings Pharma Regulatory: TEVA announced that FDA approved Weltruza (olanzapine LAI, TEV-749) for schizophrenia in adults. The PDUFA goal date was 9-Oct. (RPRX, MEDCL.FP) Conf. call at 8:00ET Research: ATR initiated neutral at UBS (Anojja Shah), target is $135 or approx. 11% upside. (FactSet average PT $166; range $150-220). Pharma segment 70% of EBITDA, firm positive on HC end market exposure, but LT growth rate in emergency medicine business concerning. Biotech Trial results: Innovent Biologics (1801.HK) announced that its phase 3 RESTORE-3 study evaluating Sycume (teprotumumab N01) met the primary endpoint in inactive Thyroid Eye Disease (TED). StreetAccount notes that NMPA-approved Sycume is based on the same active ingredient as Amgen's (AMGN) FDA-approved Tepezza (teprotumumab-trbw), with a varied formulation. IPOs priced: RTSN raised $46M with an upsized 3.8M share IPO priced at $12, the midpoint of the anticipated range. TRXB raised $117M with an 8.3M shares IPO priced at $14, the low-end of the anticipated range. Holder LLY expected to purchase shares at the offering. Research: CCCC initiated overweight at JPMorgan, target is $10 or approx. 251% upside. (FactSet average PT $13; range $7-30) DFTX initiated overweight at JPMorgan, target is $84 or approx. 146% upside. (FactSet average PT $73; range $55-91) KYMR initiated outperform at Raymond James (Thomas Deal), target is $140 or approx. 28% upside. LBRX initiated buy at Canaccord Genuity (Sumant Kulkarni), target is $65 or approx. 88% upside. (FactSet average PT $59; range $35-80) ODTX initiated outperform at Raymond James (Thomas Deal), target is $42 or approx. 132% upside. OVID initiated overweight at Cantor Fitzgerald (Imogen Mansfield) PALI initiated outperform at Raymond James (Thomas Deal), target is $6 or approx. 314% upside. NKTR initiated market perform at Raymond James (Thomas Deal) QNCX initiated outperform at Raymond James (Tiago Fauth), target is $72 or approx. 145% upside. (FactSet average PT $75; range $65-98) VCRE initiated buy at Jefferies (Faisal Khurshid), target is $25 or approx. 183% upside. Life Science & MedTech Research: ICLR upgraded to neutral from underperform at BofA (Lu Li), target increased to $185 from $160 or approx. 12% upside. (FactSet average PT $188; range $165-210) Managed Care CMS publishes 2027 Star ratings in Medicare Advantage; Humana and Alignment see largest y/y changes Post-close on Thursday, CMS revealed the 2027 Star ratings, in which each plan at each provider is graded with Stars (2 to 5). These ratings importantly drive bonus payment from the government in CY2028. Fact Sheet. Data Table (zip file). (ALHC, CI, CLOV, CNC, CVS, ELV, HUM, MOH, OSCR, UNH) Alignment Healthcare issued a press release - calling out "strong results" in the Star ratings. Company disagrees with the 3.5 star rating for California H3815 - intends to pursue all remedies. Rating changes in reaction: HUM upgraded to outperform from neutral at Baird (Michael Ha), target increased to $596 from $390 or approx. 54% upside. (FactSet average PT $446; range $280-596) ALHC downgraded to market perform from outperform at William Blair (Ryan Daniels) ALHC downgraded to neutral from buy at BofA (Kevin Fischbeck), target cut to $9 from $25 or approx. 3 upside. (FactSet average PT $18; range $10-28) On Deck: Conference (cont.): ISFTD 2026 (Oct 8-11) ACG 2026 (Oct 9-14) Peek Ahead to the following week (Oct 12-18) Overview: Q3 earnings calendar kick off with JNJ and UNH on Tue 13-Oct; next reports are eight days later Mon 12-Oct: EMA CHMP monthly meeting (Oct 12-15) Tue 13-Oct: Earnings JNJ (call at 8:30ET), UNH (call at 8:00ET) Thu 15-Oct: FDA PDUFA for ROP.SW Enspryng sBLA for TED Fri 16-Oct: EMA CHMP opinions for MAA (October 2026) Sat 17-Oct: Conference: UEGW 2026 (Oct 17-20); FDA PDUFA for IRD / VTRS Ryzumvi sNDA for presbyopia Potential IPO pricing: +IAM Iambic Therapeutics This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 1801.HK, ALHC, AMGN, ATR, BKD, CCCC, CI, CLOV, CNC, CVS, DFTX, ELV, HUM, ICLR, IRD, JNJ, KYMR, LBRX, LLY, MEDCL.FP, MOH, NKTR, ODTX, OSCR, OVID, PALI, QNCX, ROP.SW, RPRX, RTSN, TEVA, TRXB, UNH, VCRE, VTRS, +IAM, +RTSN, +TRXB...(more)	show story hide story
08-Oct-2026 17:19	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to inline overall on Thursday. Decliners narrowly outnumbered advancers on the XLV - breadth far from its worst level around midday. Healthcare (0.41%) vs S&P 500 (0.47%). Nearly all major health groups ended lower on the session, though each narrowed these declines to less than (1%) on the averages. Services group an outlier, drug distributors and hospitals benefitted from the intra-sector rotation. CAH +2.9% and HUM (2.4%) bracketed all movers on the XLV. Shares of the MA-leveraged provider remained volatile into the CMS reveal of 2027 Star ratings tonight. Thursday brought the long-awaited return of high-premium M&A to biopharma, but it wasn't helpful to the XBI (0.63%); PCRX +44% was not in the XBI. Weakness persisted throughout the Life Science Tools group, continuation of the week's roller coaster. A few moderate gainers in large-cap medical devices, but majority still traded lower. Biopharma M&A makes a return to the tape after a quiet fall. Viatris will pay $1.65B to acquire Pacira Biosciences and its two commercial-stage products, or about a 45% premium to Wednesday's close. Overnight sector news fairly quiet. One preannouncement on the wires, a small commercial-stage medical device company with the positive update. Still awaiting the CMS reveal of 2027 Star ratings in Medicare Advantage - last year the data came in a zip file post-close on a Thursday. CMS has been holding the Stars data close to the vest and providers hesitant to say anything at all, only that this year is different. Yesterday, Healthcare equities finished mixed yet higher overall. Pharma group provided the outperformance, DRG +1.67%, while Managed Care stocks were volatile ahead of the 2027 Star Ratings reveal. HUM (1.9%), despite an upbeat upgrade, and UNH (0.1%) each saw intraday gains wiped out in afternoon trading. LST subgroup was more mixed today, bioproduction weak for a second day. Macro AI trade pressured by FT report that OpenAI recently told investors annualized revenue was approaching $50B in September, below the $70B figure that had been reported in the press. Other AI themes revolved around high earnings bar (Samsung Electronics, TSM), infrastructure buildout (AVGO and ORCL following SPCX yesterday) and ramp in personal agent (GOOGL) competition. Oil another big story today as Trump comments about not attacking Iran before midterms/productive conversations didn't do much to dampen rally. However, rates once again managed to reverse upward pressure from earlier in the session. Rate stabilization and AI trade weakness seemingly boosted the broadening out trade with big equal-weight S&P outperformance. M&A back in the headlines following a ramp in activity earlier in the week with report SBUX has explored potential acquisition for CMG. Consumer also in focus on the earnings calendar with PEP helped by a low bar and LEVI hit by softer DTC. Notable Gainers +44.4% PCRX (Pacira BioSciences): acquired by VTRS for $36.50/sh cash +21.7% PROF (Profound Medical): preannouncement of Q3 results +17.5% HAE (Haemonetics): CSL provides update on US rollout of HAE plasmapheresis +14.1% MANE (VeraDermics, Inc.): on unusual volume, 5X average daily volume +9.5% ERAS (Erasca): best performer on XBI; sympathy to RVMD +7.6% NTLA (Intellia Therapeutics): on >3X average daily volume; sympathy to EDIT +6.5% RGNX (REGENXBIO): second-best on XBI; shares +11% WTD +4.6% TRAX (First Tracks Biotherapeutics Inc): sympathy to ARGX (Celiac disease) +3.7% RCKT (Rocket Pharmaceuticals): upgraded at Goldman Sachs +3.3% EDIT (Editas Medicine): upgraded at Wells Fargo +2.9% CAH (Cardinal Health): best performer on XLV; distributors benefit from rotation; shares +5% WTD +2.6% MDT (Medtronic): second-best on XLV; nearly 7X average daily volume Notable Decliners -22.1% CRBU (Caribou Biosciences): follow-through, downgraded at HC Wainwright -20.9% ANGO (AngioDynamics): earnings -11.8% ARGX (argenx): trial results in Sjogren's disease; trial results in celiac disease -8.2% PRME worst performer on XBI; shares remain +20% WTD -7.5% RXRX (Recursion Pharmaceuticals): second-worst performer on XBI -6.3% RVMD (Revolution Medicines): FDA review document for Rasonque; sell-side takeaways supportive -6.3% GKOS (Glaukos): announces license agreement for tri-specific biologic in retinal diseases; competitor presentation at Eyecelerator AAO -5.6% IMVT (Immunovant): sympathy to ARGX (Sjogren's) -3.8% ONC (BeOne Medicines): Cantor Fitzgerald comments on the PRMT5 field -3.5% VIR (Vir Biotechnology): receives FDA Fast Track designation -2.4% HUM (Humana): worst performer on XLV; shares remain volatile ahead of Star ratings reveal High-premium M&A returns to biopharma, but no help for the XBI PCRX acquired by Viatris (VTRS) for $36.50/sh in cash, or total equity value $1.65B. Price represents a 44% premium to yesterday's closing price. Two commercial products are Exparel and Zilretta. Viatris expects the deal to be immediately accretive upon closing by year-end. Revolution Medicines trading lower on Thursday; FDA reviews document cited Shares of RVMD trading (9.1%) midday on Thursday, with the XBI (2.66%). Sell-side attributing the weakness to an FDA multi-discipline review document for RASONQUE recently published to FDA.gov (see reference link here). The 321pp document shines some light on the initial labeling from August 2026, and raises questions about the subgroup of patients defined by G12V versus G12D RAS mutations. Overall, analysts view the known efficacy and safety data for Rasonque as solid, but leaves an opening for G12D specific inhibitors. ARGENX hits in celiac disease, but stock reacting to failure in Sjogren's disease ARGX announced two separate updates - the company will discontinue the phase 3 UNITY study of efgartigimod SC (Vyvgart Hytrulo) (ZLAB) in Sjogren's Disease based on the IDMC recommendation for futility at an interim analysis. The company also reported topline results from the phase 2 study evaluating FB102 in celiac disease were stat sig and clinically relevant, meeting the primary endpoint. Haemonetics higher following CSL Ltd update HAE commented on the update provided by CSL.AU that their transition to the company's devices and disposables will be completed by the end of CY2027. Haemonetics is not updating financial guidance at this time, but will provide an update next month in connection with the results call. Notable research in Healthcare today Biotech: CRBU downgraded to neutral from buy at HC Wainwright (Robert Burns) RCKT upgraded to neutral from sell at Goldman Sachs (Richard Law), target is $4 or approx. 57% upside. (FactSet average PT $9; range $3-15) ZEAL.DC downgraded to hold from accumulate at KBC (Mathijs Danau), target cut to DKK290 from DKK500 or approx. 21% upside. (FactSet average PT DKK397; range DKK290-595) EYPT added to Top Picks List (October) at Mizuho Securities. MSLE initiated buy at Craig-Hallum Capital (Adam Vogel), target is $24 or approx. 215% upside. (FactSet average PT $22; range $14-40) NGNE initiated overweight at JPMorgan (Priyanka Grover), target is $60 or approx. 132% upside. (FactSet average PT $77; range $46-166) MedTech: ESTA added to the Top Picks List (October) at Mizuho Securities TWST initiated hold at Jefferies (Matthew Stanton), target is $150 or approx. 4% downside. (FactSet average PT $150; range $45-215) Managed Care: UNH added to the Top Picks List (October) at Mizuho Securities. Post-close news Regulatory: CMS publishes 2027 Star Ratings Data Tables; shares of Humana and Alignment Health diverge sharply. Fact Sheet. Data Table (zip file). (ALHC, CI, CLOV, CNC, CVS, ELV, HUM, MOH, OSCR, UNH) Alignment Healthcare issued their own press release - calling out "strong results" in the Star ratings. Company disagrees with the 3.5 star rating for California H3815 - intends to pursue all remedies. A-H trading update: HUM +13.8%, CLOV +8.7%, UNH (0.5%), CVS (4.0%), ALHC (21.5%) Research: ATR initiated neutral at UBS (Anojja Shah), target is $135 or approx. 11% upside. (FactSet average PT $166; range $150-220). Pharma segment 70% of EBITDA, firm positive on HC end market exposure, but LT growth rate in emergency medicine business concerning. On Deck: Conference (cont.): ISFTD 2026 (Oct 8-11) ACG 2026 (Oct 9-14) Syndicate / IPO pricing +RTSN Retension Pharma +TRXB Trex Bio (LLY) Peek Ahead to the following week (Oct 12-18) Overview: Q3 earnings calendar kick off with JNJ and UNH on Tue 13-Oct; next reports are eight days later Mon 12-Oct: EMA CHMP monthly meeting (Oct 12-15) Tue 13-Oct: Earnings JNJ, UNH Thu 15-Oct: FDA PDUFA for ROP.SW Enspryng sBLA for TED Fri 16-Oct: EMA CHMP opinions for MAA (October 2026) Sat 17-Oct: Conference: UEGW 2026 (Oct 17-20); FDA PDUFA for IRD / VTRS Ryzumvi sNDA for presbyopia IPO pricing: +IAM Iambic Therapeutics This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALHC, ANGO, ARGX, ATR, CAH, CLOV, CRBU, CSL.AU, CVS, EDIT, ERAS, ESTA, EYPT, GKOS, HAE, HUM, IMVT, IRD, JNJ, MANE, MDT, MSLE, NGNE, NTLA, ONC, PCRX, PRME, PROF, RCKT, RGNX, ROP.SW, RVMD, RXRX, TRAX, TWST, UNH, VIR, VTRS, ZEAL.DC, ZLAB, +IAM, +RTSN, +TRXB...(more)	show story hide story
08-Oct-2026 16:12	HUM CMS publishes 2027 Star Ratings Data Tables; shares of Humana and Alignment Health diverge sharply Fact Sheet The 2027 Star Ratings announced today appear on Medicare Plan Finder for 2027 Open Enrollment, which begins on October 15, 2026 and runs through December 7, 2026, and will impact 2028 MA quality bonus payments. Post-close on Thursday, the CMS published 2027 Star Ratings Data Tables (zip file). A-H trading update: HUM +14.2%, UNH +2.2%, ALHC (17.7%) For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ALHC, UNH	show story hide story
08-Oct-2026 11:58	RVMD Revolution Medicines trading lower on Thursday; FDA reviews document cited ($181.14 -$19.73) Shares of RVMD trading (9.1%) midday on Thursday, with the XBI (2.66%). Sell-side attributing the weakness to an FDA multi-discipline review document for RASONQUE recently published to FDA.gov (see reference link below). The 321pp document shines some light on the initial labeling from August 2026, and raises questions about the subgroup of patients defined by G12V versus G12D RAS mutations. Overall, analysts view the known efficacy and safety data for Rasonque as solid, but leaves an opening for G12D specific inhibitors. Reference Link	show story hide story
08-Oct-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (1.90%) vs the S&P 500 (0.28%). All major health groups are red to begin the session, most by more than (1%), and biopharma more than (2%). Today's return of high-premium M&A not really helping out in biopharma; PCRX +44% not on the XBI (2.16%) and VTRS (2%) or roughly inline with the DRG (2.31%). Services group today's relative performers, but still heading lower. MDT +2% and HUM (4%) bracket the XLV. Humana an outlier among Managed Care, most MCOs are off just (1%). Star Ratings for 2027, a catalyst for '28 earnings, are expected later today. ILMN (3%) with Life Science Tools group under heavy pressure again, the roller coaster week continues. A few moderate gainers in large-cap medical devices, but majority are lower. Very few subgroups are green; Hospitals are holding firm, yet none more than fractionally higher. Drug distribution names also flat. Gainers +44.0% PCRX (Pacira BioSciences): acquired by VTRS for $36.50/sh cash +17.8% PROF (Profound Medical): preannouncement of Q3 results +13.7% HAE (Haemonetics): CSL provides update on US rollout of HAE plasmapheresis +6.1% NGNE (Neurogene): initiation; best performer on XBI +3.2% NTLA (Intellia Therapeutics): second-best on XBI +2.0% MDT (Medtronic): best performer on XLV +1.8% RCKT (Rocket Pharmaceuticals): upgraded at Goldman Sachs +1.3% TRAX (First Tracks Biotherapeutics Inc): sympathy to ARGX (celiac) Decliners -21.0% ANGO (AngioDynamics): earnings -17.7% CRBU (Caribou Biosciences): follow-through, downgraded at HC Wainwright -14.3% ARGX (argenx): trial results in Sjogren's disease; trial results in celiac disease -9.0% RVMD (Revolution Medicines): worst performer on XBI -6.8% VIR (Vir Biotechnology): receives FDA Fast Track designation -6.1% ONC (BeOne Medicines): Cantor Fitzgerald comments on the PRMT5 field -5.7% IMVT (Immunovant): sympathy to ARGX (Sjogren's) -4.5% ZLAB (ZAI Lab): sympathy to ARGX (partner on Vyvgart) -3.9% HUM (Humana): worst performer on XLV; ahead of Star ratings -3.8% LLY (Eli Lilly): shares were +3% yesterday, flat WTD -3.5% ILMN (Illumina): continued weakness in LST -3.3% RVTY (Revvity): continued weakness in LST -3.2% TMO (Thermo Fisher Scientific): continued weakness in LST -3.1% TWST (Twist Bioscience): initiation	show story hide story
08-Oct-2026 08:30	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Biopharma M&A makes a return to the tape after a quiet fall. Viatris will pay $1.65B to acquire Pacira Biosciences and its two commercial-stage products, or about a 45% premium to Wednesday's close. Shares of PCRX trading +44% in the pre-market; VTRS (flat). Overnight sector news fairly quiet. One preannouncement on the wires, a small commercial-stage medical device company with the positive update. Shares of PROF +19% in the pre-market. Still awaiting the CMS reveal of 2027 Star ratings in Medicare Advantage - last year the data came in a zip file post-close on a Thursday. CMS has been holding the Stars data close to the vest and providers hesitant to say anything at all, only that this year is different. Yesterday, Healthcare equities finished mixed yet higher overall. Pharma group provided the outperformance, DRG +1.67%, while Managed Care stocks were volatile ahead of the 2027 Star Ratings reveal. HUM (1.9%), despite an upbeat upgrade, and UNH (0.1%) each saw intraday gains wiped out in afternoon trading. LST subgroup was more mixed today, bioproduction weak for a second day. Macro S&P futures are down (0.4%) on Thursday morning, off worst levels. Defensive tilt chalked up to higher oil as headlines have shifted from flow normalization (albeit at higher costs) to conflict escalation on multiple fronts, including Iran accelerating SoH attacks (and more articles about US preparing for fresh strikes). Oil seemingly dragging yields higher following recent heightened bout of fiscal scrutiny (France). AI the other big story when it comes to yields amid recent wave of infrastructure financing headlines (latest has AVGO arranging ~$30-50B for OpenAI's custom chip buildout). While AI the big driver of a very bullish corporate profit narrative, updates from TSM and Samsung overnight also highlight the high bar going into Q3 earnings season. Elsewhere, strategists and financial press continue to flag small-cap underperformance (particularly vs NDX) amid the rate backup, along with weak breadth. Pre-market trading update Trading higher +44.2% PCRX acquired by VTRS for $36.50/sh cash +19.1% PROF preannouncement of Q3 results +16.7% HAE CSL provides update on US rollout of HAE plasmapheresis +5.6% TRAX sympathy to ARGX (celiac) +3.6% RCKT upgraded at Goldman Sachs +3.3% BHVN license agreement with Ono Pharma +2.0% ONC Cantor Fitzgerald comments on the PRMT5 field Trading lower -15.2% ARGX trial results in Sjogren's disease; trial results in celiac disease -4.9% ANGO earnings -4.4% CRBU follow-through, downgraded at HC Wainwright -3.7% TWST initiation -2.5% ZLAB sympathy to ARGX (partner on Vyvgart) -2.0% IMVT sympathy to ARGX (Sjogren's) -0.4% HALO sympathy to ARGX (partner on Vyvgart Hytrulo) -0.1% VTRS acquires PCRX for $1.65B in cash, expect deal immediately accretive to earnings Biotech M&A: PCRX acquired by Viatris (VTRS) for $36.50/sh in cash, or total equity value $1.65B. Two commercial products are Exparel and Zilretta. Viatris expects the deal to be immediately accretive upon closing by year-end. Trial results: ARGX announced two separate updates - the company will discontinue the phase 3 UNITY study of efgartigimod SC (Vyvgart Hytrulo) (ZLAB) in Sjogren's Disease based on the IDMC recommendation for futility at an interim analysis. The company also reported topline results from the phase 2 study evaluating FB102 in celiac disease were stat sig and clinically relevant, meeting the primary endpoint. Research: CRBU downgraded to neutral from buy at HC Wainwright (Robert Burns) RCKT upgraded to neutral from sell at Goldman Sachs (Richard Law), target is $4 or approx. 57% upside. (FactSet average PT $9; range $3-15) ZEAL.DC downgraded to hold from accumulate at KBC (Mathijs Danau), target cut to DKK290 from DKK500 or approx. 21% upside. (FactSet average PT DKK397; range DKK290-595) EYPT added to Top Picks List (October) at Mizuho Securities. MSLE initiated buy at Craig-Hallum Capital (Adam Vogel), target is $24 or approx. 215% upside. (FactSet average PT $22; range $14-40) NGNE initiated overweight at JPMorgan (Priyanka Grover), target is $60 or approx. 132% upside. (FactSet average PT $77; range $46-166) Life Science & MedTech Preannouncement: PROF reported preliminary Q3 revenue $9.8-10.0M vs FactSet $6.8M, representing y/y growth of 85-89%. Management highlights strong commercial momentum in core products. Corporate: HAE commented on the update provided by CSL.AU that their transition to the company's devices and disposables will be completed by the end of CY2027. Haemonetics is not updating financial guidance at this time, but will provide an update next month in connection with the results call. Research: ESTA added to the Top Picks List (October) at Mizuho Securities TWST initiated hold at Jefferies (Matthew Stanton), target is $150 or approx. 4% downside. (FactSet average PT $150; range $45-215) Managed Care Research: UNH added to the Top Picks List (October) at Mizuho Securities. On Deck: Conference (cont.): MDS Congress 2026 (Oct 4-8) Bernstein Healthcare Services Disruptors Virtual Conference ISFTD 2026 (Oct 8-11) on Fri 9-Oct: ACG 2026 (Oct 9-14) Corporate Epion Therapeutics (private) to present EpiSmart data at Eyecelerator AAO (13:13ET) (GKOS) Regulatory CMS release 2027 Star Ratings for Medicare Advantage (ALHC, CI, CLOV, CNC, CVS, ELV, HUM, MOH, OSCR, UNH) Syndicate calendar / IPO pricing (post-close) +RTSN Retension Pharma +TRXB Trex Bio (LLY) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALHC, ANGO, ARGX, BHVN, CI, CLOV, CNC, CRBU, CSL.AU, CVS, ELV, ESTA, EYPT, GKOS, HAE, HALO, HUM, IMVT, LLY, MOH, MSLE, NGNE, ONC, OSCR, PCRX, PROF, RCKT, TRAX, TWST, UNH, VTRS, ZEAL.DC, ZLAB, +RTSN, +TRXB...(more)	show story hide story
07-Oct-2026 17:14	Prime Therapeutics pushes upfront prices in new drug sales model - Bloomberg In an interview with CEO Mostafa Kamal on Wednesday, Bloomberg reports that Prime Therapeutics (05WD3P-E) will offer clients of the PBM a "net cost model" for 2028. The PBM is attempting to move away from the rebate-based system. Related: CI, CVS, UNH, 05WD3P-E Reference Link: Bloomberg	show story hide story
07-Oct-2026 16:50	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed yet higher overall on Wednesday. Advancers were equaled by decliners on the XLV. Healthcare +1.06% vs S&P 500 (0.22%). Most major health groups ended lower on their averages. Pharma group provided the outperformance, DRG +1.67%, while Managed Care stocks were volatile ahead of the 2027 Star Ratings reveal. HUM (1.9%), despite an upbeat upgrade, and UNH (0.1%) each saw intraday gains wiped out in afternoon trading. Large drugmakers were broadly higher, including MRK +0.6% which lagged on the patent infringement setback in Europe for Keytruda SC. LLY +2.7% quietly led the group. CEO Ricks interview circulated online. LST subgroup was more mixed today, bioproduction weak for a second day. AZTA (8.8%) announced a restructuring. MRNA +4.8% and COO (3.0%) bracketed the XLV. Sector news flow remains fairly quiet, and company-specific. Eg. PGNY +6.3% after an upbeat selling update. Overnight sector news fairly quiet. CAR-T cell therapy developer Caribou Biosciences (CRBU) announced the discontinuation of its lead programs, and is exploring strategic alternatives. Danaher announces it plans to launch its first AI-powered autonomous lab in early 2027. Barclays initiated twenty-six stocks in Medical Device and Equipment subgroups, including a dozen OW rated names, eleven EW rated, and three UW rated. Yesterday, Healthcare equities were mostly lower. Biotech and MedTech groups both fell under newfound pressure and ended near their worst levels of the session. MRNA (7.8%) reversed all of Monday's advance (presumably on the Russia plague headlines) amid a steep sell-off in biotech risk on Tuesday's open. No clear catalyst behind the sudden rotation away from risk in the sector. Biggest sector news story was the M&A in the infusion services field. OPCH +32.6% acquired by private equity (majority) and McKesson (minority). Macro Session found late support as rate backdrop stabilized, aided by factors including lower crude (IEA backed expedited 100M reserve release) and well-received 10Y auction. However, broader overhangs persist, including French bonds (weaker again), foreign Treasury demand retrenchment, refinancing walls, growing AI external funding needs (though IG issuance may slow in near-term). AI trade again mixed, though biggest focus on SPCX looking to raise $40B to purchase NVDA chips. Represents another bullish input for the compute demand narrative but also puts more scrutiny on the financing dynamic. Pretty quiet elsewhere. Middle East headlines mixed. Late afternoon report from The Atlantic said Trump seeking to develop strike plans against Iran ahead of November midterms. Follows recent pickup in kinetic activity (Iran, Houthis), though energy backdrop continues to improve. Weak breadth, strong Q3 earnings season expectations, and rising inflation expectations among other areas of focus. Notable Gainers +11.9% AVBP (Arrivent Biopharma): best performer on XBI; follow-through, shares were (47%) yesterday +11.4% PRME (Prime Medicine): follow-through, shares +31% WTD +6.6% VSTM (Verastem): on average volume; shares +7% WTD +6.6% GKOS (Glaukos): Mizuho raises estimates for Epioxa +6.3% PGNY (Progyny): updates on current selling season and membership +4.9% SVRA (Savara): initiation +4.8% MRNA (Moderna): best performer on XLV; shares +3% WTD +3.7% SMMT (Summit Therapeutics): on above average volume; shares +3% YTD +2.7% LLY (Eli Lilly): second-best on XLV, on average volume; CEO interview w BiotechTV Notable Decliners -45.6% CRBU (Caribou Biosciences): discontinues development of CAR-T; exploring strategic alternatives; downgrades -13.9% ALMR (Alamar Biosciences): sympathy to AZTA -10.2% ABSI (Absci Corp.): worst performer on XBI; shares (17%) WTD -8.8% AZTA (Azenta): restructuring Multiomics business -7.8% RXRX (Recursion Pharmaceuticals): shares remain +4% WTD -7.7% FMS (Fresenius Medical Care): CEO Helen Giza steps down effective 11-Oct -6.8% TWST (Twist Bioscience): shares were (19%) yesterday -5.7% TXG (10X Genomics): follow-through, shares were (18%) yesterday -5.4% MRVI (Maravai Lifesciences): sympathy to AZTA -4.2% BLLN (BillionToOne): follow-through, shares were (8%) yesterday -3.0% COO (The Cooper Cos.): worst performer on XLV -2.3% NEOG (Neogen): earnings; Investor Day Eli Lilly trading higher; CEO Ricks shares perspective with BiotechTV Trading update (with DRG +2.1%): LLY +3.3% Large-cap pharma faring well on Wednesday, most drugmakers are up +1-3% each, and the largest by market cap, Eli Lilly, is leading the charge. No new ground broken in today's interview with CEO David Ricks on BiotechTV, but the 20+ minute talk provided some context on the company's past, present and future in obesity (and Alzheimer's), plus an explainer on the intersection of 'white space' and the company's business development strategy. Halozyme wins European injunction against Merck's subcutaneous form of Keytruda Trading update (with DRG +1.48%): HALO +2.5%, MRK +0.8% Halozyme Therapeutics announced that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents (EP622) and ordered Merck to stop manufacture and sale of Keytruda SC (Keytruda QLEX) in Belgium, Denmark, France, Ireland, Sweden, Switzerland and the Netherlands. Merck utilizes SC technology licensed from Alteogen (196170.KS). Notable research in Healthcare today Pharma: 500124.IN (RDY) upgraded to outperform from neutral at Macquarie, target increased to INR1375 from INR1230 or approx. 14% upside. (FactSet average PT INR1267; range INR1039-1740) Biotech: CRBU downgraded to market perform from outperform at Leerink Partners (Daina Graybosch), target cut to $1 from $4 or approx. 12% downside. CRBU downgraded to sector perform from outperform at RBC Capital Markets (Luca Issi), target cut to $1 from $10 or approx. 12% downside. SVRA initiated overweight at JPMorgan, target is $12 or approx. 158% upside. MedTech: ABT initiated overweight at Barclays (Christopher Pasquale), target is $120 or approx. 22% upside. ALC initiated equal weight at Barclays (Christopher Pasquale), target is $70 or approx. 11% upside. AVR initiated equal weight at Barclays (Christopher Pasquale), target is $10 or approx. 42% upside. AXGN initiated overweight at Barclays (Christopher Pasquale), target is $55 or approx. 51% upside. BAX initiated underweight at Barclays (Christopher Pasquale), target is $20 or approx. 18% downside. BBNX initiated overweight at Barclays (Christopher Pasquale), target is $30 or approx. 61% upside. BDX initiated underweight at Barclays (Christopher Pasquale), target is $165 or approx. 8% downside. BLCO initiated overweight at Barclays (Christopher Pasquale), target is $24 or approx. 40% upside. BSX initiated equal weight at Barclays (Christopher Pasquale), target is $48 or approx. 14% upside. COO initiated equal weight at Barclays (Christopher Pasquale), target is $60 or approx. 6% upside. DXCM initiated overweight at Barclays (Christopher Pasquale), target is $115 or approx. 38% upside. EW initiated overweight at Barclays (Christopher Pasquale), target is $110 or approx. 27% upside. GEHC initiated overweight at Barclays (Christopher Pasquale), target is $85 or approx. 31% upside. HUMA initiated equal weight at Barclays (Christopher Pasquale), target is $0.50 or approx. 4% upside. INSP initiated underweight at Barclays (Christopher Pasquale), target is $65 or approx. 5% downside. ISRG initiated overweight at Barclays (Christopher Pasquale), target is $485 or approx. 20% upside. LIVN initiated overweight at Barclays (Christopher Pasquale), target is $105 or approx. 40% upside. MDT initiated equal weight at Barclays (Christopher Pasquale), target is $95 or approx. 9% upside. MMED initiated equal weight at Barclays (Christopher Pasquale), target is $22 or approx. 12% upside. PODD initiated equal weight at Barclays (Christopher Pasquale), target is $150 or approx. 11% upside. PRCT initiated overweight at Barclays (Christopher Pasquale), target is $30 or approx. 71% upside. SENS initiated equal weight at Barclays (Christopher Pasquale), target is $10. STVN initiated hold at Deutsche Bank (Justin Bowers), target is $22 or approx. 11% upside. SYK initiated overweight at Barclays (Christopher Pasquale), target is $375 or approx. 35% upside. TNDM initiated equal weight at Barclays (Christopher Pasquale), target is $18 or approx. 11% upside. TMDX initiated overweight at Barclays (Christopher Pasquale), target is $120 or approx. 49% upside. ZBH initiated equal weight at Barclays (Christopher Pasquale), target is $100 or approx. 12% upside. Managed Care: HUM upgraded to overweight from neutral at Cantor Fitzgerald (Sarah James). Firm raises estimates on margin improvement and STARS recovery. Target increased to $460 from $300 or approx. 14% upside. (FactSet average PT $425; range $280-515) Post-close news Research: Mizuho Securities adds three healthcare stocks to Top Picks List (October): EYPT, ESTA, UNH Week Ahead (Sat - Sun) Conference (cont.): MDS Congress 2026 (Oct 4-8) Bernstein Healthcare Services Disruptors Virtual Conference ISFTD 2026 (Oct 8-11) on Fri 9-Oct: ACG 2026 (Oct 9-14) Earnings tomorrow morning ANGO (call at 8:00ET) Corporate Epion Therapeutics (private) to present EpiSmart data at Eyecelerator AAO (13:13ET) (GKOS) Regulatory CMS release 2027 Star Ratings for Medicare Advantage (ALHC, CI, CLOV, CNC, CVS, ELV, HUM, MOH, OSCR, UNH) Syndicate / IPO pricing: on Thu 8-Oct (post-close) +RTSN Retension Pharma; +TRXB Trex Bio (LLY) StreetAccount Healthcare Reads 'Medicare for All' Message Attracts Voters Buckling Under Medical Bills (7-Oct) KFF.org In DMD, a promising therapy is available to a fortunate few (7-Oct) STAT News Trump Says He Has Call Scheduled Soon With Putin on Plague (6-Oct) Bloomberg Can you live longer for $5,500? Longevity clinics are the buzzy new trend at nonprofit hospitals (6-Oct) STAT News Most Americans support switch to Medicare for all health insurance (6-Oct) Reuters Why the FDA should not approve an ineffective multicancer screening test (6-Oct) STAT News (Opinion) Hospital and pharmaceutical prices are smothering America's businesses (5-Oct) STAT News Texas Pediatricians Face Paxton Investigations for Vaccinating Children (5-Oct) NY Times US and German scientists win Nobel medicine prize for work on light and brain (5-Oct) Reuters Dozens quarantined in Siberia after plague institute lab worker dies (5-Oct) Reuters This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 196170.KS, 500124.IN, ABSI, ABT, ALC, ALHC, ALMR, ANGO, AVBP, AVR, AXGN, AZTA, BAX, BBNX, BDX, BLCO, BLLN, BSX, CI, CLOV, CNC, COO, CRBU, CVS, DXCM, ELV, ESTA, EW, EYPT, FMS, GEHC, GKOS, HALO, HUM, HUMA, INSP, ISRG, LIVN, LLY, MDT, MMED, MOH, MRK, MRNA, MRVI, NEOG, OSCR, PGNY, PODD, PRCT, PRME, RXRX, SENS, SMMT, STVN, SVRA, SYK, TMDX, TNDM, TWST, TXG, UNH, VSTM, ZBH, +RTSN, +TRXB...(more)	show story hide story
07-Oct-2026 13:45	LLY Eli Lilly trading higher; CEO Ricks shares perspective with BiotechTV Trading update (with DRG +2.1%): LLY +3.3% Large-cap pharma faring well on Wednesday, most drugmakers are up +1-3% each, and the largest by market cap, Eli Lilly, is leading the charge. No new ground broken in today's interview with CEO David Ricks on BiotechTV, but the 20+ minute talk provided some context on the company's past, present and future in obesity (and Alzheimer's), plus an explainer on the intersection of 'white space' and the company's business development strategy. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
07-Oct-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +1.51% vs the S&P 500 (0.60%). Most major health groups are higher on the session; Pharma today's leading gainer, the DRG +1.63%. Large-cap drugmakers broadly higher, including MRK +1% despite patent infringement setback in Europe for Keytruda SC. Life Science names are soft for a second day, but much firmer than Tuesday, LSD vs MDD declines. CVS +3% and IDXX (3%) bracket the XLV. Sector news flow is fairly quiet, and company-specific. Eg. PGNY +6% after an upbeat selling update. Managed Care investors awaiting the Stars reveal. Cantor Fitzgerald ahead with an upgrade of HUM +0.5%; peers trading little changed too. Gainers +6.6% SVRA (Savara): initiation; best performer on XBI +5.2% PGNY (Progyny): updates on current selling season and membership +5.2% AVBP (Arrivent Biopharma): follow-through, shares were (47%) yesterday +5.1% GKOS (Glaukos): Mizuho raises estimates for Epioxa +3.9% VSTM (Verastem): on average volume; shares +6% WTD +3.4% RCKT (Rocket Pharmaceuticals): update on Danon Disease program; secures credit facility +2.9% AMGN (Amgen): best performer on XLV; Truist preview with PT bump +2.8% CVS (CVS Health): second-best on XLV +2.5% LLY (Eli Lilly): on average volume; shares +4% WTD +2.4% GILD (Gilead Sciences): Truist preview with PT bump +2.3% HALO (Halozyme Therapeutics): wins injunction against Keytruda SC; expands agreement with ARGX +1.8% DXCM (Dexcom): initiation +0.4% DHR (Danaher): announces AI-powered autonomous lab to launch 2027 +0.3% TEM (Tempus AI): shares were (14%) yesterday Decliners -43.6% CRBU (Caribou Biosciences): discontinues development of CAR-T; exploring strategic alternatives; downgrades -5.8% ABSI (Absci Corp.): worst performer on XBI -5.2% TWST (Twist Bioscience): second-worst on XBI; shares were (19%) yesterday -4.9% RXRX (Recursion Pharmaceuticals): shares remain +7% WTD -4.5% TXG (10X Genomics): follow-through, shares were (18%) yesterday -3.1% NEOG (Neogen): earnings; Investor Day -2.6% IDXX (IDEXX Laboratories): worst performer on XLV -2.1% ILMN (Illumina): second-worst on XLV; shares were (7%) yesterday -2.0% CRL (Charles River Laboratories): shares remain +3% WTD -0.6% HUM (Humana): upgraded at Cantor Fitzgerald	show story hide story
07-Oct-2026 10:20	Halozyme wins European injunction against Merck's subcutaneous form of Keytruda Trading update (with DRG +1.48%): HALO +2.5%, MRK +0.8% Halozyme Therapeutics announced that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents (EP622) and ordered Merck to stop manufacture and sale of Keytruda SC (Keytruda QLEX) in Belgium, Denmark, France, Ireland, Sweden, Switzerland and the Netherlands. Merck utilizes SC technology licensed from Alteogen (196170.KS). For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: 196170.KS, HALO, MRK	show story hide story
07-Oct-2026 08:27	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight sector newsflow fairly quiet. CAR-T cell therapy developer Caribou Biosciences announced the discontinuation of its lead programs, and is exploring strategic alternatives. Shares of CRBU (44%) in the pre-market. Danaher announces it plans to launch its first AI-powered autonomous lab in early 2027. Shares of DHR +2% in the pre-market. Barclays initiates twenty-six stocks in Medical Device and Equipment subgroups, including a dozen OW rated names, eleven EW rated, and three UW rated. Stocks are little changed in the pre-market. Yesterday, Healthcare equities were mostly lower. Biotech and MedTech groups both fell under newfound pressure and ended near their worst levels of the session. MRNA (7.8%) reversed all of Monday's advance (presumably on the Russia plague headlines) amid a steep sell-off in biotech risk on Tuesday's open. No clear catalyst behind the sudden rotation away from risk in the sector. Biggest sector news story was the M&A in the infusion services field. OPCH +32.6% acquired by private equity (majority) and McKesson (minority). Macro S&P futures are down (0.45%) on Wednesday morning. Big backup in global bond yields following yesterday's reprieve and ahead of more Treasury supply today and tomorrow. Nothing specific behind the move with an outsized focus still on France. AI trade under pressure following a mixed performance on Tuesday. SPCX looking to raise $40B to purchase NVDA chips. Represents another bullish input for the compute demand narrative but also puts more scrutiny on the financing dynamic. Pretty quiet elsewhere. Yields higher following yesterday's reprieve and more supply on tap with today's 10-year auction and Thursday 30-year sale. Middle East headlines remain mixed with focus on improving flows, surging costs and pickup in kinetic activity (Iran, Houthis). Despite some better internals this week, weak breadth continues to get a lot of attention in the financial press. However, reports have also previewed a strong Q3 earnings season on tap. Pre-market trading update Trading higher +13.9% NEOG earnings; ahead of I-Day +2.4% SVRA initiation +2.2% DHR announces AI-powered autonomous lab to launch 2027 +1.6% RCKT update on Danon Disease program; secures credit facility +1.4% HUM upgraded at Cantor Fitzgerald (low volume) Trading lower -43.6% CRBU discontinues development of CAR-T; exploring strategic alternatives; downgrades -2.6% RXRX on 367K shares -2.2% TXG on 34K shares -2.0% TEM on 195K shares -1.8% TWST on 38K shares Biotech Corporate: CRBU announced that it is exploring strategic alternatives and will discontinue further development of two allogenic CAR-T programs, vispa-cel (CB-010) and CB-011. Clinical update: RCKT Post-close on Wednesday held a webinar and comprehensive update on the Danon Disease program RP-A501 (RGNX). Slides here. Also secured credit facility for up to $150M with Hercules Capital. Research: CRBU downgraded to market perform from outperform at Leerink Partners (Daina Graybosch), target cut to $1 from $4 or approx. 12% downside. CRBU downgraded to sector perform from outperform at RBC Capital Markets (Luca Issi), target cut to $1 from $10 or approx. 12% downside. SVRA initiated overweight at JPMorgan, target is $12 or approx. 158% upside. Life Science & MedTech Earnings: NEOG reports Q1 EPS $0.08 ex-items vs FactSet $0.05 on revenue $222.8M vs FS $208.2M, adj EBITDA $41.6M vs FS $36.7M. Raises FY27 revenue outlook by $5M and adj EBITDA by $1M. Company also hosting Investor Day at 9:00ET Research: ABT initiated overweight at Barclays (Christopher Pasquale), target is $120 or approx. 22% upside. ALC initiated equal weight at Barclays (Christopher Pasquale), target is $70 or approx. 11% upside. AVR initiated equal weight at Barclays (Christopher Pasquale), target is $10 or approx. 42% upside. AXGN initiated overweight at Barclays (Christopher Pasquale), target is $55 or approx. 51% upside. BAX initiated underweight at Barclays (Christopher Pasquale), target is $20 or approx. 18% downside. BBNX initiated overweight at Barclays (Christopher Pasquale), target is $30 or approx. 61% upside. BDX initiated underweight at Barclays (Christopher Pasquale), target is $165 or approx. 8% downside. BLCO initiated overweight at Barclays (Christopher Pasquale), target is $24 or approx. 40% upside. BSX initiated equal weight at Barclays (Christopher Pasquale), target is $48 or approx. 14% upside. COO initiated equal weight at Barclays (Christopher Pasquale), target is $60 or approx. 6% upside. DXCM initiated overweight at Barclays (Christopher Pasquale), target is $115 or approx. 38% upside. EW initiated overweight at Barclays (Christopher Pasquale), target is $110 or approx. 27% upside. GEHC initiated overweight at Barclays (Christopher Pasquale), target is $85 or approx. 31% upside. HUMA initiated equal weight at Barclays (Christopher Pasquale), target is $0.50 or approx. 4% upside. INSP initiated underweight at Barclays (Christopher Pasquale), target is $65 or approx. 5% downside. ISRG initiated overweight at Barclays (Christopher Pasquale), target is $485 or approx. 20% upside. LIVN initiated overweight at Barclays (Christopher Pasquale), target is $105 or approx. 40% upside. MDT initiated equal weight at Barclays (Christopher Pasquale), target is $95 or approx. 9% upside. MMED initiated equal weight at Barclays (Christopher Pasquale), target is $22 or approx. 12% upside. PODD initiated equal weight at Barclays (Christopher Pasquale), target is $150 or approx. 11% upside. PRCT initiated overweight at Barclays (Christopher Pasquale), target is $30 or approx. 71% upside. SENS initiated equal weight at Barclays (Christopher Pasquale), target is $10. STVN initiated hold at Deutsche Bank (Justin Bowers), target is $22 or approx. 11% upside. SYK initiated overweight at Barclays (Christopher Pasquale), target is $375 or approx. 35% upside. TNDM initiated equal weight at Barclays (Christopher Pasquale), target is $18 or approx. 11% upside. TMDX initiated overweight at Barclays (Christopher Pasquale), target is $120 or approx. 49% upside. ZBH initiated equal weight at Barclays (Christopher Pasquale), target is $100 or approx. 12% upside. Managed Care Research: HUM upgraded to overweight from neutral at Cantor Fitzgerald (Sarah James). Firm raises estimates on margin improvement and STARS recovery. Target increased to $460 from $300 or approx. 14% upside. (FactSet average PT $425; range $280-515) On Deck: Conference (cont.): MDS Congress 2026 (Oct 4-8) on Thu 8-Oct: Bernstein Healthcare Services Disruptors Virtual Conference; ISFTD 2026 (Oct 8-11) on Fri 9-Oct: ACG 2026 (Oct 9-14) Corporate NEOG Investor Day (9:00ET) Earnings on Thu 8-Oct: before ANGO (call at 8:00ET) Regulatory by Thu 8-Oct: CMS release 2027 Star Ratings for Medicare Advantage (ALHC, CNC, CVS, ELV, HUM, MOH, OSCR, UNH) Syndicate calendar Thu 8-Oct (post-close) +RTSN Retension Pharma, +TRXB Trex Bio (LLY) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ALC, ALHC, ANGO, AVR, AXGN, BAX, BBNX, BDX, BLCO, BSX, CNC, COO, CRBU, CVS, DHR, DXCM, ELV, EW, GEHC, HUM, HUMA, INSP, ISRG, LIVN, MDT, MMED, MOH, NEOG, OSCR, PODD, PRCT, RCKT, RGNX, RXRX, SENS, STVN, SVRA, SYK, TEM, TMDX, TNDM, TWST, TXG, UNH, ZBH, +RTSN, +TRXB...(more)	show story hide story
06-Oct-2026 16:50	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly lower on Tuesday. Decliners beat advancers by nearly 2:1 on the XLV. Healthcare (0.16%) vs S&P 500 +0.58%. Morning volatility gave way to more stable price action in the afternoon. Biotech and MedTech groups both remained under their newfound pressure, ending near their worst levels of the session. Other major health groups helped moderate the overall decline. MRK +1.7% and MRNA (7.8%) bracketed the XLV; the latter quickly reversed all of Monday's advance (presumably on the Russia plague headlines) amid a steep sell-off in biotech risk on Tuesday's open. CROs remained mostly lower in the afternoon session, including FTRE (1.6%) an outlier much of the day on an upgrade. No clear catalyst behind the sudden rotation away from risk in the sector. Biggest sector news story was the M&A in the infusion services field. OPCH +32.6% an independent provider of infusion services, enterprise value around $5.8B, jointly acquired by private equity (majority) and McKesson (minority). MCK finished +0.7% on the session. Overnight, New York Governor Hochul declared a state of emergency after measles cases rise in rural parts of the state and neighboring states. As of 3-Oct, New York had 108 confirmed cases (7 in NYC, 101 outside of the city). Pennsylvania is the largest hot spot in the nation, with nearly 1000 confirmed cases and five deaths. Yesterday, Healthcare equities were mostly higher and inline overall. Biotech finished around best levels of the day, XBI +1.14%, notably MRNA +7.0% near the top of the XLV, believed to be in reaction to the plague headlines. Bio-weapon biotechs fared well today. Weekend story of a plague death of a Russian lab worker, world is watching to see how the outbreak unfolds. Looking ahead, the Medicare Advantage Star ratings update highlights the calendar this week. Macro A very quiet session though better breadth a big theme again today following all the recent scrutiny surrounding market internals. Likely helped to some extent by global rate stabilization with Eurozone the standout today (some focus on Le Pen shadow budget, "what could the ECB do" reports). While AI trade somewhat of a mixed bag, broader compute/capex demand narrative supported by MRVL guidance, while AMD CEO talked up strong demand backdrop. Also busy in terms of capacity (CEG) and fundraising headlines. M&A another area of focus following a busy Monday with both MCK and UBER doing multibillion-dollar deals. Pretty quiet overall with FOMC minutes tomorrow afternoon, 10- and 30-year Treasury auctions tomorrow and Thursday, and start of Q3 earnings next week the next key areas of focus. When it comes to earnings, preview commentary has been fairly upbeat, particularly at the index level with the tailwind from AI. Q3 expected to mark third straight Q of 25%+ earnings growth. Notable Gainers +32.6% OPCH (Option Care Health): acquired by private equity (51%) and MCK (49%) +9.0% PRME (Prime Medicine): best performer on XBI; follow-through, shares were +8% yesterday +3.9% CMPX (Compass Therapeutics): follow-through, shares were +12% yesterday +1.7% MRK (Merck): best performer on XLV; shares were (3%) yesterday Notable Decliners -47.0% AVBP (Arrivent Biopharma): trial results in NSCLC; worst performer on XBI -18.6% TWST (Twist Bioscience): on nearly 4X avg vol; shares were +9% yesterday -17.5% TXG (10X Genomics): on 3X average volume; shares remain +395% YTD -13.8% TEM (Tempus AI): on 2X average volume -13.7% NEO (NeoGenomics): CEO succession announcement; preliminary Q3 results; upgraded at BTIG -13.6% SYRE (Spyre Therapeutics): secondary offering, priced -11.6% OABI (OmniAb): Investor Day updates -10.9% GRAL (GRAIL, Inc.): on nearly 2X avg vol; shares were +8% yesterday -9.9% NVAX (Novavax, Inc.): on 3X average volume; shares were +20% yesterday -9.6% PCVX (Vaxcyte): on 6X avg vol; follow-through, secondary offering -9.0% ALEC (Alector): follow-through, shares were +10% yesterday -8.8% GH (Guardant Health): on nearly 2X average volume -8.4% IOVA (Iovance Biotherapeutics): on average volume -7.8% MRNA (Moderna): worst performer on XLV; shares were +7% yesterday -6.9% ILMN (Illumina): second-worst on XLV; shares were +8% yesterday -5.9% NTRA (Natera): on above average volume -5.8% CRSP (CRISPR Therapeutics): on above average volume -4.0% DXCM (Dexcom): on below average volume -3.0% NTLA (Intellia Therapeutics): initiation; on 2X average volume -2.7% CBIO (Crescent Biopharma): upgraded at HC Wainwright -2.5% SYK (Stryker): CEO succession announcement Option Care Health going private for $5.8B; McKesson snares minority stake OPCH Option Care Health, McKesson (MCK), and private equity firm Clayton, Dubilier & Rice (CD&R) confirm overnight media report, the companies have reached an agreement under which CD&R and McKesson will acquire Option Care Health for $32.05 per share or total enterprise value around $5.8B. CD&R will hold majority interest (51%), and McKesson minority interest (49%) after investing $1.4B. Option Care Health will continue to operate as a separate company and under existing management. Late on Monday, sources told the FT that MCK and private equity firm Clayton, Dubilier & Rice (CD&R) were near a deal to acquire Option Health Care at valuation greater than $5B. Sell-side firms highlighted the logical synergies available to McKesson in the potential deal. CEO succession announcements for Stryker and NeoGenomics NEO announces CEO succession, effective 4-Jan-2027. COO Warren Stone will become the next CEO, Tony Zook will assume the role of Executive Chair of the board. Company also provided preliminary Q3 results for revenue growth, total revenue, and reiterates FY guidance. SYK announces CEO succession, effective 1-Jan-2027. COO Spence Stiles will become the next CEO, Kevin Lobo will assume the role of Executive Chair of the board. Notable research in Healthcare today Biotech: CBIO upgraded to buy from neutral at HC Wainwright (Mitchell Kapoor), cites valuation. Target is $36 or approx. 158% upside. (FactSet average PT $31; range $27-35) RZLT upgraded to overweight from neutral at Cantor Fitzgerald (Pete Stavropoulos) FDMT transferred buy at Chardan Capital (Gautam Chukka), target is $25 or approx. 93% upside. LBRX initiated buy at Guggenheim Securities (Delma Caiati), target is $80 or approx. 131% upside. MPLT initiated neutral at Guggenheim Securities (Delma Caiati) NBIX assumed buy at Guggenheim Securities (Delma Caiati), target is $207 or approx. 44% upside. NTLA initiated underweight at Barclays (Eliana Merle), target is $8 or approx. 37% downside. (FactSet average PT $23; range $8-61) OVID initiated buy at Guggenheim Securities (Delma Caiati), target is $7 or approx. 199% upside. RAPP initiated buy at Guggenheim Securities (Delma Caiati), target is $65 or approx. 102% upside. XENE assumed buy at Guggenheim Securities (Delma Caiati), target is $73 or approx. 94% upside. MedTech: FTRE *upgraded* to overweight from equal weight at Barclays (Luke Sergott), target increased to $23 from $22 or approx. 9% upside. (FactSet average PT $21; range $13-26) NEO upgraded to buy from neutral at BTIG (Mark Massaro), cites factors including relative valuation. Target is $28 or approx. 46% upside. (FactSet average PT $20; range $16-35) QGEN upgraded to overweight from equal weight at Barclays (Luke Sergott), target increased to $55 from $40 or approx. 20% upside. (FactSet average PT $46; range $40-50) RVTY initiated outperform at William Blair (Matt Larew) Post-close news Earnings: NEOG reports Q1 EPS $0.08 ex-items vs FactSet $0.05 on revenue $222.8M vs FS $208.2M, adj EBITDA $41.6M vs FS $36.7M. Raises FY27 revenue outlook by $5M and adj EBITDA by $1M. Conf. call at 16:30ET Shares trading +9.6% in the after-hours Corporate: CRBU announced that it is exploring strategic alternatives and will discontinue further development of two allogenic CAR-T programs, vispa-cel (CB-010) and CB-011. Shares resumed, trading (41.4%) in the after-hours On Deck: Conference (cont.): MDS Congress 2026 (Oct 4-8) on Thu 8-Oct: Bernstein Healthcare Services Disruptors Virtual Conference; ISFTD 2026 (Oct 8-11) Corporate NEOG Investor Day (9:00ET) Earnings on Thu 8-Oct: before ANGO (call at 8:00ET) Regulatory on Thu 8-Oct: CMS release 2027 Star Ratings for Medicare Advantage (ALHC, CNC, CVS, ELV, HUM, MOH, OSCR, UNH) Syndicate calendar on Thu 8-Oct (post-close) +RTSN Retension Pharma; +TRXB Trex Bio (LLY) StreetAccount Healthcare Reads Can you live longer for $5,500? Longevity clinics are the buzzy new trend at nonprofit hospitals (6-Oct) STAT News Most Americans support switch to Medicare for all health insurance (6-Oct) Reuters Why the FDA should not approve an ineffective multicancer screening test (6-Oct) STAT News (Opinion) Hospital and pharmaceutical prices are smothering America's businesses (5-Oct) STAT News Texas Pediatricians Face Paxton Investigations for Vaccinating Children (5-Oct) NY Times US and German scientists win Nobel medicine prize for work on light and brain (5-Oct) Reuters Dozens quarantined in Siberia after plague institute lab worker dies (5-Oct) Reuters This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALEC, ALHC, ANGO, AVBP, CBIO, CMPX, CNC, CRBU, CRSP, CVS, DXCM, ELV, FDMT, FTRE, GH, GRAL, HUM, ILMN, IOVA, LBRX, LLY, MCK, MOH, MPLT, MRK, MRNA, NBIX, NEO, NEOG, NTLA, NTRA, NVAX, OABI, OPCH, OSCR, OVID, PCVX, PRME, QGEN, RAPP, RVTY, RZLT, SYK, SYRE, TEM, TWST, TXG, UNH, XENE, +RTSN, +TRXB...(more)	show story hide story
06-Oct-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.50%) vs the S&P 500 +0.77%. Volatility headlines the session. At the open, major health groups picked up where they left off, with CROs building on Monday's strength, and picked up an upgrade for FTRE +3%. Quick sell-off in Healthcare led by Biotech soon after the open. XBI (3.30%) trading off its worst levels of the session, with just a handful of green names on the ETF at the bottom. LST and CROs followed, only FTRE remains higher. No clear catalyst behind the sudden rotation away from risk in the sector. HSIC and ALGN +1% leading short list of gainers n the XLV; MRNA (6%) reversing nearly all of Monday's advance, an outsized move on the plague story, leading all decliners on the XLV. Biggest sector news today is M&A in the infusion services field. OPCH +33% an independent provider of infusion services, enterprise value around $5.8B, jointly acquired by private equity (majority) and McKesson (minority). MCK trading little changed. Gainers +32.7% OPCH (Option Care Health): acquired by private equity (51%) and MCK (49%) +5.5% CGEM (Cullinan Therapeutics): best performer on XBI; on strong volume +2.6% PRME (Prime Medicine): follow-through, shares were +8% yesterday +2.5% FTRE (Fortrea Holdings): upgraded at Barclays +1.3% HSIC (Henry Schein): best performer on XLV +1.3% ALGN (Align Technology): second-best on XLV Decliners -54.7% AVBP (Arrivent Biopharma): trial results in NSCLC; worst performer on XBI -12.2% TXG (10X Genomics): on heavy volume; shares +437% YT -11.3% NEO (NeoGenomics): CEO succession; preliminary Q3 results; upgrade at BTIG -11.1% PCVX (Vaxcyte): follow-through, secondary offering -10.8% TWST (Twist Bioscience): follow-through, shares were +9% yesterday -10.7% SYRE (Spyre Therapeutics): secondary offering, priced -10.1% OABI (OmniAb): updates ahead of Investor Day (11ET) -9.8% GRAL (GRAIL, Inc.): shares were +8% yesterday -6.3% ILMN (Illumina): worst performer on XLV; shares were +8% yesterday -5.7% MRNA (Moderna): second-worst on XLV; shares were +7% yesterday -5.3% CRSP (CRISPR Therapeutics): on heavy volume -3.5% NTLA (Intellia Therapeutics): initiation -3.3% ALEC (Alector): follow-through, shares were +10% yesterday -2.9% DXCM (Dexcom): on light volume -0.6% RZLT (Rezolute): upgraded at Cantor Fitzgerald	show story hide story
06-Oct-2026 08:38	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Confirmed M&A in the infusion services space. Option Care Health, an independent provider of infusion services, enterprise value around $5.8B, jointly acquired by private equity (majority) and McKesson (minority). Shares of OPCH resumed trading now +33% in the pre-market. MCK trading little changed. New York Governor Hochul declared a state of emergency after measles cases rise in rural parts of the state and neighboring states. As of 3-Oct, New York had 108 confirmed cases (7 in NYC, 101 outside of the city). Pennsylvania is the largest hot spot in the nation, with nearly 1000 confirmed cases and five deaths. Yesterday, Healthcare equities were mostly higher and inline overall. Biotech finished around best levels of the day, XBI +1.14%, notably MRNA +7.0% near the top of the XLV, believed to be in reaction to the plague headlines. Bio-weapon biotechs fared well today. Weekend story of a plague death of a Russian lab worker, world is watching to see how the outbreak unfolds. Looking ahead, the Medicare Advantage Star ratings update highlights the calendar this week. Macro S&P futures are up +0.5% on Tuesday morning. Quiet from a headline perspective. Lower oil and rates supportive for risk sentiment. When it comes to oil, flow headlines remain largely upbeat (though for crude, not products). Treasuries likely seeing some spillover from the big rally in Eurozone bonds today (fiscal discipline hopes stemming from the Le Pen budget proposal). Also some focus on Monday's better breadth day amid continued ramp in scrutiny surrounding market internals. AI headlines have revolved around fundraising, chip financing, compute demand, power deals, open-weight momentum, and the broader economic tailwind. M&A (healthcare services) also in focus again following a busy Monday. Spillover effects of bond yield backup continue to get a lot of attention in the press, including in terms of spread widening and delayed/restructured deals. Pre-market trading update Trading higher +33.4% OPCH acquired by private equity (51%) and MCK (49%) +7.8% CBIO upgraded at HC Wainwright (low volume) +6.2% RZLT upgraded at Cantor Fitzgerald +5.8% NEO CEO succession; preliminary Q3 results; upgrade at BTIG +3.5% FTRE upgraded at Barclays +3.1% CRSP on 27K shares +3.0% TXG on 65K shares +2.8% QGEN upgraded at Barclays +2.6% TWST follow-through +1.1% ALEC follow-through Trading lower -8.3% OABI updates ahead of Investor Day (11ET) -2.5% SYK CEO succession -1.7% NTLA initiation -1.4% PCVX follow-through, secondary offering -1.3% SYRE secondary offering, priced -0.0% MCK invests $1.4B for minority stake in Option Care Health (low volume) Pharma Corporate: ABBV provides IPR&D update ahead of Q3 results. Expects unfavorable ($0.11)/shr EPS impact to guidance reaffirmed 3-Sep-2026. Biotech Research: CBIO upgraded to buy from neutral at HC Wainwright (Mitchell Kapoor), cites valuation. Target is $36 or approx. 158% upside. (FactSet average PT $31; range $27-35) RZLT upgraded to overweight from neutral at Cantor Fitzgerald (Pete Stavropoulos) FDMT transferred buy at Chardan Capital (Gautam Chukka), target is $25 or approx. 93% upside. LBRX initiated buy at Guggenheim Securities (Delma Caiati), target is $80 or approx. 131% upside. MPLT initiated neutral at Guggenheim Securities (Delma Caiati) NBIX assumed buy at Guggenheim Securities (Delma Caiati), target is $207 or approx. 44% upside. NTLA initiated underweight at Barclays (Eliana Merle), target is $8 or approx. 37% downside. (FactSet average PT $23; range $8-61) OVID initiated buy at Guggenheim Securities (Delma Caiati), target is $7 or approx. 199% upside. (Editor's note: Originally reported as neutral, corrected to buy) RAPP initiated buy at Guggenheim Securities (Delma Caiati), target is $65 or approx. 102% upside. XENE assumed buy at Guggenheim Securities (Delma Caiati), target is $73 or approx. 94% upside. Life Science & MedTech Corporate: NEO announces CEO succession, effective 4-Jan-2027. COO Warren Stone will become the next CEO, Tony Zook will assume the role of Executive Chair of the board. Company also provided preliminary Q3 results for revenue growth, total revenue, and reiterates FY guidance. SYK announces CEO succession, effective 1-Jan-2027. COO Spence Stiles will become the next CEO, Kevin Lobo will assume the role of Executive Chair of the board. Research: FTRE *upgraded* to overweight from equal weight at Barclays (Luke Sergott), target increased to $23 from $22 or approx. 9% upside. (FactSet average PT $21; range $13-26) NEO upgraded to buy from neutral at BTIG (Mark Massaro), cites factors including relative valuation. Target is $28 or approx. 46% upside. (FactSet average PT $20; range $16-35) QGEN upgraded to overweight from equal weight at Barclays (Luke Sergott), target increased to $55 from $40 or approx. 20% upside. (FactSet average PT $46; range $40-50) RVTY initiated outperform at William Blair (Matt Larew) Services & Hospitals M&A: OPCH Option Care Health, McKesson (MCK), and private equity firm Clayton, Dubilier & Rice (CD&R) confirm overnight media report, the companies have reached an agreement under which CD&R and McKesson will acquire Option Care Health for $32.05 per share or total enterprise value around $5.8B. CD&R will hold majority interest (51%), and McKesson minority interest (49%) after investing $1.4B. Option Care Health will continue to operate as a separate company and under existing management. Late on Monday, sources told the FT that MCK and private equity firm Clayton, Dubilier & Rice (CD&R) were near a deal to acquire Option Health Care at valuation greater than $5B. Sell-side firms highlighted the logical synergies available to McKesson in the potential deal. On Deck: Conference (cont.): MDS Congress 2026 (Oct 4-8) Earnings after the close NEOG (call at 16:30ET) Corporate OABI Investor Day (11:00ET) on Wed 7-Oct: NEOG Investor Day (9:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ALEC, CBIO, CRSP, FDMT, FTRE, LBRX, MCK, MPLT, NBIX, NEO, NEOG, NTLA, OABI, OPCH, OVID, PCVX, QGEN, RAPP, RVTY, RZLT, SYK, SYRE, TWST, TXG, XENE...(more)	show story hide story
05-Oct-2026 16:53	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities traded mostly higher and inline overall on Monday. Advancers beat decliners by more than 3:1 on the XLV. Healthcare +0.75% vs S&P 500 +0.66%. Most major health groups ended higher on the averages for the session. Pharma group today's lone decliner, the DRG (0.56%). MedTech group continued to lead the gainers, with LST ~3% doubling up on Devices. ILMN +7.6% and CRL +7.1% were top two performers on the XLV. Biotech finished around best levels of the day, XBI +1.14%, notably MRNA +7.0% near the top of the XLV, believed to be in reaction to the plague headlines. Bio-weapon biotechs fared well today. Weekend story of a plague death of a Russian lab worker, world is watching to see how the outbreak unfolds. BMY (3.8%) lead all decliners on the XLV behind the neutral downgrade. Biotech news on Monday headlined by PCVX nearly +31% to go with its 31-valent challenger in the blockbuster field. Comparators PFE (1.4%) and MRK (3.3%). Vaxcyte with encouraging pivotal results from the first of three studies in the adult pneumococcal vaccine (PCV) market. The investigational 31-valent vaccine demonstrated broad non-inferiority against Prevnar and Capvaxive. Submission however not seen until 2028. Looking ahead, the Medicare Advantage Star ratings update highlights the calendar this week. Macro Pretty quiet session with very few meaningful directional drivers. Oil on the defensive with more push and pull between better flows and lack of diplomatic traction. Saudi Arabia, Pakistan, Turkey also agreed to rapid military deployment following recent Houthi attacks on Saudi infrastructure. Busy last few days of headlines surrounding overseas political developments (France, Spain, Brazil) though spillover effects limited. M&A the highlight on the corporate calendar. Biggest story today seems to be that stocks are up despite another backup in long-term yields. Bar seems to keep ratcheting higher when it comes to potential pain threshold for stocks. Also talk of some cushion from the stabilization at the front end/recent fade in October tightening expectations. In addition, upcoming Q3 earnings season expected to put the focus back on the elevated corporate backdrop and broader AI tailwind. Despite some near-term seasonal headwinds, Q4 historically best-performing Q for stocks. Positioning and flow dynamics (near-term resumption of corporate buybacks) cited as largely supportive as well. Notable Gainers +30.7% PCVX (Vaxcyte): trial results with 31-valent pneumococcal vaccine; best performer on XBI +20.1% NVAX (Novavax, Inc.): on >5X average volume; likely a plague reaction +16.0% RXRX (Recursion Pharmaceuticals): on >3X average volume +14.4% EBS (Emergent BioSolutions): on >2X average volume; likely a plague reaction +12.1% ALVO (Alvotech): FDA approves sBLA, marks FDA clearance of Reykjavik site +9.9% ALEC (Alector): license agreement in Parkinson's with Genentech (ROP.SW) +9.0% TEM (Tempus AI): on average volume +8.7% TWST (Twist Bioscience): on above average volume; 52-week high +7.6% ILMN (Illumina): best performer on XLV; 52-week high +7.6% GRAL (GRAIL, Inc.): follow-through; 52-week high +7.1% CRL (Charles River Laboratories): on above average volume; 52-week high +6.9% MRNA (Moderna): on below average volume; likely a plague reaction +6.7% WAY (Waystar Holding): on nearly 2X average volume +4.4% LMRI (Lumexa Imaging Holdings): initiation Notable Decliners -13.1% CAPR (Capricor Therapeutics): presentation at WMS 2026; worst performer on XBI -9.4% PGEN (Precigen): on above average volume -7.3% SRRK (Scholar Rock): on average volume -6.6% INSM (Insmed): CFO stepping down; company reaffirms guidance -4.0% PRAX (Praxis Precision Medicines): presentations at MDS 2026 -3.8% BMY (Bristol Myers Squibb): downgraded at Leerink; worst performer on XLV -3.3% MRK (Merck): sympathy to PCVX -2.8% QURE (uniQure NV): downgraded at Barclays -2.5% PBLS (Parabilis Medicines, Inc.): follow-through -2.1% ALGN (Align Technology): downgraded at Evercore ISI -1.4% PFE (Pfizer): sympathy to PCVX Vaxcyte's 31-valent PCV demonstrates broad non-inferiority against incumbents Vaxcyte (PCVX) announced topline results from its pivotal phase 3 study OPUS-1 of VAX-31, which will support BLA submission in H1 of 2028, following readouts for OPUS-2 and OPUS-3 in H1 of 2027. All 28 VAX-31 serotypes shared with PCV20 (Pfizer's Prevnar) and/or PCV21 (Merck's Capvaxive) met the prespecified noninferiority criteria. In the prespecified individual comparator analyses, VAX-31 met the noninferiority criterion (LBCI >0.667) for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21. Alvotech higher after manufacturing site update, PDUFA dates back on track ALVO announced that FDA has approved an sBLA for its Humira biosimilar SIMLANDI. Most importantly, this approval confirms resolution of the inspection matters (VAI) at the company's Reykjavik facility. Company now expects FDA to take action on its other pending applications, including AVT05 (bSimponi), AVT06 (bEylea), AVT03 (bProlia and bXgeva), and AVT16 (bEntyvio). (TEVA) Novo Nordisk lower after manufacturing site update, PDUFA missed NOVO.B.DC announced that FDA review of the BLA for denecimig (FREHEMGO) for HemA is still ongoing. Decision was anticipated during Q3 of 2026. Remediation activities continue at the manufacturing site. Small-cap biotech Alector higher following out-license agreement ALEC announced it has granted worldwide rights for AL050 to Genentech (ROP.SW) for $100M upfront and additional milestones worth up to $1.17B plus royalties. Initial indication is Parkinson's Disease. Alector states that deal extends cash runway into 2029. GE Healthcare buys assets to grow radiopharmaceuticals business GEHC confirmed earlier media report, announced the acquisition of SOFIE Biosciences for $945M in cash. SOFIE is a U.S.-based CMO for PET radiopharmaceuticals. Notable research in Healthcare today Pharma: BMY downgraded to market perform from outperform at Leerink Partners (David Risinger), target cut to $59 from $73 or approx. 4% downside. (FactSet average PT $67; range $40-82) Biotech: QURE downgraded to equal weight from overweight at Barclays (Eliana Merle), noting 48-month data and regulatory uncertainty. Target cut to $28 from $60 or approx. 19% upside. (FactSet average PT $64; range $31-95) CAMP initiated outperform at Oppenheimer (Kostas Biliouris), target is $15 or approx. 275% upside. KRSA initiated outperform at Wedbush Securities (Laura Chico), target is $44 or approx. 44% upside. ORIC initiated outperform at Leerink Partners (Asthika Goonewardene), target is $26 or approx. 113% upside. EXEL assumed market perform at Leerink Partners (Asthika Goonewardene), target increased to $55 from $52 or approx. 6% downside. GMAB resumed outperform at Leerink Partners (Asthika Goonewardene), target is $50 or approx. 44% upside. RGNX initiated outperform at Mizuho Securities (Graig Suvannavejh), target is $22 or approx. 196% upside. RVMD assumed outperform at Leerink Partners (Asthika Goonewardene), target is $288 or approx. 39% upside. ZNTL assumed outperform, prior was market perform, at Leerink Partners (Asthika Goonewardene), target increased to $8 from $4 or approx. 217% upside. ZYME assumed outperform at Leerink Partners (Asthika Goonewardene), target is $60 or approx. 139% upside. MedTech: ALGN downgraded to in line from outperform at Evercore ISI (Elizabeth Anderson), notes weakening customer conditions. Target cut to $155 from $220 or approx. 8% upside. (FactSet average PT $207; range $170-235) LMRI initiated buy at Truist (Clarke Murphy), target is $18 or approx. 74% upside. MRVI initiated buy at TD Cowen (Brendan Smith), target is $9 or approx. 14% upside. QTI initiated buy at Craig-Hallum Capital (Matthew Hewitt), target is $8 or approx. 200% upside. Post-close news M&A / media report: OPCH Sources tell the FT that MCK and CD&R are near deal to acquire Option Health Care at valuation greater than $5B. Shares of OPCH trading +21.6% in the after-hours; MCK (0.2%) Corporate: ABBV provides IPR&D update ahead of Q3 results. Expects unfavorable ($0.11)/shr EPS impact to guidance reaffirmed 3-Sep-2026. Shares trading (0.3%) in the after-hours NEO announces CEO succession, effective 4-Jan-2027. COO Warren Stone will become the next CEO, Tony Zook will assume the role of Executive Chair. Company also provided preliminary Q3 results for revenue growth, total revenue, and reiterates FY guidance. Shares trading (2.1%) in the after-hours PCVX announces proposed secondary offering of stocks, warrants and convertible notes. Shares trading (3.8%) in the after-hours Research: RZLT upgraded to overweight from neutral at Cantor Fitzgerald (Pete Stavropoulos) Shares trading +1.6% in the after-hours On Deck: Conference (cont.): MDS Congress 2026 (Oct 4-8) Earnings after the close tomorrow NEOG (call at 16:30ET) Corporate on Wed 7-Oct: NEOG Investor Day (9:00ET) StreetAccount Healthcare Reads Hospital and pharmaceutical prices are smothering America's businesses (5-Oct) STAT News Texas Pediatricians Face Paxton Investigations for Vaccinating Children (5-Oct) NY Times US and German scientists win Nobel medicine prize for work on light and brain (5-Oct) Reuters Dozens quarantined in Siberia after plague institute lab worker dies (5-Oct) Reuters This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ALEC, ALGN, ALVO, BMY, CAMP, CAPR, CRL, EBS, EXEL, GEHC, GMAB, GRAL, ILMN, INSM, KRSA, LMRI, MCK, MRK, MRNA, MRVI, NEO, NEOG, NOVO.B.DC, NVAX, OPCH, ORIC, PBLS, PCVX, PFE, PGEN, PRAX, QTI, QURE, RGNX, ROP.SW, RVMD, RXRX, RZLT, SRRK, TEM, TEVA, TWST, WAY, ZNTL, ZYME...(more)	show story hide story
05-Oct-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.08%) vs the S&P 500 +0.43%. Major health groups are split on the session. MedTech and Services groups higher, Biotech and Pharma groups lower. CRL +4% and BMY (4%) bracket the XLV movers. Former without a clear catalyst, latter with a downgrade on today's tape. No impact in Healthcare from the weekend story of a plaque death of a Russian lab worker, but the world is watching to see how the outbreak unfolds. SMID-cap biotech newsflow today headlined by PCVX +31% and its 31-valent challenger in the blockbuster field. PFE (2%), but also weighing on comparator MRK (3%). Vaxcyte with encouraging pivotal results from the first of three studies in the adult pneumococcal vaccine (PCV) market. The investigational 31-valent vaccine demonstrated broad non-inferiority against Prevnar and Capvaxive. Submission however not seen until 2028. Gainers +31.1% PCVX (Vaxcyte): trial results with 31-valent pneumococcal vaccine; best performer on XBI +25.9% ALEC (Alector): license agreement with Roche's Genentech +13.7% ALVO (Alvotech): FDA approves sBLA, marks FDA clearance of Reykjavik site +7.2% RXRX (Recursion Pharmaceuticals): on heavy volume +6.4% TWST (Twist Bioscience): on above average volume +4.6% TEM (Tempus AI): on average volume +4.0% WAY (Waystar Holding): on light volume +3.7% LMRI (Lumexa Imaging Holdings): initiation +3.7% CRL (Charles River Laboratories): best performer on XLV +3.1% SYK (Stryker): second-best on XLV Decliners -7.7% CAPR (Capricor Therapeutics): presentation at WMS 2026 -7.5% INSM (Insmed): CFO stepping down; company reaffirms guidance; worst performer on XBI -6.3% QURE (uniQure NV): downgraded at Barclays -5.3% PRAX (Praxis Precision Medicines): follow-through -5.0% PBLS (Parabilis Medicines, Inc.): follow-through -4.2% BMY (Bristol Myers Squibb): downgraded at Leerink; worst performer on XLV -3.4% MRK (Merck): sympathy to PCVX -1.8% PFE (Pfizer): sympathy to PCVX -0.9% KOD (Kodiak Sciences): follow-through, shares were +192% last week	show story hide story
05-Oct-2026 08:32	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Fairly quiet weekend of corporate newsflow across the sector. Offset by the plague death of a Russian lab worker which has the world watching whether an outbreak unfolds. On Monday morning biotech Vaxcyte reported encouraging pivotal results from the first of three studies that aim to shake up the adult pneumococcal vaccine market. The investigational 31-valent vaccine demonstrated broad non-inferiority against Prevnar and Capvaxive. Shares of PCVX +54% in the pre-market; shares of PFE and MRK off slightly. Looking ahead, the Medicare Advantage Star ratings update highlights the calendar this week. Macro S&P futures are down (0.1%) on Monday morning. Foreign political developments (France, Spain, Brazil) getting a lot of attention this morning but no real spillover effects for the US, where the usual suspects/debates were in focus in the weekend press and sell-side research. These include the upward pressure on rates vs declining October Fed tightening odds, weak equity market breadth vs index level resilience, low index vol vs elevated rate vol, another big AI tailwind for the upcoming Q3 earnings season, better energy flows out of the Middle East vs risk of renewed hostilities, and K-shaped but resilient consumer spending backdrop. Pre-market trading update Trading higher +53.0% ALEC license agreement with Roche's Genentech; call at 800ET +53.5% PCVX trial results with 31-valent pneumococcal vaccine; call at 800ET +7.7% ALVO FDA approves sBLA, marks FDA clearance of Reykjavik site +2.5% ORIC initiation Trading lower -4.6% LMRI initiation -3.0% INSM CFO stepping down; company reaffirms guidance -2.8% ALGN downgraded at Evercore ISI -2.2% QURE downgraded at Barclays -1.8% BMY downgraded at Leerink -1.2% NVO regulatory update on HemA BLA -0.3% MRK sympathy to PCVX -0.2% PFE sympathy to PCVX Pharma Regulatory: NOVO.B.DC announced that FDA review of the BLA for denecimig (FREHEMGO) for HemA is still ongoing. Decision was anticipated during Q3 of 2026. Remediation activities continue at the manufacturing site. ALVO announced that FDA has approved an sBLA for its Humira biosimilar SIMLANDI. Most importantly, this approval confirms resolution of the inspection matters (VAI) at the company's Reykjavik facility. Company now expects FDA to take action on its other pending applications, including AVT05 (bSimponi), AVT06 (bEylea), AVT03 (bProlia and bXgeva), and AVT16 (bEntyvio). (TEVA) Research BMY downgraded to market perform from outperform at Leerink Partners (David Risinger), target cut to $59 from $73 or approx. 4% downside. (FactSet average PT $67; range $40-82) Biotech Vaxcyte's 31-valent PCV demonstrates broad non-inferiority against incumbents Pre-market trading update: PCVX +57.0%, PFE (0.4%), MRK (0.6%) Vaxcyte announced topline results from its pivotal phase 3 study OPUS-1 of VAX-31, which will support BLA submission in H1 of 2028, following readouts for OPUS-2 and OPUS-3 in H1 of 2027. All 28 VAX-31 serotypes shared with PCV20 (Pfizer's Prevnar) and/or PCV21 (Merck'sCapvaxive) met the prespecified noninferiority criteria. In the prespecified individual comparator analyses, VAX-31 met the noninferiority criterion (LBCI >0.667) for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21. Conf. call at 8:00ET. License agreement: ALEC announced it has granted worldwide rights for AL050 to Genentech (ROP.SW) for $100M upfront and additional milestones worth up to $1.17B plus royalties. Initial indication is Parkinson's Disease. Alector states that deal extends cash runway into 2029. Conf. call at 8:00ET Research: QURE downgraded to equal weight from overweight at Barclays (Eliana Merle), noting 48-month data and regulatory uncertainty. Target cut to $28 from $60 or approx. 19% upside. (FactSet average PT $64; range $31-95) CAMP initiated outperform at Oppenheimer (Kostas Biliouris), target is $15 or approx. 275% upside. KRSA initiated outperform at Wedbush Securities (Laura Chico), target is $44 or approx. 44% upside. ORIC initiated outperform at Leerink Partners (Asthika Goonewardene), target is $26 or approx. 113% upside. EXEL assumed market perform at Leerink Partners (Asthika Goonewardene), target increased to $55 from $52 or approx. 6% downside. GMAB resumed outperform at Leerink Partners (Asthika Goonewardene), target is $50 or approx. 44% upside. RGNX initiated outperform at Mizuho Securities (Graig Suvannavejh), target is $22 or approx. 196% upside. RVMD assumed outperform at Leerink Partners (Asthika Goonewardene), target is $288 or approx. 39% upside. ZNTL assumed outperform, prior was market perform, at Leerink Partners (Asthika Goonewardene), target increased to $8 from $4 or approx. 217% upside. ZYME assumed outperform at Leerink Partners (Asthika Goonewardene), target is $60 or approx. 139% upside. Life Science & MedTech M&A: GEHC confirms earlier media report, announces the acquisition of SOFIE Biosciences for $945M in cash. SOFIE is a U.S.-based CMO for PET radiopharmaceuticals. Corporate: IRTC post-close on Friday provided an update on the cybersecurity incident disclosed in June 2026. Research: ALGN downgraded to in line from outperform at Evercore ISI (Elizabeth Anderson), notes weakening customer conditions. Target cut to $155 from $220 or approx. 8% upside. (FactSet average PT $207; range $170-235) LMRI initiated buy at Truist (Clarke Murphy), target is $18 or approx. 74% upside. MRVI initiated buy at TD Cowen (Brendan Smith), target is $9 or approx. 14% upside. QTI initiated buy at Craig-Hallum Capital (Matthew Hewitt), target is $8 or approx. 200% upside. On Deck: Conference (cont.): MDS Congress 2026 (Oct 4-8) Earnings on Tue 6-Oct: after NEOG (call at 16:30ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Editor's Note: This comment was revised to remove BKD from the gainers. Shares are up only +0.4% in the pre-market on light volume. (05-Oct-2026, 08:42 ET) Related: ALEC, ALGN, ALVO, BMY, CAMP, EXEL, GEHC, GMAB, INSM, IRTC, KRSA, LMRI, MRK, MRVI, NEOG, NOVO.B.DC, NVO, ORIC, PCVX, PFE, QTI, QURE, RGNX, ROP.SW, RVMD, TEVA, ZNTL, ZYME...(more)	show story hide story
05-Oct-2026 07:28	Vaxcyte's 31-valent PCV demonstrates broad non-inferiority against incumbents Pre-market trading update: PCVX +57.0%, PFE (0.4%), MRK (0.6%) Vaxcyte announced topline results from its pivotal phase 3 study OPUS-1 of VAX-31, which will support BLA submission in H1 of 2028, following readouts for OPUS-2 and OPUS-3 in H1 of 2027. All 28 VAX-31 serotypes shared with PCV20 (Pfizer's Prevnar) and/or PCV21 (Merck'sCapvaxive) met the prespecified noninferiority criteria. In the prespecified individual comparator analyses, VAX-31 met the noninferiority criterion (LBCI >0.667) for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21. Conf. call at 8:00ET. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: MRK, PCVX, PFE	show story hide story
03-Oct-2026 11:19	Trump announces Medicare improvement fund payments for seniors President Trump announced that the federal government will be making one-time payments of $90 per person to help more than 20M enrollees pay for their Medicare Part B premiums. Payments will be made from the Medicare Improvement Fund, which has been given $2B by Congress for the purposes of making improvements to the Medicare fee-for-service program, but has never before been utilized. Most eligible seniors will receive the payment in the form a direct deposit of $90 in early October. Those without direct deposit will receive a check, also sent in early October, to the mailing address they have registered with Medicare. Most Medicare Part B enrollees are eligible for the payments. Those whose premiums are already paid by Medicaid or who pay an Income-Related Monthly Adjustment Amount do not qualify. Related: ABBV, AMGN, BMY, GILD, GSK, JNJ, MRK, NVS, REGN, ROP.SW, SNY...(more) Reference Link	show story hide story
02-Oct-2026 19:58	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished mixed to slightly lower overall on Friday. Advancers narrowly outnumbered decliners on the XLV. Healthcare (0.04%) vs S&P 500 +0.73%. Major health groups ended lightly mixed for the session, Managed Care the leading gainer, while both Pharma and Biotech saw small declines. Sector newsflow was fairly quiet on the session. CNC +3.3% and VEEV (3.1%) bracketed the XLV, with moves generally modest in between. A Q3 profit-warning and business update weighed on IART (21.2%), while no clear catalyst identified for today's rally in AZTA +12.4%. Intraday the stock was on track for its largest single-day move in more than three years. Without pinpointing any one reason, KeyBanc gave several reasons why the hold-rated stock was having a week. All health groups ended with weekly declines on their averages. Macro: Stock rally to end the week sparked by softer-than-expected September payrolls report. Economist takeaways said print strengthens case for October Fed pause, though also noted Fed squarely focused on inflation, not labor market. While stocks held onto post-NFP gains, bonds ignored dovish implications, pricing slightly steeper rate hike path (27 bp of hikes through year-end, up from 25 bp pre-report and up from 17 bp immediately following release). Not much behind bond weakness, though tracked crude prices that bounced sharply higher off morning lows, which came despite coordinated G7 100M barrel oil/diesel reserve release. Usual bond headwinds also remain in play (higher global rate backdrop, sticky inflation, AI borrowing and increased AI capex estimates, high clearing yields). Lagging breadth again in focus as today's rally top-heavy, adding to narrative around market concentration risks. Other dynamics in focus included positive seasonality, accelerating corporate buyback window, firm Q3 earnings expectations, widening MOVE vs VIX divergence, and improved Middle East oil flows despite stalled US/Iran diplomacy. Notable Gainers on Friday: +12.4% AZTA (Azenta): on 4X average volume; KeyBanc comments on possible reasons +11.8% MYGN (Myriad Genetics): price target raised at Craig-Hallum +10.8% IBRX (ImmunityBio): best performer on XBI; mentioned positively at Jefferies ahead of October bladder cancer readout; shares +419% YTD +8.1% GRAL (GRAIL, Inc.): follow-through; price target raised at UBS +6.4% QGEN (Qiagen): circulation of Betaville report, we're told +3.6% SYRE (Spyre Therapeutics): follow-through, shares +9% for the week +3.3% CNC (Centene): best performer on the XLV; shares +2% for the week Notable Decliners on Friday: -30.8% FHTX (Foghorn Therapeutics): follow-through; multiple downgrades -21.2% IART (Integra LifeSciences Holdings): business updates, reduces guidance Q3 and FY -7.3% NKTR (Nektar Therapeutics): worst performer on XBI; shares (24%) for the week -3.1% VEEV (Veeva Systems): worst performer on XLV; shares (3%) for the week -1.8% SNY (Sanofi): ADRs lower for sixth straight week; (3%) for the week and (13%) over the last six Week in Review: Healthcare equities underperformed for the week. The S&P 500 Healthcare Index down (2.73%) vs the S&P 500 Index (0.27%). Outperformers: none Underperformers: Pharma, Services, Managed Care, Biotech, MedTech Major health groups were each lower for the week on the averages. Medicare Advantage providers one week closer to the reveal of Star ratings. Plan designs for 2027 were published this week, giving investors another piece of the puzzle for each MCO. CVS Health extended distribution deals with McKesson and Cardinal Health out to 2032. A major biopharma collaboration also renewed this week with Regeneron and Sanofi expanding the global I&I arrangement that brought the blockbuster Dupixent. Shares of REGN extended weekly decline on the news; on Monday blockbuster Eylea shown a new challenger in wet AMD. Kodiak Sciences +192%. Drugmaker AstraZeneca also placed a $2B bet on Summit Therapeutics. Earnings season more than a week away, the previews beginning to prep for JNJ, including Wells Fargo which believes that consensus is too high by LOE and deal dilution. JNJ with its largest one-week pullback since April 2025, also ahead of an earnings print. Year-to-date, Healthcare +7.29% vs the S&P 500 +12,81%. Healthcare fifth out of eleven major sectors in CY26. Energy +40.36% and Utilities (6.73%) bracket them all. Notable movers for the week: Gainers: KOD +192.0% - trial results in wet AMD; best performer on XBI IOVA +29.2% - raises FY26 revenue guidance IBRX +21.9% - stock higher four of five days; Jefferies comments on upcoming readout; stock +415% YTD UTHR +13.9% - court ruling in patent suit vs LQDA; upgraded at BTIG GRAL +12.9% - follows +57% last week; price target raised at UBS TXG +9.1% - initiation; begins shipping Atera; fifth straight weekly gain and 15 of last 16 weeks SYRE +8.8% - sympathy to MRK (TL1A for HS) ABCL +8.2% - initiation SMMT +7.3% - $2B investment by AZN GKOS +6.0% - snaps five week decline MCK +4.1% - extends agreement with CVS Health; best performer on XLV CAH +3.7% - extends agreement with CVS Health; second-best on XLV Decliners: QURE (38.6%) - updated clinical results in HD; worst performer on XBI VKTX (15.8%) - follows +23% last week; Novo licenses Hengrui obesity candidate ALNY (14.2%) - lower all five days BLLN (14.0%) - follows +16% last week; lower six straight days CAI (11.5%) - ended a five-day slide on Friday AXSM (8.1%) - lower six straight and 10 of last 11 days INCY (6.9%) - lower 9 of last 11 days; worst performer on XLV REGN (6.7%) - sympathy to KOD; expands agreement with SNY; worst performer on XLV INSM (5.7%) - lower 8 of last 11 days JNJ (5.6%) - largest weekly decline in 18 months; shares remain +26% YTD vs XLV +7% and DRG +8% MRNA (4.5%) - downgraded to sell at Citi; added to Nasdaq 100 Index Week Ahead (Sat - Sun): Oct 3 - 11 Earnings calendar Tue 6-Oct: after NEOG (call at 16:30ET) Thu 8-Oct: before ANGO (call at 8:00ET) Corporate calendar Wed 7-Oct: NEOG Investor Day (9:00ET) Regulatory calendar Thu 8-Oct: CMS release 2027 Star Ratings for Medicare Advantage (ALHC, CNC, CVS, ELV, HUM, MOH, OSCR, UNH) Conference calendar Thu 8-Oct: Bernstein Healthcare Services Disruptors Virtual Conference; ISFTD 2026 (Oct 8-11) Fri 9-Oct: ACG 2026 (Oct 9-14) Peek Ahead to the following week (Oct 12-18) Q3 earnings calendar kick off with JNJ and UNH on Tue 13-Oct; next reports are eight days later Related: ABCL, ALHC, ALNY, ANGO, AXSM, AZTA, BLLN, CAH, CAI, CNC, CVS, ELV, FHTX, GKOS, GRAL, HUM, IART, IBRX, INCY, INSM, IOVA, JNJ, KOD, MCK, MOH, MRK, MRNA, MYGN, NEOG, NKTR, NVO, OSCR, QGEN, QURE, REGN, SMMT, SNY, SYRE, TXG, UNH, UTHR, VEEV, VKTX...(more)	show story hide story
02-Oct-2026 14:47	StreetAccount Summary: Notable Drug Events expected for the week of 4-Oct Sun 4-Oct Industry meeting with clinical data: International Congress of Parkinson's Disease and Movement Disorders (Oct 4-8) (GANX, ARVN) Tue 6-Oct Trial results: SXTP phase 2a Interim Data readout for ARAKODA in babesiosis Investor event: RCKT RP-A501 phase 2 regulatory alignment update call Thu 8-Oct Industry meeting with clinical data: International Conference on Frontotemporal Dementias (ISFTD) (Oct 8-11) (CRVO) Fri 9-Oct Industry meeting with clinical data: American College of Gastroenterology (ACG) Scientific Meeting (Oct 9-14) (JNJ) later during October 2026 Regulatory decisions: FDA PDUFAs: ROP.SW (Enspryng sBLA, 15-Oct), IRD/VTRS (phentolamine ophthalmic solution 0.75% sNDA 17-Oct), GSK.LN/IONS (Hibsago NDA, 26-Oct), 524715.IN/MRK (ILUMYA sBLA, 29-Oct), INO (INO-3107 BLA, 30-Oct); FDA BsUFA XBRANE.SS (Xlucane BLA, 29-Oct); EMA CHMP opinions on MAA (16-Oct) Industry meetings with clinical data: European Huntington's Disease Network (EHDN) Congress (Oct 22-24); ESMO Congress 2026 (Oct 23-27); ESGCT Annual Congress (Oct 27-30) Regulatory meeting: EMA CHMP monthly meeting (Oct 12-15) Trial results: MRNA (Ph3 melanoma), PCVX (Ph3 IPD/pneumococcal pneumonia), RAPP (Ph3 FOS, Ph2 Bipolar I disorder), BMY (Ph3 IPF), CMPX (Ph2/3 biliary tract cancer), 6996.HK (Ph2 G/GEJ cancer and Ph1/2 melanoma), 7630.HK (Ph2 NSCLC and Ph1/2 mCRC), GSK.LN (Ph2 rectal cancer), PHAR (Ph2 PIDs), SXTP (Ph2 babesiosis), DMAC (Ph2 fetal growth restriction), TLSA (Ph2 na-SPMS), INBX (Ph1/2 HNSCC), ARWR (Ph1/2 Alzheimer's disease) PBLS (Ph1/2 Desmoid Tumors), TNGX (Ph1/2 pancreatic cancer), BNTC (Ph1/2 OPMD), TRDA (Ph1/2 DMD), EIKN (Ph1/2 solid tumors), CATX (Ph1/2 NETs), VSTM (Ph1/2 solid tumors), BMEA (Ph1 obesity), ALNY (Ph1 Huntington's disease), INCY (Ph1 PDAC and Ph1 MSS CRC), IMTX (Ph1 cancer), XNCR (Ph1 ccRCC), AGEN (Ph1 ovarian cancer), CHRS (Ph1 HNSCC) expected imminently Trial results: AARD (Ph3 PwS), CGON (Ph3 INT-NMIBC) Related: 524715.IN, 6996.HK, 7630.HK, AARD, AGEN, ALNY, ARVN, ARWR, BMEA, BMY, BNTC, CATX, CGON, CHRS, CMPX, CRVO, DMAC, EIKN, GANX, GSK.LN, IMTX, INBX, INCY, INO, IONS, IRD, JNJ, MRK, MRNA, PBLS, PCVX, PHAR, RAPP, RCKT, ROP.SW, SXTP, TLSA, TNGX, TRDA, VSTM, VTRS, XBRANE.SS, XNCR...(more)	show story hide story
02-Oct-2026 11:41	CDC reports 228 new cases of measles this week, Pennsylvania remains hot spot Year-to-date, CDC has reported 3,887 cases of measles, including 228 over the past week. Not quite a new weekly high, but very close to the 231 reported on 4-Sep-2026. This week's figure includes Pennsylvania with 963 cases YTD, +113 w/w, or half of the nationwide new cases. Wisconsin next at +43 w/w (and 207 YTD). CDC and Pennsylvania still at odds over death reports. Earlier this week, Pennsylvania DoH reported a fifth "measles-associated death". The CDC earlier this week acknowledged just the second death from measles in 2026 (with an asterisk). For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
02-Oct-2026 11:20	StreetAccount Sector Summary: Healthcare Monthly Recap - September 2026 Month in Review: Healthcare equities underperformed for the month of September 2026. The S&P 500 Healthcare Index declined (1.03%) vs the S&P 500 Index down (0.45%). First monthly decline in five months, and first month of relative underperformance in four. Outperformers: MedTech Underperformers: Biotech, Managed Care, Pharma, Services Most major health groups were lower by (2%) to (3%) on the averages. MedTech was the positive outlier and lone outperformer, despite wide disparity in returns between subgroups for LST, Diagnostics and Medical Devices. Rising rates and fewer M&A deals underpinned Biotech in September, though interest in Moderna remained high with the company affirming plans to present INT data at a near-term medical meeting. Grail Inc helped keep the XBI (2.97%) in range, the FDA review of its Galleri PMA on track for approval by year-end. GRAL and diagnostic-focused biotechs rallied higher on the FDA Advisory Committee hurdle. Conference season brought with it some cautious commentary from certain medical device makers, and the Cooper Companies fiscal Q3 print proved the importance of CSI to the whole. Divestiture hopes deflated after company concluded its strategic review in September. Top 5 on the XLV: +37.2% MRNA, +28.1% ILMN, +18.8% RVTY, +12.2% A, +9.4% TMO Bottom 5 on the XLV: -19.4% COO, -15.0% SYK, -12.2% PODD, -11.2% ZBH, -10.5% ABT Year-to-date, Healthcare up +8.75% vs the S&P 500 +11.77%. Healthcare third out of eleven major sectors in CY26. Energy +37.4% and Utilities (7.65%) bracket them all. For Q3 of 2026, Healthcare +6.03% vs the S&P 500 +2.03%. XBI (0.36%) first decline in six quarters. DRG (0.92%) first decline in five quarters. Two IPOs in September, twenty-eight YTD 2026: versus one in September 2025 / twenty-five YTD 2025 cumulatively raised $8.44B YTD vs $3.20B YTD 2025 ADRX +17.3% - raised $446M - Biotech ETRA (25.0%) - raised $350M - Biotech Notable movers for the month: Gainers: KOD +153.8% - trial results in wet AMD; best performer on XBI IOVA +81.4% - commentary on AMTAGVI growth at HCW conference; raised FY26 revenue guidance for AMTAGVI GRAL +76.5% - FDA briefing documents and Advisory Committee support of Galleri PMA TXG +44.7% - stock higher 17 of last 19 weeks TWST +39.0% - stock higher 14 of last 19 weeks; collaboration with LLY MRNA +37.2% - follow-through; confirms INT data will be presented at ESMO; best performer on XLV TEM +29.9% - commentary at Morgan Stanley Healthcare Conference; AI strength/rally NTRA +28.4% - DX read-across from GRAL ILMN +28.1% - DX read-across from GRAL SMMT +24.2% - partner Akeso reports trial results in HARMONi-2 (achieves overall survival endpoint) CAI +20.2% - LST rally alongside AI / GRAL sympathy RVTY +18.8% - stock higher 15 of last 19 weeks; LST rally alongside AI IBRX +18.7% - another double-digit move (6 of 9 months in CY26); stock +377% YTD A +12.2% - LST rally alongside AI / GRAL sympathy GH +12.2% - expanded reimbursement for Shield; GRAL sympathy Decliners: CMPX (56.5%) - regulatory feedback on tovecimig; downgraded at Wedbush; worst performer on XBI XENE (38.2%) - voluntarily pauses enrollment in psychiatry studies for analysis of AEs; submitted NDA in focal seizures; downgraded at Deutsche Bank IONS (26.0%) - sympathy to RARE, SRRK ARWR (20.6%) - trial results in mixed hyperlipidemia COO (19.4%) - concludes strategic review without divestiture of CSI business; worst performer on XLV IMVT (17.2%) - trial results in CLE; ends development in CLE NVO (16.4%) - strategic updates at CMD; rebranded as Novo SYK (15.0%) - commentary at Wells Fargo Healthcare Conference including persistent challenges in PV segment SRRK (14.9%) - FDA approves Isembyld for SMA w post-marketing commitments; downgraded at Barclays BBIO (14.1%) - commentary at Wells Fargo, Cantor, Morgan Stanley conferences PODD (12.2%) - stock lower 7 of 9 months in CY2026 Related: A, ABT, ADRX, ARWR, BBIO, CAI, CMPX, COO, ETRA, GH, GRAL, IBRX, ILMN, IMVT, IONS, IOVA, KOD, MRNA, NTRA, NVO, PODD, RVTY, SMMT, SRRK, SYK, TEM, TMO, TWST, TXG, XENE, ZBH...(more)	show story hide story
02-Oct-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.13%) vs the S&P 500 +0.93%. Most major health groups are higher on the session, although gains are modest and Pharma weighing on the sector. Specifically, Sanofi (2%) the single largest headwind to the DRG (0.16%), the drugmaker on track for a sixth straight weekly decline. CVS +2% and CAH (2%) bracket the XLV, one day after distributors rallied on wholesale agreements with the pharmacy. MRNA (2%) seeing no lift from the Nasdaq 100 Index add. Sector newsflow very quiet outside of IART (16%) on a Q3 profit-warning and business update. AZTA +18% rallying the most in over three years. Gainers +17.9% AZTA (Azenta): unusual volume +11.4% IBRX (ImmunityBio): best performer on XBI; mentioned positively at Jefferies ahead of October bladder readout; shares +420% YTD +5.2% GRAL (GRAIL, Inc.): price target raised at UBS +3.7% SYRE (Spyre Therapeutics): follow-through, shares +9% WTD +3.3% AVLN (Avalyn Pharma): initiation +2.2% CVS (CVS Health): best performer on XLV; shares (2%) WTD +2.1% DSGN (Design Therapeutics): initiation Decliners -15.9% FHTX (Foghorn Therapeutics): follow-through, multiple downgrades -15.8% IART (Integra LifeSciences Holdings): business updates, reduces guidance Q3 and FY -6.2% KOD (Kodiak Sciences): worst performer on XBI; shares remain +185% WTD -2.0% SNY (Sanofi): on track for sixth straight weekly decline -2.0% CAH (Cardinal Health): worst performer on XLV; shares were +4% yesterday -1.9% VEEV (Veeva Systems): second-worst on XLV -1.8% COR (Cencora): shares were +3% yesterday	show story hide story
02-Oct-2026 10:59	AZTA Azenta trading higher; catalyst unclear AZTA currently +15% on heavy volume, traded as high as +20% and on track to its biggest one day gain in over three years. Stock is +19% YTD. Peers all trading in positive territory today, but most are up low-single digits each. Specific catalyst is unclear, we will follow up when we hear more. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
02-Oct-2026 08:37	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Integra Life Sciences with a Q3 profit-warning and business update. Shares of IART down (12%) in the pre-market. Otherwise a very quiet calendar apart from the ongoing industry conferences in Milan, Vienna, Hiroshima, and Paris. Overnight, Moderna named to replace Warner Bros in the Nasdaq 100 effective 9-Oct. Shares are up +1% in the pre-market. Looking ahead to next week, Stars reveal expected for Medicare Advantage, while earnings season kickoff more than a week away. JNJ and UNH report on Tuesday 13-Oct. Yesterday, Healthcare equities finished broadly lower, led by Biotech and the XBI (2.01%) which turned red week-to-date - joining all other groups lower for the week. REGN (3%) after renewing and expanding the I&I collaboration with Sanofi. MedTech group traded split with LST stocks pulling back low- to mid-single digits after their strong performance in the month of September; Medical Devices were of little help but relatively inline. Medicare-leveraged payers declined as much as (5%) on the day; move followed the rollout of MA plan finder for CY2027. Open enrollment is now two weeks away. All three major drug distributors topped a short list of gainers on the XLV. Macro S&P futures are up +0.5% on Friday morning. Firmer tone chalked up to weaker oil, where focus seems to be on report that European countries have discussed releasing diesel stocks in response to US pressure. Pullback follows another flurry of headlines this week about improved oil exports for the region, though also more discussion about high shipping costs, fading diplomatic off-ramps and potential for renewed hostilities. Oil weakness not really helping Treasuries (though yields at least stable), which finally found some relief on Thursday with help from latest comments from Fed leadership pushing back against another rate hike in October. Pretty quiet elsewhere heading into NFP. AI headlines have revolved around Anthropic IPO before Thanksgiving, AMZN focus on balance sheet health and AVGO chip financing push. Corporate calendar light with the focus on NKE turnaround struggles. Pre-market trading update Trading higher +3.9% AVLN initiation (low volume) +2.9% DSGN initiation (low volume) +2.7% AVAH (low volume) +2.1% PGEN (low volume) +1.5% AZTA on 19K shares +0.9% ABT upgraded at Rothschild +0.7% MRNA to join Nasdaq 100 +0.5% NEOG Earnings and Investor Day are next week (low volume) Trading lower -12.1% IART business updates, reduces guidance Q3 and FY -2.8% SNY on track for sixth straight weekly decline -2.8% LQDA follow-through, downgrade at Wells Fargo -2.4% FHTX multiple downgrades -1.5% ATRC downgraded at Freedom Capital Biotech Index change: MRNA will join the Nasdaq 100 on 9-Oct, replacing Warner Bros. Research: FHTX downgraded to neutral from buy at BTIG (Jeet Mukherjee) FHTX downgraded to hold from buy at TD Cowen (Yaron Werber) FHTX downgraded to neutral from outperform at Wedbush Securities (Robert Driscoll), target cut to $2 from $10 or approx. 32% downside. (FactSet average PT $8; range $5-14) LQDA downgraded to equal weight from overweight at Wells Fargo Securities (Benjamin Burnett), target cut to $30 or approx. 7% upside. (FactSet average PT $66; range $30-130) AVLN initiated outperform at Raymond James (Tiago Fauth), target is $60 or approx. 119% upside. (FactSet average PT $62; range $52-80) DSGN initiated overweight at Wells Fargo Securities (Tinqi Hang), target is $26 or approx. 112% upside. (FactSet average PT $21; range $20-22) ELVN initiated overweight at Morgan Stanley (Sean Laaman), target is $70 or approx. 51% upside. (FactSet average PT $74; range $65-82) LBRX initiated buy at Needham (Ami Fadia), target is $68 or approx. 82% upside. (FactSet average PT $57; range $45-78) Life Science & MedTech Guidance: IART provides update on Cincinnati facility and its broader business, guides Q3 EPS $0.55-0.59 ex-items vs prior $0.53-0.61 and FactSet $0.56, and Q3 revenue $410-412M vs prior $410-425M and FS $416.3M. Also lowers FY EPS guidance by $0.10 and revenue by $30M at the midpoints. Research: ABT upgraded to buy from neutral at Rothschild & Co Redburn (Ed Ridley-Day), cites improved visibility and options around its business portfolio. Target increased to $127 from $119 or approx. 31% upside. (FactSet average PT $121; range $103-135) ATRC downgraded to hold from buy at Freedom Capital (Keith Hinton), target increased however to $57 from $43 or approx. 6% upside. (FactSet average PT $53; range $36-65) MYGN target raised to $8 from $4 at Craig-Hallum Capital (Bill Bonello), firm believes shares can double in next 4-6 months. Maintains only buy rating on the Street. New price target implies 97% upside. (FactSet average PT $4; range $2-8) On Deck: Conferences (cont.): EASD 2026 (Sep 28 - Oct 2) (cont.): WMS Congress 2026 (Sep 29 - Oct 3) (cont.): ISSjD 2026 (Sep 29 - Oct 2) (cont.): EADV Congress 2026 (Sep 30 - Oct 3) Peek Ahead to next week (Oct 5-11) Tue 6-Oct: Investor Day (OABI) Wed 7-Oct: Investor Day (NEOG) Thu 8-Oct: CMS release of 2027 Star Ratings for Medicare Advantage (CVS, HUM, UNH, CNC, MOH) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABT, ATRC, AVAH, AVLN, AZTA, DSGN, ELVN, FHTX, IART, LBRX, LQDA, MRNA, MYGN, NEOG, OABI, PGEN, SNY...(more)	show story hide story
01-Oct-2026 17:12	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished around session lows on Thursday. Decliners beat advancers nearly 5:1 on the XLV. Healthcare (1.30%) vs S&P 500 (0.19%). All major health groups ended lower for the session, most down (1%) to (2%) on the averages. Biotech today's leading decliner with the XBI (2.01%) turning red week-to-date. Mainly company-specific headlines in biotech, including trial results in ASCVD and FSCD. MedTech group traded split with LST stocks pulling back low- to mid-single digits after their strong performance in the month of September; Medical Devices were of little help but relatively inline. Medicare-leveraged payers declined as much as (5%) on the day; move followed the rollout of MA plan finder for CY2027. Open enrollment is now two weeks away. All three major drug distributors topped a short list of gainers on the XLV. MCK +5.3% and CAH +3.7%, with DHR (4.4%) leading all decliners on the XLV. Shares of REGN (3.1%) moderated a bit intraday following the renewal of their Sanofi arrangement. The partners reloaded their long-standing immunology collaboration that brought blockbuster Dupixent. Both McKesson and Cardinal Health announced key pharma distribution commitments from CVS Health. Pharma stocks were all red today despite a scaled back GLOBE model for drug prices in Medicare Part B. Payment model applicable to very few drugs after the exclusions. TEVA (0.7%) and Samsung Bioepis expand their global biosimilar agreement by up to six drug copies. Yesterday, Healthcare equities finished mixed to lower overall. Only Biotech and MedTech finding and holding positive territory. XBI +0.55% the leading advancer, with the TL1A class getting a boost from Merck's success in hidradentis supportiva (HS). Headwind however from MRNA (5.4%) recipient of a new sell rating at Citi, placing the stock worst on the XLV. VEEV +2.5% quietly topped short list of XLV gainers. Pennsylvania reported the fifth measles-related death of CY2026, in the nation-leading outbreak. Healthcare sector finished (1.03%) for the month of September, +6.03% for Q3, and +8.75% YTD. Macro Market started Q4 on a stronger note. Some help from lower Treasury yields, though these were somewhat volatile today (consistent with recent attention on divergence between elevated MOVE index vs flattish VIX). Long-end yields moved to fresh 24-year highs following September ISM manufacturing report reflecting continued cost pressures, but then retreated. Meanwhile 2s today had their strongest day since mid-July after seeing a 72 bp run-up in yields for Q3. Yields provided some offset for higher oil amid fading diplomatic momentum and concerns about re-escalation (Trump reportedly sending a third carrier battlegroup to the region). Market processed a few more upbeat AI headlines, including a new GOOGL model, favorable read-throughs from MU earnings, Tencent's ORCL lease. Notable Gainers +7.1% LXEO (Lexeo Therapeutics): on >2X average volume today; best performer on XBI; shares were down (29%) in September and are currently (64%) YTD +5.4% UTHR (United Therapeutics): follow-through, shares were +13% yesterday; upgraded at BTIG; second-best on XBI +5.3% MCK (McKesson): extends distribution agreement with CVS; best performer on XLV +4.9% WVE (Wave Life Sciences): regulatory alignment in AATD program; initiation +4.7% XENE (Xenon Pharmaceuticals): insiders buying +3.9% KOD (Kodiak Sciences): 13D filing (Baker Bros buying) +3.7% CAH (Cardinal Health): extends distribution agreement with CVS +3.2% COR (Cencora): sympathy to MCK/CAH Notable Decliners -22.4% NKTR (Nektar Therapeutics): trial results for rezpeg presented at EADV; worst performer on XBI -22.1% AGMB (AgomAb Therapeutics NV): trial results in FSCD -18.2% FHTX (Foghorn Therapeutics): small-cap biotech; pipeline decisions and 40% RIF announced; downgraded at Citizens -7.8% VRDN (Viridian Therapeutics): on >2X average volume -7.5% LQDA (Liquidia): follow-through, shares were (57%) yesterday; downgraded at BTIG and Raymond James -5.6% GLUE (Monte Rosa Therapeutics): trial results in ASCVD; initiation -5.5% CELC (Celcuity): on average volume; shares down (25%) YTD -4.4% DHR (Danaher): worst performer on XLV; shares down (6%) WTD -4.0% ABVX (Abivax): on average volume; ADRs down (29%) YTD -3.5% INCY (Incyte): second-worst on XLV -3.4% AMGN (Amgen): on below average volume -3.3% TMO (Thermo Fisher Scientific): -3.1% REGN (Regeneron): updated immunology agreement with Sanofi; upgraded at Argus Research -3.0% IQV (IQVIA Holdings): shares (4%) WTD McKesson, Cardinal higher on extended distribution agreements MCK announced it has extended its pharma distribution agreement with CVS Health (CVS) through June 2032, and reaffirmed FY27 adj EPS guidance bracketing consensus, plus its long-term growth rate of 13-16%. CAH announced it has extended its pharma distribution agreement with CVS Health (CVS) through June 2032, and reaffirmed FY27 NG EPS guidance bracketing consensus, plus its LT EPS growth rate of 12-14%. Regeneron and Sanofi renew and expand their immunology alliance Trading update with XBI (0.53%): REGN (2.7%), SNY +0.2% Pre-open on Thursday, Regeneron and Sanofi announced an expansion of their successful development and commercial alliance which dates back to 2003 and brought us Dupixent. Four new long-acting, Regeneron-invented antibodies are added, delivering $1B in upfront payments and up to $7B in contingent milestone payments. On the call: With regard to Dupixent, "LOE anywhere is coming in March 2031", but actively working to "extend this by a few years" for the US market. Medicare Advantage plan finder revealed ahead of OE27 Medicare Advantage providers issued press releases announcing their plan offerings for CY2027. Open Enrollment period begins 15-Oct and runs through 7-Dec. (ALHC, CLOV, CNC, ELV, HUM, UNH) Investors remain focused on the upcoming Stars announcements, expected in approximately one week (8-Oct). CMS finalizes GLOBE drug pricing model for Medicare Part B CMS-5545-F (585pp); Press release Excerpt: GLOBE excludes biosimilars and their reference biologicals once a biosimilar enters the market in the United States. The model will also exclude orphan-only drugs, plasma-derived products, and certain cell and gene therapies, a change from the proposed rule made in response to public comments. Teva Pharma and Samsung Bioepis expand biosimilar collaboration TEVA and Samsung Bioepis (0126Z0.KS) expanded their existing collaboration, and today announced a global development and commercialization agreement covering up to six (6) potential biosimilar medicines. Deal includes two named programs, SB41 (bFasenra) and SB44 (bIlaris). Teva gets commercial rights in US, Europe, Canada. Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars. Fasenra is marketed by AZN.LN; Ilaris is marketed by NOVN.SW. Trial results in SMID-cap biotech AGMB announced results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with FSCD. Favorable safety and tolerability profile maintained through up to 60 weeks of treatment. Results support initiation of global NOV-ERA Phase 2b study in FSCD in the coming months. GLUE announced data from phase 1 GFORCE-1 study evaluating MRT-8102 for the treatment of inflammatory conditions driven by the NEK7/NLRP3 pathway. Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses - key pathogenic drivers of ASCVD. Phase 2 trials planned across coronary artery disease, gout, and moderate to severe hidradenitis suppurativa (HS). Notable research in Healthcare today Pharma: AZN.LN (AZN) downgraded to hold from buy at Intron Health (Naresh Chouhan), target cut to 13000p from 17000p or approx. 8% upside. (FactSet average PT 16041p; range 11669-20147p) TEVA initiated buy at TD Cowen, target is $55 or approx. 39% upside. (FactSet average PT $46; range $40-55) Stifel analyst Dara Azar publishes deep dive on ADCs, a field crowded with large-cap pharma names - and initiates two small-cap biotech names. Biotech: REGN upgraded to buy from hold at Argus Research, target is $850 or approx. 12% upside. (FactSet average PT $856; range $737-1030) UTHR upgraded to buy from neutral at BTIG (Julian Harrison), target is $728 or approx. 34% upside. (FactSet average PT $638; range $321-725) LQDA downgraded to neutral from buy at BTIG (Julian Harrison) LQDA downgraded to outperform from strong buy at Raymond James (Ryan Deschner), target cut to $53 from $106 or approx. 75% upside. (FactSet average PT $84; range $40-130) FHTX downgraded to market perform from market outperform at Citizens (Silvan Turkcan). ELVN initiated overweight at JPMorgan (Pryanka Grover), target is $75 or approx. 64% upside. (FactSet average PT $74; range $65-82) IMNM initiated hold at Stifel (Dara Azar), target is $24 or approx. 12% upside. KURA initiated overweight at JPMorgan (Hardik Parikh), target is $30 or approx. 180% upside. (FactSet average PT $32; range $15-76) SYRE initiated overweight at JPMorgan (Hardik Parikh), target is $110 or approx. 24% upside. (FactSet average PT $121; range $110-130) WVE initiated buy at Ladenburg Thalmann, target is $10 or approx. 170% upside. (FactSet average PT $19; range $10-42) WHWK initiated buy at Stifel (Dara Azar), target is $9 or approx. 139% upside. MedTech: VEEV added to Tactical Ideas List at Wells Fargo (Stan Berenshteyn) for CQ4 (FQ3). Post-close news Research: FHTX downgraded to neutral from buy at BTIG (Jeet Mukherjee) FHTX downgraded to hold from buy at TD Cowen (Yaron Werber) On Deck: Conferences (cont.): EASD 2026 (Sep 28 - Oct 2) (cont.): WMS Congress 2026 (Sep 29 - Oct 3) (cont.): ISSjD 2026 (Sep 29 - Oct 2) (cont.): EADV Congress 2026 (Sep 30 - Oct 3) Peek Ahead to next week (Oct 5-11) Tue 6-Oct: Investor Day (OABI) Wed 7-Oct: Investor Day (NEOG) Thu 8-Oct: CMS release of 2027 Star Ratings for Medicare Advantage (CVS, HUM, UNH, CNC, MOH) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 0126Z0.KS, ABVX, AGMB, ALHC, AMGN, AZN.LN, CAH, CELC, CLOV, CNC, COR, CVS, DHR, ELV, ELVN, FHTX, GLUE, HUM, IMNM, INCY, IQV, KOD, KURA, LQDA, LXEO, MCK, MOH, NEOG, NKTR, NOVN.SW, OABI, REGN, SNY, SYRE, TEVA, TMO, UNH, UTHR, VEEV, VRDN, WHWK, WVE, XENE...(more)	show story hide story
01-Oct-2026 11:17	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.57%) vs the S&P 500 (0.23%). All major health groups are red for the session, most are down less than (1%) on the averages. Managed Care an outlier with large-cap MCO declines as much as (4%), following today's rollout of Medicare Advantage plan finder for CY2027 - open enrollment is two weeks away. MCK +4% and REGN (3%) bracketing the XLV movers. Regeneron and Sanofi renew and reload their long-standing immunology collaboration that brought Dupixent. Both McKesson and Cardinal Health announced key pharma distribution commitments from CVS Health. Pharma stocks all red today despite a scaled back GLOBE model for drug prices in Medicare Part B. Payment model applicable to very few drugs after the exclusions. XBI (0.56%) roughly inline with mainly company-specific headlines, including trial results in ASCVD and FSCD. Gainers +6.8% WVE (Wave Life Sciences): regulatory alignment in AATD program; initiation +5.9% UTHR (United Therapeutics): best performer on XBI; follow-through, shares were +13% yesterday; upgraded at BTIG +4.9% XENE (Xenon Pharmaceuticals): insiders buying +4.3% KOD (Kodiak Sciences): insiders buying; second-best on XBI +4.2% MCK (McKesson): extends distribution agreement with CVS; best performer on XLV +3.3% CAH (Cardinal Health): extends distribution agreement with CVS; second-best on XLV +3.3% SYRE (Spyre Therapeutics): follow-through; initiation +2.8% MRNA (Moderna): follow-through, shares were (5%) yesterday Decliners -39.2% FHTX (Foghorn Therapeutics): small-cap biotech; pipeline decisions and 40% RIF announced -18.5% NKTR (Nektar Therapeutics): trial results for Rezpeg presented at EADV; worst performer on XBI -14.7% LQDA (Liquidia): follow-through, shares were (57%) yesterday; downgraded at BTIG and Raymond James -8.5% AGMB (AgomAb Therapeutics NV): trial results in FSCD -6.3% VRDN (Viridian Therapeutics): on average volume -5.7% GLUE (Monte Rosa Therapeutics): trial results in ASCVD; initiation -4.8% CELC (Celcuity): on average volume; stock (24%) YTD -4.7% ABVX (Abivax): on average volume; ADRs (30%) YTD -3.3% REGN (Regeneron): updated immunology agreement with Sanofi; upgraded at Argus Research; worst performer on XLV -2.6% CNC (Centene): Medicare Advantage plan finder; second-worst on XLV -2.1% ELV (Elevance Health): Medicare Advantage plan finder -1.5% TEVA (Teva Pharmaceutical): expands biosimilar agreement with Samsung Bioepis; initiation	show story hide story
01-Oct-2026 08:32	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight newsflow fairly quiet. CMS finalized a scaled-back GLOBE model for drug prices in Medicare Part B. Applicable to very few drugs after the exclusions. Biotech newsflow includes trial results in ASCVD and FSCD, plus Teva and Samsung Bioepis expand their global biosimilar agreement by up to six drugs. Yesterday, Healthcare equities finished mixed to lower overall. Only Biotech and MedTech finding and holding positive territory. XBI +0.55% the leading advancer, with the TL1A class getting a boost from Merck's success in hidradentis supportiva (HS). Headwind however from MRNA (5.4%) recipient of a new sell rating at Citi, placing the stock worst on the XLV. VEEV +2.5% quietly topped short list of XLV gainers. Pennsylvania reported the fifth measles-related death of CY2026, in the nation-leading outbreak. Healthcare sector finished (1.03%) for the month of September, +6.03% for Q3, and +8.75% YTD. Macro S&P futures are up +0.3% on Thursday morning. Rate stabilization in focus following further upward pressure earlier in the session, along with a flurry of articles in the financial press highlighting the Q3/September damage in bonds. Oil higher with lack of diplomatic traction in the Middle East still seemingly overshadowing better flow data, though off best levels. Still an outsized focus on tight product markets (and China reportedly suspended refined exports). AI/ Mag 7 providing a cushion again with new GOOGL model, favorable read-throughs from MU earnings and Tencent's ORCL lease. However, this also keeps the focus on the divergence between weak breadth and index-level resistance, as well as the divergence between the VIX and MOVE index. Pretty quiet elsewhere. Earnings calendar a relative bright spot with ACN and MKC the standouts this morning. Pre-market trading update Trading higher +6.5% GLUE trial results in ASCVD; call at 800ET; initiation +5.4% AGMB trial results in FSCD; call at 830ET +4.5% KURA initiation +4.1% WVE regulatory alignment in AATD program; initiation +2.1% WHWK initiation +1.5% UTHR follow-through, shares were +13% yesterday; upgraded at BTIG +1.4% REGN upgraded at Argus Research +1.2% ELVN initiation +1.1% SYRE initiation Trading lower -49.6% FHTX small-cap biotech; pipeline decisions and 40% RIF announced -12.4% LQDA follow-through, shares were (57%) yesterday; downgraded at BTIG and Raymond James -3.7% MRNA follow-through, shares were (5%) yesterday -2.3% ABVX on 16K ADRs -0.1% TEVA expands biosimilar agreement with Samsung Bioepis; initiation Pharma Collaboration agreement: TEVA and Samsung Bioepis (0126Z0.KS) expanded their existing collaboration, and today announced a global development and commercialization agreement covering up to six (6) potential biosimilar medicines. Deal includes two named programs, SB41 (bFasenra) and SB44 (bIlaris). Teva gets commercial rights in US, Europe, Canada. Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars. Fasenra is marketed by AZN.LN; Ilaris is marketed by NOVN.SW. Regulatory: CMS finalizes GLOBE drug pricing model for Medicare Part B. CMS-5545-F (585pp); Press release Excerpt: GLOBE excludes biosimilars and their reference biologicals once a biosimilar enters the market in the United States. The model will also exclude orphan-only drugs, plasma-derived products, and certain cell and gene therapies, a change from the proposed rule made in response to public comments. Research: AZN.LN (AZN) downgraded to hold from buy at Intron Health (Naresh Chouhan), target cut to 13000p from 17000p or approx. 8% upside. (FactSet average PT 16041p; range 11669-20147p) TEVA initiated buy at TD Cowen, target is $55 or approx. 39% upside. (FactSet average PT $46; range $40-55) Stifel analyst Dara Azar publishes deep dive on ADCs, a field crowded with large-cap pharma names - and initiates two small-cap biotech names. Biotech Trial results: AGMB announced results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with FSCD. Favorable safety and tolerability profile maintained through up to 60 weeks of treatment. Results support initiation of global NOV-ERA Phase 2b study in FSCD in the coming months. Conf. call at 8:30ET GLUE announced data from phase 1 GFORCE-1 study evaluating MRT-8102 for the treatment of inflammatory conditions driven by the NEK7/NLRP3 pathway. Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses - key pathogenic drivers of ASCVD. Phase 2 trials planned across coronary artery disease, gout, and moderate to severe hidradenitis suppurativa (HS). Conf. call at 8:00ET Research: REGN upgraded to buy from hold at Argus Research, target is $850 or approx. 12% upside. (FactSet average PT $856; range $737-1030) UTHR upgraded to buy from neutral at BTIG (Julian Harrison), target is $728 or approx. 34% upside. (FactSet average PT $638; range $321-725) LQDA downgraded to neutral from buy at BTIG (Julian Harrison) LQDA downgraded to outperform from strong buy at Raymond James (Ryan Deschner), target cut to $53 from $106 or approx. 75% upside. (FactSet average PT $84; range $40-130) ELVN initiated overweight at JPMorgan (Pryanka Grover), target is $75 or approx. 64% upside. (FactSet average PT $74; range $65-82) IMNM initiated hold at Stifel (Dara Azar), target is $24 or approx. 12% upside. KURA initiated overweight at JPMorgan (Hardik Parikh), target is $30 or approx. 180% upside. (FactSet average PT $32; range $15-76) SYRE initiated overweight at JPMorgan (Hardik Parikh), target is $110 or approx. 24% upside. (FactSet average PT $121; range $110-130) WVE initiated buy at Ladenburg Thalmann, target is $10 or approx. 170% upside. (FactSet average PT $19; range $10-42) WHWK initiated buy at Stifel (Dara Azar), target is $9 or approx. 139% upside. Services & Hospitals Corporate: MCK announced it has extended its pharma distribution agreement with CVS Health (CVS) through June 2032, and reaffirmed FY27 adj EPS guidance bracketing consensus, plus its long-term growth rate of 13-16%. Managed Care Corporate: Medicare Advantage providers issued press releases announcing their plan offerings for CY2027. Open Enrollment period begins 15-Oct and runs through 7-Dec. (ALHC, CLOV, CNC, ELV, HUM, UNH) Investors remain focused on the upcoming Stars announcements, expected in approximately one week (8-Oct). On Deck: Conferences (cont.): EASD 2026 (Sep 28 - Oct 2) (cont.): WMS Congress 2026 (Sep 29 - Oct 3) (cont.): ISSjD 2026 (Sep 29 - Oct 2) (cont.):) EADV Congress 2026 (Sep 30 - Oct 3) UBS Virtual Oncology Day (Oct 1) Peek Ahead to next week (Oct 5-11) Tue 6-Oct: Investor Day (OABI) Wed 7-Oct: Investor Day (NEOG) Thu 8-Oct: CMS release of 2027 Star Ratings for Medicare Advantage (CVS, HUM, UNH, CNC, MOH) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 0126Z0.KS, ABVX, AGMB, ALHC, AZN.LN, CLOV, CNC, CVS, ELV, ELVN, FHTX, GLUE, HUM, IMNM, KURA, LQDA, MCK, MOH, MRNA, NEOG, NOVN.SW, OABI, REGN, SYRE, TEVA, UNH, UTHR, WHWK, WVE...(more)	show story hide story
30-Sep-2026 17:19	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to lower overall on Wednesday. Decliners beat advancers by more than 7:1 on the XLV, around peak level of negative breadth. Healthcare (1.39%) vs S&P 500 (0.25%). Major health groups ended widely mixed for the session, with only Biotech and MedTech finding and holding positive territory. Decliners saw even more choppy price action. Pharma, Services and Managed Care all down more than (1%) on the averages. CI (1.3%) in choppy trading after Investor Day. XBI +0.55% today's leading advancer, with the TL1A class getting a boost from Merck's success in hidradentis supportiva (HS). Headwind however from MRNA (5.4%) recipient of a new sell rating at Citi, placing the stock worst on the XLV. VEEV +2.5% quietly topped short list of XLV gainers. The software name nearly found green territory for the month of September (0.08%). Overall sector news was relatively quiet on the final session of the month and quarter. Healthcare sector finished (1.03%) for the month of September, +6.03% for Q3, and +8.75% YTD. Pennsylvania reported the fifth measles-related death of CY2026, in the nation-leading outbreak. Moderna downgraded to sell at Citi, citing unjustifiable valuation amid the runup for its oncology opportunity. Small-cap biotech Connect Biopharma announced midstage trial results in adults with COPD. Overnight, Eli Lilly presented detailed results for GGG agonist in obesity with diabetes at EASD. High-dose retatrutide demonstrated impressive results in weight loss and A1C reductions. Yesterday, Healthcare were mostly lower and generally inline with the tape. Newsflow light, with interest rate expectations entering the narrative in afternoon trading. Huntington's data update from uniQure remained a headwind to the XBI. AstraZeneca's $2B investment in Summit Therapeutics reignited interest in bispecifics. Managed Care focus turns to Stars update, expected by 8-Oct. Macro Stocks faded into the close, finishing near session lows despite Mag 7 outperformance. Breadth negative again amid continued debate about how the divergence between weak breadth and index-level resilience gets resolved. Rates still a big area of focus with Treasuries failing to sustain earlier gains following a cooler core PCE print (and another move lower in October Fed tightening odds) and long end yields seeing further upward pressure. Rates seemingly back to trading with oil, where dampened diplomatic traction appears to be overshadowing better flow dynamics. Pretty quiet overall heading into month- and quarter-end and ahead of MU earnings after the close, ISM manufacturing on Thursday and NFP on Friday. Notable Gainers +16.8% MNKD (MannKind): court ruling against LQDA; best performer on XBI +16.7% CTNM (Contineum Therapeutics): follow-through, shares were (10%) yesterday +12.5% UTHR (United Therapeutics): court ruling against LQDA +10.9% CNTB (Connect Biopharma Holdings): trial results in COPD +10.5% CAPR (Capricor Therapeutics): trial results in DMD presented at WMS; B Riley reiterates buy rating +6.9% IBRX (ImmunityBio): shares +377% YTD +5.9% SGMT (Sagimet Biosciences): trial results in acne vulgaris at EADV +5.2% ACHV (Achieve Life Sciences): initiation +5.1% SYRE (Spyre Therapeutics): read-across from MRK TL1A; shares +172% YTD +4.3% STTK (Shattuck Labs): read-across from MRK TL1A; shares +87% YTD +3.8% TWST (Twist Bioscience): shares were +4% yesterday +3.8% HIMS (Hims & Hers Health): shares (8%) YTD +3.2% SMMT (Summit Therapeutics): follow-through +2.8% CELC (Celcuity): launches Revtorpyk +2.6% GRAL (GRAIL, Inc.): follow-through, shares +64% YTD +2.5% VEEV (Veeva Systems): on average volume; best performer on XLV Notable Decliners -57.2% LQDA (Liquidia): court ruling against UTHR -35.0% RFL (Rafael Holdings): small-cap biotech; trial results in NPC -13.2% QTTB (Q32 Bio): poster presentation at EADV -5.5% OCGN (Ocugen): worst performer on XBI -5.5% CMPX (Compass Therapeutics): second-worst on XBI; follow-through, shares (56%) in September -5.4% MRNA (Moderna): downgraded at Citi; worst performer on XLV -2.9% AVAH (Aveanna Healthcare Holdings): on unusual volume -2.7% MRK (Merck): presented TL1A in HS at EADV -2.5% ZBH (Zimmer Biomet Holdings): shares (11%) in September and (1%) YTD -2.4% COR (Cencora): on average volume; sympathy to CI / defended at Leerink -2.4% VNDA (Vanda Pharmaceuticals): trial results in DSWPD -2.0% EW (Edwards Lifesciences): on strong volume; sell-side previews of PROGRESS Cigna shares volatile around Investor Day meeting; also Cencora in reaction CI reaffirmed FY26 guidance in press release ahead of today's Investor Day meeting (begins at 8:30ET). Company also provides 2026-30 financial targets, including 10-14% adj EPS CAGR, and ~$50B in cumulative CFO. Targets also included one for specialty distribution, and Cigna introduced a new "wholesale distribution channel", which led to some early volatility for shares of COR. Eli Lilly data for GGG agonist continues to impress, shares flat however LLY announced detailed results from its phase 3 TRIUMPH-2 study of the triple G agonist (GGG) retatrutide at EASD. Results were simultaneously published in The Lancet. At the high dose 12mg, participants lost 20.8% (or 16.8% pbo adj) at 80 weeks. Participants with BMI >35 lost 23.4% or on average 60 pounds. At the end of the study, nearly 60% of those on high-dose no longer met the BMI criteria for obesity. TL1A stocks trading higher in apparent reaction to Merck's HS data at EADV Mid-morning trading update: STTK +9.0%, SYRE +6.6%, MRK (1.5%) While Spyre was not active at EADV, the move appears to be a reaction to Merck's presentation at EADV for TL1A mAb tulisokibart for hidradentis supportiva (HS). Wells Fargo (overweight MRK) sees HS an underappreciated opportunity for Merck and the TL1A class of drugs. Cantor Fitzgerald (overweight STTK) highlights read-across for Shattuck Labs. StreetAccount notes that Spyre's drug pipeline is currently focused on TL1A for IBD and HS. Shattuck's DR3 antibodies (receptor for TL1A) are entering the clinic for both IBD and HS. Liquidia resumes trading at $35/shr or (51%) on the session Afternoon trading update: LQDA (51.0%), UTHR +13.1%, MNKD +12.6% Shares of Liquidia were halted after today's court ruling which found the defendant had infringed upon United Therapeutics '327 patent. Liquidia CEO issued a statement in disagreement with the court, and that the company plans to pursue all appellate options. FDA approves Camzyos sNDA for adolescents with symptomatic obstructive HCM Camzyos (BMY) is the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. FDA press release Competitor: CYTK Myqorzo Trial results in SMID-cap biotech VNDA announced topline results from its pivotal Phase III study of HETLIOZ in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Study met its primary endpoint. Company plans to file sNDA for the indication. CNTB announced topline results from its phase 2 study evaluating IL-4Ra monoclonal antibody rademikibart (2096.HK) as an add-on treatment for acute exacerbations in adults with COPD. Treatment significantly reduced the rate of treatment failure through one month by 81% (p=0.0122), and significantly reduced the rate of new exacerbations by 85% over the same. Company plans to engage FDA on phase 3 alignment. Notable research in Healthcare today Biotech: MRNA downgraded to sell from neutral at Citi (Geoff Meacham), target increased however to $80 from $60 or approx. 61% downside. (FactSet average PT $115; range $40-170) ACHV initiated buy at Stifel (James Condulis), target is $18 or approx. 134% upside. JAZZ initiated buy at Citi (Geoff Meacham), target is $325 or approx. 40% upside. NUVB initiated buy at Citi (Geoff Meacham), target is $12 or approx. 114% upside. TRAX initiated buy at Canaccord Genuity (Edward Nash), target is $50 or approx. 39% upside. Wells Fargo transferring coverage of KNSA, STRO, and ZNTL to Yanan Zhu, XNCR to Derek Archila. Estimates, targets and ratings maintained. Dropping coverage of another ten (10) SMID-cap biotech stocks. MedTech: UBS analyst Kevin Caliendo resumes coverage of the CRO space. Top picks are CRL and IQV with buy ratings. Neutral ratings on FTRE, CERT, ICLR, MEDP Wells Fargo dropping coverage of nineteen (19) large-cap Diagnostics and Life Sciences Tools, citing analyst change. (A, BLLN, GH, NTRA, WAT, others) Jefferies analyst Tycho Peterson publishes research on AI-driven drug discovery, which the firm believes will equate to more wet-lab spending not less. Tools stocks a beneficiary. Highlights RVTY from the AI angle. Post-close news Regulatory: CMS finalizes GLOBE drug pricing model for Medicare Part B. CMS-5545-F (585pp) Press release Excerpt: GLOBE excludes biosimilars and their reference biologicals once a biosimilar enters the market in the United States. The model will also exclude orphan-only drugs, plasma-derived products, and certain cell and gene therapies, a change from the proposed rule made in response to public comments. Trial results: GLUE schedules investor call for tomorrow morning, 8:00ET, to discuss results from phase 1 GFORCE-1 study of MRT-8102 in ASCVD. Shares trading +8.4% in the after-hours Research: Stifel analyst Dara Azar publishes deep dive on ADCs - and initiates two small-cap biotech names. IMNM initiated hold at Stifel (Dara Azar), target is $24 or approx. 12% upside. Shares trading (1.3%) in the after-hours WHWK initiated buy at Stifel (Dara Azar), target is $9 or approx. 139% upside. Shares trading +2.4% in the after-hours On Deck: Conferences (cont.): EASD 2026 (Sep 28 - Oct 2) (cont.): WMS Congress 2026 (Sep 29 - Oct 3) (cont.): ISSjD 2026 (Sep 29 - Oct 2) (cont.): EADV Congress 2026 (Sep 30 - Oct 3) UBS Virtual Oncology Day (Oct 1) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 2096.HK, A, ACHV, AVAH, BLLN, BMY, CAPR, CELC, CERT, CI, CMPX, CNTB, COR, CRL, CTNM, CYTK, EW, FTRE, GH, GLUE, GRAL, HIMS, IBRX, ICLR, IMNM, IQV, JAZZ, KNSA, LLY, LQDA, MEDP, MNKD, MRK, MRNA, NTRA, NUVB, OCGN, QTTB, RFL, RVTY, SGMT, SMMT, STRO, STTK, SYRE, TRAX, TWST, UTHR, VEEV, VNDA, WAT, WHWK, XNCR, ZBH, ZNTL...(more)	show story hide story
30-Sep-2026 16:46	Follow-up: CMS finalizes GLOBE drug pricing model for Medicare Part B CMS press release link added below. Excerpt: GLOBE excludes biosimilars and their reference biologicals once a biosimilar enters the market in the United States. The model will also exclude orphan-only drugs, plasma-derived products, and certain cell and gene therapies, a change from the proposed rule made in response to public comments. See Related StreetAccount comments: 9/30/2026 4:23:28 PM - CMS finalizes GLOBE drug pricing model for Medicare Part B Related: ABBV, AMGN, BMY, GILD, GSK, JNJ, MRK, NVS, REGN, ROP.SW, SNY, +BOEHRINGER...(more) Reference Link	show story hide story
30-Sep-2026 16:23	CMS finalizes GLOBE drug pricing model for Medicare Part B This final rule implements the Global Benchmark for Efficient Drug Pricing Model (GLOBE Model), a new mandatory Medicare payment model under section 1115A of the Social Security Act. The GLOBE Model will test whether a payment model that uses an alternative method for calculating Medicare Part B drug inflation rebate amounts for certain separately payable Medicare Part B drugs and biological products reduces costs for Original Medicare (OM) beneficiaries and the Medicare program while preserving quality of care. See Related StreetAccount comments: 12/19/2025 4:58:27 PM - CMS announces GLOBE and GUARD pricing models for Medicare Part B and Part D Related: ABBV, AMGN, BMY, GILD, GSK, JNJ, MRK, NVS, REGN, ROP.SW, SNY, +BOEHRINGER...(more) Reference Link: CMS-5545-F (585pp)	show story hide story
30-Sep-2026 13:49	LQDA Liquidia resumes trading at $35/shr or (51%) on the session ($36.52 -$34.17) Trading update: LQDA (51.0%), UTHR +13.1%, MNKD +12.6% See Related StreetAccount comments: 9/30/2026 1:33:59 PM - Liquidia will resume trading at 13:40 ET Related: MNKD, UTHR	show story hide story
30-Sep-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.24%) vs the S&P 500 +0.58%. Major health groups are mixed for the session, with Biotech and MedTech finding positive territory after the red open. Declines are moderating too, including Managed Care with CI (2%) paring early weakness amid today's Investor Day. XBI +0.82% leading advancer, with TL1A class getting a boost from Merck's success in hidradentis supportiva (HS). Headwind however from MRNA (6%), a new sell rating at Citi placing the stock worst on the XLV and the XBI. VEEV +3% quietly leading gainer on the XLV; the software name finding green territory for the month of September. Overall sector news relatively quiet on the final session of the month and quarter. Healthcare tracking flattish MTD September and ~7% gain Q3 QTD. Gainers +30.0% CNTB (Connect Biopharma Holdings): trial results in COPD +14.0% CTNM (Contineum Therapeutics): follow-through, shares were (10%) yesterday +12.5% CAPR (Capricor Therapeutics): trial results in DMD presented at WMS; B Riley reiterates buy rating +12.2% IBRX (ImmunityBio): shares +364% YTD +10.0% SGMT (Sagimet Biosciences): trial results in acne vulgaris at EADV +9.9% STTK (Shattuck Labs): read-across from MRK TL1A +6.6% HIMS (Hims & Hers Health): shares (6%) YTD +6.6% SYRE (Spyre Therapeutics): read-across from MRK TL1A; shares +175% YTD +4.5% QURE (uniQure NV): shares were (37%) yesterday +4.0% ACHV (Achieve Life Sciences): initiation +3.5% VEEV (Veeva Systems): on light volume; best performer on XLV +1.7% BMY (Bristol Myers Squibb): bounce, shares were (2%) yesterday +1.6% CELC (Celcuity): launches Revtorpyk Decliners -36.9% RFL (Rafael Holdings): small-cap biotech; trial results in NPC -6.2% MRNA (Moderna): downgraded at Citi; worst performer on XLV and XBI -3.2% AVAH (Aveanna Healthcare Holdings): on strong volume -2.3% CI (Cigna Group): reiterates FY26 guidance; Investor Day meeting ongoing -1.2% COR (Cencora): on average volume; sympathy to CI / defended at Leerink -1.2% EW (Edwards Lifesciences): on strong volume; sell-side previews of PROGRESS -1.1% UNH (UnitedHealth Group): on average volume	show story hide story
30-Sep-2026 10:43	TL1A stocks trading higher in apparent reaction to Merck's HS data at EADV Mid-morning trading update: STTK +9.0%, SYRE +6.6%, MRK (1.5%) While Spyre was not active at EADV, the move appears to be a reaction to Merck's presentation at EADV for TL1A mAb tulisokibart for hidradentis supportiva (HS). Wells Fargo (overweight MRK) sees HS an underappreciated opportunity for Merck and the TL1A class of drugs. Cantor Fitzgerald (overweight STTK) highlights read-across for Shattuck Labs. StreetAccount notes that Spyre's drug pipeline is currently focused on TL1A for IBD and HS. Shattuck's DR3 antibodies (receptor for TL1A) are entering the clinic for both IBD and HS. See Related StreetAccount comments: 9/30/2026 8:17:16 AM - Follow-up: Merck's Tulisokibart met primary and Key secondary endpoints in Phase 2B study in patients with moderate to severe Hidradenitis Suppurativa (HS) Related: MRK, STTK, SYRE	show story hide story
30-Sep-2026 08:21	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Moderna downgraded to sell at Citi, citing unjustifiable valuation amid the runup for its oncology opportunity. Share of MRNA (7%) in the pre-market. Small-cap biotech Connect Biopharma announced midstage trial results in adults with COPD. Shares are +86% in the pre-market. Overnight, Eli Lilly presented detailed results for GGG agonist in obesity with diabetes at EASD. High-dose retatrutide demonstrated impressive results in weight loss and A1C reductions. Shares of LLY trading little changed in the pre-market. Yesterday, Healthcare were mostly lower and generally inline with the tape. Newsflow light, with interest rate expectations entering the narrative in afternoon trading. Huntington's data update from uniQure remained a headwind to the XBI. AstraZeneca's $2B investment in Summit Therapeutics reignited interest in bispecifics. Managed Care focus turns to Stars update, expected by 8-Oct. Macro S&P futures are little changed on Wednesday morning. Quiet heading into month-and quarter-end and some high profile earnings (MU after the close) and economic data (PCE inflation today, ISM manufacturing on Thursday and NFP on Friday) over the next few days. Rates continue to get outsized attention with recent focus on comments from Fed's Williams that only one more rate hike may be needed this year, headwinds from corporate supply, breakdown in correlation with oil, and stretched short positioning. When it comes to oil, latest reports have flagged dampened diplomacy traction, a continued pickup in oil flows and still very tight product markets. In terms of AI, focus has been on more agentic offerings on the heels of the Muse momentum (and more competition for enterprise software), cheaper frontier models and a still favorable capex and earnings backdrop. Pre-market trading update Trading higher +85.5% CNTB trial results in COPD; call at 800ET +14.8% CAPR trial results in DMD presented at WMS +10.9% SGMT trial results in acne vulgaris at EADV +8.1% QTTB poster presentation at EADV +4.3% NUVB initiation +4.0% VNDA trial results in DSWPD +3.6% ACHV initiation (low volume) +0.9% CTNM follow-through (low volume) +0.9% BMY follow-through +0.7% JAZZ initiation Trading lower -30.5% RFL small-cap biotech; trial results in NPC; call at 830ET -6.8% MRNA downgraded at Citi -6.0% AVAH on 82K shares Pharma Trial results: LLY announced detailed results from its phase 3 TRIUMPH-2 study of the triple G agonist (GGG) retatrutide at EASD. Results were simultaneously published in The Lancet. At the high dose 12mg, participants lost 20.8% (or 16.8% pbo adj) at 80 weeks. Participants with BMI >35 lost 23.4% or on average 60 pounds. At the end of the study, nearly 60% of those on high-dose no longer met the BMI criteria for obesity. Regulatory: ROP.SW announced that the NDA in RMS and PPMS for BTK inhibitor fenebrutinib has been accepted for priority review at FDA. Biotech Trial results: VNDA announced topline results from its pivotal Phase III study of HETLIOZ in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Study met its primary endpoint. Company plans to file sNDA for the indication. CNTB announced topline results from its phase 2 study evaluating IL-4Ra monoclonal antibody rademikibart (2096.HK) as an add-on treatment for acute exacerbations in adults with COPD. Treatment significantly reduced the rate of treatment failure through one month by 81% (p=0.0122), and significantly reduced the rate of new exacerbations by 85% over the same. Company plans to engage FDA on phase 3 alignment. Conf. call at 8:00ET Corporate: MRNA announced the rehiring of Juan Andres, to the newly created role of COO, effective 5-Oct-2026. Company also announced that Jerh Collins, who had replaced Andres in 2022 as CTO, will retire from the company. Research: MRNA downgraded to sell from neutral at Citi (Geoff Meacham), target increased however to $80 from $60 or approx. 61% downside. (FactSet average PT $115; range $40-170) ACHV initiated buy at Stifel (James Condulis), target is $18 or approx. 134% upside. JAZZ initiated buy at Citi (Geoff Meacham), target is $325 or approx. 40% upside. NUVB initiated buy at Citi (Geoff Meacham), target is $12 or approx. 114% upside. TRAX initiated buy at Canaccord Genuity (Edward Nash), target is $50 or approx. 39% upside. Wells Fargo transferring coverage of KNSA, STRO, and ZNTL to Yanan Zhu, XNCR to Derek Archila. Estimates, targets and ratings maintained. Dropping coverage of another ten (10) SMID-cap biotech stocks. Life Science & MedTech Research: UBS analyst Kevin Caliendo resumes coverage of the CRO space. Top picks are CRL and IQV with buy ratings. Neutral ratings on FTRE, CERT, ICLR, MEDP Wells Fargo dropping coverage of nineteen (19) large-cap Diagnostics and Life Sciences Tools, citing analyst change. (A, BLLN, GH, NTRA, WAT, others) Managed Care Corporate: CI reaffirms FY26 guidance in press release ahead of today's Investor Day meeting (begins at 8:30ET). Company also provides 2026-30 financial targets, including 10-14% adj EPS CAGR, and ~$50B in cumulative CFO. On Deck: Conference (cont.): EASD 2026 (Sep 28 - Oct 2) (cont.): WMS Congress 2026 (Sep 29 - Oct 3) (cont.): ISSjD 2026 (Sep 29 - Oct 2) EADV Congress 2026 (Sep 30 - Oct 3) on Thu 1-Oct: UBS Virtual Oncology Day (Oct 1) Corporate CI Investor Day (8:30ET) LLY to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026 Regulatory on Wed 30-Sep: BMY FDA PDUFA for Camzyos sNDA for adolescents with symptomatic obstructive HCM This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 2096.HK, A, ACHV, AVAH, BLLN, BMY, CAPR, CERT, CI, CNTB, CRL, CTNM, FTRE, GH, ICLR, IQV, JAZZ, KNSA, LLY, MEDP, MRNA, NTRA, NUVB, QTTB, RFL, ROP.SW, SGMT, STRO, TRAX, VNDA, WAT, XNCR, ZNTL...(more)	show story hide story
29-Sep-2026 16:52	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly lower on Tuesday. Decliners beat advancers by more than 2:1 on the XLV, with breadth markedly improved by the close. Healthcare (0.32%) vs S&P 500 (0.17%). Most major health groups ended red for the session, although declines moderated in the afternoon session, and the XBI +0.13% edged out small gain overall, despite the ETF's headwind from QURE (37.3%) on today's updated clinical data in Huntington's. No real change to the narrative, although some noted a shift in rate hike expectations. MRNA +3.1% and MDT (2.7%) bracketed the XLV, but in general the moves were more modest. IOVA +31.5% was the other end of the spectrum for the XBI, with an upgrade of guidance for the Amtagvi sales outlook. Managed Care traded lightly mixed to inline after CMS last night published its landscape file for Medicare Advantage ahead of OE 2027. Investors are peering more than one week ahead for Stars ratings, expected by 8-Oct. Back to biopharma, SMMT +5.9% traded with a boost of confidence, and of the coffers, as AstraZeneca made a $2B investment in its bispecific challenger to Keytruda. Yesterday, Healthcare equities were mixed yet outperformed the wider tape. Biggest story was in the wet AMD treatment space where SMID-cap biotech Kodiak Sciences delivered a challenger to Regeneron's Eylea, pressuring the large-cap and other hopefuls in the field. Macro No big directional influences in play today. Still a lot of focus on bond yield backup, though several moving pieces there as well. Long end saw further upward pressure today while short end found some reprieve. Some focus on comments from Fed's Williams about no need for urgency to act on rates as it waits for more data. Consumer confidence and JOLTS job openings data also came in softer. October tightening odds fell to ~50%. Oil weaker despite anything particularly incremental on the diplomacy front (much quieter day of Middle East headlines). AI trade largely outperformed with semis (particularly semicap equipment) the standouts. Busy day of AI headlines with initial focus on report of Anthropic IPO details (though nothing really stood out) and OpenAI decision to scrap planned October release of GPT-6.1 Astra, citing deception and control issues. OpenAI stayed in the headlines as the day progressed with reports ARR nearing $70B, seeking $1.4T valuation in latest funding round, and DevDay updates including Dots agentic AI assistant (which seemed to underwhelm and provide renewed support for META). Notable Gainers +31.5% IOVA (Iovance Biotherapeutics): raises FY26 revenue guidance for AMTAGVI; best performer on XBI +23.0% NAUT (Nautilus Biotechnology): initiation +13.8% ALDX (Aldeyra Therapeutics): regulatory update on reproxalap +7.5% STAA (STAAR Surgical): upgraded at Stifel +6.5% ABCL (AbCellera Biologics): initiation +5.9% SMMT (Summit Therapeutics): $2B investment by AstraZeneca +3.6% TWST (Twist Bioscience): Leerink comments on Roche I-Day readthrough +3.1% MRNA (Moderna): on light volume; best performer on XLV +3.0% HNGE (Hinge Health, Inc.): reinstated at BofA +3.0% GRAL (GRAIL, Inc.): on avg volume; shares +69% since FDA briefing documents / advisory committee Notable Decliners -37.3% QURE (uniQure NV): updated data from phase 1/2 studies; worst performer on XBI -31.0% BYSI (BeyondSpring): divests China portion of plinabulin program -23.1% CLPT (Clearpoint Neuro): sympathy to QURE -11.8% WGS (GeneDx Holdings): on above average volume -10.5% IVVD (Invivyd): trial results in COVID-19 -9.7% CTNM (Contineum Therapeutics): sympathy to BMY (LPA1) -8.1% IMMX (Immix Biopharma): updated interim data; secondary offering -7.2% NEOG (Neogen): FDA warning letter following product quality defect -4.0% AXSM (Axsome Therapeutics): on above average volume -3.0% FMS (Fresenius Medical Care): downgraded at Berenberg -2.7% MDT (Medtronic): on 2X avg volume; worst performer on the XLV -2.4% DGX (Quest Diagnostics): on above avg volume; second-worst on XLV -1.6% JNJ (Johnson & Johnson): on light volume -1.6% BMY (Bristol Myers Squibb): Wells Fargo comments on safety signals in LPA1 program Trial results in SMID-cap biotech QURE announced four-year data from its ongoing phase 1/2 studies of AMT-130 for Huntington's Disease, with data cutoff 30-Jun. For the primary endpoint at 48 months, cUHDRS showed a 44% slowing of disease progression compared to the updated external control and did not reach statistical significance (p=0.144). Three-year data remain robust, cUHDRS showing 80% slowing of disease progression. (CLPT) Slide deck here IMMX announced an interim update to NEXICART-2 study evaluating NXC-201 in r/r AL Amyloidosis, including 89% CR rate (40/45). Company also announced an equity raise of $125M on the update. Summit Therapeutics fills the coffers in deal with AstraZeneca SMMT AstraZeneca (AZN.LN) announced an agreement to invest $2B in newly issued equity in Summit Therapeutics to accelerate development of bispecific antibody ivonescimab in combination with ADCs across tumor types. The agreement also includes a clinical collaboration to evaluate AstraZeneca's CLDN18.2-targeting ADC Sone-Ve in combo with ivonescimab. Each company retains rights to their medicine. Novo licenses oral, dual agonist for obesity from Jiangsu Hengrui Pharma NOVO.B.DC (NVO) has in-licensed global rights (ex-China) for an oral GLP1/GIP dual agonist from Jiangsu Hengrui Pharma (600276.CH). Novo paying $300M upfront and total consideration of up to $2.6B for rights to HRS-1596. StreetAccount notes that Kailera Therapeutics (KLRA) is developing a separate portfolio of metabolic drug candidates originated by Jiangsu Hengrui Pharma. Bristol Myers Squibb trading lower; Wells Fargo comments on liver safety disclosures with LPA1 BMY traded sharply lower and finished down (1.6%) late on Tuesday afternoon. Wells Fargo analyst Mohit Bansal writes that they have unearthed new liver safety disclosures in the phase 3 trials of admilparant. Firm believes it remains too soon to determine if the signals are commercially limiting, or more manageable. StreetAccount notes that Contineum Therapeutics (CTNM) also closed sharply lower, down (9.7%) on the session, the company is developing a LPA1 receptor antagonist called PIPE-791. Notable research in Healthcare today Pharma: RDY upgraded to buy from sell at Citi (Vivek Agrawal), notes optimism around North American recovery. Target increased to INR1450 from INR1040 or approx. 16% upside. (FactSet average PT INR1262; range INR1039-1740) Biotech: RZLT upgraded to buy from hold at Craig-Hallum Capital (Albert Lowe), citing optimism around topline data from ersodetug's phase 3 trial. Target is $7 or approx. 67% upside. (FactSet average PT $9; range $6-11) ABCL initiated overweight at JPMorgan, target is $17 or approx. 22% upside. (FactSet average PT $17; range $9-30) NAUT initiated buy at Roth Capital (Max Masucci), target is $3.50 or approx. 215% upside. QTTB initiated buy at Clear Street (Kaveri Pohlman), target is $38 or approx. 312% upside. MedTech: STAA upgraded to buy from hold at Stifel (Tom Stephan), citing factors including valuation. Target increased to $31 from $28 or approx. 49% upside. (FactSet average PT $28; range $19-37) HNGE reinstated buy at BofA (Tomer Zilberman), target is $110 or approx. 19% upside. (FactSet average PT $108; range $90-140) ADPT initiated buy at Goldman Sachs (Evie Koslosky), target is $35 or approx. 23% upside. (FactSet average PT $26; range $21-34) APYX initiated buy at Maxim Group (Anthony Vendetti), target is $6 or approx. 140% upside. (FactSet average PT $7; range $6-8) BFLY initiated outperform at Evercore ISI (Daniel Markowitz), target is $15 or approx. 64% upside. (FactSet average PT $10; range $10-11) RPID initiated buy at Roth Capital (Max Masucci), target is $3 or approx. 173% upside. (FactSet average PT $6; range $3-8) Services: FME.GR (FMS) downgraded to hold from buy at Berenberg in a transfer of coverage to analyst Harry Gillis. Target cut to €42 from €60 or approx. 4% upside. (FactSet average PT €41; range €30-64) Post-close news Research: ACHV initiated buy at Stifel (James Condulis), target is $18 or approx. 134% upside. Wells Fargo transferring coverage of KNSA, STRO, and ZNTL to Yanan Zhu, XNCR to Derek Archila. Estimates, targets and ratings maintained. Dropping coverage of another ten (10) SMID-cap biotech stocks. Wells Fargo dropping coverage of nineteen (19) large-cap Diagnostics and Life Sciences Tools, citing analyst change. (A, BLLN, GH, NTRA, WAT, others) On Deck: Conferences (cont.): EASD 2026 (Sep 28 - Oct 2) (cont.): WMS Congress 2026 (Sep 29 - Oct 3) (cont.): ISSjD 2026 (Sep 29 - Oct 2) EADV Congress 2026 (Sep 30 - Oct 3) on Thu 1-Oct: UBS Virtual Oncology Day (Oct 1) Corporate DYN to present phase 1/2 data from the ACHIEVE trial in DM1 at WMS tonight (23:30ET) CI Investor Day (8:30ET) LLY to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026 Regulatory BMY FDA PDUFA tomorrow for Camzyos sNDA for adolescents with symptomatic obstructive HCM StreetAccount Healthcare Reads Lundbeck has expressed interest in buying Xeris Biopharma (29-Sep) Bloomberg Eric Cantor, former House leader, named PhRMA president and CEO (29-Sep) Axios Oura delays $2.2B IPO, citing uncertainty in market (29-Sep) San Francisco Business Times US CDC confirms two measles-related deaths in 2026, does not disclose state (29-Sep) Reuters What if ADHD Isn't About Attention at All? (29-Sep) NY Times She's spent two decades talking to parents who don't vaccinate their children. Here's what she's learned (29-Sep) STAT News US House Democratic Women's Caucus press health secretary on estrogen patch shortages (29-Sep) Reuters This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 600276.CH, A, ABCL, ACHV, ADPT, ALDX, APYX, AXSM, AZN.LN, BFLY, BLLN, BMY, BYSI, CI, CLPT, CTNM, DGX, DYN, FME.GR, FMS, GH, GRAL, HLUN.B.DC, HNGE, IMMX, IOVA, IVVD, JNJ, KLRA, KNSA, LLY, MDT, MRNA, NAUT, NEOG, NOVO.B.DC, NTRA, QTTB, QURE, RDY, RPID, RZLT, SMMT, STAA, STRO, TWST, WAT, WGS, XERS, XNCR, ZNTL, +OURA...(more)	show story hide story
29-Sep-2026 16:10	BMY Bristol Myers Squibb trading lower; Wells Fargo comments on liver safety disclosures with LPA1 ($62.69 -$1.19) BMY traded sharply lower and finished down (1.6%) late on Tuesday afternoon. Wells Fargo analyst Mohit Bansal writes that they have unearthed new liver safety disclosures in the phase 3 trials of admilparant. Firm believes it remains too soon to determine if the signals are commercially limiting, or more manageable. StreetAccount notes that Contineum Therapeutics (CTNM) also closed sharply lower, down (9.7%) on the session, the company is developing a LPA1 receptor antagonist called PIPE-791. Related: CTNM	show story hide story
29-Sep-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (1.19%) vs the S&P 500 (0.12%). All major health groups are red on the session, most by more than (1%) on the averages. SYK +1% and JNJ (2%) bracket the XLV movers list. BAX +0.5% the only other advancer on the XLV. XBI (0.93%) - about half of that owed to the drag from QURE (39%) on its latest Huntington's clinical data. IOVA +23% the other end of the spectrum for the XBI, with upgrade of guidance for Amtagvi sales outlook. MCOs trading lower yet inline after CMS published its landscape file for Medicare Advantage ahead of OE 2027. SMMT +6% with a boost of confidence, and of the coffers, as AstraZeneca made a $2B investment in its bispecific challenger to Keytruda. Gainers +23.4% IOVA (Iovance Biotherapeutics): raises FY26 revenue guidance for AMTAGVI; best performer on XBI +19.8% ALDX (Aldeyra Therapeutics): regulatory update on reproxalap +8.0% STAA (STAAR Surgical): upgraded at Stifel +5.7% SMMT (Summit Therapeutics): $2B investment by AstraZeneca +3.2% RDY (Dr. Reddy's Laboratories): upgraded at Citi +2.8% BFLY (Butterfly Network): initiation at Evercore ISI +2.4% ABCL (AbCellera Biologics): initiation +1.4% VCYT (Veracyte): data presented today at ASTRO meeting +1.2% TWST (Twist Bioscience): Leerink comments on Roche I-Day readthrough +0.8% SYK (Stryker): on light volume; best performer on XLV Decliners -38.9% QURE (uniQure NV): updated data from phase 1/2 studies; worst performer on XBI -31.3% BYSI (BeyondSpring): divests China portion of plinabulin program -21.3% CLPT (Clearpoint Neuro): sympathy to QURE -10.6% IMMX (Immix Biopharma): updated interim data; secondary offering -7.9% IVVD (Invivyd): trial results in COVID-19 -3.6% FMS (Fresenius Medical Care): downgraded at Berenberg -3.4% NEOG (Neogen): FDA warning letter following product quality defect -2.9% KOD (Kodiak Sciences): follow-through, shares were +170% yesterday -2.3% JNJ (Johnson & Johnson): on light volume; worst performer on XLV -2.2% INCY (Incyte): on light volume; second-worst on XL	show story hide story
29-Sep-2026 08:29	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight, CMS published its landscape file for Medicare Advantage ahead of OE 2027, and AstraZeneca made a $2B investment in Summit Therapeutics and its bispecific challenger to Keytruda. Shares of SMMT are up +17% in the pre-market. Tuesday morning flush with updates across the biotech group, with uniQure back in the spotlight after updated clinical data for its gene therapy in Huntington's Disease. Shares of QURE trading down (56%) ahead of the investor call; CLPT (24%). SMID-cap Iovance Biotherapeutics with a more upbeat outlook on FY26 sales for Amtagvi. Shares of IOVA are up +10% in the pre-market. Yesterday, Healthcare equities were mixed yet outperformed the wider tape. Biggest story was in the wet AMD treatment space where SMID-cap biotech Kodiak Sciences delivered a challenger to Regeneron's Eylea, pressuring the large-cap and other hopefuls in the field. Macro S&P futures are up +0.2% on Tuesday morning, near pre-market highs and off earlier weakness. Yields pulling back a bit after a notable rise in Monday's session. Recent bond yield backup continues to get a lot of attention in the press though nothing really new on the catalyst front. Focus remains on hotter growth, stickier inflation/persistent supply shocks/hawkish central bank reaction functions, AI capex, and fiscal. Busy day of AI headlines with some reported details on the Anthropic IPO, another new (cheaper) model release from Anthropic, OpenAI model delay due to deception/control issues and a high-profile acquisition by AMD. OpenAI holding its DevDay 2026 today (some expectations for personal AI assistant announcement to counter Muse momentum), while top AI execs meeting at White House today. US-Iran headlines remain mixed. While diplomatic efforts have ramped up, sequencing remains the big sticking point. More headlines about better oil flows from the region, though also thoughts this could trigger an escalation phase from Iran. Pre-market trading update Trading higher +17.1% SMMT $2B investment by AstraZeneca +9.8% IOVA raises FY26 revenue guidance for AMTAGVI +5.7% RZLT upgraded at Craig-Hallum +5.1% STAA upgraded at Stifel +3.0% ABCL initiation +2.6% ALDX regulatory update on reproxalap; call at 800ET +1.6% RDY upgraded at Citi +0.3% IMMX updated interim data; secondary offering; call at 800ET Trading lower -56.3% QURE updated data from phase 1/2 studies; call at 830ET -24.0% CLPT sympathy to QURE -19.7% BYSI divests China portion of plinabulin program; call at 800ET -2.6% KOD follow-through, shares were +170% yesterday -2.2% IVVD trial results in COVID-19; call at 830ET -2.0% FMS downgraded at Berenberg Pharma Regulatory: TEVA announces the FDA approval of Degevma, a biosimilar of Amgen's Xgeva (denosumab). Teva says that FDA approved Ponlimsi, their biosimilar of Amgen's Prolia in March. Teva plans to launch both in the coming months. Research: RDY upgraded to buy from sell at Citi (Vivek Agrawal), notes optimism around North American recovery. Target increased to INR1450 from INR1040 or approx. 16% upside. (FactSet average PT INR1262; range INR1039-1740) Biotech M&A: SMMT AstraZeneca (AZN.LN) announced an agreement to invest $2B in newly issued equity in Summit Therapeutics to accelerate development of bispecific antibody ivonescimab in combination with ADCs across tumor types. The agreement also includes a clinical collaboration to evaluate AstraZeneca's CLDN18.2-targeting ADC Sone-Ve in combo with ivonescimab. Each company retains rights to their medicine. Trial results: QURE announced four-year data from its ongoing phase 1/2 studies of AMT-130 for Huntington's Disease, with data cutoff 30-Jun. For the primary endpoint at 48 months, cUHDRS showed a 44% slowing of disease progression compared to the updated external control and did not reach statistical significance (p=0.144). Three-year data remain robust, cUHDRS showing 80% slowing of disease progression. (CLPT) Conf. call at 8:30ET IMMX announced an interim update to NEXICART-2 study evaluating NXC-201 in r/r AL Amyloidosis, including 89% CR rate (40/45). Company also announced an equity raise of $125M on the update. Conf. call at 8:00ET Research: RZLT upgraded to buy from hold at Craig-Hallum Capital (Albert Lowe), citing optimism around topline data from ersodetug's phase 3 trial. Target is $7 or approx. 67% upside. (FactSet average PT $9; range $6-11) ABCL initiated overweight at JPMorgan, target is $17 or approx. 22% upside. (FactSet average PT $17; range $9-30) NAUT initiated buy at Roth Capital (Max Masucci), target is $3.50 or approx. 215% upside. QTTB initiated buy at Clear Street (Kaveri Pohlman), target is $38 or approx. 312% upside. Life Science & MedTech Research: STAA upgraded to buy from hold at Stifel (Tom Stephan), citing factors including valuation. Target increased to $31 from $28 or approx. 49% upside. (FactSet average PT $28; range $19-37) HNGE reinstated buy at BofA (Tomer Zilberman), target is $110 or approx. 19% upside. (FactSet average PT $108; range $90-140) ADPT initiated buy at Goldman Sachs (Evie Koslosky), target is $35 or approx. 23% upside. (FactSet average PT $26; range $21-34) APYX initiated buy at Maxim Group (Anthony Vendetti), target is $6 or approx. 140% upside. (FactSet average PT $7; range $6-8) BFLY initiated outperform at Evercore ISI (Daniel Markowitz), target is $15 or approx. 64% upside. (FactSet average PT $10; range $10-11) RPID initiated buy at Roth Capital (Max Masucci), target is $3 or approx. 173% upside. (FactSet average PT $6; range $3-8) Services & Hospitals Research: FME.GR (FMS) downgraded to hold from buy at Berenberg in a transfer of coverage to analyst Harry Gillis. Target cut to €42 from €60 or approx. 4% upside. (FactSet average PT €41; range €30-64) Managed Care Regulatory: CMS announces projected Medicare Advantage premiums ahead of Open Enrollment 2027. Press release. On Deck: Conferences (cont.): EASD 2026 (Sep 28 - Oct 2) World Muscle Society (WMS) Congress (Sep 29 - Oct 3) International Symposium on Sjögren's Disease (ISSjD) (Sep 29 - Oct 2) on Wed 30-Sep: EADV Congress 2026 (Sep 30 - Oct 3) on Thu 1-Oct: UBS Virtual Oncology Day (Oct 1) Corporate ALDX to discuss formal dispute resolution request submission for reproxalap (8:00ET) BYSI to discuss strategic transaction with Biolin Investment Ltd for plinabulin (8:00ET) IMMX to discuss interim update of NEXICART-2 study of NXC-201 in AL amyloidosis (8:00ET) IVVD to discuss results from phase 3 LIBERTY trial with VYD2311 for COVID-19 (8:30ET) QURE to discuss updated data from phase 1/2 studies of AMT-130 in HD (8:30ET) DYN to present phase 1/2 data from the ACHIEVE trial in DM1 at WMS on Wed 30-Sep: CI Investor Day (8:30ET); LLY to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026 Regulatory on Wed 30-Sep: BMY FDA PDUFA for Camzyos sNDA for adolescents with symptomatic obstructive HCM Syndicate calendar / IPO pricing: POSTPONED +OURA (Oura Ring) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABCL, ADPT, ALDX, APYX, AZN.LN, BFLY, BMY, BYSI, CI, CLPT, FME.GR, FMS, HNGE, IMMX, IOVA, IVVD, KOD, LLY, NAUT, QTTB, QURE, RDY, RPID, RZLT, SMMT, STAA, TEVA...(more)	show story hide story
28-Sep-2026 16:54	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished lightly mixed yet ahead of the tape on Monday. Advancers beat decliners by 2:1 on the XLV. Healthcare +0.29% vs S&P 500 (0.77%). Most major health groups ended up little changed on their averages, while early laggard Biotech rallied the most to lead gainers; XBI +1.02%. Gains were quite modest everywhere. VTRS +2.5% and REGN (4.5%) bracketed the XLV; the latter pressured by today's readout from a SMID-cap biotech challenger in the wet AMD space once dominated by Eylea; KOD +178.0% on Monday, stretching towards $6B in market cap. Otherwise a fairly quiet weekend and beginning of the week for sector newsflow. Kodiak Sciences plans a broad-based BLA submission this quarter for its Eylea challenger. REGN and OCUL (20.7%) lower in reaction; latter defended on the Street, analysts see room for more players in the space. Last week, Healthcare equities were mild outperformers overall, although that performance was primarily driven by the Diagnostic and Life Science subgroups. Grail Inc climbed +57% following the positive FDA Advisory Committee votes supporting their MCED test Galleri. Macro Equities were weaker in Monday trading with higher yields again in focus; 10Y intraday approached its highest level since 2006 while 30Y earlier hit a fresh post-2004 high. Came amid noisy headlines about possible US-Iran diplomatic progress, with reports Trump could be open to offering sanctions relief in exchange for "concrete progress" on nuclear issues (though he also said US would win the war "very soon"). Note oil moved sharply higher overnight before finishing little changed. Overall AI trade also came pressure. While nothing specific behind the move, aside from still-bubbling headlines about security issues, group has been a big outperformer lately on agentic AI optimism. Among other narrative factors from strategist commentary include weak breadth and elevated dispersion, along with the related resolution debate (catch up vs catch down). Busy week ahead includes OpenAI DevDay on Tuesday, MU earnings on Wednesday, ISM manufacturing on Thursday and NFP on Friday. Notable Gainers +178.0% KOD (Kodiak Sciences): best performer on XBI; trial results in wet AMD; 52-week high +55.2% LFCR (Lifecore Biomedical): acquired by private equity for cash plus CVR +39.4% ARAY (Accuray): microcap; agreement with Samsung unit for CyberKnife system +10.2% ANNX (Annexon): on nearly 2X average daily volume +7.9% ADMA (ADMA Biologics): stock closed lower last 5 days, (14%) last week +6.4% ABVX (Abivax): UEGW abstract released; ADRs were down (13%) last week +5.8% LXRX (Lexicon Pharmaceuticals): initiation +4.8% AMPH (Amphastar Pharma.): shares +11% last week, and up 8 of last 9 weeks +4.5% GRAL (GRAIL, Inc.): 52-week high; shares were +57% last week +4.4% TFX (Teleflex): upgraded at BofA +3.3% TXG (10X Genomics): initiation +2.5% VTRS (Viatris): best performer on XLV; on above avg vol; shares +50% YTD +2.4% ISRG (Intuitive Surgical): on average volume; stock higher 12 of last 14 days Notable Decliners -29.6% ACET (Adicet Bio): trial results in SLE -20.7% OCUL (Ocular Therapeutix): sympathy to KOD; defended at RBC and Needham -7.1% VKTX (Viking Therapeutics): on nearly 2X average daily volume; worst performer on XBI -4.7% COAG (Hemab Therapeutics): on light volume; shares (16%) last week -4.5% REGN (Regeneron): worst performer on XLV; sympathy to KOD -3.4% ALHC (Alignment Healthcare): stock lower 10 of last 12 weeks -2.7% EDIT (Editas Medicine): on below average volume -2.2% PODD (Insulet): on average volume; shares (53%) YTD -1.9% MIRM (Mirum Pharmaceuticals): follow-through; trial results in HDV Regeneron trading lower following Kodiak Sciences readout in wet AMD KOD announced topline results from the pivotal phase 3 DAYBREAK trial evaluating anti-VEGF Zenkuda (tarcocimab tedromer) and bispecific anti-VEGF/anti-IL-6 tabirafusp-ted (KSI-501) in wet AMD. Both treatments met their primary endpoints. BLA submission for Zenkuda planned for Q4 of 2026 in multiple indications. (REGN, OCUL) Quick take: RBC Capital Markets defends Ocular Therapeutix after competitor readout. Firm believes that today's sell-off is overdone, that the current market for wet AMD dominated by duopoly Regeneron and Roche has room for multiple players, and that Ocular's Axpaxli (axitinib) remains well positioned with dosing advantages, and on track to file in Q4 of 2026. Reiterates outperform rating, target is $30. Analyst is Lisa Walter Adicet Bio lower following phase 1 interim results in SLE ACET announced interim safety and efficacy data from the phase 1 study evaluating prula-cel (formerly ADI-001) in patients with SLE with or without LN. Data cutoff is 28-Aug-2026. Merck paying up to $2.13B for preclinical oncology program MRK announced a license agreement with privately-held SciBrunch Therapeutics for the preclinical oral KRAS G12D (ON) inhibitor SPR2015. Merck paying up to $2.13B for worldwide rights to the program, terms include $400M upfront. Merck will take a $0.13 per share charge to Q3 earnings related to this transaction. Separately, Merck and Daiichi Sankyo (4568.JP) announced they have voluntarily withdrawn the pending BLA for I-DXd (ifinatamab deruxtecan) for previously treated ES-SCLC. Follows FDA feedback that the existing data do not support the accelerated approval pathway. A phase 3 trial is underway in lung cancer; as are two phase 3 trials in CRPC and ESCC. Notable research in Healthcare today Pharma: HC Wainwright analyst Mitchell Kapoor publishes deep dive on ADCs. (MRK, PFE, AZN, 4568.JP, SMMT, CBIO, HALO, GENB, ABBV, ROP.SW, GILD, GSK, GMAB, JNJ, BNTX, MRK.GR, SOBI.SS, NOVN.SW, 4502.JP) Biotech: AGEN initiated buy at Rodman & Renshaw (Michael King), target is $19 or approx. 122% upside. DRUG initiated outperform at LifeSci Capital (Francois Brisebois), target is $146 or approx. 182% upside. (FactSet average PT $150; range $91-220) KRSA initiated buy at Guggenheim Securities (Yatin Suneja), target is $70 or approx. 126% upside. LXRX initiated overweight at Cantor Fitzgerald (Steve Seedhouse), target is $8 or approx. 344% upside. (FactSet average PT $4; range $2-6) QTTB initiated buy at Jefferies (Maury Raycroft), target is $29 or approx. 231% upside. (FactSet average PT $42; range $34-59) RVMD initiated buy at Brookline Capital Markets, target is $318 or approx. 55% upside. (FactSet average PT $254; range $179-320) MedTech: TFX upgraded to buy from neutral at BofA (Travis Steed), target increased to $158 from $145 or approx. 29% upside. (FactSet average PT $154; range $138-170) LNSR initiated buy at Lucid Capital Markets (Alex Nowak), target is $11 or approx. 59% upside. TXG initiated buy at Argus Research (John Eade), target is $110 or approx. 28% upside. (FactSet average PT $59; range $40-90) Services: ACHC downgraded to outperform from strong buy at Raymond James (Andrew Cooper), target remains $39 or approx. 39% upside. (FactSet average PT $34; range $17-41) ADUS assumed outperform at Raymond James (Andrew Cooper), target is $137 or approx. 21% upside. AVAH assumed strong buy at Raymond James (Andrew Cooper), target is $15 or approx. 21% upside. CYH assumed underperform at Raymond James (Andrew Cooper) EHC assumed strong buy at Raymond James (Andrew Cooper), target is $150 or approx. 21% upside. HCA assumed market perform at Raymond James (Andrew Cooper) LMRI assumed strong buy at Raymond James (Andrew Cooper), target is $17 or approx. 67% upside. RDNT assumed strong buy at Raymond James (Andrew Cooper), target is $95 or approx. 34% upside. THC assumed outperform at Raymond James (Andrew Cooper), target is $285 or approx. 10% upside. UHS assumed market perform at Raymond James (Andrew Cooper) Post-close news Regulatory: TEVA announces the FDA approval of Degevma, a biosimilar of Amgen's Xgeva (denosumab). Teva says that FDA approved Ponlimsi, their biosimilar of Amgen's Prolia in March. Teva plans to launch both in the coming months. CMS announces projected Medicare Advantage premiums ahead of Open Enrollment 2027. Press release. Research: QTTB initiated buy at Clear Street (Kaveri Pohlman), target is $38 or approx. 312% upside. On Deck: Regulatory EGTX.SS FDA PDUFA today for Emcitate NDA for AHDS on Wed 30-Sep: BMY FDA PDUFA for Camzyos sNDA for adolescents with symptomatic obstructive HCM Conference (cont.): EASD 2026 (Sep 28 - Oct 2) on Tue 29-Sep: World Muscle Society (WMS) Congress (Sep 29 - Oct 3); International Symposium on Sjögren's Disease (ISSjD) (Sep 29 - Oct 2) on Wed 30-Sep: EADV Congress 2026 (Sep 30 - Oct 3) on Thu 1-Oct: UBS Virtual Oncology Day (Oct 1) Corporate DYN to present phase 1/2 data from the ACHIEVE trial in DM1 at WMS on Tuesday on Wed 30-Sep: CI Investor Day (8:30ET); LLY to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026 Syndicate calendar / IPO pricing: Tue 29-Sep (post-close): +OURA Oura Ring - S-1A This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4502.JP, 4568.JP, ABBV, ABVX, ACET, ACHC, ADMA, ADUS, AGEN, ALHC, AMPH, ANNX, ARAY, AVAH, AZN, BMY, BNTX, CBIO, CI, COAG, CYH, DRUG, DYN, EDIT, EGTX.SS, EHC, GENB, GILD, GMAB, GRAL, GSK, HALO, HCA, ISRG, JNJ, KOD, KRSA, LFCR, LLY, LMRI, LNSR, LXRX, MIRM, MRK, MRK.GR, NOVN.SW, OCUL, PFE, PODD, QTTB, RDNT, REGN, ROP.SW, RVMD, SMMT, SOBI.SS, TEVA, TFX, THC, TXG, UHS, VKTX, VTRS...(more)	show story hide story
28-Sep-2026 16:41	CMS expects Medicare Advantage premiums to decline more than 16% y/y CMS expects the programs will remain stable in 2027, while 'weighted average MA premiums' are expected to decline more than 16%. Average premium for stand-alone Part D prescription drug plans is projected to rise by less than $1 per month in 2027 - from $35.09 in 2026 to $36 in 2027. Based on plan projections, enrollment in MA is estimated to be 34 million in 2027. Plan enrollment projections have historically understated actual enrollment, and CMS expects actual 2027 MA enrollment to again be more robust than current plan projections indicate. Medicare Open Enrollment begins 15-Oct-2026, and ends 7-Dec-2026. Related: ALHC, CI, CLOV, CNC, CVS, ELV, HUM, MOH, OSCR, UNH...(more) Reference Link	show story hide story
28-Sep-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.13% vs the S&P 500 (0.91%). All major health groups are little changed on their averages. Services and MCO groups are leading gainers, though gains are modest. Biotech lone decliner with the XBI (0.08%). DVA +2% and REGN (3%) bracket the XLV. Fairly quiet weekend for sector newsflow. Monday morning brings a few biotech readouts, headlined by the wet AMD space. SMID-cap biotech KOD +153% planning broad-based BLA submission this quarter for its Eylea challenger. REGN and OCUL (24%) in reaction. Gainers +152.6% KOD (Kodiak Sciences): trial results in wet AMD; 52-week high; best performer on XBI +56.3% LFCR (Lifecore Biomedical): acquired by private equity for cash plus CVR +41.2% ARAY (Accuray): microcap; agreement with Samsung unit for CyberKnife system +11.4% LXRX (Lexicon Pharmaceuticals): initiation +5.4% ABVX (Abivax): ADRs were down (13%) last week +3.9% AMPH (Amphastar Pharmaceuticals): shares were up +11% last week, and up 8 of last 9 weeks +3.2% TFX (Teleflex): upgraded at BofA +2.1% DVA (DaVita): best performer on XLV; shares +60% YTD +1.9% ISRG (Intuitive Surgical): on average volume; second-best on XLV +0.7% GRAL (GRAIL, Inc.): 52-week high; shares were +57% last week +0.7% THC (Tenet Healthcare): assumed outperform at Raymond James +0.7% UHS (Universal Health Services): assumed MP at Raymond James +0.3% CYH (Community Health Systems): assumed underperform at Raymond James Decliners -24.4% OCUL (Ocular Therapeutix): sympathy to KOD -21.0% ACET (Adicet Bio): trial results in SLE -5.8% EDIT (Editas Medicine): worst performing biotech on XBI -5.0% COAG (Hemab Therapeutics): on avg volume; second-worst on XBI -4.1% MIRM (Mirum Pharmaceuticals): trial results in HDV -3.3% GPCR (Structure Therapeutics): on average volume; shares (50%) YTD -2.9% REGN (Regeneron): worst performer on XLV; sympathy to KOD -2.5% ACHC (Acadia Healthcare): downgraded at Raymond James -2.4% MRNA (Moderna): shares were +29% last week -2.2% PODD (Insulet): on average volume; shares (53%) YTD -0.7% ALHC (Alignment Healthcare): stock lower 10 of last 12 weeks -0.3% TXG (10X Genomics): initiation	show story hide story
28-Sep-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Fairly quiet weekend for sector newsflow. Monday morning brings a few biotech readouts, headlined by the wet AMD space. SMID-cap biotech Kodiak Sciences planning broad-based BLA submission this quarter. Shares of KOD +70% in the pre-market. Last week, Healthcare equities were mild outperformers overall, although that performance was primarily driven by the Diagnostic and Life Science subgroups. Grail Inc climbed +57% following the positive FDA Advisory Committee votes supporting their MCED test Galleri. Macro S&P futures are off (0.4%) on Monday morning. Defensive tone with renewed upward pressure on oil and rates. Trump rejected Iran's seven-day ceasefire proposal and reportedly told aides he expects to resume bombing after midterms, though also told Axios he expects talks this week. Two sides still seem very far apart on sequencing and some of the discussion in the press highlighted Trump's heightened emphasis on extracting nuclear concessions. Oil the go-to excuse for the bond yield backup, though also more discussion about the impact from hotter growth. Flurry of other headlines about higher rates in recent days, including ramp in volatility, potential signaling from curve flattening and competition for stocks. Along with rates, recent strategist commentary has focused on weak breadth, elevated dispersion, index-level resilience and depressed sentiment. Pre-market trading update Trading higher +69.7% KOD trial results in wet AMD; call at 830ET +38.0% ARAY microcap; agreement with Samsung unit for CyberKnife system +5.3% LXRX initiation +1.8% TFX upgraded at BofA Trading lower -2.9% ACET trial results in SLE; call at 800ET -2.7% ATEC on 20K shares -2.4% CYH assumed underperform at Raymond James (low volume) -2.3% MRNA shares were +29% last week -1.5% TXG initiation -1.5% TEM on 156K shares -0.8% THC assumed outperform at Raymond James (low volume) -0.5% ACHC downgraded at Raymond James (low volume) Pharma Regulatory: LLY announced that FDA approved the pediatric label expansion for Olumiant, in patients 12 and older with alopecia areata (AA). MRK and Daiichi Sankyo (4568.JP) announced they have voluntarily withdrawn the pending BLA for I-DXd (ifinatamab deruxtecan) for previously treated ES-SCLC. Follows FDA feedback that the existing data do not support the accelerated approval pathway. A phase 3 trial is underway in lung cancer; as are two phase 3 trials in CRPC and ESCC. License agreement: MRK announced a license agreement with privately-held SciBrunch Therapeutics for the preclinical oral KRAS G12D (ON) inhibitor SPR2015. Merck paying up to $2.13B for worldwide rights to the program, terms include $400M upfront. Merck will take a $0.13 per share charge to Q3 earnings related to this transaction. Biotech Trial results: KOD announced topline results from the pivotal phase 3 DAYBREAK trial evaluating anti-VEGF Zenkuda (tarcocimab tedromer) and bispecific anti-VEGF/anti-IL-6 tabirafusp-ted (KSI-501) in wet AMD. Both treatments met their primary endpoints. BLA submission for Zenkuda planned for Q4 of 2026 in multiple indications. Conf. call at 8:30ET ACET announced interim safety and efficacy data from the phase 1 study evaluating prula-cel (formerly ADI-001) in patients with SLE with or without LN. Data cutoff is 28-Aug-2026. Conf. call at 8:00ET Research: AGEN initiated buy at Rodman & Renshaw (Michael King), target is $19 or approx. 122% upside. DRUG initiated outperform at LifeSci Capital (Francois Brisebois), target is $146 or approx. 182% upside. (FactSet average PT $150; range $91-220) KRSA initiated buy at Guggenheim Securities (Yatin Suneja), target is $70 or approx. 126% upside. LXRX initiated overweight at Cantor Fitzgerald (Steve Seedhouse), target is $8 or approx. 344% upside. (FactSet average PT $4; range $2-6) QTTB initiated buy at Jefferies (Maury Raycroft), target is $29 or approx. 231% upside. (FactSet average PT $42; range $34-59) RVMD initiated buy at Brookline Capital Markets, target is $318 or approx. 55% upside. (FactSet average PT $254; range $179-320) Life Science & MedTech Partnership: DXCM and Novo (NOVO.B.DC) announced a partnership making DexCom the official continuous glucose monitoring partner for Team Novo Nordisk, the professional cycling team. Research: TFX upgraded to buy from neutral at BofA (Travis Steed), target increased to $158 from $145 or approx. 29% upside. (FactSet average PT $154; range $138-170) LNSR initiated buy at Lucid Capital Markets (Alex Nowak), target is $11 or approx. 59% upside. TXG initiated buy at Argus Research (John Eade), target is $110 or approx. 28% upside. (FactSet average PT $59; range $40-90) Services & Hospitals Research: ACHC downgraded to outperform from strong buy at Raymond James (Andrew Cooper), target remains $39 or approx. 39% upside. (FactSet average PT $34; range $17-41) ADUS assumed outperform at Raymond James (Andrew Cooper), target is $137 or approx. 21% upside. AVAH assumed strong buy at Raymond James (Andrew Cooper), target is $15 or approx. 21% upside. CYH assumed underperform at Raymond James (Andrew Cooper) EHC assumed strong buy at Raymond James (Andrew Cooper), target is $150 or approx. 21% upside. HCA assumed market perform at Raymond James (Andrew Cooper) LMRI assumed strong buy at Raymond James (Andrew Cooper), target is $17 or approx. 67% upside. RDNT assumed strong buy at Raymond James (Andrew Cooper), target is $95 or approx. 34% upside. THC assumed outperform at Raymond James (Andrew Cooper), target is $285 or approx. 10% upside. UHS assumed market perform at Raymond James (Andrew Cooper) On Deck: Corporate ACET to discuss interim trial results for prula-cel in patients with SLE 8:00ET KOD to discuss phase 3 results for DAYBREAK study of KSI-501 in wet AMD 8:30ET MIRM to discuss phase 3 results for AZURE-1 study of BJT-778 in HDV 8:30ET ZYME to discuss updated guidance following Theravance Bio transaction 8:30ET CAMP Investor Day (12:00ET) on Tue 29-Sep: DYN to present phase 1/2 data from the ACHIEVE trial in DM1 at WMS on Wed 30-Sep: CI Investor Day (8:30ET); LLY to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026 Regulatory EGTX.SS FDA PDUFA today for Emcitate NDA on Wed 30-Sep: BMY FDA PDUFA for Camzyos sNDA Conference EASD 2026 (Sep 28 - Oct 2) on Tue 29-Sep: World Muscle Society (WMS) Congress (Sep 29 - Oct 3); International Symposium on Sjögren's Disease (ISSjD) (Sep 29 - Oct 2) on Wed 30-Sep: EADV Congress 2026 (Sep 30 - Oct 3) on Thu 1-Oct: UBS Virtual Oncology Day Syndicate calendar / IPO pricing: Tue 29-Sep (post-close): +OURA Oura Ring - S-1A This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4568.JP, ACET, ACHC, ADUS, AGEN, ARAY, ATEC, AVAH, BMY, CI, CYH, DRUG, DXCM, DYN, EGTX.SS, EHC, HCA, KOD, KRSA, LLY, LMRI, LNSR, LXRX, MIRM, MRK, MRNA, NOVO.B.DC, QTTB, RDNT, RVMD, TEM, TFX, THC, TXG, UHS, ZYME...(more)	show story hide story
25-Sep-2026 16:25	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities ended higher overall on Friday. Advancers outnumbered decliners 2:1 on the XLV. Healthcare +0.49% vs S&P 500 +0.51%. Major health groups ended mostly higher and mixed around the tape. Biotech was the only declining group, with XBI (0.65%), while managed care and services were relative outperformers. HUM +4.66% following an upgrade to Overweight from Equal Weight at Barclays, while BSX (3%) is the worst performer. Otherwise, sector news flow very quiet. Notable Gainers on Friday: +4.8% CVS (CVS Health): best performer on XLV +4.6% HUM (Humana): upgraded at Barclays +3.3% CHE (Chemed): initiation +2.2% RGNX (REGENXBIO): trial results in diabetic retinopathy +2.1% MRNA (Moderna): shares remain +26% WTD +2.0% OCGN (Ocugen): OCU400 granted provisional approval from the LARTA +1.9% SPTX (Seaport Therapeutics, Inc.): initiation Notable Decliners on Friday: -6.8% ACAD (Acadia Pharmaceuticals): follow through; worst biotech performer on XBI -5.5% PRME (Prime Medicine): FDA clearance of IND for phase 1/2 trial with PM647 in AATD -3.9% NKTR (Nektar Therapeutics): litigation against LLY -2.6% TEVA (Teva Pharmaceutical): on high volume -2.0% ENTX (Entera Bio): initiation -1.7% BSX (Boston Scientific): worst performer on XLV Week in Review: Healthcare equities outperformed for the week. The S&P 500 Healthcare Index +1.70% vs the S&P 500 Index +1.21%. Outperformers: MedTech Underperformers: Pharma, Biotech, Services, Managed Care Major health groups ended the week widely mixed. Biotech was the primary source of volatility, with XBI staging a modest rebound after Wednesday's sharp sell-off, helped by a broad slate of clinical readouts and company-specific catalysts. TWST also rallied sharply on renewed interest in the Bio AI opportunity following comments from Anthropic's CEO, while MRNA benefited from upcoming oncology data at ESMO. GRAL was a notable standout after relatively benign FDA briefing documents ahead of the Galleri MCED advisory committee, although the Adcom subsequently raised questions around efficacy. MedTech was otherwise supported by strength in diagnostics and company-specific catalysts, including CRL's Investor Day. In Washington, the Senate HELP Committee questioned FDA Commissioner nominee Heidi Overton, with her confirmation prospects still uncertain following Thursday's hearing. Looking ahead, conference season continues and the first large-cap earnings slots remain weeks away. Year-to-date, Healthcare +10.31% vs the S&P 500 +13.12%. Healthcare third out of eleven major sectors in CY26. Energy +38.4% and Utilities (7.4%) bracket them all. Notable movers for the week: Gainers: GRAL +57.1% - FDA Adcom for Galleri MCED test MRNA +29.1% - announced INT data presentations at ESMO VKTX +22.7% - trial results in obesity CDNA +18.3% - DX sympathy to GRAL BLLN +16.2% - DX sympathy to GRAL TNGX +14.6% - Cantor Fitzgerald comments on PRMT5 inhibitor and Tango a Top Pick ILMN +12.7% - DX sympathy to GRAL TXG +11.9% - DX sympathy to GRAL NTRA +11.7% - DX sympathy to GRAL TWST +9.5% - Leerink comments on Anthropic developments AMGN +7.5% - trial results in Sjogren's disease HUM +3.0% - upgraded at Barclays LLY +2.7% - FDA approves Onswik, once-weekly basal insulin Decliners: ACAD (24.2%) - trail results in Alzheimer's Disease Psychosis (ADP) CLDX (18.7%) - trial results in CSU ARCT (13.6%) - reported trial results in OTC deficiency ABVX (13.3%) - earnings WGS (12.5%) - preliminary CLFS for CY2027 ORKA (11.1%) - trial results in plaque psoriasis NVO (10.3%) - strategic updates at CMD; trial results with CagriSema highlighted IMVT (9.9%) - trial results in CLE; ends development TLX (9.1%) - acquired ITM Munich for cash & stock; upgraded at RBC Capital Markets CNC (5.0%) - managed Care weakness on ACA fraud headlines DGX (4.1%) - preliminary CLFS for CY2027 Week Ahead (Sat - Sun): Sep 28 - Oct 4 Mon 28-Sep: Investor Day: ROP.SW (4:30ET), CAMP (12:00ET); FDA PDUFA for EGTX.SS Emcitate NDA Wed 30-Sep: Investor Day: CI (8:30ET); FDA PDUFA for BMY Camzyos sNDA Thu 1-Oct: Conference: UBS Virtual Oncology Day Syndicate / IPO pricing: +OURA Oura Ring - S-1A	show story hide story
25-Sep-2026 13:44	StreetAccount Summary: Notable Drug Events expected for the week of 27-Sep Mon 28-Sep Regulatory decision: EGTX.SS FDA PDUFA for Emcitate NDA in Allan-Herndon-Dudley Syndrome Industry meeting with clinical data: European Association for the Study of Diabetes (EASD) Annual Meeting (Sep 28 - Oct 2) (KLRA, LLY, ADOC.FP) Investor event: ROP.SW Pharma Day Tue 29-Sep Industry meetings with clinical data: World Muscle Society (WMS) Congress (Sep 29 - Oct 3) (DYN) International Symposium on Sjögren's Disease (ISSjD) (Sep 29 - Oct 2) (ARTV) Trial results: DYN to present phase 1/2 data from the ACHIEVE trial in DM1 at WMS Investor event: ZBIO Obexelimab IgG4-RD virtual investor event (8:00ET) Wed 30-Sep Regulatory decision: BMY FDA PDUFA for Camzyos sNDA in obstructive hypertrophic cardiomyopathy Trial results: LLY to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026 also expected September 2026 Trial results: KOD (Ph3 Wet AMD), IMMX (Ph2 R/R AL Amyloidosis), CNTB (Ph2 COPD), QURE (Ph1/2 Huntington's disease), CNTX (Ph1 solid tumors), PHIL.IM (Ph1 glioblastoma), ZNTL (Ph1 PROC), PMN (Ph1 AD), ACET (Ph1 SLE), CGEM (Ph1 RA) later during October 2026 Regulatory decisions: FDA PDUFAs: MRK/4568.JP (Ifinatamab deruxtecan BLA, 10-Oct), ROP.SW (Enspryng sBLA, 15-Oct), IRD (phentolamine ophthalmic solution 0.75% sNDA 17-Oct), GSK.LN/IONS (Hibsago NDA, 26-Oct), 524715.IN/MRK (ILUMYA sBLA, 29-Oct), INO (INO-3107 BLA, 30-Oct); FDA BsUFA XBRANE.SS (Xlucane BLA, 29-Oct); EMA CHMP opinions on MAA (16-Oct) Industry meetings with clinical data: International Gynecologic Cancer Society (IGCS) Meeting (Oct 1-3), International Conference on Frontotemporal Dementias (ISFTD) (Oct 8-11); American Academy of Ophthalmology (AAO) Annual Meeting (Oct 9-12); American College of Gastroenterology (ACG) Scientific Meeting (Oct 9-14); European Huntington's Disease Network (EHDN) Congress (Oct 22-24); ESMO Congress 2026 (Oct 23-27); ESGCT Annual Congress (Oct 27-30) Regulatory meeting: EMA CHMP monthly meeting (Oct 12-15) Trial results: 7630.HK (Ph3 ovarian cancer and Ph1/2 solid tumors), PCVX (Ph3 IPD/pneumococcal pneumonia), RAPP (Ph3 FOS, Ph2 Bipolar I disorder), BMY (Ph3 IPF), CMPX (Ph2/3 biliary tract cancer), 6996.HK (Ph2 G/GEJ cancer and Ph1/2 melanoma), SXTP (Ph2 babesiosis), CRVO (Ph2 nfvPPA), PBLS (Ph1/2 Desmoid Tumors), TNGX (Ph1/2 pancreatic cancer), BNTC (Ph1/2 OPMD), TRDA (Ph1/2 DMD), EIKN (Ph1/2 solid tumors), CATX (Ph1/2 NETs), BMEA (Ph1 obesity), BRNS (Ph1 celiac disease), ALNY (Ph1 Huntington's disease), INCY (Ph1 PDAC and Ph1 MSS CRC), IMTX (Ph1 cancer), XNCR (Ph1 ccRCC), AGEN (Ph1 ovarian cancer) Related: 4568.JP, 524715.IN, 6996.HK, 7630.HK, ACET, ADOC.FP, AGEN, ALNY, ARTV, BMEA, BMY, BNTC, BRNS, CATX, CGEM, CMPX, CNTB, CNTX, CRVO, DYN, EGTX.SS, EIKN, GSK.LN, IMMX, IMTX, INCY, INO, IONS, IRD, KLRA, KOD, LLY, MRK, PBLS, PCVX, PHIL.IM, PMN, QURE, RAPP, ROP.SW, SXTP, TNGX, TRDA, XBRANE.SS, XNCR, ZBIO, ZNTL...(more)	show story hide story
25-Sep-2026 11:04	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.07%) vs the S&P 500 +0.25%. Major health groups are mixed around the tape. Biotech is the worst-performing group, with XBI (1.04%), while managed care is the relative outperformer. HUM +3% the best on the XLV following an upgrade to Overweight from Equal Weight at Barclays, while RVTY (2%) is the worst performer, giving back some of yesterday's outperformance among LST names. Otherwise, sector news flow fairly quiet. Gainers +3.3% SPTX (Seaport Therapeutics, Inc.): initiation +3.0% OCGN (Ocugen): OCU400 granted provisional approval from the LARTA +2.7% HUM (Humana): upgraded at Barclays; best performer on XLV +1.4% CHE (Chemed): initiation Decliners -5.5% IMMX (Immix Biopharma): worst biotech performer on XBI -2.6% PRME (Prime Medicine): FDA clearance of IND for phase 1/2 trial with PM647 in AATD -2.4% TEVA (Teva Pharmaceutical): on high volume -1.5% RVTY (Revvity): worst performer on XLV -1.3% LGND (Ligand Pharmaceuticals): intitiation -0.9% ENTX (Entera Bio): initiation -0.6% RGNX (REGENXBIO): trial results in diabetic retinopathy -0.4% MRNA (Moderna): shares remain +26% WTD	show story hide story
25-Sep-2026 08:38	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Sector news flow is fairly quiet overnight, although HUM is benefiting from an upgrade to Overweight from Equal Weight at Barclays. The firm also initiated coverage of LGND with an Overweight rating. PRME shares are rallying after announcing FDA clearance of its IND for a Phase 1/2 trial of PM647 in AATD. ADARx Pharmaceuticals (ADRX), the 23rd biotech IPO of CY26 and 28th Healthcare IPO this year, raised $446M in an upsized offering at $17/shr, high-end of the anticipated range. Shares are scheduled to begin trading today. Yesterday, major health groups ended widely split. MedTech led advancers after an FDA advisory committee supported the Galleri MCED test. Elsewhere, Leerink's Puneet Souda highlighted the Bio AI opportunity at TWST following comments from Anthropic's CEO. In Washington, Sen. Cassidy and the Senate HELP Committee grilled FDA Commissioner nominee Dr. Overton, whose confirmation battle continues. Macro S&P futures up 0.3% in Friday morning trading. Oil down on latest round of seemingly recycled US-Iran diplomacy headlines. Lower oil providing some reprieve for rates, which continue to drive a stream of superlatives and debates about drivers in the financial press. Also more focus on broadening of AI compute demand narrative to inference/agentic with the AKAM cloud infrastructure deal with Anthropic coming amid the Muse momentum. Trump-Xi summit takeaways have focused on lack of deliverables outside of the two-month trade truce extension, though the bar was fairly low. Big macro week on tap next week, which also brings MU earnings and month- and quarter-end on Wednesday. Pre-market trading update Trading higher +11.4% PRME FDA clearance of IND for phase 1/2 trial with PM647 in AATD +4.8% ENTX initiated buy at Guggenheim Securities +2.3% SPTX initiated strong buy at Raymond James +2.0% NKTR litigation against Lilly Pharma Trial results: JNJ reports phase 4 STAR study of TREMFYA in axial PsA meets primary endpoint. JNJ reports new long-term data from cohort A of Phase 2 CARTITUDE-2 study of CARVYKTI in r/r MM. Biotech Regulatory: PRME announces FDA clearance of IND for phase 1/2 trial with PM647 in AATD. Research: ENTX initiated buy at Guggenheim Securities (Vamil Divan), target is $11 or approx. 293% upside. (FactSet average target $9.75; range $9-11) LGND initiated overweight at Barclays (Glen Santangelo), target is $345 or approx. 15% upside. (FactSet average target $353.09; range $330-397) SPTX initiated strong buy at Raymond James (Tiago Fauth), target is $46 or approx. 118% upside. (FactSet average target $37; range $30-50) Life Science & MedTech Corporate: STAA announces $50M share repurchase authorization. Research: LMRI initiated overweight at Keybanc (Matthew Gillmor), target is $18 or approx. 82% upside. (FactSet average PT $18; range $13-23) TELA initiated buy at Craig-Hallum Capital (Chase Knickerbocker), target is $2 or approx. 57% upside. (FactSet average target $2.10; range $1-3) Services & Hospitals Research: HUM upgraded to overweight from equal weight at Barclays (Andrew Mok), target increased to $515 from $407 or approx. 35% upside. (FactSet average target $425.46; range $280-515) CHE initiated buy at UBS (AJ Rice), target is $650 or approx. 31% upside. (FactSet average target $552; range $520-590) On Deck: Sep 19 - 27 Regulatory calendar Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY eligible for royalties) Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB eligible for royalties) Peek Ahead to next week Sep 28 - Oct 4 Mon 28-Sep: Investor Day: ROP.SW (4:30ET), CAMP (12:00ET); FDA PDUFA for EGTX.SS Emcitate NDA Wed 30-Sep: Investor Day: CI (8:30ET); FDA PDUFA for BMY Camzyos sNDA Thu 1-Oct: Conference: UBS Virtual Oncology Day Syndicate / IPO pricing: +OURA Oura Ring - S-1A This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ADRX, CHE, ENTX, HUM, JNJ, KLRA, LGND, LMRI, NKTR, PBLS, PRME, SPTX, STAA, TELA...(more)	show story hide story
24-Sep-2026 16:47	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to moderately higher overall on Thursday. Decliners narrowly outnumbered advancers on the XLV, versus a highly positive breadth around the open. Healthcare +0.65% vs S&P 500 (0.02%). Major health groups ended widely split on the session. MedTech group today's primary source of upside, behind two specific catalysts. First the diagnostic subgroup received support overnight from the FDA Adcom on Galleri MCED test. GRAL +15.4% also a tailwind for the broader space. Second, TWST +16.1% following pre-open comments by Leerink analyst Puneet Souda, highlighted the Bio AI opportunity in Twist Bio, in the wake of yesterday's AI for Biology comments from the CEO of Anthropic. Timely Investor Day for CRL +6.2%, third-best on the XLV. ILMN +7.3% today's top advancer on the XLV; DVA (4.6%) quietly today's top decliner. Biotech shares choppy amid the ongoing yield curve worries. XBI +0.55% managed a bounce-back from Wednesday's sell-off. Senator Cassidy and the Senate HELP Committee grilled the nominee for FDA Commissioner, who believes that all FDA approved vaccines have been proven safe and effective, including the MMR vaccine. Dr Overton's uphill battle for confirmation continues. Trial results in Alzheimer's Disease Psychosis highlight the biotech newsflow. ACADIA Pharmaceuticals announced that its RADIANT study missed on the primary endpoint. Company removing the lower 30mg dosage arm, and amending the ongoing trials. Post-close on Wednesday, an FDA advisory committee voted in support of the Galleri MCED test. Yesterday, Healthcare equities finished broadly lower and roughly inline overall. Biotech group an outlier with XBI (4.12%) - worst one-day decline since 2-Jun-2026. Just five modest gainers on the Biotech ETF, which erased all weekly gains and more. Sector newsflow remained very quiet. No specific catalyst identified for the pullback, but rate worries a plausible excuse. An FDA advisory committee for Galleri test for MCED raised questions about efficacy. Shares of GRAL halted throughout the day. Macro Stocks bounced off session lows following Reuters report US and Iran exploring phased deal to end conflict, starting with reopening Strait of Hormuz in exchange for lifting US economic blockade and unfreezing assets, though sequencing remains an obstacle. Oil, short-end Treasury yields retreated from highs (though still elevated). However, long end of the curve remains under pressure with yields near session highs after Treasury bought just $4.08B of 20-30Y debt in today's buyback (below the $6B max), compounding growth/inflation scrutiny. Short end seemingly facing a floor given hawkish Fed pricing (70% chance of an October hike, ~37 bp through year-end, both up slightly d/d). AI sentiment somewhat cautious as focus shifted to regulatory bottlenecks, financing risks after ORCL declared force majeure on delayed New Mexico data center project. Other areas of focus include few concrete takeaways from today's Trump/Xi summit, another META rally (Connect, Muse momentum), AI product discounting (AMZN), CTA positioning suggesting downside risk, ramping buyback blackout. Notable Gainers +108.4% SRZN (Surrozen): small-cap biotech; read-through from MRK trial results +16.1% TWST (Twist Bioscience): best performer on XBI; Leerink comments on Anthropic developments; shares +481% YTD +15.4% GRAL (GRAIL, Inc.): following FDA panel votes on Galleri PMA +13.0% CDNA (CareDx): DX sympathy to GRAL; 52-week high +11.2% TXG (10X Genomics): DX sympathy to GRAL; shares +416% YTD +10.8% VCYT (Veracyte): DX sympathy to GRAL +9.2% BLLN (BillionToOne): DX sympathy to GRAL +7.3% ILMN (Illumina): DX sympathy to GRAL; 52-week high; best performer on XLV +7.0% MRNA (Moderna): shares +26% WTD; 52-week high +6.2% CRL (Charles River Laboratories): Investor Day; LST strength +6.2% ARCT (Arcturus Therapeutics): trial results in OTC deficiency; upgraded at Citi +6.0% RVTY (Revvity): LST strength +4.6% NTRA (Natera): DX sympathy to GRAL; 52-week high +4.5% A (Agilent Technologies): LST strength; 52-week high +2.7% LLY (Eli Lilly): FDA approves Onswik, once-weekly basal insulin Notable Decliners -12.8% ACAD (Acadia Pharmaceuticals): trail results in Alzheimer's Disease Psychosis (ADP); worst performer on XBI -12.6% SGMT (Sagimet Biosciences): resumed sell at Goldman Sachs -11.8% VKTX (Viking Therapeutics): secondary offerings (common stock and convertible notes) -10.4% QURE (uniQure NV): on >3X average daily volume -9.9% VOGX (Vogenx, Inc.): recent IPO; shares (26%) WTD -8.5% CGEM (Cullinan Therapeutics): pipeline updates; shares were (22%) yesterday -4.6% DVA (DaVita): worst performer on XLV; on below average volume -3.5% UTHR (United Therapeutics): initiation at Goldman Sachs Twist Biosciences trading higher; Leerink comments on Anthropic and AI for Biology TWST +11.4% and leading gainer on the XBI around midday Thursday. Move at least in part due to comments made by Leerink Partners (outperform rating) highlighting Twist as the single most important beneficiary of Bio AI efforts, as Anthropic CEO mentioned yesterday. Firm also bullish on the LST space more broadly. Grail's successful Adcom at FDA lifts diagnostic space GRAL FDA panel votes to support PMA approval of Galleri MCED test. The advisory committee voted 10-0 on safety, 6-4 on efficacy, and 7-2-1 on benefit-risk profile. Merck clinical results in DME deliver mixed review of Wnt pathway MRK announced topline results from the pivotal phase 2b/3 BRUNELLO trial evaluating remigromig in adults with DME. Study demonstrated non-inferiority to active control ranibizumab (Lucentis, ROP.SW) in BCVA at week 52. Read-across to SRZN which is developing Wnt pathway antibodies for DME and other retinal disease. Trial results in SMID-cap biotech ACAD announced topline results from the phase 3 RADIANT study evaluating remlifanserin for the treatment of Alzheimer's Disease Psychosis (ADP). Study demonstrated evidence of dose effect - with 60mg once daily. Narrowly missed the primary endpoint. Company implementing protocol amendments, including dropping the 30mg dosage arm, and the phase 3 studies will continue. Detailed data will be presented at CTAD in November. KYTX announced topline results from KYSA-8 (one-year data) in stiff person syndrome, and longer-term data from the phase 2 portion of KYSA-6, a registrational study for miv-cel in gMG. CEO comments: "The durable clinical responses achieved in SPS and gMG, combined with a consistently favorable safety profile, set a new benchmark for autoimmune CAR T and reinforce miv-cel's potential best-in-class profile and ability to transform the treatment landscape across neurologic autoimmune diseases." ARCT announced interim phase 2 results from study of ARCT-810 in ornithine transcarbamylase (OTC) deficiency. Company also announced LUNAR 2.0, its next-gen mRNA delivery platform. Also disclosed the acquisition of myNEO. Terms not disclosed. Stock upgraded in reaction FDA approves Merck/Eisai combo for 2L+ ccRCC Ten days ahead of the 4-Oct PDUFA goal date, the FDA approved the sNDAs filed for Welireg (MRK) and Lenvima (4523.JP), for a new combination treatment for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. (EXEL, RCUS) Notable research in Healthcare today Biotech: ARCT upgraded to buy from neutral at Citi (Yigal Nochomovitz), follows phase 2 results. Target increased to $20 from $8 or approx. 50% upside. (FactSet average PT $23; range $9-41) EPRX initiated outperform at Wedbush Securities (Martin Fan), target is $17 or approx. 109% upside. MGTX initiated neutral at Goldman Sachs (Andrea Newkirk), target is $16 or approx. 36% upside. (FactSet average PT $28; range $16-50) NTHI initiated buy at Roth Capital (Jonathan Aschoff), target is $20 or approx. 521% upside. (FactSet average PT $17; range $13-20) QNCX initiated buy at Rodman & Renshaw (Seema Sheoran), target is $70 or approx. 132% upside. TTRX initiated buy at Lucid Capital Markets (Dev Prasad), target is $24 or approx. 78% upside. UTHR initiated sell at Goldman Sachs (Andrea Newkirk), target is $321 or approx. 34% downside. (FactSet average PT $638; range $321-725) Goldman Sachs (Andrea Newkirk) also resumed seven biotech stocks with buy ratings (INSM, IOVA, JAZZ, KRYS, MDGL, RVMD, TARS), four with neutral ratings (ABCL, ALKS, ARWR, KOD) and one sell (SGMT) MedTech: MMED initiated buy at Truist (Richard Newitter), target is $29 or approx. 41% upside. (FactSet average PT $26; range $21-29) TWST Leerink Partners analyst Puneet Souda highlights Twist as the single-most important beneficiary of AI for Biology. Also sees upside for LST more broadly. Post-close news Regulatory: PRME announces FDA clearance of IND for phase 1/2 trial with PM647 in AATD. Shares trading +14.0% in the after-hours Corporate: STAA announces $50M share repurchase authorization. Shares trading +2.0% in the after-hours Research: LMRI initiated overweight at Keybanc (Matthew Gillmor), target is $18 or approx. 82% upside. (FactSet average PT $18; range $13-23) Shares trading +1.2% in the after-hours On Deck: Syndicate calendar / IPO pricing Thu 24-Sep (post-close) +ADRX Adarx Pharmaceuticals - S-1A Regulatory on Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY eligible for royalties) on Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB eligible for royalties) Peek Ahead to next week Sep 28 - Oct 4 Mon 28-Sep: Investor Day: ROP.SW (4:30ET), CAMP (12:00ET); FDA PDUFA for EGTX.SS Emcitate NDA Wed 30-Sep: Investor Day: CI (8:30ET); FDA PDUFA for BMY Camzyos sNDA Thu 1-Oct: Conference: UBS Virtual Oncology Day Syndicate / IPO pricing: +OURA Oura Ring - S-1A StreetAccount Healthcare Reads FDA nominee voices support for vaccines at Senate hearing scrutinizing Trump administration efforts (24-Sep) AP US CDC confirms first measles-related death of 2026, does not disclose state (23-Sep) Reuters Nominee to lead FDA aims to speed up medical research, combat China's rise (23-Sep) STAT News Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA (22-Sep) STAT News (opinion) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4523.JP, A, ABCL, ACAD, ALKS, ARCT, ARWR, BIIB, BLLN, BMY, CAMP, CDNA, CGEM, CI, CRL, DVA, EGTX.SS, EPRX, EXEL, GRAL, ILMN, INCY, INSM, IOVA, JAZZ, KOD, KRYS, KYTX, LLY, LMRI, MDGL, MGTX, MIRM, MMED, MRK, MRNA, NTHI, NTRA, PRME, QNCX, QURE, RCUS, ROP.SW, RVTY, SGMT, SRZN, STAA, TARS, TTRX, TWST, TXG, UTHR, VCYT, VKTX, VOGX, +ADRX, +OURA...(more)	show story hide story
24-Sep-2026 11:04	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.97% vs the S&P 500 (0.41%). Most major health groups remain higher on the averages; Biotech again an outlier to the down side but not to the extent of yesterday's sell-off. XBI (0.18%) on today's session. Diagnostic stocks keeping the ETF afloat, and recent "AI for Biology" comments from the CEO of Anthropic. Leerink highlighted the Bio AI opportunity in TWST +11%. GRAL +8% the other tailwind for several DX stocks on the XBI. CRL +6%, hosting I-Day, leading advancer on the XLV; DVA (2%) quietly leading decliners. Live on Capital Hill: Sen. Cassidy and the Senate HELP Committee hold hearing on the FDA Commissioner nomination (10:30ET). Gainers +101.2% SRZN (Surrozen): small-cap biotech; read-through from MRK trial results +10.7% TWST (Twist Bioscience): Leerink comments on Anthropic developments; best performer on XBI; shares +451% YTD +8.4% GRAL (GRAIL, Inc.): resumed following FDA panel votes on Galleri PMA +8.4% CDNA (CareDx): DX sympathy to GRAL; 52-week high +7.1% ARCT (Arcturus Therapeutics): trial results in OTC deficiency; upgraded at Citi in reaction +6.9% TXG (10X Genomics): shares +396% YTD +6.9% BLLN (BillionToOne): DX sympathy to GRAL +6.1% VCYT (Veracyte): DX sympathy to GRAL +6.1% CRL (Charles River Laboratories): Investor Day; LST strength; best performer on XLV +4.7% ILMN (Illumina): DX sympathy to GRAL; 52-week high +3.8% RVTY (Revvity): LST strength +3.8% A (Agilent Technologies): LST strength; 52-week high +3.6% LLY (Eli Lilly): FDA approves Onswik, once-weekly basal insulin +3.5% MRNA (Moderna): shares are up +22% WTD +2.9% NTRA (Natera): DX sympathy to GRAL; 52-week high Decliners -14.7% SGMT (Sagimet Biosciences): worst performer on XBI; resumed sell at Goldman Sachs -14.0% VKTX (Viking Therapeutics): secondary offerings (common stock and convertible notes) -10.6% VOGX (Vogenx, Inc.): recent IPO; shares (26%) WTD -10.1% CGEM (Cullinan Therapeutics): pipeline updates; shares were (22%) yesterday -8.6% ACAD (Acadia Pharma.): trail results in Alzheimer's Disease Psychosis (ADP) -3.8% KYTX (Kyverna Therapeutics): trial results in gMG -2.3% UTHR (United Therapeutics): initiation at Goldman Sachs -2.0% DVA (DaVita): worst performer on XLV; on light volume	show story hide story
24-Sep-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Trial results in Alzheimer's Disease Psychosis highlight the biotech newsflow. ACADIA Pharmaceuticals announced that its RADIANT study missed on the primary endpoint. Company removing the lower 30mg dosage arm, and amending the ongoing trials. Shares of ACAD (5%) in the pre-market. Post-close on Wednesday, an FDA advisory committee voted in support of the Galleri MCED test. Shares of GRAL resumed trading higher by as much as +10%, currently down (8%) in the pre-market. Today, Senator Cassidy and the Senate HELP Committee hold hearing on the FDA Commissioner nomination (10:30ET). Yesterday, Healthcare equities finished broadly lower and roughly inline overall. Biotech group an outlier with XBI (4.12%) - worst one-day decline since 2-Jun-2026. Just five modest gainers on the Biotech ETF, which erased all weekly gains and more. Sector newsflow remained very quiet. No specific catalyst identified for the pullback, but rate worries a plausible excuse. An FDA advisory committee for Galleri test for MCED raised questions about efficacy. Shares of GRAL halted throughout the day. Macro S&P futures are down (0.6%) on Thursday morning. Bond yield backup still the big story (though yields off worst levels). Market now pricing in a 70%+ probability of another Fed tightening in October and just over 35 bp of rate hikes through end of the year. Usual suspects in play though some heightened focus on growth vs inflation. Spike in bond vol another area of scrutiny, along with adverse spillover effects for small caps. US-China trade truce extended by just two months and no additional details heading into Trump-Xi meeting today. Oil higher for a second straight session as lack of diplomatic traction at UN seems to be overshadowing latest headlines about Saudi efforts to boost shipments through SoH. AI headlines have revolved around the hardware announcements at the META Connect event, agentic proliferation moving pieces/debates, recent surge in discounting for AI products (AMZN latest), higher financing costs (SoftBank) and build-out as biggest economic bet in US history. Pre-market trading update Trading higher +69.3% SRZN small-cap biotech; read-through from MRK trial results +10.9% KYTX trial results in gMG; call at 8ET +6.5% ARCT trial results in OTC deficiency; upgraded at Citi in reaction +1.0% NKTR on light volume; shares (14%) WTD amid litigation Trading lower -12.9% VKTX secondary offerings (common stock and convertible notes) -8.1% GRAL resumed following FDA panel votes on Galleri PMA -5.2% ACAD trail results in Alzheimer's Disease Psychosis (ADP) -2.1% MRNA shares are up +18% WTD -2.0% UTHR initiation at Goldman Sachs -1.7% SGMT resumed sell at Goldman Sachs Pharma Trial results: MRK announced topline results from the pivotal phase 2b/3 BRUNELLO trial evaluating remigromig in adults with DME. Study demonstrated non-inferiority to active control ranibizumab (Lucentis, ROP.SW) in BCVA at week 52. Read-across to SRZN which is developing Wnt pathway antibodies for DME and other retinal disease. Biotech Trial results: ACAD announced topline results from the phase 3 RADIANT study evaluating remlifanserin for the treatment of Alzheimer's Disease Psychosis (ADP). Study demonstrated evidence of dose effect - with 60mg once daily. Narrowly missed the primary endpoint. Company implementing protocol amendments, including dropping the 30mg dosage arm, and the phase 3 studies will continue. Detailed data will be presented at CTAD in November. Conf. call at 8:00ET KYTX announced topline results from KYSA-8 (one-year data) in stiff person syndrome, and longer-term data from the phase 2 portion of KYSA-6, a registrational study for miv-cel in gMG. CEO comments: "The durable clinical responses achieved in SPS and gMG, combined with a consistently favorable safety profile, set a new benchmark for autoimmune CAR T and reinforce miv-cel's potential best-in-class profile and ability to transform the treatment landscape across neurologic autoimmune diseases." Conf. call at 8:00ET ARCT announced interim phase 2 results from study of ARCT-810 in ornithine transcarbamylase (OTC) deficiency. Company also announced LUNAR 2.0, its next-gen mRNA delivery platform. Also disclosed the acquisition of myNEO. Terms not disclosed. Stock upgraded in reaction Regulatory: GOSS announced the submission of seralutinib NDA for the treatment of PAH. Litigation: RGNX and UPenn announce settlement agreement with Sarepta Therapeutics (SRPT) regarding patent litigation over Elevidys IP. Sarepta will pay $39M to REGNEXBIO within ten days. All litigation between the parties terminated. Research: ARCT upgraded to buy from neutral at Citi (Yigal Nochomovitz), follows phase 2 results. Target increased to $20 from $8 or approx. 50% upside. (FactSet average PT $23; range $9-41) EPRX initiated outperform at Wedbush Securities (Martin Fan), target is $17 or approx. 109% upside. MGTX initiated neutral at Goldman Sachs (Andrea Newkirk), target is $16 or approx. 36% upside. (FactSet average PT $28; range $16-50) NTHI initiated buy at Roth Capital (Jonathan Aschoff), target is $20 or approx. 521% upside. (FactSet average PT $17; range $13-20) QNCX initiated buy at Rodman & Renshaw (Seema Sheoran), target is $70 or approx. 132% upside. TTRX initiated buy at Lucid Capital Markets (Dev Prasad), target is $24 or approx. 78% upside. UTHR initiated sell at Goldman Sachs (Andrea Newkirk), target is $321 or approx. 34% downside. (FactSet average PT $638; range $321-725) Goldman Sachs (Andrea Newkirk) also resumed seven biotech stocks with buy ratings (INSM, IOVA, JAZZ, KRYS, MDGL, RVMD, TARS), four with neutral ratings (ABCL, ALKS, ARWR, KOD) and one sell (SGMT) Life Science & MedTech Regulatory: GRAL FDA panel votes to support PMA approval of Galleri MCED test. The advisory committee voted 10-0 on safety, 6-4 on efficacy, and 7-2-1 on benefit-risk profile Corporate: CRL reaffirms FY26 guidance ahead of Investor Day meeting (9:00ET) Research: MMED initiated buy at Truist (Richard Newitter), target is $29 or approx. 41% upside. (FactSet average PT $26; range $21-29) Services & Hospitals Regulatory: CMS initiates NCA for Screening of HCV in adults. At the request Quest Diagnostics and others, the agency will re-evaluate the 2014 NCD. (DGX, LH, GILD, ABBV) On Deck: Conferences (cont.): Bernstein Healthcare Forum (Sep 23-24) (cont.): Stifel Immunology & Inflammation Virtual Forum (Sep 23-24) Regulatory Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) on Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY eligible forroyalties) on Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB eligible for royalties) Corporate CRL hosting Investor Day (9:00ET) INFU hosting Investor Update call (14:00ET) Syndicate calendar / IPO pricing Thu 24-Sep (post-close) +ADRX Adarx Pharmaceuticals - S-1A Peek Ahead to next week Sep 28 - Oct 4 Mon 28-Sep: Investor Day: ROP.SW (4:30ET), CAMP (12:00ET); FDA PDUFA for EGTX.SS Emcitate NDA Wed 30-Sep: Investor Day: CI (8:30ET); FDA PDUFA for BMY Camzyos sNDA Thu 1-Oct: Conference: UBS Virtual Oncology Day Sun 4-Oct: FDA PDUFA for MRK/Eisai Welireg/Lenvima sNDA Syndicate / IPO pricing: +OURA Oura Ring - S-1A This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4523.JP, ABBV, ABCL, ACAD, ALKS, ARCT, ARWR, BIIB, BMY, CAMP, CI, CRL, DGX, EGTX.SS, EPRX, GILD, GOSS, GRAL, INCY, INFU, INSM, IOVA, JAZZ, KOD, KRYS, KYTX, LH, MDGL, MGTX, MIRM, MMED, MRK, MRNA, NKTR, NTHI, QNCX, RGNX, ROP.SW, SGMT, SRPT, SRZN, TARS, TTRX, UTHR, VKTX, +OURA...(more)	show story hide story
23-Sep-2026 18:02	CMS initiates NCA for Screening for HCV in Adults; proposed decision coverage memo expected in March 2027 CMS received five complete formal requests to reconsider the current NCD (210.13 ; effective June 2014) including Quest Diagnostics (DGX) CMS initiates this national coverage analysis for Screening for HCV in adults. Public comment period open for 30 days. Proposed Decision Memo Due Date: 03/23/2027 Expected NCA Completion Date: 06/21/2027 StreetAccount notes tickers included for the national labs (DGX, LH) and the drugmakers (GILD, ABBV) Related: ABBV, DGX, GILD, LH Reference Link	show story hide story
23-Sep-2026 17:35	GRAL FDA panel votes to support the safety, efficacy, and benefit-risk profile of Galleri MCED test ($108.52) 1. Panel voted 10 Yes, 0 No, 0 Abstain Full question: Is there reasonable assurance that Galleri is safe for patients who meet the criteria specified in the proposed indication? 2. Panel voted 6 Yes, 4 No, 0 Abstain Full question: Is there reasonable assurance that Galleri is effective for use in patients who meet the criteria specified in the proposed indication? 3. Panel voted 7 Yes, 2 No, 1 Abstain Full question: Do the benefits of Galleri outweigh the risks for use in patients who meet the criteria specified in the proposed indication? This concludes the charge to the committee. Shares of GRAL remain halted, up +34% WTD See Related StreetAccount comments: 9/23/2026 2:37:58 PM - FDA adcomm raises questions on effectiveness of Grail's next-generation sequencing test for the early detection of multiple types of cancer in patients over 50 - Endpoint News 9/23/2026 6:56:52 AM - GRAIL, Inc.halted; news pending, ahead of today's AdCom meeting 9/21/2026 9:14:02 AM - FDA releases briefing materials ahead of Wednesday's Adcom 1/29/2026 7:40:28 PM - GRAIL, Inc. submits FDA premarket approval application for Galleri MCED test	show story hide story
23-Sep-2026 16:54	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly lower and roughly inline overall on Wednesday. Decliners beat advancers by more than 3:1 on the XLV, breadth around worst level of the session. Healthcare (0.65%) vs S&P 500 (0.75%). All major health groups ended lower by (1%) or more on the averages; Biotech an outlier with XBI (4.12%) - worst one-day decline since 2-Jun-2026. Just five modest gainers on the Biotech ETF, which erased all weekly gains and more. Sector newsflow remained very quiet. No specific catalyst identified for the pullback, but rate worries a plausible excuse. An FDA advisory committee for Galleri test for MCED raised questions about efficacy. Shares of GRAL halted throughout; votes on safety, efficacy and benefit-risk later tonight. VEEV +3.8%, outperforming CRM, and ALGN (3.3%) bracketed the XLV, with more modest moves in between. Overnight newsflow fairly quiet with a smattering of sell-side research spread all around the sector. Generic drugmakers, biotechs, diabetes tech, pharmacy, and acute care hospitals among the multitude of initiations. Labcorp reaffirms long-term outlook given at Investor Day earlier this month, commenting on PAMA/CLFS and supportive of the RESULTS Act in Congress. Shares of Grail Inc are halted today for the FDA Advisory Committee meeting (9:00ET to 17:55ET). GRAL +34% week-to-date and +27% year-to-date. Yesterday, Healthcare equities climbed higher overall and outperformed the broader tape. Care providers joined Biotech as key outperformers. Biotech topped the sector for a second-straight day; XBI +2.30% with broad support coming from SMID-caps; large-caps finished more mixed, including AMGN +4.3% on today's Sjogren's data. Labs faced down PAMA implementation after years of advance notice. Macro Bond yield backup (and further bearish flattening) the big story today with 2s earlier above 4.90% (highest in more than two years), 10s back through 5.10% and at new post-2007 highs, and 30s briefly trading at highest yield since 2004. Move triggered by hotter September flash PMIs, which rose to highest levels since 2022 and featured heightened price pressures. Latest Fedspeak also continued to lean hawkish. In addition, oil higher with Brent snapping a five-day losing streak that was largely driven by better Saudi export/SoH transit headlines and diplomacy chatter (which received plenty of scrutiny). However, still concerns about potential US diesel export ban; Politico said WH looking at a 90-day proposal (though administration called it fake news). AI trade largely on the defensive following recent outperformance driven by Muse momentum, which continues to dominate the headlines. Lot of discussion/debate about winners and losers from agentic proliferation. Recent displacement/disruption laggards have put in a mixed performance today. Notable Gainers +3.8% VEEV (Veeva Systems): update on CRM retention; best performer on XLV; shares (5%) MTD and +21% YTD +3.2% ILMN (Illumina): on below average volume +2.7% KLRA (Kailera Therapeutics): best performer on XBI; on 2X avg daily volume +2.0% VKTX (Viking Therapeutics): follow-through, shares were +36% yesterday +1.8% LKFT (Lakefront Biotherapeutics): upgraded at RBC Capital Markets +1.0% BIIB (Biogen): one of five advancers on XBI Notable Decliners -22.2% CGEM (Cullinan Therapeutics): worst performer on XBI; on above average volume; shares were +109% YTD thru Tuesday -15.5% INNV (InnovAge Holding): share offering for holders -11.6% PRME (Prime Medicine): gene-editing weakness with XBI sell-off; Anthropic / CRISPR headlines -7.9% EDIT (Editas Medicine): despite upgrade at Guggenheim -7.4% IMVT (Immunovant): trial results in CLE; ends development -6.8% RLAY (Relay Therapeutics): despite late-day FDA approval of Elevar's LYRFIGTU; Relay eligible for economics -5.6% CMPX (Compass Therapeutics): follow-through, downgraded at Wedbush -5.5% CRSP (CRISPR Therapeutics): gene-editing weakness with XBI sell-off; Anthropic / CRISPR headlines -4.9% ORKA (Oruka Therapeutics): trial results in plaque psoriasis -4.0% IONS (Ionis Pharmaceuticals): trial results in IgAN with Roche -3.3% ALGN (Align Technology): worst performer on XLV; on 1.5X avg daily volume -3.3% ZBH (Zimmer Biomet Holdings): on 1.4X avg daily volume -2.8% NTLA (Intellia Therapeutics): gene-editing weakness with XBI sell-off; Anthropic / CRISPR headlines -2.7% BBNX (Beta Bionics, Inc.): initiation -2.4% LH (Labcorp Holdings): reaffirms L-T outlook and support for RESULTS Act; shares were down (3%) yesterday -2.2% ASTH (Astrana Health): disclosed cybersecurity incident; provides FY26 guidance Veeva Systems announces another biopharma win for Vault CRM Pre-open on Wednesday, VEEV announced that it secured a new Top 20 biopharma commitment, bringing the scoreboard to Veeva 14 - Salesforce 6. Wells Fargo analyst Stan Berenshteyn (overweight VEEV) sees today's update as a clearing event, and the 14 wins is above expectations for a LDD ceiling. Grail Inc shares halted through today's Adcom GRAL shares are halted ahead of today's FDA Advisory Committee review of the PMA for Galleri test in cancer detection. Note: On the eve of the meeting, NEJM published an abstract and an editorial on the early detection of cancer. Immunovant lower following setback in CLE IMVT announced topline results from the proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus (CLE). Study did not achieve stat sig improvement on its primary endpoint. Company plans to stop development for CLE, but remains focused on '1402 for multiple autoimmune diseases. (ROIV) Labcorp reaffirms LT outlook following CLFS/PAMA volatility LH Via 8-K Reg FD filing, reaffirms long-term outlook 2026-29 it announced at Investor Day in September. Company continues to lobby in favor of the RESULTS Act. Note that shares were down (3%) on Tuesday following CMS issuance of preliminary CLFS for CY27 which implements PAMA impacted payment rates. Ionis Pharma lower following trial results in IgAN ROP.SW announced interim topline results for the phase 3 IMAgINATION study evaluating sefaxersen in adults with primary IgAN. Study met its primary endpoint compared with placebo at 37 weeks, a prespecified interim analysis. Study continues blinded for two years to evaluate kidney function. (IONS) Notable research in Healthcare today Phama: AMRX initiated outperform at Oppenheimer (Les Sulewski), target is $27 or approx. 38% upside. TEVA initiated outperform at Oppenheimer (Les Sulewski), target is $50 or approx. 27% upside. VTRS initiated outperform at Oppenheimer (Les Sulewski), target is $25 or approx. 46% upside. Biotech: EDIT upgraded to buy from neutral at Guggenheim Securities (Debjit Chattopadhyay), target is $5 or approx. 71% upside. (FactSet average PT $5; range $1-8) LKFT upgraded to outperform from sector perform at RBC Capital Markets (Brian Abrahams), firm sees opportunity for gamgertamig in rare autoimmune diseases. Target increased to $45 from $26 or approx. 49% upside. (FactSet average PT $31; range $22-43) CMPX downgraded to neutral from outperform Wedbush Securities (Robert Driscoll), target cut to $1 from $5 or approx. 19% downside. (FactSet average PT $7; range $1-24) ANIP initiated perform at Oppenheimer (Les Sulewski), target is $85 or approx. 9% upside. COLL initiated outperform at Oppenheimer (Les Sulewski), target is $50 or approx. 119% upside. CRMD initiated outperform at Oppenheimer (Les Sulewski), target is $15 or approx. 93% upside. ENTX initiated outperform at LifeSci Capital (Patrick Dolezal), target is $10 or approx. 236% upside. INVA assumed outperform at Oppenheimer (Les Sulewski), target is $35 or approx. 67% upside. MAZE initiated buy at Citi (Eric Joseph), target is $50 or approx. 76% upside. MDGL initiated buy at Citi (Eric Joseph), target is $725 or approx. 40% upside. ORIC initiated buy at BTIG (Jeet Mukherjee), target is $26 or approx. 93% upside. PCRX initiated outperform at Oppenheimer (Les Sulewski), target is $32 or approx. 30% upside. VNDA initiated outperform at Oppenheimer (Les Sulewski), target is $10 or approx. 92% upside. MedTech: BBNX initiated overweight at Wells Fargo Securities (Larry Biegelsen), target is $28 or approx. 23% upside. (FactSet average PT $22; range $16-30) PLSE initiated buy at BTIG (Marie Thibault), target is $70 or approx. 33% upside. (FactSet average PT $51; range $35-73) Services: ARDT initiated market perform at BMO Capital Markets (Sean Dodge), target is $11. CYH initiated market perform at BMO Capital Markets (Sean Dodge), target is $3 or approx. 1% downside. GRDN initiated overweight at KeyBanc (Zach Haggerty), target is $52 or approx. 16% upside. HCA initiated outperform at BMO Capital Markets (Sean Dodge), target is $495 or approx. 13% upside. THC initiated market perform at BMO Capital Markets (Sean Dodge), target is $265 or approx. 1% upside. Post-close news Trial results: ARCT announced interim results from the phase 2 trial of ARCT-810 in OTC deficiency. Conf. call at 16:30ET, as previously scheduled. Shares of ARCT +6.4% in the after-hours Regulatory: GOSS announced the submission of seralutinib NDA for the treatment of PAH. Shares of GOSS +2.0% in the after-hours Litigation: RGNX and UPenn announce settlement agreement with Sarepta Therapeutics (SRPT) regarding patent litigation over Elevidys IP. Sarepta will pay $39M to REGNEXBIO within ten days. All litigation between the parties terminated. Shares of RGNX trading UNCH in the after-hours; SRPT +0.2% Corporate: TBPH Zymeworks (ZYME) completes acquisition of Theravance Biopharma. Deal was announced on 29-Jun-2026. On Deck: Conference (cont.): Bernstein Healthcare Forum (Sep 23-24) (cont.): Stifel Immunology & Inflammation Virtual Forum (Sep 23-24) Regulatory (ongoing): FDA Adcom for GRAL Galleri PMA (9:00-17:55ET) Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) Corporate INFU hosting Investor Update call (14:00ET) Syndicate calendar / IPO pricing Thu 24-Sep (post-close): +ADRX Adarx Pharmaceuticals - S-1A StreetAccount Healthcare Reads In a changed world for cystic fibrosis, a family's fight reveals a new gap in care (23-Sep) Endpoints News Ozempic maker Novo open to upgrading New York listing (23-Sep) FT A private equity-owned hospital chain is becoming a nonprofit. Is it just a bailout for investors? (23-Sep) STAT News US halts Obamacare enrollment for over 760,000 enrollees, claiming fraud (22-Sep) Reuters Former FDA commissioners: Heidi Overton has an opportunity to strengthen the FDA (22-Sep) STAT News (opinion) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALGN, AMRX, ANIP, ARCT, ARDT, ASTH, BBNX, BIIB, CGEM, CMPX, COLL, CRMD, CRSP, CYH, EDIT, ENTX, GOSS, GRAL, GRDN, HCA, ILMN, IMVT, INFU, INNV, INVA, IONS, KLRA, LH, LKFT, MAZE, MDGL, NTLA, NVO, ORIC, ORKA, PCRX, PLSE, PRME, RGNX, RLAY, ROIV, ROP.SW, SRPT, TBPH, TEVA, THC, VEEV, VKTX, VNDA, VRTX, VTRS, ZBH, ZYME, +ADRX...(more)	show story hide story
23-Sep-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is generally inline with the S&P 500 Healthcare Index (0.23%) vs the S&P 500 (0.41%). Most major health groups are very little changed on the averages; all have turned lower for the session. Early upside coming from a few names in the large-cap Pharma group, but the DRG currently an inline (0.48%). VEEV +3% and ZBH (3%) quietly bracket the XLV, with many more modest moves in between. Sector newsflow remains fairly quiet. FDA advisory committee meeting today to discuss Galleri test for cancer detection. Three votes planned later tonight. Shares of GRAL are halted. XBI (3.29%) reversing yesterday's moves, the ETF clinging to weekly gains. Gainers +5.7% TLSI (TriSalus Life Sciences): receives FDA clearance for TriNav Advance +4.3% LKFT (Lakefront Biotherapeutics): upgraded at RBC Capital Markets +3.0% VEEV (Veeva Systems): best performer on XLV; shares (6%) MTD and +20% YTD +2.7% UHS (Universal Health Services): +2.4% EDIT (Editas Medicine): upgraded at Guggenheim; best performer on XBI +1.8% MRNA (Moderna): presented at Bernstein conference +0.4% BBNX (Beta Bionics, Inc.): initiation +0.09% PLSE (Pulse Biosciences): initiation +0.0% GRAL (GRAIL, Inc.): shares halted thru today's FDA Adcom Decliners -11.6% INNV (InnovAge Holding): share offering for holders -8.9% CGEM (Cullinan Therapeutics): worst performer on XBI; on average volume; shares were +109% YTD thru Tuesday -7.6% IMVT (Immunovant): trial results in CLE; ends development -6.9% CMPX (Compass Therapeutics): follow-through, downgraded at Wedbush -6.1% ORKA (Oruka Therapeutics): trial results in plaque psoriasis -5.3% CTMX (CytomX Therapeutics): follow-through, shares even WTD -4.9% ASTH (Astrana Health): disclosed cybersecurity incident; provides FY26 guidance -4.9% VKTX (Viking Therapeutics): follow-through, shares were +36% yesterday -4.5% IONS (Ionis Pharmaceuticals): trial results in IgAN with Roche -3.4% ZBH (Zimmer Biomet Holdings): worst performer on XLV -2.4% AMRX (Amneal Pharmaceuticals): initiation -0.02% LH (Labcorp Holdings): reaffirms L-T outlook and support for RESULTS Act; shares were down (3%) yesterday	show story hide story
23-Sep-2026 08:01	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight newsflow fairly quiet with a smattering of sell-side research spread all around the sector. Generic drugmakers, biotechs, diabetes tech, pharmacy, and acute care hospitals among the multitude of initiations. Labcorp reaffirms long-term outlook given at Investor Day earlier this month, commenting on PAMA/CLFS and supportive of the RESULTS Act in Congress. Shares of Grail Inc are halted today for the FDA Advisory Committee meeting (9:00ET to 17:55ET). GRAL +34% week-to-date and +27% year-to-date. Yesterday, Healthcare equities climbed higher overall and outperformed the broader tape. Care providers joined Biotech as key outperformers. Biotech topped the sector for a second-straight day; XBI +2.30% with broad support coming from SMID-caps; large-caps finished more mixed, including AMGN +4.3% on today's Sjogren's data. Labs faced down PAMA implementation after years of advance notice. Macro S&P futures are flat on Wednesday morning. Nothing really new from a narrative perspective. Some focus on recent pullback in oil (longest losing streak in a year for Brent) on better Saudi export/SoH transit headlines and diplomacy chatter. However, also more talk about how a diesel ban could do more harm than good. Agentic proliferation remains the big theme around AI amid the Muse momentum (and META Connect keynote this evening) with the Street and financial press highlighting (and debating) early winners and losers. Also more focus on cheaper frontier models and shift from peak performance to cost efficiency. Hawkish Fedspeak, yield curve flattening, bank underperformance, weaker breadth, index-level resilience, buyback blackouts and more subdued retail flows have also received some recent attention. Pre-market trading update Trading higher +13.0% TLSI receives FDA clearance for TriNav Advance +5.1% EDIT upgraded at Guggenheim +3.8% LKFT upgraded at RBC Capital Markets +1.5% BBNX initiation +1.5% PLSE initiation +1.4% IONS trial results in IgAN with Roche +1.1% GRAL shares halted ahead of today's FDA Adcom +0.9% LH reaffirms L-T outlook and support for RESULTS Act; shares were down (3%) yesterday Trading lower -5.3% IMVT trial results in CLE; ends development -2.9% ROIV sympathy to IMVT -0.8% CMPX follow-through, downgraded at Wedbush Pharma Trial results: ROP.SW announced interim topline results for the phase 3 IMAgINATION study evaluating sefaxersen in adults with primary IgAN. Study met its primary endpoint compared with placebo at 37 weeks, a prespecified interim analysis. Study continues blinded for two years to evaluate kidney function. (IONS) Corporate: NOVO.B.DC (NVO) CEO Mike Doustdar tells the FT in an interview that he sees advantages to replacing the ADRs with a direct listing in New York. Research: AMRX initiated outperform at Oppenheimer (Les Sulewski), target is $27 or approx. 38% upside. TEVA initiated outperform at Oppenheimer (Les Sulewski), target is $50 or approx. 27% upside. VTRS initiated outperform at Oppenheimer (Les Sulewski), target is $25 or approx. 46% upside. Biotech Trial results: IMVT announced topline results from the proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus (CLE). Study did not achieve stat sig improvement on its primary endpoint. Company plans to stop development for CLE, but remains focused on '1402 for multiple autoimmune diseases. (ROIV) Research: EDIT upgraded to buy from neutral at Guggenheim Securities (Debjit Chattopadhyay), target is $5 or approx. 71% upside. (FactSet average PT $5; range $1-8) LKFT upgraded to outperform from sector perform at RBC Capital Markets (Brian Abrahams), firm sees opportunity for gamgertamig in rare autoimmune diseases. Target increased to $45 from $26 or approx. 49% upside. (FactSet average PT $31; range $22-43) CMPX downgraded to neutral from outperform Wedbush Securities (Robert Driscoll), target cut to $1 from $5 or approx. 19% downside. (FactSet average PT $7; range $1-24) ANIP initiated perform at Oppenheimer (Les Sulewski), target is $85 or approx. 9% upside. COLL initiated outperform at Oppenheimer (Les Sulewski), target is $50 or approx. 119% upside. CRMD initiated outperform at Oppenheimer (Les Sulewski), target is $15 or approx. 93% upside. ENTX initiated outperform at LifeSci Capital (Patrick Dolezal), target is $10 or approx. 236% upside. INVA assumed outperform at Oppenheimer (Les Sulewski), target is $35 or approx. 67% upside. MAZE initiated buy at Citi (Eric Joseph), target is $50 or approx. 76% upside. MDGL initiated buy at Citi (Eric Joseph), target is $725 or approx. 40% upside. ORIC initiated buy at BTIG (Jeet Mukherjee), target is $26 or approx. 93% upside. PCRX initiated outperform at Oppenheimer (Les Sulewski), target is $32 or approx. 30% upside. VNDA initiated outperform at Oppenheimer (Les Sulewski), target is $10 or approx. 92% upside. Life Science & MedTech Regulatory: GRAL shares are halted ahead of today's FDA Advisory Committee review of the PMA for Galleri test in cancer detection. On the eve of the meeting, NEJM published an abstract and an editorial on the early detection of cancer. Research: BBNX initiated overweight at Wells Fargo Securities (Larry Biegelsen), target is $28 or approx. 23% upside. (FactSet average PT $22; range $16-30) PLSE initiated buy at BTIG (Marie Thibault), target is $70 or approx. 33% upside. (FactSet average PT $51; range $35-73) Services & Hospitals Corporate: LH Via 8-K Reg FD filing, reaffirms long-term outlook 2026-29 it announced at Investor Day in September. Company continues to lobby in favor of the RESULTS Act. Note that shares were down (3%) on Tuesday following CMS issuance of preliminary CLFS for CY27 which implements PAMA impacted payment rates. Research: ARDT initiated market perform at BMO Capital Markets (Sean Dodge), target is $11. CYH initiated market perform at BMO Capital Markets (Sean Dodge), target is $3 or approx. 1% downside. GRDN initiated overweight at KeyBanc (Zach Haggerty), target is $52 or approx. 16% upside. HCA initiated outperform at BMO Capital Markets (Sean Dodge), target is $495 or approx. 13% upside. THC initiated market perform at BMO Capital Markets (Sean Dodge), target is $265 or approx. 1% upside. On Deck: Conferences (cont.): Bank of America Global Healthcare Conference (Sep 22-23) Bernstein Healthcare Forum (Sep 23-24) Stifel Immunology & Inflammation Virtual Forum (Sep 23-24) Regulatory FDA Adcom for GRAL Galleri PMA (9:00-17:55ET) on Thu 24-Sep: Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) Corporate ARCT Trial results call for ph2 trial with ARCT-810 OTC deficiency (16:30ET) on Thu 24-Sep: INFU hosting Investor Update call (14:00ET) Syndicate calendar / IPO pricing on Thu 24-Sep (post-close) +ADRX Adarx Pharmaceuticals - S-1A This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AMRX, ANIP, ARCT, ARDT, BBNX, CMPX, COLL, CRMD, CYH, EDIT, ENTX, GRAL, GRDN, HCA, IMVT, INFU, INVA, IONS, LH, LKFT, MAZE, MDGL, NOVO.B.DC, ORIC, PCRX, PLSE, ROIV, ROP.SW, TEVA, THC, TLSI, VNDA, VTRS, +ADRX...(more)	show story hide story
22-Sep-2026 16:47	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to moderately higher overall on Tuesday. Advancers beat decliners by 2:1 on the XLV. Healthcare +0.54% vs S&P 500 (0.00%). Major health groups ended widely mixed around the tape. Care providers joined Biotech in today's outperformance. Biotech lead the sector for a second-straight day; XBI +2.30% with broad support coming from SMID-caps; large-caps finished more mixed, including AMGN +4.3% on today's Sjogren's data. Busy morning of clinical readouts all across the biotech spectrum, new clinical data in AMKD, obesity, hives, and Sjogren's. VKTX +35.7% leading gainer on the XBI on its next-gen dual agonist for weight management. MAZE +26.8% in reaction to MoA validation by VRTX +0.8% for AMKD. Roche (0.2%) with mid-stage results from the acquired asset enicepatide (CT-388), which met its primary endpoints in obesity. MRNA +5.6% and DGX (4.1%) continued to bracket the XLV all day, with LH (2.9%) close behind. Labs facing down PAMA implementation after years of advance notice. After the close on Monday, CMS announced preliminary CLFS payment rates for CY2027. Highlighted by the long-awaited implementation of PAMA, CMS says that Medicare rates are 16% higher than private rates. Impact primarily seen for DGX and LH. Yesterday, Healthcare equities climbed higher overall, while lagging the broader tape. Biggest story was benign briefing documents ahead of the Grail Galleri PMA Adcom on Wednesday. Moderna also confirmed that new INT data will be presented at ESMO next month - both melanoma and PDAC. Novo ADRs under pressure following CMD updates where company discussed M&A needed to deliver LT pipeline growth goals. LST stocks unmoved by a weekend report that White House plans to grab power over NIH grants. Macro A few moving pieces today with AI, geopolitics/energy and rates among some of the higher-profile areas of focus. Muse momentum still the big story in AI, though more affordable versions of frontier models from Anthropic and OpenAI also in the headlines. Both play into the broadening out of inference infrastructure demand (and semis, memory standouts). However, Muse momentum has also ratcheted up disruption/displacement scrutiny. In terms of geopolitics, oil on the defensive again with supply dynamics (Saudis reportedly reopening East-West pipeline) and UN diplomatic hopes seemingly overshadowing Trump's latest Iran threats (and comments about no deal expected until after midterms). Some push and pull surrounding rates today with more hawkish post-FOMC Fedspeak and the move lower in oil. Notable Gainers +35.7% VKTX (Viking Therapeutics): trial results in obesity; best performer on XBI +26.8% MAZE (Maze Therapeutics, Inc.): read-across from VRTX trial results +22.0% BFLY (Butterfly Network): initiation +15.7% SGRY (Surgery Partners): on >3X average daily volume; providers strength standout +14.3% TNGX (Tango Therapeutics): on 3X average daily volume; Cantor Fitzgerald comments on PRMT5 inhibitor and Tango a Top Pick +13.8% OMER (Omeros): upgraded at Cantor Fitzgerald +11.8% BLLN (BillionToOne): on above average volume +9.9% IBRX (ImmunityBio): on >2X average daily volume +7.7% MDLN (Medline): on below average volume +5.6% PRTA (Prothena): insider buying (Form 4) +5.6% MRNA (Moderna): best performer on XLV; shares were +12% yesterday +4.8% VSTM (Verastem): partnered program receives BTD in China +4.5% CYH (Community Health Systems): provider strength +4.4% ALGN (Align Technology): on below average volume +4.3% AMGN (Amgen): trial results in Sjogren's disease +4.2% MTD (Mettler-Toledo International): on average volume +2.9% HCA (HCA Healthcare): provider strength +2.6% UHS (Universal Health Services): provider strength +2.6% WST (West Pharmaceutical Services): upgraded at Morgan Stanley Notable Decliners -31.9% CMPX (Compass Therapeutics): regulatory feedback on tove BLA submission; worst performer on XBI -11.6% CLDX (Celldex Therapeutics): trial results in CSU -8.8% NKTR (Nektar Therapeutics): on >4X average daily volume; amid Rezpeg litigation; specific reason uncertain -7.2% WGS (GeneDx Holdings): preliminary CLFS for CY2027 -5.8% INSP (Inspire Medical Systems): on above average volume -5.6% BRVE (Braveheart Bio): on above average volume -5.2% ALMR (Alamar Biosciences): on above average volume -5.0% ABVX (Abivax): earnings -4.1% DGX (Quest Diagnostics): preliminary CLFS for CY2027; worst performer on XLV -4.1% TVTX (Travere Therapeutics): announces CEO transition -3.3% MOH (Molina Healthcare): Managed Care weakness on ACA Fraud headlines -3.3% AMRX (Amneal Pharmaceuticals): follow-through, shares were +8% yesterday -2.9% LH (Labcorp Holdings): preliminary CLFS for CY2027; second-worst on XLV -2.6% CNC (Centene): Managed Care weakness on ACA Fraud headlines CMS announces action to prevent fraudulent Obamacare enrollments Cancelling 315K enrollments covering more than 760K individuals - returning ~$2.2B in subsidies CMS issuing temporary moratorium on new registration of agents for the 2027 plan year. Press release; Fact Sheet Trading update (with XLV +0.79%): Hospitals at session highs, most +2-4% each. Payers remain mostly lower on the session, down (1%) to (3%) each. Trump officials plan to cut hundreds of thousands from ACA, claiming fraud - WaPo Washington Post citing three people familiar with the forthcoming announcement, reporting that the Trump Administration will remove hundreds of thousands from ACA health insurance coverage, citing widespread fraud. StreetAccount notes effectuated enrollment via the ACA exchanges in 2026 was 19.2M people. Trading update (with XLV +0.89%): MCOs continue to lag the sector on Tuesday, down between (1%) to (5%) each. OSCR (5%), CNC (3%), MOH (3%), HUM (2%) Preliminary CLFS includes PAMA implementation After the close on Monday, CMS published preliminary CLFS for CY2027. Medicare has been paying about 16% more for laboratory services than private payors. With the preliminary 2027 rates, most Medicare laboratory test payments will be aligned with these private sector rates. Final rates expected in November; in effect 1-Jan-2027 Fact Sheet; Press Release LH, DGX Trial results in biopharma AMGN announced topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity. Study demonstrated stat sig and clinically meaningful improvement. The phase 3 OASIZ 303 study on track to readout in Q4 of 2026. CLDX announced topline results from the EMBARQ-CSU1 and CSU2 trials evaluating barzolvolimab. Both trials met the primary endpoint at Week 12. Both trials are ongoing to Week 52. ROP.SW announced topline results from its phase 2 CT-388-104 study evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity. Enicepatide met both primary endpoints in the study, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. VKTX announced topline results from the maintenance study of dual agonist VK2735. Company plans to explore oral maintenance dosing regimens in an upcoming part 2 of the current study. VRTX announced topline results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes (T2D). Vertex has completed enrollment in the AMPLITUDE trial and remains on track for interim analysis results in early 2027 - basis for an Accelerated Approval submission. Read-across for MAZE Merck secures label expansion for Winrevair MRK announced that FDA approved the Winrevair sBLA to expand its label based upon the HYPERION trial - to include recently diagnosed adults with PAH. BMY eligible for royalties via its acquisition of Celgene. Notable research in Healthcare today Biotech: OMER upgraded to overweight from neutral at Cantor Fitzgerald (Olivia Brayer Saunders), firm growing more positive on Yartemlea. Target reinstated at $22 or approx. 19% upside. QNCX upgraded to market outperform at Citizens (Jonathan Wolleben), target is $77 or approx. 148% upside. (FactSet average PT $75; range $65-98) ENTX initiated overweight at Cantor Fitzgerald (Imogen Mansfield) OBX initiated outperform at Leerink Partners (Daina Graybosch), target is $32 or approx. 85% upside. TNGX Cantor Fitzgerald analyst Eric Schmidt (overweight-rating) believes that investors are underappreciating the Tango story. Lucid Capital Markets publishes deep dive on anti-aging / longevity. Analyst is Elemer Piros. MedTech: WST upgraded to overweight from equal-weight at Morgan Stanley (Kallum Titchmarsh), target increased to $400 from $365 or approx. 11% upside. (FactSet average PT $410; range $365-459) BEAT downgraded to neutral from buy at HC Wainwright (Yi Chen) BFLY initiated buy at Needham (David Saxon), target is $10 or approx. 23% upside. GEHC initiated buy at Needham (David Saxon), target is $93 or approx. 43% upside. IRMD initiated hold at Needham (David Saxon) Piper Sandler published deep dive on fully closed loop pump systems. Analyst is Matt O'Brien. (MMED, PODD, TNDM, BBNX) Post-close news Research: ARDH initiated market perform at BMO Capital Markets (Sean Dodge), target is $11. CYH initiated market perform at BMO Capital Markets (Sean Dodge), target is $3 or approx. 1% downside. HCA initiated outperform at BMO Capital Markets (Sean Dodge), target is $495 or approx. 13% upside. THC initiated market perform at BMO Capital Markets (Sean Dodge), target is $265 or approx. 1% upside. On Deck: Conferences (cont.): Bank of America Global Healthcare Conference (Sep 22-23) Bernstein Healthcare Forum (Sep 23-24) Regulatory FDA Adcom for GRAL Galleri PMA (9:00-17:55ET) on Thu 24-Sep: Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) Corporate ARCT Trial results call for ph2 trial with ARCT-810 OTC deficiency (16:30ET) on Thu 24-Sep: INFU hosting Investor Update call (14:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABVX, ALGN, ALMR, AMGN, AMRX, ARCT, ARDH, BBNX, BEAT, BFLY, BLLN, BMY, BRVE, CLDX, CMPX, CNC, CYH, DGX, ENTX, GEHC, GRAL, HCA, HUM, IBRX, INFU, INSP, IRMD, LH, MAZE, MDLN, MMED, MOH, MRK, MRNA, MTD, NKTR, OBX, OMER, OSCR, PODD, PRTA, QNCX, ROP.SW, SGRY, THC, TNDM, TNGX, TVTX, UHS, VKTX, VRTX, VSTM, WGS, WST...(more)	show story hide story
22-Sep-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.64% vs the S&P 500 (0.00%). Major health groups are widely mixed around the tape, growth outperforming value. Biotech again today's leading advancer, the XBI +1.49% with broad support coming from SMID-caps and large-caps mixed to flat. Busy morning of clinical readouts across the group, new clinical data in AMKD, obesity, hives, and Sjogren's. VKTX +22% leading gainer on XBI on its next-gen dual agonist for weight management. MAZE +24% on the MoA validation by VRTX +1% for AMKD. Roche (1%) with mid-stage results from the acquired asset enicepatide (CT-388), which met its primary endpoints in obesity. MRNA +5% and DGX (4%) bracket the XLV; LH (3%) close behind, labs facing down PAMA implementation after years of advance notice. Gainers +23.5% MAZE (Maze Therapeutics, Inc.): read-across from VRTX trial results +21.5% VKTX (Viking Therapeutics): trial results in obesity; best performer on XBI +14.0% BFLY (Butterfly Network): initiation +8.0% OMER (Omeros): upgraded at Cantor Fitzgerald +6.1% VSTM (Verastem): partnered program receives BTD in China +5.0% MDLN (Medline): on light volume +4.9% PRTA (Prothena): insider buying (Form 4) +4.6% MRNA (Moderna): best performer on XLV; shares were +12% yesterday +3.1% CAI (Caris Life Sciences): on light volume +2.8% GEHC (GE HealthCare Technologies): initiation +2.6% WST (West Pharmaceutical Services): upgraded at Morgan Stanley +2.6% AMGN (Amgen): trial results in Sjogren's disease +1.5% LXEO (Lexeo Therapeutics): acquires Mantle Therapeutics for up to $21M +1.1% VRTX (Vertex Pharmaceuticals): trial results in proteinuria and AMKD +0.7% IONS (Ionis Pharmaceuticals): licensee Otsuka reports trial results in ALS +0.5% LGND (Ligand Pharmaceuticals): acquires royalty interest in Ryjunea for $23M Decliners -28.6% CMPX (Compass Therapeutics): regulatory feedback on tove BLA submission; worst performer on XBI -16.6% CLDX (Celldex Therapeutics): trial results in CSU -9.3% WGS (GeneDx Holdings): preliminary CLFS for CY2027 -5.3% ABVX (Abivax): earnings -4.3% DGX (Quest Diagnostics): preliminary CLFS for CY2027; worst performer on XLV -3.4% TVTX (Travere Therapeutics): announces CEO transition -3.3% TNDM (Tandem Diabetes Care): Piper Sandler comments on FCL pumps -3.3% AMRX (Amneal Pharmaceuticals): follow-through, shares were +8% yesterday -2.8% LH (Labcorp Holdings): preliminary CLFS for CY2027; second-worst on XLV -1.7% PODD (Insulet): Piper Sandler comments on FCL pumps -1.6% GRAL (GRAIL, Inc.): shares were +34% yesterday -0.9% MYGN (Myriad Genetics): preliminary CLFS for CY2027 -0.6% ROP.SW (Roche Holding): trial results in obesity	show story hide story
22-Sep-2026 08:08	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis New clinical results in obesity, highlighted by maintenance data from Viking Therapeutics. Shares of VKTX +36% in the pre-market. Roche also announced mid-stage results from the acquired asset enicepatide (CT-388), which met its primary endpoints. Shares of Roche (1%) lower in European trading today. Celldex also reported late-stage data in Hives. Shares of CLDX (9%) in the pre-market. After the close on Monday, CMS announced preliminary CLFS payment rates for CY2027. Highlighted by the long-awaited implementation of PAMA, CMS says that Medicare rates are 16% higher than private rates. Impact primarily seen for DGX and LH. Shares are down (7%) and (6%) respectively in the pre-market. Yesterday, Healthcare equities climbed higher overall, while lagging the broader tape. Biggest story was benign briefing documents ahead of the Grail Galleri PMA Adcom on Wednesday. Moderna also confirmed that new INT data will be presented at ESMO next month - both melanoma and PDAC. Novo ADRs under pressure following CMD updates where company discussed M&A needed to deliver LT pipeline growth goals. LST stocks unmoved by a weekend report that White House plans to grab power over NIH grants. Macro S&P futures are slightly higher on Tuesday morning. Not much new this morning after AI optimism and some better geopolitical/energy headlines dominated the narrative on Monday. Some focus on how tech momentum faded in APAC overnight. Geopolitics should be a big story again today with President Trump to address world leaders at UN General Assembly this morning and meet with Gulf leaders this afternoon. Following nearly 4% pullback to start the week, oil on the defensive again. Iran reportedly offered to reopen SoH within seven days if US takes stakes initial steps to dial back military pressure in the region. In addition, Saudis reportedly restarted East-West pipeline. Lot of discussion in the press about the early momentum behind META Muse and implications of the next layers of agentic proliferation. Pre-market trading update Trading higher +35.5% VKTX trial results in obesity; call at 8ET +3.9% AMRX follow-through, shares were +8% yesterday +3.1% OMER upgraded at Cantor Fitzgerald +2.8% BFLY initiation +2.3% WST upgraded at Morgan Stanley Trading lower -7.6% CLDX trial results in CSU; call at 8ET -6.8% DGX preliminary CLFS for CY2027 -6.2% LH preliminary CLFS for CY2027 (low volume) -2.4% MRNA shares were +12% yesterday -2.0% TVTX announces CEO transition -0.8% ROP.SW in European trading; trial results in obesity Pharma Trial results: ROP.SW announced topline results from its phase 2 CT-388-104 study evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity. Enicepatide met both primary endpoints in the study, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Regulatory: MRK announced that FDA approved the Winrevair sBLA to expand its label based upon the HYPERION trial - to include recently diagnosed adults with PAH. BMY eligible for royalties via its acquisition of Celgene. Biotech Trial results: VKTX announced topline results from the maintenance study of dual agonist VK2735. Company plans to explore oral maintenance dosing regimens in an upcoming part 2 of the current study. Conf. call at 8:00ET CLDX announced topline results from the EMBARQ-CSU1 and CSU2 trials evaluating barzolvolimab. Both trials met the primary endpoint at Week 12. Both trials are ongoing to Week 52. Conf. call at 8:00ET Earnings: ABVX.FP (ABVX) reported H1 net income (€171.7M) vs FactSet (€139.5M). Cash runway into Q4 of 2029. Corporate: TVTX announces CEO transition. Eric Dube steps down to focus on health. Research: OMER upgraded to overweight from neutral at Cantor Fitzgerald (Olivia Brayer Saunders), firm growing more positive on Yartemlea. Target reinstated at $22 or approx. 19% upside. QNCX upgraded to market outperform at Citizens (Jonathan Wolleben), target is $77 or approx. 148% upside. (FactSet average PT $75; range $65-98) ENTX initiated overweight at Cantor Fitzgerald (Imogen Mansfield) OBX initiated outperform at Leerink Partners (Daina Graybosch), target is $32 or approx. 85% upside. Lucid Capital Markets publishes deep dive on anti-aging / longevity. Analyst is Elemer Piros. IPO filed: +IAM (Iambic Therapeutics) files for Nasdaq IPO of indeterminate amount (S-1). Pre-open on Monday, the company announced a license agreement with AbbVie (ABBV) Life Science & MedTech Research: WST upgraded to overweight from equal-weight at Morgan Stanley (Kallum Titchmarsh), target increased to $400 from $365 or approx. 11% upside. (FactSet average PT $410; range $365-459) BFLY initiated buy at Needham (David Saxon), target is $10 or approx. 23% upside. GEHC initiated buy at Needham (David Saxon), target is $93 or approx. 43% upside. IRMD initiated hold at Needham (David Saxon) Piper Sandler published deep dive on fully closed loop pump systems. Analyst is Matt O'Brien. (MMED, PODD, TNDM, BBNX) Services & Hospitals Regulatory: After the close on Monday, CMS published preliminary CLFS for CY2027. Medicare has been paying about 16% more for laboratory services than private payors. With the preliminary 2027 rates, most Medicare laboratory test payments will be aligned with these private sector rates. Final rates expected in November; in effect 1-Jan-2027 Fact Sheet; Press Release LH, DGX On Deck: Conferences Bank of America Global Healthcare Conference (Sep 22-23) on Wed 23-Sep: Bernstein Healthcare Forum (Sep 23-24) Regulatory on Wed 23-Sep: FDA Adcom for GRAL Galleri PMA on Thu 24-Sep: Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) Corporate on Wed 23-Sep: ARCT Trial results call for ph2 trial with ARCT-810 OTC deficiency (16:30ET) on Thu 24-Sep: INFU hosting Investor Update call (14:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ABVX.FP, AMRX, ARCT, BBNX, BFLY, BMY, CLDX, DGX, ENTX, GEHC, GRAL, INFU, IRMD, LH, MMED, MRK, MRNA, OBX, OMER, PODD, QNCX, ROP.SW, TNDM, TVTX, VKTX, WST, +IAM...(more)	show story hide story
21-Sep-2026 17:08	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed and moderately higher overall on Monday. Advancers beat decliners by nearly 2:1 on the XLV, breadth near session highs. Healthcare +0.67% vs S&P 500 +1.49% Most major health groups ended higher on their averages, yet all lagged the broader tape, including Biotech. XBI +0.96% best performer, yet off its best levels of the day. Large-cap biotechs were inline; SMID-caps lower without a specific catalyst. Biggest lift came from GRAL +33.7% following rather benign reading briefing documents from FDA; Adcom set to meet on Wednesday to discuss PMA for Galleri test for multi-cancer detection (MCED). MRNA +12.3% the other notable standout, and Monday's leading gainer on the XLV, after confirming new oncology data will be presented at ESMO next month (both melanoma and PDAC). Managed Care stocks closed mostly lower, led by HUM (2.0%). Only COO (2.1%) fared worse on the XLV. Weekend newsflow headlined by M&A in the radioisotopes field, and the White House reportedly seeking to assert more political control over the NIH funding grants. LST stocks traded roughly inline on Monday. Freshly rebranded as Novo - the Danish drugmaker formerly known as Novo Nordisk shared its strategy update with investors. ADRs down (7.9%) on Monday. Certain SMID-cap metabolic stocks higher in reaction to Novo's growth plans and commentary on M&A appetite. "Novo" held its CMD on Monday in London where it discussed plans to grow and diversify its pipeline, and its targets for 2030 and 2035. Weekend M&A in the radioisotopes field, with Telix Pharma buying ITM Isotope Technologies for up to $2.35B in cash and stock, inclusive of upfront and contingent consideration. White House seeking political control and veto power over NIH grants, according to a weekend media reports from Politico and the NY Times. Biotech newsflow highlighted by early-stage results in ADHD, mid-stage trial results in Hives, and pivotal trial results in bipolar disorder. Post-close on Friday CMS announced that all 50 states have applied to participate in the upcoming Medicaid drug payment model GENEROUS. Details remain scarce. Macro AI trade extended its rebound from recent pacing worries with focus on agent momentum (META Muse). Lower oil and yields another positive for risk sentiment. Oil pullback chalked up to positive supply updates and hope for diplomatic progress at this week's UN meeting. Rates likely helped by oil move amid some hawkish post-FOMC Fedspeak (busy week of Fedspeak on tap and $183B of Treasury supply). US-China talks ahead of Trump-Xi summit described as "successful" with establishment of a formal "AI dialogue" (no slowdown). However, still no formal extension of trade truce. Recent strategist commentary has focused on resilience at the index level, weak breadth, depressed sentiment, strong inflows (but sluggish retail) and favorable corporate profit backdrop (biggest bullish talking point for stocks). Notable Gainers +35.0% IVVD (Invivyd): follow-through; Cantor Fitzgerald comments on Friday +33.7% GRAL (GRAIL, Inc.): FDA briefing documents benign for Galleri; best performer on XBI +12.3% MRNA (Moderna): announces INT data presentations at ESMO; best performer on XLV; second-best on XBI +5.2% GPCR (Structure Therapeutics): sympathy to Novo CMD comments on pipeline and M&A +5.1% ETRA (Electra Therapeutics, Inc.): IPO on Friday; shares were (12%) on debut +5.0% AAPG (Ascentage Pharma): sympathy to Novo CMD comments on pipeline and M&A +4.6% IMNM (Immunome): initiation +4.1% HLUN.B.DC (H. Lundbeck): upgraded at UBS +3.9% VKTX (Viking Therapeutics): sympathy to Novo CMD comments on pipeline and M&A +3.5% A (Agilent Technologies): second-best on XLV +3.3% CADL (Candel Therapeutics): upgraded at BofA +3.2% SRRK (Scholar Rock): sympathy to Novo CMD comments on pipeline and M&A Notable Decliners -23.7% CUE (Cue Biopharma): trial results in CSU -11.5% PBLS (Parabilis Medicines, Inc.): shares were +13% last week -10.2% TLX (Telix Pharmaceuticals): acquires ITM Munich for cash & stock; upgraded at RBC Capital Markets -7.9% NVO (Novo Nordisk): strategic updates at CMD; trial results with CagriSema highlighted -5.3% SMMT (Summit Therapeutics): worst performer on XBI; shares +24% MTD -4.2% CMPX (Compass Therapeutics): shares (24%) MTD -2.1% COO (The Cooper Cos.): worst performer on XLV; shares down (23%) MTD GRAIL higher on benign briefing documents GRAL sharply higher on Monday following FDA release of briefing materials ahead of Wednesday's Adcom meeting for the Galleri PMA. GRAIL seeking US FDA approval for the first test indicated for the screening for multiple types of cancer (MCED). The Molecular and Clinical Genetics Panel of MDAC is scheduled to meet on Wednesday 23-Sep at 900ET. (ABT, CAI, FRNM, GH) Novo trades lower following strategy update, M&A comments at CMD NOVO.B.DC (NVO) hosted CMD on Monday in London. 'Novo' targets the launch of at least five multi-blockbusters by 2023 and to deliver more than DKK150B of pipeline sales in 2035. Press release Consolidation in radioisotopes and radiopharma space TLX.AU (TLX) announced an agreement to acquire privately-held ITM Isotope Technologies Munich SE ("ITM") for up to $2.35B in cash and stock, inclusive of upfront and contingent consideration. Latest in the consolidation of the radiopharmaceutical / radioisotopes supplier industry. Last month Curium bought out Lantheus (LNTH) in a deal worth up to $8B. ITM is both a key supplier of Pluvicto to NOVN.SW and a potential competitor to Lutathera with its therapeutic treatment for GEP-NET (ITM-11) recently given a CRL (limited to third-party PAI). Trial results in biopharma ALKS announced topline results from a phase 1 POC study evaluating ALKS 7290 in adults with ADHD. First orexin 2 RA to demonstrate clinically meaningful improvements in ADHD symptoms in adults. Phase 2 trial currently enrolling, data expected in 2027. CUE announced topline results from the Phase 2 clinical trial of CUE-221 (UB-221) in China. Primary endpoint and the key secondary endpoint were met with high statistical significance. Measured against placebo, however efficacy comparisons drawn with Xolair (omalizumab, ROP.SW) JNJ announced topline results from the pivotal Phase 3 study evaluating CAPLYTA for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder. The study met its primary endpoint. A second pivotal study has been completed, with analysis underway. White House seeks more power over NIH grant funds - Politico On Saturday (19-Sep) Politico reported that the White House is drafting an Executive Order to bring veto power over the NIH grant process. The proposed board would include NIH director Jay Bhattacharya and OMB director Russ Vought; the two would 'be required to reach unanimous decisions on grant awards'. Leerink analyst Puneet Souda writes that while a potential disruptor and headwind to FY27, the firm expects bipartisan pushback to continue to prevail, and that the NIH budget will likely rise 'regardless of the midterm outcomes'. (ALMR, BRKR, ILMN, NAUT, QTRX, TECH, TMO, TWST, TXG) Notable research in Healthcare today Biotech: HLUN.B.DC upgraded to buy from neutral at UBS (Xian Deng), firm believes in the R&D turnaround underway. Target increased to DKK52 from DKK45 or approx. 22% upside. (FactSet average PT DKK49; range DKK34-65) CADL upgraded to buy from neutral at BofA (Alec Stranahan), target increased to $18 from $12 or approx. 66% upside. (FactSet average PT $22; range $15-29) IMNM initiated buy at Alliance Global Partners, target is $32 or approx. 34% upside. MedTech: TEM initiated neutral at Goldman Sachs (Evie Koslosky), target is $75 or approx. 4% downside. (FactSet average PT $68; range $35-100) Post-close news Regulatory: CMS publishes preliminary CLFS for CY2027 Final rates expected in November; in effect 1-Jan-2027 Fact Sheet Press Release Earnings: ABVX.FP (ABVX) reports H1 net income (€171.7M) vs FactSet (€139.5M). Cash runway into Q4 of 2029. ADRs trading (0.3%) in the after-hours Corporate: TVTX announces CEO transition. Eric Dube steps down to focus on health. Shares trading UNCH in the after-hours On Deck: Regulatory FDA PDUFA today for MRK Winrevair sBLA (based on HYPERION study) (BMY royalties via Celgene acquisition) on Wed 23-Sep: FDA Adcom for GRAL Galleri PMA Corporate TLX hosting R&D Day meeting (8:30ET) on Wed 23-Sep: ARCT Trial results call for ph2 trial with ARCT-810 OTC deficiency (16:30ET) Conference Bank of America Global Healthcare Conference (Sep 22-23) on Wed 23-Sep: Bernstein Healthcare Forum (Sep 23-24) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, AAPG, ABT, ABVX.FP, ALKS, ALMR, ARCT, BMY, BRKR, CADL, CAI, CMPX, COO, CUE, DGX, ETRA, FRNM, GH, GPCR, GRAL, HLUN.B.DC, ILMN, IMNM, IVVD, JNJ, LH, LNTH, MRK, MRNA, NAUT, NOVN.SW, NOVO.B.DC, NVO, PBLS, QTRX, ROP.SW, SMMT, SRRK, TECH, TEM, TLX, TLX.AU, TMO, TVTX, TWST, TXG, VKTX...(more)	show story hide story
21-Sep-2026 16:37	CMS publishes preliminary CY2027 CLFS CMS is releasing the data and information used to determine the preliminary 2027 Medicare payment rates for laboratory services showing that Medicare has been paying about 16% more for laboratory services than private payors. Basing Medicare's rates on those paid by the private sector helps ensure that Medicare is paying appropriate amounts for laboratory tests and protecting taxpayer dollars. With the preliminary 2027 rates, most Medicare laboratory test payments will be aligned with these private sector rates. By law, Medicare payment for a clinical diagnostic laboratory test cannot be reduced by more than 15% per year through 2029. CMS will gradually phase in the reductions through 2029. CMS anticipates final CLFS will be announced in November 2026, and rates will go into effect 1-Jan-2027. Related: BNGO, CSTL, DGX, GH, LH, MYGN, NTRA...(more) Reference Link: Fact Sheet Reference Link	show story hide story
21-Sep-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index +0.64% vs the S&P 500 +0.94%. Most major health groups in positive territory to begin the week. Managed Care stocks mostly lower. Only Biotech is trading ahead of the broader tape. XBI +1.60%. Biggest lift coming from GRAL +35% following rather benign reading briefing documents from FDA; Adcom set to meet on Wednesday to discuss PMA for Galleri test for multi-cancer detection. MRNA +10% the other standout, and leading gainer on the XLV, after confirming new oncology data will be presented at ESMO next month. CVS (1.4%) leading decliners on the XLV. Weekend newsflow headlined by M&A in the radioisotopes field, and the White House reportedly seeking to assert more political control over the NIH funding grants. LST stocks inline overall on Monday. Freshly rebranded as just Novo - the Danish drugmaker formerly known as Novo Nordisk shared its strategy update with investors. ADRs down (8%) today. SMID-cap metabolic stocks higher in reaction to Novo's growth plans and commentary on M&A appetite. Gainers +35.2% GRAL (GRAIL, Inc.): FDA briefing documents benign for Galleri; best performer on XBI +19.2% IVVD (Invivyd): follow-through; Cantor Fitzgerald comments on Friday +9.7% MRNA (Moderna): announces INT data presentations at ESMO; best performer on XLV; second-best on XBI +8.3% ETRA (Electra Therapeutics, Inc.): IPO on Friday; shares were (12%) on debut +6.2% CADL (Candel Therapeutics): upgraded at BofA +5.5% AAPG (Ascentage Pharma): sympathy to Novo CMD comments on pipeline and M&A +5.2% GPCR (Structure Therapeutics): sympathy to Novo CMD comments on pipeline and M&A +5.0% SRRK (Scholar Rock): sympathy to Novo CMD comments on pipeline and M&A +3.7% HLUN.B.DC (H. Lundbeck): upgraded at UBS +3.4% IMNM (Immunome): initiation +3.0% INSM (Insmed): priority review for Arikayce sNDA +1.1% TEM (Tempus AI): initiation +1.1% CAI (Caris Life Sciences): sympathy to GRAL +1.0% NVS (Novartis): sympathy to TLX +0.8% ALKS (Alkermes): trial results in ADHD +0.7% JNJ (Johnson & Johnson): trial results in bipolar disorder Decliners -28.0% CUE (Cue Biopharma): trial results in CSU -10.0% TLX (Telix Pharmaceuticals): acquires ITM Munich for cash & stock; upgraded at RBC Capital Markets -8.0% NVO (Novo Nordisk): strategic updates at CMD; trial results with CagriSema highlighted -5.4% PBLS (Parabilis Medicines, Inc.): shares were +13% last week -4.7% CMPX (Compass Therapeutics): worst performer on XBI; shares (24%) MTD -1.6% OSCR (Oscar Health): stock distribution to Thrive Capital limited partners -1.4% CVS (CVS Health): worst performer on XLV; MCO weakness -1.1% HUM (Humana): MCO weakness -0.7% MOH (Molina Healthcare): MCO weakness -0.3% ABT (Abbott Labs): sympathy to GRAL	show story hide story
21-Sep-2026 09:21	GRAIL higher on benign briefing documents GRAL trading +14.0% in the pre-market following FDA release of briefing materials ahead of Wednesday's Adcom meeting for the Galleri PMA. GRAIL seeking US FDA approval for the first test indicated for the screening for multiple types of cancer (MCED). For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: GRAL	show story hide story
21-Sep-2026 08:42	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis "Novo" held its CMD on Monday in London where it discussed plans to grow and diversify its pipeline, and its targets for 2030 and 2035. ADRs trading down (4%) in the pre-market Monday morning. Weekend M&A in the radioisotopes field, with Telix Pharma buying ITM Isotope Technologies for up to $2.35B in cash and stock, inclusive of upfront and contingent consideration. ADRs for TLX are lower (10%) on Monday morning. Novartis ADS trading slightly higher. White House seeking political control and veto power over NIH grants, according to a weekend media reports from Politico and the NY Times. Shares of LST names unmoved on Monday morning. Biotech newsflow highlighted by midstage trial results in Hives. Shares of small-cap biotech Cue Biopharma are up +5% in the pre-market, after trading as high as +63% ahead of the 800ET call. Also Alkermes with anticipated readout in ADHD; share of ALKS +9% in the pre-market. Post-close on Friday CMS announced that all 50 states have applied to participate in the upcoming Medicaid drug payment model GENEROUS. Details remain scarce. Macro S&P futures are up +0.7% on Monday morning; Nasdaq futures are up +1.1%. Lower oil flagged as tailwind for risk sentiment with Saudi export recovery, six-month high in SoH traffic and hope for diplomatic progress at this week's UN meeting seemingly overshadowing Houthi strike on Riyadh. Lower rates another bright spot after oil and yields decoupled on Friday. AI trade an early standout after recovering a good chunk of the frontier pacing call selloff as last week progressed. Compute demand takeaways remain very positive with agentic an increasingly high-profile area of focus. US-China talks ahead of Trump-Xi summit described as "successful" with establishment of a formal "AI dialogue". Two sides also said they operationalized a Board of Trade, though no extension of trade truce yet. Strategist commentary focused on resilience at the index level, weak breadth, depressed sentiment, strong inflows, easier financial conditions following Fed and earnings as the big bullish talking point. Pre-market trading update Trading higher +10.6% IVVD follow-through; Cantor Fitzgerald comments on Friday +8.8% ALKS trial results in ADHD +6.0% CADL upgraded at BofA +5.1% CUE trial results in CSU; call at 800ET +4.1% SMMT on 39K shares +3.3% HLUN.B.DC in European trading; upgraded at UBS +2.0% INSM priority review for Arikayce sNDA +1.5% GRAL ahead of briefing documents today / Adcom Wednesday +0.8% NVS sympathy to TLX +0.6% TEM initiation Trading lower -10.1% TLX acquires ITM Munich for cash & stock -4.3% NVO strategic updates at CMD; trial results with CagriSema highlighted -2.3% OSCR stock distribution to Thrive Capital limited partners Pharma Corporate: NOVO.B.DC (NVO) hosted CMD on Monday in London. 'Novo' targets the launch of at least five multi-blockbusters by 2023 and to deliver more than DKK150B of pipeline sales in 2035. Press release Trial results: JNJ announced topline results from the pivotal Phase 3 study evaluating CAPLYTA for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder. The study met its primary endpoint. A second pivotal study has been completed, with analysis underway. Regulatory: AMRX post-close on Friday announced that FDA has approved lanreotide injection in a single-dose, pre-filled syringe. The product will launch immediately, with FDA CGT designation. The RLD is Ipsen's (IPN.FP) Somatuline Depot. StreetAccount notes patent/exclusivity expiration in the US was March 2020. CGT confers 180-day exclusivity in the marketplace from time of launch. Quick take: UBS analyst Ash Verma (buy-rating on AMRX) says this approval unlocks a long-awaited growth opportunity, and predicts rapid uptake. CMS announces that all 50 states have applied to participate in Medicaid drug payment model 47 states and Puerto Rico have already signed agreements to participate in the GENEROUS Model program. Remaining states will have until 30-Sep to sign agreements with CMS. Press release Biotech M&A: TLX.AU (TLX) announced an agreement to acquire privately-held ITM Isotope Technologies Munich SE ("ITM") for up to $2.35B in cash and stock, inclusive of upfront and contingent consideration. Latest in the consolidation of the radiopharmaceutical / radioisotopes supplier industry. Last month Curium bought out Lantheus (LNTH) in a deal worth up to $8B. ITM is both a key supplier of Pluvicto to NOVN.SW and a potential competitor to Lutathera with its therapeutic treatment for GEP-NET (ITM-11) recently given a CRL (limited to third-party PAI). Trial results: ALKS announced topline results from a phase 1 POC study evaluating ALKS 7290 in adults with ADHD. First orexin 2 RA to demonstrate clinically meaningful improvements in ADHD symptoms in adults. Phase 2 trial currently enrolling, data expected in 2027. CUE announced topline results from the Phase 2 clinical trial of CUE-221 (UB-221) in China. Primary endpoint and the key secondary endpoint were met with high statistical significance. Measured against placebo, however efficacy comparisons drawn with Xolair (omalizumab, ROP.SW) Conf. call at 8:00ET Research: HLUN.B.DC upgraded to buy from neutral at UBS (Xian Deng), firm believes in the R&D turnaround underway. Target increased to DKK52 from DKK45 or approx. 22% upside. (FactSet average PT DKK49; range DKK34-65) CADL upgraded to buy from neutral at BofA (Alec Stranahan), target increased to $18 from $12 or approx. 66% upside. (FactSet average PT $22; range $15-29) IMNM initiated buy at Alliance Global Partners, target is $32 or approx. 34% upside. Life Science & MedTech Regulatory: White House seeks more power over NIH grant funds - Politico On Saturday (19-Sep) Politico reported that the White House is drafting an Executive Order to bring veto power over the NIH grant process. The proposed board would include NIH director Jay Bhattacharya and OMB director Russ Vought; the two would 'be required to reach unanimous decisions on grant awards'. Leerink analyst Puneet Souda writes that while a potential disruptor and headwind to FY27, the firm expects bipartisan pushback to continue to prevail, and that the NIH budget will likely rise 'regardless of the midterm outcomes'. (ALMR, BRKR, ILMN, NAUT, QTRX, TECH, TMO, TWST, TXG) GRAL Briefing documents expected today for FDA review of PMA for Galleri test. The Molecular and Clinical Genetics Panel of MDAC is scheduled to meet on Wednesday 23-Sep at 900ET. Research: TEM initiated neutral at Goldman Sachs (Evie Koslosky), target is $75 or approx. 4% downside. (FactSet average PT $68; range $35-100) On Deck: Regulatory FDA briefing documents ahead of Wed Adcom (GRAL) FDA PDUFA for MRK Winrevair sBLA (based on HYPERION study) (BMY royalties via Celgene acquisition) Earnings after the close today ABVX.FP (ABVX) Corporate on Tue 22-Sep: TLX hosting R&D Day meeting (8:30ET) Conference on Tue 22-Sep: Bank of America Global Healthcare Conference (Sep 22-23) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABVX, ALKS, ALMR, AMRX, BMY, BRKR, CADL, CUE, GRAL, HLUN.B.DC, ILMN, IMNM, INSM, IPN.FP, IVVD, JNJ, LNTH, MRK, NAUT, NOVN.SW, NOVO.B.DC, NVO, NVS, OSCR, QTRX, ROP.SW, SMMT, TECH, TEM, TLX, TLX.AU, TMO, TWST, TXG...(more)	show story hide story
21-Sep-2026 07:38	White House seeks more power over NIH grant funds - Politico On Saturday (19-Sep) Politico reported that the White House is drafting an Executive Order to bring veto power over the NIH grant process. The proposed board would include NIH director Jay Bhattacharya and OMB director Russ Vought; the two would 'be required to reach unanimous decisions on grant awards'. Leerink analyst Puneet Souda writes that while a potential disruptor and headwind to FY27, the firm expects bipartisan pushback to continue to prevail, and that the NIH budget will likely rise 'regardless of the midterm outcomes'. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ALMR, BRKR, ILMN, NAUT, QTRX, TECH, TMO, TWST, TXG...(more)	show story hide story
19-Sep-2026 00:46	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished mixed to slightly lower overall on Friday. Decliners beat advancers by nearly 3:1 on the XLV. Healthcare (0.20%) vs S&P 500 +0.17%. All major health groups ended lower on the session, including Pharma on a late-afternoon drift lower. Declines were all less than (1%) on the averages. Pharma held firm to weekly gains above 2% in a fairly quiet session, even after Reuters reported this morning that the White House is nearing support for China drug licensing deals. MedTech traded softer on Friday, but still concluded the week with strong gains overall - including broad MSD to LDD gains for the Life Science subgroup. COO +2.8%, on overnight activist headlines, and CNC (3.0%) bracketed the XLV. Very modest moves seen in between. XBI (0.97%) on the session / +0.33% for the week. Today's Electra Therapeutics IPO traded lower against the red tape. Macro: Market struggled for direction in fairly quiet Friday session following Thursday's gains. Backup in Treasury yields the biggest area of focus as yields reversed Thursday's post-FOMC gains. Not much specific behind move. Some thoughts earlier pressure came from less hawkish than expected BoJ hike, putting some scrutiny on whether Japan may have to sell Treasuries, though not much reaction following yen rally off reported BoJ rate check. Rate weakness also came despite oil selloff, though not much new around Middle East narrative ahead of next week's UN General Assembly. Other areas of focus include depressed sentiment (AAII bulls > bears by most since May-25), expected slowdown in FY27 EPS growth, narrow breadth (five largest companies account for record 27% of NTM S&P 500 earnings, according to BofA), falling global oil inventories, today's second-largest triple witching on record (~$7T of US options notional value expiring), CTAs selling in all scenarios next week (according to GS). Notable Gainers on Friday: +8.9% ALMR (Alamar Biosciences): on nearly 6X average daily volume; proteomics name, closed higher six straight days; +25% for the week +8.7% AGEN (Agenus): initiation +8.2% RXRX (Recursion Pharmaceuticals): best performing biotech on XBI; follow-through, shares were +11% yesterday +7.3% TWST (Twist Bioscience): follow-through, shares +31% for the week +6.6% PRLD (Prelude Therapeutics): initiation +2.8% COO (The Cooper Cos.): activist letter from JANA Partners; best performer on XLV +2.7% SCTX (Scribe Therapeutics, Inc.): on 9X average daily volume +2.6% ISRG (Intuitive Surgical): second-best on XLV Notable Decliners on Friday: -30.7% XENE (Xenon Pharmaceuticals): voluntarily pauses enrollment in psychiatry studies for analysis of AEs; submitted NDA in focal seizures; downgraded at Deutsche Bank -17.0% SION (Sionna Therapeutics): worst performer on XBI; shares (24%) for the week / (86%) YTD -11.7% ETRA (Electra Therapeutics): day one biotech IPO -7.9% NBTX (Nanobiotix): fourth straight weekly decline -7.4% TNGX (Tango Therapeutics): shares remain +146% YTD -7.1% ALKS (Alkermes): sixth straight weekly decline (and 7 of last 8 weeks) -7.1% MIRM (Mirum Pharmaceuticals): one week until PDUFA for zilurgisertib NDA -5.3% DYN (Dyne Therapeutics): stock lower 7 of 9 days since NVS data in DM1 -4.8% SRRK (Scholar Rock): EMA CHMP update, withdrawal of application -4.0% SDGR (Schrödinger): follow-through, shares were +26% yesterday -3.7% PCVX (Vaxcyte): vaccine sympathy to RFK Jr keynote speech -3.0% CNC (Centene): worst performer on XLV; shares down (2%) for the week Week in Review: Healthcare equities outperformed for the week. The S&P 500 Healthcare Index climbed +1.76% vs the S&P 500 Index down (0.08%). Outperformers: MedTech, Pharma, Biotech Underperformers: Managed Care, Services Major health groups were widely mixed for the week. A volatile week for AI stocks resulted in strong outperformance by Life Science subgroup. Corporate updates at the brokerage conferences were another primary source of news and direction for the space. With Stars cut points recently communicated, a few Managed Care companies participated, but were careful not to tip their hand with regard to 2027 Stars. Alignment Healthcare said succinctly that this year its different. CMS is expected to update in early October. Biotech choppy on a typical flow of clinical readouts, and even less so following the FOMC rate decision. Theoretically Biotech should underperform in a rising rate environment, however some analysts say that rising rates are already baked in - the XBI essentially flat since mid-July. Looking ahead, more broker conferences on tap, plus an FDA advisory committee for Grail Inc's Galleri, and Senate HELP nomination hearing for FDA Commissioner Heidi Overton. Earnings season still weeks away, but the bellwether reporting slots are set with UNH and JNJ now scheduled for Tuesday 13-Oct. Year-to-date, Healthcare +8.47% vs the S&P 500 +11.76%. Healthcare fifth out of eleven major sectors in CY26. Energy +42.65% and Consumer Discretionary (4.45%) bracket them all. Notable movers for the week: Gainers: TEM +31.9% - presented at Morgan Stanley; AI names rally TWST +31.3% - collaboration with LLY; stock closed higher last 7 days; best performer on XBI CAI +23.2% - LST rally alongside AI IOVA +19.2% - follow-through, shares +275% YTD; presented at HC Wainwright ILMN +16.1% - LST rally alongside AI RVTY +15.4% - presented at Morgan Stanley and Baird conferences; LST rally alongside AI; best performer on XLV BRKR +14.9% - presented at Morgan Stanley conference; LST rally alongside AI GH +14.0% - follow-through from WCLC; Shield reimbursement update; presented at MS conference PBLS +13.2% - best weekly gain for shares; data update for ESMO in October NTRA +12.3% - presented at MS and Baird conferences; molecular diagnostics strength TXG +11.7% - follow-through; stock higher 16 of last 18 weeks CRSP +9.4% - presented at Morgan Stanley; gene editing rally with XBI WAY +9.3% - Reuters report - exploring sale; downgraded at Barclays Decliners: ALHC (33.8%) - presentation at Baird conference; comments on cost trends & Stars ARWR (19.8%) - trial results in mixed hyperlipidemia IONS (18.0%) - sympathy to SRRK; stock lower 15 of last 17 days SRRK (15.8%) - FDA approves Isembyld; downgrade at Barclays; MAA withdrawn ETRA (11.7%) - biotech IPO #22 / healthcare #27 in CY26 BBIO (8.0%) - stock lower 20 of last 21 days CVS (6.1%) - stock closed lower 11 of last 12 days; quiet period ahead of Stars update; worst performer on XLV HUM (5.8%) - quiet period ahead of 2027 Stars update (early October) Week Ahead (Sat - Sun): Sep 19 - 27 Corporate calendar Mon 21-Sep: NOVO.B.DC (NVO) holding CMD and brand update (4:00ET) Tue 22-Sep: TLX hosting R&D Day meeting (8:30ET) Wed 23-Sep: ARCT Trial results call for ph2 trial with ARCT-810 OTC deficiency (16:30ET) Thu 24-Sep: INFU hosting Investor Update call (14:00ET) Regulatory calendar Mon 21-Sep: FDA briefing documents ahead of Wed Adcom (GRAL); FDA PDUFA for MRK Winrevair sBLA (based on HYPERION study) (BMY royalties via Celgene acquisition) Wed 23-Sep: FDA Adcom for GRAL Galleri PMA Thu 24-Sep: Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) Fri 25-Sep: FDA PDUFA for Elevar Therapeutics lirafugratinib NDA in cholangiocarcinoma (RLAY royalties) Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY royalties) Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB royalties) Earnings calendar Mon 21-Sep: after US market close ABVX.FP (ABVX) Conference calendar Tue 22-Sep: Bank of America Global Healthcare Conference (Sep 22-23) Wed 23-Sep: Bernstein Healthcare Forum (Sep 23-24) Syndicate calendar / potential IPO pricing n/a Related: AGEN, ALHC, ALKS, ALMR, ARCT, ARWR, BBIO, BIIB, BMY, BRKR, CAI, CNC, COO, CRSP, CVS, DYN, ETRA, GH, GRAL, HUM, ILMN, INCY, INFU, IONS, IOVA, ISRG, MIRM, MRK, NBTX, NTRA, NVO, PBLS, PCVX, PRLD, RLAY, ROP.SW, RVTY, RXRX, SCTX, SDGR, SION, SRRK, TEM, TLX, TNGX, TWST, TXG, WAY, XENE...(more)	show story hide story
18-Sep-2026 16:53	CMS announces that all 50 states have applied to participate in Medicaid drug payment model CMS announces that 47 states and Puerto Rico have already signed agreements to participate in the GENEROUS Model program. Remaining states will have until 30-Sep to sign agreements with CMS. Under the GENEROUS Model: Participating manufacturers will make covered outpatient drugs available at most-favored nation pricing to participating state Medicaid programs. Under agreements with states, participating manufacturers will be invoiced by states for supplemental rebates to effectuate international prices. CMS will monitor pricing accuracy. CMS will share in rebates with states via a reduction in the federal share of Medicaid payments. Trump Administration has announced agreements with major drugmakers including AZN, PFE, MRK.GR. "As a result of these agreements, these manufacturers will participate in the GENEROUS Model after certain terms are finalized, and state Medicaid programs will pay lower prices on drugs made by those manufacturers. The manufacturers that have entered into these agreements, plus any additional manufacturers that choose to participate in GENEROUS, would complete an RFA document and then negotiate the coverage terms for their drugs with CMS. The manufacturer would then sign a supplemental rebate agreement with each state that is interested in participating, as well as a participation agreement with CMS." Source: FAQ GENEROUS is voluntary for state Medicaid agencies. In addition, states can determine for which (if any) covered outpatient drugs they would like to obtain a price similar to what other countries pay with respect to a participating manufacturer, providing additional flexibility for states to make the choices that align with their fiscal and coverage priorities. See Related StreetAccount comments: 3/2/2026 2:32:18 PM - CMS extends deadline for drug manufacturers to apply for MFN pilot in Medicaid 11/6/2025 4:46:05 PM - CMS announces pilot program to lower drug prices in Medicaid Related: AZN, MRK.GR, PFE Reference Link	show story hide story
18-Sep-2026 15:13	StreetAccount Summary: Notable Drug Events expected for the week of 20-Sep Mon 21-Sep Regulatory decision: MRK FDA PDUFA for Winrevair sBLA in PAH BMY (Celgene) is eligible for a 22% royalty on global sales Tue 22-Sep Investor event: TLX R&D day (8:30ET) Wed 23-Sep Trial results: ARCT to present data for ARCT-810 Phase 2 trial in Ornithine transcarbamylase (OTC) deficiency (webcast 16:30ET) Industry meeting with clinical data: International Myeloma Society (IMS) annual meeting (Sep 23-26) (HPHA.GR, ABBV) Thu 24-Sep Regulatory meeting: Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) Fri 25-Sep Regulatory decision: Elevar Therapeutics FDA PDUFA for lirafugratinib NDA in metastatic cholangiocarcinoma RLAY eligible to receive up to $485 million in regulatory/commercial milestone payments and tiered royalties Sat 26-Sep Regulatory decision: MIRM FDA PDUFA for zilurgisertib NDA in FOP patients 12 years and older INCY is eligible for development/regulatory milestone payments, sales-based milestones, and tiered royalties on worldwide net sales Sun 27-Sep Regulatory decision: ROP.SW FDA PDUFA for Gazyva sBLA in idiopathic nephrotic syndrome BIIB is eligible to receive a share of U.S. pre-tax operating profits from the drug later during September 2026 Regulatory decisions: FDA PDUFAs: EGTX.SS (Emcitate NDA, 28-Sep), BMY (Camzyos sNDA, 30-Sep) Industry meeting with clinical data: European Association for the Study of Diabetes (EASD) annual meeting (Sep 28 - Oct 2) Trial results: LLY (Ph3 obesity and T2D), KOD (Ph3 Wet AMD), KLRA (Ph 3 T2D and Ph1 obesity), PAR.AU (Ph3 OA), IMMX (Ph2 R/R AL Amyloidosis), CNTB (Ph2 COPD), QURE (Ph1/2 Huntington's disease), DYN (Ph1/2 DM1), CNTX (Ph1 solid tumors), PHIL.IM (Ph1 glioblastoma), ZNTL (Ph1 PROC), PMN (Ph1 AD), VKTX (Ph1 obesity), ACET (Ph1 SLE), CGEM (Ph1 RA) Related: ABBV, ACET, ARCT, BIIB, BMY, CGEM, CNTB, CNTX, DYN, EGTX.SS, HPHA.GR, IMMX, INCY, KLRA, KOD, LLY, MIRM, MRK, PAR.AU, PHIL.IM, PMN, QURE, RLAY, ROP.SW, TLX, VKTX, ZNTL...(more)	show story hide story
18-Sep-2026 11:04	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.44%) vs the S&P 500 (0.16%). All major health groups are lower on the session, although declines are all less than (1%) on the averages. MedTech and Pharma are holding onto nice weekly gains (+4% and +2% respectively) in a very quiet session. COO +2% a leading gainer on today's activist headlines, although ISRG +3% top gainer on the XLV; leading decliner is CNC (2%). MRNA (2%) trimming its weekly advance to just +8%. Very modest moves in between. XBI currently (0.57%) on the session / +0.73% WTD while awaiting the Nasdaq debut for Electra Therapeutics. Gainers +10.7% ALMR (Alamar Biosciences): proteomics name; on strong volume; +27% WTD +7.2% SCTX (Scribe Therapeutics, Inc.): on average volume +5.8% ATTO (Attovia Therapeutics): on light volume +3.5% TWST (Twist Bioscience): best performing biotech on XBI; follow-through, shares +27% WTD +2.6% FDMT (4D Molecular Therapeutics): follow-through; shares +14% WTD +2.5% TRAX (First Tracks Biotherapeutics Inc): initiation; shares +10% WTD +2.5% ISRG (Intuitive Surgical): best performer on XLV +2.4% COO (The Cooper Cos.): activist letter from JANA Partners +1.9% AGEN (Agenus): initiation Decliners -29.0% XENE (Xenon Pharmaceuticals): voluntarily pauses enrollment in psychiatry studies for analysis of AEs; submitted NDA in focal seizures; downgraded at Deutsche Bank -8.8% SION (Sionna Therapeutics): worst performer on XBI; shares (17%) WTD -6.3% SGP (SpyGlass Pharma Inc): on above average volume -4.4% SRRK (Scholar Rock): EMA CHMP update, withdrawal of application -3.7% MYGN (Myriad Genetics): shares +16% WTD -2.9% GSK (GSK Plc): ADRs remain +3% WTD -2.3% SDGR (Schrödinger): follow-through, shares were +26% yesterday -1.9% CNC (Centene): worst performer on XLV; shares (1%) WTD -1.8% CVS (CVS Health): shares down (6%) WTD -1.7% RVTY (Revvity): shares remain +16% WTD -1.6% MRNA (Moderna): shares remain +7% WTD -1.5% VRTX (Vertex Pharmaceuticals): EMA CHMP updates	show story hide story
18-Sep-2026 08:39	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Biotech IPO #22, Healthcare IPO #27 of CY2026 priced overnight. Electra Therapeutics priced upsized 23.3M share offering at the midpoint of the anticipated range, raising $350M on the Nasdaq offering. EMA CHMP recommends MAA for twelve new medicines, extension of MAA for eleven more. No real stock movers on the EMA actions. RFK Jr reinvigorated the anti-vaccine crowd during a keynote speech on Thursday afternoon. Next week the Senate HELP Committee is scheduled to vote on the FDA Commissioner nominee. Yesterday, Healthcare equities were mixed and moderately higher overall, led by Biopharma groups. XBI +2.64% and DRG +1.28%. Services group remain an outlier, distributors remained under pressure and extended weekly declines; joined by dialysis providers with MSD pullback for the session. No specific catalyst in biotech, which rallied despite the fresh rate hike and rising rate environment. Macro S&P futures are up +0.1% on Friday morning. Very quiet session thus far with no real headline development of the major themes. Some help from another day of lower oil amid relatively calm geopolitical headlines. Tensions remain high in the Mideast though crude was helped yesterday by more constructive headlines about repairs on the Saudi East-West pipeline and reports of China pressuring Iran rein in their Houthi allies. Yields a bit higher today after some notable Treasury strength Thursday, but 10Y holding below the 5% level it breached earlier in the week. Otherwise, newsflow today fairly quiet. AI trade looking to continue to its recovery from early-week shock on frontier model pacing concerns (analysts suggested this need not hit capex/compute demand). Big story overnight was BoJ's long-expected rate hike, though yen has been pressured given two dissents and commentary from Ueda that was seen as not as hawkish as hoped. Pre-market trading update Trading higher +12.5% PRLD initiation (low volume) +3.8% RCUS on 11K shares +2.5% AGEN initiation (low volume) +2.2% BEAM follow-through, shares were +7% yesterday +1.6% NPCE initiation (low volume) +0.6% NTLA follow-through, shares were +7% yesterday +0.4% COO activist letter from JANA Partners +0.4% NVO EMA CHMP updates +0.3% RARE follow-through; announced WAC price $3.95M Trading lower -22.9% XENE voluntarily pauses enrollment in psychiatry studies for analysis of AEs; submitted NDA in focal seizures; downgraded at Deutsche Bank -3.3% SDGR follow-through, shares were +26% yesterday -1.9% INCY despite positive EMA CHMP opinion -1.8% GSK ADRs are +6% WTD vs DRG +2% -0.5% SRRK EMA CHMP update, withdrawal of application EMA CHMP publishes summary of opinions for September 2026 meeting Summary here. EMA recommends twelve (12) new medicines for approval (including two biosimilar and two generics), and extension of therapeutic indication for another eleven (11). CHMP issued zero (0) negative opinions for MAA. Positive opinions for MAA include: Novo Nordisk (NOVO.B.DC) Frehemgo (denecimig), Betta Pharmaceuticals (300558.CH) Gevalka (ensartinib), AstraZeneca (AZN.LN) Klygefa (gefurulimab), Corcept Therapeutics (CORT) Lifyorli (relacorilant), Incyte (INCY) Povofortay (povorcitinib), Pharmanovia (0KG4J4-E) / IMPACT Therapeutics (7630.HK) Sepalna (senaparib), Sanofi (SAN.FP) VaxRabeo (rabies virus (inactivated) strain WISTAR (PM/WI38 1503-3M)), Zealand Pharma (ZEAL.DC) Zeydovio (glepaglutide) Plus two biosimilar and two generics. Extensions of indication were recommended for: Anzupgo (+LEOP.DC), Abiraterone Mylan (VTRS), Cosentyx (NOVN.SW), Enhertu (AZN.LN, 4568.JP), Jyseleca (0GRZB6-E, GILD), Keytruda (MRK), Ocrevus (ROP.SW, BIIB), Padcev (4503.JP, PFE), Pepaxti (ONCO.SS), Sogroya (NOVO.B.DC), and Tecvayli (JNJ, GMAB). Re-examination of application: Proveca Pharma Limited (0YFM7C-E) Kemsu (sufentanil / ketamine), Zevra Denmark A/S (0YY57X-E) Meplyffa (arimoclomol) and CATS Consultants' (private) Qezzaqar (catequentinib) Withdrawal of application: SRRK Isembyld (apitegromab), +BOEHRINGER Zinmyleo (trilaciclib) extension of MAA only: NOVO.B.DC Alhemo (concizumab), VRTX Kaftrio (ivacaftor/tezacaftor/elexacaftor), VRTX Kalydeco (ivacaftor) Biotech Regulatory: XENE announced it has submitted an NDA for azetukalner in focal seizures (FS), as planned for Q3. Company also announced it has voluntarily paused enrollment in its ongoing psychiatry studies - MMD and bipolar - following an analysis of neuropsychiatric adverse events in these studies. RARE hosted an investor call to discuss the FDA approval of Fayuvi (rebisufligene etisparvovec-hopf) (formerly UX111) for the treatment of MPS IIIA, also known as Sanfilippo syndrome type A. Company announced WAC pricing of $3.95M per patient. (ABEO) Company also announced it will monetize the new PRV in addition to the one received this summer. IPO priced: ETRA (Electra Therapeutics) priced upsized 23.3M share offering at the midpoint of the anticipated range, raising $350M on the Nasdaq offering. #22 Biotech IPO this year, and #27 Healthcare IPO. A clinical-stage biotech focused on precision oncology, lead candidate ipsoprubart for secondary hemophagocytic lymphohistiocytosis (sHLH) Research: XENE downgraded to hold from buy at Deutsche Bank (David Hoang), target cut to to $46 from $90 or approx. 20% downside. AGEN initiated buy at Chardan Capital (Andreas Argyrides), target is $40 or approx. 454% upside. CATX initiated outperform at William Blair (Andy Hsieh) CUE initiated buy at B Riley Securities (Mayank Mamtani), target is $83 or approx. 118% upside. DBVT initiated outperform at Evercore ISI (Gavin Clark-Gartner), target is $30 or approx. 140% upside. ELOX initiated outperform at Leerink Partners (Joseph Schwartz), target is $32 or approx. 82% upside. ENTX initiated outperform at Leerink Partners (David Risinger), target is $9 or approx. 197% upside. PRLD initiated outperform at Evercore ISI (Gavin Clark-Gartner), target is $10 or approx. 119% upside. QNCX initiated outperform at Evercore ISI (Gavin Clark-Gartner), target is $65 or approx. 141% upside. TRAX initiated outperform at Evercore ISI (Gavin Clark-Gartner), target is $65 or approx. 66% upside. Life Science & MedTech Activist: COO Jana Partners sends letter to Cooper Companies, seeks new CEO, new Board Chair, urgent overhaul. States "Cooper is suffering from a crisis of its own creation." Research: NPCE initiated overweight at KeyBanc (Brett Fishbin), target is $18 or approx. 27% upside. (FactSet average PT $20; range $18-22) STMN.SW re-initiated buy at Berenberg (Beatrice Fairbairn), target is CHF118 or approx. 25% upside. (FactSet average PT CHF115; range CHF86-136) On Deck: Regulatory on Sat 19-Sep: FDA PDUFA for IntraBio (0JX4J8-E) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Peek Ahead to next week Sep 21-27 Mon 21-Sep: NOVO.B.DC (NVO) holding CMD and brand update (4:00ET); Earnings after US market close ABVX.FP (ABVX); FDA PDUFA for MRK Winrevair sBLA (based on HYPERION study) (BMY royalties via Celgene acquisition) Tue 22-Sep: Bank of America Global Healthcare Conference (Sep 22-23) Wed 23-Sep: Bernstein Healthcare Forum (Sep 23-24); FDA Adcom for GRAL Galleri PMA Thu 24-Sep: Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) Fri 25-Sep: FDA PDUFA for RLAY lirafugratinib NDA in cholangiocarcinoma Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY) Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 300558.CH, 4503.JP, 4568.JP, 7630.HK, ABEO, ABVX, AGEN, AZN.LN, BEAM, BIIB, BMY, CATX, COO, CORT, CUE, DBVT, ELOX, ENTX, ETRA, GILD, GMAB, GRAL, GSK, INCY, JNJ, MIRM, MRK, NOVN.SW, NOVO.B.DC, NPCE, NTLA, NVO, ONCO.SS, PFE, PRLD, QNCX, RARE, RCUS, RLAY, ROP.SW, SAN.FP, SDGR, SRRK, STMN.SW, TRAX, VRTX, VTRS, XENE, ZEAL.DC, +BOEHRINGER, +LEOP.DC, 0JX4J8-E, 0KG4J4-E, 0YFM7C-E, 0YY57X-E...(more)	show story hide story
18-Sep-2026 08:02	EMA CHMP publishes summary of opinions for September 2026 meeting Summary here. EMA recommends twelve (12) new medicines for approval (including two biosimilar and two generics), and extension of therapeutic indication for another eleven (11). CHMP issued zero (0) negative opinions for MAA. Positive opinions for MAA include: Novo Nordisk (NOVO.B.DC) Frehemgo (denecimig), Betta Pharmaceuticals (300558.CH) Gevalka (ensartinib), AstraZeneca (AZN.LN) Klygefa (gefurulimab), Corcept Therapeutics (CORT) Lifyorli (relacorilant), Incyte (INCY) Povofortay (povorcitinib), Pharmanovia (0KG4J4-E) / IMPACT Therapeutics (7630.HK) Sepalna (senaparib), Sanofi (SAN.FP) VaxRabeo (rabies virus (inactivated) strain WISTAR (PM/WI38 1503-3M)), Zealand Pharma (ZEAL.DC) Zeydovio (glepaglutide) Plus two biosimilar and two generics. Extensions of indication were recommended for: Anzupgo (~+LEOP.DC~), Abiraterone Mylan (VTRS), Cosentyx (NOVN.SW), Enhertu (AZN.LN), Jyseleca (0GRZB6-E, GILD), Keytruda (MRK), Ocrevus (ROP.SW, BIIB), Padcev (4503.JP, PFE), Pepaxti (ONCO.SS), Sogroya (NOVO.B.DC), and Tecvayli (JNJ, GMAB). Re-examination of application: Proveca Pharma Limited (0YFM7C-E) Kemsu (sufentanil / ketamine), Zevra Denmark A/S (0YY57X-E) Meplyffa (arimoclomol) and CATS Consultants' (private) Qezzaqar (catequentinib) Withdrawal of application: SRRK Isembyld (apitegromab), ~+BOEHRINGER~ Zinmyleo (trilaciclib) extension of MAA only: NOVO.B.DC Alhemo (concizumab), VRTX Kaftrio (ivacaftor/tezacaftor/elexacaftor), VRTX Kalydeco (ivacaftor) For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: 300558.CH, 4503.JP, 7630.HK, AZN.LN, BIIB, CORT, GILD, GMAB, INCY, JNJ, MRK, NOVN.SW, NOVO.B.DC, ONCO.SS, PFE, ROP.SW, SAN.FP, SRRK, VRTX, VTRS, ZEAL.DC, +BOEHRINGER, +LEOP.DC, 0KG4J4-E, 0YFM7C-E, 0YY57X-E...(more)	show story hide story
17-Sep-2026 17:12	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed and moderately higher overall on Thursday. Advancers outnumbered decliners on the XLV, breadth at neither highs nor lows at the close. Healthcare +0.64% vs S&P 500 +1.14%. Most major health groups ended higher on the session, led by Biopharma groups. XBI +2.64% and DRG +1.28%. Services group remain an outlier, distributors remained under pressure and extended weekly declines; joined by dialysis providers with MSD pullback for the session. No specific catalyst in biotech today, the XBI midday was on track for a top-five day this year, before cooling down in the afternoon. Newsflow quiet even rally came despite the fresh rate hike and rising rate environment. High-beta names like gene-editing stocks saw HSD gains. MRNA +8.6% leading gainer on the XLV, while DVA (5.6%) bracketed the XLV. Corporate newsflow very quiet overnight. Sell-side research includes Boston Scientific downgraded to neutral at Citi. In addition, Deutsche Bank lowered the European Health Care sector to neutral from overweight; firm prefers more defensive sectors in the rising rate environment. Today's Biotech noise highlighted by STAT News' opinion piece from Adam Feuerstein, who predicts a Sellas Life Science blow-up. Shares are up more than 200% YTD into a pivotal, event-driven phase 3 trial for AML. Yesterday, Healthcare equities were lightly mixed and little changed overall. Growth outperformed value with market squarely focused on FOMC and the 25bp bump to rates, as was widely expected. Payers were the outlier today, large-cap MCOs weaker post-FOMC to end down as much as (3%) on the day. ALHC shed another (16%). Overall sector-specific newsflow was fairly quiet overnight, while ongoing brokerage conferences remained the primary source of updates. Looking ahead, more broker conferences, and potentially the first biotech IPO to price in over a month. Macro Stocks found some footing following three-straight declines. Oil a tailwind (though finished off lows) despite mixed takeaways from latest Middle East updates (Trump considering again whether to resume combat operations, China asking Iran to rein in Houthis, more focus on resilient Saudi oil flows). Treasury bid also supportive, coming despite Street takeaways that flagged more hawkish-than-expected Warsh and FOMC alongside morning data (claims, Philly Fed) that underscored labor resilience and sticky prices. Other areas of focus included positive AI updates (GNRC/AMZN deal, NBIS pricing, CRWV deals and positive commentary around equity and debt raises), CTAs selling in all scenarios (including $30B in flat tape, according to GS), largely upbeat sell-side conference takeaways, and next week's Trump-Xi summit. Notable Gainers +374.1% AEMD (Aethlon Medical): microcap; reverse merger with North Immunology +36.9% MNOV (MediciNova): initiation +26.4% SDGR (Schrödinger): AI-levered names rallying +15.3% ABSI (Absci Corp.): best performer on XBI +14.8% TEM (Tempus AI): AI-levered names rallying +12.6% RARE (Ultragenyx Pharmaceutical): FDA approves gene therapy Fayuvi for MPS IIIA; second-best on XBI +11.0% RXRX (Recursion Pharmaceuticals): AI-levered names rallying +9.8% CRSP (CRISPR Therapeutics): gene editing group outperforming with XBI rallying +8.7% TWST (Twist Bioscience): follow-through +8.5% MRNA (Moderna): best performer on XLV; on below average volume +7.1% ILMN (Illumina): molecular diagnostics strength +6.8% BEAM (Beam Therapeutics): gene editing group outperforming with XBI rallying +6.7% NTLA (Intellia Therapeutics): gene editing group outperforming with XBI rallying +6.4% GRAL (GRAIL, Inc.): molecular diagnostics strength; initiation +6.1% NTRA (Natera): molecular diagnostics strength +5.9% IBIO (iBio, Inc.): initiation +5.5% MIRA (MIRA Pharmaceuticals): initiation +5.0% NUVB (Nuvation Bio): FDA approves Ibtrozi sNDA with DOR labeling +4.7% ALVO (Alvotech): follow-through +4.7% PRME (Prime Medicine): gene editing group outperforming with XBI rallying nearly +4.1% ABEO (Abeona Therapeutics): sympathy to RARE; royalties on Fayuvi +3.4% QGEN (Qiagen): Manager Magazin report Notable Decliners -59.4% LGVN (Longeveron Inc.): microcap biotech; trial results in HLHS -9.0% ASTH (Astrana Health): short report by Glasshouse Research -7.5% XRAY (Dentsply Sirona): sympathy to NVST -7.1% DMRA (Damora Therapeutics): worst performer on XBI; unusual volume again -5.6% DVA (DaVita): dialysis names weak; worst performer on XLV -5.1% NVST (Envista Holdings): Investor Day; updates medium term outlook -4.2% SGRY (Surgery Partners): updated guidance; Jefferies comments on investor meetings -3.9% FMS (Fresenius Medical Care): dialysis names weak -2.9% COR (Cencora): weakness in distributors; second-worst on XLV -2.7% CAH (Cardinal Health): weakness in distributors -2.6% ZBH (Zimmer Biomet Holdings): shares 1% WTD -2.3% VRDN (Viridian Therapeutics): worst performer on XBI -2.0% HSIC (Henry Schein): sympathy to NVST; weakness in distributors FDA approves Ultragenyx Pharma's gene therapy for MPS IIIA On Thursday, the FDA announced it has approved Fayuvi (rebisufligene etisparvovec-hopf) (formerly UX111) for the treatment of MPS IIIA, also known as Sanfilippo syndrome type A. Action came two days ahead of the PDUFA goal date. Sponsor is RARE; ABEO entitled to royalties on sales. Conference call scheduled for 17:30ET RFK and HHS seek public input on RF/EMF exposure and health outcomes Secretary RFK Jr and the HHS today published notice of a Request for Information (RFI) on Electromagnetic Fields (EMFs), Radiofrequency (RF) Radiation, and Wireless Radiation Exposure. HHS is interested in clear, balanced, and evidence-informed information about RF/EMF exposure that can support decision-making, identify research priorities, and inform practical strategies to reduce unnecessary exposure where appropriate. Comment period open for 30 days after Federal Register publication (21-Sep-2026). Per the MAHA Report (May 2025): Electromagnetic Radiation (EMR): an exposure due to the proliferation of cell phones, WiFi routers, cell towers, and wearables) Some studies have linked EMR exposure to reduced sperm counts and motility but not quality. The NIH's National Toxicology Program identified "clear evidence" of DNA damage and increased cancer risk in rats. However, a recent systematic review of over 50 studies found low to inadequate evidence on impact in children and called for more high-quality research. StreetAccount notes that In October 2025, the NY Times wrote about the conflict between MAHA and MAGA, when it comes to EMF and radiofrequency radiation from devices such as cellphones and Wi-Fi routers. Pennsylvania asks for CDC measles help amid Kennedy dispute - Reuters PA Sec of Health: "The CDC's choice not to publicly recognize the deaths undermines our response. For this reason, if CDC is unable to transparently and accurately communicate information about those measles-associated deaths, the Department will respectfully rescind our request for a CDC Epi-Aid." Reuters, citing letter sent by Pennsylvania to CDC on Wednesday Envista Holdings updates outlook at Investor Day NVST Investor Day meeting began at 9:00ET. Slides here. Slide 73: Performing at or above our medium-term outlook Slide 74: Raising our medium-term outlook Core Growth to +2-5% vs prior +2-4% Adj EBITDA growth to +5-8% vs prior +4-7% Adj EPS growth +7-11% vs prior +7-10% Reaffirms FCF conversion 100% Quick take: Revisions viewed as incremental not transformational by BMO (maintains market perform rating). Novo continues to make pipeline deals ahead of CMD next week NOVO.B.DC (NVO) and privately-held Orbis Medicines enter into multi-target drug discovery collaboration worth up to $1.4B - terms include upfront payment and milestone payments, plus royalties. Novo also making strategic investment in the partner. Qiagen higher following media report QGEN under the guide of its new CEO reportedly continues to evaluate a potential sale, with TPG and Bain Capital seen as incremental to the prior media reports of PE interest in the company. (Manager Magazin) AstraZeneca higher on pair of regulatory updates in oncology AZN.LN (AZN) With partner 4568.JP (Daiichi Sankyo) Enhertu now recommended by NICE for HER2-low advanced breast cancer. Previously the committee was unable to recommend based on price. The change came about following the US/UK Pharmaceutical Pricing Agreement, says NICE. Separately, AstraZeneca received FDA approval for an efficacy supplement (sNDA) for Truqap. An updated label is not yet available on the FDA website. Nuvation Bio higher following quick label expansion NUVB FDA approved sNDA for IBTROZI four months ahead of the PDUFA goal date. Supplement to the indication for ROS1+ NSCLC. The updated label reflects TRUST-I TKI-naïve median duration of response (DOR) of nearly 50 months. SELLAS Life Sciences lagging after STAT OpEd SLS mentioned cautiously by STAT News' Adam Feuerstein ahead of the readout of phase 3 REGAL trial - predicts the study with GPS for AML will fail. Through Wednesday, shares were +209% YTD. Notable research in Healthcare today Biotech: ROIV initiated buy at Stifel (Alex Thompson), target is $51 or approx. 29% upside. (FactSet average PT $47; range $38-55) ABEO initiated buy at Roth Capital (Boobalan Pachaiyappan), target is $17 or approx. 217% upside. (FactSet average PT $19; range $14-28) CELC initiated overweight at JPMorgan (Anupam Rama), target is $157 or approx. 90% upside. (FactSet average PT $161; range $140-177) IBIO initiated buy at HC Wainwright (Ananda Ghosh), target is $7 or approx. 493% upside. (FactSet average PT $5.52; range $4.20-7) MIRA initiated buy at Maxim Group, target is $3.50 or approx. 386% upside. MNOV initiated buy at Roth Capital (Boobalan Pachaiyappan), target is $6 or approx. 138% upside. (FactSet average PT $8; range $6-11) PRE initiated buy at Craig-Hallum Capital (Eric Des Lauriers), target is $40 or approx. 82% upside. (FactSet average PT $36; range $30-40) RYTM initiated outperform at Wolfe Research (Kalpit Patel), target is $125 or approx. 28% upside. (FactSet average PT $139; range $105-160) TELO initiated buy at Maxim Group, target is $4 or approx. 254% upside. TSHA initiated outperform at Wolfe Research (Kalpit Patel) VSTM initiated outperform at Wolfe Research (Kalpit Patel) ZYME initiated outperform at Wolfe Research (Kalpit Patel) MedTech: BSX downgraded to neutral from buy at Citi (Joanne Wuensch), target cut to $50 from $57 or approx. 14% upside. (FactSet average PT $61; range $44-85) HAE upgraded to buy from neutral at Citi (Joanne Wuensch), target increased to $123 from $92 or approx. 16% upside. (FactSet average PT $108; range $86-125) GRAL initiated sector perform at RBC Capital Markets (Dan Leonard), target is $84 or approx. 12% upside. (FactSet average PT $77; range $60-105) TKNO initiated buy at Jefferies (Matthew Stanton), target is $9 or approx. 27% upside. (FactSet average PT $9; range $7-12) Post-close news Regulatory: XENE announced it has submitted an NDA for azetukalner in focal seizures (FS), as planned for Q3. Company also announced it has voluntarily paused enrollment in its ongoing psychiatry studies - MMD and bipolar - following an analysis of neuropsychiatric adverse events in these studies. Conf. call at 16:30ET Shares trading (23.7%) in the after-hours On Deck: Syndicate calendar / IPO pricing +ETRA (Electra Therapeutics) expected to raise $325M (at midpoint) - clinical-stage biotech focused on precision oncology, lead candidate ipsoprubart for secondary hemophagocytic lymphohistiocytosis (sHLH) Regulatory EMA CHMP MAA opinions (18-Sep) (ONCO.SS) on Sat 19-Sep: FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Peek Ahead to next week Sep 21-27 Mon 21-Sep: NOVO.B.DC (NVO) holding CMD and brand update (4:00ET); Earnings after US market close ABVX.FP (ABVX); FDA PDUFA for MRK Winrevair sBLA (based on HYPERION study) (BMY royalties via Celgene acquisition) Tue 22-Sep: Bank of America Global Healthcare Conference (Sep 22-23) Wed 23-Sep: Bernstein Healthcare Forum (Sep 23-24); FDA Adcom for GRAL Galleri PMA Thu 24-Sep: Senate HELP Committee: FDA Commissioner Nomination Hearing (Heidi Overton) (10:30ET) Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY) Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB) StreetAccount Healthcare Reads Pennsylvania asks for CDC measles help amid Kennedy dispute (17-Sep) Reuters The FDA's rebuilding effort is running into a new challenge (17-Sep) STAT News Sen Cassidy faults Trump vaccine policy for US measles deaths as panel weight health nominees (16-Sep) Reuters Why We Can't Stop Arguing About S.S.R.I.s (16-Sep) NY Times (opinion) HHS Plans New Research Into Autism Development, Treatment (16-Sep) Bloomberg Novo partners with Anthropic to speed up drug development with Claude (16-Sep) Reuters A onetime Gilead exec's novel startup eyes $1B IPO valuation (15-Sep) SF Business Times New Measles Deaths Send US Fatality Total to Highest in Decades (15-Sep) Bloomberg This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4568.JP, ABEO, ABSI, ABVX, AEMD, ALVO, ASTH, AZN.LN, BEAM, BMY, BSX, CAH, CELC, COR, CRSP, DMRA, DVA, FMS, GRAL, HAE, HSIC, IBIO, ILMN, INCY, LGVN, MIRA, MIRM, MNOV, MRK, MRNA, NOVO.B.DC, NTLA, NTRA, NUVB, NVO, NVST, ONCO.SS, PRE, PRME, QGEN, RARE, ROIV, ROP.SW, RXRX, RYTM, SDGR, SGRY, SLS, TELO, TEM, TKNO, TSHA, TWST, VRDN, VSTM, XENE, XRAY, ZBH, ZYME, +ETRA...(more)	show story hide story
17-Sep-2026 12:54	RFK and HHS seek public input on RF/EMF exposure and health outcomes Secretary RFK Jr and the HHS today published notice of a Request for Information (RFI) on Electromagnetic Fields (EMFs), Radiofrequency (RF) Radiation, and Wireless Radiation Exposure. HHS is interested in clear, balanced, and evidence-informed information about RF/EMF exposure that can support decision-making, identify research priorities, and inform practical strategies to reduce unnecessary exposure where appropriate. Comment period open for 30 days after Federal Register publication (21-Sep-2026). Per the MAHA Report (May 2025): Electromagnetic Radiation (EMR): an exposure due to the proliferation of cell phones, WiFi routers, cell towers, and wearables) Some studies have linked EMR exposure to reduced sperm counts and motility but not quality. The NIH's National Toxicology Program identified "clear evidence" of DNA damage and increased cancer risk in rats. However, a recent systematic review of over 50 studies found low to inadequate evidence on impact in children and called for more high-quality research. StreetAccount notes that In October 2025, the NY Times wrote about the conflict between MAHA and MAGA, when it comes to EMF and radiofrequency radiation from devices such as cellphones and Wi-Fi routers. Reference Link: RFI Reference Link: NY Times (10-28-2025)	show story hide story
17-Sep-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index +0.31% vs the S&P 500 +0.89%. Most major health groups higher on the session, but mixed around the tape. Biotech group is leading with the market bouncing, the XBI +3.66% is on track for Top 5 day this year. Nothing specific in the corporate newsflow driving Biotech higher, and despite the fresh rate hike and rising rate environment. High-beta names like gene-editing stocks are leading with double-digit gains today. MRNA +10% and HSIC (3%) bracket the XLV. BSX (2%) downgraded at Citi, with the stock cut in half this year. Gainers +374.8% AEMD (Aethlon Medical): microcap; reverse merger with North Immunology +30.4% MNOV (MediciNova): initiation +18.9% ABSI (Absci Corp.): best performer on XBI +13.3% TWST (Twist Bioscience): follow-through, second-best on XBI +12.7% PRME (Prime Medicine): gene editing group outperforming with XBI rallying nearly +4% +12.5% CRSP (CRISPR Therapeutics): gene editing group outperforming with XBI rallying nearly +4% +11.1% NTLA (Intellia Therapeutics): gene editing group outperforming with XBI rallying nearly +4% +9.8% BEAM (Beam Therapeutics): gene editing group outperforming with XBI rallying nearly +4% +9.6% MRNA (Moderna): best performer on XLV; on average volume +8.8% TELO (Telomir Pharmaceuticals): initiation +7.2% VSTM (Verastem): initiation +7.0% EDIT (Editas Medicine): gene editing group outperforming with XBI rallying nearly +4% +5.5% IBIO (iBio, Inc.): initiation +5.2% CELC (Celcuity): initiation +5.2% ALVO (Alvotech): follow-through +4.9% NUVB (Nuvation Bio): FDA approves Ibtrozi sNDA with DOR labeling +4.5% PRLD (Prelude Therapeutics): initiation +4.2% GRAL (GRAIL, Inc.): initiation +3.4% QGEN (Qiagen): Manager Magazin report +3.3% TSHA (Taysha Gene Therapies): initiation +3.1% CRL (Charles River Laboratories): shares +1% WTD +2.7% HAE (Haemonetics): upgraded at Citi +2.0% ROIV (Roivant Sciences): initiation +1.2% MIRA (MIRA Pharmaceuticals): initiation Decliners -56.5% LGVN (Longeveron Inc.): microcap biotech; trial results in HLHS -5.1% ARQT (Arcutis Biotherapeutics): worst performer on XBI; shares remain +4% WTD -4.3% NVST (Envista Holdings): Investor Day; updates medium term outlook -2.9% HSIC (Henry Schein): worst performer on XLV -2.9% COO (The Cooper Cos.): second-worst on XLV -2.1% BSX (Boston Scientific): downgraded at Citi; shares flat WTD -0.6% SLS (SELLAS Life Sciences Group, Inc.): STAT News' Feuerstein comments on REGAL trial	show story hide story
17-Sep-2026 08:27	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Corporate newsflow very quiet overnight. Sell-side research includes Boston Scientific downgraded to neutral at Citi; shares trading slightly lower in the pre-market. In addition, Deutsche Bank lowered the European Health Care sector to neutral from overweight; firm prefers more defensive sectors in the rising rate environment. Today's Biotech noise highlighted by STAT News' opinion piece from Adam Feuerstein, who predicts a Sellas Life Science blow-up. Shares are up more than 200% YTD into a pivotal, event-driven phase 3 trial for AML. Stock lower (4%) in the pre-market. Yesterday, Healthcare equities were lightly mixed and little changed overall. Growth outperformed value with market squarely focused on FOMC and the 25bp bump to rates, as was widely expected. Payers were the outlier today, large-cap MCOs weaker post-FOMC to end down as much as (3%) on the day. ALHC shed another (16%). Overall sector-specific newsflow was fairly quiet overnight, while ongoing brokerage conferences remained the primary source of updates. Looking ahead, more broker conferences, and potentially the first biotech IPO to price in over a month. Macro S&P futures up +0.8% on Thursday morning. Bounce attempt following a three-day losing streak with upside leadership from the AI trade. Improvement in risk sentiment partly chalked up to oil pullback with focus on Trump's upcoming meeting with Gulf leaders (and latest round of comments about war ending soon), as well as some recent headlines suggesting improved Saudi supply dynamics. Oil seemingly helping rates following big bearish flattening move yesterday. Bulk of the attention continues to revolve around the Fed. While takeaways were hawkish, there were still a lot of moving pieces/debates. Quiet elsewhere with the BoJ decision tonight (rate hike widely expected), end of the Fed quiet period and the Trump-Xi meeting next week on the near-term radar. Pre-market trading update Trading higher +412.0% AEMD microcap; reverse merger with North Immunology +8.3% MNOV initiation +5.8% MIRA initiation (low volume) +5.4% MRNA on 306K shares +3.8% NUVB FDA approves Ibtrozi sNDA with DOR labeling +3.7% ALVO follow-through (low volume) +3.5% QGEN Manager Magazin report +3.4% IBIO initiation (low volume) +3.2% PRLD initiation (low volume) +2.5% CELC initiation (low volume) +2.3% VSTM initiation (low volume) +2.1% HAE upgraded at Citi +1.4% ROIV initiation (low volume) +1.2% GRAL initiation (low volume) +0.6% TSHA initiation (low volume) Trading lower -4.3% SLS STAT News' Feuerstein comments on REGAL trial -2.7% TELO initiation (low volume) -0.5% BSX downgraded at Citi Pharma Regulatory: AZN.LN (AZN) / 4568.JP (Daiichi Sankyo) Enhertu now recommended by NICE for HER2-low advanced breast cancer. Previously the committee was unable to recommend based on price. The change came about following the US/UK Pharmaceutical Pricing Agreement, says NICE. AZN.LN (AZN) received FDA approval for an efficacy supplement (sNDA) for Truqap. An updated label is not yet available on the FDA website. Biotech Regulatory: NUVB FDA approves sNDA for IBTROZI four months ahead of the PDUFA goal date. Supplement to the indication for ROS1+ NSCLC. The updated label reflects TRUST-I TKI-naïve median duration of response (DOR) of nearly 50 months. Media report: SLS mentioned cautiously by STAT News' Adam Feuerstein ahead of the readout of phase 3 REGAL trial - predicts the study with GPS for AML will fail. Research: ROIV initiated buy at Stifel (Alex Thompson), target is $51 or approx. 29% upside. (FactSet average PT $47; range $38-55) ABEO initiated buy at Roth Capital (Boobalan Pachaiyappan), target is $17 or approx. 217% upside. (FactSet average PT $19; range $14-28) CELC initiated overweight at JPMorgan (Anupam Rama), target is $157 or approx. 90% upside. (FactSet average PT $161; range $140-177) IBIO initiated buy at HC Wainwright (Ananda Ghosh), target is $7 or approx. 493% upside. (FactSet average PT $5.52; range $4.20-7) MIRA initiated buy at Maxim Group, target is $3.50 or approx. 386% upside. MNOV initiated buy at Roth Capital (Boobalan Pachaiyappan), target is $6 or approx. 138% upside. (FactSet average PT $8; range $6-11) PRE initiated buy at Craig-Hallum Capital (Eric Des Lauriers), target is $40 or approx. 82% upside. (FactSet average PT $36; range $30-40) RYTM initiated outperform at Wolfe Research (Kalpit Patel), target is $125 or approx. 28% upside. (FactSet average PT $139; range $105-160) TELO initiated buy at Maxim Group, target is $4 or approx. 254% upside. TSHA initiated outperform at Wolfe Research (Kalpit Patel) VSTM initiated outperform at Wolfe Research (Kalpit Patel) ZYME initiated outperform at Wolfe Research (Kalpit Patel) Life Science & MedTech Media report / M&A: QGEN under the guide of its new CEO reportedly continues to evaluate a potential sale, with TPG and Bain Capital seen as incremental to the prior media reports of PE interest in the company. (Manager Magazin) Research: BSX downgraded to neutral from buy at Citi (Joanne Wuensch), target cut to $50 from $57 or approx. 14% upside. (FactSet average PT $61; range $44-85) HAE upgraded to buy from neutral at Citi (Joanne Wuensch), target increased to $123 from $92 or approx. 16% upside. (FactSet average PT $108; range $86-125) GRAL initiated sector perform at RBC Capital Markets (Dan Leonard), target is $84 or approx. 12% upside. (FactSet average PT $77; range $60-105) TKNO initiated buy at Jefferies (Matthew Stanton), target is $9 or approx. 27% upside. (FactSet average PT $9; range $7-12) On Deck: Conferences (cont.) Deutsche Bank Healthcare Summit (Sep 16-17) Citizens Private Ophthalmology Summit (Sep 17) Regulatory (cont.): EMA CHMP monthly meeting (Sep 14-17) on Fri 18-Sep: EMA CHMP MAA opinions (18-Sep) (ONCO.SS) on Sat 19-Sep: FDA PDUFA for RARE reb-vec (UX111) BLA resubmission in Sanfilippo Syndrome (MPS IIIA) (ABEO royalties); FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate NVST Investor Day (900ET) Syndicate calendar / IPO pricing Thu 17-Sep (post-close) +ETRA (Electra Therapeutics) expected to raise $325M (at midpoint) - clinical-stage biotech focused on precision oncology, lead candidate ipsoprubart for secondary hemophagocytic lymphohistiocytosis (sHLH) Peek Ahead to next week Sep 21-27 Mon 21-Sep: NOVO.B.DC (NVO) holding CMD and brand update (4:00ET); Earnings after US market close ABVX.FP (ABVX); FDA PDUFA for MRK Winrevair sBLA (based on HYPERION study) (BMY royalties via Celgene acquisition) Tue 22-Sep: Bank of America Global Healthcare Conference (Sep 22-23) Wed 23-Sep: Bernstein Healthcare Forum (Sep 23-24); FDA Adcom for GRAL Galleri PMA Sat 26-Sep: FDA PDUFA for MIRM zilurgisertib NDA in FOP ages 12+ (INCY) Sun 27-Sep: FDA PDUFA for ROP.SW Gazyva sBLA in INS (BIIB) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4568.JP, ABEO, ABVX, AEMD, ALVO, AZN.LN, BIIB, BMY, BSX, CELC, GRAL, HAE, IBIO, INCY, MIRA, MIRM, MNOV, MRK, MRNA, NUVB, NVO, NVST, ONCO.SS, PRE, PRLD, QGEN, RARE, ROIV, ROP.SW, RYTM, SLS, TELO, TKNO, TSHA, VSTM, ZYME, +ETRA...(more)	show story hide story
16-Sep-2026 16:57	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed and little changed overall on Wednesday. Decliners equaled advancers on the XLV by the market close, breadth far from session highs. Healthcare +0.04% vs S&P 500 (0.45%). Most major health groups closed higher and ahead of the wider tape. Growth outperformed value with market squarely focused on FOMC and today's 25bp bump to rates, as was widely expected. Payers were the outlier today, large-cap MCOs weaker post-FOMC to end down as much as (3%) on the day. ALHC shed another (16%). Overall sector-specific newsflow was fairly quiet overnight, while ongoing brokerage conferences remained the primary source of updates. EW +4.1% and HUM (3.0%) bracketed the XLV. OSCR (0.3%) essentially flat following Investor Day, and a relative performer with the favorable update to MLR guidance beforehand. Biotech noise included a double upgrade and a double downgrade on the tape - both from Barclays - ALVO +1.6% and CLLS (14.6%), respectively. Looking ahead, more broker conferences, and potentially the first biotech IPO to price in over a month. Yesterday, Healthcare equities were lightly mixed and little changed overall. Only MedTech group was higher, led by LST subgroup following corporate updates at the broker conferences. Managed Care the biggest drag on the sector following updates made by Alignment Healthcare at Baird, specifically hotter cost trends in July/August, though management maintained FY guidance. Macro Fed raised rates by 25 bp as widely expected, while dot plot showed one additional rate hike for 2026 and nothing more in 2027. Statement highlighted resilient spending and strong productivity growth, framing the tightening as supportive for quicker return to 2% inflation goal. However, Treasuries sold off after some hawkish Warsh comments, including that price stability is FOMC's predominant focus and hike removes a dose of accommodation. Market still pricing in 25 bp of hikes through year-end. Beyond Fed, oil posted its largest daily decrease since early August amid some better headlines surrounding the Saudi East-West pipeline. Corporate updates from sell-side conferences continue to largely echo what was heard during Q2 earnings season (which produced 30%+ growth). Solid macro backdrop underpinned by better-than-expected retail sales data this morning. Notable Gainers +15.3% BBNX (Beta Bionics, Inc.): secondary offering, priced +11.2% ARQT (Arcutis Biotherapeutics): best performer on XBI; unusual volume nearly 3X average; shares (10%) YTD +8.8% BRKR (Bruker): LST strength for second day; shares +14% WTD +8.6% AMRX (Amneal Pharmaceuticals): on nearly 3X average volume +7.7% TNDM (Tandem Diabetes Care): on 2X average volume +6.3% PNTG (Pennant Group): presented at Jefferies late Tuesday +5.4% IOVA (Iovance Biotherapeutics): presented at HC Wainwright late Tuesday; 52-week high; shares +262% YTD +5.3% TGTX (TG Therapeutics): on slightly higher volume +4.2% SLDB (Solid Biosciences): initiation +4.1% EW (Edwards Lifesciences): best performer on XLV; presented at Deutsche Bank +4.0% RVTY (Revvity): second-best on XLV; follow-through, shares were +9% yesterday; 52-week high +3.7% ADPT (Adaptive Biotechnologies): presented at Morgan Stanley late Tuesday +3.6% MTD (Mettler-Toledo International): LST strength for second day +3.6% TWST (Twist Bioscience): agreement with Eli Lilly TuneLab Notable Decliners -48.7% XBIO (Xenetic Biosciences): microcap; reverse merger with Santersus AG -16.0% ALHC (Alignment Healthcare): follow-through, shares were (20%) yesterday -14.6% CLLS (Cellectis SA): double downgrade at Barclays -10.1% PLSE (Pulse Biosciences): stock sales agreement -8.9% GPCR (Structure Therapeutics): presented at Morgan Stanley conference -7.9% ELVN (Enliven Therapeutics): presented at Morgan Stanley conference -7.6% SANA (Sana Biotechnology): worst performer on XBI -6.9% ARWR (Arrowhead Pharmaceuticals): follow-through, shares were down (12%) yesterday; presented at HCW pre-open today -5.6% VERA (Vera Therapeutics): presented at Morgan Stanley late Tuesday -5.5% ERAS (Erasca): presented at Morgan Stanley conference yesterday -3.0% HUM (Humana): worst performer on XLV; MCO weakness -2.9% CVS (CVS Health): second-worst on XLV; MCO weakness -2.9% CI (Cigna Group): MCO weakness -2.4% CNC (Centene): MCO weakness Oscar Health guides lower MLR ahead of I-Day; Centene reaffirms ahead of investor meeting OSCR guides FY operating income $600-800M vs prior $500-700M and FactSet $598.2M. Also guides 50bps improvement to FY MLR outlook, ahead of today's Investor Day meeting. CNC reaffirmed FY26 EPS guidance ahead of participation today at Deutsche Bank Healthcare Summit. Note: Scheduled to report Q3 earnings on Tuesday 27-Oct before the open. UNH announces that Q3 earnings will be reported before the market open on Tuesday 13-Oct, with a conference call at 8:00ET. Note: Bellwether spot on the Q3 earnings calendar. JNJ is also scheduled to report the same day, to kick off Q3 season. Novartis secures rights to neuroscience drug platform NOVN.SW (NVS) exercises option to acquire full global rights to privately-held Sironax's proprietary brain delivery platform. Per option agreement between the companies July 2025, Sironax to receive $125M. "The platform comprises proprietary brain delivery modules engineered to potentially enable the in vivo transport of diverse therapeutic modalities including monoclonal antibodies, peptides, proteins, gene therapies, and other large biologics to the brain, with the potential to expand treatment options for diseases such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis (ALS), and other neurological disorders." Notable research in Healthcare today Biotech: ALVO upgraded to overweight from underweight at Barclays (Glen Santangelo), noting risk/reward into December FDA decision. Target increased to $8 from $4 or approx. 59% upside. (FactSet average PT $7; range $4-9) CLLS downgraded to underweight from overweight at Barclays (Lukas Shumway), cites lack of confidence in new gene editing programs. Target cut to $1.30 from $9 or approx. 19% downside. (FactSet average PT $5; range $1.30-8) RCKT upgraded to buy from hold at Needham (Gil Blum), follows FDA alignment in Danon disease. Target is $9 or approx. 164% upside. (FactSet average PT $9; range $3-15) FTH initiated buy at Guggenheim Securities (Brad Canino), target is $70 or approx. 98% upside. (FactSet average PT $57; range $46-70) RCUS initiated buy at TD Cowen (Tara Bancroft) SLDB initiated outperform at RBC Capital Markets (Luca Issi), target is $18 or approx. 115% upside. (FactSet average PT $19; range $11-26) TRAX initiated buy at Guggenheim Securities (Yatin Suneja), target is $100 or approx. 160% upside. (FactSet average PT $73; range $55-100) ZNTL initiated outperform at William Blair (Matt Phipps) Mizuho analyst Graig Suvannavejh assumes coverage of five stocks following departure of analyst. Targets and ratings unchanged; outperform ratings on ALKS, CLYM, EIKN, and STRO; neutral rating on NBIX. Post-close news Research: ROIV initiated buy at Stifel (Alex Thompson), target is $51 or approx. 29% upside. (FactSet average PT $47; range $38-55) On Deck: Conferences (cont.) Deutsche Bank Healthcare Summit (Sep 16-17) Citizens Private Ophthalmology Summit (Sep 17) Regulatory (cont.): EMA CHMP monthly meeting (Sep 14-17) on Fri 18-Sep: EMA CHMP MAA opinions on Sat 19-Sep: FDA PDUFA for RARE reb-vec (UX111) BLA resubmission in Sanfilippo Syndrome (MPS IIIA) (ABEO royalties); FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate NVST Investor Day (9:00ET) Syndicate calendar / IPO pricing Thu 17-Sep (post-close): +ETRA (Electra Therapeutics) expected to raise $325M (at midpoint) - clinical-stage biotech focused on precision oncology, lead candidate ipsoprubart for secondary hemophagocytic lymphohistiocytosis (sHLH) StreetAccount Healthcare Reads Sen Cassidy faults Trump vaccine policy for US measles deaths as panel weight health nominees (16-Sep) Reuters Why We Can't Stop Arguing About S.S.R.I.s (16-Sep) NY Times (opinion) HHS Plans New Research Into Autism Development, Treatment (16-Sep) Bloomberg Novo partners with Anthropic to speed up drug development with Claude (16-Sep) Reuters A onetime Gilead exec's novel startup eyes $1B IPO valuation (15-Sep) SF Business Times New Measles Deaths Send US Fatality Total to Highest in Decades (15-Sep) Bloomberg This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABEO, ADPT, ALHC, ALKS, ALVO, AMRX, ARQT, ARWR, BBNX, BRKR, CI, CLLS, CLYM, CNC, CVS, EIKN, ELVN, ERAS, EW, FTH, GPCR, HUM, IOVA, JNJ, MTD, NBIX, NOVN.SW, NVO, NVST, OSCR, PLSE, PNTG, RARE, RCKT, RCUS, ROIV, RVTY, SANA, SLDB, STRO, TGTX, TNDM, TRAX, TWST, UNH, VERA, XBIO, ZNTL, +ETRA...(more)	show story hide story
16-Sep-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is generally inline with the S&P 500 Healthcare Index +0.31% vs the S&P 500 +0.39%. Major health groups all lightly mixed around the tape. Payers and providers bracketing the movers, but all moves are quite modest. Sector newsflow remained fairly quiet overnight, with several brokerage conferences ongoing to break the intraday monotony. RVTY +3% and BAX (2%) bracket the XLV. OSCR (flat) favorably updated MLR guidance ahead of Investor Day meeting today. Biotech noise includes a double upgrade, ALVO +6%, and a double downgrade, CLLS (12%), on the tape - both from Barclays. Gainers +6.3% ALVO (Alvotech): double upgrade at Barclays +6.0% ARQT (Arcutis Biotherapeutics): on heavy volume +5.7% BBNX (Beta Bionics, Inc.): secondary offering, priced +5.7% TGTX (TG Therapeutics): best performer on XBI; on average volume +4.9% TWST (Twist Bioscience): agreement with Lilly TuneLab +4.7% BRKR (Bruker): LST strength for second day; shares +10% WTD +3.2% TRAX (First Tracks Biotherapeutics Inc): initiation +3.1% RVTY (Revvity): best performer on XLV; follow-through, shares were +9% yesterday; 52-week high +3.0% ALGN (Align Technology): second-best on XLV +2.4% COO (The Cooper Cos.): shares were (23%) last week following earnings updates and conclusion of strategic review +2.2% SYK (Stryker): shares +5% WTD +2.1% RCKT (Rocket Pharmaceuticals): upgrade at Needham +1.9% ADPT (Adaptive Biotechnologies): presented at Morgan Stanley late Tuesday Decliners -48.5% XBIO (Xenetic Biosciences): microcap; reverse merger with Santersus AG -12.4% CLLS (Cellectis SA): double downgrade at Barclays -9.7% PLSE (Pulse Biosciences): stock sales agreement -7.1% ALHC (Alignment Healthcare): follow-through, shares were (20%) yesterday -4.9% ARWR (Arrowhead Pharmaceuticals): worst performer on XBI; follow-through, shares were down (12%) yesterday; presented at HCW pre-open today -3.6% VERA (Vera Therapeutics): presented at Morgan Stanley (on Tuesday post-mkt) -1.6% BAX (Baxter International): worst performer on XLV	show story hide story
16-Sep-2026 08:46	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Sector newsflow fairly quiet overnight, yet several brokerage conferences underway to break the intraday monotony. Oscar Health favorably updated MLR guidance ahead of Investor Day meeting today. Shares up +2% in the pre-market. Biotech noise includes a double upgrade and a double downgrade on the tape from Barclays. Yesterday, Healthcare equities were lightly mixed and little changed overall. Only MedTech group was higher, led by LST subgroup following corporate updates at the broker conferences. Managed Care the biggest drag on the sector following updates made by Alignment Healthcare at Baird, specifically hotter cost trends in July/August, though management maintained FY guidance. Macro S&P futures are up +0.3% on Wednesday morning, near pre-market highs. Waiting game for the Fed. Market pricing in a 90%+ probability of a tightening, though lots of uncertainty about how Fed will frame the policy path going forward, particularly given Warsh's continued reluctance to give color on the reaction function. More signs of stabilization in the AI trade, though still no meaningful bounce as safety debate headlines continue to dominate the narrative (after focus earlier in the month was model momentum). Oil on the defensive following the recent flurry of headlines around Saudi supply constraints (and now China reportedly may reimpose export restrictions on refined products). However, Bloomberg report today highlighted pivot to spot sales via Persian Gulf. Iranian Foreign Minister Araghchi's visit to Beijing today has put some focus back on potential for China to play a diplomatic role. China also in focus ahead of Trump-Xi meeting next week and latest reports about low-level tariff relief. However, FT reported US may push for a shorter, six-month trade truce extension amid frustration with Beijing over raw earths. Pre-market trading update Trading higher +6.5% RCKT upgrade at Needham +5.2% ALVO double upgrade at Barclays +4.7% SLDB initiation (low volume) +4.4% NAMS shares (17%) MTD / since Novartis/ HORIZON readout +4.1% MOH on light volume +3.8% ZNTL initiation (low volume) +3.4% TWST agreement with Lilly TuneLab +2.7% TRAX initiation (low volume) +2.2% COO shares were (23%) last week following earnings updates and conclusion of strategic review +1.7% OSCR updated guidance ahead of I-Day (9ET) +1.3% NVS exercises option for brain delivery platform Trading lower -32.6% XBIO microcap; reverse merger with Santersus AG -11.6% CLLS double downgrade at Barclays -4.6% BBNX secondary offering, priced Pharma License agreement: NOVN.SW (NVS) exercises option to acquire full global rights to privately-held Sironax's proprietary brain delivery platform. Per option agreement between the companies July 2025, Sironax to receive $125M. "The platform comprises proprietary brain delivery modules engineered to potentially enable the in vivo transport of diverse therapeutic modalities including monoclonal antibodies, peptides, proteins, gene therapies, and other large biologics to the brain, with the potential to expand treatment options for diseases such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis (ALS), and other neurological disorders." Biotech Research: ALVO upgraded to overweight from underweight at Barclays (Glen Santangelo), noting risk/reward into December FDA decision. Target increased to $8 from $4 or approx. 59% upside. (FactSet average PT $7; range $4-9) CLLS downgraded to underweight from overweight at Barclays (Lukas Shumway), cites lack of confidence in new gene editing programs. Target cut to $1.30 from $9 or approx. 19% downside. (FactSet average PT $5; range $1.30-8) RCKT upgraded to buy from hold at Needham (Gil Blum), follows FDA alignment in Danon disease. Target is $9 or approx. 164% upside. (FactSet average PT $9; range $3-15) FTH initiated buy at Guggenheim Securities (Brad Canino), target is $70 or approx. 98% upside. (FactSet average PT $57; range $46-70) RCUS initiated buy at TD Cowen (Tara Bancroft) SLDB initiated outperform at RBC Capital Markets (Luca Issi), target is $18 or approx. 115% upside. (FactSet average PT $19; range $11-26) TRAX initiated buy at Guggenheim Securities (Yatin Suneja), target is $100 or approx. 160% upside. (FactSet average PT $73; range $55-100) ZNTL initiated outperform at William Blair (Matt Phipps) Mizuho analyst Graig Suvannavejh assumes coverage of five stocks following departure of analyst. Targets and ratings unchanged; outperform ratings on ALKS, CLYM, EIKN, and STRO; neutral rating on NBIX. Managed Care Corporate: OSCR guides FY operating income $600-800M vs prior $500-700M and FactSet $598.2M. Also guides 50bps improvement to FY MLR outlook. Investor Day meeting begins at 9:00ET CNC reaffirmed FY26 EPS guidance ahead of participation today at Deutsche Bank Healthcare Summit (9:00ET). Note: Scheduled to report Q3 earnings on Tuesday 27-Oct before the open. UNH announces that Q3 earnings will be reported before the market open on Tuesday 13-Oct, with a conference call at 8:00ET. Note: Bellwether spot on the Q3 earnings calendar. JNJ is also scheduled to report the same day, to kick off Q3 season. On Deck: Conferences (cont.) Jefferies Healthcare Services and Technology Conference (Sep 14-16) (cont.) HC Wainwright Global Investment Conference (Sep 14-16) (cont.) Morgan Stanley Global Healthcare Conference (Sep 14-16) Deutsche Bank Healthcare Summit (Sep 16-17) on Thu 17-Sep: Citizens Private Ophthalmology Summit (Sep 17) Regulatory (cont.): EMA CHMP monthly meeting (Sep 14-17); MAA opinions on Friday (18-Sep) on Sat 19-Sep: FDA PDUFA for RARE UX111 BLA in Sanfilippo Syndrome; FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate OSCR Investor Day (900ET) on Thu 17-Sep: NVST Investor Day (900ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALKS, ALVO, BBNX, CLLS, CLYM, CNC, COO, EIKN, FTH, JNJ, MOH, NAMS, NBIX, NOVN.SW, NVS, NVST, OSCR, RARE, RCKT, RCUS, SLDB, STRO, TRAX, TWST, UNH, XBIO, ZNTL...(more)	show story hide story
15-Sep-2026 16:59	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished lightly mixed and little changed overall on Tuesday. Decliners outnumbered advancers at the market close, yet breadth far from worst levels of the morning session. Healthcare (0.08%) vs S&P 500 (0.45%). Most major health groups ended lower on the averages; only MedTech was skewed higher by the LST subgroup following corporate updates at today's broker conferences. RVTY +9.1% today's leading gainer on the XLV following updates at Baird pre-open; TMO +4.6% presented at Morgan Stanley. Medical devices partially offset LST gains, although LC device makers were widely mixed to essentially flat, including BSX (2.6%) partially reversing Monday's strength. ALGN (3.9%) today's leading decliner on the XLV, followed by BSX then a pair of Managed Care names. Another notable update at Baird, ALHC (19.9%). Management avoided 'poking the bear' and declined to comment on Stars. Highlighted elevated cost trends however in July/August - and is taking steps to address them. Also spotlighted the 'short-term noise' and told investors to ignore it. WAY +7.1% on an overnight media report; Reuters reported that Waystar has hired bankers to advise on the sale process. XBI (2.27%) with a risk-off/defensive tone in the market, combined with several Biopharma trial readouts across a wide range of fields - Asthma, IgAN, MDD, and long COVID. Yesterday, Healthcare equities were broadly higher with defensive groups leading, plus a pocket of strength in orthopedic device manufacturers following the Apollo-JNJ headline. Mixed biopharma newsflow in lung cancer and breast cancer. Conference season in full swing with multiple meetings ongoing. Macro Stocks extended Monday's selloff with biggest focus on another oil rally amid latest cautious Middle East and global supply updates (Saudi Arabia suspended Yanbu shipments and canceled some September loadings, latest Libya suspension, Houthi momentum). Consumer names came under particular pressure, tied to growing scrutiny on squeeze from oil/fuel prices, with restaurants, apparel, travel, and leisure among the worst performers. Treasuries were weaker again, with 10Y remaining near 5% and today's 20Y auction very poorly received (highest 20Y sale on record, lowest foreign purchase share ever). Other areas of focus included AI trade stabilization (compute/capex demand offsetting political and regulatory worries), anticipation for tomorrow's FOMC decision (market pricing nearly 95% chance of a hike) and market response, rising bond volatility (MOVE), and a strategist S&P price target cut (Wells Fargo) despite very favorable earnings backdrop. Notable Gainers +9.1% RVTY (Revvity): management comments at Baird conference; best performer on XLV; 52-week high +8.9% TLX (Telix Pharmaceuticals): follow-through, upgraded at Bell Potter +7.1% WAY (Waystar Holding): Reuters report - exploring sale; downgraded at Barclays +4.6% TMO (Thermo Fisher Scientific): presented at Morgan Stanley conference +4.2% CADL (Candel Therapeutics): presented at HC Wainwright conference; best performer on XBI +3.9% DGX (Quest Diagnostics): presented at Baird conference +3.5% MTD (Mettler-Toledo International): sympathy to RVTY, TMO; shares +3% WTD +2.9% RMD (ResMed): upgraded at RBC Capital Markets +2.7% LH (Labcorp Holdings): presented at Morgan Stanley conference +2.6% NTRA (Natera): 52-week high; shares +7% WTD +2.5% TWST (Twist Bioscience): shares +9% WTD +2.3% CRDF (Cardiff Oncology): upgraded at HC Wainwright +1.7% MDXG (MiMedx Group): stock on track for fifth straight monthly gain, remains (29%) YTD Notable Decliners -32.2% CNTB (Connect Biopharma Holdings): trial results in Asthma -19.9% ALHC (Alignment Healthcare): management comments at Baird fireside -16.7% SION (Sionna Therapeutics): updates on CF program; worst performer on XBI -14.6% BIVI (BioVie): microcap biotech; trial results in long COVID -12.4% ARWR (Arrowhead Pharmaceuticals): trial results in mixed hyperlipidemia -12.0% CLLS (Cellectis SA): follow-through, downgraded at Citizens -9.5% ASND (Ascendis Pharma): downgraded at Raymond James; regains rights to TransCon technology for metabolic disease from NVO -8.6% CLOV (Clover Health): sympathy to ALHC -6.7% CTNM (Contineum Therapeutics): trial results in MDD with JNJ -5.0% CMPS (Compass Pathways): takeaways from Monday's public hearing on psychedelic drugs -4.6% LEGN (Legend Biotech): appoints outside CEO (joins from NVS) -3.9% ALGN (Align Technology): worst performer on XLV -3.6% SRRK (Scholar Rock): follow-through, downgraded at Barclays -2.6% BSX (Boston Scientific): shares were +5% yesterday -2.6% HUM (Humana): shares down (3%) WTD -2.5% CNC (Centene): shares were +5% yesterday Pennsylvania reports two additional measles-associated deaths Confirmed deaths in the state now four (4), according to the Pennsylvania Department of Health. Year-to-date, DOH has confirmed 693 measles cases in 38 counties. Media coverage: Bloomberg; Reuters; AP Alignment Healthcare declines to comment on Stars; addressing cost trends seen in July/August; maintains guide Management was asked at Baird to comment on final cutpoints (for Stars). CEO declined comment, stating that CMS this year is very sensitive to anyone talking about it. "This year is different." Wait a couple of weeks, mid-October for the formal release by CMS. There is going to be short-term noise around the company's change management initiatives, claims transformation and growth to 1M members. Almost through that stretch of investments. With regard to Medical cost, the headwind is in institutional acute (hospital billing), a higher level of disputes. Also skilled nursing, saw length of stay go up. Called out "heat" in those two categories - an update for the quarter. Don't expect to persist into 2027. We're not changing 2026 guidance right now. Trading update: Shares of ALHC (15.7%), CLOV (7.0%) Waystar reportedly hires bankers to explore potential sale WAY Reuters reporting on Tuesday that Waystar has hired Evercore to advise on an exploratory sale process. StreetAccount notes that shares are down (24%) YTD amid the broader software sell-off this year, including down (1%) since the company's positive-tone Investor Day meeting on 25-Aug-2026. GSK acquires rights to TCE for multiple myeloma in deal worth up to $750M GSK.LN (GSK) announced it has acquired worldwide rights to develop a preclinical T Cell Engager (TCE) from existing partner Chimagen Biosciences (private) for deal worth up to $750M. Terms include an upfront payment (undisclosed amount) plus milestones both development and commercial. Plans to enter clinic for multiple myeloma in 2027. Trial results in SMID-cap biotech BIVI announced topline results from its phase 2 ADDRESS-LC trial evaluating oral bezisterim in Long COVID. In pre-specified subgroups, the treatment demonstrated stat sig improvements on multiple endpoints. CNTB announced topline results from the global phase 2 Seabreeze STAT Asthma study evaluating anti-IL4 antibody rademikibart as an add-on treatment. Trial demonstrated stat sig rapid improvements in FEV1, and meaningfully reduced rate of treatment failure - although the latter endpoint did not reach stat sig. CTNM announced topline results from the phase 2 MOONLIGHT-1 trial evaluating PIPE-307 / JNJ-5120 in major depressive disorder did not achieve its primary efficacy endpoint. (JNJ) VERA announced the final efficacy analysis of the ORIGIN 3 trial evaluating TRUTAKNA in adults with IgAN. Study met all prespecified endpoints. Plans to submit sBLA in Q4 of 2026. Since gaining FDA Accelerated Approval, says "early momentum" of the "launch is very encouraging". Notable research in Healthcare today Pharma: GSK.LN (GSK) upgraded to buy from hold at Berenberg (Kerry Holford), target increased to 2200p from 2000p or approx. 19% upside. LLY upgraded to buy from hold at Berenberg (Kerry Holford), target increased to $1400 from $1220 or approx. 23% upside. Biotech: ASND downgraded to outperform from strong buy at Raymond James (Martin Auster), target remains $287 or approx. 8% upside. (FactSet average PT $312; range $270-360) CLLS downgraded to market perform from market outperform at Citizens (Silvan Turkcan), notes valuation. CRDF upgraded to buy from neutral at HC Wainwright (Robert Burns), follows company's settlement of litigation with Nerviano. Target is $9 or approx. 587% upside. SRRK downgraded to equal weight from overweight at Barclays (Etzer Darout), notes valuation. Target increased however to $58 from $55 or approx. 12% upside. (FactSet average PT $70; range $58-84) TLX.AU (TLX) upgraded to buy from hold at Bell Potter (John Hester), target remains A$19 or approx. 16% upside. (FactSet average PT A$26; range A$19-31) MedTech: WAY downgraded (intraday) to equal weight from overweight at Barclays (Glen Santangelo) RMD upgraded to outperform from sector perform at RBC Capital Markets (Craig Wong-Pan), cites factors including company's earnings outlook. Target increased to $262 from $244 or approx. 17% upside. (FactSet average PT $262; range $175-331) Services: AGL upgraded to outperform at Bernstein (Lance Wilkes), target increased to $125 from $86 or approx. 35% upside. (FactSet average PT $118; range $85-146) ASTH initiated outperform at Oppenheimer (Michael Wiederhorn), target is $53 or approx. 34% upside. (FactSet average PT $52; range $41-65) Post-close news Corporate: UNH announces that Q3 earnings will be reported before the market open on Tuesday 13-Oct, with a conference call at 8:00ET. Note: Bellwether spot on the Q3 earnings calendar. JNJ is also scheduled to report the same day, to kick off Q3 season. Research: ZNTL initiated outperform at William Blair (Matt Phipps) On Deck: Conferences (cont.) Jefferies Healthcare Services and Technology Conference (Sep 14-16) (cont.) HC Wainwright Global Investment Conference (Sep 14-16) (cont.) Morgan Stanley Global Healthcare Conference (Sep 14-16) Deutsche Bank Healthcare Summit (Sep 16-17) on Thu 17-Sep: Citizens Private Ophthalmology Summit (Sep 17) Regulatory (cont.): EMA CHMP monthly meeting (Sep 14-17); MAA opinions on Friday (18-Sep) on Sat 19-Sep: FDA PDUFA for RARE UX111 BLA in Sanfilippo Syndrome; FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate OSCR Investor Day (900ET) on Thu 17-Sep: NVST Investor Day (900ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AGL, ALGN, ALHC, ARWR, ASND, ASTH, BIVI, BSX, CADL, CLLS, CLOV, CMPS, CNC, CNTB, CRDF, CTNM, DGX, GSK.LN, HUM, JNJ, LEGN, LH, LLY, MDXG, MTD, NTRA, NVO, NVS, NVST, OSCR, RARE, RMD, RVTY, SION, SRRK, TLX, TLX.AU, TMO, TWST, UNH, VERA, WAY, ZNTL...(more)	show story hide story
15-Sep-2026 11:14	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index (0.39%) vs the S&P 500 (0.52%). Most major health groups are lower to begin the session, only MedTech skewed slightly higher by Life Science Tools subgroup, specifically RVTY +7% leading gainer on the XLV following updates at Baird pre-open. TMO +3% also presented at Morgan Stanley. Devices subgroup offsetting however. BSX (2%) partially reversing Monday's strength, and is a leading decliner on the XLV. MRNA (3%) faring worse. Another notable update at Baird from ALHC (17%), management avoids poking the bear / declines comment on Stars. Highlights elevated cost trends in July/August - taking steps to address them - and the short-term noise that management tells investors to ignore. WAY +7% on the media report overnight, Reuters reporting that Waystar has hired bankers to advise on the sale process. XBI (3.01%); several Biopharma trial readouts across a wide range of fields - Asthma, IgAN, MDD, and long COVID. Gainers +9.8% TLX (Telix Pharmaceuticals): follow-through, upgraded at Bell Potter +7.3% WAY (Waystar Holding): Reuters report - exploring sale +7.0% RVTY (Revvity): management comments at Baird conference; best performer on XLV; 52-week high +5.1% CRDF (Cardiff Oncology): upgraded at HC Wainwright +3.0% TMO (Thermo Fisher Scientific): presented at Morgan Stanley conference +3.0% RMD (ResMed): upgraded at RBC Capital Markets +2.0% MYGN (Myriad Genetics): best performer on XBI +1.5% AGL (agilon health): upgraded at Bernstein +0.5% LLY (Eli Lilly): upgraded at Berenberg +0.0% GSK (GSK Plc): upgraded at Berenberg; acquires TCE for MM from Chimagen Decliners -32.8% ~CNTB~ (Connect Biopharma Holdings): trial results in Asthma -18.0% ~BIVI~ (BioVie): microcap biotech; trial results in long COVID -17.4% ~ALHC~ (Alignment Healthcare): management comments at Baird fireside -13.5% ~ASND~ (Ascendis Pharma): downgraded at Raymond James; regains rights to TransCon technology for metabolic disease from NVO -12.7% ~SION~ (Sionna Therapeutics): updates on CF program; worst performer on XBI -10.9% ~CLLS~ (Cellectis SA): follow-through, downgraded at Citizens -9.4% ~CTNM~ (Contineum Therapeutics): trial results in MDD with JNJ -8.8% ~SRRK~ (Scholar Rock): follow-through, downgraded at Barclays -8.2% ~ARWR~ (Arrowhead Pharmaceuticals): trial results in mixed hyperlipidemia -8.1% ~CLOV~ (Clover Health): sympathy to ALHC -5.3% ~LEGN~ (Legend Biotech): appoints outside CEO (joins from NVS) -5.0% ~RCKT~ (Rocket Pharmaceuticals): FDA alignment on phase 2 trial of RP-A501 in Danon disease -4.8% ~CMPS~ (Compass Pathways): takeaways from Monday's public hearing on psychedelic drugs -3.1% ~CNC~ (Centene): shares were +5% yesterday -2.4% ~BSX~ (Boston Scientific): shares were +5% yesterday -2.4% ~MRNA~ (Moderna): worst performer on XLV -2.3% ~VERA~ (Vera Therapeutics): trial results in IgAN	show story hide story
15-Sep-2026 10:20	ALHC Alignment Healthcare declines to comment on Stars; addressing cost trends seen in July/August; maintains guide ($10.96 -$1.98) Management was asked at Baird to comment on final cutpoints (for Stars). CEO declined comment, stating that CMS this year is very sensitive to anyone talking about it. "This year is different." Wait a couple of weeks, mid-October for the formal release by CMS. There is going to be short-term noise around the company's change management initiatives, claims transformation and growth to 1M members. Almost through that stretch of investments. With regard to Medical cost, the headwind is in institutional acute (hospital billing), a higher level of disputes. Also skilled nursing, saw length of stay go up. Called out "heat" in those two categories - an update for the quarter. Don't expect to persist into 2027. We're not changing 2026 guidance right now. Trading update: Shares of ALHC (15.7%), CLOV (7.0%) See Related StreetAccount comments: 9/15/2026 9:59:17 AM - Alignment Healthcare trading lower following early morning presentation at Baird Related: CLOV	show story hide story
15-Sep-2026 09:59	ALHC Alignment Healthcare trading lower following early morning presentation at Baird ALHC (11.9%), but coming in from worst levels around (20%), on heavy volume. Company was scheduled for a Fireside chat and presentation at Baird Global Healthcare Conference at 12:50ET. Company's IR site says 9:05ET (and pending replay). We will follow-up once more detail is available. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
15-Sep-2026 08:35	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Media report of potential M&A in the HCIT space the highlight overnight. Reuters reporting that Waystar has hired bankers to advise on the sale process. Shares of WAY +13% in the pre-market. Also several Biopharma trial readouts across a wide range of fields - Asthma, IgAN, MDD, and long COVID. Yesterday, Healthcare equities were broadly higher with Defensive groups leading, plus a pocket of strength in orthopedic device manufacturers following the Apollo-JNJ headline. Mixed biopharma newsflow in lung cancer and breast cancer. Conference season in full swing with multiple meetings ongoing. Macro S&P futures are down (0.1%) on Tuesday morning, off worst levels. AI trade showing some signs of stabilization amid continued pushback against the notion that the compute/capex demand narrative has really changed. Higher oil and higher yields an overhang on sentiment. Oil market focused on closure of Saudi East-West pipeline and perceived lack of near-term diplomatic off-ramps into the US midterm elections. Fiscal scrutiny may back in play for bonds with developments surrounding Japan (reported defense spending boost, cabinet approval of food sales tax cut). Also a flurry of headlines about 10-year Treasury yields hitting 5% on Monday, though reports have largely rehashed the usual talking points, including the increasingly price-sensitive nature of the marginal buyer (hedge funds). Fed decision on Wednesday next big catalyst for markets with probability of a 25 bp rate hike at 90%+. Pre-market trading update Trading higher +16.7% VERA trial results in IgAN +12.5% WAY Reuters report - exploring sale +6.9% CRDF upgraded at HC Wainwright +5.7% TLX follow-through, upgraded at Bell Potter +3.0% CMPS takeaways from Monday's public hearing on psychedelic drugs +2.7% LEGN appoints outside CEO (joins from NVS) +1.1% RMD upgraded at RBC Capital Markets (low volume) +0.2% SRRK follow-through, downgraded at Barclays (low volume) +0.2% AGL upgraded at Bernstein (low volume) +0.0% LLY upgraded at Berenberg Trading lower -35.1% CNTB trial results in Asthma -10.2% BIVI microcap biotech; trial results in long COVID -9.9% CLLS follow-through, downgraded at Citizens -9.8% KMTS earnings -2.8% CTNM trial results in MDD with JNJ -1.3% CNC shares were +5% yesterday -1.3% ASND downgraded at Raymond James; regains rights to TransCon technology for metabolic disease from NVO -0.3% GSK upgraded at Berenberg; acquires TCE for MM from Chimagen Pharma License agreement: GSK.LN (GSK) announced it has acquired worldwide rights to develop a preclinical T Cell Engager (TCE) from existing partner Chimagen Biosciences (private) for deal worth up to $750M. Terms include an upfront payment (undisclosed amount) plus milestones both development and commercial. Plans to enter clinic for multiple myeloma in 2027. Research: GSK.LN (GSK) upgraded to buy from hold at Berenberg (Kerry Holford), target increased to 2200p from 2000p or approx. 19% upside. LLY upgraded to buy from hold at Berenberg (Kerry Holford), target increased to $1400 from $1220 or approx. 23% upside. Biotech Trial results: BIVI announced topline results from its phase 2 ADDRESS-LC trial evaluating oral bezisterim in Long COVID. In pre-specified subgroups, the treatment demonstrated stat sig improvements on multiple endpoints. Shares are trading lower Conf. call at 8:30ET CNTB announced topline results from the global phase 2 Seabreeze STAT Asthma study evaluating anti-IL4 antibody rademikibart as an add-on treatment. Trial demonstrated stat sig rapid improvements in FEV1, and meaningfully reduced rate of treatment failure - although the latter endpoint did not reach stat sig. Shares are trading lower Conf. call at 8:00ET CTNM announced topline results from the phase 2 MOONLIGHT-1 trial evaluating PIPE-307 / JNJ-5120 in major depressive disorder did not achieve its primary efficacy endpoint. (JNJ) Shares are trading lower VERA announced the final efficacy analysis of the ORIGIN 3 trial evaluating TRUTAKNA in adults with IgAN. Study met all prespecified endpoints. Plans to submit sBLA in Q4 of 2026. Since gaining FDA Accelerated Approval, says "early momentum" of the "launch is very encouraging". Shares are trading higher Research: ASND downgraded to outperform from strong buy at Raymond James (Martin Auster), target remains $287 or approx. 8% upside. (FactSet average PT $312; range $270-360) CLLS downgraded to market perform from market outperform at Citizens (Silvan Turkcan), notes valuation. CRDF upgraded to buy from neutral at HC Wainwright (Robert Burns), follows company's settlement of litigation with Nerviano. Target is $9 or approx. 587% upside. SRRK downgraded to equal weight from overweight at Barclays (Etzer Darout), notes valuation. Target increased however to $58 from $55 or approx. 12% upside. (FactSet average PT $70; range $58-84) TLX.AU (TLX) upgraded to buy from hold at Bell Potter (John Hester), target remains A$19 or approx. 16% upside. (FactSet average PT A$26; range A$19-31) Life Science & MedTech Media report / M&A: WAY Reuters reporting on Tuesday that Waystar has hired Evercore to advise on an exploratory sale process. StreetAccount notes that shares are down (24%) YTD amid the broader software sell-off this year, including down (1%) since the company's positive-tone Investor Day meeting on 25-Aug-2026. Corporate: DXCM announced that CFO Jereme Sylvain will add COO title and duties. Note: Exactly one year ago, Kevin Sayer took medical leave from the CEO role, and then-COO Jacob Leach was appointed CEO effective 1-Jan Research: RMD upgraded to outperform from sector perform at RBC Capital Markets (Craig Wong-Pan), cites factors including company's earnings outlook. Target increased to $262 from $244 or approx. 17% upside. (FactSet average PT $262; range $175-331) Services & Hospitals Research: AGL upgraded to outperform at Bernstein (Lance Wilkes), target increased to $125 from $86 or approx. 35% upside. (FactSet average PT $118; range $85-146) ASTH initiated outperform at Oppenheimer (Michael Wiederhorn), target is $53 or approx. 34% upside. (FactSet average PT $52; range $41-65) On Deck: Conferences (cont.) World Conference on Lung Cancer (WCLC) (Sep 12-15) (cont.) Jefferies Healthcare Services and Technology Conference (Sep 14-16) (cont.) H.C. Wainwright Global Investment Conference (Sep 14-16) (cont.) Morgan Stanley Global Healthcare Conference (Sep 14-16) on Wed 16-Sep: Deutsche Bank Healthcare Summit (Sep 16-17) Regulatory (cont.): EMA CHMP monthly meeting (Sep 14-17) on Fri 18-Sep: EMA CHMP opinions on MAA (September) on Sat 19-Sep: FDA PDUFA for RARE UX111 BLA in Sanfilippo Syndrome; FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate on Wed 16-Sep: OSCR Investor Day (900ET) on Thu 17-Sep: NVST Investor Day (900ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AGL, ASND, ASTH, BIVI, CLLS, CMPS, CNC, CNTB, CRDF, CTNM, DXCM, GSK, GSK.LN, JNJ, KMTS, LEGN, LLY, NVST, OSCR, RARE, RMD, SRRK, TLX, TLX.AU, VERA, WAY...(more)	show story hide story
14-Sep-2026 16:54	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly higher on Monday. Advancers beat decliners by nearly 9:1 on the XLV. Healthcare +1.35% vs S&P 500 (0.48%). All major health groups are higher by ~1% or more on their averages to begin the week. Just six modest decliners on the XLV. Defensive groups lead all gainers; however orthopedic device manufacturers lifted MedTech to edge out Pharma on the session. Managed Care. A busy weekend of lung cancer headlines, plus some breast cancer news, however weekend M&A headlines dominated early price action on Monday morning. The private equity put supported stocks. BSX +4.8% and CRL (1.8%) bracketed the XLV. PODD +4.4%, ZBH +3.3%, and SYK +2.3% were just off the pace, in reaction to media reports of private equity interest in JNJ ortho business - the unit represented 10% of the major's sales last year. Following early choppiness, the XBI +0.90% finished just off its best levels in afternoon trading. Post-close on Friday, AstraZeneca announced that phase 3 SERENA-4 trial with Etcamah did not meet its primary endpoint of PFS in 1L advanced breast cancer. Readout follows FDA accelerated approval on 4-Sep based on SERENA-6. WCLC 2026 meeting also started on Saturday and brought several notable updates to the lung cancer space. Weekend M&A headlines include AstraZeneca CEO telling the London Times the company is not pursuing megadeals, and JNJ reportedly in talks to sell orthopedic business (represents 10% of FY25 sales) to Apollo for $20B. Biotech readouts include generalized anxiety disorder and obesity, plus a long-awaited, first-time approval in spinal muscular atrophy (SMA) for Scholar Rock. Broad label, PRV award, priced at $11,659 per vial. Macro AI infrastructure space came under pressure following weekend warning from Anthropic's Dario Amodei, who called for a slower pace of frontier evolution. Cited concerns about cybersecurity and unchecked recursive self-improvement (RSI). But also market voices arguing impacts could be limited, with capability slowdown not necessarily translating to capex slowdown. Rates also grabbed the headlines today with 10Y yield moving above 5% for first time in three years, though it soon retreated back below. Oil was also higher today but came well off early strength; focus was on breakdown of Iran-GCC talks on the SoH but today also brought reports Russia and Ukraine have agreed not to target each other's energy infrastructure. Trump also said (again) Iran is eager for a deal. Otherwise, heightened anticipation for Wednesday's FOMC meeting where Fed is widely expected to hike, but also discussions about how tightening is rarely a one-and-done affair. Notable Gainers +13.8% TYRA (Tyra Biosciences): secondary offering, priced; best performer on XBI +13.5% IVVD (Invivyd): BTIG comments; shares remain (64%) YTD +7.7% IOVA (Iovance Biotherapeutics): on above average volume +6.6% HCM (Hutchmed): ADRs closed lower last five days +6.2% CLDX (Celldex Therapeutics): unusual option volume; above average share volume +5.9% TWST (Twist Bioscience): on above average volume +5.3% CAPR (Capricor Therapeutics): upgraded at B Riley Securities +5.0% SMMT (Summit Therapeutics): partner Akeso presented HARMONi-2 at WCLC +4.8% BSX (Boston Scientific): sympathy to JNJ; best performer on XLV; shares remain (53%) YTD +4.7% HIMS (Hims & Hers Health): on below average volume +4.5% CNC (Centene): 52-week high; second-best on XLV +4.5% FDMT (4D Molecular Therapeutics): upgraded at Cantor Fitzgerald +4.4% PODD (Insulet): shares (52%) YTD +4.3% DVA (DaVita): shares +67% YTD +4.2% AVLN (Avalyn Pharma): shares were down (10%) last week +4.0% GSK (GSK Plc): presented trial results in NSCLC at WCLC +3.5% DFTX (Definium Therapeutics): trial results in GAD +3.3% MCK (McKesson): presented today at Morgan Stanley +3.3% CI (Cigna Group): on light volume +3.3% ZBH (Zimmer Biomet Holdings): sympathy to JNJ +3.2% ARMP (Armata Pharmaceuticals): small-cap biotech; on heavy volume +3.1% MDT (Medtronic): sympathy to JNJ Notable Decliners -41.0% CLLS (Cellectis SA): announces strategic refocus on in vivo gene editing -6.4% SRRK (Scholar Rock): FDA approves Isembyld for SMA; worst performer on XBI -5.5% SPRY (ARS Pharmaceuticals): 52-week low; stock (25%) MTD -5.1% IONS (Ionis Pharmaceuticals): sympathy to SRRK -4.8% RARE (Ultragenyx Pharmaceutical): 52-week low; stock (46%) MTD; despite orphan drug designation -3.5% NBTX (Nanobiotix): presented lung cancer data at WCLC -1.9% CRL (Charles River Laboratories): on volume 1.5X average; worst performer on XLV Apollo in talks to acquire JNJ orthopedic business - Bloomberg JNJ Post-close on Friday Bloomberg reported that Apollo was in talks to acquire the orthopedics business of JNJ at a valuation around $20B. Deal could be finalized within weeks, or JNJ could continue with previously announced plans to spin-off the unit. Recall that the planned separation was announced in October 2025, and that Ortho represented 10% of FY2025 sales). (SNN, SYK, ZBH) Orthopedic stocks Zimmer Biomet, Stryker trade higher following Apollo-JNJ headline Trading update Monday morning with XLV +1.5%: SYK +4.0%, ZBH +3.2%, JNJ +1.5% Stryker and Zimmer are leading gainers on the XLV. On Friday evening, Bloomberg reported that Apollo was in talks to acquire JNJ's orthopedics unit at a valuation of about $20B. AstraZeneca trading inline following lung cancer readout, CEO comments on megadeals Post-close on Friday AZN.LN (AZN) announced that the phase 3 SERENA-4 trial with Etcamah did not meet its primary endpoint of PFS in 1L advanced breast cancer. Readout follows FDA accelerated approval for Etcamah on 4-Sep, based on SERENA-6. (OLMA, ROP.SW) CEO Pascal Soriot also told the London Times that the company is not pursing megadeals. Follows early August media reports that the company held talks with Bristol Myers (BMY). Scholar Rock trading choppy following FDA approval, drug pricing, launch update SRRK announced that FDA approved Isembyld (apitegromab) BLA for the treatment of SMA in adults and children two years and older. Approval includes a PRV award. Decision comes ahead of the 30-Sep PDUFA following BLA resubmission, the Sep 2025 CRL and delay due to third party inspection at Catalent Indiana. On the call, announced WAC price $11,659 per vial. Average patient cost $310K per year, based on patient weight, mandatory discounts, payer mix. Company receives PRV which it will monetize. Quick take: Truist (buy-rated) had modeled price per vial $9K with each additional $500 adding $5/DCF. On the approval and broad label, but before pricing, firm raised PT to $76 from $55. Notable research in Healthcare today Biotech: CAPR upgraded to buy from neutral at B Riley Securities (Madison El-Saadi), target increased to $21 from $5 or approx. 151% upside. FDMT upgraded to overweight from neutral at Cantor Fitzgerald (Josh Schimmer), notes confidence in 4D-150. Target is $20 or approx. 52% upside. (FactSet average PT $29; range $18-37) IFRX initiated buy at Needham (Joseph Stringer), target is $8 or approx. 283% upside. (FactSet average PT $8; range $3-14) LRMR assumed outperform at Leerink Partners (Basma Radwan), target increased to $13 from $12 or approx. 232% upside. RYTM assumed outperform at Leerink Partners (Basma Radwan), target decreased to $133 from $145 or approx. 27% upside. KRSA initiated buy at Stifel (Paul Matteis), target is $43 or approx. 35% upside. KRSA initiated buy at TD Cowen (Tyler Van Buren) MedTech: STMN.SW upgraded to buy from neutral at Goldman Sachs (Richard Felton), target increased to CHF125 from CHF106 or approx. 33% upside. (FactSet average PT CHF115; range CHF86-136) Post-close news Corporate: DXCM announced that CFO Jereme Sylvain will add COO title and duties. Note: Exactly one year ago, Kevin Sayer took medical leave from the CEO role, and then-COO Jacob Leach was appointed CEO effective 1-Jan. Shares trading UNCH in the after-hours Trial results: CTNM announced topline results from the phase 2 MOONLIGHT-1 trial evaluating PIPE-307 / JNJ-5120 in major depressive disorder did not achieve its primary efficacy endpoint. (JNJ) Shares of CTNM trading (8.2%) in the after-hours On Deck: Conferences (cont.) World Conference on Lung Cancer (WCLC) (Sep 12-15) (cont.) Jefferies Healthcare Services and Technology Conference (Sep 14-16) (cont.) H.C. Wainwright Global Investment Conference (Sep 14-16) (cont.) Morgan Stanley Global Healthcare Conference (Sep 14-16) on Wed 16-Sep: Deutsche Bank Healthcare Summit (Sep 16-17) Regulatory (cont.): EMA CHMP monthly meeting (Sep 14-17) on Fri 18-Sep: EMA CHMP opinions on MAA (September) on Sat 19-Sep: FDA PDUFA for RARE UX111 BLA in Sanfilippo Syndrome; FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate on Wed 16-Sep: OSCR Investor Day (900ET) on Thu 17-Sep: NVST Investor Day (900ET) StreetAccount Healthcare Reads The GOP's $50B rural health fund is coming up short, hospital leaders say. The cash amounts to just 5% of the cuts, and comes with plenty of red tape (14-Sep) STAT News Pennsylvania's measles toll grows (14-Sep) Politico What's in a name? Novo looks to a rebrand (14-Sep) STAT News Major Novartis shareholder calls for board shake-up after drug trial setbacks (10-Sep) Reuters This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ARMP, AVLN, AZN.LN, BMY, BSX, CAPR, CI, CLDX, CLLS, CNC, CRL, CTNM, DFTX, DVA, DXCM, FDMT, GSK, HCM, HIMS, IFRX, IONS, IOVA, IVVD, JNJ, KRSA, LRMR, MCK, MDT, NBTX, NVO, NVST, OLMA, OSCR, PODD, RARE, ROP.SW, RYTM, SMMT, SNN, SPRY, SRRK, STMN.SW, SYK, TWST, TYRA, ZBH...(more)	show story hide story
14-Sep-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +1.00% vs the S&P 500 (0.80%). All major health groups are still higher on their averages to begin the week, with defensive groups today's leading gainers; modest gains elsewhere. Managed Care and Pharma are followed by a pocket of strength in medical device manufacturers. Busy weekend of lung cancer headlines, plus some breast cancer news, however weekend M&A headlines dominate the price action today. SYK +3.5% and MRNA (2.8%) bracket the XLV. Stryker along with orthopedic device maker peers are leading XLV gainers in reaction to media reports of private equity interest in JNJ ortho business which represented 10% of the major's sales last year. BSX +3.3% and ZBH +2.2%. Gainers +14.9% TYRA (Tyra Biosciences): secondary offering, priced; best performer on XBI +13.3% ARMP (Armata Pharmaceuticals): small-cap biotech +6.6% IVVD (Invivyd): BTIG comments; shares remain (66%) YTD +5.9% HCM (Hutchmed): ADRs closed lower last five days +5.6% CAPR (Capricor Therapeutics): upgraded at B Riley Securities +4.8% SMMT (Summit Therapeutics): Akeso presented HARMONi-2 at WCLC +4.6% DFTX (Definium Therapeutics): trial results in GAD +4.5% AVLN (Avalyn Pharma): shares were down (10%) last week +4.2% HIMS (Hims & Hers Health): on average volume +3.6% FDMT (4D Molecular Therapeutics): upgraded at Cantor Fitzgerald +3.5% SYK (Stryker): best performer on XLV; sympathy to JNJ +3.4% GSK (GSK Plc): presented trial results in NSCLC at WCLC +2.9% GHRS (GH Research): sympathy to DFTX +2.9% BSX (Boston Scientific): second-best performer on XLV; sympathy to JNJ +2.5% CI (Cigna Group): on light volume +2.4% ZBH (Zimmer Biomet Holdings): sympathy to JNJ +2.2% MDT (Medtronic): sympathy to JNJ +2.1% ERAS (Erasca): on light volume; shares +341% YTD +1.8% MCK (McKesson): presented today at Morgan Stanley +1.6% AZN (AstraZeneca): trial results in breast cancer; CEO comments on M&A +1.5% BNTX (BioNTech): presented trial results in NSCLC at WCLC +1.5% CRBP (Corbus Pharmaceuticals): trial results in obesity +1.3% JNJ (Johnson & Johnson): media report - Apollo in talks to acquire ortho business Decliners -39.2% CLLS (Cellectis SA): announces strategic refocus on in vivo gene editing -4.4% NBTX (Nanobiotix): presented lung cancer data at WCLC -4.3% VERA (Vera Therapeutics): on average volume; worst performer on XBI -4.2% CGEM (Cullinan Therapeutics): trial results in lung cancer -3.9% TXG (10X Genomics): shares were +9% last week and 52-week high -3.4% SRRK (Scholar Rock): FDA approves Isembyld for SMA -2.9% MRNA (Moderna): worst performer on XLV -1.9% OLMA (Olema Pharmaceuticals): sympathy to AZN	show story hide story
14-Sep-2026 09:40	Orthopedic stocks Zimmer Biomet, Stryker trade higher following Apollo-JNJ headline Trading update Monday morning with XLV +1.5%: SYK +4.0% ZBH +3.2% JNJ +1.5% Stryker and Zimmer are leading gainers on the XLV. On Friday evening, Bloomberg reported that Apollo was in talks to acquire JNJ's orthopedics unit at a valuation of about $20B. See Related StreetAccount comments: 9/11/2026 7:49:37 PM - Apollo in talks to acquire Johnson & Johnson's orthopedics unit at valuation of about $20B - Bloomberg 10/14/2025 9:24:12 AM - Johnson & Johnson shares muted following a Q3 beat, announced Orthopedics separation Related: JNJ, SYK, ZBH	show story hide story
14-Sep-2026 09:31	CDC denies petitions to add PAD and Stroke to list of World Trade Center Health Program Three days after the 25th anniversary of 9/11, the CDC discloses it has denied two petitions for addition of a health condition to the WTC Health Program. The Administrator received two petitions to add Stroke to the list of WTC-Related Health Conditions, and a separate petition to add peripheral arterial disease (PAD) to the list of WTC-Related Health Conditions. The Administrator has determined that there is insufficient evidence available to support taking further action at this time.	show story hide story
14-Sep-2026 08:52	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Post-close on Friday, AstraZeneca announced that phase 3 SERENA-4 trial with Etcamah did not meet its primary endpoint of PFS in 1L advanced breast cancer. Readout follows FDA accelerated approval on 4-Sep based on SERENA-6. In sympathy, OLMA (8%) in the pre-market Monday. WCLC 2026 meeting also started on Saturday and brought several notable updates to the lung cancer space. Weekend M&A headlines include AstraZeneca CEO telling the London Times the company is not pursuing megadeals, and JNJ reportedly in talks to sell orthopedic business (represents 10% of FY25 sales) to Apollo for $20B. ADRs for AZN +2% in the pre-market, BMY +1%. JNJ +1%. Biotech readouts include generalized anxiety disorder and obesity, plus a long-awaited, first-time approval in spinal muscular atrophy (SMA) for Scholar Rock. Broad label, PRV award, priced at $11,659 per vial. Shares of SRRK +5% in the pre-market. Macro S&P futures are down (0.6%) on Monday morning. Defensive tone with AI trade under pressure on the back of Anthropic CEO Dario Amodei's call for slowing AI model development, citing concerns about recursive self-improvement (RSI) and cybersecurity. However, also skepticism about a sustained drawdown given capability slowdown does not mean a capex slowdown. In addition, software a rotational beneficiary this morning. Oil rally the other big story this morning with the focus on the closure of Saudi Arabia's East-west pipeline and the postponement of the meeting between the GCC and Iran intended to discuss a temporary shipping lane through SoH. Fed also in focus with more sell-side firms now expecting a rate hike this week and reports in the financial press about how Fed tightening is rarely a one-and-done event. Pre-market trading update Trading higher +12.5% DFTX trial results in GAD; call at 8ET +5.8% BNTX presented trial results in NSCLC at WCLC +5.4% CAPR upgraded at B Riley Securities +5.0% SRRK FDA approves Isembyld for SMA; call at 8ET +4.0% GSK presented trial results in NSCLC at WCLC +3.5% CRBP trial results in obesity; call at 8ET +3.1% SMMT Akeso presented HARMONi-2 at WCLC +2.3% STMN.SW in European trading; upgraded at Goldman Sachs +2.2% AZN trial results in breast cancer; CEO comments on M&A +2.1% FDMT upgraded at Cantor Fitzgerald +1.3% JNJ media report - Apollo in talks to acquire ortho business Trading lower -18.4% CLLS announces strategic update; call at 8ET -11.7% SLS on heavy volume -8.0% OLMA sympathy to AZN -4.8% GHRS sympathy to DFTX (low volume) Pharma M&A / media report: AZN.LN (AZN) CEO Pascal Soriot told the London Times that the company is not pursing megadeals. Follows early August media reports that the company held talks with Bristol Myers (BMY). Trial results: AZN.LN (AZN) Post-close on Friday announced that the phase 3 SERENA-4 trial with Etcamah did not meet its primary endpoint of PFS in 1L advanced breast cancer. Readout follows FDA accelerated approval for Etcamah on 4-Sep, based on SERENA-6. (OLMA, ROP.SW) Biotech Regulatory: SRRK announced that FDA approved Isembyld (apitegromab) BLA for the treatment of SMA in adults and children two years and older. Approval includes a PRV award. Decision comes ahead of the 30-Sep PDUFA following BLA resubmission, the Sep 2025 CRL and delay due to third party inspection at Catalent Indiana. Conf. call at 8:00ET On the call, announced WAC price $11,659 per vial. Average patient cost $310K per year, based on patient weight, mandatory discounts, payer mix. Company receives PRV which it will monetize. Quick take: Truist (buy-rated) had modeled price per vial $9K with each additional $500 adding $5/DCF. On the approval and broad label, but before pricing, firm raised PT to $76 from $55. Research: CAPR upgraded to buy from neutral at B Riley Securities (Madison El-Saadi), target increased to $21 from $5 or approx. 151% upside. FDMT upgraded to overweight from neutral at Cantor Fitzgerald (Josh Schimmer), notes confidence in 4D-150. Target is $20 or approx. 52% upside. (FactSet average PT $29; range $18-37) IFRX initiated buy at Needham (Joseph Stringer), target is $8 or approx. 283% upside. (FactSet average PT $8; range $3-14) LRMR assumed outperform at Leerink Partners (Basma Radwan), target increased to $13 from $12 or approx. 232% upside. RYTM assumed outperform at Leerink Partners (Basma Radwan), target decreased to $133 from $145 or approx. 27% upside. KRSA initiated buy at Stifel (Paul Matteis), target is $43 or approx. 35% upside. KRSA initiated buy at TD Cowen (Tyler Van Buren) Life Science & MedTech M&A / media report: JNJ Post-close on Friday Bloomberg reported that Apollo was in talks to acquire the orthopedics business of JNJ at a valuation around $20B. Deal could be finalized within weeks, or JNJ could continue with previously announced plans to spin-off the unit. Recall that the planned separation was announced in October 2025, and that Ortho represented 10% of FY2025 sales). (SNN, SYK, ZBH) Research: STMN.SW upgraded to buy from neutral at Goldman Sachs (Richard Felton), target increased to CHF125 from CHF106 or approx. 33% upside. (FactSet average PT CHF115; range CHF86-136) On Deck: Conference (cont.) World Conference on Lung Cancer (WCLC) (Sep 12-15) Jefferies Healthcare Services and Technology Conference (Sep 14-16) H.C. Wainwright Global Investment Conference (Sep 14-16) Morgan Stanley Global Healthcare Conference (Sep 14-16) on Wed 16-Sep: Deutsche Bank Healthcare Summit (Sep 16-17) Regulatory EMA CHMP monthly meeting (Sep 14-17) Corporate CLLS call to discuss a business update (800ET) CRBP call to discuss topline results from CANYON-1 trial in obesity (800ET) DFTX call to discuss topline results from PANORAMA trial in adults with GAD (800ET) SRRK call to discuss FDA approval of Isembyld (apitegromab) for SMA in adults and children 2 years and up (800ET) on Wed 16-Sep: OSCR Investor Day (900ET) on Thu 17-Sep: NVST Investor Day (900ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AZN, AZN.LN, BMY, BNTX, CAPR, CLLS, CRBP, DFTX, FDMT, GHRS, GSK, IFRX, JNJ, KRSA, LRMR, NVST, OLMA, OSCR, ROP.SW, RYTM, SLS, SMMT, SNN, SRRK, STMN.SW, SYK, ZBH...(more)	show story hide story
11-Sep-2026 16:15	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equites ended mixed overall on Friday. Advancers slightly outnumbered decliners on the XLV. Healthcare (0.15%) vs the S&P 500 +0.86%. Major health groups were mixed in smaller moves, with all groups underperforming the broader tape. Sector news flow very quiet outside of a Morgan Stanley downgrade of Novo Nordisk, citing challenges to its mid-term growth outlook and semaglutide LOE. NVO ADRs (2.1%). MRNA +5.4% and EW (2.8%) bracketed the XLV. Notable Gainers on Friday: +19.7% ATEC (Alphatec Holdings): insider transaction +11.1% RLMD (Relmada Therapeutics): insider transaction +5.4% MRNA (Moderna): best performer on the XLV and XBI +3.7% OBX (Obsidian Therapeutics): on high volume +2.8% DNTH (Dianthus Therapeutics): initiated overweight at JPMorgan Notable Decliners on Friday: -14.4% SLS (SELLAS Life Sciences Group, Inc.): worst performer on XBI -10.3% BBOT (BridgeBio Oncology Therapeutics): shares (45%) for the week -3.4% TMDX (TransMedics Group): appoints Fernando Araujo as CFO -2.8% EW (Edwards Lifesciences): worst performer on XLV -2.3% EXEL (Exelixis): FDA extension of zanzalintinib NDA -2.1% NVO (Novo Nordisk): downgraded at Morgan Stanley -0.5% COO (The Cooper Cos.): follow-through Week in Review: Healthcare equities underperformed for the week. The S&P 500 Healthcare Index (3.56%) vs the S&P 500 Index (0.80%). Outperformers: Services, Managed Care Underperformers: Pharma, Biotech, MedTech All health groups were lower for the week, with mixed performance around the tape. Biotech was the leading decliner, while Managed Care showed relative strength, benefiting from reaffirmed guidance from ELV and CFO commentary that Q3 is trending ahead of expectations. Sector sentiment was pressured by Novartis' disappointing pelacarsen data in the Phase 3 HORIZON trial. MedTech also faced pressure, with BSX warning of a material Q3 and FY financial impact from its cybersecurity incident and SYK coming under renewed pressure following an operational update. Earnings returned to the tape, with COO lower following a mixed Q3, including a CVI miss and below-consensus Q4 guidance, while the company confirmed it will retain CSI following its strategic review. Elsewhere, hospital presentations at WFC highlighted relative earnings resilience amid exchange-based headwinds. Year-to-date, Healthcare 6.59%% vs the S&P 500 +11.85%. Healthcare 7th out of eleven major sectors in CY26. Energy +44.5% and Consumer Discretionary (2.95%) bracket them all. Notable movers for the week: Gainers: ROIV +16.9% - trial results in PH-ILD HCA +5.4% - presented at Wells Fargo conference ELV +2.8% - reaffirmed guidance Decliners: DYN (25.0%) - sympathy to NVS (DM1); downgraded at JPMorgan TYRA (23.1%) - trial results in bladder cancer COO (22.5%) - earnings; downgrades (2) BEAM (19.1%) - trial results in AATD NVS (14.3%) - trial results for Lp(a); trial results in DM1 AMGN (13.7%) - sympathy to NVS (LP(a)); downgrades (2) BSX (10.1%) - cybersecurity update; guidance SYK (9.1%) - presented at WF Healthcare conference RPRX (8.4%) - sympathy to NVS (LP(a)) NVO (7.6%) - trials with ziltivekimab halted; downgraded at Morgan Stanley Week Ahead (Sat - Sun) Sep 14-20 Conference calendar Mon 14-Sep: Jefferies Healthcare Services and Technology Conference (Sep 14-16); H.C. Wainwright Global Investment Conference (Sep 14-16); Morgan Stanley Global Healthcare Conference (Sep 14-16) Wed 16-Sep: Deutsche Bank Healthcare Summit (Sep 16-17) Regulatory calendar Mon 14-Sep: EMA CHMP monthly meeting (Sep 14-17) Sat 19-Sep: FDA PDUFAs: RARE UX111 BLA in Sanfilippo Syndrome; IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate calendar Wed 16-Sep: OSCR Investor Day Thu 17-Sep: NVST Investor Day	show story hide story
11-Sep-2026 14:38	StreetAccount Summary: Notable Drug Events expected for the week of 13-Sep (cont.) Industry meeting with clinical data: World Conference on Lung Cancer (WCLC) 2026 (Sep 12-15) (ABBV, BNTX, CAI, BLSM) Sun 13-Sep Industry meeting with clinical data: International Pathogenic Neisseria Conference (IPNC) (Sep 13 -17) (GSK.LN) Mon 14-Sep Regulatory meeting: EMA CHMP monthly meeting (Sep 14-17) Tue 15-Sep Trial results: BLSM to present updated data on Phase 1/2 SOLARA trial in EGFR-mutant NSCLC at WCLC Wed 16-Sep Investor event: RNAZ business update call (16:15ET) Fri 18-Sep Regulatory decision: EMA CHMP opinions on MAA Sat 19-Sep Regulatory decisions: RARE FDA PDUFA for rebisufligene etisparvovec BLA in Sanfilippo syndrome type A IntraBio (private) FDA PDUFA for Aqneursa sNDA in Ataxia-Telangiectasia later during September 2026 Regulatory decisions: FDA PDUFAs: MRK (Winrevair sBLA, 21-Sep), INCY/MIRM (zilurgisertib NDA, 26-Sep), ROP.SW (Gazyva sBLA, 27-Sep), EGTX.SS (Emcitate NDA, 28-Sep), BFRI (Ameluz sNDA, 28-Sep), SRRK (apitegromab BLA, 30-Sep), BMY (Camzyos sNDA, 30-Sep) Industry meetings with clinical data: International Myeloma Society (IMS) annual meeting (Sep 23-26); European Association for the Study of Diabetes (EASD) annual meeting (Sep 28 - Oct 2) Trial results: KOD (Ph3 Wet AMD), KLRA (Ph 3 T2D and Ph1 obesity), PAR.AU (Ph3 OA), IMMX (Ph2 R/R AL Amyloidosis), CNTB (Ph2 Acute asthma and Ph2 COPD), LGVN (Ph2 HLHS), ARCT (Ph2 OTC deficiency), Revelyx Bio (Ph2 aesthetics), BIVI (Ph2 long COVID), QURE (Ph1/2 Huntington's disease), DYN (Ph1/2 DM1), HPHA.GR (Ph1/2 RRMM), CNTX (Ph1 solid tumors), PHIL.IM (Ph1 glioblastoma), CRBP (Ph1 obesity), ZNTL (Ph1 PROC), PMN (Ph1 AD), VKTX (Ph1 obesity), ACET (Ph1 SLE) Related: ABBV, ACET, ARCT, BFRI, BIVI, BLSM, BMY, BNTX, CAI, CNTB, CNTX, CRBP, DYN, EGTX.SS, GSK.LN, HPHA.GR, IMMX, INCY, KLRA, KOD, LGVN, MIRM, MRK, PAR.AU, PHIL.IM, PMN, QURE, RARE, RNAZ, ROP.SW, SRRK, VKTX, ZNTL...(more)	show story hide story
11-Sep-2026 11:04	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.10%) vs the S&P 500 +0.86%. Major health groups are mixed in smaller moves, with all groups underperforming the broader tape. Sector news flow remains very quiet outside of a Morgan Stanley downgrade of Novo Nordisk, citing challenges to its mid-term growth outlook and semaglutide LOE. NVO ADRs (3%). MRNA +8% and UNH (3%) bracket the XLV. Gainers +14.4% ATEC (Alphatec Holdings): insider transaction +9.0% RLMD (Relmada Therapeutics): insider transaction +7.5% MRNA (Moderna): best performer on the XLV; best biotech performer on XBI +7.3% OBX (Obsidian Therapeutics): on high volume +5.1% DNTH (Dianthus Therapeutics): initiated overweight at JPMorgan Decliners -11.1% CADL (Candel Therapeutics): worst performer on XBI -6.6% TMDX (TransMedics Group): appoints Fernando Araujo as CFO -4.3% BBOT (BridgeBio Oncology Therapeutics): shares (41%) WTD -2.9% EXEL (Exelixis): FDA extension of zanzalintinib NDA -2.7% NVO (Novo Nordisk): downgraded at Morgan Stanley -2.5% UNH (UnitedHealth Group): worst performer on XLV -1.5% COO (The Cooper Cos.): follow-through	show story hide story
11-Sep-2026 08:22	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Novo Nordisk downgraded at Morgan Stanley, citing challenges to its mid-term growth outlook and semaglutide LOE. Otherwise, sector newsflow is very quiet. The World Conference on Lung Cancer in Seoul, South Korea, is set to kick off Saturday. Yesterday, most major health groups ended lower, with managed care the lone group in positive territory, led by ELV with reaffirmed guidance and CFO commentary that Q3 is trending ahead of expectations. COO lower after a mixed Q3, CVI miss, and below-consensus Q4 guidance; confirmed it will retain CSI following its strategic review. The Biotech group was the leading decliner, XBI (1.57%). Macro S&P futures up 0.6% in Friday morning trading. Bounce attempt likely driven by oil pullback on report that Gulf foreign ministers will meet with Iranian counterparts on Monday in push for deal to reopen SoH. ORCL earnings the latest positive for the AI trade, while also some focus on report MSFT planning to more than triple data center capacity to alleviate computing shortages and OpenAI pausing Pro subscriptions amid outsized Astra demand. Pretty quiet elsewhere with a lot of headlines surrounding the surge in diesel prices, Houthi advance and global bond yield backup. All about CPI today with the probability of a September rate hike at 67% going into the print. Pre-market trading update Trading higher +8.4% ATEC insider transaction +8.1% RLMD insider transaction Trading lower -3.3% EXEL FDA extension of zanzalintinib NDA -1.1% NVO downgraded at Morgan Stanley Pharma Research: NOVO.B.DC (NVO) downgraded to underweight from equal-weight at Morgan Stanley (Thibault Boutherin), cites outlook for mid-term growth and semaglutide LOE overhang. Target remains DKK250 or approx. 13% downside (FactSet average target DKK316.81; range DKK200-457) Biotech Regulatory: EXEL discloses FDA extension of NDA for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer. - 8-K Research: DNTH initiated overweight at JPMorgan (Brian Cheng), target is $135 or approx. 31% upside. (FactSet average target $140.12; range $122-200) VRTX moved to overweight from not rated at JPMorgan (Jessica Fye), target is $560 or approx. 9% upside. (FactSet average target $573.77; range $350-672) Life Science & MedTech Corporate: ATEC CEO Patrick Miles discloses purchase of 115K shares (yesterday post-close). Research: HIMS assumed neutral at JPMorgan (Bryan Smilek), target is $32 or approx. 17% upside. (FactSet average target $32.21; range $24-42) On Deck Sep 5 - 13 Conference calendar (cont.): Cantor Fitzgerald Global Healthcare Conference (Sep 9-11) Sat 12-Sep: World Conference on Lung Cancer (WCLC) (Sep 12-15) Regulatory calendar Fri 11-Sep: TLX.AU FDA PDUFA for Pixclara NDA for imaging of gliomas Peek Ahead to next week (Sep 14-20) Conferences: Jefferies Healthcare Services and Technology Conference, H.C. Wainwright Global Investment Conference ,Morgan Stanley Global Healthcare Conference, Deutsche Bank Healthcare Summit Regulatory: EMA CHMP monthly meeting (September 2026); FDA PDUFA for RARE UX111 BLA in Sanfilippo Syndrome; FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate: Investor Day OSCR; Investor Day NVST This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ATEC, DNTH, EXEL, HIMS, NOVO.B.DC, NVO, RLMD, VRTX...(more)	show story hide story
10-Sep-2026 16:16	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equites ended mostly lower on Thursday. Decliners outnumbered advancers more than 3:1 on the XLV. Healthcare (0.53%) vs the S&P 500 (0.58%). Most major health groups were lower, with managed care the lone group in positive territory, led by ELV +5.9% following reaffirmed guidance and CFO commentary that Q3 is trending ahead of expectations. Earnings are back on the tape, with COO (14.7%) following a mixed Q3, including a CVI miss and below-consensus Q4 guidance. The company also confirmed it will retain CSI following its strategic review. The Biotech group the leading decliner, with the XBI (1.57%). BHVN (14.8%) after the FDA issued a Partial Clinical Hold on Phase 2/3 trials for epilepsy drug candidate Opakalim (BHV-7000). Axogen announced a definitive agreement to acquire private BioCircuit Technologies, developer of NerveTape, the first FDA-approved sutureless nerve repair device, for $200M. Macro US equities were lower in Thursday trading as stocks ended a bit off worst levels. Market on the defensive against continued strength in crude and notable jump in Treasury yields. WTI crude up for eighth consecutive session (and up ~20% over that stretch) with focus on Mideast headlines, particularly regarding Houthi influence over Bab el-Mandeb strait. Contributing to big Treasury selloff, with 2Y yield back above 4.55% (highest since Jul '24), 10Y above 4.95% (highest since Oct '23). Hotter PPI components translating to PCE in the discussion as well. Also hawkish ECB takeaways, fiscal concerns (though Trump's $5K promise dismissed as unrealistic). Notable Gainers +8.5% CLOV (Clover Health): initiation +7.0% TYRA (Tyra Biosciences): shares (18%) yesterday; best performer on XBI +5.4% ELV (Elevance Health): reaffirmed guidance; best performer on the XLV +2.2% WST (West Pharmaceutical Services): raised FY26 gudiance +2.1% CNC (Centene): sympathy to ELV +1.0% ALMS (Alumis): insider transaction +0.2% HUM (Humana): sympathy the ELV Notable Decliners -18.3% BBOT (BridgeBio Oncology Therapeutics): follow through; worst performer on XBI -14.8% BHVN (Biohaven): FDA partial clinical hold on BHV-7000 studies -14.7% COO (The Cooper Cos.): earnings; downgrades (2); worst performer on the XLV -11.5% AXGN (AxoGen): to acquire BioCircuit Technologies; common stock offering -8.1% OBX (Obsidian Therapeutics): on high volume -6.3% CMPS (Compass Pathways): shares remain +7% WTD; new FDA framework for Psychedelic Drugs -6.1% HELP (Cybin Inc): shares remain +5% WTD; new FDA framework for Psychedelic Drugs -5.8% BCRX (BioCryst Pharmaceuticals): downgrade -4.4% LH (Labcorp Holdings): guidance -4.1% BSX (Boston Scientific): following presentation at Wells Fargo Healthcare Conference -3.1% IRON (Disc Medicine): trial results in PV -2.1% RVMD (Revolution Medicines): initiation -0.3% JNJ (Johnson & Johnson): received CE Marking for ACUVUE OASYS MAX The Cooper Cos. lower on CVI weakness; CSI sale off the table COO reports fiscal Q3 EPS $1.15 ex-items vs FactSet $1.12 on revenue $1.066B vs FS $1.098B. Updated FY26 guidance and guides Q4 below consensus. Q4 organic growth: CSI +4-6%, CVI (2%) to +0% Concludes strategic review - keeping CSI; Board remains open to all options to create shareholder value. Quick take: CVI softness attributed to U.S. channel inventory destocking, with pressure expected to continue through Q4. The decision not to sell CSI was seen as surprising given recent commentary. Notable research in Healthcare today Pharma: NOVN.SW (NVS) upgraded to hold from reduce at HSBC (Rajesh Kumar), target increased to CHF110 from CHF95 or approx. 1% downside. (FactSet average target CHF126.15; range CHF102.90-149.57) Biotech: KYMR upgraded to outperform from peer perform at Wolfe Research (Andy Chen), target is $180 or approx. 56% upside. (FactSet average target $136.77; range $111-180) AMGN downgraded to hold from buy at HSBC (Rajesh Kumar), target cut to $425 from $445 or approx. 9% upside. (FactSet average target $395.75; range $225-530) BCRX downgraded to sector perform from outperform at RBC Capital Markets (Brian Abrahams), target cut to $11 from $13, 25% upside. (FactSet average target $20.82; range $12-32) ADAG initiated buy at Chardan Capital (Gautam Chukka), target is $9 or approx. 175% upside. (FactSet average target $10.86; range $8-17.45) ANL initiated buy at Jefferies (Maury Raycroft), target is $31 or approx. 111% upside. (FactSet average target $29.50; range $20-49) RVMD initiated overweight at Morgan Stanley (Sean Laaman), target is $255 or approx. 23% upside. Life Science & MedTech: OBIO upgraded to buy from neutral at BTIG (Marie Thibault), cites near-term catalysts. Target is $10 or approx. 83% upside. (FactSet average target $12.33; range $9-20) COO downgraded to neutral from overweight at Piper Sandler (Jason Bednar), cites factors including lack of catalysts. Target is $59 or approx. 7% downside. (FactSet average target $79.54; range $61-92) COO downgraded to neutral from outperform at Baird (Jeff Johnson), target cut to $61 from $85, 4% downside (FactSet average target $71.62; range $58-92) MASS initiated buy at Canaccord Genuity (Austin Moeller), target is $13.50 or approx. 39% upside. Services & Hospitals and Managed Care: CLOV initiated buy at Deutsche Bank (George Hill), target is $6 or approx. 38% upside. (FactSet average target $5.38; range $5-6) Post-close news Corporate: TMDX appoints Fernando Araujo as CFO, effective 21-Sep. On Deck: Sep 5 - 13 Conference calendar (cont.): Wells Fargo Healthcare Conference (Sep 8-10) Cantor Fitzgerald Global Healthcare Conference (Sep 9-11) Citi Back to School Conference (Sep 9-10) Goldman Sachs European MedTech and Healthcare Services Conference (Sep 9-10) Sat 12-Sep: World Conference on Lung Cancer (WCLC) (Sep 12-15) Regulatory calendar Fri 11-Sep: TLX.AU FDA PDUFA for Pixclara NDA for imaging of gliomas Peek Ahead to next week (Sep 14-20) Conferences: Jefferies Healthcare Services and Technology Conference, H.C. Wainwright Global Investment Conference ,Morgan Stanley Global Healthcare Conference, Deutsche Bank Healthcare Summit Regulatory: EMA CHMP monthly meeting (September 2026); FDA PDUFA for RARE UX111 BLA in Sanfilippo Syndrome; FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate: Investor Day OSCR; Investor Day NVST This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ADAG, ALMS, AMGN, ANL, AXGN, BBOT, BCRX, BHVN, BSX, CLOV, CMPS, CNC, COO, ELV, HELP, HUM, IRON, JNJ, KYMR, LH, MASS, NOVN.SW, OBIO, OBX, RVMD, TMDX, TYRA, WST...(more)	show story hide story
10-Sep-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.53%) vs the S&P 500 (0.45%). Most major health groups are lower, with managed care the lone group in positive territory, led by ELV +4% following reaffirmed guidance and CFO commentary that Q3 is trending ahead of expectations. CNC +3% and HUM +1% are higher in sympathy. Earnings are back on the tape, with COO (14%) following a mixed Q3, including a CVI miss and below-consensus Q4 guidance. The company also confirmed it will retain CSI following its strategic review. The Biotech group the leading decliner, with the XBI (1.04%). Gainers +8.8% CLOV (Clover Health): initiation +5.2% TYRA (Tyra Biosciences): shares (18%) yesterday +3.8% OMDA (Omada Health, Inc.): announced LT financial targets ahead of 13:00ET investor day +3.7% ELV (Elevance Health): reaffirmed guidance; best performer on the XLV +3.7% DMRA (Damora Therapeutics): best performer on XBI +2.7% CNC (Centene): sympathy to ELV; second-best performer on the XLV +1.7% OBX (Obsidian Therapeutics): on high volume +1.4% HUM (Humana): sympathy the ELV +1.1% ALMS (Alumis): insider transaction +1.0% NVS (Novartis): upgraded at HSBC Decliners -15.4% BHVN (Biohaven): FDA partial clinical hold on BHV-7000 studies -15.1% BBOT (BridgeBio Oncology Therapeutics): follow through; worst performer on XBI -13.8% COO (The Cooper Cos.): earnings; downgrades (2); worst performer on the XLV -8.2% BCRX (BioCryst Pharmaceuticals): downgrade -7.6% AXGN (AxoGen): to acquire BioCircuit Technologies; common stock offering -5.0% HELP (Cybin Inc): shares reamin +6% WTD; new FDA framework for Psychedelic Drugs -2.3% CMPX (Compass Therapeutics): shares remain +8% WTD; new FDA framework for Psychedelic Drugs -1.6% RVMD (Revolution Medicines): initiation -1.6% BSX (Boston Scientific): following presentation at Wells Fargo Healthcare Conference -1.3% IRON (Disc Medicine): trial results -0.3% JNJ (Johnson & Johnson): received CE Marking for ACUVUE OASYS MAX	show story hide story
10-Sep-2026 08:28	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings are back on the tape, with COO down sharply premarket following a mixed Q3, including a CVI miss and below-consensus Q4 guidance. BHVN shares pressured after the FDA issued a Partial Clinical Hold on Phase 2/3 trials for epilepsy drug candidate Opakalim (BHV-7000). Axogen announced a definitive agreement to acquire private BioCircuit Technologies, developer of NerveTape, the first FDA-approved sutureless nerve repair device, for $200M. Yesterday, healthcare equities finished mostly lower and roughly inline overall. Healthcare (0.37%) modestly outperformed the S&P 500 (0.48%). Most major health groups ended lower by around (1%) on the averages, led by Biotech and MedTech; XBI (1.57%). Managed Care group mostly red as well, only CI +0.9% finished higher with an initiation on the tape. Macro S&P futures down 0.1% in Thursday morning trading, near premarket lows. No big directional drivers in play with focus seemingly starting to shift toward August CPI on Friday. Probability of a September Fed rate hike currently at just over 62%. Oil higher again as US-Iran conflict timeline continues to get extended. Yields also higher again with focus on energy market and structural forces. When it comes to the latter, fiscal dynamic in play even when considering Trump's $5K dividend pledge is a nonstarter. Pre-market trading update Trading higher +5.8% ALMS insider transaction +3.8% ELV reaffirmed guidance +1.8% CLOV initiation +1.3% NVS upgraded at HSBC +1.0% IRON trial results Trading lower -18.2% COO earnings; downgrades (2) -13.4% BHVN FDA partial clinical hold on BHV-7000 studies -4.8% AXGN to acquire BioCircuit Technologies; common stock offering -1.1% BCRX downgrade Pharma Regulatory: JNJ receives CE Marking for ACUVUE OASYS MAX reusable contact lenses. Research: NOVN.SW upgraded to hold from reduce at HSBC (Rajesh Kumar), target increased to CHF110 from CHF95 or approx. 1% downside. (FactSet average target CHF126.15; range CHF102.90-149.57) Biotech Research: KYMR upgraded to outperform from peer perform at Wolfe Research (Andy Chen), target is $180 or approx. 56% upside. (FactSet average target $136.77; range $111-180) AMGN downgraded to hold from buy at HSBC (Rajesh Kumar), target cut to $425 from $445 or approx. 9% upside. (FactSet average target $395.75; range $225-530) BCRX downgraded to sector perform from outperform at RBC Capital Markets (Brian Abrahams), target cut to $11 from $13, 25% upside. (FactSet average target $20.82; range $12-32) ADAG initiated buy at Chardan Capital (Gautam Chukka), target is $9 or approx. 175% upside. (FactSet average target $10.86; range $8-17.45) ANL initiated buy at Jefferies (Maury Raycroft), target is $31 or approx. 111% upside. (FactSet average target $29.50; range $20-49) RVMD initiated overweight at Morgan Stanley (Sean Laaman), target is $255 or approx. 23% upside. Corporate: ALMS with an insider transaction as Director Srinivas Akkaraju (managing member of Samsara BioCapital) discloses purchase of 890.6K shares. - Form 4 Regulatory: BHVN announced the FDA issued a Partial Clinical Hold on Phase 2/3 clinical trials for the epilepsy drug candidate Opakalim. (BHV-7000) Life Science & MedTech Earnings: COO reports fiscal Q3 EPS $1.15 ex-items vs FactSet $1.12 on revenue $1.066B vs FS $1.098B. Updated FY26 guidance and guides Q4 below consensus. Q4 organic growth: CSI +4-6%, CVI (2%) to +0% Concludes strategic review - keeping CSI; Board remains open to all options to create shareholder value. M&A: AXGN to acquire BioCircuit Technologies for $200M. Financing: AXGN announces pricing of $208.7M public offering of common stock in connection with its previously announced acquisition of BioCircuit Technologies. Research: OBIO upgraded to buy from neutral at BTIG (Marie Thibault), cites near-term catalysts. Target is $10 or approx. 83% upside. (FactSet average target $12.33; range $9-20) COO downgraded to neutral from overweight at Piper Sandler (Jason Bednar), cites factors including lack of catalysts. Target is $59 or approx. 7% downside. (FactSet average target $79.54; range $61-92) COO downgraded to neutral from outperform at Baird (Jeff Johnson), target cut to $61 from $85, 4% downside (FactSet average target $71.62; range $58-92) MASS initiated buy at Canaccord Genuity (Austin Moeller), target is $13.50 or approx. 39% upside. Services & Hospitals and Managed Care Guidance: ELV reaffirms FY26 EPS guidance at least $27.00 ex-items vs FactSet $27.15 ahead of investor meetings. - 8-K LH reaffirms FY26 guidance, provides long-term outlook through 2029 ahead of Investor Day. Research: CLOV initiated buy at Deutsche Bank (George Hill), target is $6 or approx. 38% upside. (FactSet average target $5.38; range $5-6) On Deck: Sep 5 - 13 Conference calendar (cont.): Wells Fargo Healthcare Conference (Sep 8-10) Cantor Fitzgerald Global Healthcare Conference (Sep 9-11) Citi Back to School Conference (Sep 9-10) Goldman Sachs European MedTech and Healthcare Services Conference (Sep 9-10) Sat 12-Sep: World Conference on Lung Cancer (WCLC) (Sep 12-15) Regulatory calendar Fri 11-Sep: TLX.AU FDA PDUFA for Pixclara NDA for imaging of gliomas Peek Ahead to next week (Sep 14-20) Conferences: Jefferies Healthcare Services and Technology Conference, H.C. Wainwright Global Investment Conference ,Morgan Stanley Global Healthcare Conference, Deutsche Bank Healthcare Summit Regulatory: EMA CHMP monthly meeting (September 2026); FDA PDUFA for RARE UX111 BLA in Sanfilippo Syndrome; FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate: Investor Day OSCR; Investor Day NVST This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ADAG, ALMS, AMGN, ANL, AXGN, BCRX, BHVN, CLOV, COO, ELV, IRON, JNJ, KYMR, LH, MASS, NOVN.SW, NVS, OBIO, RVMD...(more)	show story hide story
09-Sep-2026 17:26	FDA's New Framework for Psychedelic Drugs - NEJM In the NEJM on Wednesday evening, the FDA Director of CDER Michael Davis presents updated FDA guidance for psychedelic drug development, including expedited programs and regulatory flexibility. See reference link below. StreetAccount notes that the FDA has previously scheduled a public hearing on psychedelic drugs on 14-Sep (see linked comment). See Related StreetAccount comments: 7/13/2026 9:12:17 AM - FDA issues final guidance for designing clinical trials for psychedelic drugs; schedules public hearing on 14-Sep Related: ABBV, ANRO, ATAI, CMPS, DFTX, GHRS, HELP, JNJ, NMRA...(more) Reference Link: NEJM	show story hide story
09-Sep-2026 16:51	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly lower and roughly inline overall on Wednesday. Decliners beat advancers by nearly 4:1 on the XLV. Healthcare (0.37%) vs S&P 500 (0.48%). Most major health groups ended lower by around (1%) on the averages, led by Biotech and MedTech; XBI (1.57%). Managed Care group mostly red as well, only CI +0.9% finished higher with an initiation on the tape. Worst moves of the morning session moderated by the close, specifically UNH (1.9%) after speaking pre-open at Wells Fargo Healthcare Conference. UNH traded as low as (6%) soon after the open. High level trajectory of the business remains unchanged from the Q2 print; Optum leaders spoke about ongoing work to grow earnings, margins are their focus for 2027. Company also expects to re-engage in M&A in the coming years. HCA +4.9% and COO (6.2%) bracket ed the XLV; the latter with an important print tonight with focus on the strategic review outcome. Hospital presentations at WFC highlighted earnings resiliency amidst exchange-based headwinds. Elsewhere, sector newsflow still largely concentrated in SMID-cap biotech clinical updates with data in bladder cancer, retinal disease, head-and-neck cancer, and atopic dermatitis. Looking ahead, Conference season accelerates in this Holiday-shortened week with few other catalysts on the calendar. Cooper Companies reports FQ3 after the close today. Macro Defensive tone once again chalked up to continued escalation in kinetic activity in the Middle East (and no diplomatic off-ramps in sight) that pushed oil back to four-month highs (Brent back above $100 a barrel). Rates also a headwind (10Y highest since Oct-23), tabbed in part to oil as well as underwhelming Treasury buyback announcement, with Street expecting more than announced $6B. AI trade somewhat of a mixed bag today after outperforming yesterday. GPT-6/Astra sentiment remains very upbeat, META a big gainer today on recently released Muse consumer AI agent, while also plenty of positive spin surrounding sell-side conference presentations. Broader earnings takeaways mixed to negative with some continued scrutiny surrounding updates out of the consumer staples space. Market still on catalyst watch with August CPI on Friday most important given Fed policy implications. Notable Gainers +32.0% IRD (Opus Genetics): trial results in retinal degeneration +20.7% NAUT (Nautilus Biotechnology): initiation +8.6% PLSE (Pulse Biosciences): initiation +5.7% TNGX (Tango Therapeutics): best performer on XBI; shares +171% YTD +5.2% SRPT (Sarepta Therapeutics): second-best on XBI; shares were (7%) yesterday +4.9% HCA (HCA Healthcare): best performer on XLV; presented at Wells Fargo conference +4.8% INNV (InnovAge Holding): earnings +3.9% CYH (Community Health Systems): sympathy to HCA & THC +3.9% THC (Tenet Healthcare): presented at Wells Fargo conference +3.1% INSM (Insmed): presented at Cantor conference +2.5% ACHC (Acadia Healthcare): sympathy to HCA & THC +2.3% UHS (Universal Health Services): sympathy to HCA & THC Notable Decliners -23.8% BBOT (BridgeBio Oncology Therapeutics): updated clinical data in NSCLC; breast cancer deprioritized; strategic pipeline updates; worst performer on XBI -17.7% TYRA (Tyra Biosciences): trial results in bladder cancer -17.1% EVMN (Evommune): trial results in atopic dermatitis -6.2% COO (The Cooper Cos.): worst performer on XLV; ahead of earnings tonight -6.2% BEAM (Beam Therapeutics): follow-through, shares were down (10%) yesterday -5.5% DYN (Dyne Therapeutics): downgraded at JPMorgan; follow-through, shares were (16%) yesterday -3.4% MRNA (Moderna): second-worst on XLV; shares +360% YTD -3.1% PODD (Insulet): shares (7%) MTD and (52%) YTD Hospitals highlight success of earnings resiliency initiatives Afternoon trading update: HCA +5.2%, ACHC +4.3%, CYH +3.9%, THC +3.9% HCA at Wells Fargo: Q4 growth is expected to improve versus Q3, helped by greater contribution from financial resiliency initiatives and easier y/y comparisons on exchange-related pressure. 2026 pressure from the expiration of enhanced premium tax credits appears concentrated in a relatively small portion of admissions, while the rest of the business is performing near the high end of HCA's long-term 4% to 6% EBITDA growth framework; second-half guidance assumes surgical trends stay soft rather than rebound. THC at Wells Fargo: Hospital earnings resilience in 2026 has depended on offsetting exchange-related headwinds through prior planning, operating efficiencies, and returns from earlier hospital capex, and Tenet is applying the same offset mindset to the following year. Exchange-related coverage disruption has increased uninsured volumes in hospitals, but Tenet expects coverage to improve over time as affected patients find alternatives, while USPI has been largely unaffected and elective surgery demand there has held up better than in hospitals. UnitedHealth trading lower; presented at Wells Fargo pre-open UNH (2.4%) but far from worst levels of the morning, decline approached (6%). Company presented at Wells Fargo Healthcare Conference pre-open (8:00ET), where the CFO said "nothing has changed from the Q2 earnings call". Optimistic for the trajectory. Regarding cost trends seen through Q1, with regard to Q3, durability has not dissipated - see similar momentum out of Q2 into the last two months. All trends pointing in the right direction. Optum leadership commented on the ongoing work to grow earnings - topline growth not a focus for 2027, focus is on earnings and margin improvement next year. CFO also said they expect to re-engage in M&A in the coming years. Trial results in SMID-cap biotech EVMN announced topline results from phase 2B trial evaluating MRGPRX2 antagonist EVO756 in adults with atopic dermatitis did not meet the primary and secondary endpoints over a 12-week treatment period. Company will not advance in AD. IRD announced 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, its ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases. Clinically meaningful best-corrected visual acuity improvements in 3 of 5 participants and retinal sensitivity improvements on microperimetry observed in 3 of 4 evaluable participants. PYXS announced updated clinical data from its ongoing phase 1 study evaluating MICVO (PFE) in patients with 2L+ HNSCC. Demonstrated 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups. Data support advancement of MICVO into a pivotal program in 2L+ R/M HNSCC, with initiation of Phase 3 Headliner™ trial planned for mid-2027. TYRA announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). 79% ORR and 64% best overall response CR rate with 60 mg QD in combined single and multiple marker lesion patients (n=14), with 100% ORR and 75% best overall response CR rate with 60 mg QD in single marker lesion patients (n=8), supporting planned adjuvant Phase 3 strategy. Notable research in Healthcare today Pharma: NOVN.SW (NVS) downgraded to hold from buy at Deutsche Bank (Emmanuel Papadakis), target cut to CHF120 from CHF140 or approx. 7% upside. (FactSet average PT CHF126; range CHF95-150) NOVN.SW (NVS) initiated sector perform at RBC Capital Markets (Trung Huynh), target is CHF120 or approx. 7% upside. AMRX initiated outperform at Leerink Partners (Daniel Clark), target is $23 or approx. 35% upside. AZN.LN (AZN) initiated outperform at RBC Capital Markets (Trung Huynh), target is 14,500p or approx. 22% upside. GSK.LN (GSK) initiated sector perform at RBC Capital Markets (Trung Huynh), target is 1,975p or approx. 10% upside. ROP.SW initiated outperform at RBC Capital Markets (Trung Huynh), target is CHF400 or approx. 14% upside. SAN.FP (SNY) initiated sector perform at RBC Capital Markets (Trung Huynh), target is €80 or approx. 7% upside. TEVA initiated outperform at Leerink Partners (Daniel Clark), target is $45 or approx. 22% upside. VTRS initiated outperform at Leerink Partners (Daniel Clark), target is $20 or approx. 20% upside. Biotech: DYN downgraded to underweight from neutral at JPMorgan (Tessa Romero), target cut to $10 from $17 or approx. 51% downside. (FactSet average PT $40; range $30-50) SGMT upgraded to overweight from equal weight at Barclays (Eliana Merle), sees further upside in acne market. Target increased to $18 from $8 or approx. 68% upside. (FactSet average PT $29; range $18-56) SMMT upgraded to buy from hold at Jefferies (Faisal Khurshid), notes optimism going into HARMONi-3 PFS data release. Target increased to $25 from $15 or approx. 45% upside. (FactSet average PT $28; range $11-41) ABSI initiated outperform at LifeSci Capital (Rami Katkhuda), target is $16 or approx. 80% upside. AEON initiated buy at Laidlaw & Company (Yale Jen), target is $1.80 or approx. 650% upside. AKTS initiated outperform at Oppenheimer (Jeff Jones), target is $40 or approx. 60% upside. ANIP initiated outperform at Leerink Partners (Daniel Clark), target is $104 or approx. 48% upside. COLL initiated outperform at Leerink Partners (Daniel Clark), target is $45 or approx. 93% upside. COLL assumed buy at Truist (Alexander Xenakis), target is $49 or approx. 110% upside. FTH initiated buy at TD Cowen (Tara Bancroft) HROW initiated outperform at Leerink Partners (Daniel Clark), target is $45 or approx. 19% upside. OBX initiated outperform at William Blair (Sami Corwin) PCRX initiated market perform at Leerink Partners (Daniel Clark), target is $38 or approx. 8% upside PHAT initiated market perform at Leerink Partners (Daniel Clark), target is $10 or approx. 6% upside. SGMT initiated overweight at Cantor Fitzgerald (Yanni Souroutzidis) TLSI initiated buy at HC Wainwright (Swayampakula Ramakanth), target is $11 or approx. 133% upside. MedTech: UBS analyst Doug Schenkel initiates coverage on 25 stocks in the LST&D space. Includes ten (10) buy-rated stocks (GH, GRAL, ILMN, NTRA, RGEN, VCYT, WAT, WST, TMO, DHR), and fifteen (15) neutral ratings (A, AVTR, BRKR, CAI, HTFL, MRVI, MTD, MYGN, PACB, QGEN, RVTY, STVN, TEM, TWST, TXG). Assumed coverage on TMO at buy; prior rating was neutral. Assumed coverage on DHR at buy, maintained. BLCO initiated outperform at Leerink Partners (Daniel Clark), target is $24 or approx. 35% upside. NAUT initiated outperform at Leerink Partners (Puneet Souda), target is $4 or approx. 330% upside. PLSE initiated buy at Freedom Capital (Keith Hinton), target is $73 or approx. 50% upside. (FactSet average PT $45; range $35-58) Managed Care: CI initiated in line at Evercore ISI (Elizabeth Anderson), target is $290 or approx. 5% upside. (FactSet average PT $341; range $297-400) Post-close news Earnings: COO reports fiscal Q3 EPS $1.15 ex-items vs FactSet $1.12 on revenue $1.066B vs FS $1.098B. Updated FY26 guidance and guides Q4 below consensus. Q4 organic growth: CSI +4-6%, CVI (2%) to +0% Concludes strategic review - keeping CSI; Board remains open to all options to create shareholder value Conf. call at 17:00ET Shares trading (15.0%) in the after-hours, ahead of the call. Research: BIIB Stifel analyst Paul Matteis (buy-rated) with deep dive into Lupus ahead of Q4 readout with litifilimab (BIIB059). On Deck: Conferences (cont.): Wells Fargo Healthcare Conference (Sep 8-10) (cont.) Cantor Fitzgerald Global Healthcare Conference (Sep 9-11) (cont.) Citi Back to School Conference (Sep 9-10) (cont.) Goldman Sachs European MedTech and Healthcare Services Conference (Sep 9-10) on Sat 12-Sep: World Conference on Lung Cancer (WCLC) (Sep 12-15) Regulatory on Fri 11-Sep: TLX.AU FDA PDUFA for Pixclara NDA for imaging of gliomas Peek Ahead to next week (Sep 14-20) Conferences: Jefferies Healthcare Services and Technology Conference, H.C. Wainwright Global Investment Conference ,Morgan Stanley Global Healthcare Conference, Deutsche Bank Healthcare Summit Regulatory: EMA CHMP monthly meeting (September 2026); FDA PDUFA for RARE UX111 BLA in Sanfilippo Syndrome; FDA PDUFA for IntraBio (private) Aqneursa sNDA in Ataxia-Telangiectasia (A-T) Corporate: Investor Day OSCR; Investor Day NVST This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, ABSI, ACHC, AEON, AKTS, AMRX, ANIP, AVTR, AZN.LN, BBOT, BEAM, BIIB, BLCO, BRKR, CAI, CI, COLL, COO, CYH, DHR, DYN, EVMN, FTH, GH, GRAL, GSK.LN, HCA, HROW, HTFL, ILMN, INNV, INSM, IRD, MRNA, MRVI, MTD, MYGN, NAUT, NOVN.SW, NTRA, OBX, PACB, PCRX, PFE, PHAT, PLSE, PODD, PYXS, QGEN, RGEN, ROP.SW, RVTY, SAN.FP, SGMT, SMMT, SRPT, STVN, TEM, TEVA, THC, TLSI, TLX.AU, TMO, TNGX, TWST, TXG, TYRA, UHS, UNH, VCYT, VTRS, WAT, WST...(more)	show story hide story
09-Sep-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is generally inline with the S&P 500 Healthcare Index (0.20%) vs the S&P 500 (0.24%). All major health groups are red on the averages, led by Managed Care group although moves are moderating from their worst levels of the morning, including UNH (3%) after today's presentation at Wells Fargo Healthcare Conference - stock traded as low as (6%) after the open. High level trajectory of the business remains unchanged from the Q2 print; Optum leaders spoke about ongoing work to grow earnings, margins are their focus for 2027. Company also expects to re-engage in M&A in the coming years. HCA +3% and RVTY (3%) bracket the XLV. Sector newsflow still mostly concentrated in SMID-cap biotech clinical updates with data in bladder cancer, retinal disease, head-and-neck cancer, and atopic dermatitis. XBI (0.90%), DRG (0.09%). Gainers +43.6% IRD (Opus Genetics): trial results in retinal degeneration +10.7% INBX (Inhibrx Biosciences): best performer on XBI; shares down (6%) yesterday +9.6% INNV (InnovAge Holding): earnings +7.6% SRPT (Sarepta Therapeutics): second-best on XBI; shares were (7%) yesterday +5.4% TNGX (Tango Therapeutics): +3.3% HCA (HCA Healthcare): best performer on XLV +2.3% BSX (Boston Scientific): second-best on XLV; shares were (6%) yesterday Decliners -22.4% TYRA (Tyra Biosciences): trial results in bladder cancer; worst performer on XBI -15.4% EVMN (Evommune): trial results in atopic dermatitis -5.1% BEAM (Beam Therapeutics): follow-through, shares were down (10%) yesterday -3.6% RVTY (Revvity): worst performer on XLV; initiation -3.0% UNH (UnitedHealth Group): presented at Wells Fargo Conference this morning -2.8% DYN (Dyne Therapeutics): downgraded at JPMorgan; follow-through, shares were (16%) yesterday Editor's Note: This comment was revised to correct the swapped rationale for IRD and for TYRA - for retinal disease and for bladder cancer respectively. Apologies for the confusion. (09-Sep-2026, 11:22 ET)	show story hide story
09-Sep-2026 08:17	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Morning newsflow mostly concentrated in SMID-cap biotech clinical updates with data in bladder cancer, retinal disease, head-and-neck cancer, and atopic dermatitis. Overnight, HHS announced that acting directors of FDA CBER and FDA CDER were selected to continue in their leadership roles. Both were named acting before the appointment of FDA Commissioner Heidi Overton. Yesterday, Healthcare equities were broadly lower with just three modest gainers on the XLV. Healthcare (2.50%) underperformed by 200bps for its worst day in thirteen months. Disappointment two-fold for Novartis (14%) the leading storyline. Boston Scientific issued profit warning for its previously disclosed cybersecurity incident; and Stryker management at WF Healthcare Conference struck a cautious tone on Q3 trends to date. Looking ahead, Conference season accelerates in this Holiday-shortened week with few other catalysts on the calendar. Cooper Companies reports FQ3 after the close today. Macro S&P futures are down (0.3%) on Wednesday morning. Defensive tone once again chalked up to continued escalation in kinetic activity in the Middle East (and no diplomatic off-ramps in sight) that has pushed Brent back above $100 a barrel. Biggest bullish talking point for stocks right now seems to revolve around the AI compute demand narrative. GPT-6/Astra release continues to reverberate, while Tuesday's tech conference takeaways were also upbeat (including from a monetization standpoint).A couple of high-profile events on tap today with Treasury to provide details on its expanded long-term buybacks (Bessent widely expected to go >$4B) and AAPL holding its product event (foldable iPhone the highlight). Pre-market trading update Trading higher +11.1% INNV earnings +9.3% IRD trial results in bladder cancer; call at 800ET +4.2% SGMT upgraded at Barclays; also initiation +3.7% SMMT upgraded at Jefferies +2.8% HUM on 6K shares +2.4% MNKD enters license agreement for inhaled GLP-1 +2.0% HNGE CEO interview / Morgan Stanley podcast; on 21K shares +1.0% TMO upgraded at UBS (on low volume) +0.2% NVS downgraded at Deutsche Bank; follow-through, ADRs were (14%) yesterday Trading lower -27.6% TYRA trial results in retinal degeneration; call at 800ET -19.8% PYXS trial results in HNSCC; call at 730ET -10.0% EVMN trial results in atopic dermatitis -4.5% DYN downgraded at JPMorgan; follow-through, shares were (16%) yesterday -3.5% LFST share offering for holders Pharma Research: NOVN.SW (NVS) downgraded to hold from buy at Deutsche Bank (Emmanuel Papadakis), target cut to CHF120 from CHF140 or approx. 7% upside. (FactSet average PT CHF126; range CHF95-150) NOVN.SW (NVS) initiated sector perform at RBC Capital Markets (Trung Huynh), target is CHF120 or approx. 7% upside. AMRX initiated outperform at Leerink Partners (Daniel Clark), target is $23 or approx. 35% upside. AZN.LN (AZN) initiated outperform at RBC Capital Markets (Trung Huynh), target is 14,500p or approx. 22% upside. GSK.LN (GSK) initiated sector perform at RBC Capital Markets (Trung Huynh), target is 1,975p or approx. 10% upside. ROP.SW initiated outperform at RBC Capital Markets (Trung Huynh), target is CHF400 or approx. 14% upside. SAN.FP (SNY) initiated sector perform at RBC Capital Markets (Trung Huynh), target is €80 or approx. 7% upside. TEVA initiated outperform at Leerink Partners (Daniel Clark), target is $45 or approx. 22% upside. VTRS initiated outperform at Leerink Partners (Daniel Clark), target is $20 or approx. 20% upside. Biotech Trial results: EVMN announced topline results from phase 2B trial evaluating MRGPRX2 antagonist EVO756 in adults with atopic dermatitis did not meet the primary and secondary endpoints over a 12-week treatment period. Company will not advance in AD. IRD announced 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, its ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases. Clinically meaningful best-corrected visual acuity improvements in 3 of 5 participants and retinal sensitivity improvements on microperimetry observed in 3 of 4 evaluable participants. Conf. call at 8:00ET PYXS announced updated clinical data from its ongoing phase 1 study evaluating MICVO (PFE) in patients with 2L+ HNSCC. Demonstrated 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups. Data support advancement of MICVO into a pivotal program in 2L+ R/M HNSCC, with initiation of Phase 3 Headliner™ trial planned for mid-2027. Conf. call at 7:30ET TYRA announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). 79% ORR and 64% best overall response CR rate with 60 mg QD in combined single and multiple marker lesion patients (n=14), with 100% ORR and 75% best overall response CR rate with 60 mg QD in single marker lesion patients (n=8), supporting planned adjuvant Phase 3 strategy. Conf. call at 8:00ET Regulatory: HHS announces senior leaders at FDA including Directors of CBER and CDER Jared Seehafer, has been selected to serve as FDA's first Deputy Commissioner for Technology and Artificial Intelligence; Michael Davis has been selected as Director of the Center for Drug Evaluation and Research (CDER); Karim Mikhail has been selected as Director of the Center for Biologics Evaluation and Research (CBER); and Bret Koplow has been selected as Director of the Center for Tobacco Products (CTP) Research: DYN downgraded to underweight from neutral at JPMorgan (Tessa Romero), target cut to $10 from $17 or approx. 51% downside. (FactSet average PT $40; range $30-50) SGMT upgraded to overweight from equal weight at Barclays (Eliana Merle), sees further upside in acne market. Target increased to $18 from $8 or approx. 68% upside. (FactSet average PT $29; range $18-56) SMMT upgraded to buy from hold at Jefferies (Faisal Khurshid), notes optimism going into HARMONi-3 PFS data release. Target increased to $25 from $15 or approx. 45% upside. (FactSet average PT $28; range $11-41) ABSI initiated outperform at LifeSci Capital (Rami Katkhuda), target is $16 or approx. 80% upside. AEON initiated buy at Laidlaw & Company (Yale Jen), target is $1.80 or approx. 650% upside. AKTS initiated outperform at Oppenheimer (Jeff Jones), target is $40 or approx. 60% upside. ANIP initiated outperform at Leerink Partners (Daniel Clark), target is $104 or approx. 48% upside. COLL initiated outperform at Leerink Partners (Daniel Clark), target is $45 or approx. 93% upside. COLL assumed buy at Truist (Alexander Xenakis), target is $49 or approx. 110% upside. FTH initiated buy at TD Cowen (Tara Bancroft) HROW initiated outperform at Leerink Partners (Daniel Clark), target is $45 or approx. 19% upside. OBX initiated outperform at William Blair (Sami Corwin) PCRX initiated market perform at Leerink Partners (Daniel Clark), target is $38 or approx. 8% upside PHAT initiated market perform at Leerink Partners (Daniel Clark), target is $10 or approx. 6% upside. SGMT initiated overweight at Cantor Fitzgerald (Yanni Souroutzidis) TLSI initiated buy at HC Wainwright (Swayampakula Ramakanth), target is $11 or approx. 133% upside. Life Science & MedTech Research: UBS analyst Doug Schenkel initiates coverage on 25 stocks in the LST&D space. Includes ten (10) buy-rated stocks (GH, GRAL, ILMN, NTRA, RGEN, VCYT, WAT, WST, TMO, DHR), and fifteen (15) neutral ratings (A, AVTR, BRKR, CAI, HTFL, MRVI, MTD, MYGN, PACB, QGEN, RVTY, STVN, TEM, TWST, TXG). Assumed coverage on TMO at buy; prior rating was neutral. Assumed coverage on DHR at buy, maintained. BLCO initiated outperform at Leerink Partners (Daniel Clark), target is $24 or approx. 35% upside. NAUT initiated outperform at Leerink Partners (Puneet Souda), target is $4 or approx. 330% upside. PLSE initiated buy at Freedom Capital (Keith Hinton), target is $73 or approx. 50% upside. (FactSet average PT $45; range $35-58) Managed Care Research: CI initiated in line at Evercore ISI (Elizabeth Anderson), target is $290 or approx. 5% upside. (FactSet average PT $341; range $297-400) On Deck: Conference (cont.): ERS 2026 (Sep 5-9) (cont.): EEC 2026 (Sep 5-9) (cont.) Wells Fargo Healthcare Conference (Sep 8-10) Cantor Fitzgerald Global Healthcare Conference (Sep 9-11) Citi Back to School Conference (Sep 9-10) Goldman Sachs European MedTech and Healthcare Services Conference (Sep 9-10) on Sat 12-Sep: World Conference on Lung Cancer (WCLC) (Sep 12-15) Earnings after the close today COO (call at 17:00ET) Regulatory on Fri 11-Sep: TLX.AU FDA PDUFA for Pixclara NDA for imaging of gliomas This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, ABSI, AEON, AKTS, AMRX, ANIP, AVTR, AZN.LN, BLCO, BRKR, CAI, CI, COLL, COO, DHR, DYN, EVMN, FTH, GH, GRAL, GSK.LN, HNGE, HROW, HTFL, HUM, ILMN, INNV, IRD, LFST, MNKD, MRVI, MTD, MYGN, NAUT, NOVN.SW, NTRA, NVS, OBX, PACB, PCRX, PFE, PHAT, PLSE, PYXS, QGEN, RGEN, ROP.SW, RVTY, SAN.FP, SGMT, SMMT, STVN, TEM, TEVA, TLSI, TLX.AU, TMO, TWST, TXG, TYRA, VCYT, VTRS, WAT, WST...(more)	show story hide story
08-Sep-2026 16:37	HHS announces senior leaders at FDA including Directors of CBER and CDER HHS on Tuesday announced four senior leaders at FDA including the Director of CBER and Director of CDER. Jared Seehafer, M.S. has been selected to serve as FDA's first Deputy Commissioner for Technology and Artificial Intelligence; Michael Davis, M.D., Ph.D., has been selected as Director of the Center for Drug Evaluation and Research (CDER); Karim Mikhail, B.Pharm, MSc, has been selected as Director of the Center for Biologics Evaluation and Research (CBER); and Bret Koplow, Ph.D., J.D., has been selected as Director of the Center for Tobacco Products (CTP). For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
08-Sep-2026 16:30	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly lower on Tuesday. Just three modest gainers on the XLV. Healthcare (2.50%) vs S&P 500 (0.56%). All major health groups ended lower by (1%) to (3%) for the session, led by Pharma with the DRG Index (2.90%). All groups lagged the tape on their averages, including most defensive names. UNH +0.9% and HUM +0.4% among today's leading gainers on the XLV; both subject of timely sell-side research. Only UHS +1.3% fared better, the hospital operator presented Tuesday morning at the Wells Fargo Healthcare Conference. STAT today also discussed the ongoing rural hospital struggle and industry consolidation. AMGN (10.1%) continued to lead all decliners on the XLV, coming under pressure after NVS (13.9%) disappointing news with cardiovascular drug pelacarsen targeting Lp(a). Perhaps the most anticipated H2 catalyst in CVOT if not all of biopharma, the phase 3 HORIZON trial evaluating the ASO for prevention of ASCVD did not meet its primary endpoint. Read-through to partners and competitors also significant. BSX (5.9%) provided an update on the previously disclosed cybersecurity update, now stating that the company expects a material impact on Q3 and FY financial results. Peer SYK (8.8%), which quickly resolved its own incident in March/April, came under new pressure following an operational update at the Wells Fargo Healthcare conference this morning. Additional biopharma readouts on the tape included Novartis (again) in DM1, Roivant in interstitial lung disease, Pharvaris in hereditary angioedema, and Beam Therapeutics in alpha-1 antitrypsin deficiency. Novo Nordisk also reportedly stopped two late-stage studies in heart failure - which followed an earlier failure by the anti-IL6 drug. Looking ahead, Conference season accelerates in this Holiday-shortened week with few other catalysts on the calendar. Cooper Companies reports FQ3 after the close on Wednesday. Macro Defensive tilt chalked up to latest hawkish US/Iran updates following weekend ramp in kinetic activity. Earlier Tuesday Houthis attacked Saudi oil facilities, while late afternoon reports said US struck Iranian tankers near Kharg Island, previously undisclosed report said Iran attacked US Navy ship on Monday. Brent not far from earlier highs, holding just below $100 a barrel, while record diesel prices continue to be flagged as a global growth concern. Other big development today has been strength in some pockets of the AI trade. OpenAI's recent Astra release still a widely cited tailwind, while today's headlines have focused on infrastructure collaboration between QCOM and AMZN and INTC CPU price hikes. Fairly quiet elsewhere ahead of a number of high-profile potential catalysts this week. CPI on Friday seen as most important given implications for next week's FOMC decision. Market pricing in just under a 60% probability of a September rate hike and ~35 bp of Fed tightening through year-end. Notable Gainers +18.8% ROIV (Roivant Sciences): trial results in PH-ILD; best performer on XBI +10.3% MLYS (Mineralys Therapeutics): shares were +10% last week +7.3% PHVS (Pharvaris BV): trial results in HAE +2.1% ARQT (Arcutis Biotherapeutics): to join SmallCap 600 Index +1.4% UHS (Universal Health Services): hospitals relatively firm; presented at WF Healthcare Conference; best performer on XLV +0.9% UNH (UnitedHealth Group): Leerink comments on AEP2026 and plan design; one of three gainers on XLV +0.4% HUM (Humana): Leerink comments on AEP2026 and plan design Notable Decliners -16.4% DYN (Dyne Therapeutics): sympathy to NVS (DM1); worst performer on XBI -14.7% GPCR (Structure Therapeutics): trial results in lead programs for obesity -13.9% NVS (Novartis): trial results for Lp(a); trial results in DM1 -10.1% AMGN (Amgen): sympathy to NVS (LP(a)); downgraded at BMO Capital Markets; worst performer on XLV -9.5% BEAM (Beam Therapeutics): trial results in AATD -9.0% BCRX (BioCryst Pharmaceuticals): sympathy to PHVS; on heavy volume -8.8% SYK (Stryker): shares were (8%) last week; management comments at Wells Fargo Healthcare Conference; 52-week low -8.4% PLSE (Pulse Biosciences): shares were +12% last week -6.9% SRPT (Sarepta Therapeutics): sympathy to NVS (DM1) -6.1% BHVN (Biohaven): downgraded at RBC Capital Markets -5.9% BSX (Boston Scientific): updates on cybersecurity incident and Q3/FY guidance -5.6% INBX (Inhibrx Biosciences): trial results in HNSCC -5.3% RPRX (Royalty Pharma): sympathy to NVS (LP(a)) -4.9% BNTX (BioNTech): downgraded at BMO Capital Markets -3.9% ICLR (ICON plc): CROs weak; on below average volume -3.9% ZBH (Zimmer Biomet Holdings): sympathy to SYK -3.6% FTRE (Fortrea Holdings): CROs weak; on average volume -3.6% MRNA (Moderna): FDA VRBPAC planned for influenza strains -3.2% IQV (IQVIA Holdings): CROs weak; on below average volume -3.1% NVO (Novo Nordisk): trials with ziltivekimab halted -2.7% CRL (Charles River Laboratories): CROs weak; on below average volume -2.4% IONS (Ionis Pharmaceuticals): sympathy to NVS (LP(a)) Novartis lower on clinical results are two-fold Post-close on Friday Novartis announced topline results from phase 3 HORIZON trial evaluating ASO pelacarsen (RPRX, IONS) for prevention of ASCVD in patients with elevated Lp(a). Trial did not meet its primary endpoint. Data will be presented at an upcoming medical congress. (AMGN, LLY, NAMS) On Tuesday morning announced that the phase 3 HARBOR study of delpacibart etedesiran (del-desiran) for DM1 did not meet its primary endpoint. (Read-through to DYN, SRPT). Asset was one of three added to the pipeline with the Avidity Biosciences acquisition, a $12B deal announced in October 2025, after which Novartis raised its five-year sales growth outlook. In the same release today, company maintains its 5-6% five-year sales CAGR guidance for 2025-2030. DM1 news comes on top of Friday's clinical update for Lp(a). Stryker lower following comments at Wells Fargo conference SYK (7%) following today's presentation at WF Healthcare Conference, including cautious comments on persistent challenges in the peripheral vascular segment, and seasonality in the joint replacement business. Boston Scientific now sees August cybersecurity incident impacting Q3/FY results BSX disclosed via 8-K filing an update on the cybersecurity incident (identified 25-Aug and reported 26-Aug), company has now determined that the incident is likely to have a material impact on results of operations for Q3 and FY 2026. Novo Nordisk inflammation program dealt another setback NOVO.B.DC (NVO) Reportedly ended the phase 3 trials HERMES and ATHENA which were evaluating anti-IL6 candidate ziltivekimab in heart failure. STAT News reported on Monday (7-Sep) that the company informed investigators on Friday (4-Sep) that the IDMC found they were unlikely to succeed. News follows an earlier failure in the ZEUS trial. Trial results in SMID-cap biotech ROIV Pulmovant, a Roivant company, announced the presentation of results from phase 2 PHocus trial evaluating mosliciguat (BAYN.GR) for pulmonary hypertension associated with interstitial lung disease (PH-ILD) met its primary endpoint, and its secondary endpoints. Results are being presented at ERS Congress today. PHVS announced topline results from the phase 3 CHAPTER-3 pivotal study of deucrictibant XR tablets for the prevention of HAE attacks. Study met primary and all secondary endpoints with statistical significance. CHAPTER-4 OLE study is ongoing. Company plans to submit NDA to FDA in H1 of 2027. INBX announced topline results from phase 2 portion of HexAgon study evaluating INBRX-106 in combo with Keytruda (MRK) in 1L HNSCC. Study demonstrated 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab alone. Company plans to expand the phase 2 portion by approx. 50 patients to support the AA pathway. GPCR announced topline clinical trial results for two lead product candidates, ACCG-2671 in a phase 1/2a SAD trial and aleniglipron in a phase 2B OLE trial. (SDGR) Notable research in Healthcare today Pharma: HIK.LN upgraded to equal weight from underweight at Barclays (James Gordon), target increased to 1700p from 1350p or approx. 6% upside. (FactSet average PT 2004p; range 1700-2615p) Biotech: AMGN downgraded to market perform from outperform at BMO Capital Markets (Evan Seigerman), target remains $450 or approx. 3% upside. BHVN downgraded to sector perform from outperform at RBC Capital Markets (Leonid Timashev), cites factors including valuation. Target cut to $19 from $23 or approx. 21% upside. (FactSet average PT $23; range $10-42) BNTX downgraded to market perform from outperform at BMO Capital Markets (Evan Seigerman), target cut to $105 or approx. 1% upside. IPN.FP downgraded to underweight from equal weight at Barclays (Yihan Li), target cut to €155 from €170 or approx. 5% downside. ZEAL.DC downgraded to equal weight from overweight at Barclays (Yihan Li), target cut to DKK330 from DKK425 or approx. 8% upside. ARWR initiated buy at Citi (Eric Joseph), target is $108 or approx. 25% upside. (FactSet average PT $111; range $100-126) Mizuho analyst Uy Ear assumes coverage of CLYM, EIKN, QTTB, STRO. Firm drops coverage of eleven (11) other SMID-cap biotech names, formerly covered by Joseph Catanzaro. Clear Street analyst Mara Goldstein assumes coverage of MOLN, maintains buy rating and $8 price target. ANL assumed buy at Lucid Capital Markets (Dev Prasad), target increased to $49 from $46 or approx. 226% upside. TVRD assumed buy at Lucid Capital Markets (Elemer Piros), target increased to $14 from $6 or approx. 633% upside. MedTech: PHR downgraded to market perform from outperform at Raymond James (Parker Snure) SN.LN (SNN) downgraded to neutral from buy at BofA (Julien Ouaddour), target cut to 1150p from 1340p or approx. 7% upside. (FactSet average PT 1249p; range 1052-1536p) GH initiated buy at Rothschild & Co Redburn (Jamie Clark), target is $203 or approx. 26% upside. NTRA initiated buy at Rothschild & Co Redburn (Jamie Clark), target is $385 or approx. 17% upside. TEM initiated neutral at Rothschild & Co Redburn (Jamie Clark), target is $67 or approx. 4% upside. Managed Care: Leerink Partners analyst Whit Mayo comments on early look at plan design and benefit cuts for AEP 2026. Firm believes HUM and UNH may have cut the most, and views these changes as most favorable for risk/reward for Humana. Post-close news: Trial results: PYXS schedules investor call for tomorrow morning (7:30ET) to discuss updated clinical data from its ongoing phase 1 study evaluating MICVO in patients with 2L+ HNSCC. Shares trading +5.9% in the after-hours Research: AZN.LN (AZN) initiated outperform at RBC Capital Markets (Trung Huynh), target is 14,500p or approx. 22% upside. GSK.LN (GSK) initiated sector perform at RBC Capital Markets (Trung Huynh), target is 1,975p or approx. 10% upside. NOVN.SW (NVS) initiated sector perform at RBC Capital Markets (Trung Huynh), target is CHF120 or approx. 7% upside. ROP.SW initiated outperform at RBC Capital Markets (Trung Huynh), target is CHF400 or approx. 14% upside. SAN.FP (SNY) initiated sector perform at RBC Capital Markets (Trung Huynh), target is €80 or approx. 7% upside. Week Ahead (Sat - Sun) Conference (cont.): ERS 2026 (Sep 5-9); EEC 2026 (Sep 5-9); Wells Fargo Healthcare Conference (Sep 8-10) Cantor Fitzgerald Global Healthcare Conference (Sep 9-11) Citi Back to School Conference (Sep 9-10) Goldman Sachs European MedTech and Healthcare Services Conference (Sep 9-10) on Sat 12-Sep: World Conference on Lung Cancer (WCLC) (Sep 12-15) Corporate TYRA (ph2 SURF302 trial in NMIBC) call at 8:00ET IRD (ph1/2 cohort 1 data in retinal degeneration) call at 8:00ET Earnings after the close on Wed 9-Sep COO (call at 17:00ET) Regulatory on Fri 11-Sep: TLX.AU FDA PDUFA for Pixclara NDA for imaging of gliomas StreetAccount Healthcare Reads I'm a fat medical student. I refuse to let myself be shamed for it (8-Sep) STAT News (opinion) A Doctor Sued 700 Patients for Debts; 81 Were Arrested. Now He's a Senator. (8-Sep) NY Times Hospitals pursue deals to ensure survival as Trump's Medicaid cuts loom (8-Sep) STAT News Elizabeth Holmes Documentary Upends Telluride Film Festival (7-Sep) NY Times This Is The Biggest Obstacle to New Cancer Cures (4-Sep) NY Times (opinion) Large employers drop health benefits as costs rise (4-Sep) Axios This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AMGN, ANL, ARQT, ARWR, AZN.LN, BAYN.GR, BCRX, BEAM, BHVN, BNTX, BSX, CLYM, COO, CRL, DYN, EIKN, FTRE, GH, GPCR, GSK.LN, HIK.LN, HUM, ICLR, INBX, IONS, IPN.FP, IQV, IRD, LLY, MLYS, MOLN, MRK, MRNA, NAMS, NOVN.SW, NOVO.B.DC, NTRA, NVO, NVS, PHR, PHVS, PLSE, PYXS, QTTB, ROIV, ROP.SW, RPRX, SAN.FP, SDGR, SN.LN, SRPT, STRO, SYK, TEM, TLX.AU, TVRD, TYRA, UHS, UNH, ZBH, ZEAL.DC...(more)	show story hide story
08-Sep-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (2.23%) vs the S&P 500 (0.35%). All major health groups lower by (1%) to (3%) to begin the holiday-shortened week, led by Pharma and the DRG Index (2.76%). Hospital stocks are relatively firm with UHS +0.2% and HCA (0.5%) essentially flat. STAT today discussing rural hospital struggle and industry consolidation. MRNA flat is another relative performer on the XLV. AMGN (9%) brackets the XLV, coming under pressure after NVS (13%) disappointing news with cardiovascular drug pelacarsen targeting Lp(a). Perhaps the most anticipated H2 catalyst in CVOT if not all of biopharma, the phase 3 HORIZON trial evaluating ASO pelacarsen for prevention of ASCVD in patients with elevated Lp(a) did not meet its primary endpoint. Read-through to partners and competitors also significant. BSX (4%) provided an update on the previously disclosed cybersecurity update, now stating that the company expects a material impact on Q3 and FY financial results; read-across may be weighing on SYK (7%) which quickly resolved its own incident in March/April. Stryker speaking at Wells Fargo conference this morning. Gainers +17.0% ROIV (Roivant Sciences): trial results in PH-ILD; best performer on XBI +12.3% PHVS (Pharvaris BV): trial results in HAE +7.1% MLYS (Mineralys Therapeutics): shares were +10% last week +1.7% ARQT (Arcutis Biotherapeutics): to join SmallCap 600 Index +0.6% NAMS (NewAmsterdam Pharma): sympathy to NVS (LP(a)) +0.2% UHS (Universal Health Services): best performer on XLV; lone gainer on XLV; presented at WF Healthcare Conference Decliners -21.2% DYN (Dyne Therapeutics): sympathy to NVS (DM1); worst performer on XBI -16.9% INBX (Inhibrx Biosciences): trial results in HNSCC -13.2% NVS (Novartis): trial results for Lp(a); trial results in DM1 -12.8% BEAM (Beam Therapeutics): trial results in AATD -9.9% SRPT (Sarepta Therapeutics): sympathy to NVS (DM1) -9.0% AMGN (Amgen): sympathy to NVS (LP(a)); downgraded at BMO Capital Markets; worst performer on XLV -8.5% PLSE (Pulse Biosciences): shares were +12% last week -8.1% BCRX (BioCryst Pharmaceuticals): sympathy to PHVS; on heavy volume -7.3% SYK (Stryker): shares were (8%) last week; presented at WF Healthcare Conference -5.7% RPRX (Royalty Pharma): sympathy to NVS (LP(a)) -4.3% IONS (Ionis Pharmaceuticals): sympathy to NVS (LP(a)) -4.3% GPCR (Structure Therapeutics): trial results in lead programs for obesity -4.1% BSX (Boston Scientific): updates on cybersecurity incident and Q3/FY guidance -3.7% FTRE (Fortrea Holdings): on light volume -3.6% BHVN (Biohaven): downgraded at RBC Capital Markets -2.4% CRSP (CRISPR Therapeutics): sympathy to BEAM -2.2% NVO (Novo Nordisk): trials with ziltivekimab halted -0.9% MRNA (Moderna): FDA VRBPAC planned for influenza strains -0.6% GH (Guardant Health): follow-through (CDx for Etcamah) -0.5% HCA (HCA Healthcare): hospitals relatively firm	show story hide story
08-Sep-2026 09:05	FDA panel to meet 1-Oct to discuss strain selection for influenza virus vaccines in Southern Hemisphere On 1-Oct-2026, the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet from 9:00-13:00ET to discuss strain selection for influenza virus vaccines for the 2027 Southern Hemisphere influenza season and provide recommendations. StreetAccount notes that this is the first annual meeting on seasonal flu strain selection since the VRBAC recommended licensure in June (and the FDA formally approved Moderna's mFlusiva in August) of the first mRNA-based vaccine. GSK is also currently advancing an mRNA seasonal flu vaccine candidate into phase 3. See Related StreetAccount comments: 2/11/2026 9:42:55 AM - FDA panel to meet 12-Mar to discuss flu vaccine strain composition for 26-27 Related: AZN.LN, CSL.AU, GSK.LN, MRNA, SAN.FP Reference Link	show story hide story
08-Sep-2026 08:38	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Ahead of the long Holiday weekend, Novartis delivered disappointing news on perhaps the most anticipated H2 catalyst in CVOT, if not all of biopharma. The phase 3 HORIZON trial evaluating ASO pelacarsen for prevention of ASCVD in patients with elevated Lp(a) did not meet its primary endpoint. ADRs are down 13% in the pre-market Tuesday. Read-through to partners and competitors also significant. Boston Scientific provided an update on the previously disclosed cybersecurity update, now stating that the company expects a material impact on Q3 and FY financial results. Shares of BSX (2%) in the pre-market. Additional biopharma readouts on the tape include Novartis (again) in DM1, Roivant in interstitial lung disease, Pharvaris in hereditary angioedema, and Beam Therapeutics in alpha-1 antitrypsin deficiency. Novo Nordisk also reportedly stopped two late-stage studies in heart failure - which followed an earlier failure by the anti-IL6 drug. Macro S&P futures are down (0.2%) on Tuesday morning. Defensive lean chalked up to recent ramp in kinetic activity in the Middle East, including Houthi attacks on Saudi oil facilities today. Brent near $100 a barrel, while bigger concern from a global growth perspective continues to revolve around refined products. Some cushion from continued memory/semi strength on the back of favorable Astra release sentiment. No other big directional drivers in play with much of the focus on a catalyst-heavy next couple of weeks on tap. August CPI on Friday widely seen as the biggest event for the market given the implications for the 16-Sep FOMC decision. Probability of a September rate hike currently stands at just over 60%. Pre-market trading update Trading higher +20.3% PHVS trial results in HAE; call at 8ET +17.1% ROIV trial results in PH-ILD; call at 8ET +2.3% GH follow-through (CDx for Etcamah); initiation Trading lower -29.0% DYN sympathy to NVS (DM1) -12.7% NVS trial results for Lp(a); trial results in DM1 -10.5% IONS sympathy to NVS (LP(a)) -9.6% SRPT sympathy to NVS (DM1) -9.5% NAMS sympathy to NVS (LP(a)) -9.2% RPRX sympathy to NVS (LP(a)) -7.6% INBX trial results in HNSCC; call at 8ET -6.0% AMGN sympathy to NVS (LP(a)); downgraded at BMO Capital Markets -5.3% ALNY on light volume -3.7% BHVN downgraded at RBC Capital Markets -2.3% QGEN on light volume -2.5% BSX updates on cybersecurity incident and Q3/FY guidance -1.8% NVO trials with ziltivekimab halted -1.0% BEAM trial results in AATD; call at 7ET Pharma Trial results: NOVN.SW (NVS) post-close on Friday announced topline results from phase 3 HORIZON trial evaluating ASO pelacarsen (RPRX, IONS) for prevention of ASCVD in patients with elevated Lp(a). Trial did not meet its primary endpoint. Data will be presented at an upcoming medical congress. (AMGN, LLY, NAMS) NOVN.SW (NVS) on Tuesday morning announced that the phase 3 HARBOR study of delpacibart etedesiran (del-desiran) for DM1 did not meet its primary endpoint. (Read-through to DYN, SRPT). Asset was one of three added to the pipeline with the Avidity Biosciences acquisition, a $12B deal announced in October 2025, after which Novartis raised its five-year sales growth outlook. In the same release today, company maintains its 5-6% five-year sales CAGR guidance for 2025-2030. DM1 news comes on top of Friday's clinical update for Lp(a). NOVO.B.DC (NVO) Reportedly ended the phase 3 trials HERMES and ATHENA which were evaluating anti-IL6 candidate ziltivekimab in heart failure. STAT News reported on Monday (7-Sep) that the company informed investigators on Friday (4-Sep) that the IDMC found they were unlikely to succeed. News follows an earlier failure in the ZEUS trial. Research: HIK.LN upgraded to equal weight from underweight at Barclays (James Gordon), target increased to 1700p from 1350p or approx. 6% upside. (FactSet average PT 2004p; range 1700-2615p) Biotech Trial results: ROIV Pulmovant, a Roivant company, announced the presentation of results from phase 2 PHocus trial evaluating mosliciguat (BAYN.GR) for pulmonary hypertension associated with interstitial lung disease (PH-ILD) met its primary endpoint, and its secondary endpoints. Results are being presented at ERS Congress today. Conf. call at 8:00ET PHVS announced topline results from the phase 3 CHAPTER-3 pivotal study of deucrictibant XR tablets for the prevention of HAE attacks. Study met primary and all secondary endpoints with statistical significance. CHAPTER-4 OLE study is ongoing. Company plans to submit NDA to FDA in H1 of 2027. Conf. call at 8:00ET INBX announced topline results from phase 2 portion of HexAgon study evaluating INBRX-106 in combo with Keytruda (MRK) in 1L HNSCC. Study demonstrated 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab alone. Company plans to expand the phase 2 portion by approx. 50 patients to support the AA pathway. Conf. call at 8:00ET GPCR announced topline clinical trial results for two lead product candidates, ACCG-2671 in a phase 1/2a SAD trial and aleniglipron in a phase 2B OLE trial. (SDGR) Conf. call at 8:30ET Research: AMGN downgraded to market perform from outperform at BMO Capital Markets (Evan Seigerman), target remains $450 or approx. 3% upside. BHVN downgraded to sector perform from outperform at RBC Capital Markets (Leonid Timashev), cites factors including valuation. Target cut to $19 from $23 or approx. 21% upside. (FactSet average PT $23; range $10-42) BNTX downgraded to market perform from outperform at BMO Capital Markets (Evan Seigerman), target cut to $105 or approx. 1% upside. IPN.FP downgraded to underweight from equal weight at Barclays (Yihan Li), target cut to €155 from €170 or approx. 5% downside. ZEAL.DC downgraded to equal weight from overweight at Barclays (Yihan Li), target cut to DKK330 from DKK425 or approx. 8% upside. ARWR initiated buy at Citi (Eric Joseph), target is $108 or approx. 25% upside. (FactSet average PT $111; range $100-126) Mizuho analyst Uy Ear assumes coverage of CLYM, EIKN, QTTB, STRO. Firm drops coverage of eleven (11) other SMID-cap biotech names, formerly covered by Joseph Catanzaro. Clear Street analyst Mara Goldstein assumes coverage of MOLN, maintains buy rating and $8 price target. ANL assumed buy at Lucid Capital Markets (Dev Prasad), target increased to $49 from $46 or approx. 226% upside. TVRD assumed buy at Lucid Capital Markets (Elemer Piros), target increased to $14 from $6 or approx. 633% upside. Life Science & MedTech Corporate: BSX disclosed via 8-K filing an update on the cybersecurity incident (identified 25-Aug and reported 26-Aug), company has now determined that the incident is likely to have a material impact on results of operations for Q3 and FY 2026. Index change: ILMN Post-close on Friday, stock was added to the S&P 500 Index effective 21-Sep-2026. Research: PHR downgraded to market perform from outperform at Raymond James (Parker Snure) SN.LN (SNN) downgraded to neutral from buy at BofA (Julien Ouaddour), target cut to 1150p from 1340p or approx. 7% upside. (FactSet average PT 1249p; range 1052-1536p) GH initiated buy at Rothschild & Co Redburn (Jamie Clark), target is $203 or approx. 26% upside. NTRA initiated buy at Rothschild & Co Redburn (Jamie Clark), target is $385 or approx. 17% upside. TEM initiated neutral at Rothschild & Co Redburn (Jamie Clark), target is $67 or approx. 4% upside. On Deck: Conference (cont): ERS 2026 (Sep 5-9) (cont): EEC 2026 (Sep 5-9) Wells Fargo Healthcare Conference (Sep 8-10) on Wed 9-Sep: Cantor Fitzgerald Global Healthcare Conference (Sep 9-11); Citi Back to School Conference (Sep 9-10); Goldman Sachs European MedTech and Healthcare Services Conference (Sep 9-10) on Sat 12-Sep: World Conference on Lung Cancer (WCLC) (Sep 12-15) Corporate on Wed 9-Sep: TYRA (ph2 SURF302 trial in NMIBC) call at 8:00ET; IRD (ph1/2 cohort 1 data in retinal degeneration) call at 8:00ET Earnings on Wed 9-Sep: after COO (call at 17:00ET) Regulatory on Fri 11-Sep: FDA PDUFA for TLX.AU Pixclara NDA for imaging of gliomas This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALNY, AMGN, ANL, ARWR, BAYN.GR, BEAM, BHVN, BNTX, BSX, CLYM, COO, DYN, EIKN, GH, GPCR, HIK.LN, ILMN, INBX, IONS, IPN.FP, IRD, LLY, MOLN, MRK, NAMS, NOVN.SW, NOVO.B.DC, NTRA, NVO, NVS, PHR, PHVS, QGEN, QTTB, ROIV, RPRX, SDGR, SN.LN, SRPT, STRO, TEM, TLX.AU, TVRD, TYRA, ZEAL.DC...(more)	show story hide story
04-Sep-2026 20:09	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished broadly lower on a very quiet session Friday. Decliners beat advancers by more than 6:1 on the XLV. Healthcare (1.04%) vs S&P 500 (0.38%). All major health groups ended lower for the session, with most declines less than (1%) on the averages. Defensive groups down more than (1%). Most held onto modest weekly gains; MedTech the lone decliner for the week. BSX +1.8% and VEEV (3.3%) bracketed the XLV with generally modest moves in between. Sector newsflow very quiet into the long Holiday weekend. Two medical conferences kick off Saturday in Europe. Brokerage conferences the highlight of next week. Macro: Market ended the week on a defensive note with breadth solidly negative. Came on the heels of today's very strong +162K August payrolls headline; unemployment rate also held at 4.1% alongside a bounce-back in labor-force participation. Report drove a bit of a boost in September hike odds (now near 58% from 50-50 pre-report). However, unclear payrolls will have a huge impact on September FOMC, especially with CPI data out next week and current narrative focused on persistent above-target inflation. Otherwise it was a very quiet session ahead of the US Labor Day holiday weekend. Earnings takeaways mixed, though some scrutiny surrounding another disappointing batch of retail results. Software results largely underwhelmed as well. Nothing particularly incremental when it comes to US-Iran conflict with Washington focused on a combination of inflicting economic pain and improving SoH transit. Along with CPI, next week brings the AAPL iPhone event, ORCL earnings, a pickup in sell-side conferences and the waiting game for the Anthropic S-1. Notable Gainers on Friday: +15.2% TYRA (Tyra Biosciences): schedules call for next Wednesday to discuss ph2 trial results in bladder cancer; best performer on XBI +13.2% BLTE (Belite Bio): initiation +5.6% ATTO (Attovia Therapeutics): follow-through, shares +23% for the week +3.0% RARE (Ultragenyx Pharmaceutical): follow-through, shares (40%) for the week +1.8% BSX (Boston Scientific): best performer on XLV; shares +2% for the week Notable Decliners on Friday: -4.8% TRAX (First Tracks Biotherapeutics Inc): worst performer on XBI; shares (3%) for the week -4.8% VCYT (Veracyte): second-worst on XBI; shares (2%) for the week -3.9% WAY (Waystar Holding): software weakness -3.3% VEEV (Veeva Systems): software weakness; worst performer on XLV -2.2% MRNA (Moderna): shares finish +5% for the week -2.1% SRPT (Sarepta Therapeutics): shares finish +8% for the week -1.3% AZN (AstraZeneca): FDA approved Etcamah for breast cancer Week in Review: Healthcare equities were roughly inline overall for the week. The S&P 500 Healthcare Index added +0.17% vs the S&P 500 Index +0.09%. Outperformers: Managed Care, Biotech, Services, Pharma Underperformers: MedTech Major health groups were mostly little changed on the averages this week. Very little newsflow this late summer week ahead of the Labor Day Holiday. A few earnings reports in MedTech, and the White House announced MFN pricing deals made with another nine companies paraded through the Oval Office, including some mid-sized drugmakers. In addition, Incyte Corp announced an agreement over Jakafi in Medicaid, and then stated that the agreement would have no material impact on its financial outlook. Looking ahead, a long weekend, and then conference season begins again in earnest. Year-to-date, Healthcare +10.53% vs the S&P 500 +12.75%. Healthcare now fifth out of eleven major sectors in CY26. Energy +41.59% and Consumer Discretionary (1.81%) bracket them all. Notable movers for the week: Gainers: SMMT +28.2% - Akeso trial update (overall survival in HARMONi-2); best performer on XBI BLTE +27.6% - initiation ATTO +23.4% - recent IPO; initiations; earnings MMED +15.8% - earnings ALNY +12.2% - ESC 2026 presentations PLSE +11.9% - insider buying (COO) ASND +9.1% - settlement with BMRN on Yuviwel royalties MRNA +5.5% - follow-through; downgraded at Rothschild; best performer on XLV CAH +5.4% - rotation; 52-week high MDT +3.2% - earnings Decliners: ALMS (50.4%) - trial results in lupus (SLE) RARE (40.3%) - trial results in Angelman Syndrome; downgrades; worst performer on XBI ENOV (25.5%) - acquires eCential Robotics for €211M TWST (11.8%) - stock lower six straight days, follows (8%) last Friday ERAS (10.2%) - stock lower six straight days, follows (7%) last Friday QURE (8.7%) - submits BLA (US) and MAA (UK) SYK (8.3%) - stock lower all five days; worst performer on XLV UTHR (5.4%) - FDA accepts nebulized Tyvaso sNDA for IPF (standard review) IONS (4.8%) - sympathy to RARE (Angelman); FDA approves Zanvastro (Alexander); WAC price $1.14M annually TEVA (0.2%) - trial results in Celiac disease Week Ahead (Sat - Sun): Sep 5 - 13 Holiday calendar Mon 7-Sep: US equity markets closed for Labor Day Holiday Conference calendar Sat 5-Sep: ERS 2026 (Sep 5-9); EEC 2026 (Sep 5-9) Tue 8-Sep: Wells Fargo Healthcare Conference (Sep 8-10) Wed 9-Sep: Cantor Fitzgerald Global Healthcare Conference (Sep 9-11); Citi Back to School Conference (Sep 9-10); Goldman Sachs European MedTech and Healthcare Services Conference (Sep 9-10) Sat 12-Sep: World Conference on Lung Cancer (WCLC) (Sep 12-15) Corporate calendar Wed 9-Sep: TYRA (ph2 SURF302 trial in NMIBC) call at 8:00ET; IRD (ph1/2 cohort 1 data in retinal degeneration) call at 8:00ET Earnings calendar Wed 9-Sep: after COO (call at 17:00ET) Regulatory calendar Fri 11-Sep: FDA PDUFA for TLX.AU Pixclara NDA for imaging of gliomas Related: ALMS, ALNY, AMGN, ASND, ATTO, AZN, BLTE, BSX, CAH, COO, ENOV, ERAS, IONS, IRD, LLY, MDT, MMED, MRNA, NVS, PLSE, QURE, RARE, SMMT, SRPT, SYK, TEVA, TLX.AU, TRAX, TWST, TYRA, UTHR, VCYT, VEEV, WAY...(more)	show story hide story
04-Sep-2026 14:45	StreetAccount Summary: Notable Drug Events expected for the week of 6-Sep (cont.) Industry meeting with clinical data: European Epilepsy Congress (EEC) (Sep 5-9) (XENE, STOK, BIIB, HRMY) Mon 7-Sep Trial results: XENE to present Phase 3 X-TOLE2 clinical data for Azetukalner in focal onset seizures (FOS) at EEC Tue 8-Sep Broker conference: Wells Fargo Healthcare Conference (Sep 8-10) Wed 9-Sep Industry meeting with clinical data: Society of Hematologic Oncology (SOHO) Meeting (Sep 9-12) (IRON, ELVN) Trial results: TYRA to discuss initial results from the SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC) (webcast 8:00ET) IRD present topline data from its Phase 1/2 study of OPGx-BEST1 in BVMD and ARB (webcast 8:00ET) Thu 10-Sep Trial results: IRON to present initial data from RESTORE-PV Phase 2 study in polycythemia vera (PV) at SOHO Fri 11-Sep Regulatory decision: TLX.AU FDA PDUFA for Pixclara NDA for imaging of gliomas Sat 12-Sep Industry meeting with clinical data: World Conference on Lung Cancer (WCLC) 2026 (Sep 12-15) (ABBV, BNTX, CAI, BLSM) later during September 2026 Regulatory decisions: FDA PDUFAs: RARE (rebisufligene etisparvovec BLA, 19-Sep), IntraBio (Aqneursa sNDA, 19-Sep), MRK (Winrevair sBLA, 21-Sep), INCY/MIRM (zilurgisertib NDA, 26-Sep), ROP.SW (Gazyva sBLA, 27-Sep), EGTX.SS (Emcitate NDA, 28-Sep), BFRI (Ameluz sNDA, 28-Sep), SRRK (apitegromab BLA, 30-Sep), BMY (Camzyos sNDA, 30-Sep); EMA CHMP opinions on MAA (18-Sep) Regulatory meeting: EMA CHMP monthly meeting (Sep 14-17) Industry meetings with clinical data: International Pathogenic Neisseria Conference (IPNC) (Sep 13 -17); European Association for the Study of Diabetes (EASD) annual meeting (Sep 28 - Oct 2) Trial results: NOVN.SW (Ph3 DM1), GSK.LN (Ph3 IMD), KOD (Ph3 Wet AMD), KLRA (Ph 3 T2D and Ph1 obesity), ABBV (Ph3 NSCLC), BNTX (Ph3 NSCLC), PAR.AU (Ph3 OA), OSTX (Ph2 Metastatic Osteosarcoma), IMMX (Ph2 R/R AL Amyloidosis), CNTB (Ph2 Acute asthma and Ph2 COPD), LGVN (Ph2 HLHS), ARCT (Ph2 OTC deficiency), EVMN (Ph2 atopic dermatitis), Revelyx Bio (Ph2 aesthetics), BIVI (Ph2 long COVID), QURE (Ph1/2 Huntington's disease), CNTX (Ph1 solid tumors), PHIL.IM (Ph1 glioblastoma), CRBP (Ph1 obesity), ZNTL (Ph1 PROC), PMN (Ph1 AD), VKTX (Ph1 obesity), ACET (Ph1 SLE) expected imminently Trial results: NOVN.SW phase 3 HORIZON results in CVD Related: ABBV, ACET, ARCT, BFRI, BIIB, BIVI, BLSM, BMY, BNTX, CAI, CNTB, CNTX, CRBP, EGTX.SS, ELVN, EVMN, GSK.LN, HRMY, IMMX, INCY, IRD, IRON, KLRA, KOD, LGVN, MIRM, MRK, NOVN.SW, OSTX, PAR.AU, PHIL.IM, PMN, QURE, RARE, ROP.SW, SRRK, STOK, TLX.AU, TYRA, VKTX, XENE, ZNTL...(more)	show story hide story
04-Sep-2026 11:27	CDC reports 231 new cases of measles this week, another high Year-to-date, CDC has reported 3,134 cases of measles, including 231 over the past week, exceeding the daily case rate high set two weeks ago. This week's case count represents roughly 2X the trailing five-week average. The CDC continues to report YTD 2026 deaths as an asterisk (*) while the CDC "reviews additional information regarding the circumstances and causes of death" in the Pennsylvania DoH report on 25-Aug. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
04-Sep-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (1.12%) vs the S&P 500 (0.47%). All major health groups are red for the session, with declines around (1%) on the averages. Most groups are holding onto very modest weekly advances; MedTech the week-to-date decliner. BSX +1% / BAX +1% and MRNA (4%) bracket the XLV with generally modest moves in between. Sector newsflow very quiet into the long Holiday weekend. Two medical conferences kick off Saturday in Europe. Brokerage conferences the highlight of next week. Gainers +12.8% TYRA (Tyra Biosciences): schedules call for next Wednesday to discuss ph2 trial results in bladder cancer; best performer on XBI +11.5% ATTO (Attovia Therapeutics): follow-through, shares +26% WTD +6.7% BLTE (Belite Bio): initiation +5.1% RARE (Ultragenyx Pharmaceutical): follow-through; shares (39%) WTD +1.2% BSX (Boston Scientific): best performer on XLV; shares +2% WTD +1.2% BAX (Baxter International): second-best on XLV; shares (1%) WTD Decliners -4.4% MRNA (Moderna): worst performer on XLV; shares remain +3% WTD -3.9% SRPT (Sarepta Therapeutics): shares +6% WTD -3.3% PODD (Insulet): second-worst on XLV -2.2% NVO (Novo Nordisk): on good volume -2.1% GSK (GSK Plc): on good volume -0.1% IONS (Ionis Pharmaceuticals): follow-through, issued PR on FDA approval; prices at $1.14M per patient year	show story hide story
04-Sep-2026 08:44	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Sector newsflow very quiet as expected into the long Holiday weekend. Two medical conferences kick off Saturday in Europe. Brokerage conferences the highlight of next week. Yesterday, Healthcare equities were lightly mixed and very little changed overall. Sector on track for modest weekly advance, led by the more defensive groups amid intra-sector rotation. Macro S&P futures are down (0.2%) on Friday morning. Futures near premarket lows following strong August job gains; unemployment rate held a 4.1% alongside a bounce-back in labor-force participation. Unclear how firmer job report will impact Fed rate decision for September, especially with CPI data out next week and current narrative focused on persistent above-target inflation. Otherwise fairly quiet overall heading into the long holiday weekend. Earnings takeaways mixed, though some scrutiny surrounding another disappointing batch of retail results. Nothing particularly incremental when it comes to US-Iran conflict. with Washington focused on a combination of inflicting economic pain and improving SoH transit. Along with CPI, next week brings the AAPL iPhone event, ORCL earnings, a pickup in sell-side conferences and the waiting game for the Anthropic S-1. Pre-market trading update Trading higher +8.1% CNTB on 51K shares +4.5% MRNA shares up +8% WTD +3.2% PRME on 57K shares +2.3% MANE on 6K share +2.3% LTGO earnings (on low volume) +2.0% DNTH initiation +1.1% BLTE initiation +0.5% IONS follow-through, issued PR on FDA approval Trading lower -4.3% IVA on 30K ADRs -2.0% NVO on 215K ADRs -1.9% GSK on 48K ADRs -1.6% NVS on 18K ADRs -0.6% PCVX trial timeline update (on low volume) Pharma Research: MRK Wells Fargo analyst Mohit Bansal (overweight rating) raises price target to $170 from $150 or approx. 12% upside, citing PCSK9 survey work. Firm raises peak sales on Lipfendra to $5B, up from $3B and versus consensus $4.5B. (FactSet average PT $149; range $105-186) Biotech Corporate update: IONS post-close on Thursday issued a press release on the FDA approval of Zanvastro (zilganersen). StreetAccount reported on the approval prior to the market close. PRV awarded with the approval. Conf. call at 10:00ET to discuss Quick take: Analysts highlight the third wholly-owned therapy, but just the first in its neuro franchise. Canaccord Genuity expects ultra-rare disease pricing. PCVX announces that the phase 3 OPUS-1 trial readout for VAX-31 now expected by the end of October vs prior guidance for during Q4. Earnings: LTGO reports Q2 results, initial print following the biotech IPO on 7-Aug. Projects cash sufficient into 2029. Research: BLTE initiated buy at Canaccord Genuity (Whitney Ijem), target is $303 or approx. 77% upside. (FactSet average PT $224; range $185-303) DNTH initiated buy at Citi (Samantha Semenkow), target is $156 or approx. 45% upside. (FactSet average PT $139; range $122-200) IMMX added as a Top Pick at Mizuho Securities. Life Science & MedTech Research: HQY added as a Top Pick at Mizuho Securities. Services & Hospitals Research: BTSG added as a Top Pick at Mizuho Securities. NUTX transferred buy at B Riley Securities (Yuan Zhi), target is $325 or approx. 64% upside. (FactSet average PT $283; range $280-325) Week Ahead (Sat - Sun) Aug 29 - Sep 6 Corporate calendar Fri 4-Sep: IONS call to discuss FDA approval of Zanvastro in Alexander disease (10:00ET) Conference calendar Sat 5-Sep: European Respiratory Society (ERS) Congress (Sep 5-9) European Epilepsy Congress (Sep 5-9) Peek Ahead to next week Sep 7 - 13 Mon 7-Sep: US equity markets closed for Labor Day Holiday Tue 8-Sep: Wells Fargo Healthcare Conference Wed 9-Sep: Earnings after the close: COO; Cantor Fitzgerald Global Healthcare Conference (Sep 9-11); Citi Back to School Conference (Sep 9-10); Goldman Sachs European Medtech and Healthcare Services Conference (Sep 9-10) Fri 11-Sep: FDA PDUFA for TLX.AU Pixclara NDA for imaging of gliomas Imminent / event-driven trial readout: NOVN.SW (NVS) phase 3 CVOT results for HORIZON study evaluating ASO pelacarsen for prevention of ASCVD in patients with elevated Lp(a) Read-across for AMGN and LLY This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AMGN, BLTE, BTSG, CNTB, COO, DNTH, GSK, HQY, IMMX, IONS, IVA, LLY, LTGO, MANE, MRK, MRNA, NUTX, NVO, NVS, PCVX, PRME, TLX.AU...(more)	show story hide story
03-Sep-2026 16:31	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished lightly mixed and little changed overall on Thursday. By the market close, breadth improved and advancers outnumbered decliners on the XLV. Healthcare +0.19% vs S&P 500 +1.06%. All major health groups lagged the broader tape however. Most were little changed on the averages and remain on track for moderate weekly gains. Managed Care group today's relative performer, after seeing some intra-sector rotation with early softness in both Biotech and MedTech groups. Not much new in terms of narrative or newsflow, apart from the typical noise of biotech. IQV +3.0% and BSX (2.9%) bracketed the XLV, with mainly modest moves in between. Overall, sector newsflow was very quiet ahead of the long Holiday weekend. Weighing most on the XBI (0.60%) was RARE (44.0%) with disappointing topline results in phase 3 with its ASO for Angelman syndrome; multiple downgrades followed. Offsetting was SMMT +17.3% whose partner Akeso reported that HARMONi-2 achieved the key secondary endpoint for overall survival (OS). Yesterday, Healthcare equities were mostly higher in quiet trading in the leadup to the long Holiday weekend. Calendar remains very quiet. Macro Thursday's upside tabbed in large part to rate stabilization following Fed Governor Waller offering support for a September hold should data show continued disinflation progress. September hike probabilities now at close to 50-50 vs hike odds near 68% on Tuesday. Latest Iran updates have leaned dovish with Trump considering whether to declare war over, White House deescalating at least until after midterms, highest SoH oil flows since start of war (though Trump also stressed US munitions stockpile more than sufficient). AI updates mostly positive, including earnings suggesting positive compute/capex demand trends, latest model updates (Open AI GPT-6 Astra, META Muse Spark 1.3), though some concerns around token prices falling faster than consumption growing. Other areas of focus include improving breadth, more reasonable S&P 500 valuations, ongoing debate over recent rate pressure/real rates, resilient macro data though sticky inflation (August ISM services prices-paid component highest in four years). Notable Gainers +17.3% SMMT (Summit Therapeutics): sympathy to Akeso trial results in HARMONi-2; best performer on XBI +17.2% HCM (Hutchmed): licensing agreement with GSK; upgraded at Daiwa +9.8% ALMS (Alumis): follow-through, downgrade +6.3% OSCR (Oscar Health): intra-sector rotation +4.6% ATTO (Attovia Therapeutics): earnings; first print since IPO +3.9% PLSE (Pulse Biosciences): insider buying (COO) +3.0% IQV (IQVIA Holdings): on above average volume; best performer on XLV; 52-week high +2.2% ELV (Elevance Health): intra-sector rotation Notable Decliners -44.0% RARE (Ultragenyx Pharmaceutical): trial results in Angelman syndrome; downgrades; worst performer on XBI -7.7% SION (Sionna Therapeutics): shares remain +15% WTD and (83%) YTD -7.2% JBIO (Jade Biosciences): sympathy to CLYM -6.3% PHR (Phreesia): earnings -6.2% CAPR (Capricor Therapeutics): follow-through, shares (3%) WTD -6.1% TRAX (First Tracks Biotherapeutics Inc): follow-through, shares +2% WTD -5.2% IONS (Ionis Pharmaceuticals): sympathy to RARE; FDA approves Zanvastro ahead of 22-Sep PDUFA goal date -3.1% CLYM (Climb Bio): initial data with '116 in IgAN -3.0% QURE (uniQure NV): follow-through, shares (8%) WTD -2.9% BSX (Boston Scientific): worst performer on XLV; on average volume Trial results and Clinical updates in Biotech RARE announced that the phase 3 ASPIRE trial evaluating apazunersen (GTX-102) in Angelman syndrome did not achieve the primary endpoint. Company is evaluating the next steps for the program. (IONS, TSHA, ACAD) SMMT partner Akeso (9926.HK) announced that a pre-specified interim analysis of HARMONi-2 study with ivonescimab achieved the secondary endpoint of overall survival (OS). CLYM announced initial phase 1 data with anti-APRIL mAb CLYM116 and provided an update on its development for IgAN. Phase 2 trial is ongoing, with initial data in H1 of 2027. Planning for phase 3 trial initiation in 2027. RVMD data from phase 1/2 trial of daraxonrasib (RASONQUE) in NSCLC were published in NEJM. (ONC, RPRX) Quick take: the updated data cut provide constructive support to the development beyond PDAC and into RAS-mutant NSCLC GSK paying up to $1.3B for drug conjugate developed by Hutchmed 13.HK (HCM) announced that GSK will in-license worldwide rights (ex-China) to HMPL-A830, a conjugate therapy targeting KRAS and EGFR, for up to $1.3B including $110M upfront. Brain implants fuel U.S.-China bioscience rivalry - Axios The Axios report discusses the emerging national security implications of the race to develop brain implants. The National Security Commission on Emerging Biotechnology in a recent report also called on the US FDA to develop a pathway to approval, and the CMS to develop a payment model for brain-computer interfaces (BCIs). Companies mentioned - all privately held - include Elon Musk's Neuralink (+NEURALINK), Precision Neuroscience (0NS5KV-E), Paradromics (0G34C9-E) and Synchron (0G682T-E). Notable research in Healthcare today Biotech: RARE downgraded to neutral from outperform at Baird (Jack Allen), target cut to $16 from $40 or approx. 40% downside. downgraded to neutral from buy at BofA (Tazeen Ahmad), target cut to $20 from $48 or approx. 41% upside. downgraded to in line from outperform at Evercore ISI (Gavin Clark-Gartner), target cut to $16 from $34 or approx. 40% downside. downgraded to neutral from overweight at JPMorgan (Anupam Rama), target cut to $36 from $80 or approx. 36% upside. downgraded to sector perform from outperform at RBC Capital Markets (Luca Issi), target cut to $19 from $40 or approx. 28% downside. downgraded to equal weight from overweight at Wells Fargo (Benjamin Burnett), target is $18 or approx. 32% downside. downgraded to market perform from outperform at William Blair (Sami Corwin) MRNA downgraded to sell from neutral at Rothschild & Co Redburn (Simon Baker), target increased however to $81 from $40 or approx. 46% downside. (FactSet average PT $108; range $40-170) HCM upgraded to buy from hold at Daiwa (Jing Yang) ALMS downgraded to neutral from buy at Guggenheim Securities (Yatin Suneja), follows LUMUS trial NRSN initiated buy at HC Wainwright (Lander Egaña Gorroño), target is $8 or approx. 1851% upside. TLSA initiated buy at BTIG (Thomas Shrader), target is $7 or approx. 653% upside. MedTech: NVST upgraded to overweight from neutral at JPMorgan (Lilia-Celine Lozada), target increased to $32 from $29 or approx. 17% upside. (FactSet average PT $31; range $23-35) TMO initiated outperform at CLSA, target is $748 or approx. 23% upside. Post-close news Corporate update: PCVX announces that the phase 3 OPUS-1 trial readout for VAX-31 now expected by the end of October vs prior guidance for during Q4. Earnings: LTGO reports Q2 results, initial print following the biotech IPO on 7-Aug. Projects cash sufficient into 2029. Research: BTSG, HQY, and IMMX added as Top Picks at Mizuho Securities. On Deck: Conference on Sat 5-Sep: European Respiratory Society (ERS) Congress (Sep 5-9) on Sat 5-Sep: European Epilepsy Congress (Sep 5-9) Peek Ahead to next week (Sep 7 - 13) Mon 7-Sep: US equity markets closed for Labor Day Holiday Wed 9-Sep: Earnings after the close: COO; Cantor Fitzgerald Global Healthcare Conference (Sep 9-11); Citi Back to School Conference (Sep 9-10); Goldman Sachs European Medtech and Healthcare Services Conference (Sep 9-10) Fri 11-Sep: FDA PDUFA for TLX.AU Pixclara NDA for imaging of gliomas Imminent / event-driven trial readout: NOVN.SW (NVS) phase 3 CVOT results for HORIZON study evaluating ASO pelacarsen for prevention of ASCVD in patients with elevated Lp(a) Read-across for AMGN and LLY StreetAccount Healthcare Reads The pediatricians who take in vaccine-skeptical parents others won't (3-Sep) STAT News Kennedy asked to remove Pennsylvania measles death from CDC tally, sources say (3-Sep) Reuters GoodRx offers health subscription for families, to launch employee benefit in 2027 (3-Sep) Reuters Deaths in Novartis CAR-T trial force a reckoning over acceptable risk in autoimmune disease (2-Sep) Endpoints News Hospitals say coming Trump administration rules are worse than GOP's Medicaid cuts (2-Sep) Politico The White House Can't Hype Away Healthcare Sticker Shock (1-Sep) Bloomberg (opinion) The CDC hasn't added 2 deaths to its measles database. Here's why. (31-Aug) WaPo This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 13.HK, 9926.HK, ACAD, ALMS, AMGN, ATTO, BSX, BTSG, CAPR, CLYM, COO, ELV, GDRX, GSK, HCM, HQY, IMMX, IONS, IQV, JBIO, LLY, LTGO, MRNA, NRSN, NVS, NVST, ONC, OSCR, PCVX, PHR, PLSE, QURE, RARE, RPRX, RVMD, SION, SMMT, TLSA, TLX.AU, TMO, TRAX, TSHA, +NEURALINK...(more)	show story hide story
03-Sep-2026 11:04	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.31%) vs the S&P 500 +0.59%. Most major health groups are red on their averages, trimming their weekly gains. Biotech and MedTech groups are down more than (1%). Intra-sector rotation helping out Managed Care stocks, but gains are modest. HUM +2% and MRNA (4%) bracket the XLV. Latter remains volatile as investors and analysts evaluate last week's INT outcome in melanoma. Overall sector newsflow remains fairly quiet, primarily just biotech flow ahead of the long Holiday weekend. Weighing most on the XBI (0.99%) is RARE (46%) which announced disappointing topline results in phase 3 with its ASO for Angelman syndrome; multiple downgrades followed. Offsetting is SMMT +11% whose partner Akeso reported that HARMONi-2 achieved the key secondary endpoint for overall survival (OS). Gainers +14.5% HCM (Hutchmed): licensing agreement with GSK +10.8% SMMT (Summit Therapeutics): sympathy to Akeso trial results in HARMONi-2; best performer on XBI +9.3% ALMS (Alumis): follow-through, downgrade +7.6% ATTO (Attovia Therapeutics): earnings; first print since IPO +4.4% OSCR (Oscar Health): intra-sector rotation +2.6% PLSE (Pulse Biosciences): insider buying (COO) +2.0% HUM (Humana): intra-sector rotation; best performer on XLV +0.5% RVMD (Revolution Medicines): updated lung cancer data published in NEJM Decliners -45.9% RARE (Ultragenyx Pharmaceutical): trial results in Angelman syndrome; downgrades; worst performer on XBI -8.4% PHR (Phreesia): earnings -6.6% CAPR (Capricor Therapeutics): follow-through, second-worst on XBI -4.3% JBIO (Jade Biosciences): sympathy to CLYM -4.2% MRNA (Moderna): downgraded at Rothschild; worst performer on XLV -3.9% CLYM (Climb Bio): initial data with '116 in IgAN -3.7% IONS (Ionis Pharmaceuticals): sympathy to RARE -3.4% QURE (uniQure NV): follow-through, shares (8%) WTD -2.5% BSX (Boston Scientific): second-worst on XLV -0.5% ABBV (AbbVie): trial results in multiple myeloma -0.2% NVST (Envista Holdings): upgraded at JPMorgan	show story hide story
03-Sep-2026 08:52	FDA seeking input on botanical drug products FDA seeks to accelerate development of BDPs - Federal Register notice Botanical drug products (or BDPs) refer to drug products that include or may be derived from plant materials, algae, macroscopic fungi, or combinations thereof and that are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
03-Sep-2026 08:43	FDA working with manufacturers to improve availability of estradiol transdermal patch FDA is aware of reports of patients having difficulty readily accessing their usual estradiol transdermal patches due to increased demand and is working with all six manufacturers to increase supply. Although availability of certain products or brands may vary by pharmacy or location, estradiol transdermal patches remain available. Demand for these products increased following the November 2025 action by the FDA to request that manufacturers make changes to the labeling to remove boxed warnings about a probable risk of breast cancer, cardiovascular disease, and probable dementia for patients receiving menopausal hormone therapy products for menopause. See Related StreetAccount comments: 2/12/2026 10:45:01 AM - FDA removes boxed warning from Mayne Pharma's Bijuva 12/5/2025 9:37:03 AM - FDA announces availability of draft guidance on Estradiol, including Imvexxy and Vagifem 10/15/2025 9:04:24 AM - Hers announces launch of menopause and perimenopause treatments Related: 532321.IN, AMRX, HIMS, SDZ.SW, VTRS Reference Link	show story hide story
03-Sep-2026 08:33	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight, Ultragenyx announced disappointing topline results in phase 3 with its ASO for Angelman syndrome. Multiple downgrades followed. Shares of RARE (47%) in the pre-market. Summit Therapeutics partner Akeso reported that HARMONi-2 achieved the key secondary endpoint for overall survival (OS). Shares of SMMT +7% in the pre-market. Yesterday, Healthcare equities were mostly higher in quiet trading in the leadup to the long Holiday weekend. Calendar remains very quiet. Macro S&P futures are up +0.1% on Thursday morning, reversing earlier drift. No big directional drivers in play. Yield stabilization seems to be the big story as of late with some credit going to softer ADP private payrolls and centrist camp comments from Fed's Williams yesterday. Probability of a September Fed rate hike has slipped to near 61% from approx 68% earlier in the week. Fed's Waller this morning, NFP tomorrow and CPI next Friday the next key areas of focus for the bond market (along with BoJ on 18-Sep). No new kinetic activity in the Middle East following recent escalation, Trump reportedly having discussions about whether to declare Iran war over (and said to favor the idea) and US has talked up 17-18M bpd of oil recently exiting SoH. Positive AI compute/capex demand takeaways from latest batch of reporters, though price action mixed. AI model updates (and jockeying for leaderboard positioning) continue to get a lot of attention in the press. Pre-market trading update Trading higher +12.3% HCM licensing agreement with GSK; call at 730ET +12.0% NRSN microcap biotech; initiation +6.8% SMMT sympathy to Akeso trial results in HARMONi-2 +3.6% CLYM initial data with 116 in IgAN; call at 800ET +2.3% NVST upgraded at JPMorgan +1.3% RVMD updated lung cancer data published in NEJM Trading lower -46.7% RARE trial results in Angelman syndrome; downgrades -6.1% PHR earnings -2.7% IONS sympathy to RARE -2.4% MRNA downgraded at Rothschild Biotech Trial results: RARE announced that the phase 3 ASPIRE trial evaluating apazunersen (GTX-102) in Angelman syndrome did not achieve the primary endpoint. Company is evaluating the next steps for the program. (IONS, TSHA, ACAD) SMMT partner Akeso (9926.HK) announced that a pre-specified interim analysis of HARMONi-2 study with ivonescimab achieved the secondary endpoint of overall survival (OS). CLYM announced initial phase 1 data with anti-APRIL mAb CLYM116 and provided an update on its development for IgAN. Phase 2 trial is ongoing, with initial data in H1 of 2027. Planning for phase 3 trial initiation in 2027. Conf. call at 8:00ET RVMD data from phase 1/2 trial of daraxonrasib (RASONQUE) in NSCLC were published in NEJM. (ONC, RPRX) Quick take: the updated data cut provide constructive support to the development beyond PDAC and into RAS-mutant NSCLC License agreement: 13.HK (HCM) announced that GSK will in-license worldwide rights (ex-China) to HMPL-A830, a conjugate therapy targeting KRAS and EGFR, for up to $1.3B including $110M upfront. Conf. call at 7:30ET Research: ALMS downgraded to neutral from buy at Guggenheim Securities (Yatin Suneja), follows LUMUS trial MRNA downgraded to sell from neutral at Rothschild & Co Redburn (Simon Baker), target increased however to $81 from $40 or approx. 46% downside. (FactSet average PT $108; range $40-170) RARE downgraded to neutral from outperform at Baird (Jack Allen), target cut to $16 from $40 or approx. 40% downside. downgraded to in line from outperform at Evercore ISI (Gavin Clark-Gartner), target cut to $16 from $34 or approx. 40% downside. downgraded to neutral from overweight at JPMorgan (Anupam Rama), target cut to $36 from $80 or approx. 36% upside. downgraded to sector perform from outperform at RBC Capital Markets (Luca Issi), target cut to $19 from $40 or approx. 28% downside. downgraded to equal weight from overweight at Wells Fargo (Benjamin Burnett), target is $18 or approx. 32% downside. downgraded to market perform from outperform at William Blair (Sami Corwin) NRSN initiated buy at HC Wainwright (Lander Egaña Gorroño), target is $8 or approx. 1851% upside. TLSA initiated buy at BTIG (Thomas Shrader), target is $7 or approx. 653% upside. Life Science & MedTech Brain implants fuel U.S.-China bioscience rivalry - Axios The Axios report discusses the emerging national security implications of the race to develop brain implants. The National Security Commission on Emerging Biotechnology in a recent report also called on the US FDA to develop a pathway to approval, and the CMS to develop a payment model for brain-computer interfaces (BCIs). Companies mentioned - all privately held - include Elon Musk's Neuralink (+NEURALINK), Precision Neuroscience (0NS5KV-E), Paradromics (0G34C9-E) and Synchron (0G682T-E). Research: NVST upgraded to overweight from neutral at JPMorgan (Lilia-Celine Lozada), target increased to $32 from $29 or approx. 17% upside. (FactSet average PT $31; range $23-35) On Deck: Conference on Sat 5-Sep: European Respiratory Society (ERS) Congress (Sep 5-9) on Sat 5-Sep: European Epilepsy Congress (Sep 5-9) Peek Ahead to next week Sep 7 - 13 Mon 7-Sep: US equity markets closed for Labor Day Holiday Wed 9-Sep: Earnings after the close: COO; Cantor Fitzgerald Global Healthcare Conference (Sep 9-11); Citi Back to School Conference (Sep 9-10); Goldman Sachs European Medtech and Healthcare Services Conference (Sep 9-10) Fri 11-Sep: FDA PDUFA for TLX.AU Pixclara NDA for imaging of gliomas This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 13.HK, 9926.HK, ACAD, ALMS, CLYM, COO, GSK, HCM, IONS, MRNA, NRSN, NVST, ONC, PHR, RARE, RPRX, RVMD, SMMT, TLSA, TLX.AU, TSHA...(more)	show story hide story
03-Sep-2026 08:25	Brain implants fuel U.S.-China bioscience rivalry - Axios The Axios report discusses the emerging national security implications of the race to develop brain implants. The National Security Commission on Emerging Biotechnology in a recent report also called on the US FDA to develop a pathway to approval, and the CMS to develop a payment model for brain-computer interfaces (BCIs). Companies mentioned - all privately held - include Elon Musk's Neuralink (+NEURALINK), Precision Neuroscience (0NS5KV-E), Paradromics (0G34C9-E) and Synchron (0G682T-E). Related: +NEURALINK, 0G34C9-E, 0G682T-E, 0NS5KV-E Reference Link: Axios	show story hide story
02-Sep-2026 17:03	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly higher in quiet trading Wednesday. Advancers beat decliners by nearly 4:1 on the XLV. Healthcare +0.79% vs S&P 500 +0.46%. All major health groups ended up in positive territory for the session, including Biotech with the XBI +1.21% after some initial volatility. RVTY +3.4% and HCA (2.8%) bracketed the XLV. Most declines quite modest on the XLV including fractional declines for two hospitals. Politico today discussed the ramp in lobbying against recent rule proposals by CMS. In general, the sector calendar and newsflow remains very quiet, as expected this week, and ahead of the upcoming three-day weekend. Shares of MRNA (2.2%) took a breather after rising another 10% yesterday. TEVA +3.6% after mid-stage clinical results in Celiac disease; read-across seen positive for TRAX +10.0% among others. QURE (3.4%) volatile despite an upgrade and a regulatory submissions in the US and the UK. Standard review timeline for UTHR (4.0%) nebulized Tyvaso sNDA. Yesterday, healthcare equities were mixed yet mostly higher. Another strong day for Moderna as investors continue to debate what to make of the melanoma breakthrough for INT; GSK also advanced a mRNA-based influenza vaccine. Macro A very quiet, low volume session with market bouncing following three-day losing streak that was largely chalked up to higher rates, higher energy prices, hawkish central bank reaction function concerns, elevated geopolitical tensions, dampened positive macro surprise momentum and seasonal headwinds. These were also some of the key inputs for the recent batch of more cautious strategist commentary. When it comes to today's move, rate and oil stabilization likely providing some semblance of support. Earnings takeaways largely positive as well, particularly in terms of AI compute/capex demand, though price action mixed. Pretty quiet elsewhere. ADP private payrolls latest softer than expected data point, though comes ahead of NFP on Friday and more importantly for Fed's policy calculus, CPI the following Friday. Comments from Fed's Williams fit with the more centrist (hold) camp. Yen strength has triggered intervention speculation (BoJ's Takata earlier highlighted potential for more aggressive normalization). Notable Gainers +13.6% MLYS (Mineralys Therapeutics): on nearly 3X average daily volume; best performer on XBI +10.0% TRAX (First Tracks Biotherapeutics Inc): sympathy to TEVA +9.3% ALMS (Alumis): follow-through, shares were (57%) yesterday; upgraded at HCW +8.7% ALNY (Alnylam Pharmaceuticals): shares +13% WTD +6.0% MMED (MiniMed Group): follow-through, shares were +11% yesterday on earnings +5.3% BRKR (Bruker): on below average volume +4.6% EYPT (EyePoint Pharmaceuticals): despite downgrade at TD Cowen +4.1% BLLN (BillionToOne): initiation +3.6% FTRE (Fortrea Holdings): acquires bioanalytical lab operations from Early Phase +3.6% TEVA (Teva Pharmaceutical): trial results in celiac disease +3.4% RVTY (Revvity): best performer on XLV; 52-week high +3.4% REGN (Regeneron): 52-week high; second-best on XLV +3.3% CRL (Charles River Laboratories): on light volume +3.2% CNC (Centene): on average volume +3.1% BIIB (Biogen): 52-week high; shares lagged LC Biotech yesterday +3.1% INCY (Incyte): shares +4% WTD +2.7% ALGN (Align Technology): shares +1% WTD +1.8% HALO (Halozyme Therapeutics): amid Novartis-Alteogen news +1.5% JNJ (Johnson & Johnson): assumed buy at UBS, new street-high PT Notable Decliners -4.0% UTHR (United Therapeutics): worst performer on XBI; FDA accepts nebulized Tyvaso sNDA for IPF -4.0% CLPT (Clearpoint Neuro): sympathy to QURE -3.6% XNCR (Xencor): shares remain +76% YTD -3.4% QURE (uniQure NV): submits BLA to US FDA, MAA to UK MHRA; upgraded at Wm Blair -2.8% HCA (HCA Healthcare): worst performer on XLV; Politico article on lobbying against CMS rules -2.7% THC (Tenet Healthcare): Politico article on lobbying against CMS rules -2.2% MRNA (Moderna): shares were up +10% yesterday -1.9% UHS (Universal Health Services): Politico article on lobbying against CMS rules -1.0% CYH (Community Health Systems): Politico article on lobbying against CMS rules Novartis follows Merck's route on recombinant hyaluronidase; deal potentially worth over $3B to Alteogen On Wednesday Novartis (NOVN.SW) and Alteogen (196170.KS) announced an option and license agreement for berahyaluronidase alfa (ALT-B4), the recombinant human hyaluronidase technology that underpins subcutaneous formulations of biologic drugs. Alteogen eligible to receive up to $3.2B in milestones across multiple Novartis programs. Alteogen's Hybrozyme platform is most recognized in subcutaneous Keytruda Qlex (MRK), and competes against Halozyme's (HALO) ENHANZE technology which is utilized by subcutaneous Opdivo Qvantig (BMY) and many other top-selling subcutaneous biologics. Celiac disease stocks higher after Teva study achieves endpoint TEVA announced topline results from the phase 2A trial of TEV-408 (OABI, RPRX) in adults with celiac disease. Study met its primary endpoint, demonstrating stat sig and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8. Teva plans to present further data from the study at a future scientific meeting. (TRAX) Hospitals say coming Trump administration rules are worse than GOP's Medicaid cuts - Politico Politico article published pre-open on Wednesday discusses industry lobbying against the CMS proposed rules on state directed payments and the impact on federal funding for Medicaid. Trading update: THC (3.0%), HCA (1.7%), UHS (1.3%), CYH (1.0%) United Therapeutics lower following update on nebulized Tyvaso sNDA UTHR announced on Wednesday that FDA has accepted for review the sNDA for nebulized Tyvaso for the treatment of IPF. Company expects decision during late April 2027. Note: MNKD partners on the dry powder (DPI) formulation of Tyvaso, not the nebulized (liquid inhalation) form. uniQure shares volatile following upgrade and regulatory submissions QURE announced it has submitted BLA to FDA and MAA to UK MHRA, for AMT-130 in Huntington's Disease. (CLPT). Separately, QURE was resumed outperform at William Blair, an effective upgrade from the previous rating. PACS Group higher on Florida market entry PACS announces agreements to acquire the operations of 32 skilled nursing facilities (SNF) across Florida. Financial terms were not disclosed. Also comments on the Eduro Healthcare acquisition, PACS Group has now closed on 31 of the 34 facilities (deal announced 29-Jun-2026). Notable research in Healthcare today Pharma: JNJ assumed buy at UBS (Michael Yee), target $320 or approx. 18% upside. (FactSet average PT $278; range $210-305) Biotech: ALMS upgraded to buy from neutral at HC Wainwright (Mitchell Kapoor), target decreased however to $15 from $25 or approx. 58% upside. EYPT downgraded to hold from buy at TD Cowen (Tara Bancroft), cites LUGANO topline miss. Target cut to $4 from $20 or approx. 13% downside. TCRX downgraded to hold from buy at Needham (Gil Blum), cites strategic reorg. TCRX downgraded to neutral from outperform at Wedbush Securities (David Nierengarten), target cut to $1 from $5 or approx. 163% upside. QURE resumed outperform at William Blair (Sami Corwin), previous rating was market perform. VRTX resumed overweight at Morgan Stanley (Terence Flynn), target is $665 or approx. 21% upside. (FactSet average PT $572; range $350-672) VOGX initiated speculative buy at WBB Securities (Steve Brozak), target is $42 or approx. 27% upside. XTNT initiated buy at Lucid Capital Markets (Alex Nowak), target is $1 or approx. 170% upside. MedTech: SN.LN (SNN) downgraded to equal-weight from overweight at Morgan Stanley (Jack Reynolds-Clark), target cut to 1158p from 1304p or approx. 8% upside. (FactSet average PT 1265p; range 1050-1533p) BLLN initiated buy at Canaccord Genuity (Kyle Mikson), target is $120 or approx. 30% upside. CDNA initiated buy at Canaccord Genuity (Kyle Mikson), target is $65 or approx. 33% upside. MTD initiated sell at Rothschild & Co Redburn (Natalya Davies), target is $1200 or approx. 13% downside. (FactSet average PT $1473; range $1200-1600) TEM initiated overweight at Cantor Fitzgerald (Sarah James), target is $89 or approx. 43% upside. (FactSet average PT $66; range $35-100) Post-close news Trial results: RARE announced that the phase 3 ASPIRE trial evaluating apazunersen (GTX-102) in Angelman syndrome did not achieve the primary endpoint. Company is evaluating the next steps for the program. Shares of RARE trading (44.8%) in the after-hours; IONS (3.2%), ACAD and TSHA are flat On Deck: Corporate on Thu 3-Sep:CLYM hosting Investor event to discuss ph1 data in IgAN (8:00ET) Conference on Sat 5-Sep: European Respiratory Society (ERS) Congress (Sep 5-9) on Sat 5-Sep: European Epilepsy Congress (Sep 5-9) Holiday on Mon 7-Sep: US equity markets closed for Labor Day Holiday StreetAccount Healthcare Reads Deaths in Novartis CAR-T trial force a reckoning over acceptable risk in autoimmune disease (2-Sep) Endpoints News Hospitals say coming Trump administration rules are worse than GOP's Medicaid cuts (2-Sep) Politico The White House Can't Hype Away Healthcare Sticker Shock (1-Sep) Bloomberg (opinion) The CDC hasn't added 2 deaths to its measles database. Here's why. (31-Aug) WaPo This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 196170.KS, ACAD, ALGN, ALMS, ALNY, BIIB, BLLN, BMY, BRKR, CDNA, CLPT, CLYM, CNC, CRL, CYH, EYPT, FTRE, HALO, HCA, INCY, IONS, JNJ, MLYS, MMED, MNKD, MRK, MRNA, MTD, NOVN.SW, OABI, PACS, QURE, RARE, REGN, RPRX, RVTY, SN.LN, TCRX, TEM, TEVA, THC, TRAX, TSHA, UHS, UTHR, VOGX, VRTX, XNCR, XTNT...(more)	show story hide story
02-Sep-2026 16:14	Novartis follows Merck's route on recombinant hyaluronidase; deal potentially worth over $3B to Alteogen On Wednesday Novartis (NOVN.SW) and Alteogen (196170.KS) announced an option and license agreement for berahyaluronidase alfa (ALT-B4), the recombinant human hyaluronidase technology that underpins subcutaneous formulations of biologic drugs. Alteogen eligible to receive up to $3.2B in milestones across multiple Novartis programs. Alteogen's Hybrozyme platform is most recognized in subcutaneous Keytruda Qlex (MRK), and competes against Halozyme's (HALO) ENHANZE technology which is utilized by subcutaneous Opdivo Qvantig (BMY) and many other top-selling subcutaneous biologics. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: 196170.KS, BMY, HALO, MRK, NOVN.SW	show story hide story
02-Sep-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.90% vs the S&P 500 +0.51%. Most major health groups still higher on the session, but each is off initial highs, and the XBI currently (0.47%) has pulled back sharply from morning highs. ALGN +3% and MRNA (3%) are bracketing the XLV. Just a handful of modest decliners on the XLV including fractional declines for two large hospitals. Sector calendar and newsflow is very quiet as expected this week, ahead of the upcoming three-day weekend. Shares of MRNA getting a breather after rising another 10% yesterday. TEVA flat on today's midstage clinical results in celiac disease; read-across seen positive for TRAX +10%, among others. QURE (3%) volatile despite an upgrade and a regulatory submission in the UK. Standard review timeline for UTHR (3%) nebulized Tyvaso sNDA. Gainers +9.9% ALMS (Alumis): follow-through, shares were (57%) yesterday; upgraded at HCW +9.0% TRAX (First Tracks Biotherapeutics Inc): best performer on XBI; sympathy to TEVA +6.8% MMED (MiniMed Group): follow-through, shares were +11% yesterday on earnings +4.4% BRKR (Bruker): on average volume +4.2% FTRE (Fortrea Holdings): acquires bioanalytical lab operations from Early Phase +3.7% ALNY (Alnylam Pharmaceuticals): shares +8% WTD +3.4% ALGN (Align Technology): best performer on XLV +2.7% RVTY (Revvity): 52-week high; second-best on XLV +2.6% ISRG (Intuitive Surgical): shares +2% WTD +2.3% TEM (Tempus AI): initiation +1.2% JNJ (Johnson & Johnson): assumed buy at UBS, new street-high PT Decliners -5.3% EYPT (EyePoint Pharmaceuticals): downgraded at TD Cowen -4.1% ABSI (Absci Corp.): worst performer on XBI -3.6% MRNA (Moderna): worst performer on XLV; shares were up +10% yesterday -3.4% QURE (uniQure NV): upgraded at Wm Blair; submits MAA to UK MHRA -3.3% UTHR (United Therapeutics): FDA accepts neb. Tyvaso sNDA -0.3% UHS (Universal Health Services): one of eight decliners on XLV -0.2% HCA (HCA Healthcare): one of eight decliners on XLV	show story hide story
02-Sep-2026 08:56	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Sector calendar and newsflow is very quiet as expected this week, ahead of the upcoming three-day weekend. Teva Pharmaceutical with midstage results in celiac disease among the notable news. ADRs for TEVA +2% in the pre-market. uniQure submitted its MAA for Huntington's Disease in the UK; shares of QURE +4% in the pre-market. Yesterday, healthcare equities were mixed yet mostly higher. Another strong day for Moderna as investors continue to debate what to make of the melanoma breakthrough for INT; GSK also advanced a mRNA-based influenza vaccine. Macro S&P futures are slightly higher on Wednesday morning. Some signs of stabilization this morning with downside reversal in yields and oil. Nothing notable behind the move. Sentiment has been leaned cautious as of late with focus on higher rates, higher energy prices, hawkish central bank reaction functions, elevated geopolitical tensions, dampened positive macro surprise momentum and seasonal headwinds. Fairly quiet today as waiting game continues for NFP this Friday and more importantly for Fed policy, CPI on 11-Sep. Earnings calendar a relative bright spot with DELL offering the latest support for the insatiable AI compute/capex demand narrative. Mixed takeaways from the other notable tech reporters, while AVGO reports after the close. Pre-market trading update Trading higher +5.1% ALMS follow-through, shares were (57%) yesterday; upgraded at HCW +4.7% CLPT sympathy to QURE +3.9% QURE submits MAA to UK MHRA +2.0% TEVA trial results in celiac disease Trading lower -3.5% EYPT downgraded at TD Cowen -2.6% MRNA shares were up +10% yesterday -1.4% SNN downgraded at Morgan Stanley -1.3% TWST shares were down (5%) yesterday Pharma Trial results: TEVA announced topline results from the phase 2A trial of TEV-'408 in adults with celiac disease. Study met its primary endpoint, demonstrating stat sig and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8. Teva plans to present further data from the study at a future scientific meeting. Biotech Regulatory: QURE announced it has submitted MAA to UK MHRA for AMT-130 in Huntington's Disease. (CLPT) Research: ALMS upgraded to buy from neutral at HC Wainwright (Mitchell Kapoor), target decreased however to $15 from $25 or approx. 58% upside. EYPT downgraded to hold from buy at TD Cowen (Tara Bancroft), cites LUGANO topline miss. Target cut to $4 from $20 or approx. 13% downside. Life Science & MedTech Corporate: RMD announced an Accelerated Share Repurchase agreement with Citibank for $450M of common stock. Research: SN.LN (SNN) downgraded to equal-weight from overweight at Morgan Stanley (Jack Reynolds-Clark), target cut to 1158p from 1304p or approx. 8% upside. (FactSet average PT 1265p; range 1050-1533p) Services & Hospitals M&A: PACS announces agreements to acquire the operations of 32 skilled nursing facilities (SNF) across Florida. Financial terms were not disclosed. Also comments on the Eduro Healthcare acquisition, PACS Group has now closed on 31 of the 34 facilities (deal announced 29-Jun-2026). On Deck: Conference Jefferies Swiss Healthcare (Sep 2) on Sat 5-Sep: European Respiratory Society (ERS) Congress (Sep 5-9); European Epilepsy Congress (Sep 5-9) Corporate on Thu 3-Sep: CLYM hosting Investor event to discuss ph1 data in IgAN (8:00ET) Holiday on Mon 7-Sep: US equity markets closed for Labor Day Holiday This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALMS, CLPT, CLYM, EYPT, MRNA, PACS, QURE, RMD, SN.LN, SNN, TEVA, TWST...(more)	show story hide story
01-Sep-2026 17:19	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to mostly higher on Tuesday. At the market close, decliners narrowly outnumbered advancers on the XLV. Healthcare +0.66% vs the S&P 500 (0.71%). Most major health groups ended higher for the session, led by Managed Care and Pharma. MRNA +9.9% and RMD (3.6%) bracketed the XLV. CVS +3.9% outperformed for a second-straight day, whilst HUM +3% reaffirmed guidance, and all MCO peers joined in today with gains of +2% to +3% each. MedTech group today's laggard; August gains in bioproduction space peeled back. Earnings were back in focus today with Medtronic and its diabetes spin-off MiniMed each reporting. The large-cap device maker announced strategic investments in cardiovascular and robotic surgery, in addition to a fiscal Q1 beat-and-raise; MDT +1.5%, while MMED +10.7% following a more mixed fiscal Q1 print. GSK +0.8% announced that it will advance its mRNA seasonal flu vaccine to Phase 3; MRNA +9.9% higher in sympathy, today's top performer on the XLV. Novartis made multiple headlines on Tuesday. The drugmaker reported topline results from a phase 3 trial in relapsing Multiple Sclerosis with plans to submit regulatory applications; separately subject of a report by Endpoints News of CD19 CAR-T trial deaths. NVS higher +6.0% on the session. Humana reaffirmed its FY26 EPS outlook ahead of investor meetings in the month of September 2026. Also reminded investors that CMS' final Star Ratings for 2027 will be released in October 2026. Yesterday healthcare equities were lower but inline overall, the final trading session of August 2026, headlined with MRNA +156.0% and MRK +13.5% for the month. Investors continue to debate what to make of the melanoma breakthrough for INT. Sector notched its fourth-straight monthly advance, and third-straight month of outperforming the wider tape. Macro Market was on the defensive again today. Big focus on rising global bond yields; US 30Y yield up seven out of past nine sessions following brief August buyback relief. Narrative remains focused on fiscal imbalances, AI debt crowding-out, and inflationary pressure. No help from another day of rising oil on headlines about fresh US strikes on Iranian targets. WTI up 9%+ over past four sessions; more commentary on rising diesel prices as well. AI trade was weaker again with no great explanation for the move and more talk about the waiting game for Anthropic's S-1, though top-down capacity constraint dynamics have received some recent attention. Economic data missed expectations though still some moving pieces and nothing to shift the macro narrative, while next week's release of August CPI is what matters most for Fed. Sluggish start to the month fits with flurry of strategist commentary about numerous potential September headwinds, including weak seasonality, fading earnings tailwind and waning corporate bid. Notable Gainers +10.7% MMED (MiniMed Group): earnings +9.9% MRNA (Moderna): best performer on XLV and XBI; sympathy to GSK flu vaccine; MRNA was +156% in August +9.2% CTMX (CytomX Therapeutics): on 3X average volume; shares were +5% yesterday +8.0% NVAX (Novavax, Inc.): shares remain +51% YTD +6.3% VIR (Vir Biotechnology): 52-week high, shares +93% YTD +6.0% NVS (Novartis): trial results in relapsing MS; media reports on CAR-T trials paused +4.1% EXEL (Exelixis): on average volume +4.0% SMMT (Summit Therapeutics): on below average volume +3.9% CVS (CVS Health): outperformed second-straight day; second-best on XLV +3.7% STMN.SW (Straumann Holding): upgraded at UBS +3.1% REGN (Regeneron): on below average volume; shares +7% YTD +3.0% HUM (Humana): reaffirmed FY guidance ahead of investor meetings Notable Decliners -56.6% ALMS (Alumis): trial results in lupus (SLE) -16.5% ENOV (Enovis): acquires eCential Robotics in deal worth up to €211M -6.3% ERAS (Erasca): worst performing biotech on XBI; shares remain +351% YTD -6.1% RGEN (Repligen Corp.): shares were +28% in August; remain +4% YTD -5.0% TWST (Twist Bioscience): shares remain +316% YTD -4.5% MRVI (Maravai Lifesciences): shares were +16% in August; remain +125% YTD -3.6% RMD (ResMed): worst performer on XLV; shares (3%) YTD -3.1% DHR (Danaher): shares were +10% in August; currently (9%) YTD -3.0% ALGN (Align Technology): follow-through, stock lower 10 of last 12 days Earnings in Life Science & MedTech MDT reports Q1 EPS $1.45 ex-items vs FactSet $1.39 on revenue $9.76B vs FS $9.55B. Topline beat driven by Cardiovascular segment while MedSurg and Neuro segments were roughly inline. Raises low-end of FY EPS guidance by $0.04, raises FY revenue growth outlook by 50bps, including benefit from improved FX. Also announced strategic investments in both Cardio and Robotics. MMED reports Q1 EPS $0.00 on revenue $843M vs FactSet $826.8M; EPS not comparable to FactSet $0.12. Raises FY organic revenue outlook by 50bps, reaffirms adj EBITDA margin. Novartis trades higher on topline results in Multiple Sclerosis NOVN.SW (NVS) announced topline results from the phase 3 trials REMODEL-1 and REMODEL-2 evaluating remibrutinib (Rhapsido) in patients with relapsing Multiple Sclerosis (rMS). Studies met their primary endpoints. Data to be presented at MSToronto2026, and applications planned to regulatory authorities. Note: Rhapsido was approved by FDA eleven months ago for treatment of CSU. Novatis and Bristol Myers pause CAR-T programs An Endpoints News report highlights three patient deaths in the NOVN.SW (NVS) trials of CAR-T rapcabtagene autoleucel (rap-cel). Fierce Biotech confirmed with the drugmaker that it has temporarily halted the CD19 CAR-T program. Also confirmed with Bristol Myers (BMY) that their CD19 CAR-T program zola-cel has been voluntarily paused to review safety events. Alumis shares down sharply following negative results in SLE ALMS shares (54%) after its Phase 2b trials of envudeucitinib for moderate-to-severe SLE failed to meet primary or secondary endpoints in the overall trial populateion. Alumis notes that it intends to move forward with Phase 3 trials in a patient subpopulation. Quick Take: Well Fargo sees the stock reaction as overdone given credible path forward for Ph3 in the IFNGS-high subgroup. Cantor suggests a negative read-through to BMY POETYK-SLE-1 and -2 trials in SLE with readouts expected later in the year. Notable research in Healthcare today Biotech: CAPR upgraded to overweight from neutral at Piper Sandler (Edward Tenthoff), cites deramiocel developments. Target increased to $25 from $2 or approx. 152% upside. (FactSet average PT $29; range $2-60) BLSM seeing initial sell-side coverage following IPO on 6-Aug. Shares have traded +14% since pricing at $16/shr. All buy-equivalent ratings so far (Guggenheim, HC Wainwright, JPMorgan, Leerink, LifeSci Capital) with an average PT $32 or approx. 76% upside; range $28-36. LTGO seeing initial sell-side coverage following IPO on 7-Aug. Shares have traded +22% since pricing at $18/shr. All buy-equivalent ratings so far (Goldman Sachs, Guggenheim, Jefferies, Leerink) with an average PT $52 or approx. 137% upside; range $36-73. ACRS initiated buy at Canaccord Genuity (Edward Nash), target is $10 or approx. 65% upside. ASMB initiated buy at UBS (Ashwani Verma), target is $52 or approx. 55% upside. (FactSet average PT $52; range $43-62) NVCT assumed buy at Lucid Capital Markets (Elemer Piros)m target increased to $40 from $34 or approx. 76% upside. (FactSet average PT $34; range $30-39) VOGX initiated buy at Jones (Catherine Novack), target is $55 or approx. 62% upside. (Note: First sell-side coverage since the IPO on 12-Aug priced at $13/shr; shares have traded +162%.) VRTX added to the US Conviction List at Goldman Sachs. Life Science & MedTech: MYGN downgraded to underweight from overweight at Piper Sandler (David Westenberg) TEM upgraded to overweight from neutral at Piper Sandler (David Westenberg), target increased to $76 from $56 or approx. 21% upside. (FactSet average PT $63; range $35-100) MRK.GR upgraded to buy from hold at HSBC (Rajesh Kumar), target remains €170 or approx. 22% upside. (FactSet average PT €153; range €121-179) STMN.SW upgraded to buy from neutral at UBS (Graham Doyle), target increased to CHF115 from CHF90 or approx. 22% upside. (FactSet average PT $112; range CHF86-136) MTD initiated sector perform at RBC Capital Markets (Dan Leonard), target is $1515 or approx. 8% upside. RVTY initiated sector perform at RBC Capital Markets (Dan Leonard), target is $135 or approx. 5% upside. TXG initiated sector perform at RBC Capital Markets (Dan Leonard), target is $70 or approx. 12% upside. Post-close news Corporate: RMD announced an Accelerated Share Repurchase agreement with Citibank for $450M of common stock. ADRs trading UNCH in the after-hours M&A: PACS announces agreements to acquire the operations of 32 skilled nursing facilities (SNF) across Florida. Financial terms were not disclosed. Also comments on the Eduro Healthcare acquisition, PACS Group has now closed on 31 of the 34 facilities (deal announced 29-Jun-2026). Shares trading UNCH in the after-hours On Deck: Conference Jefferies Swiss Healthcare (Sep 2) on Sat 5-Sep: European Respiratory Society (ERS) Congress (Sep 5-9); European Epilepsy Congress (Sep 5-9) Corporate on Thu 3-Sep: CLYM hosting Investor event to discuss ph1 data in IgAN (8:00ET) Holiday on Mon 7-Sep: US equity markets closed for Labor Day Holiday StreetAccount Healthcare Reads The White House Can't Hype Away Healthcare Sticker Shock (1-Sep) Bloomberg (opinion) The CDC hasn't added 2 deaths to its measles database. Here's why. (31-Aug) WaPo President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans (31-Aug) White House Trump's Drug Pricing Deals Are a Farce (31-Aug) Public Citizen The Measles-Stricken Mother Who Lost Her Newborn Son (30-Aug) The Atlantic Measles deaths may have been 'fabricated,' RFK Jr claims after coroner raises questions (28-Aug) Fox News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACRS, ALGN, ALMS, ASMB, BLSM, BMY, CAPR, CLYM, CTMX, CVS, DHR, ENOV, ERAS, EXEL, HUM, LTGO, MDT, MMED, MRK.GR, MRNA, MRVI, MTD, MYGN, NOVN.SW, NVAX, NVCT, NVS, PACS, REGN, RGEN, RMD, RVTY, SMMT, STMN.SW, TEM, TWST, TXG, VIR, VOGX, VRTX...(more)	show story hide story
01-Sep-2026 15:14	StreetAccount Sector Summary: Healthcare Monthly Recap - August 2026 Month in Review: Healthcare equities outperformed for the month of August 2026. The S&P 500 Healthcare Index added +4.78% vs the S&P 500 Index +2.62%. Fourth straight month of gains for Healthcare, and third straight month of outperformance. Outperformers: Biotech, MedTech Underperformers: Services, Managed Care, Pharma Most major health groups were higher on their averages for the month, with the Services group skewed lower by the dialysis providers DaVita and Fresenius Medical Care. Earnings and M&A remained themes of the continued biotech strength that highlighted the month, but one clinical catalyst stood out, the positive interim analysis of INTerpath-001 trial evaluating mRNA-4157 in combination with Keytruda in patients with melanoma. The trial outcome drove over $73B in market-cap gains on 19-Aug for the personalized cancer vaccine partners, breathed new life into mRNA as a platform, and fueled competitors and boosted the mRNA supply chain. XBI +10.54% in August, green for the 13th time in the past 15 months. Large-cap biotech names ex-MRNA were also up low-teen percentages on average in August. Away from oncology, trial results in dermatomyositis and cystic fibrosis were top clinical drivers. In Pharma, ex-Merck the large-cap drugmakers were up just +1% on average, and most of that attributable to Pfizer, with its best month since the COVID pediatric jab and adult booster (Fall 2021). Q2 earnings beat, followed by $1M open-market stock purchase by Chairman & CEO Albert Bourla. In Animal Health a price battle took hold, and Elanco slipped (9%) on the pricing flex from Zoetis. Top 5 on the XLV: +156.0% MRNA, +40.2% VEEV, +24.0% CRL, +14.4% RVTY, +14.1% VRTX Bottom 5 on the XLV: -26.7% DVA, -10.1% PODD, -10.1% CVS, -6.0% UNH, -6.0% VTRS Year-to-date, Healthcare +9.88% vs the S&P 500 +12.28%. Healthcare sixth out of eleven major sectors in CY26. Energy +41.38% and Utilities (1.60%) bracket them all. Five IPOs in August, twenty-six YTD 2026: versus four in August 2025 / twenty-four YTD 2025 cumulatively raised $7.64B YTD vs $2.91B YTD 2025 VOGX +161.5% - raised $81M - Biotech BRVE +41.7% - raised $382M - Biotech ATTO +25.9% - raised $289M - Biotech LTGO +22.3% - raised $345M - Biotech BLSM +14.4% - raised $150M - Biotech Notable movers for the month: Gainers: CAPR +157.4% - FDA extends PDUFA goal date three months for planned amendment; best performer on XBI ARCT +156.3% - sympathy to MRNA MRNA +156.0% - trial results with INT in melanoma w/ MRK; best performer on XLV (and second-best on XBI) TEM +43.7% - pending acquisition of PSNL which is contracted with MRNA for tumor profiling VEEV +40.2% - software recovery; earnings CRL +24.0% - earnings; upgraded at JPMorgan ARGX +20.3% - trial results in dermatomyositis ALNY +17.1% - upgraded at Raymond James; shares were (32%) in prior month RVTY +14.4% - bioprocessing read-across from MRNA news VRTX +14.1% - sympathy to SION MRK +13.5% - trial results with INT in melanoma w/ MRNA Decliners: SION (87.2%) - trial results in Cystic Fibrosis; worst performer on XBI BLLN (34.6%) - earnings DVA (26.7%) - earnings; upgraded at TD Cowen; worst performer on XLV FMS (11.4%) - earnings, LT growth outlook PODD (10.1%) - earnings, guidance; multiple downgrades in reaction CVS (10.1%) - earnings, guidance Related: ALNY, ARCT, ARGX, ATTO, BLLN, BLSM, BRVE, CAPR, CRL, CVS, DVA, FMS, LTGO, MRK, MRNA, PODD, PSNL, RVTY, SION, UNH, VEEV, VOGX, VRTX, VTRS...(more)	show story hide story
01-Sep-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.62% vs the S&P 500 (0.46%). Most major health groups are higher, with Managed Care leading the advancers while MedTech is the only group in the red. Calendar turns to September, and earnings are back on the tape with Medtronic and its diabetes spin-off, MiniMed. The large-cap device maker announced strategic investments in cardiovascular and robotic surgery, in addition to a fiscal Q1 beat-and-raise. MDT +1%. Shares of MMED +8% following a mixed fiscal Q1 update. Elsewhere, GSK announced that it will advance its mRNA seasonal flu vaccine to Phase 3, with MRNA +4% in sympathy, topping the XLV. Gainers +7.8% MMED (MiniMed Group): earnings +6.1% CAPR (Capricor Therapeutics): upgraded at Piper Sandler; best performer on XBI +6.0% NVS (Novartis): trial results in rMS; Endpoints News report on CAR-T trials +3.5% MRNA (Moderna): shares were +156% in August; sympathy to GSK flu vaccine; best performer on the XLV +3.5% STMN.SW (Straumann Holding): upgraded at UBS +3.5% CVS (CVS Health): second-best on the XLV +1.4% SNN (Smith & Nephew): on high volume +1.1% MRK.GR (Merck KGaA): upgraded at HSBC +0.9% GSK (GSK Plc): advancing mRNA-based flu vaccine into phase 3 trial +0.9% MDT (Medtronic): announces strategic investments; earnings +0.8% TEM (Tempus AI): upgraded at Piper Sandler Decliners -54.4% ALMS (Alumis): trial results in SLE -6.7% MYGN (Myriad Genetics): downgraded at Piper Sandler; worst performer on XBI -2.3% RMD (ResMed): worst performer on XLV -2.2% LTGO (Latigo Biotherapeutics): initiations -1.4% RVTY (Revvity): initiation	show story hide story
01-Sep-2026 08:21	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Calendar turn to September, and Earnings back on the tape with Medtronic and its Diabetes spin-off MiniMed. The large-cap devicemaker announced strategic investments cardio and robotic surgery, in addition to a fiscal Q1 beat-and-raise. Shares of MDT +5% in the pre-market. Shares of MMED (4%) following a mixed fiscal Q1 update. ADRs for Novartis higher +5% in the pre-market. Drugmaker reported topline results from a phase 3 trial in relapsing Multiple Sclerosis with plans to submit regulatory applications; separately subject of a report by Endpoints News of CD19 CAR-T trial deaths. Yesterday healthcare equities were lower but inline overall, the final trading session of August 2026, headlined with MRNA +156.0% and MRK +13.5% for the month. Investors continue to debate what to make of the melanoma breakthrough for INT. Sector notched its fourth-straight monthly advance, and third-straight month of outperforming the wider tape. Macro S&P futures are down (0.5%) on Tuesday morning. Global bond yield backup the big story this morning with seemingly every major financial outlet running the same story about the pressure from fiscal dynamics, higher oil and corporate supply/AI capex boom. Higher oil in focus again with recent pickup in kinetic activity in the Middle East. Two oil supertankers were struck by unknown projectiles in the SoH today. This has overshadowed another call from Iran's president for Washington and Tehran to return to the MoU. Semis and memory under some premarket pressure despite the latest support for the AI compute/capex demand narrative from the Anthropic/Lambda deal (though it also plays into circular financing concerns). Pre-market trading update Trading higher +5.2% MDT announces strategic investments; earnings; call at 745ET +5.0% NVS trial results in rMS; Endpoints News report on CAR-T trials +4.6% LTGO initiations +4.5% CAPR upgraded at Piper Sandler +3.3% STMN.SW in European trading; upgraded at UBS +2.7% TEM upgraded at Piper Sandler +2.3% SNN on 21K ADS +1.8% MRK.GR in European trading; upgraded at HSBC +0.5% GSK advancing mRNA-based flu vaccine into phase 3 trial Trading lower -8.1% MYGN downgraded at Piper Sandler -3.8% MMED earnings; call at 845ET -2.3% ALMS shares halted; trial results in SLE -2.3% RVTY initiation -2.1% MRNA shares were +156% in August; sympathy to GSK flu vaccine -2.0% SMMT on 25K shares -1.3% ONC follow-through Tuesday AM conference call - Healthcare 7:45ET earnings call: MDT 8:30ET ALMS to discuss phase 2 LUMUS trial results envudeutcitinib in SLE 8:30ET ENOV to discuss acquisition of eCential Robotics (private) 8:45ET earnings call: MMED Biotech Trial results: ALMS announced that their phase 2B trial LUMUS evaluating envudeucitinib for SLE did not meet its primary endpoint and secondary endpoints in the overall trial population. Shares halted for news Conf. call at 8:30ET Corporate: INCY While not present at the Oval Office meeting on Monday or mentioned by name by the President, disclosed late Monday that it will provide Medicaid access to Jakafi XR at MFN pricing. Research: CAPR upgraded to overweight from neutral at Piper Sandler (Edward Tenthoff), cites deramiocel developments. Target increased to $25 from $2 or approx. 152% upside. (FactSet average PT $29; range $2-60) BLSM seeing initial sell-side coverage following IPO on 6-Aug. Shares have traded +14% since pricing at $16/shr. All buy-equivalent ratings so far (Guggenheim, HC Wainwright, JPMorgan, Leerink, LifeSci Capital) with an average PT $32 or approx. 76% upside; range $28-36. LTGO seeing initial sell-side coverage following IPO on 7-Aug. Shares have traded +22% since pricing at $18/shr. All buy-equivalent ratings so far (Goldman Sachs, Guggenheim, Jefferies, Leerink) with an average PT $52 or approx. 137% upside; range $36-73. ACRS initiated buy at Canaccord Genuity (Edward Nash), target is $10 or approx. 65% upside. ASMB initiated buy at UBS (Ashwani Verma), target is $52 or approx. 55% upside. (FactSet average PT $52; range $43-62) NVCT assumed buy at Lucid Capital Markets (Elemer Piros)m target increased to $40 from $34 or approx. 76% upside. (FactSet average PT $34; range $30-39) VOGX initiated buy at Jones (Catherine Novack), target is $55 or approx. 62% upside. (Note: First sell-side coverage since the IPO on 12-Aug priced at $13/shr; shares have traded +162%.) VRTX added to the US Conviction List at Goldman Sachs. Pharma Trial results: NOVN.SW (NVS) announced topline results from the phase 3 trials REMODEL-1 and REMODEL-2 evaluating remibrutinib (Rhapsido) in patients with relapsing Multiple Sclerosis (rMS). Studies met their primary endpoints. Data to be presented at MSToronto2026, and applications planned to regulatory authorities. Note: Rhapsido was approved by FDA eleven months ago for treatment of CSU. GSK.LN (GSK) presented positive phase 2 data for its mRNA seasonal flu vaccine and announced it will begin a phase 3 efficacy trial with FLUm3HA.b-3NA in September 2026. Note: Moderna's (MRNA) mFlusiva, an mRNA-based seasonal flu vaccine, was recently approved by the FDA for the upcoming season. Media reports: NOVN.SW (NVS) subject of a report by Endpoints News overnight. The report highlights three patient deaths in Novartis trials of CAR-T rapcabtagene autoleucel (rap-cel). Fierce Biotech confirmed with the drugmaker that it has temporarily halted the CD19 CAR-T program. Also confirmed with Bristol Myers (BMY) that their CD19 CAR-T program zola-cel has been paused to review safety events. Life Science & MedTech Earnings: MDT reports Q1 EPS $1.45 ex-items vs FactSet $1.39 on revenue $9.76B vs FS $9.55B. Topline beat driven by Cardiovascular segment while MedSurg and Neuro segments were roughly inline. Raises low-end of FY EPS guidance by $0.04, raises FY revenue growth outlook by 50bps, including benefit from improved FX. Also announced strategic investments in both Cardio and Robotics. Conf. call at 7:45ET MMED reports Q1 EPS $0.00 on revenue $843M vs FactSet $826.8M; EPS not comparable to FactSet $0.12. Raises FY organic revenue outlook by 50bps, reaffirms adj EBITDA margin. Conf. call at 8:45ET Research: MYGN downgraded to underweight from overweight at Piper Sandler (David Westenberg) TEM upgraded to overweight from neutral at Piper Sandler (David Westenberg), target increased to $76 from $56 or approx. 21% upside. (FactSet average PT $63; range $35-100) MRK.GR upgraded to buy from hold at HSBC (Rajesh Kumar), target remains €170 or approx. 22% upside. (FactSet average PT €153; range €121-179) STMN.SW upgraded to buy from neutral at UBS (Graham Doyle), target increased to CHF115 from CHF90 or approx. 22% upside. (FactSet average PT $112; range CHF86-136) MTD initiated sector perform at RBC Capital Markets (Dan Leonard), target is $1515 or approx. 8% upside. RVTY initiated sector perform at RBC Capital Markets (Dan Leonard), target is $135 or approx. 5% upside. TXG initiated sector perform at RBC Capital Markets (Dan Leonard), target is $70 or approx. 12% upside. Managed Care Corporate: HUM reaffirms FY26 EPS outlook ahead of investor meetings in the month of September 2026. Reminder that CMS final Star Ratings for 2027 will be released in October 2026. On Deck: Conference on Wed 2-Sep: Jefferies Swiss Healthcare (Sep 2) on Sat 5-Sep: European Respiratory Society (ERS) Congress (Sep 5-9); European Epilepsy Congress (Sep 5-9) Corporate on Thu 3-Sep: CLYM hosting Investor event to discuss ph1 data in IgAN (8:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACRS, ALMS, ASMB, BLSM, BMY, CAPR, CLYM, ENOV, GSK, GSK.LN, HUM, INCY, LTGO, MDT, MMED, MRK.GR, MRNA, MTD, MYGN, NOVN.SW, NVCT, NVS, ONC, RVTY, SMMT, SNN, STMN.SW, TEM, TXG, VOGX, VRTX...(more)	show story hide story
31-Aug-2026 17:26	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly lower, yet inline overall on Monday. Decliners beat advancers by nearly 2:1 on the XLV. Healthcare (0.42%) vs S&P 500 (0.33%). Almost all major health groups ended lower on the averages. Biotech an outlier, turning slightly positive into the close following White House drug pricing announcements. Another nine companies joined the Oval Office parade, including some mid-sized drugmakers. XBI +0.07% higher on the session, inclusive of Monday's M&A newsflow. VEEV +3.3% and DVA (2.6%) bracketed the XLV. LLY (1.5%) one of today's top decliners on the XLV after paying up to $2.9B for privately-held Merida Biosciences. Targeted asset an early-stage autoimmune treatment for Graves and TED. CVS +0.9% the lone advancer amongst Payers; Leerink reiterated outperform and believes post-earnings pullback is overdone. MCK (0.9%) whilst investors evaluate the cybersecurity incident disclosure made Friday post-close. One notable biopharma acquisition on the tape Monday morning - Eli Lilly buying Merida Biosciences for up to $2.875B. Targeted lead asset is phase 1 development for Graves disease and TED. Another cybersecurity incident disclosed late Friday. McKesson says it was targeted on 25-Aug, same day as the Boston Scientific incident last week. BMO discusses the need for cybersecurity investment by MedTech. Final session of trading in August 2026, and MRNA finished +156.0%, MRK +13.5%. Investors continue to debate what to make of the melanoma breakthrough for INT. Overall the XLV +4.78% higher in the month of August, beaten only by Energy, Tech and Materials sectors. Healthcare notched its fourth-straight monthly advance, and third-straight month of outperforming the wider tape. Macro Stocks lower in a very quiet session with latest Middle East escalation/higher oil seemingly the excuse. Rates remain in focus with a lot of moving pieces in the takeaways surrounding Warsh's Jackson Hole speech last Friday. Market now pricing ~38 bp of hikes through year-end, highest in over a month (since before July FOMC meeting). Treasury Secretary Bessent said Monday Treasury, Fed in alignment on bonds, but argued policymakers historically don't tighten in response to policy shocks. Very quiet elsewhere in wait for catalysts later this week (ISM manufacturing, AI and software earnings, Fed's Waller, August NFP). Notable Gainers +6.1% ASND (Ascendis Pharma): settlement with BMRN over Yuviwel royalties +4.8% ALVO (Alvotech): FDA accepts BLA for Entyvio biosimilar AVT80 +4.7% CTMX (CytomX Therapeutics): best performing biotech on XBI +3.4% ATTO (Attovia Therapeutics): initiations +3.3% VEEV (Veeva Systems): shares were +12% last week; +40% in August +3.1% BSX (Boston Scientific): FDA clearance for SEISMIQ IVL; best performer on XLV +2.5% JAZZ (Jazz Pharmaceuticals): trial results in GEA with ONC +2.4% PODD (Insulet): stock down (10%) in August +2.4% PTGX (Protagonist Therapeutics): FDA approves Mimrylo +1.8% PFE (Pfizer): stock +14% in August Notable Decliners -15.9% TECX (Tectonic Therapeutic): sympathy to AZN oral relaxin data at ESC -13.6% TENX (Tenax Therapeutics): downgraded at Guggenheim -7.1% BRVE (Braveheart Bio): initiations -4.6% OVID (Ovid Therapeutics): worst performer on XBI; stock +64% in August -3.8% FDMT (4D Molecular Therapeutics): stock +39% in August -3.0% ARWR (Arrowhead Pharmaceuticals): presentation at ESC -2.6% DVA (DaVita): worst performer on XLV; stock (27%) in August Boston Scientific higher on FDA clearance of SEISMIQ IVL BSX +3.1% on Monday afternoon, a leading advancer on the XLV after receiving FDA clearance for the SEISMIQ IVL system. 510(k) clearance published on the FDA website on Monday. Piper Sandler analyst Matt O'Brien sees a differentiated IVL system contributing to the company's topline growth in the coming years. M&A Monday in biopharma, Eli Lilly buying in autoimmune disorders Privately-held Merida Biosciences acquired by Eli Lilly (LLY) for up to $2.875B in cash. Their lead program, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease (TED). Tectonic Therapeutics lower following competitor data at ESC; analysts remain upbeat on relaxin and TECX Shares of TECX (14%) on Monday morning, after AstraZeneca presented AZD5462 at the ESC Congress. Takeaways by sell-side analysts were largely supportive of relaxin as a meaningful therapeutic target, with several viewing the data as a validation of the target, supporting further development of TX45. Lack of safety signals a key positive read-through, including Stifel which highlighted data as heavily nuanced. StreetAccount notes that sell-side maintains an unanimous buy rating (10/10) on TECX. Press release for the LUMINARA trial with AZD5462 is also linked here. McKesson lower but inline following disclosure of cybersecurity incident MCK post-close on Friday disclosed a cybersecurity incident was discovered on 25-Aug. Company has not yet determined whether the incident is material or likely to have a material impact on the company. Note: BSX on 26-Aug disclosed a cybersecurity incident that occurred on 25-Aug. BMO Capital Markets wrote about the need for increased investment by MedTech. Bayer, Takeda, CSL, others expected to announce drug pricing agreements with White House - media reports White House drug pricing agreements expanding beyond the seventeen large pharma companies that announced Fall 2025 / early 2026. Reuters notes that White House event scheduled for 15:00ET on Monday. Headline companies include Bayer, Takeda, CSL Ltd, and other mid-size biotechs are expected. Last week Bloomberg reported that several midsized biotechs were set to announce drug price discounts. White House confirms nine additional MFN drug price agreements Fact Sheet Nine new agreements -- Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB -- brings total to twenty-six since the Pfizer agreement in the Fall of 2025. Each of these manufacturers has agreed to fundamentally rebalance international drug pricing by providing MFN pricing to American patients. President Trump is calling on Congress to codify these agreements Refilling the Biotech IPO pipeline +ETRA Electra Therapeutics Inc filed for IPO of indeterminate amount. The company is a clinical-stage biotech with focus on precision medicines for immune-mediated diseases and oncology. Notable research in Healthcare today Biotech: TENX downgraded to neutral from buy at Guggenheim Securities (Seamus Fernandez) ATTO seeing initial sell-side coverage following IPO on 5-Aug. Shares have traded +22% since pricing at $17/shr. All buy-equivalent ratings so far (Citi, Leerink, LifeSci, Morgan Stanley, RBC) with an average PT $42 or approx. 104% upside; range $30-52. BRVE seeing initial sell-side coverage following IPO on 6-Aug. Shares have traded +52% since pricing at $18/shr. All buy-equivalent ratings so far (Cantor, Goldman Sachs, Jefferies, Stifel, TD Cowen) with an average PT $45 or approx. 65% upside; range $40-48. QNTM initiated buy at Rodman & Renshaw (Michael King), target is $8 or approx. 160% upside. SCTX initiated buy at HC Wainwright (Mitchell Kapoor), target is $60 or approx. 111% upside. MedTech: SNN initiated neutral at BTIG (Ryan Zimmerman) BMO Capital Markets analyst Vik Chopra writes about the need for MedTech investments on cybersecurity. (BSX, SYK) Managed Care: CVS Leerink Partners analyst Michael Cherny believes that the post-earnings stock reaction to Health Services Segment headwinds are overdone. Reiterates outperform rating and $119 price target, or approx. 28% upside. Post-close news Research: VOGX initiated buy at Jones (Catherine Novack), target is $55 or approx. 62% upside. Note: First sell-side coverage since the IPO on 12-Aug priced at $13/shr; shares have traded +162%. On Deck: Regulatory during August: AZN FDA PDUFA (estimated date) for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (follows 3-month extension announced 27-May; brand name ETCAMAH in EU) Earnings tomorrow morning: MDT (call at 7:45ET), MMED (call at 8:45ET) Conference on Wed 2-Sep: Jefferies Swiss Healthcare (Sep 2) Imminent / event-driven trial readout: NOVN.SW (NVS) phase 3 CVOT results for HORIZON study evaluating ASO pelacarsen for prevention of ASCVD in patients with elevated Lp(a) Read-across for AMGN and LLY This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4151.JP, 4503.JP, 524715.IN, ALC, ALVO, AMGN, ARWR, ASND, ATTO, AZN, BBIO, BRVE, BSX, CSL.AU, CTMX, CVS, DVA, FDMT, JAZZ, LLY, MCK, MDT, MMED, NVS, ONC, OVID, PFE, PODD, PTGX, QNTM, SCTX, SNN, SYK, TECX, TENX, TEVA, UCB.BB, VEEV, VOGX...(more)	show story hide story
31-Aug-2026 15:29	White House confirms 9 new MFN agreements with drug manufacturers including midsized biotech Nine new agreements -- Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB -- brings total to twenty-six since the Pfizer agreement in the Fall of 2025. Each of these manufacturers has agreed to fundamentally rebalance international drug pricing by providing MFN pricing to American patients. President Trump is calling on Congress to codify these agreements. See Related StreetAccount comments: 8/31/2026 3:07:02 PM - BeOne Medicines announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients 8/31/2026 1:32:03 PM - Bayer, Takeda, CSL, others expected to announce drug pricing agreements with White House - media reports Related: 4151.JP, 4503.JP, 524715.IN, ALC, BBIO, CSL.AU, ONC, TEVA, UCB.BB...(more) Reference Link	show story hide story
31-Aug-2026 13:32	Bayer, Takeda, CSL, others expected to announce drug pricing agreements with White House - media reports White House drug pricing agreements expanding beyond the seventeen large pharma companies that announced Fall 2025 / early 2026. Reuters notes that White House event scheduled for 15:00ET on Monday. Headline companies include Bayer, Takeda, CSL Ltd, and other mid-size biotechs are expected. Last week Bloomberg reported that several midsized biotechs were set to announce drug price discounts. See Related StreetAccount comments: 8/26/2026 12:45:39 PM - Trump administration reportedly reaches drug pricing agreements with biotech companies -- Bloomberg Related: 4502.JP, BAYN.GR, CSL.AU Reference Link: Reuters	show story hide story
31-Aug-2026 11:29	TECX Tectonic Therapeutics lower following competitor data at ESC; analysts remain upbeat on relaxin and TECX ($30.86 -$4.76) Shares of TECX (14%) on Monday morning, after AstraZeneca presented AZD5462 at the ESC Congress. Takeaways by sell-side analysts were largely supportive of relaxin as a meaningful therapeutic target, with several viewing the data as a validation of the target, supporting further development of TX45. Lack of safety signals a key positive read-through, including Stifel which highlighted data as heavily nuanced. StreetAccount notes that sell-side maintains an unanimous buy rating (10/10) on TECX. Press release for the LUMINARA trial with AZD5462 is also linked below. Related: AZN Reference Link	show story hide story
31-Aug-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is inline with the S&P 500 Healthcare Index (0.47%) vs the S&P 500 (0.45%). All major health groups are lower on the averages; Biotech today's leading decliner despite the Monday M&A newsflow. XBI (1.20%). BSX +4% and ABT (2%) bracket the XLV. LLY (2%) another top decliner on XLV after paying up to $2.9B for privately-held Merida Biosciences. Targeted asset an early-stage autoimmune treatment for Graves and TED. CVS +0.3% leading a lightly mixed Payers group; Leerink reiterated outperform and believes post-earnings pullback is overdone. MCK (1%) inline despite the cybersecurity incident disclosure. Gainers +6.2% ASND (Ascendis Pharma): settlement with BMRN over Yuviwel royalties +5.5% NVAX (Novavax, Inc.): best performer on XBI; shares +33% MTD +5.2% ALVO (Alvotech): FDA accepts BLA for Entyvio biosimilar AVT80 +4.1% BSX (Boston Scientific): best performer on XLV +3.0% VEEV (Veeva Systems): shares were +12% last week +2.5% MRNA (Moderna): shares 157% MTD +2.0% JAZZ (Jazz Pharmaceuticals): trial results in gastroesophageal adenocarcinoma (ONC) +1.0% BMRN (Biomarin Pharmaceutical): settlement with ASND over Yuviwel royalties Decliners -12.9% TENX (Tenax Therapeutics): downgraded at Guggenheim -12.4% TECX (Tectonic Therapeutic): on heavy volume -5.9% BRVE (Braveheart Bio): initiations -4.8% RGNX (REGENXBIO): worst performer on XBI -4.5% ERAS (Erasca): shares remain +364% YTD -3.9% ARWR (Arrowhead Pharmaceuticals): presentation at ESC -3.4% ONC (BeOne Medicines): trial results in gastroesophageal adenocarcinoma w JAZZ -2.3% ATTO (Attovia Therapeutics): initiations -1.9% CRSP (CRISPR Therapeutics): shares were (3%) last week and +20% MTD -1.9% ABT (Abbott Labs): despite tricuspid presentation at ESC and NEJM publication; worst performer on XLV -1.7% LLY (Eli Lilly): acquires Merida for up to $2.88B -1.0% VRDN (Viridian Therapeutics): sympathy to LLY-Merida Biosciences	show story hide story
31-Aug-2026 08:44	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis One notable biopharma acquisition on the tape Monday morning - Eli Lilly buying Merida Biosciences for up to $2.875B. Targeted lead asset is phase 1 development for Graves disease and TED. Another cybersecurity incident disclosed late Friday. McKesson says it was targeted on 25-Aug, same day as the Boston Scientific incident last week. BMO discusses the need for cybersecurity investment by MedTech. Final session of trading in August 2026, and MRNA +152% MTD and MRK +14% MTD. Investors continue to debate what to make of the melanoma breakthrough for INT. MSD gain for Healthcare overall in August, edged only by Materials and Tech sectors. Healthcare on track for a fourth-straight monthly advance, and third-straight month of outperformance. Macro S&P futures are down (0.3%) on Monday morning. Oil higher with re-escalation of kinetic activity in the Middle East. Also skepticism about any near-term impact from US-Venezuela oil deal that grabbed a lot of headlines this weekend. Rates lower despite higher oil. While Warsh's speech last Friday was hawkish on inflation, also thoughts it does not necessarily seal the deal for a September rate hike. Pretty quiet overall heading into month-end and what is expected to be a fairly quiet week ahead (even with some high-profile macro data) of the Labor Day holiday next Monday in the US. Strong US corporate profit backdrop, Big Tech earnings tailwind from investments in AI companies, momentum factor underperformance, weak September seasonality, AI capex boom still early days, surge in diesel and food costs and this week's G20 finance meeting (where Bessent will push for Iran sanctions and reducing trade imbalances with China) some of the recent topics in the financial press. Pre-market trading update Trading higher +6.9% ATTO initiations (low volume) +4.7% BRVE initiations (low volume) +3.0% BMRN settlement with ASND over Yuviwel royalties +2.6% SLS shares were (15%) last week +0.5% CVS Leerink comments on recent underperformance +0.4% TAK FDA approves Mimrylo; PTGX hosting call at 830ET +0.2% JAZZ trial results in gastroesophageal adenocarcinoma (ONC) Trading lower -2.8% MRNA shares were (5%) last week and +152% MTD -2.8% CRSP shares were (3%) last week and +20% MTD -1.9% VRDN sympathy to LLY-Merida Biosciences (low volume) -1.4% ARWR presentation at ESC; call at 800ET -0.6% PTGX FDA approves Mimrylo; call at 830ET Pharma Regulatory: TAK FDA announced it has approved Mimrylo (rusfertide) as treatment for adults with polycythemia vera (PV). PDUFA date was expected during August 2026. (PTGX, RPRX, ZEAL.DC) PTGX will host an approval call on Monday morning (8:30ET) JNJ FDA announced it has approved two pediatric indications for Stelara - for Ulcerative Colitis (UC) and for Crohn's Disease (CD) - in patients two years and older. Trial results: LLY announced new 52-week data from the phase 3B trials evaluating concomitant use of Taltz and Zepbound in plaque psoriasis or psoriatic arthritis. Recall 36-week data was stat-sig. 52-week data showed improvements were maintained or further improved. Data will be presented at medical meetings. Biotech M&A: Privately-held Merida Biosciences acquired by Eli Lilly (LLY) for up to $2.875B in cash. Their lead program, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease (TED). Regulatory: 6446.TT (PharmaEssentia) On the FDA PDUFA goal date, the agency approved Besremi sNDA for adults with essential thrombocythemia (ET). ALDVI.FP (Advicenne) announced it has withdrawn the NDA for Sibnayal in dRTA. The PDUFA goal date was Thursday 3-Sep. Research: TENX downgraded to neutral from buy at Guggenheim Securities (Seamus Fernandez) ATTO seeing initial sell-side coverage following IPO on 5-Aug. Shares have traded +22% since pricing at $17/shr. All buy-equivalent ratings so far (Citi, Leerink, LifeSci, Morgan Stanley, RBC) with an average PT $42 or approx. 104% upside; range $30-52. BRVE seeing initial sell-side coverage following IPO on 6-Aug. Shares have traded +52% since pricing at $18/shr. All buy-equivalent ratings so far (Cantor, Goldman Sachs, Jefferies, Stifel, TD Cowen) with an average PT $45 or approx. 65% upside; range $40-48. SCTX initiated buy at HC Wainwright (Mitchell Kapoor), target is $60 or approx. 111% upside. IPO filing: +ETRA Electra Therapeutics Inc filed for IPO of indeterminate amount. The company is a clinical-stage biotech with focus on precision medicines for immune-mediated diseases and oncology. Life Science & MedTech Research: SNN initiated neutral at BTIG (Ryan Zimmerman) BMO Capital Markets analyst Vik Chopra writes about the need for MedTech investments on cybersecurity. (BSX, SYK) Services & Hospitals Corporate: MCK post-close on Friday disclosed a cybersecurity incident was discovered on 25-Aug. Company has not yet determined whether the incident is material or likely to have a material impact on the company. Note: BSX on 26-Aug disclosed a cybersecurity incident that occurred on 25-Aug. Managed Care Research: CVS Leerink Partners analyst Michael Cherny believes that the post-earnings stock reaction to Health Services Segment headwinds are overdone. Reiterates outperform rating and $119 price target, or approx. 28% upside. On Deck: Conference (cont.): European Society of Cardiology (ESC) 2026 (Aug 28-31) on Wed 2-Sep: Jefferies Swiss Healthcare (Sep 2) Regulatory during August: AZN FDA PDUFA (estimated date) for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (follows 3-month extension announced 27-May; brand name ETCAMAH in EU) Earnings on Tue morning: MDT (call at 7:45ET), MMED (call at 8:45ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 6446.TT, ALDVI.FP, ARWR, ATTO, AZN, BMRN, BRVE, BSX, CRSP, CVS, JAZZ, JNJ, LLY, MCK, MDT, MMED, MRNA, PTGX, RPRX, SCTX, SLS, SNN, SYK, TAK, TENX, VRDN, ZEAL.DC, +ETRA...(more)	show story hide story
28-Aug-2026 21:28	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished mostly lower and inline overall on Friday. Decliners outnumbered advancers on the XLV. Healthcare (0.25%) vs S&P 500 (0.25%). All major health groups ended red on their averages; only Managed Care with a modest gain for the week. ZTS +3.1% and MRNA (3.3%) bracketed the XLV. Biotech group leading decliner, the XBI fell (3.48%) turning red for the week after closing at ATH on Tuesday. Biopharma's focus today quickly jumped from Munich to Mainz (Germany) with the negative surprise update by BNTX (8.4%) and Genentech; ROP.SW ended lower (1.5%). The companies which are jointly developing an individualized mRNA cancer immunotherapy (similar to Moderna-Merck) announced that their mid-stage trial in colorectal cancer would end early following a futility analysis by the DSMB. In Munich, the ESC Congress 2026 is well underway, after AZN (1.1%) and IONS (2.2%) presented detailed data on their failed phase 3 trial of eplontersen in ATTR-CM, while CYTK (7.5%) detailed data on its phase trial of aficamten in nHCM. ALNY +0.2% fully recovered from initial morning lows, in read-through from AstraZeneca. Macro Big backup in yields weighed on stocks (and debasement plays) amid sizable post-Warsh bear steepening move driven by more hawkish rate hike path pricing. Warsh's Jackson Hole speech leaned hawkish on the inflation side of the equation, though along with commitment to 2% PCE inflation targets and rates as the primary policy tool, likely helps from a credibility perspective following some of the July FOMC meeting takeaways. Nothing on longer-term yields amid perceived tension with Treasury buyback boost, while AI commentary was upbeat. Market now sees 56% chance of September rate hike, 38 bp of hikes through year-end (up 10 bp d/d). Pretty quiet elsewhere. Tech a laggard (after driving all of the market strength on Thursday) with several notable reporters up against a high bar. Nothing particularly incremental on US-Iran conflict with oil down this week on some semblance of perceived diplomatic traction and pickup in SoH "dark crossings." Russia-Ukraine conflict escalation has grabbed more attention this week with the spike in wheat costs. Notable Gainers on Friday: +3.4% APMD (Apnimed): shares +6% for the week (initiations) +3.1% RGNX (REGENXBIO): best performer on XBI; shares (10%) for the week +3.1% ZTS (Zoetis): light volume; best performer on XLV; shares flat for the week +2.7% SYK (Stryker): second-best on XLV; shares flat for the week +2.6% PRTA (Prothena): on average volume; second-best on XBI +2.3% NVAX (Novavax, Inc.): FDA authorizes COVID-19 vaccines for '26-27 season Notable Decliners on Friday: -19.6% KZIA (Kazia Therapeutics): trial results in TNBC; secondary offering -13.1% SLS (SELLAS Life Sciences Group, Inc.): worst performer on XBI; shares were +11% yesterday -9.8% XNCR (Xencor): on nearly 2X average volume -8.9% HIMS (Hims & Hers Health): shares (15%) for the week -8.4% BNTX (BioNTech): terminates ph2 trial in CRC; FDA authorizes COVID-19 vaccines for '26-27 season -7.6% ROIV (Roivant Sciences): follow-through (FDA approval); announces WAC price for Lisraya -7.5% CYTK (Cytokinetics): presentation of ACACIA-HCM at ESC Congress -6.1% ARCT (Arcturus Therapeutics): sympathy to BNTX -6.0% RVMD (Revolution Medicines): shares down (1%) for the week (FDA approval) -3.4% SRPT (Sarepta Therapeutics): shares were +11% yesterday -3.3% MRNA (Moderna): worst performer on XLV; sympathy to BNTX; upsized convertible notes offering priced; FDA authorizes COVID-19 vaccines for '26-27 season; upgraded at Argus Research -3.0% GRAL (GRAIL, Inc.): shares +1% for the week -2.6% BBIO (BridgeBio Pharma): sympathy to AZN/IONS data in ATTR -2.2% IONS (Ionis Pharmaceuticals): data presentation for eplontersen at ESC Congress / NEJM Week in Review: Healthcare equities underperformed for the week. The S&P 500 Healthcare Index slipped (2.00%) vs the S&P 500 Index up +0.49%. Outperformers: none Underperformers: Pharma, Biotech, MedTech, Services, Managed Care Major health groups all underperformed the broader tape this week. Trading dynamics highlighted by ups and downs for Moderna and Merck as investors continue to evaluate the size of the opportunity with the INT program. The week ended on a down turn in sentiment after BioNTech and Roche announced that their mid-stage program failed a futility test in colorectal cancer. Elsewhere, a handful of July-quarter end earnings reports hit the tape; Veeva Systems the standout on earnings. Services groups benefitted from some intra-sector rotation, but finished the week essentially flat on the averages. Calendar remains quiet for one more full week of trading before the long Holiday weekend. Year-to-date, Healthcare up +10.34% vs the S&P 500 up +12.65%. Healthcare remains sixth out of eleven major sectors in CY26. Energy +38.47% and Utilities (0.43%) bracket them all. Notable movers for the week: Gainers: CAPR +52.5% - FDA extends PDUFA by three months; best performer on XBI VEEV +11.6% - earnings; best performer on XLV BHVN +11.3% - outlicense agreement / monetizes Kv7 program SRPT +11.0% - unusual volume on Thursday / Elevidys Ph4 trial updated on CT.gov VIR +10.7% - follow-through, higher 14 of last 16 days; +25% MTD and +80% YTD WAY +4.9% - inaugural Investor Day SMMT +4.3% - partner Akeso reported trial results in gastrointestinal cancers MCK +4.0% - acquired Precision Medicine Group for $2.25B Decliners: ORKA (15.6%) - worst performer on XBI; stock lower all 5 days; remains +201% YTD SYRE (15.1%) - trial results in Rheumatoid Arthritis HIMS (14.6%) - shares were +20% last week; employer GLP-1 coverage headlines (Pepsi) BNTX (12.4%) - follow-through; terminates BNT122 trial in CRC following DSMB review TEM (11.9%) - follow-through, shares up +40% last week; remain +46% MTD RGNX (9.9%) - FDA places gene therapy on clinical hold BSX (7.0%) - discloses cybersecurity incident on 25-Aug; worst performer on XLV COO (6.6%) - largest weekly deline in four months LLY (6.4%) - stock lower all 5 days; employer GLP-1 coverage headlines (Pepsi) ROIV (4.4%) - FDA approves Lisraya for DM ABT (3.6%) - FDA approves Libre Duo A (3.2%) - earnings RVMD (0.8%) - FDA approves Rasonque to treat 2L PDAC Week Ahead (Sat - Sun): Aug 29 - Sep 6 Conference calendar (cont.): European Society of Cardiology (ESC) 2026 (Aug 28-31) Wed 2-Sep: Jefferies Swiss Healthcare (Sep 2) Sat 5-Sep: European Respiratory Society (ERS) Congress (Sep 5-9); European Epilepsy Congress (Sep 5-9) Regulatory calendar Sun 30-Aug: 6446.TT (PharmaEssentia) FDA PDUFA for Besremi sNDA for Essential Thrombocythemia (ET) during August: AZN FDA PDUFA (estimated date) for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (follows 3-month extension announced 27-May; brand name ETCAMAH in EU) Thu 3-Sep: ALDVI.FP (Advicenne) FDA PDUFA for Sibnayal NDA in dRTA Corporate calendar Sun 30-Aug: KARD to present phase 2 follow-up data in hypertension at ESC Congress Mon 31-Aug: ARWR hosting Investor event from ESC 2026 (8:00ET); PTGX hosting call to discuss FDA approval of Mimrylo (8:30ET) Thu 3-Sep: CLYM hosting Investor event to discuss ph1 data in IgAN (8:00ET) Earnings calendar Tue 1-Sep: before MDT (call at 7:45ET), MMED (call at 8:45ET) Holiday calendar Mon 7-Sep: US equity markets closed for Labor Day Holiday Related: 6446.TT, A, ABT, ALDVI.FP, APMD, ARCT, ARWR, AZN, BBIO, BHVN, BNTX, BSX, CAPR, CLYM, COO, CYTK, GRAL, HIMS, IONS, KARD, KZIA, LLY, MCK, MDT, MMED, MRNA, NVAX, ORKA, PRTA, PTGX, RGNX, ROIV, RVMD, SLS, SMMT, SRPT, SYK, SYRE, TEM, VEEV, VIR, WAY, XNCR, ZTS...(more)	show story hide story
28-Aug-2026 15:13	StreetAccount Summary: Notable Drug Events expected for the week of 30-Aug Preface: The FDA PUDUFA for 6446.TT for Besremi sBLA in Essential Thrombocythemia (ET) is expected Sunday, 30-Aug. Generally, weekend PDUFA dates tend to be Friday announcements. (cont.) Industry meeting with clinical data: European Society of Cardiology (ESC) Congress (Aug 28-31) (KARD, NOVN.SW, BAYN.GR, AMGN, TENX, BBIO, ALNY, PFE, SAN.FP) Sun 30-Aug Trial results: KARD to present Phase 2 follow-up data for its KARDINAL trial in uncontrolled hypertension Mon 31-Aug Investor event: ARWR to review SHASTA-3 and SHASTA-4 pivotal trial 12-month results (webcast 8:00ET) Thu 3-Sep Regulatory decision: ALDVI.FP FDA PDUFA for Sibnayal NDA in distal renal tubular acidosis Trial results: CLYM to present Phase 1 CLYM116 data in IgAN (webcast 8:00ET) Sat 5-Sep Industry meetings with clinical data: European Respiratory Society (ERS) Congress (Sep 5-9) (BEAM, GENB, SAN.FP, UPB, AZN.LN) European Epilepsy Congress (Sep 5-9) (XENE) also expected August 2026 Regulatory decisions: FDA PDUFAs: PTGX/4502.JP (rusfertide NDA), AZN.LN (camizestrant NDA) later during September 2026 Regulatory decisions: FDA PDUFAs: RARE (rebisufligene etisparvovec BLA, 19-Sep), IntraBio (Aqneursa sNDA, 19-Sep), MRK (Winrevair sBLA, 21-Sep), IONS (zilganersen NDA, 22-Sep), INCY/MIRM (zilurgisertib NDA, 26-Sep), ROP.SW (Gazyva sBLA, 27-Sep), EGTX.SS (Emcitate NDA, 28-Sep), BFRI (Ameluz sNDA, 28-Sep), SRRK (apitegromab BLA, 30-Sep), BMY (Camzyos sNDA, 30-Sep); EMA CHMP opinions on MAA (18-Sep) Regulatory meeting: EMA CHMP monthly meeting (Sep 14-17) Industry meetings with clinical data: World Conference on Lung Cancer (WCLC) 2026 (Sep 12-15); International Pathogenic Neisseria Conference (IPNC) (Sep 13 -17); European Association for the Study of Diabetes (EASD) annual meeting (Sep 28 - Oct 2) Trial results: GSK.LN (Ph3 IMD), KOD (Ph3 Wet AMD), DFTX (Ph3 GAD), KLRA (Ph 3 T2D and Ph1 obesity), ABBV (Ph3 NSCLC), BNTX (Ph3 NSCLC), PAR.AU (Ph3 OA), OSTX (Ph2 Metastatic Osteosarcoma), IMMX (Ph2 R/R AL Amyloidosis), CNTB (Ph2 Acute asthma and Ph2 COPD), TYRA (Ph2 IR NMIBC), LGVN (Ph2 HLHS), EVMN (Ph2 atopic dermatitis), IRD (Ph1/2 BVMD & ARB), QURE (Ph1/2 Huntington's disease), CNTX (Ph1 solid tumors), PHIL.IM (Ph1 glioblastoma), CRBP (Ph1 obesity), ZNTL (Ph1 PROC) expected imminently Trial results: NOVN.SW phase 3 HORIZON results in CVD Related: 4502.JP, 6446.TT, ABBV, ALDVI.FP, ALNY, AMGN, ARWR, AZN.LN, BAYN.GR, BBIO, BEAM, BFRI, BMY, BNTX, CLYM, CNTB, CNTX, CRBP, DFTX, EGTX.SS, EVMN, GENB, GSK.LN, IMMX, INCY, IONS, IRD, KARD, KLRA, KOD, LGVN, MIRM, MRK, NOVN.SW, NVS, OSTX, PAR.AU, PFE, PHIL.IM, PTGX, QURE, RARE, ROP.SW, SAN.FP, SRRK, TENX, TYRA, UPB, XENE, ZNTL...(more)	show story hide story
28-Aug-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.25%) vs the S&P 500 +0.51%. All major health groups now red for the session; all except Managed Care remain on track for weekly declines. PODD +2% and MRNA (6%) bracket the XLV. Biopharma's focus quickly jumped from Munich to Mainz (Germany) with the negative surprise update by BNTX (9%) and Genentech; ROP.SW (1%). The companies which are jointly developing an individualized mRNA cancer immunotherapy (similar to Moderna-Merck) announced that their mid-stage trial in colorectal cancer would end early following futility analysis by the DSMB. In Munich, the ESC Congress 2026 is underway, and AZN (1%) / IONS (2%) presented detailed data on their failed phase 3 trial of eplontersen in ATTR-CM, while CYTK (6%) detailed data on its phase trial of aficamten in nHCM. ALNY (1%) recovering from morning lows, in read-through from AstraZeneca. Gainers +10.6% APMD (Apnimed): shares +12% WTD +2.2% SRPT (Sarepta Therapeutics): best performing biotech on XBI; shares were +11% yesterday +1.8% PODD (Insulet): best performer on XLV +1.6% ZTS (Zoetis): second-best on XLV Decliners -16.6% KZIA (Kazia Therapeutics): trial results in TNBC; secondary offering -8.8% BNTX (BioNTech): terminates ph2 trial in CRC; FDA authorizes COVID-19 vaccines for '26-27 season -8.1% SLS (SELLAS Life Sciences Group, Inc.): worst performer on XBI; shares were +11% yesterday -6.6% HIMS (Hims & Hers Health): shares (12%) WTD -6.5% MRNA (Moderna): worst performer on XLV; sympathy to BNTX; upsized convertible notes offering priced; FDA authorizes COVID-19 vaccines for '26-27 season; upgraded at Argus Research -6.4% CYTK (Cytokinetics): presentation of ACACIA-HCM at ESC Congress -6.3% ARCT (Arcturus Therapeutics): sympathy to BNTX -5.5% ROIV (Roivant Sciences): follow-through (FDA approval); announces WAC price for Lisraya -5.5% RVMD (Revolution Medicines): shares flat WTD -3.2% GRAL (GRAIL, Inc.): shares flat WTD -2.2% IONS (Ionis Pharmaceuticals): data presentation for eplontersen at ESC Congress / NEJM -1.1% MRK (Merck): sympathy to BNTX -1.1% NVAX (Novavax, Inc.): FDA authorizes COVID-19 vaccines for '26-27 season -1.1% ALNY (Alnylam Pharmaceuticals): sympathy to AZN/IONS data in ATTR -1.1% AZN (AstraZeneca): data presentation for eplontersen at ESC Congress / NEJM -0.5% BBIO (BridgeBio Pharma): sympathy to AZN/IONS data in ATTR -0.4% PFE (Pfizer): FDA authorizes COVID-19 vaccines for '26-27 season	show story hide story
28-Aug-2026 09:27	Individualized cancer immunotherapy stocks fall on BioNTech update Trading update: BNTX (7.8%), ARCT (5.9%) , MRNA (3.7%), MRK (2.4%) BioNTech and Roche announced Friday they have terminated the phase 2 trial evaluating autogene cevumeran (BNT122/RO7198457) in Resected Colorectal Cancer (CRC). For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. See Related StreetAccount comments: 8/28/2026 9:20:24 AM - BioNTech terminates phase 2 trial of autogene cevumeran in resected colorectal cancer following DSMB review - 6-K Related: ARCT, BNTX, MRK, MRNA	show story hide story
28-Aug-2026 08:35	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Biopharma's focus turns to Munich where ESC Congress is underway, and AstraZeneca presented detailed data on its failed phase 3 trial of eplontersen in ATTR-CM, and Cytokinetics detailed data on its phase trial of aficamten in nHCM. In reaction to AZN/IONS, shares of ALNY down (5%) in the pre-market. Overnight, FDA authorized all three COVID-19 vaccines formulations for the upcoming 2026-27 season, including Pfizer/BioNTech, Moderna, and Novavax/Sanofi. First two expected to be available immediately, the non-MRNA version in September. FDA also approved a new oral HIV treatment from Gilead Sciences. Yesterday's action broadly lower on light sector newsflow. Investors continue to assess the meaning of last week's melanoma data from Moderna and Merck. FDA regulatory action picking up with the recent approvals in pancreatic cancer for Revolution Medicines, and Thursday's approvals for Priovant's drug for dermatomyositis. Macro S&P futures a touch lower on Friday morning. Still a lot of uncertainty surrounding Fed Chair Warsh's speech this morning, including what he will talk about, whether the speech leans dovish or hawkish (and potential for market to trade in the opposite direction) and whether he addresses competing yield/buyback dynamics. A number of the higher-profile tech reporters from Thursday evening have traded off following their prints, though high-bar dynamic has played a role. Retail reporter takeaways mixed with no notable macro implications. Nothing particularly incremental on US-Iran conflict as some of the SoH reopening/diplomacy hopes have failed to sustain the momentum from earlier this week. Russia-Ukraine conflict escalation has grabbed more attention this week with the spike in wheat costs. Hotter/firming inflation prints out of Europe and Japan have kept some focus on the global monetary policy tightening dynamic. Pre-market trading update Trading higher +2.0% BBIO sympathy to AZN/IONS data in ATTR +0.3% ROIV follow-through (FDA approval); call at 8ET - $35K per month WAC +0.3% NVAX FDA authorizes COVID-19 vaccines for '26-27 season +0.1% PFE FDA authorizes COVID-19 vaccines for '26-27 season Trading lower -10.0% KZIA trial results in TNBC; secondary offering -4.9% ALNY sympathy to AZN/IONS data in ATTR -2.5% CYTK presentation of ACACIA-HCM at ESC Congress -2.3% IONS data presentation for eplontersen at ESC Congress / NEJM -0.9% BNTX FDA authorizes COVID-19 vaccines for '26-27 season -0.6% MRNA upsized convertible notes offering priced; FDA authorizes COVID-19 vaccines for '26-27 season; upgraded at Argus Research -0.1% AZN data presentation for eplontersen at ESC Congress / NEJM Pharma Data presentation: AZN and IONS presented detailed data from the failed phase 3 CARDIO-TTRansform trial evaluating eplontersen in ATTR-CM at ESC Congress. Topline results were announced in early July. Read-across to ALNY Amvuttra. STAT News published a write-up on today's presentation of the trial and concurrent publish by NEJM. Additional results on the monotherapy are expected on Sunday, with AstraZeneca telling the room that the next steps on monotherapy are still to be determined. Regulatory: LLY announced that FDA approved Mounjaro to lower the risk of MACE in adults with T2D. Biotech Data presentation: CYTK presented detailed data from the phase 3 ACACIA-HCM trial evaluating aficamten in non-obstructive HCM at ESC Congress. Topline results were announced in early May. Company plans to submit sNDA in Q4 of 2026. Conf. call at 8:00ET Trial results and secondary offering: KZIA announced new interim data from the phase 1B study evaluating paxalisib, an inhibitor of the PI3K/Akt /mTOR pathway, in combo with Keytruda in patients with stage IV TNBC. Of six evaluable patients, five achieved an objective response (4 CR, 1 PR) and one stable disease. Study remains ongoing with completion by July 2027 and interim updates throughout '26 and '27. Pax is licensed from Roche's Genentech (ROP.SW). Company also announced an offering of ADS + warrants; $120M offering priced on Friday. Regulatory: BNTX and PFE announced receipt of FDA approval of COMIRNATY XFG for the 2026-27 season. Shipping immediately. StreetAccount notes that MRNA announced their own respective SPIKEVAX and mNEXSPIKE approvals just before the market close. NVAX FDA disclosed that Nuvaxovid vaccine for '26-27, commercialized by Sanofi (SAN.FP), has also been approved. Companies tell FDA that it will be available in September. GILD announced that FDA approved Bixlenvo (bic/len) NDA for once-daily treatment of HIV. Approval came on the FDA PDUFA goal date. ROIV on Friday's approval call announced WAC price $35K per 30-day supply of Lisraya, and net price around low to mid $300K range. For reference, Leerink Partners had modeled a net annual price around $300K. Research: MRNA upgraded to buy from hold at Argus Research (Jasper Hellweg), target is $180 or approx. 26% upside. (FactSet average PT $101; range $40-170) RYTM initiated hold at Deutsche Bank (David Hoang), target is $120 or approx. 7% upside. (FactSet average PT $140; range $105-160) CV resumed buy at Roth Capital (Kevin Holder), target is $9 or approx. 49% upside. On Deck: Regulatory on Thu 27-Aug: AZN FDA PDUFA for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (estimated, following 3-month extension announced 27-May; brand name ETCAMAH in EU) (OLMA, ROP.SW) on Sun 30-Aug: 6446.TT (PharmaEssentia) FDA PDUFA for Besremi sNDA for Essential Thrombocythemia (ET) during August 2026: TAK FDA PDUFA for rusfertide NDA for polycythemia vera (PV) (PTGX, RPRX, ZEAL.DC) Conference European Society of Cardiology (ESC) 2026 (Aug 28-31) (AZN.LN, IONS, BBIO, CRSP, KARD, NOVN.SW, BAYN.GR, AMGN, TENX, ALNY, NTLA, PFE, SAN.FP) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 6446.TT, ALNY, AZN, BBIO, BNTX, CV, CYTK, GILD, IONS, KZIA, LLY, MRNA, NVAX, OLMA, PFE, PTGX, ROIV, ROP.SW, RPRX, RYTM, SAN.FP, TAK, ZEAL.DC...(more)	show story hide story
28-Aug-2026 07:27	ALNY Alnylam Pharma trading lower; AstraZeneca detailed failure of CARDIO-TTRansform trial, reports STAT ALNY shares down (5.1%) in the pre-market on Friday, in read-across following STAT News writeup on today's presentation by AstraZeneca (AZN) and Ionis Pharma (IONS) of the failed phase 3 trial CARDIO-TTRansform. Topline results with eplontersen were published in early July. Full data were published by NEJM and presented at ESC Congress on Friday. Additional results on the monotherapy are expected on Sunday, with AstraZeneca telling the room that the next steps on monotherapy are still to be determined. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: AZN, IONS	show story hide story
27-Aug-2026 18:30	NVAX FDA approves Nuvaxovid 2026-27 formula; all three COVID-19 vaccines now authorized ($9.05) According to FDA.gov, the agency has approved the sBLA for NUVAXOVID , COVID-19 Vaccine adjuvanted, manufactured at the Serum Institute of India Private Limited (SIIPL) facility located in Pune, Maharashtra, India, to include the 2026-2027 Formula and associated labeling revisions. StreetAccount notes that Sanofi will lead commercial activities for the 2026-27 season in select markets, including the US. Moderna and Pfizer/BioNTech announced FDA approval for their updated vaccines earlier today. See Related StreetAccount comments: 5/28/2026 2:27:13 PM - FDA panel votes 8-0-1 to recommend JN.1-lineage XFG variant for the 2026-27 formula of COVID-19 vaccine Related: SAN.FP Reference Link	show story hide story
27-Aug-2026 17:39	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly lower on Thursday. Decliners beat advancers by more than 2:1 on the XLV. Healthcare (1.10%) vs S&P 500 +0.72%. All major health groups ended red for the session, lead by Pharma and Health Services. SMID-cap biotech squeeze briefly had the XBI green, the ETF ended (0.10%), similar to the MedTech group. Newsflow often didn't align with the volume in SMID-cap biotech. SRPT +10.9% saw its best one-day gain in five months. Moderate gains for LST subgroup after the Agilent beat; A ended +1.7% on the day. Overall, however, broad declines across the medical device space offset all tools group gains. Yesterday's rotation into Health Services groups short-lived as Big Tech continues to attract new investment today. VEEV +15.2%, on earnings strength, and MRNA (4.6%), on follow-through plus convertible offering, continue to bracket the XLV. Earnings highlights include a few July quarter-end reports: Veeva Systems reported Q2 beat and Q3 guide strong; Agilent reported fiscal Q3 beat including tariff impacts; HQY (10.6%) reported fiscal Q2 generally inline. Sector calendar fairly quiet after the earnings prints. ESC 2026 begins on Friday, and a handful of PDUFA goal dates expected in the coming week. Came on the heels of Wednesday's recurrent pullback in biopharma, driven by ongoing volume in Moderna and Merck follow-through from last week's melanoma breakthrough, and despite FDA approval of Revolution Medicines' pancreatic cancer drug. Dynamic combined with intra-sector rotation that benefitted payers and providers. Macro A very quiet session with tech rally (and AI and software upside specifically) the only real market narrative. Move driven by NVDA's well-received report and guidance (+70% FY28 revenue guide in the spotlight), while software also rallied following multiple solid earnings reports that also helped pushback against the AI disruption narrative (and toward AI monetization). In contrast, today's retail reporters largely traded lower despite generally positive releases. Very quiet elsewhere. Not much new around US-Iran with improving Hormuz flows, White House reportedly rejecting return to June MOU among biggest areas of focus. Much discussion ahead of Fed Chair Warsh's speech at Jackson Hole tomorrow; anticipation heightened due to recent Treasury buyback headlines and market concern after thin updates on reaction function following July FOMC. Other areas of focus include tariffs (White House reportedly considering new round of sweeping levies on semis), more debate around why rates remain elevated, token economics, dampened vol, potential month end flows (GS expects $5B equity sales from pension, equal bond buying). Notable Gainers +15.2% VEEV (Veeva Systems): earnings; best performer on XLV +10.9% SRPT (Sarepta Therapeutics): on nearly 3X average volume; best performing biotech on XBI +10.8% AAPG (Ascentage Pharma): on nearly 3X average volume +10.8% SLS (SELLAS Life Sciences Group, Inc.): on nearly 2X average volume +7.3% NEO (NeoGenomics): expanded CMS coverage for MRD assay +4.5% WAY (Waystar Holding): follow-through, shares +1% WTD +3.7% GRAL (GRAIL, Inc.): on above avg volume; shares +4% WTD and +20% MTD +2.7% RVTY (Revvity): sympathy to Agilent; 52-week high +2.7% RVMD (Revolution Medicines): follow-through, shares were +2% yesterday +2.3% ROIV (Roivant Sciences): FDA approves Lisraya for DM +1.7% WAT (Waters): upgraded at Piper Sandler; sympathy to Agilent; 52-week high Notable Decliners -10.6% HQY (HealthEquity): earnings -6.0% VERA (Vera Therapeutics): worst performer on XBI; shares remain +7% WTD -5.2% CHE (Chemed): Capitol Forum report, we're told -4.9% BHVN (Biohaven): shares were +18% yesterday -4.6% MRNA (Moderna): worst performer on XLV; convertible notes private placement $2B -4.2% KYMR (Kymera Therapeutics): on below average volume; shares +16% MTD -3.4% UHS (Universal Health Services): shares were +2% yesterday -3.2% ZTS (Zoetis): shares down (3%) WTD -3.1% BSX (Boston Scientific): follow-through, shares (7%) WTD -2.4% COO (The Cooper Cos.): shares (7%) WTD -2.3% THC (Tenet Healthcare): insider selling (CEO) -2.0% NVO (Novo Nordisk): downgraded at Deutsche Bank Earnings in Life Science & MedTech A (Agilent) reported fiscal Q3 (Jul) EPS $1.62 including $0.06 tariff refund benefit, on revenue $1.88B vs FactSet $1.84B. Guides Q4 EPS $1.71-1.74 ex-items vs FS $1.72 and revenue $1.98-2.00B vs FS $1.97B. HQY reported fiscal Q2 (Jul) NG EPS $1.24 vs FactSet $1.19 on revenue $350.7M vs FS $349.2M, adj EBITDA $167.0M vs FS $160.2M. Reaffirms FY EPS guidance, and a slight raise to revenue and EBITDA outlook. VEEV reported fiscal Q2 (Jul) NG EPS $2.35 vs FactSet $2.22 on revenue $928.0M vs FS $905.4M. Guides Q3 and FY ahead of consensus. Sarepta Therapeutics trading higher; ClinicalTrial.gov record updated today SRPT higher +12.8% on Thursday afternoon, on volume ~181% of its daily average. Shares on track for their best one-day gain since 25-Mar-2026 when the company reported clinical results from FSHD and DM1 programs. Catalyst for today's move not perfectly clear, but we noted a modified record ClinicalTrials.gov for the phase 4 study of Elevidys in patients with DMD. The study was first posted in April, but this week the start date was updated to 31-Aug and the first location - Baylor College of Medicine - was disclosed. Amgen lower despite positive readout in eosinophilic esophagitis (EoE) AMGN and AZN announced topline results from their phase 3 trial CROSSING which evaluated Tezspire (tezepelumab) in patients with EoE. Study achieved co-primary and key secondary endpoints at week 24 which were sustained through week 52. Data to be shared with regulatory authorities and for upcoming scientific meeting. Roivant Sciences higher on FDA approval of Lisraya for dermatomyositis (DM) FDA announced on Thursday it has approved Priovant's Lisraya (brepocitinib) tablets for the treatment of adults with dermatomyositis (DM). Priovant, majority owned by Roivant Sciences (ROIV) has rights under license from Pfizer (PFE), which holds 25% stake. Roivant to host investor call on Friday morning at 8:00ET. Phibro Animal Health modestly higher following Q4 print PAHC reported Q4 EPS $0.85 ex-items vs FactSet $0.71 on revenue $396.7M vs FS $381.2M, and adj EBITDA $64.2M vs FS $58.8M. Guides FY (Jun 2027) EPS $3.41-3.59 ex-items vs FS $3.32, revenue $1.55-1.60B vs FS $1.55B, and adj EBITDA $258-268M vs FS $264.6M Notable research in Healthcare today Pharma: NOVO.B.DC (NVO) downgraded to sell from hold at Deutsche Bank (Emmanuel Papadakis), target cut to DKK265 from DKK290 or approx. 13% downside. (FactSet average PT DKK316; range DKK200-457) Biotech: ASND initiated buy at HC Wainwright (Mitchell Kapoor), target is $345 or approx. 38% upside. (FactSet average PT $314; range $272-363) ODTX initiated buy at HC Wainwright (Emily Bodnar), target is $44 or approx. 72% upside. VRCA initiated buy at Lake Street (Thomas Flaten), target is $9 or approx. 83% upside. (FactSet average PT $15; range $10-20) MedTech: WAT upgraded to overweight at Piper Sandler (David Westenberg), cites factors including replacement cycle. Post-close news Trial results and offering: KZIA announced new interim data from the phase 1B study evaluating paxalisib, an inhibitor of the PI3K/Akt /mTOR pathway, in combo with Keytruda in patients with stage IV TNBC. Of six evaluable patients, five achieved an objective response (4 CR, 1 PR) and one stable disease. Study remains ongoing with completion by July 2027 and interim updates throughout '26 and '27. Pax is licensed from Roche's Genentech (ROP.SW). Company also announced an offering of ADS + warrants. ADRs for KZIA trading (23.2%) in the after-hours Regulatory: BNTX and PFE announced receipt of FDA approval of COMIRNATY XFG for the 2026-27 season. Shipping immediately. StreetAccount notes that MRNA announced their own respective SPIKEVAX and mNEXSPIKE approvals just before the market close. Now awaiting the Novavax (NVAX) Nuvaxovid vaccine for '26-27, commercialized by Sanofi (SAN.FP). On Deck: Regulatory GILD FDA PDUFA for BIC/LEN NDA (single-tablet bictegravir 75 mg/lenacapavir 50 mg) for treatment of HIV AZN FDA PDUFA for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (estimated, following 3-month extension announced 27-May; brand name ETCAMAH in EU) (OLMA, ROP.SW) on Sun 30-Aug: 6446.TT (PharmaEssentia) FDA PDUFA for Besremi sNDA for Essential Thrombocythemia (ET) during August 2026: TAK FDA PDUFA for rusfertide NDA for polycythemia vera (PV) (PTGX, RPRX, ZEAL.DC) Conference European Society of Cardiology (ESC) 2026 (Aug 28-31) (AZN.LN, IONS, CRSP, KARD, NOVN.SW, BAYN.GR, AMGN, TENX, ALNY, NTLA, PFE, SAN.FP) Corporate IONS and AZN to present Phase 3 CARDIO-TTRansform study of epolontersen at ESC (ALNY) StreetAccount Healthcare Reads Popular Sugar Substitute Linked to Higher Risk of Heart Attack and Stroke (27-Aug) Newsweek Hospitals are plotting a long-shot push to roll back $1T in Medicaid cuts (27-Aug) STAT News $50B Rural Health Transformation Program Needs More Transparency, Groups Say (27-Aug) KFF Health News China's drug regulator accepts Novo Nordisk application for oral Wegovy (27-Aug) Reuters More US employers to drop weight-loss drugs in 2027, as healthcare costs increase (25-Aug) Reuters Inside Moderna and Merck's cancer vaccine triumph (24-Aug) STAT News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 6446.TT, A, AAPG, ALNY, AMGN, ASND, AZN, AZN.LN, BAYN.GR, BHVN, BNTX, BSX, CHE, COO, CRSP, GILD, GRAL, HQY, IONS, KARD, KYMR, KZIA, MRNA, NEO, NOVN.SW, NOVO.B.DC, NTLA, NVAX, NVO, ODTX, OLMA, PAHC, PFE, PTGX, ROIV, ROP.SW, RPRX, RVMD, RVTY, SAN.FP, SLS, SRPT, TAK, TENX, THC, UHS, VEEV, VERA, VRCA, WAT, WAY, ZEAL.DC, ZTS...(more)	show story hide story
27-Aug-2026 14:35	SRPT Sarepta Therapeutics trading higher; ClinicalTrial.gov record updated today ($21.94 +$2.48) SRPT higher +12.8% on Thursday afternoon, on volume ~181% of its daily average. Shares on track for their best one-day gain since 25-Mar-2026 when the company reported clinical results from FSHD and DM1 programs. Catalyst for today's move not perfectly clear, but we noted a modified record ClinicalTrials.gov for the phase 4 study of Elevidys in patients with DMD. The study was first posted in April, but this week the start date was updated to 31-Aug and the first location - Baylor College of Medicine - was disclosed.	show story hide story
27-Aug-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.55%) vs the S&P 500 +0.61%. Most major health groups lower on the session, though declines have moderated since the open. A short-lived rally yesterday for Health Services groups as Big Tech today continues to attract new investment. MedTech group lone advancer in Healthcare, the LST subgroup keeping it in positive territory but offset by declines across Medical Devices. VEEV +19%, on earnings strength, and MRNA (4%), on follow-through plus convertible offering, bracket the XLV. Earnings highlights include a few July quarter-end reports: Veeva Systems reported Q2 beat and Q3 guide strong; Agilent reported fiscal Q3 beat including tariff impacts; HQY (15%) reported fiscal Q2 generally inline. Sector calendar fairly quiet after the earnings prints. ESC 2026 begins on Friday, and a handful of PDUFA goal dates expected in the coming week. Gainers +18.5% VEEV (Veeva Systems): earnings; best performer on XLV +9.8% AAPG (Ascentage Pharma): on heavy volume +9.8% NEO (NeoGenomics): expanded CMS coverage for MRD assay +5.2% GENB (Generate Biomedicines): follow-through, shares were (21%) yesterday +4.8% WAY (Waystar Holding): follow-through, shares +1% WTD +2.5% CRL (Charles River Laboratories): sympathy to A; 52-week high +2.2% WAT (Waters): upgraded at Piper Sandler; sympathy to A; 52-week high +1.8% MTD (Mettler-Toledo International): sympathy to A +1.5% A (Agilent Technologies): earnings; 52-week high Decliners -14.7% HQY (HealthEquity): earnings -7.3% BHVN (Biohaven): shares were +18% yesterday -6.9% VERA (Vera Therapeutics): worst performer on XBI; shares remain +6% WTD -4.2% MRNA (Moderna): worst performer on XLV; convertible notes private placement $2B -2.7% NVO (Novo Nordisk): downgraded at Deutsche Bank -2.6% ZTS (Zoetis): shares down (3%) WTD	show story hide story
27-Aug-2026 08:20	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings highlights include a couple of July quarter end reports. Agilent reported fiscal Q3 beat including tariff impacts. Shares of A +2% in the pre-market. HealthEquity reports fiscal Q2 generally inline. Shares of HQY down (5%) in the pre-market, ahead of the call. Sector calendar fairly quiet after those two prints. ESC 2026 begins on Friday, and a handful of PDUFA goal dates expected in the coming week. Yesterday's trading action another pullback in biopharma, driven by ongoing volume in Moderna and Merck follow-through from last week's melanoma breakthrough, and despite FDA approval of Revolution Medicines' pancreatic cancer drug. Dynamic combined with intra-sector rotation that benefitted payers and providers. Macro S&P futures are up +0.4% on Thursday morning. AI sentiment boosted by another blowout Q/guidance from NVDA, with takeaways focused on +70% FY28 revenue guide (vs ~45% consensus), which was explicitly framed as a supply-constrained number. Software earnings another bright spot, including via semblance of pushback against the AI disruption narrative. Pretty quiet elsewhere with nothing really incremental on US-Iran conflict following big oil pullback earlier on the week on select signs of diplomatic traction, particularly surrounding SoH. Fed Chair Warsh's speech in Jackson Hole on Friday morning the next big area of focus, particularly given reaction function uncertainty and Treasury's recently announced buyback boost. Tariffs in the headlines again with White House reportedly considering new round of sweeping levies on semis. Pre-market trading update Trading higher +6.0% GENB follow-through, shares were (21%) yesterday +3.5% RVMD follow-through, shares were +2% yesterday +3.4% SMMT follow-through, shares were +7% yesterday +1.9% A earnings +0.8% WAT upgraded at Piper Sandler Trading lower -5.2% HQY earnings; call at 830ET -3.8% MRNA convertible note private placement $2B -2.1% VTRS on light volume -2.4% NVO downgraded at Deutsche Bank -1.8% MRK follow-through, shares were (2%) yesterday Pharma Earnings: PAHC reported Q4 EPS $0.85 ex-items vs FactSet $0.71 on revenue $396.7M vs FS $381.2M, and adj EBITDA $64.2M vs FS $58.8M. Guides FY (Jun 2027) EPS $3.41-3.59 ex-items vs FS $3.32, revenue $1.55-1.60B vs FS $1.55B, and adj EBITDA $258-268M vs FS $264.6M Conf. call at 9:00ET Research: NOVO.B.DC (NVO) downgraded to sell from hold at Deutsche Bank (Emmanuel Papadakis), target cut to DKK265 from DKK290 or approx. 13% downside. (FactSet average PT DKK316; range DKK200-457) Biotech Trial results: AMGN and AZN announced topline results from their phase 3 trial CROSSING which evaluated Tezspire (tezepelumab) in patients with EoE. Study achieved co-primary and key secondary endpoints at week 24 which were sustained through week 52. Data to be shared with regulatory authorities and for upcoming scientific meeting. Corporate: MRNA announced it intends to offer up to $2.3B in convertible notes due 2032 in a private placement. Research: ASND initiated buy at HC Wainwright (Mitchell Kapoor), target is $345 or approx. 38% upside. (FactSet average PT $314; range $272-363) ODTX initiated buy at HC Wainwright (Emily Bodnar), target is $44 or approx. 72% upside. Life Science & MedTech Earnings A (Agilent) reported fiscal Q3 (Jul) EPS $1.62 including $0.06 tariff refund benefit, on revenue $1.88B vs FactSet $1.84B. Guides Q4 EPS $1.71-1.74 ex-items vs FS $1.72 and revenue $1.98-2.00B vs FS $1.97B. HQY reports fiscal Q2 (Jul) NG EPS $1.24 vs FactSet $1.19 on revenue $350.7M vs FS $349.2M, adj EBITDA $167.0M vs FS $160.2M. Reaffirms FY EPS guidance, and a slight raise to revenue and EBITDA outlook. Conf. call at 8:30ET Research: WAT upgraded to overweight at Piper Sandler (David Westenberg), cites factors including replacement cycle. On Deck: Regulatory GILD FDA PDUFA for BIC/LEN NDA (single-tablet bictegravir 75 mg/lenacapavir 50 mg) for treatment of HIV AZN FDA PDUFA for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (estimated, following 3-month extension announced 27-May; brand name ETCAMAH in EU) (OLMA, ROP.SW) on Sun 30-Aug: 6446.TT (PharmaEssentia) FDA PDUFA for Besremi sNDA for Essential Thrombocythemia (ET) during August 2026: TAK FDA PDUFA for rusfertide NDA for polycythemia vera (PV) (PTGX, RPRX, ZEAL.DC) Conference on Fri 28-Aug: European Society of Cardiology (ESC) 2026 (Aug 28-31) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 6446.TT, A, AMGN, ASND, AZN, GENB, GILD, HQY, MRK, MRNA, NOVO.B.DC, NVO, ODTX, OLMA, PAHC, PTGX, ROP.SW, RPRX, RVMD, SMMT, TAK, VTRS, WAT, ZEAL.DC...(more)	show story hide story
26-Aug-2026 17:05	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed yet significantly lower overall on Wednesday. Decliners outnumbered advancers on the XLV. Healthcare (1.01%) vs S&P 500 (0.02%). Most major health groups ended lower on their averages. With intra-sector rotation in play Managed Care and Services groups benefitted from the pullback in risk and biopharma. MRNA (5.6%) today's leading decliner on the XLV, edging out BSX (3.4%) with the cybersecurity incident disclosure, and LLY (3.6%) amidst pharma pullback. MCOs crowded the top spots early on the XLV, and Medicaid names outperformed, however providers such as UHS +1.7% topped the XLV gainers list. CVS also higher by +1.5%. FDA formally approved Rasonque, the once-daily oral pill for pancreatic cancer, after a quick CNPV-aided review; 2L indication scrutinized however. Shares of RVMD +1.9% on the session, while investigational peers in the RAS(ON) space traded better on the 1L opening. DRG (2.01%) and XBI (0.42%) with drug pricing headlines returned. Trump admin reportedly turning eye towards SMID-cap biotech. RevMed declined comment when asked if today's drug approval was connected to the Trump pricing agreements reported by Bloomberg. Boston Scientific the latest medical device company to disclose a cybersecurity incident with global disruption to its operations. Impacting ability to ship customer orders; timeline for restoration not yet known. Elsewhere sector newsflow remains fairly quiet apart from the usual Biotech updates. Summit Therapeutics' partner Akeso announced a highly successful interim readout, a first in gastrointestinal cancers for the bispecific ivonescimab. Spyre Therapeutics announced that while mid-stage results were stat-sig, it will not advance SPY072 monotherapy into phase 3 for rheumatoid arthritis. Yesterday's trading action another advancer for Moderna, Merck and biopharma on follow-through from last week's melanoma breakthrough. Calendar remains fairly quiet across the sector, with Agilent the highlight of earnings (post-close on Wednesday), and a handful of PDUFA dates in the coming week. Macro Stocks dragged lower with higher yields, higher oil. Oil higher on latest geopolitical uncertainties (Trump said no timeline for Iran talks to resume, Putin reportedly looking to escalate war with Ukraine), offsetting earlier updates around Strait of Hormuz, sanctions > strikes. Latest tensions between Fed vs Treasury strategies adding to rate uncertainty, while today's economic data mixed; July core PCE in line though durable goods report saw light core capital goods orders. Other areas of focus include software AI disruption (weaker growth outlook at INTU), latest questions around AI ROI economics, rising capex forecasts, and consumer headwinds. However, still a waiting game ahead to NVDA earnings (post-close today), Warsh speech at Jackson Hole on Friday morning. Also some notable semi, software and retail reporters over the next few days. Notable Gainers +17.9% BHVN (Biohaven): favorable judgment in Avilar/RA litigation; monetizes Kv7 program +12.9% CAPR (Capricor Therapeutics): best performer on XBI; follow-through, shares +143% MTD +12.7% ACTU (Actuate Therapeutics): sympathy to RVMD +9.6% ANL (Adlai Nortye): sympathy to RVMD +7.8% ERAS (Erasca): sympathy to RVMD; Wolfe Research comments +7.0% CRDL (Cardiol Therapeutics): initiation +6.7% ZYME (Zymeworks): follow-through +6.5% SMMT (Summit Therapeutics): Akeso reports interim analysis of HARMONI-GI1 +2.8% TNGX (Tango Therapeutics): sympathy to RVMD; Wolfe Research comments +2.7% ARGX (argenx): upgraded at UBS +2.4% ACHC (Acadia Healthcare): rotation/services strength; shares higher fourth straight day +2.3% ALHC (Alignment Healthcare): rotation/Managed Care strength; shares higher fifth straight day +1.9% RVMD (Revolution Medicines): FDA approves Rasonque to treat 2L PDAC +1.7% UHS (Universal Health Services): rotation/services strength; best performer on XLV Notable Decliners -20.8% GENB (Generate Biomedicines): data disclosures ahead of ERS 2026 -12.8% SYRE (Spyre Therapeutics): trial results in rheumatoid arthritis; worst performer on XBI -5.8% MRNA (Moderna): worst performer on XLV; follow-through, shares +173% MTD -5.4% RLAY (Relay Therapeutics): holder SVP Pauling 144 filing -4.2% JAZZ (Jazz Pharmaceuticals): follow-through; notes offering and share repurchase -3.6% LLY (Eli Lilly): sector rotation; second-worst on XLV -3.4% BSX (Boston Scientific): discloses cybersecurity incident -2.1% MRK (Merck): sector rotation; follow-through, shares +18% MTD Boston Scientific lower on disclosure of cybersecurity incident; too soon to judge impact BSX disclosed via 8-K filing on Wednesday morning that yesterday it identified a cybersecurity incident that has resulted in a global disruption of the company's operations. Full scope of operational and financial impacts are not yet known. Quick take: Analysts note that this is the latest in a string of medical device companies to face similar attacks this year, and while the extent of the impact is not yet known drawing comparison to the Stryker (SYK) incident which was quickly resolved in March/April. Stifel (buy-rated BSX) says 8K confirms what were just initial industry reports yesterday. Disclosure seems boilerplate, but firm acknowledges heightened risk to FY estimates. Wells Fargo (equal-weight rated BSX) suggests that peers may benefit from disruption (ABT, MDT, JNJ). Trump administration reportedly reaches drug pricing agreements with biotech companies -- Bloomberg No specific companies were mentioned in the article. Tickers for distribution purposes include (AXSM, BBIO, EXEL, JAZZ, NBIX). FDA approves Rasonque as second-line treatment for pancreatic cancer FDA today announced it has approved Revolution Medicines' (RVMD) Rasonque (daraxonrasib) (RPRX) under the CNPV pathway. The approval is for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. First in class drug approval. With second-line PDAC approval for Rasonque, analyst sees opening in 1L for peers. Wolfe Research analyst Kalpit Patel sees today's approval as an unconventional second-line approval, which offers flexibility to use Rasonque in certain chemo-ineligible 1L patients, while leaving the door open for a true 1L indication for developers such as Erasca (not covered) and Tango Therapeutics (outperform-rated). Outperform rating on RVMD, and target $220, now under review. Trading update: ERAS +7.6%, TNGX +7.2%, RVMD (0.1%), RPRX (0.1%) Revolution Medicines prices Rasonque at $39,800 per month - conf call Stifel analyst Laura Prendergast (buy-rated RVMD) recently noted that consensus was around mid-$30k WAC per month, Jefferies analyst Faisal Khurshid (buy-rated) modeled $35k per month, however noted that recent buyside survey suggested expectations were higher, around $41.8k per month. Company PR includes link to the label, which notably does not include a Boxed Warning. Company says Rasonque now available for physicians to prescribe. Spyre Therapeutics lower as development opportunity narrowed SYRE announced topline results from phase 2 SKYWAY study evaluating SPY072 in rheumatic disease. Both doses demonstrated stat-sig benefits vs placebo on one or more endpoints, however the magnitude of efficacy did not meet company's target for monotherapy development for RA. Results do provide proof-of-mechanism and support other development plans. Gastrointestinal cancer readout positive for invonescimab SMMT Partner Akeso (9926.HK) announced that HARMONI-GI1 evaluating ivonescimab chemo combo versus durvalumab (Imfinzi, AZN) chemo combo in 1L biliary tract cancer achieved its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Study also met all secondary endpoints (PFS, ORR). First successful phase 3 trial for ivonescimab in gastrointestinal tumors (priors were in lung cancer). Notable research in Healthcare today Biotech: ARGX upgraded to buy from neutral at UBS (Xian Deng), target increased to $1400 from $960 or approx. 37% upside. (FactSet average PT $1192; range $932-1450) CRDL initiated buy at B Riley Securities (Mayank Mamtani), target is $11 or approx. 450% upside. (FactSet average PT $8.50; range $5-11) EVMN initiated buy at Needham (Serge Belanger), target is $26 or approx. 103% upside. (FactSet average PT $30; range $22-50) HRMY initiated outperform at Wolfe Research (Rudy Li), target is $60 or approx. 54% upside. (FactSet average PT $46; range $30-70) SPTX initiated buy at Jones (Justin Walsh), target is $32 or approx. 29% upside. (FactSet average PT $37; range $30-50) MedTech: NEOG upgraded to overweight from neutral at Piper Sandler (David Westenberg), thinks company is entering a period of sustainable profitable growth. Target increased to $14 or approx. 20% upside. AXGN initiated buy at Truist (Ravi Misra), target is $60 or approx. 20% upside. (FactSet average PT $53; range $48-58) Post-close news Earnings A (Agilent) reports fiscal Q3 EPS $1.62 including $0.06 tariff refund benefit, on revenue $1.88B vs FactSet $1.84B. Guides Q4 EPS $1.71-1.74 ex-items vs FS $1.72 and revenue $1.98-2.00B vs FS $1.97B. Conf. call at 16:30ET Shares trading +3.1% in the after-hours PAHC reports Q4 EPS $0.85 ex-items vs FactSet $0.71 on revenue $396.7M vs FS $381.2M, and adj EBITDA $64.2M vs FS $58.8M. Guides FY (Jun 2027) EPS $3.41-3.59 ex-items vs FS $3.32, revenue $1.55-1.60B vs FS $1.55B, and adj EBITDA $258-268M vs FS $264.6M Conf. call tomorrow at 9:00ET Shares trading +3.1% in the after-hours On Deck: Earnings tomorrow morning HQY (call at 8:30ET) Regulatory GILD FDA PDUFA tomorrow for BIC/LEN NDA (single-tablet bictegravir 75 mg/lenacapavir 50 mg) for treatment of HIV AZN FDA PDUFA tomorrow for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (estimated, following 3-month extension announced 27-May; brand name ETCAMAH in EU) (OLMA, ROP.SW) on Sun 30-Aug: 6446.TT (PharmaEssentia) FDA PDUFA for Besremi sNDA for Essential Thrombocythemia (ET) during August 2026: TAK FDA PDUFA for rusfertide NDA for polycythemia vera (PV) (PTGX, RPRX, ZEAL.DC) Conference on Fri 28-Aug: European Society of Cardiology (ESC) 2026 (Aug 28-31) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 6446.TT, 9926.HK, A, ABT, ACHC, ACTU, ALHC, ANL, ARGX, AXGN, AXSM, AZN, BBIO, BHVN, BSX, CAPR, CRDL, ERAS, EVMN, EXEL, GENB, GILD, HQY, HRMY, JAZZ, JNJ, LLY, MDT, MRK, MRNA, NBIX, NEOG, OLMA, PAHC, PTGX, RLAY, ROP.SW, RPRX, RVMD, SMMT, SPTX, SYK, SYRE, TAK, TNGX, UHS, ZEAL.DC, ZYME...(more)	show story hide story
26-Aug-2026 12:29	With second-line PDAC approval for Rasonque, analyst sees opening in 1L for peers Wolfe Research analyst Kalpit Patel sees today's approval as an unconventional second-line approval, which offers flexibility to use Rasonque in certain chemo-ineligible 1L patients, while leaving the door open for a true 1L indication for developers such as Erasca (not covered) and Tango Therapeutics (outperform-rated). Outperform rating on RVMD, and target $220, now under review. Trading update: ERAS +7.6%, TNGX +7.2%, RVMD (0.1%), RPRX (0.1%) See Related StreetAccount comments: 8/26/2026 10:44:46 AM - Follow-up: FDA approves Rasonque to treat pancreatic cancer Related: ERAS, RPRX, RVMD, TNGX	show story hide story
26-Aug-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.62%) vs the S&P 500 +0.04%. Most major health groups are lower on the averages, sector rotation in play with Managed Care and Services groups benefitting from the pullback in risk and biopharma. MRNA (7%) leading decliner on the XLV, edging out BSX (5%) with the cybersecurity incident. Managed Care stocks crowding top spots on the XLV, with Medicaid names outperforming; CNC +3%. FDA officially approved Rasonque, the oral pill for pancreatic cancer. Shares of RVMD +1% volatile in early reaction. Gainers +12.1% CAPR (Capricor Therapeutics): follow-through; best performer on XBI +8.3% ZYME (Zymeworks): follow-through +6.4% SMMT (Summit Therapeutics): Akeso reports interim analysis of HARMONI-GI1; +6.0% ACHC (Acadia Healthcare): shares higher fourth straight day +4.1% BHVN (Biohaven): favorable judgment in Avilar/RA litigation; monetizes Kv7 +3.4% ALHC (Alignment Healthcare): rotation/Managed Care strength; shares higher fifth straight day +3.1% CNC (Centene): rotation/Managed Care strength; Medicaid MCOs leading advancers; best performer on XLV +3.0% CRDL (Cardiol Therapeutics): initiation +2.8% ARGX (argenx): upgraded at UBS +2.3% MOH (Molina Healthcare): rotation/Managed Care strength; Medicaid MCOs leading advancers +2.0% DVA (DaVita): second-best on XLV +1.5% NEOG (Neogen): upgraded at Piper Sandler +1.5% RVMD (Revolution Medicines): FDA approves Rasonque to treat 2L PDAC Decliners -12.4% SYRE (Spyre Therapeutics): trial results in rheumatoid arthritis; worst performer on XBI -12.3% GENB (Generate Biomedicines): data disclosures ahead of ERS 2026 -6.8% MRNA (Moderna): worst performer on XLV; follow-through, shares +4% WTD -5.5% RLAY (Relay Therapeutics): holder SVP Pauling 144 filing -4.8% BSX (Boston Scientific): discloses cybersecurity incident' second-worst on XLV -1.3% LLY (Eli Lilly): sector rotation -1.0% MRK (Merck): sector rotation; follow-through, shares +1% WTD -0.7% JAZZ (Jazz Pharmaceuticals): follow-through; notes offering and share repurchase	show story hide story
26-Aug-2026 08:43	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Boston Scientific the latest medical device company to disclose a cybersecurity incident with global disruption to its operations. Impacting ability to ship customer orders; timeline for restoration not yet known. Shares of BSX (6%) in the pre-market. Elsewhere sector newsflow remains fairly quiet apart from the usual Biotech updates. Summit Therapeutics' partner Akeso announced a highly successful interim readout, a first in gastrointestinal cancers for the bispecific ivonescimab. Shares of SMMT +14% in the pre-market. Spyre Therapeutics announced that while mid-stage results were stat-sig, it will not advance SPY072 monotherapy into phase 3 for rheumatoid arthritis. Shares of SYRE (11%) in the pre-market. Yesterday's trading action another advancer for Moderna, Merck and biopharma on follow-through from last week's melanoma breakthrough. Calendar remains fairly quiet across the sector, with Agilent the highlight of earnings (post-close on Wednesday), and a handful of PDUFA dates in the coming week. Macro S&P futures are down (0.1%) on Wednesday morning. Oil weakness in focus on recent flurry of headlines surrounding US-Iran conflict. However, unable to provide support for yields today, unlike on Monday and Tuesday when Treasuries firmed despite the continued pushback against Bessent's buyback boost. This week's pullback in crude also has not done much for broader risk sentiment or cyclical/reopening trades. Software under some AI disruption scrutiny this morning following the weaker growth outlook INTU. Pretty quiet elsewhere as market continues to wait for NVDA earnings after the close today and Warsh speech in Jackson Hole on Friday morning. Also some notable semi, software and retail reporters over the next few days. Pre-market trading update Trading higher +14.0% SMMT Akeso reports interim analysis of HARMONI-GI1 +8.1% EVMN initiation (low volume) +6.8% IVA unusual volume +3.5% CRDL initiation +3.0% NEOG upgraded at Piper Sandler +2.6% BHVN favorable judgment in Avilar/RA litigation +2.5% ARGX upgraded at UBS Trading lower -10.6% SYRE trial results in rheumatoid arthritis -5.8% BSX discloses cybersecurity incident -3.7% RLAY holder SVP Pauling 144 filing -2.4% JAZZ follow-through; notes offering and share repurchase Biotech Trial results: SMMT Partner Akeso (9926.HK) announced that HARMONI-GI1 evaluating ivonescimab chemo combo versus durvalumab (Imfinzi, AZN) chemo combo in 1L biliary tract cancer achieved its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Study also met all secondary endpoints (PFS, ORR). First successful phase 3 trial for ivonescimab in gastrointestinal tumors (priors were in lung cancer). SYRE announced topline results from phase 2 SKYWAY study evaluating SPY072 in rheumatic disease. Both doses demonstrated stat-sig benefits vs placebo on one or more endpoints, however the magnitude of efficacy did not meet company's target for monotherapy development for RA. Results do provide proof-of-mechanism and support other development plans. Research: ARGX upgraded to buy from neutral at UBS (Xian Deng), target increased to $1400 from $960 or approx. 37% upside. (FactSet average PT $1192; range $932-1450) CRDL initiated buy at B Riley Securities (Mayank Mamtani), target is $11 or approx. 450% upside. (FactSet average PT $8.50; range $5-11) EVMN initiated buy at Needham (Serge Belanger), target is $26 or approx. 103% upside. (FactSet average PT $30; range $22-50) HRMY initiated outperform at Wolfe Research (Rudy Li), target is $60 or approx. 54% upside. (FactSet average PT $46; range $30-70) SPTX initiated buy at Jones (Justin Walsh), target is $32 or approx. 29% upside. (FactSet average PT $37; range $30-50) Life Science & MedTech Corporate: BSX disclosed via 8-K filing on Wednesday morning that yesterday it identified a cybersecurity incident that has resulted in a global disruption of the company's operations. Full scope of operational and financial impacts are not yet known. Quick take: Analysts note that this is the latest in a string of medical device companies to face similar attacks this year, and while the extent of the impact is not yet known drawing comparison to the Stryker (SYK) incident which was quickly resolved in March/April. Stifel (buy-rated BSX) says 8K confirms what were just initial industry reports yesterday. Disclosure seems boilerplate, but firm acknowledges heightened risk to FY estimates. Wells Fargo (equal-weight rated BSX) suggests that peers may benefit from disruption (ABT, MDT, JNJ). Research: NEOG upgraded to overweight from neutral at Piper Sandler (David Westenberg), thinks company is entering a period of sustainable profitable growth. Target increased to $14 or approx. 20% upside. AXGN initiated buy at Truist (Ravi Misra), target is $60 or approx. 20% upside. (FactSet average PT $53; range $48-58) On Deck: Earnings after the close today: A (Agilent) (call at 16:30ET), PAHC (call Thu at 9:00ET) Earnings on Thu 27-Aug: before HQY (call at 8:30ET) Regulatory on Thu 27-Aug: GILD FDA PDUFA for BIC/LEN NDA (single-tablet bictegravir 75 mg/lenacapavir 50 mg) for treatment of HIV; AZN FDA PDUFA for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (estimated, following 3-month extension announced 27-May; brand name ETCAMAH in EU) (OLMA, ROP.SW) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 9926.HK, A, ABT, ARGX, AXGN, AZN, BHVN, BSX, CRDL, EVMN, GILD, HQY, HRMY, IVA, JAZZ, JNJ, MDT, NEOG, OLMA, PAHC, RLAY, ROP.SW, SMMT, SPTX, SYK, SYRE...(more)	show story hide story
26-Aug-2026 08:36	BSX Boston Scientific lower on disclosure of cybersecurity incident; too soon to judge impact ($49.86) Shares of BSX (5.8%) in the pre-market on Wednesday, following this morning's 8-K disclosure that yesterday it identified a cybersecurity incident that has resulted in a global disruption of the company's operations. Full scope of operational and financial impacts are not yet known. Quick take: Analysts note that this is the latest in a string of medical device companies to face similar attacks this year, and while the extent of the impact is not yet known drawing comparison to the Stryker (SYK) incident which was quickly resolved in March/April. Stifel (buy-rated BSX) says 8K confirms what were just initial industry reports yesterday. Disclosure seems boilerplate, but firm acknowledges heightened risk to FY estimates. Wells Fargo (equal-weight rated BSX) suggests that peers may benefit from disruption (ABT, MDT, JNJ). See Related StreetAccount comments: 8/26/2026 6:10:17 AM - Boston Scientific discloses cybersecurity incident resulting in a global disruption to the company's operations - 8-K Related: ABT, JNJ, MDT, SYK	show story hide story
25-Aug-2026 16:55	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished lightly mixed to higher and inline overall on Tuesday. By market close, advancers had equaled the decliners on the XLV. Healthcare +0.33% vs S&P 500 +0.32%. Most major health groups ended lightly mixed around the tape. Biotech was back on the upswing today, an outlier with MRNA +14.4% once again leading the XLV; MRK +3.8% second on the XLV, again. Only CAPR +22% and INBX +17% fared better on the XBI +3.00%. Risk-on trade extended much broader however, just eleven very modest decliners on the biotech ETF and gene editing names were broadly higher on the day. COO (3.6%) today's leading decliner on the XLV, edging out several Diabetes Tech names - the subgroup soft following Abbott Lab's FDA authorization for Libre Duo. Elsewhere corporate newsflow was fairly quiet. MCK +3.6% another exception, expanding capabilities in the oncology and contract research intersection. M&A by a distributor expanding into the oncology service field - McKesson paying $2.25B to acquire Precision Medicine Group. No M&A for SMID-cap biotech, however a trio of upgrades in the space today - two are from sell-equivalent to hold, for Moderna and Summit Therapeutics. Capricor Therapeutics also won over another analyst, Oppenheimer moved into the bull camp. Calendar remains fairly quiet across the sector. WAY hosts an Investor Day meeting on Tuesday afternoon; Agilent the highlight of this week's earnings calendar (post-close on Wednesday), and a handful of PDUFA dates scattered across the next six days. Yesterday's trading action balanced with a second pullback in biopharma, although declines moderated significantly by Monday's market close. Impact from the Moderna-Merck melanoma results continues to be evaluated by investors. Macro Several dynamics in focus today. AI trade a standout after coming under further pressure on Monday (and last week). Nothing specific behind either move, though some of the recent weakness invited more backfitting with the usual suspects (financing, open-weight competition). NVDA earnings tomorrow after the close next key area of focus (as usual, big beat and raise expected). Oil weaker again with the market seemingly more focused on headlines about SoH (Trump said all mines cleared, Iran-Oman framework) and renewed diplomatic efforts (Iran and Pakistan talk progress on Monday) than China's pushback against US economic threats. Lower oil helped drive a rate rally with some positioning dynamics (CTA shorts) also mentioned as supportive. No market traction behind latest bout of buyback criticism/skepticism (Druckenmiller op-ed). However, combination of lower oil/yields unable to help retail, which underperformed on the back of the Q2 miss and FY guidance cut at DKS (Foot Locker the culprit). Notable Gainers +21.9% CAPR (Capricor Therapeutics): upgraded at Oppenheimer; best performer on XBI +16.9% INBX (Inhibrx Biosciences): shares +55% YTD +14.4% MRNA (Moderna): upgraded at Wolfe Research; best performer on XLV +14.2% PRME (Prime Medicine): gene editing higher with XBI +3%; transferred buy at Chardan +9.6% KURA (Kura Oncology): insider buying (CEO) +9.5% BEAM (Beam Therapeutics): gene editing higher with XBI +3%; HC Wainwright comments, reiterates +9.4% AGMB (AgomAb Therapeutics NV): initiation +8.0% IBRX (ImmunityBio): on above average volume +7.5% TWST (Twist Bioscience): on above average volume +6.8% APMD (Apnimed): initiations (recent IPO) +6.7% CRSP (CRISPR Therapeutics): gene editing higher with XBI +3%; Citizens comments, reiterates +6.3% IMTX (Immatics): underwritten offering $150M +4.9% SMMT (Summit Therapeutics): upgraded at Bernstein; HARMONi published in The Lancet +3.8% MRK (Merck): follow-through; second-best on XLV +3.6% MCK (McKesson): acquires Precision Medical Group for $2.25B +2.3% JAZZ (Jazz Pharmaceuticals): FDA approves Ziihera sBLA, doublet and triplet for GEA Notable Decliners -29.3% SLQT (SelectQuote): earnings -4.5% ZYME (Zymeworks): sympathy to JAZZ -4.5% WAY (Waystar Holding): afternoon weakness during Investor Day presentation -3.6% COO (The Cooper Cos.): worst performer on XLV -2.7% PTGX (Protagonist Therapeutics): worst performer on XBI -2.1% DXCM (Dexcom): sympathy to ABT -1.9% MDT (Medtronic): sympathy to ABT -1.6% PODD (Insulet): sympathy to ABT -0.5% ABT (Abbott Labs): FDA authorizes Libre Duo Two deaths from measles reported in Pennsylvania - Reuters Reuters reports that two PA residents have died due to measles, citing the Pennsylvania Department of Health, which confirmed the first deaths related to measles in 35 years. StreetAccount notes these are the first measles deaths in the US this year. Per CDC, there were three (3) deaths in 2025 - two children in Texas and one adult in New Mexico. McKesson higher following CRO and oncology services acquisition MCK today announced it will acquire Precision Medicine Group for $2.25B, enhancing its clinical research and commercialization services. Will report within Oncology & Multispecialty segment. FDA approves Ziihera sBLA for gastric cancers JAZZ announced FDA approval of two Ziihera (zanidatamab) containing regimens for HER2+ gastroesophageal adenocarcinoma (GEA). Approval comes on the FDA PDUFA goal date. (ZYME, RPRX, ONC) Jazz hosting an investor conference call at 16:30ET FDA also approved two companion diagnostics made by Roche (ROP.SW) for use with the expanded labeling. JNJ receives FDA approval for first treatment of wAIHA JNJ announced that FDA has approved an sBLA for IMAAVY (nipocalimab) for the treatment of wAIHA (warm autoimmune hemolytic anemia), exactly six months from initial submission. First drug approved by the FDA for this indication. Previously approved as a treatment for myasthenia gravis (gMG) in April 2025 - the drug was central to their August 2020 acquisition of Momenta Pharmaceuticals for $6.5B. FDA approved label. Notable insider transactions in Healthcare today DHR disclosed Form 4 filing with CEO Rainer Blair selling more than 60% of his equity stake. GH disclosed Form 4 filing with co-CEO AmirAli Talasaz selling half of his equity stake. KURA disclosed Form 4 filing with CEO Troy Wilson buying 100K shares for $1.239M. Notable research in Healthcare today Biotech: ARGX downgraded to hold from buy at Deutsche Bank (Emmanuel Papadakis), target increased however to €925 from €900 or approx. 7% upside. CAPR upgraded to outperform from perform at Oppenheimer (Leland Gershell), noting optimism for approval of the deramiocel BLA. Target is $54 or approx. 694% upside. (FactSet average PT $26; range $2-60) MRNA upgraded to peer perform from underperform at Wolfe Research (Alexandria Hammond) SMMT upgraded to market perform from underperform at Bernstein (Jeffrey Walch), target increased to $11.90 from $9.80 or approx. 7% downside. (FactSet average PT $28; range $11-41) APMD seeing initial sell-side coverage following IPO on 31-Jul. Shares have traded +60% since pricing at $16/shr. All buy-equivalent ratings so far (BofA, Cantor Fitzgerald, Evercore ISI, LifeSci Capital) with an average PT $50, range $41-60. AGMB initiated overweight at Piper Sandler (Yasmeen Rahimi), target is $60 or approx. 368% upside. (FactSet average PT $38; range $28-60) MSLE initiated outperform at LifeSci Capital (Francois Brisebois), target is $22 or approx. 132% upside. (FactSet average PT $22; range $14-40) Post-close news Trial results: SYRE announced topline results from phase 2 SKYWAY study evaluating SPY072 in rheumatic disease. Both doses demonstrated stat-sig benefits vs placebo on one or more endpoints, however the magnitude of efficacy did not meet company's target for monotherapy development for RA. Results do provide proof-of-mechanism and support other development plans. Shares trading (12.4%) in the after-hours On Deck: Earnings on Wed 26-Aug: after A (Agilent) (call at 16:30ET), PAHC (call Thu at 9:00ET) on Thu 27-Aug: before HQY (call at 8:30ET) Regulatory on Thu 27-Aug: GILD FDA PDUFA for BIC/LEN NDA (single-tablet bictegravir 75 mg/lenacapavir 50 mg) for treatment of HIV; AZN FDA PDUFA for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (estimated, following 3-month extension announced 27-May; brand name ETCAMAH in EU) (OLMA, ROP.SW) on Sun 30-Aug: 6446.TT (PharmaEssentia) FDA PDUFA for Besremi sNDA for Essential Thrombocythemia (ET) during August 2026: TAK FDA PDUFA for rusfertide NDA for polycythemia vera (PV) (PTGX, RPRX, ZEAL.DC) Conference on Fri 28-Aug: European Society of Cardiology (ESC) 2026 (Aug 28-31) StreetAccount Healthcare Reads More US employers to drop weight-loss drugs in 2027, as healthcare costs increase (25-Aug) Reuters HHS plans new FDA deputy commissioner roles for technology and drugs, sources say (25-Aug) CNBC California Weighs Penalties for Healthcare Providers That Don't Rein In Costs (24-Aug) KFF Inside Moderna and Merck's cancer vaccine triumph (24-Aug) STAT News Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance (24-Aug) Reuters Hims' Weight-Loss Plans Draw Penalties Over Credit Card Disputes (21-Aug) Bloomberg This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, ABT, AGMB, APMD, ARGX, AZN, BEAM, CAPR, COO, CRSP, DHR, DXCM, GH, GILD, HQY, IBRX, IMTX, INBX, JAZZ, JNJ, KURA, MCK, MDT, MRK, MRNA, MSLE, OLMA, ONC, PAHC, PODD, PRME, PTGX, ROP.SW, RPRX, SLQT, SMMT, SYRE, TWST, WAY, ZYME...(more)	show story hide story
25-Aug-2026 11:52	Two deaths from measles reported in Pennsylvania - Reuters Reuters reports that two PA residents have died due to measles, citing the Pennsylvania Department of Health, which confirmed the first deaths related to measles in 35 years. StreetAccount notes these are the first measles deaths in the US this year. Per CDC, there were three (3) deaths in 2025 - two children in Texas and one adult in New Mexico. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
25-Aug-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.32% vs the S&P 500 +0.13%. Most major health groups are very lightly mixed around the tape. Biotech back on the upswing today, MRNA +12% again leading the XLV. MRK +2% second on the XLV. Only CAPR +15% and VIR +12% are faring better on the XBI +3.06%. Risk-on trade extending broader however, just five very modest decliners on the biotech ETF and gene editing names are broadly higher on the day. COO and BAX (2%) each, leading decliners on the XLV today. Corporate newsflow is very quiet today. MCK +1% an exception, expanding capabilities in the oncology and contract research intersection. Gainers +15.4% CAPR (Capricor Therapeutics): upgraded at Oppenheimer; best performer on XBI +11.5% MRNA (Moderna): upgraded at Wolfe Research; best performer on XLV +10.2% KURA (Kura Oncology): insider buying (CEO) +9.2% IMTX (Immatics): underwritten offering $150M +9.0% PRME (Prime Medicine): gene editing higher with XBI +3.06%; transferred buy at Chardan +7.8% BEAM (Beam Therapeutics): gene editing higher with XBI +3.06%; HC Wainwright comments, reiterates +7.0% CRSP (CRISPR Therapeutics): gene editing higher with XBI +3.06%; Citizens comments, reiterates +5.3% APMD (Apnimed): initiations (recent IPO) +4.9% SMMT (Summit Therapeutics): upgraded at Bernstein; HARMONi published in The Lancet +3.5% JAZZ (Jazz Pharmaceuticals): FDA approves Ziihera sBLA, doublet and triplet for GEA +3.4% AGMB (AgomAb Therapeutics NV): initiation +2.0% MRK (Merck): follow-through; second-best on XLV +1.7% GH (Guardant Health): insider selling (co-CEO) +1.3% ARGX (argenx): downgraded at Deutsche Bank +0.8% RPRX (Royalty Pharma): sympathy to JAZZ/ZYME +0.3% DHR (Danaher): insider selling (CEO) +0.3% JNJ (Johnson & Johnson): FDA approves IMAAVY sBLA for wAIHA Decliners -28.8% SLQT (SelectQuote): earnings -2.7% ZYME (Zymeworks): sympathy to JAZZ -2.6% COO (The Cooper Cos.): worst performer on XLV -2.5% XRAY (Dentsply Sirona): dental space lagging on light volume -2.1% ANAB (AnaptysBio): worst performer on XBI -1.6% BAX (Baxter International): second-worst on XLV -0.8% ABUS (Arbutus Biopharma Corp.): one of four decliners on XBI	show story hide story
25-Aug-2026 08:26	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Sector newsflow remains quiet. More M&A by a distributor expanding into the oncology service field - McKesson paying $2.25B to acquire Precision Medicine Group. No M&A for SMID-cap biotech, however a trio of upgrades in the space today - two are from sell-equivalent to hold, for Moderna and Summit Therapeutics. Capricor Therapeutics also won over another analyst, Oppenheimer moved into the bull camp. Shares of CAPR +6% in the pre-market. Calendar remains fairly quiet across the sector. WAY hosts an Investor Day meeting on Tuesday afternoon; Agilent the highlight of this week's earnings calendar (post-close on Wednesday), and a handful of PDUFA dates scattered across the next six days. Yesterday's trading action balanced with a second pullback in biopharma, although declines moderated significantly by Monday's market close. Impact from the Moderna-Merck melanoma results continues to be evaluated by investors. Macro S&P futures are up +0.4%, and Nasdaq up +0.8%, on Tuesday morning. Momentum rebound in focus this morning though nothing seemingly behind the move, just as recent bout of softness was largely seen as lacking a fundamental catalyst. Some of the backfitting surrounding the pullback has revolved around the usual suspects, including financing scrutiny, open-weight competition and data center backlash. NVDA earnings after the close on Wednesday the next key area of focus, though another big beat and raise widely expected. Not much going on elsewhere with the waiting game for Fed Chair Warsh on Friday. Lot of uncertainty about what Warsh will focus on, though still seen as unlikely to provide anything meaningfully incremental on reaction function. Treasury buyback boost has continued to grab a lot of attention with latest focus on Druckenmiller's op-ed criticism, though longer-term yields have ralliedfor a second straight session. Oil on the defensive again amid a number of pieces surrounding the US-Iran conflict, including reported diplomacy traction out of recent talks between Iran and Pakistan and China's pushback against US economic threats. Pre-market trading update Trading higher +10.4% KURA insider buying (CEO) +5.6% CAPR upgraded at Oppenheimer +4.1% APMD initiations (recent IPO) +2.6% AGMB initiation (low volume) +1.9% MRNA upgraded at Wolfe Research +1.7% GH insider selling (co-CEO) (low volume) +0.9% SMMT upgraded at Bernstein; HARMONi published in The Lancet +0.7% ARGX downgraded at Deutsche Bank (low volume) Trading lower -16.6% SLQT earnings -0.5% DHR insider selling (CEO) (low volume) -0.4% JNJ FDA approves IMAAVY sBLA for wAIHA (low volume) Pharma Regulatory: JNJ announced that FDA has approved an sBLA for IMAAVY (nipocalimab) for the treatment of wAIHA (warm autoimmune hemolytic anemia), exactly six months from initial submission. First drug approved by the FDA for this indication. Previously approved as a treatment for myasthenia gravis (gMG) in April 2025 - the drug was central to their August 2020 acquisition of Momenta Pharmaceuticals for $6.5B. Biotech Insider buying: KURA disclosed Form 4 filing with CEO Troy Wilson buying 100K shares for $1.239M. Regulatory: LKFT issues press release and confirms FDA orphan drug designation for gamgertamig (GILD) for pemphigus. StreetAccount reported the designation from FDA.gov on 20-Aug. Research: ARGX downgraded to hold from buy at Deutsche Bank (Emmanuel Papadakis), target increased however to €925 from €900 or approx. 7% upside. CAPR upgraded to outperform from perform at Oppenheimer (Leland Gershell), noting optimism for approval of the deramiocel BLA. Target is $54 or approx. 694% upside. (FactSet average PT $26; range $2-60) MRNA upgraded to peer perform from underperform at Wolfe Research (Alexandria Hammond) SMMT upgraded to market perform from underperform at Bernstein (Jeffrey Walch), target increased to $11.90 from $9.80 or approx. 7% downside. (FactSet average PT $28; range $11-41) APMD seeing initial sell-side coverage following IPO on 31-Jul. Shares have traded +60% since pricing at $16/shr. All buy-equivalent ratings so far (BofA, Cantor Fitzgerald, Evercore ISI, LifeSci Capital) with an average PT $50, range $41-60. AGMB initiated overweight at Piper Sandler (Yasmeen Rahimi), target is $60 or approx. 368% upside. (FactSet average PT $38; range $28-60) MSLE initiated outperform at LifeSci Capital (Francois Brisebois), target is $22 or approx. 132% upside. (FactSet average PT $22; range $14-40) Life Science & MedTech Insider selling: DHR disclosed Form 4 filing with CEO Rainer Blair selling more than 60% of his equity stake. GH disclosed Form 4 filing with co-CEO AmirAli Talasaz selling half of his equity stake. Services & Hospitals M&A: MCK announced it will acquire Precision Medicine Group for $2.25B, enhancing its clinical research and commercialization services. Will report within Oncology & Multispecialty segment. On Deck: Corporate WAY Investor Day meeting today (14:00ET) Regulatory JAZZ FDA PDUFA today for Ziihera sBLA for gastric cancers (RPRX, ZYME) on Thu 27-Aug: GILD FDA PDUFA for BIC/LEN NDA (single-tablet bictegravir 75 mg/lenacapavir 50 mg) for treatment of HIV; AZN FDA PDUFA for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (estimated, following 3-month extension announced 27-May; brand name ETCAMAH in EU) (OLMA, ROP.SW) Earnings on Wed 26-Aug: after A (Agilent) (call at 16:30ET), PAHC (call Thu at 9:00ET) on Thu 27-Aug: before HQY (call at 8:30ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, AGMB, APMD, ARGX, AZN, CAPR, DHR, GH, GILD, HQY, JNJ, KURA, LKFT, MCK, MRNA, MSLE, OLMA, ROP.SW, RPRX, SLQT, SMMT, WAY, ZYME...(more)	show story hide story
24-Aug-2026 16:33	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to little changed overall on Monday. Advancers outnumbered decliners on the XLV, a reversal of breadth in afternoon trading. Healthcare +0.02% vs S&P 500 (0.28%). Most major health groups ended little changed and lightly mixed around the tape on Monday. Today's key dynamic was another modest pullback in biopharma against the backdrop of broad MSD gains last week. MRNA (4.3%) pullback, shares were +129% last week, led all decliners on the XLV, and weighed on the XBI (0.94%). DRG (0.19%) finished far from its worst levels of the morning. Sector newsflow very quiet over the weekend - and no notable M&A announcements on Monday morning. Biggest regulatory headline perhaps a clinical hold on a gene therapy from RGNX (24.9%). CAPR +8.1% announced the FDA has extended the PDUFA for deramiocel by three months. Payers were today's leading advancer, the group is up ~1% on the average; UNH +2.2% leading gainer on the XLV, after trading places with HUM +2.0%. Looking ahead, WAY +1.4% hosting I-Day tomorrow, Agilent highlights the earnings calendar with its Wednesday evening report, and a handful of FDA PDUFA dates scattered across the next seven days. Macro Not a lot of action to start the trading week with market somewhat in waiting mode for key catalysts later this week (NVDA earnings, Warsh Jackson Hole speech). Latest Treasury buyback update (Bessent considering tapping TGA to fund buybacks) helped rates at longer-end. Move takes some pressure off Fed, shorter end of the curve (which were tabbed to finance purchases through "twist"), though structural rate pressures (debt/deficits, global yield backdrop, AI-linked supply) remain. Momentum extended recent underperformance with memory under under outsized pressure. AI narrative busy with a number of recent headlines (NVDA price hikes driven by memory surge and open-weight moves, Deepseek/OpenAI price cuts, rising AI-linked CDS). US and Canada trade war also a key focus. After talks collapsed and US implemented 50% tariff on $20B of Canadian imports Saturday, Trump said Monday Canadian cars, truck auto parts, steel to be hit with 50% tariffs starting in 2027, though delayed Canadian implementation, next US ramp not until January seen offering time for resolution. Not much new from Bessent's "economic D-Day" announcement, did not offer any detail on how China would be handled (recall China buys 90% of Iran's oil exports). Notable Gainers +18.5% ALVO (Alvotech): initiation +8.1% CAPR (Capricor Therapeutics): PDUFA extension by 3 months; best performer on XBI +7.0% JANX (Janux Therapeutics): upgraded at Wolfe Research; assumed at TD Cowen; second-best on XBI +4.5% VERA (Vera Therapeutics): on average volume +4.3% KURA (Kura Oncology): on above average volume +2.2% UNH (UnitedHealth Group): on below average volume; best performer on XLV Notable Decliners -24.9% RGNX (REGENXBIO): FDA places gene therapy RGX-121 on clinical hold; worst performer on XBI -12.1% AZTA (Azenta): CEO resigns; guidance update -9.0% TEM (Tempus AI): shares were +40% last week -8.0% HIMS (Hims & Hers Health): Bloomberg report on Visa notice -7.3% SLS (SELLAS Life Sciences Group, Inc.): shares +279% YTD -5.2% QGEN (Qiagen): appoints new CEO effective 1-Sep -4.4% GH (Guardant Health): TwinStrand judgment; Leerink comments -4.4% MANE (VeraDermics, Inc.): shares were down (9%) last week -4.3% MRNA (Moderna): shares were +129% last week; worst performer on XLV -3.3% SMMT (Summit Therapeutics): shares were +6% on Friday -2.7% BSX (Boston Scientific): shares were down (3%) last week Regulatory headlines in SMID-cap biotech RGNX announced that FDA has placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study. CEO comments: "We believe these findings are unique and limited to our Hunter Syndrome program, and require longer-term follow-up and additional data analysis to assess the benefit-risk profile of RGX-121." CAPR announced that FDA has extended the PDUFA for deramiocel by three months until 22-Nov-2026. Follows negative FDA Adcomm for the current proposed indication, and CEO comments that an amendment would soon be filed to modify the proposed indication. UTHR announced that FDA has accepted for review its NDA for oral formulaton of ralinepag as a treatment for pulmonary arterial hypertension (PAH). The PDUFA goal date is 24-Jun-2027. StreetAccount notes that MNKD is partnered on the DPI formulation of ralinepag (MNKD-1501). Azenta lower following CEO resignation AZTA announced that CEO John Marotta has resigned from the company, and that current board member Martin Madaus has been appointed interim CEO. Search for a permanent CEO is underway. Company reaffirms fiscal Q4 revenue guidance issued on 4-Aug-2026, and now expects a one-time EBITDA impact of $3M for consulting expense in Q4. Hims & Hers Health lower following surge in credit card disputes HIMS Bloomberg reports that Visa has issued notice to the company of a high number of credit card disputes over their weight loss service. Telehealth company was put in the Acquirer Monitoring Program after a "surge" of disputes. Roche diagnostic for Alzheimer's Disease gains FDA clearance LH and DGX each announced they would offer Roche's (ROP.SW) Elecsys Phospho-Tau Plasma blood test for Alzheimer's diagnosis. Roche announced earlier today that FDA has cleared the pTau217 assay. (QTRX) FDA accepts Jemperli sBLA for rectal cancer GSK announced that FDA has accepted for priority review its sBLA for Jemperli (ANAB) for patients with 1L dMMR/MSI-H rectal cancer. The PDUFA goal date is in February 2027, however the application is eligible for CNPV thus decision could come sooner. Notable research in Healthcare today Biotech: JANX upgraded to outperform from peer perform at Wolfe Research (Kalpit Patel), target is $23 or approx. 32% upside. (FactSet average PT $32; range $14-60) ALVO initiated buy at BofA (Jason Gerberry), target is $7 or approx. 58% upside. (FactSet average PT $6; range $4-9) INBX initiated buy at HC Wainwright (Robert Burns), target is $245 or approx. 136% upside. NVCT initiated overweight at Cantor Fitzgerald (Pete Stavropoulos) QTTB initiated overweight at Morgan Stanley (Judah Frommer), target is $34 or approx. 113% upside. STTK initiated strong buy at Raymond James (Martin Auster), target is $18 or approx. 139% upside. (FactSet average PT $15; range $11-18) MedTech: PSNL downgraded to hold from buy at Craig-Hallum Capital (Bill Bonello). Cites acquisition by TEM, and believes that a competing bid is unlikely even after the positive development by Moderna-Merck last week. Target is $16.25 or approx. 12% downside. NXGL downgraded to hold from buy at Maxim Group (Naz Rahman) VEEV transferred overweight at Piper Sandler (Billy Fitzsimmons), target increased to $295 from $235. NCNO transferred overweight at Piper Sandler (Billy Fitzsimmons), target increased to $25 from $22. IMDX initiated buy at Lucid Capital Markets (Alex Nowak), target is $8 or approx. 84% upside. Services: VMD initiated outperform at Barrington Research (Michael Petusky), target is $14 or approx. 58% upside. Post-close news Regulatory: LKFT issues press release and confirms FDA orphan drug designation for gamgertamig (GILD) for pemphigus. StreetAccount reported the designation from FDA.gov on 20-Aug. On Deck: Corporate WAY Investor Day meeting (14:00ET) Regulatory JAZZ FDA PDUFA on Tuesday for Ziihera sBLA for gastric cancers (RPRX, ZYME) Earnings on Wed 26-Aug: after A (Agilent) (call at 16:30ET), PAHC (call Thu at 9:00ET) StreetAccount Healthcare Reads California Weighs Penalties for Healthcare Providers That Don't Rein In Costs (24-Aug) KFF Inside Moderna and Merck's cancer vaccine triumph (24-Aug) STAT News Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance (24-Aug) Reuters Hims' Weight-Loss Plans Draw Penalties Over Credit Card Disputes (21-Aug) Bloomberg This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, ALVO, ANAB, AZTA, BSX, CAPR, DGX, GH, GILD, GSK, HIMS, IMDX, INBX, JANX, JAZZ, KURA, LH, LKFT, LLY, MANE, MNKD, MRK, MRNA, NCNO, NVCT, NXGL, PAHC, PSNL, QGEN, QTRX, QTTB, RGNX, ROP.SW, RPRX, SLS, SMMT, STTK, TEM, UNH, UTHR, VEEV, VERA, VMD, WAY, ZYME...(more)	show story hide story
24-Aug-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.42%) vs the S&P 500 (0.27%). Major health groups are lightly mixed to begin the session. Key dynamic is another modest pullback in biopharma with the backdrop of broad MSD gains last week. MRNA (7%) pullback, shares were +129% last week, leads all decliners on the XLV, and weighs on the XBI (1.57%). DRG (1.04%). Sector newsflow very quiet over the weekend - no notable M&A announcements on Monday morning. Biggest regulatory headline perhaps a clinical hold on a gene therapy from RGNX (23%). CAPR +15% announced the FDA has extended the PDUFA for deramiocel by three months. Payers are leading advancer, the group is up by 1% on the average; HUM +2% leading gainer on the XLV. Gainers +15.2% CAPR (Capricor Therapeutics): PDUFA extension by 3 months; best performer on XBI +11.5% ALVO (Alvotech): initiation +4.9% JANX (Janux Therapeutics): upgraded at Wolfe Research; assumed at TD Cowen +1.6% HUM (Humana): best performer on XLV +1.1% UNH (UnitedHealth Group): second-best on XLV Decliners -23.4% RGNX (REGENXBIO): FDA places gene therapy RGX-121 on clinical hold; worst performer on XBI -9.1% AZTA (Azenta): CEO resigns; guidance update -7.9% HIMS (Hims & Hers Health): Bloomberg report on Visa notice -7.3% MANE (VeraDermics, Inc.): shares were down (9%) last week -6.8% MRNA (Moderna): shares were +129% last week; worst performer on XLV -6.5% TEM (Tempus AI): shares were +40% last week -5.5% SMMT (Summit Therapeutics): shares were +6% on Friday -3.7% QGEN (Qiagen): appoints new CEO effective 1-Sep -3.2% GH (Guardant Health): TwinStrand judgment; Leerink comments -3.2% ZYME (Zymeworks): ahead of Ziihera PDUFA on Tuesday (JAZZ) -2.7% BSX (Boston Scientific): shares were down (3%) last week	show story hide story
24-Aug-2026 08:43	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Very quiet weekend for the Healthcare sector, and no notable M&A announcements on Monday morning. Shares of Moderna largely holding onto current levels, after gaining +129% last week. MRNA off (1%) in the pre-market. Biggest regulatory headline is a clinical hold on a gene therapy from small-cap biotech REGENXBIO. Shares of RGNX (21%) in the pre-market. Nothing official yet from Capricor Therapeutics or FDA following Saturday's PDUFA date for deramiocel. Recall that they were attempting to get an extension to amend the proposed indication. Shares of CAPR +6% in the pre-market. Macro S&P futures are down (0.2%) on Monday morning. Momentum weakness in focus this morning with memory under outsized pressure (hit overnight in Asia). However, lower oil/rates may be providing some cushion. Waiting game for details of Bessent's "economic D-Day" plan against Iran this afternoon and more importantly, NVDA earnings on Wednesday and Fed Chair Warsh's speech on Friday. Busy weekend of AI headlines with the focus on NVDA price hikes (driven by memory surge) and open-weight foray, frontier model competitive headwinds and price cuts and financing/supply/capex. The other big story from the weekend revolved around a US-Canada trade war. Washington levied 50% tariffs on $20B worth of Canadian goods and Canada said it would respond with dollar-for-dollar" retaliatory levies on American goods. Also more discussion/debate around Treasury's recent buyback boost. Last week's renewed momentum underperformance another area of focus. Pre-market trading update Trading higher +6.5% CAPR PDUFA was on Saturday +4.2% JANX upgraded at Wolfe Research; assumed at TD Cowen +1.6% ZYME ahead of Ziihera PDUFA on Tuesday (JAZZ) Trading lower -20.9% RGNX FDA places gene therapy RGX-121 on clinical hold -5.4% AZTA CEO resigns. guidance update -2.5% HIMS Bloomberg report on Visa notice -2.4% TEM shares were +40% last week -2.2% CAI shares were +21% last week -1.0% MRNA shares were +129% last week Pharma Regulatory: GSK announced that FDA has accepted for priority review its sBLA for Jemperli (ANAB) for patients with 1L dMMR/MSI-H rectal cancer. The PDUFA goal date is in February 2027, however the application is eligible for CNPV thus decision could come sooner. Biotech Regulatory: RGNX announced that FDA has placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study. CEO comments: "We believe these findings are unique and limited to our Hunter Syndrome program, and require longer-term follow-up and additional data analysis to assess the benefit-risk profile of RGX-121." UTHR announced that FDA has accepted for review its NDA for oral formulaton of ralinepag as a treatment for pulmonary arterial hypertension (PAH). The PDUFA goal date is 24-Jun-2027. StreetAccount notes that MNKD is partnered on the DPI formulation of ralinepag (MNKD-1501). Research: JANX upgraded to outperform from peer perform at Wolfe Research (Kalpit Patel), target is $23 or approx. 32% upside. (FactSet average PT $32; range $14-60) INBX initiated buy at HC Wainwright (Robert Burns), target is $245 or approx. 136% upside. NVCT initiated overweight at Cantor Fitzgerald (Pete Stavropoulos) QTTB initiated overweight at Morgan Stanley (Judah Frommer), target is $34 or approx. 113% upside. STTK initiated strong buy at Raymond James (Martin Auster), target is $18 or approx. 139% upside. (FactSet average PT $15; range $11-18) Life Science & MedTech Corporate: AZTA announced that CEO John Marotta has resigned from the company, and that current board member Martin Madaus has been appointed interim CEO. Search for a permanent CEO is underway. Company reaffirms fiscal Q4 revenue guidance issued on 4-Aug-2026, and now expects a one-time EBITDA impact of $3M for consulting expense in Q4. Media report: HIMS Bloomberg reports that Visa has issued notice to the company of a high number of credit card disputes over their weight loss service. Telehealth company was put in the Acquirer Monitoring Program after a "surge" of disputes. Insider buying: PODD CEO Ashley McEvoy discloses purchase of 1,100 shares raising stake by around 5%. (Form 4) Research: NXGL downgraded to hold from buy at Maxim Group (Naz Rahman) VEEV transferred overweight at Piper Sandler (Billy Fitzsimmons), target increased to $295 from $235. NCNO transferred overweight at Piper Sandler (Billy Fitzsimmons), target increased to $25 from $22. IMDX initiated buy at Lucid Capital Markets (Alex Nowak), target is $8 or approx. 84% upside. Services & Hospitals Research: VMD initiated outperform at Barrington Research (Michael Petusky), target is $14 or approx. 58% upside. On Deck: Regulatory Sat 22-Aug: CAPR FDA PDUFA for deramiocel BLA for cardiomyopathy in DMD patients on Tue 25-Aug: JAZZ FDA PDUFA for Ziihera sBLA for gastric cancers (RPRX, ZYME) Earnings on Wed 26-Aug: after A (Agilent) (call at 16:30ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, ANAB, AZTA, CAI, CAPR, GSK, HIMS, IMDX, INBX, JANX, JAZZ, MNKD, MRNA, NCNO, NVCT, NXGL, PODD, QTTB, RGNX, RPRX, STTK, TEM, UTHR, VEEV, VMD, ZYME...(more)	show story hide story
21-Aug-2026 19:52	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished broadly higher on Friday. Advancers beat decliners by 7:1 on the XLV. Healthcare +1.32% vs S&P 500 +0.43%. All major health groups ended higher by 1% or more to outperform the broader tape. After some profit-taking yesterday, Biopharma groups surged higher again, led by MRNA +8.9% and MRK +2.4%. XBI +1.44% and DRG +1.26%, finished the week higher +5.29% and +5.79% respectively. News flow very quiet across the sector. ABT +2.2% reached a key settlement in baby formula litigation; terms viewed as in line with expectations. Some small-cap biotech headlines including over $400M in private placements and Ambros Therapeutics going public via all-stock merger. A weekend PDUFA date for small-cap biotech CAPR (8.0%) remained the only catalyst on the calendar. CDC on Friday reported that weekly US measles cases are back at new highs, up more than double w/w. Macro: A very quiet end to a down trading week with little movement around the major market themes. Momentum trade quiet with some mixed (though not very incremental) updates around major AI narratives (Anthropic IPO valuation, potential Broadcom $60B debt offering, data center backlash). No progress toward any kind of diplomatic resolution to US/Iran war, though latest updates have suggested Trump has little appetite to return to kinetic action, Iran's president called for end of conflict (though he does not hold much sway), while "Economic D-Day" seen as unlikely to include China (which buys 90% of Iranian oil exports) given potential retaliation, further economic pain. Rates weaker again in Friday trading, tabbed in part to latest strong economic data. However, Treasuries yields higher for the week, more than erasing Treasury buyback announcement rally. Rate weakness added to latest scrutiny around debasement trade (gold, bitcoin rallying again, dollar index lowest in three months). Also somewhat of a waiting game ahead of key catalysts next week (Nvidia earnings, Jackson Hole). Notable Gainers on Friday: +102.6% HOWL (Werewolf Therapeutics): microcap; all-stock merger with Ambros Therapeutics; private placement ($150M) +15.4% SLS (SELLAS Life Sciences Group, Inc.): best performer on XBI; ~2X avg volume +9.2% ABUS (Arbutus Biopharma Corp.): share repurchase / tender offer +9.1% TEM (Tempus AI): follow-through; on nearly 3X average volume +8.9% MRNA (Moderna): follow-through; best performer on XLV +7.3% TGTX (TG Therapeutics): Betaville comments, we're told +6.2% NVAX (Novavax, Inc.): follow-through +5.9% SMMT (Summit Therapeutics): sympathy to ABBV/RemeGen +5.6% HCA (HCA Healthcare): second-best on XLV; on above average volume +2.4% MRK (Merck): follow-through +2.2% INNV (InnovAge Holding): upgraded at Keybanc +2.2% ABT (Abbott Labs): litigation settlement (infant formula) Notable Decliners on Friday: -8.0% CAPR (Capricor Therapeutics): worst performer on XBI; PDUFA is on Saturday -7.8% IOVA (Iovance Biotherapeutics): shares remain +19% for the week -3.2% PGEN (Precigen): off 52-week high, shares remain +18% for the week -1.1% RVMD (Revolution Medicines): Favus comments, we're told; Bernstein also commented on fair valuation -1.0% VEEV (Veeva Systems): worst performer on XLV; on light volume Week in Review: Healthcare equities outperformed for the week. The S&P 500 Healthcare Index up +4.30% vs the S&P 500 Index down (1.43%). Outperformers: Pharma, Biotech, MedTech, Services Underperformers: Managed Care Most major health groups were up mid-single digits on the week, each fueled in one way or another by a planned interim analysis of the phase 3 INTerpath-001 trial evaluating mRNA-4157 in combination with Keytruda in patients with melanoma. Wednesday's readout by Moderna and Merck resulted in over $73B in market-cap gains combined for the personalized cancer vaccine partners. The mRNA platform seen as de-risked again, for the first time outside of respiratory disease. Detailed data for the melanoma indication are expected in October, and topline results for larger indications such as lung cancer later this year. Beyond the biopharma read-throughs, mRNA supply chain and life science tools stocks saw their patience rewarded this week, boosting the MedTech group higher overall, and more than offsetting continued weakness in the medical device subgroup, where HIX enrollment changes remain a headwind. LST also boosted by the AI trade after Anthropic mentioned Twist Biosciences among its collaborators. Managed Care stocks were the lone decliner this week, largely a source of funds for the growth and risk-on trade. The White House named a current domestic policy aide as the next FDA Commissioner, and the measles outbreak continued to accelerate with the largest number of new cases this week. The Ebola outbreak in Congo now spread to an area bigger than France, and growing exponentially said the UN Coordinator on Ebola. Year-to-date, Healthcare +12.60% vs the S&P 500 +12.11%. Healthcare fifth out of eleven major sectors in CY26. Energy +41.24% and Utilities (0.23%) bracket them all. Notable movers for the week: Gainers: MRNA +129.2% - trial results in melanoma; upgrades; best performer on XLV and XBI AMLX +78.7% - trial results in post-bariatric hypoglycemia (PBH); secondary offering ARCT +63.4% - sympathy to MRNA (mRNA vaccine) MRVI +51.6% - sympathy to MRNA (mRNA supplier) TEM +39.5% - sympathy to MRNA via pending acquisition of PSNL PSNL +30.9% - sympathy to MRNA (genomic testing for cancer vaccines); deal stock / pending acquisition by TEM BNTX +25.2% - sympathy to MRNA (mRNA vaccine) TWST +22.8% - Anthropic blog post on protein design names Twist an external evaluator ARGX +22.1% - trial results in autoimmune myositis CAI +20.5% - sympathy to MRNA (LST subgroup) HIMS +20.0% - reaction to Heidi Overton appointment for FDA Commissioner HAE +19.8% - supply agreement with CSL.AU GRAL +17.2% - higher all five days; best week in 9 months TXG +16.1% - sympathy to TWST / Anthropic ILMN +14.9% - sympathy to TWST / Anthropic MRK +12.3% - trial results in melanoma; upgrade; downgrade TGTX +11.3% - Betaville comments on M&A CRSP +11.1% - gene editing squeeze higher with XBI rally NVAX +11.1% - sympathy to MRNA (vaccine adjuvants) IQV +9.8% - sympathy to TWST / Anthropic HALO +9.6% - sympathy to ARGX RGEN +8.6% - sympathy to MRNA (bioprocessing) VRTX +8.4% - 52W / all-time high DHR +8.1% - sympathy to MRNA (bioprocessing) Decliners: EYPT (63.9%) - trial results in wet AMD ALGN (10.3%) - July ortho data from Piper Sandler; worst performer on XLV; worst week since Aug 2025 MOH (5.7%) - follows +8% prior week; sympathy to CNC; MCO weakness on sector rotation CVS (4.3%) - sympathy to CNC; MCO weakness on sector rotation ISRG (4.0%) - West Coast Bus Trip comments; Piper Sandler defends on weakness CNC (3.6%) - CFO to retire; announced replacement; MCO weakness on sector rotation RARE (2.5%) - despite FDA approval of GENGLYCOS gene therapy for GSDIa Week Ahead (Sat - Sun): Aug 22 - 30 Regulatory calendar Sat 22-Aug: CAPR FDA PDUFA for deramiocel BLA for cardiomyopathy in DMD patients Tue 25-Aug: JAZZ FDA PDUFA for Ziihera sBLA for gastric cancers (RPRX, ZYME) Thu 27-Aug: GILD FDA PDUFA for BIC/LEN NDA (single-tablet bictegravir 75 mg/lenacapavir 50 mg) for treatment of HIV; AZN FDA PDUFA for camizestrant NDA in 1L HER2- breast cancer with ESR1 mutation (estimated, following 3-month extension announced 27-May; brand name ETCAMAH in EU) (OLMA, ROP.SW) Sun 30-Aug: 6446.TT (PharmaEssentia) FDA PDUFA for Besremi sNDA for Essential Thrombocythemia (ET) during August 2026: TAK FDA PDUFA for rusfertide NDA for polycythemia vera (PV) (PTGX, RPRX, ZEAL.DC) Earnings calendar Wed 26-Aug: after A (Agilent) (call at 16:30ET) Thu 27-Aug: before HQY (call at 8:30ET) Conference calendar Fri 28-Aug: European Society of Cardiology (ESC) 2026 (Aug 28-31) Related: 6446.TT, A, ABT, ABUS, ALGN, AMLX, ARCT, ARGX, AZN, BNTX, CAI, CAPR, CNC, CRSP, CVS, DHR, EYPT, GILD, GRAL, HAE, HALO, HCA, HIMS, HOWL, HQY, ILMN, INNV, IOVA, IQV, ISRG, JAZZ, MOH, MRK, MRNA, MRVI, NVAX, OLMA, PGEN, PSNL, PTGX, RARE, RGEN, ROP.SW, RPRX, RVMD, SLS, SMMT, TAK, TEM, TGTX, TWST, TXG, VEEV, VRTX, ZEAL.DC, ZYME, +AMBX...(more)	show story hide story
21-Aug-2026 14:21	StreetAccount Summary: Notable Drug Events expected for the week of 23-Aug Preface: The FDA PDUFA for CAPR for deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD) is expected Saturday 22-Aug. Generally, weekend PDUFA dates tend to be Friday announcements. Tue 25-Aug Regulatory decision: JAZZ FDA PDUFA for ZIIHERA sBLA in locally advanced or metastatic GEA Thu 27-Aug Regulatory decision: GILD FDA PDUFA for bictegravir+ lenacapavir NDA in HIV Fri 28-Aug Industry meeting with clinical data: European Society of Cardiology (Aug 28-31) (AZN.LN, IONS, CRSP, KARD, NOVN.SW, BAYN.GR, AMGN, TENX) Trial results: CRSP to discuss phase 1 results for CTX310 trial in sHTG and refractory hypercholesterolemia at ESC (10:30ET) Later during August 2026 Regulatory decisions: FDA PDUFAs: 6446.TT (Besremi sBLA, 30-Aug), PTGX/4502.JP (rusfertide NDA), AZN.LN (camizestrant NDA) Trial results: CGON (Ph3 NMIBC), LGVN (Ph2 HLHS), TYRA (Ph2 IR NMIBC) Related: 4502.JP, 6446.TT, AMGN, AZN.LN, BAYN.GR, CAPR, CGON, CRSP, GILD, IONS, JAZZ, KARD, LGVN, NOVN.SW, PTGX, TENX, TYRA...(more)	show story hide story
21-Aug-2026 11:05	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +1.83% vs the S&P 500 +0.51%. All major health groups higher to begin the session. After some profit-taking yesterday, Biopharma groups surge higher again led by MRNA +14% and MRK +3%. XBI +2.09% and DRG +1.60%, both are tracking toward 6% weekly gains. Very quiet overnight across the Health sector. ABT +1% reached a key settlement in baby formula litigation; terms viewed as in line with expectations. Some small-cap biotech headlines including over $400M in private placements and Ambros Therapeutics going public via merger. A weekend PDUFA date for small-cap biotech CAPR (1%) the only remaining item on the calendar this week. CDC reports weekly Measles cases at new highs, more than double w/w. Gainers +119.7% HOWL (Werewolf Therapeutics): microcap; all-stock merger with Ambros Therapeutics; private placement ($150M) +13.9% MRNA (Moderna): follow-through; best performer on XLV and XBI +10.2% TGTX (TG Therapeutics): Betaville comments, we're told +9.3% ABUS (Arbutus Biopharma Corp.): share repurchase / tender offer +7.8% SMMT (Summit Therapeutics): sympathy to ABBV/RemeGen +7.5% NVAX (Novavax, Inc.): follow-through +5.4% TEM (Tempus AI): on strong volume; follow-through, shares +35% WTD +5.0% HCA (HCA Healthcare): on light volume +3.9% INNV (InnovAge Holding): upgraded at Keybanc +3.0% MRK (Merck): follow-through +2.6% NUVB (Nuvation Bio): initiation +2.2% AVAH (Aveanna Healthcare Holdings): secondary offering for holders, priced Decliners -5.8% GOSS (Gossamer Bio): private placement ($250M) -3.4% PGEN (Precigen): worst performer on XBI; off 52-week high, shares +18% WTD -1.3% RVTY (Revvity): worst performer on XLV; shares remain +5% WTD -1.2% TNDM (Tandem Diabetes Care): initiation -0.8% TMO (Thermo Fisher Scientific): shares remain +6% WTD	show story hide story
21-Aug-2026 10:48	CDC reports 211 new cases of measles this week, highest daily rate this outbreak Highest weekly count since the report on 23-Jan-2026*, more than 2X the prior week, and roughly 3X the trailing five-week average. Year-to-date, US CDC has reported 2,777 cases of measles, including 211 over the past week. Note: The third week of January marked a shift in reporting from Wednesdays to Fridays, and the 245 cases covered nine days rather than seven. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
21-Aug-2026 09:17	Ebola spreading exponentially in Congo, says UN - Reuters Reuters reports that the death toll has topped 2,500 in the ongoing Ebola outbreak, and the UN Ebola coordinator says that funds are running out within weeks. There are no approved vaccines or treatments yet for the Bundibugyo species of Ebola. Yesterday, the WHO announced the release of 70K doses of the Ervebo vaccine (MRK) which is licensed and recommended for prior species of Ebola virus. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: MRK	show story hide story
21-Aug-2026 08:52	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Very quiet overnight across the Health sector. Abbott Labs reached a key settlement in baby formula litigation; terms viewed as in line with expectations. Shares of ABT unchanged in the pre-market. Some small-cap biotech headlines including over $400M in private placements and Ambros Therapeutics going public via merger. A weekend PDUFA date for small-cap biotech Capricor Therapeutics the only remaining item on the calendar this week. Heading into the catalyst, shares of CAPR are +78% MTD and (76%) YTD. Story of the week remains the Moderna-Merck trial results in melanoma, which fueled the biotech rally on Wednesday - and Life Science rally on Thursday. DRG, XBI, and the life science tools subgroup are all on track for around 4% weekly gains. Macro S&P futures are up +0.5% on Friday morning. Quiet end to a fairly volatile week. Debasement trade remains a key area of focus with all of the skepticism surrounding ability of Treasury's buyback boost to offset the more structural forces putting upward pressure on long-term yields. Lots of moving pieces surrounding the US-Iran conflict with the lack of kinetic escalation and improved SoH transit dynamics the positives while also skepticism about US's ability to inflict more economic pain without the risk of negative spillover effects for the US/global economy, and relations with China. AI headlines continue to revolve around the upcoming Anthropic IPO, financing deals and data center backlash, the latter of which was flagged as one of the potential overhangs amid the Tues-Wed momentum selloff. Pre-market trading update Trading higher +134.0% HOWL microcap; all-stock merger with Ambros Therapeutics; private placement ($150M) +12.5% GOSS private placement ($250M) +10.1% ABUS share repurchase (tender offer) +5.0% INNV upgraded at Keybanc +3.2% NUVB initiation +1.7% TNDM initiation +1.0% CAPR ahead of Saturday PDUFA goal date +0.1% ABT litigation settlement (infant formula) Trading lower -6.0% AVAH secondary offering for holders, priced -2.4% TEM on 134K shares Biotech Private placement: GOSS announced a $250M private placement ($150M committed) to fund seralutinib development. Together with existing cash expects operations funded into 2028. Merger with private placement: Ambros Therapeutics and Werewolf Therapeutics (HOWL) announced they have entered into an all-stock merger agreement, and a concurrent $150M private placement. Combined company will focus on Ambros' neridronate program for CRPS type 1, and ticker will change to "AMBX". Cash runway into H1 of 2029. Regulatory: BIIB FDA approved an efficacy supplement (sNDA) for Empaveli. Agency says only 'efficacy-labeling change with clinical data' - an updated label is not yet available on the FDA website. Research: FTH initiated buy at Needham (Gil Blum), target is $56 or approx. 74% upside. IMA initiated buy at HC Wainwright (Arthur He), target is $28 or approx. 399% upside. NUVB initiated overweight at Cantor Fitzgerald (Li Watsek), target is $12 or approx. 73% upside. AMRN reinstated underweight at JPMorgan (Jessica Fye), target is $13 or approx. 8% downside. EBS reinstated underweight at JPMorgan (Jessica Fye) IMCR reinstated overweight at JPMorgan (Jessica Fye), target is $50 or approx. 38% upside. MBX reinstated overweight at JPMorgan (Jessica Fye), target is $88 or approx. 33% upside. NKTR reinstated neutral at JPMorgan (Jessica Fye), target is $65 or approx. 13% downside. STOK reinstated overweight at JPMorgan (Jessica Fye), target is $40 or approx. 27% upside. Life Science & MedTech Corporate / litigation: ABT announced a settlement of a portion of NEC-formula cases, including the Gill case and claims involving ~2000 other individuals, for an aggregate payment of $670M. Quick take: Still some outstanding suits and work to do, but analysts view the terms as in line with expectations, and the marginal cost per claim favorable compared to the landmark Gill, and to the JNJ talc proposal. Per the notes reviewed, most see an ultimate resolution in the range of $1.0-1.3B. Leerink sees settlement incrementally de-risking for ABT. Research: HCAT downgraded to hold from buy at Canaccord Genuity (Richard Close), target cut to $1.80 from $3. BBNX initiated market perform at William Blair (Steven Lichtman) TNDM initiated outperform at William Blair (Steven Lichtman) Services & Hospitals Secondary offering: AVAH announced 15M share offering for holders, with an option for another 2.3M shares. The 15M share offering later priced at $11.75/share, or (9.4%) below Thursday's close of $12.97. On Deck: Regulatory on Sat 22-Aug: CAPR FDA PDUFA for deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD). Note: Negative FDA Adcomm on 29-Jul. Note x2: Management commented on 13-Aug that extension was possibility, based on BLA amendment and upper limb function in patients with DMD indication. Peek Ahead to next week (Aug 23-30) Regulatory: JAZZ FDA PDUFA for Ziihera sBLA for gastric cancers on Tue 25-Aug GILD FDA PDUFA for single-tablet bictegravir 75 mg/lenacapavir 50 mg NDA for treatment of HIV on Thu 27-Aug Earnings: Agilent (A) fiscal Q3 report on Wed 26-Aug (call at 16:30ET) Conference: European Society of Cardiology (ESC) 2026 (Aug 28-31) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, ABT, ABUS, AMRN, AVAH, BBNX, BIIB, CAPR, EBS, FTH, GILD, GOSS, HCAT, HOWL, IMA, IMCR, INNV, JAZZ, MBX, NKTR, NUVB, STOK, TEM, TNDM, +AMBX...(more)	show story hide story
21-Aug-2026 08:49	ABT Abbott seen as resolving NEC litigation from a position of leverage ($114.14) ABT last night announced a settlement of a portion of NEC-formula cases, including the Gill case and claims involving ~2000 other individuals, for an aggregate payment of $670M. Quick take: Still some outstanding suits and work to do, but analysts view the terms as in line with expectations, and the marginal cost per claim favorable compared to the landmark Gill, and to the JNJ talc proposal. Per the notes reviewed, most see an ultimate resolution in the range of $1.0-1.3B. Leerink sees settlement incrementally de-risking for ABT. See Related StreetAccount comments: 8/20/2026 4:19:35 PM - Abbott announces settlement of portion of cases in infant formula litigation: to resolve Gill case and claims involving ~2K other individuals for aggregate of $670M	show story hide story
20-Aug-2026 16:36	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to lower overall on Thursday. Decliners beat advancers by nearly 4:1 on the XLV. Healthcare (1.89%) vs S&P 500 (0.87%). All major health groups ended lower on the session, and many were lightly mixed around the tape. Profit taking hit biopharma after yesterday's outsized moves; XBI (3.64%) and DRG (2.10%) today. Pullback for MRNA (23.6%), leading decliners on both the XLV and XBI. MRK and inline (2.0%) with off-setting rating changes in the name. LifeSci subgroup was relatively firm, with many names extending yesterday's advances on the mRNA renewal theme. Medical devices a source of funds in the group; ISRG (5.8%) cut August gains in half. IQV +2.7% and on track for +8% week, stock hit fresh 52-week highs, beat only by RVTY +3.9% on the XLV. DHR +2.1% another leading gainer and on track for +7% week, stock at a 6-month high. Insider selling at CAH (2.7%) raised some eyebrows, but Leerink (outperform) says nothing to see here. Peers were down 1-2%. Overnight, FDA approved a new gene therapy for a rare disease, and awarded a PRV to Ultragenyx which the company plans to monetize. RARE (3.5%). Executives at Cardinal Health disclosed the sale of a combined 250K shares of stock. Leerink analyst Michael Cherny says this is normal activity for the company. Analysts continue to debate the meaning of yesterday's INTerpath-001 trial results, leading to one upgrade (new street high PT) and one downgrade (valuation) for Merck. Yesterday, Healthcare equities saw their best day in 16 months, with optimism fueled by the Moderna-Merck trial results in melanoma. The XBI +5.90% saw its second-best gain of the year, the DRG +3.77% best day in ten months. Not only were mRNA pipelines rewarded on Wednesday, the life sciences subgroup that supports mRNA processing saw strong gains in reaction. Not much focus yet on the White House appointment of Heidi Overton for the next FDA Commissioner. Macro More defensive tone with several dynamics in play. Long-end rates have given back a big chunk of yesterday's buyback boost support with takeaways skepticism about Treasury's ability to offset structural pressures already at work, though Bessent flagged an increased focus on fiscal consolidation during CNBC interview today. Oil higher again as Trump ratcheted up economic threats against Iran, while bigger issue from a global growth perspective seems to be refining capacity constraints and implication for products (diesel in focus). Today has also brought another batch of softer results out of retail (and more tariff refund noise), playing into some of the more recent concerns about the waning tailwind from outsized tax refunds. Some pockets of stabilization in momentum following a big two-day selloff that seemed to be more about quant/systematic flows but also raised some questions about the bar for AI headlines. Notable Gainers +14.8% MRVI (Maravai Lifesciences): follow-through, shares were +26% yesterday +12.5% IOVA (Iovance Biotherapeutics): best performer on XBI; follow-through, shares +29% WTD +8.8% TEM (Tempus AI): follow-through, shares were +24% yesterday +6.9% ARCT (Arcturus Therapeutics): follow-through, shares were +25% yesterday +6.6% DIM.FP (Sartorius Stedim Biotech): upgraded at UBS +6.1% SRT3.GR (Sartorius): upgraded at UBS +5.4% GRAL (GRAIL, Inc.): follow-through, shares +16% WTD +3.9% RVTY (Revvity): best performer on XLV; on heavy volume, shares +6% WTD +2.8% IQV (IQVIA Holdings): 52-week high; above average volume, shares +8% WTD +2.5% HIMS (Hims & Hers Health): above average volume +2.1% DHR (Danaher): on average volume, shares +7% WTD Notable Decliners -23.5% MRNA (Moderna): worst performer on XLV and XBI; follow-through, shares were +177% yesterday -14.3% CAPR (Capricor Therapeutics): PDUFA is Saturday; Feuerstein article -14.3% EYPT (EyePoint Pharmaceuticals): on 2X volume, shares down (63%) WTD -5.8% ISRG (Intuitive Surgical): on above average volume -5.0% BSX (Boston Scientific): on above average volume -4.6% RXRX (Recursion Pharmaceuticals): on above average volume -3.5% RARE (Ultragenyx Pharmaceutical): FDA approves GENGLYCOS gene therapy; WAC price $2.7M -2.9% IDXX (IDEXX Laboratories): on below average volume -2.5% ALGN (Align Technology): follow-through, shares down (12%) WTD -2.0% MRK (Merck): follow-through; upgraded at Morgan Stanley; downgraded at RBC Capital Markets -2.0% BNTX (BioNTech): follow-through, shares were +22% yesterday Capricor Therapeutics DMD treatment is headed for FDA rejection, writes STAT News' Feuerstein STAT News' Adam Feuerstein writes an opinion piece where he repeats his belief that deramiocel will be rejected by FDA, and that recent CEO comments on a BLA amendment are a hollow and unsupported stall tactic. Shares of CAPR traded down (14.4%) on Thursday, and are currently +3% WTD / +78% MTD / (76%) YTD. Ultragenyx Pharmaceuticals with muted reaction to FDA approval RARE announced that FDA approves Genclycos (pariglasgene brecaparvovec, formerly DTX401) BLA for treatment of glycogen storage disease type IA (GSDIa). PDUFA goal date was Sunday 23-Aug. On the call: Announced WAC price $2.7M, and affirmed sufficient launch inventory. Plans to provide no revenue guidance until the products sixth quarter post-launch. Cardinal Health execs sell company stock CAH C-suite sold approximately 250K shares combined, representing nearly $60M in stock. Quick take: Leerink Partners analyst Michael Cherny (outperform rated) writes that this is normal activity for the company, given the fiscal calendar and awards, and sees no reason to believe it signals any change in insider views. Notable research in Healthcare today Pharma: MRK upgraded to overweight from equal-weight at Morgan Stanley (Terence Flynn), target increased to $179 from $116 or approx. 18% upside. (FactSet average PT $146; range $105-179) MRK downgraded to sector perform from outperform at RBC Capital Markets (Trung Huynh), notes valuation. Target increased however to $150 from $142 or approx. 1% downside. Leerink Partners analyst Lili Nsongo publishes a deep dive on mRNA vaccine pipelines from respiratory to cancer - not just Merck-Moderna. (ARCT, BNTX, CSL.AU, GSK, PFE, SNY) UBS analyst Michael Yee publishes a deep dive on BMY ahead of phase 3 readout in Q4 (estimates October) for admilparant in IPF. Biotech: ACOG initiated buy at B Riley Securities (William Wood), target is $21 or approx. 136% upside. CALC initiated buy at Guggenheim Securities (Vamil Divan), target is $9 or approx. 1375% upside. ELOX initiated buy at Lucid Capital Markets (Dev Prasad), target is $38 or approx. 109% upside. INCY initiated buy at Canaccord Genuity (John Newman), target is $152 or approx. 18% upside. MIST initiated overweight at Cantor Fitzgerald (Olivia Brayer Saunders), target is $3 or approx. 178% upside. PRQR initiated buy at BofA (Alec Stranahan), target is $8 or approx. 260% upside. QNCX initiated buy at Craig-Hallum Capital (Albert Lowe), target is $68 or approx. 97% upside. SRZN initiated outperform at William Blair (Lachlan Hanbury-Brown) MedTech: DIM.FP upgraded to buy from neutral at UBS (Matthew Weston), target increased to €260 from €220 or approx. 42% upside. SRT3.GR upgraded to buy from neutral at UBS (Matthew Weston), target increased to €300 from €240 or approx. 24% upside. CERS initiated buy at Freedom Broker (Ilya Zubkov), target is $6.50 or approx. 132% upside. FRNM initiated buy at Guggenheim Securities (Subbu Nambi), target is $21 or approx. 54% upside. (FactSet average PT $17; range $17-18) Services: PGNY initiated overweight at Wells Fargo Securities (Stan Berenshteyn), target is $37 or approx. 45% upside. Post-close news Secondary offering: AVAH announced 15M share offering for holders, with an option for another 2.3M shares. Shares trading (8.3%) in the after-hours Research: HCAT downgraded to hold from buy at Canaccord Genuity (Richard Close), target cut to $1.80 from $3. On Deck: Regulatory on Sat 22-Aug: CAPR FDA PDUFA for deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD). Note: Negative FDA Adcomm on 29-Jul. Note x2: Management commented on 13-Aug that extension was possibility, based on BLA amendment and upper limb function in patients with DMD indication. Peek Ahead to next week (Aug 23-30) Regulatory: JAZZ FDA PDUFA for Ziihera sBLA for gastric cancers on Tue 25-Aug GILD FDA PDUFA for single-tablet bictegravir 75 mg/lenacapavir 50 mg NDA for treatment of HIV on Thu 27-Aug Earnings: Agilent (A) fiscal Q3 report on Wed 26-Aug (call at 16:30ET) Conference: European Society of Cardiology (ESC) 2026 (Aug 28-31) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, ACOG, ALGN, ARCT, AVAH, BMY, BNTX, BSX, CAH, CALC, CAPR, CERS, CSL.AU, DHR, DIM.FP, ELOX, EYPT, FRNM, GILD, GRAL, GSK, HCAT, HIMS, IDXX, INCY, IOVA, IQV, ISRG, JAZZ, MIST, MRK, MRNA, MRVI, PFE, PGNY, PRQR, QNCX, RARE, RVTY, RXRX, SNY, SRT3.GR, SRZN, TEM...(more)	show story hide story
20-Aug-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.80%) vs the S&P 500 (0.20%). Major health groups are lightly mixed around the tape, with some profit taking hitting biopharma after yesterday's outsized moves; XBI (3.39%) and DRG (1.40%) today. MRNA (20%) pullback leads both the XLV and XBI. MRK (1%) with off-setting rating changes. LifeSci subgroup relatively firm, with many extending yesterday's advances on the mRNA renewal theme. DHR +2% leading gainer on the XLV today and on track for a +7% week, stock at a 6-month high. Insider selling at CAH (1%) raised some eyebrows, but Leerink (outperform) says nothing to see here. Gainers +11.0% MRVI (Maravai Lifesciences): follow-through, shares were +26% yesterday +8.1% TEM (Tempus AI): follow-through, shares were +24% yesterday +5.6% IOVA (Iovance Biotherapeutics): follow-through, shares +18% WTD +5.2% DIM.FP (Sartorius Stedim Biotech): upgraded at UBS +4.9% SRT3.GR (Sartorius): upgraded at UBS +4.7% HIMS (Hims & Hers Health): on strong volume +3.4% RNTX (Rein Therapeutics): FDA fast track designation in IPF +2.5% DHR (Danaher): best performer on XLV +1.8% IQV (IQVIA Holdings): 52-week high +1.2% ARCT (Arcturus Therapeutics): follow-through, shares were +25% yesterday Decliners -20.1% MRNA (Moderna): worst performer on XLV and XBI; follow-through, shares were +177% yesterday -10.6% EYPT (EyePoint Pharmaceuticals): shares (62%) WTD -9.2% CAPR (Capricor Therapeutics): PDUFA is Saturday; Feuerstein article -5.7% RXRX (Recursion Pharmaceuticals): on strong volume -5.0% BNTX (BioNTech): follow-through, shares were +22% yesterday -1.8% RARE (Ultragenyx Pharmaceutical): FDA approves GENGLYCOS gene therapy; WAC price $2.7M -1.3% MRK (Merck): follow-through; upgraded at Morgan Stanley; downgraded at RBC Capital Markets	show story hide story
20-Aug-2026 09:15	CAPR Capricor Therapeutics DMD treatment is headed for FDA rejection, writes STAT News' Feuerstein ($7.98) Shares of CAPR (2.8%) in the pre-market on Thursday - the stock is up +20% WTD through Wednesday. STAT News' Adam Feuerstein writes an opinion piece where he repeats his belief that deramiocel will be rejected by FDA, and that recent CEO comments on a BLA amendment are a hollow and unsupported stall tactic. See Related StreetAccount comments: 8/13/2026 5:35:39 PM - Capricor Therapeutics to submit amendment to BLA for upper limb function - conf call Reference Link	show story hide story
20-Aug-2026 08:34	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight, FDA approved a new gene therapy for a rare disease, and awarded a PRV to Ultragenyx which the company plans to monetize. Shares of RARE +6% in the pre-market. Executives at Cardinal Health disclosed the sale of a combined 250K shares of stock. Analysts continue to debate the meaning of yesterday's INTerpath-001 trial results, leading to one upgrade (new street high PT) and one downgrade (valuation) for Merck. Shares of MRNA (9%) and MRK (2%) in the pre-market. Yesterday, Healthcare equities saw their best day in 16 months, with optimism fueled by the Moderna-Merck trial results in melanoma. The XBI +5.90% saw its second-best gain of the year, the DRG +3.77% best day in ten months. Not only were mRNA pipelines rewarded on Wednesday, the life sciences subgroup that supports mRNA processing saw strong gains in reaction. Not much focus yet on the White House appointment of Heidi Overton for the next FDA Commissioner. Macro S&P futures are down (0.3%) on Thursday morning. Fairly quiet from a headline perspective but market continuing to debate familiar themes. Lot of reflection on yesterday's surprise announcement from Treasury that it will increase long end liquidity buybacks by at least $2B per operation through early November. Move widely viewed as more about signaling than duration removal, with a lot of debate about its effectiveness; Treasuries have been selling off this morning with 30Y yield back above 5.25%. Big two-day momentum selloff another area of scrutiny, particularly given cleaner positioning dynamics following July unwind, though no great fundamental explanation for the move. Higher oil no help; focus largely on Trump's warning of economic consequences for any country helping Iran, along with some traction behind US efforts to boost SoH traffic. Pre-market trading update Trading higher +5.8% RARE FDA approves GENGLYCOS gene therapy; WAC price $2.7M +4.8% RNTX FDA fast track designation in IPF +4.6% SRT3.GR in European trading; upgraded at UBS +4.4% DIM.FP in European trading; upgraded at UBS +2.5% MRVI follow-through, shares were +26% yesterday Trading lower -9.1% MRNA follow-through, shares were +177% yesterday -5.1% RXRX on 2M shares -3.2% HIMS on 123K shares -2.2% BNTX follow-through, shares were +22% yesterday -1.6% MRK follow-through; upgraded at Morgan Stanley; downgraded at RBC Capital Markets -1.6% ARCT follow-through, shares were +25% yesterday Pharma Research: MRK upgraded to overweight from equal-weight at Morgan Stanley (Terence Flynn), target increased to $179 from $116 or approx. 18% upside. (FactSet average PT $146; range $105-179) MRK downgraded to sector perform from outperform at RBC Capital Markets (Trung Huynh), notes valuation. Target increased however to $150 from $142 or approx. 1% downside. Leerink Partners analyst Lili Nsongo publishes a deep dive on mRNA vaccine pipelines from respiratory to cancer - not just Merck-Moderna. (ARCT, BNTX, CSL.AU, GSK, PFE, SNY) UBS analyst Michael Yee publishes a deep dive on BMY ahead of phase 3 readout in Q4 (estimates October) for admilparant in IPF. Biotech Regulatory: RARE announced that FDA approves Genclycos (pariglasgene brecaparvovec, formerly DTX401) BLA for treatment of glycogen storage disease type IA (GSDIa). PDUFA goal date was Sunday 23-Aug. On the call: Announced WAC price $2.7M, and affirmed sufficient launch inventory. Plans to provide no revenue guidance until the products sixth quarter post-launch. Earnings: ALVO reported H1 EBITDA $46.9M on revenue $211.9M. Reaffirms FY26 guidance. Conf. call at 8:00ET. Research: ACOG initiated buy at B Riley Securities (William Wood), target is $21 or approx. 136% upside. CALC initiated buy at Guggenheim Securities (Vamil Divan), target is $9 or approx. 1375% upside. ELOX initiated buy at Lucid Capital Markets (Dev Prasad), target is $38 or approx. 109% upside. INCY initiated buy at Canaccord Genuity (John Newman), target is $152 or approx. 18% upside. MIST initiated overweight at Cantor Fitzgerald (Olivia Brayer Saunders), target is $3 or approx. 178% upside. PRQR initiated buy at BofA (Alec Stranahan), target is $8 or approx. 260% upside. QNCX initiated buy at Craig-Hallum Capital (Albert Lowe), target is $68 or approx. 97% upside. SRZN initiated outperform at William Blair (Lachlan Hanbury-Brown) Life Science & MedTech Research: DIM.FP upgraded to buy from neutral at UBS (Matthew Weston), target increased to €260 from €220 or approx. 42% upside. SRT3.GR upgraded to buy from neutral at UBS (Matthew Weston), target increased to €300 from €240 or approx. 24% upside. FRNM initiated buy at Guggenheim Securities (Subbu Nambi), target is $21 or approx. 54% upside. (FactSet average PT $17; range $17-18) Services & Hospitals Insider sales: CAH C-suite sold approximately 250K shares combined, representing nearly $60M in stock. SHC disclosed via Form 4 filing that Executive Chairman Michael Petras sold 1.1M shares, or 20% of his stake. Research: PGNY initiated overweight at Wells Fargo Securities (Stan Berenshteyn), target is $37 or approx. 45% upside. On Deck: Regulatory (cont): EMA CHMP monthly meeting (Aug 17-20, replaced by written procedure) on Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD). Note: Negative FDA Adcomm on 29-Jul. Note x2: Management commented on 13-Aug that extension was possibility, based on BLA amendment and upper limb function in patients with DMD indication. This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACOG, ALVO, ARCT, BMY, BNTX, CAH, CALC, CAPR, CSL.AU, DIM.FP, ELOX, FRNM, GSK, HIMS, INCY, MIST, MRK, MRNA, MRVI, PFE, PGNY, PRQR, QNCX, RARE, RNTX, RXRX, SHC, SNY, SRT3.GR, SRZN...(more)	show story hide story
19-Aug-2026 16:54	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly higher on Wednesday. Top performing sector, and best day in 16 months for the XLV. Advancers beat decliners by more than 4:1 on the XLV. Healthcare +3.52% vs S&P 500 +0.21%. Most major health groups ended higher, only Managed Care lower on the session. Biotech, Pharma, and MedTech led the advancers. XBI +5.90% for only the second-best day this year (+7.5% on March 31st tops with risk-on trade and biopharma premium M&A totaling nearly $14B). Today's primary driver was the cancer breakthrough as Merck and Moderna announced topline, interim results from phase 3 trial evaluating intismeran autogene in combination with Keytruda for melanoma. Trial met its primary endpoint (PFS) - first for an individualized neoantigen therapy (INT) and for a mRNA-based cancer therapy. MRNA +177.0% and MRK +12.6% were one and two on the XLV; ALGN (2.9%), with a hold-equivalent initiation, extended weekly decline beyond (10%) and was leading decliner on the XLV. Tangent to the oncology drug developers, bioprocessing names very strong on the mRNA news, particularly those who have remained steadfast with investments in the field. TWST +22.6% added an AI kicker with ambitious mention in Anthropic's blog. DRG +3.77% saw its best day in ten months (+5.4% on 1-Oct when White House drug pricing deals dodged tariff threats). White House today confirmed earlier media report by Bloomberg, and appointed domestic policy aide Heidi Overton to become the next FDA Commissioner. Picking CBER and CDER leadership near the top of her agenda. Baxter appointed John Rogers as next CFO, coming from the same position at Smith & Nephew. Macro Treasury rally big focus in Wednesday trading with significant bull flattening move following Treasury announcement on ramp in size of buyback operations for longer-term paper. However, some early analyst reads noted some skepticism whether it would durably pressure long-end of the curve, while today's 20Y auction was poorly received. Adds to latest rate concerns around Fed uncertainty, higher real rates, AI-related supply concerns, growing US debt/deficits. July FOMC minutes seen as a bit more dovish than expected (officials see inflation step down ahead, inflation expectations healthy), though not doing much to Fed rate path pricing (~24 bp of hikes through year-end, little changed pre-release). Fairly quiet elsewhere. Latest retail/consumer results offered more micro than macro takeaways, though analysts noted support for resilient consumer narrative (TGT guidance, TJX mixed but highlighted strong Q3 start). Not much new around US/Iran with no credible diplomatic off-ramps; some press coverage of US operations to shepherd oil through the SoH. Other areas of focus include cautious AI updates (OpenAI revenue challenges, political challenges to data centers, widening CDS spreads), still-elevated momentum positioning despite recent selloff, elevated earnings growth expectations. Notable Gainers +177.0% MRNA (Moderna): trial results in melanoma with MRK; upgraded at William Blair and BofA; best performer on XLV and XBI +52.4% NYKD.NO (Nykode Therapeutics): sympathy to MRNA +25.8% MRVI (Maravai Lifesciences): bioprocessing read-across from MRNA +25.2% ARCT (Arcturus Therapeutics): sympathy to MRNA +24.1% TEM (Tempus AI): sympathy to MRNA +22.6% TWST (Twist Bioscience): Anthropic blog post / AI evaluator; 52-week high +22.0% BNTX (BioNTech): sympathy to MRNA +16.1% PRME (Prime Medicine): gene-editing risk-on trade XBI; initiation +13.7% PSNL (Personalis): sympathy to MRNA +13.7% IOVA (Iovance Biotherapeutics): 52-week high +12.9% CRSP (CRISPR Therapeutics): gene-editing risk-on trade XBI +12.6% MRK (Merck): trial results in melanoma with MRNA +10.8% NVAX (Novavax, Inc.): sympathy to MRNA +9.9% AMLX (Amylyx Pharmaceuticals): follow-through, secondary offering +9.4% BEAM (Beam Therapeutics): gene-editing risk-on trade XBI +6.1% RGEN (Repligen Corp.): bioprocessing read-across from MRNA +6.1% DHR (Danaher): bioprocessing read-across from MRNA +5.0% RVTY (Revvity): bioprocessing read-across from MRNA +4.7% A (Agilent Technologies): bioprocessing read-across from MRNA +4.2% TMO (Thermo Fisher Scientific): bioprocessing read-across from MRNA +3.8% REGN (Regeneron): FDA approves Pasatru for adults with FOP +3.6% WAT (Waters): bioprocessing read-across from MRNA +2.8% BAX (Baxter International): names new CFO (from SNN) Notable Decliners -23.0% XSPRAY.SS (Xspray Pharma): FDA issues CRL - manufacturing -4.9% REPL (Replimune Group): worst performer on XBI, shares (1%) WTD -4.2% JBIO (Jade Biosciences): follow-through, shares (9%) WTD -3.3% HLUN.B.DC (H. Lundbeck): earnings, guidance -3.0% ORKA (Oruka Therapeutics): off 52-week high -2.9% SNN (Smith & Nephew): CFO steps down for outside opportunity (BAX) -2.9% ALGN (Align Technology): worst performer on XLV; follow-through, shares (10%) WTD Moderna shares double on mRNA-based cancer therapy interim analysis; de-risks platform again Shares of MRNA traded +177% on Wednesday, with MRK +13%, following today's announcement that the phase 3 INTerpath-001 trial evaluating mRNA-4157 in combination with Keytruda in patients with melanoma met its primary endpoint at a planned interim analysis. Improvements in recurrence free survival (RFS) primary, and distant metastasis free survival (DMFS) secondary endpoints were stat-sig and clinically meaningful. (ARCT, EIKN, MRVI, NVAX, TEM, PSNL, RGEN, NYKD.NO) Quick take: First phase 3 success for mRNA outside of respiratory diseases, and reactions are joyous and upbeat on the platform again. Interim results viewed as de-risking the platform, beginning with melanoma but perhaps beyond into even larger opportunities such as the companies' phase 3 program for lung cancer. Full data in melanoma to be presented at an upcoming medical meeting, widely believed to be ESMO in late October. Positive read-across highlighted for BNTX which has its own readout later this year (BNT113). And of course for MRK as it tries to fill the LOE gap for Keytruda. LST analysts also noted potential read-through to bioprocessing companies (RGEN, MRVI, DHR, TMO), particularly those who remained steadfast with mRNA investments. StreetAccount reports one early upgrade for MRNA, coming out of William Blair. FactSet data shows just 23% of analysts (6 of 26) are buy-rated in the name, sixteen are hold, four are sell-rated. One additional upgrade in reaction, BofA moves from underperform to neutral, increased PT of $170 reflects a new street high. Street Takeaways: Analysts were largely upbeat ... Despite anticipated regulatory submission in 2027, and data presentations in H2'26, some remain sidelined, seeing a balanced risk/reward for MRNA following the 100%+ move in the stock, undisclosed hazard ratios and mixed metastatic data, while long term MRK benefit is seen dependent on commercial pricing/COGS execution. Additional headlines in SMID-cap biotech HLUN.B.DC reported Q2 adj EPS DKK1.54 vs consensus DKK1.49 on revenue DKK6.46B vs consensus DKK6.23B, adj EBITDA ahead. Confirms FY revenue outlook and adj EBITDA growth. XSPRAY.SS announced that FDA issued a Complete Response Letter (CRL) for Dasynoc. Reinspection of third party manufacturer remains the gating issue. Company hopes to resubmit NDA this year. AMLX announces $350.0M proposed public offering of common stock. Notable research in Healthcare today Biotech: MRNA upgraded to outperform from market perform at William Blair (Myles Minter) MRNA upgraded to neutral from underperform at BofA (Alec Stranahan), target increased to $170 from $40 or approx. 8% upside. (FactSet average PT $61; range $25-135) MREO downgraded to underweight from neutral at JPMorgan (Priyanka Grover) AGMB initiated overweight at Cantor Fitzgerald (Yanni Souroutzidis) AKTS initiated outperform at Wedbush Securities (David Nierengarten), target is $35 or approx. 40% upside. AKTS initiated market outperform at BMO Capital Markets (David Lebowitz), target is $37 or approx. 48% upside. ALNY initiated market outperform at BMO Capital Markets (David Lebowitz), target is $319 or approx. 39% upside. ASND initiated market outperform at BMO Capital Markets (David Lebowitz), target is $319 or approx. 28% upside. BCAX initiated market outperform at BMO Capital Markets (David Lebowitz), target is $35 or approx. 40% upside. BMRN initiated market outperform at BMO Capital Markets (David Lebowitz), target is $98 or approx. 46% upside. CATX initiated market outperform at BMO Capital Markets (David Lebowitz), target is $11 or approx. 243% upside. PRME initiated market outperform at BMO Capital Markets (David Lebowitz), target is $9 or approx. 195% upside. EXEL initiated market perform at BMO Capital Markets (David Lebowitz), target is $54 or approx. 2% upside. IONS initiated market perform at BMO Capital Markets (David Lebowitz), target is $60 or approx. 1% upside. MedTech: DRIO initiated buy at Alliance Global Partners, target is $12 or approx. 67% upside. RMD initiated neutral at Rothschild & Redburn (Jackson Philips), target is $230 or approx. 5% upside. Services: MD downgraded to hold from buy at Jefferies (Jack Slevin), target increased however to $28 from $27 or approx. 5% upside. (FactSet average PT $26; range $21-28) CAH initiated outperform at RBC Capital Markets (Ryan Halsted), target is $276 or approx. 17% upside. COR initiated sector perform at RBC Capital Markets (Ryan Halsted), target is $330 or approx. 4% upside. HCSG initiated outperform at Oppenheimer (Michael Wiederhorn), target is $28 or approx. 28% upside. (FactSet average PT $27; range $24-30) MCK initiated sector perform at RBC Capital Markets (Ryan Halsted), target is $845 or approx. 3% downside. Post-close news Earnings: ALVO reports H1 EBITDA $46.9M on revenue $211.9M. Reaffirms FY26 guidance. Conf. call tomorrow at 8:00ET. Shares trading +1.5% in the after-hours Insider sales: SHC disclosed via Form 4 filing that Executive Chairman Michael Petras sold 1.1M shares, or 20% of his stake. Shares (0.5%) in the after-hours On Deck: Regulatory (cont): EMA CHMP monthly meeting (Aug 17-20, replaced by written procedure) on Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD). Note: Negative FDA Adcomm on 29-Jul. Note x2: Management commented on 13-Aug that extension was possibility, based on BLA amendment and upper limb function in patients with DMD indication. on Sun 23-Aug: FDA PDUFA for RARE DTX401 (pariglasgene brecaparvovec) BLA for treatment of glycogen storage disease type IA (GSDIa) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: A, AGMB, AKTS, ALGN, ALNY, ALVO, AMLX, ARCT, ASND, BAX, BCAX, BEAM, BMRN, BNTX, CAH, CAPR, CATX, COR, CRSP, DHR, DRIO, EIKN, EXEL, HCSG, HLUN.B.DC, IONS, IOVA, JBIO, MCK, MD, MREO, MRK, MRNA, MRVI, NVAX, NYKD.NO, ORKA, PRME, PSNL, RARE, REGN, REPL, RGEN, RMD, RVTY, SHC, SNN, TEM, TMO, TWST, WAT, XSPRAY.SS...(more)	show story hide story
19-Aug-2026 11:03	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare index +3.30% vs the S&P 500 +0.65%. Best day in 16 months for the XLV. All major health groups are higher, although Services just inline, while Biotech, Pharma, and MedTech are each higher by more than 4% on the averages. XBI +4.54% for only the second-best day this year (+7.5% on March 31st tops with risk-on trade and biopharma premium M&A totaling nearly $14B). Today's driver is the cancer breakthrough as Merck and Moderna announced topline, interim results from phase 3 trial evaluating intismeran autogene in combination with Keytruda for melanoma. Trial met its primary endpoint (PFS) - first for an individualized neoantigen therapy (INT) and for a mRNA-based cancer therapy. MRNA +143% and MRK +11% are one and two on the XLV; MCK (1%), with a hold-equivalent initiation, leading a short list of decliners on the XLV. Tangent to the oncology drug developers, bioprocessing names very strong on the mRNA news, particularly those who have remained steadfast with investments in the field. CNC (0.5%) the only other decliner on the XLV, and only decliner among large payers. Gainers +142.9% MRNA (Moderna): trial results in melanoma with MRK; upgrade at Wm Blair; best performer on XLV and XBI +52.4% NYKD.NO (Nykode Therapeutics): sympathy to MRNA +29.6% MRVI (Maravai Lifesciences): bioprocessing read-across from MRNA +23.1% BNTX (BioNTech): sympathy to MRNA +19.5% TWST (Twist Bioscience): Anthropic blog post / AI evaluator +18.5% ARCT (Arcturus Therapeutics): sympathy to MRNA +16.5% TEM (Tempus AI): sympathy to MRNA +13.3% PRME (Prime Medicine): gene-editing risk-on trade XBI; initiation +10.7% MRK (Merck): trial results in melanoma with MRNA +10.2% AMLX (Amylyx Pharmaceuticals): follow-through, secondary offering +8.8% PSNL (Personalis): sympathy to MRNA +8.5% CRSP (CRISPR Therapeutics): gene-editing risk-on trade XBI +8.4% BEAM (Beam Therapeutics): gene-editing risk-on trade XBI +7.7% NVAX (Novavax, Inc.): sympathy to MRNA +6.6% RVTY (Revvity): bioprocessing read-across from MRNA +6.0% RGEN (Repligen Corp.): bioprocessing read-across from MRNA +5.5% DHR (Danaher): bioprocessing read-across from MRNA +4.5% TMO (Thermo Fisher Scientific): bioprocessing read-across from MRNA +4.2% A (Agilent Technologies): bioprocessing read-across from MRNA +3.1% WAT (Waters): bioprocessing read-across from MRNA +2.5% BAX (Baxter International): names new CFO (from SNN) Decliners -20.8% XSPRAY.SS (Xspray Pharma): FDA issues CRL - manufacturing -3.9% HLUN.B.DC (H. Lundbeck): earnings, guidance -3.1% REPL (Replimune Group): worst performer on XBI, shares +1% WTD -2.0% SNN (Smith & Nephew): CFO steps down for outside opportunity (BAX) -1.7% MD (Pediatrix Medical Group): downgraded at Jefferies -0.9% MCK (McKesson): initiation; worst performer on XLV -0.4% CNC (Centene): one of two decliners on XLV -0.3% MREO (Mereo BioPharma Group): downgraded at JPMorgan	show story hide story
19-Aug-2026 09:25	MRNA Moderna shares double on mRNA-based cancer therapy interim analysis; de-risks platform again ($62.96) Shares of MRNA +96% in the pre-market, and MRK +8%, following today's announcement that the phase 3 INTerpath-001 trial evaluating mRNA-4157 in combination with Keytruda in patients with melanoma met its primary endpoint at a planned interim analysis. Improvements in recurrence free survival (RFS) primary, and distant metastasis free survival (DMFS) secondary endpoints were stat-sig and clinically meaningful. Quick take: First phase 3 success for mRNA outside of respiratory diseases, and reactions are joyous and upbeat on the platform again. Interim results viewed as de-risking the platform, beginning with melanoma but perhaps beyond into even larger opportunities such as the companies' phase 3 program for lung cancer. Full data in melanoma to be presented at an upcoming medical meeting, widely believed to be ESMO in late October. Positive read-across highlighted for BNTX which has its own readout later this year (BNT113). And of course for MRK as it tries to fill the LOE gap for Keytruda. LST analysts also noted potential read-through to bioprocessing companies (RGEN, MRVI, DHR, TMO), particularly those who remained steadfast with mRNA investments. StreetAccount reports one early upgrade for MRNA, coming out of William Blair. FactSet data shows just 23% of analysts (6 of 26) are buy-rated in the name, sixteen are hold, four are sell-rated. See Related StreetAccount comments: 8/19/2026 6:47:59 AM - Merck and Moderna announce topline results from Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene + KEYTRUDA Related: ARCT, BNTX, DHR, MRK, MRVI, NYKD.NO, PSNL, RGEN, TEM, TMO...(more)	show story hide story
19-Aug-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Big news is the cancer breakthrough as Merck and Moderna announce topline, interim results from phase 3 trial evaluating intismeran autogene in combination with Keytruda for melanoma. Trial met its primary endpoint (PFS) - first for an individualized neoantigen therapy (INT) and for a mRNA-based cancer therapy. Shares of MRNA +92% and MRK +8% in the pre-market. Rising tide in INT space lifting others too: ARCT +26%, BNTX +17%, NYKD.NO +8%, TEM +8%. Bloomberg reports that the White House will appoint domestic policy aide Heidi Overton to become the next FDA Commissioner. Baxter appoints John Rogers as next CFO, coming from the same position at Smith & Nephew. Shares of BAX +3% / ADRs for SNN (4%) in the pre-market. Macro S&P futures are little changed on Wednesday morning. Rate and momentum stabilization in focus this morning. No great explanation for former amid continued flurry of fiscal and corporate supply scrutiny, while latter partly chalked up to nearly $30B SKHY buyback announcement. Busy day of retail earnings with mixed takeaways and seemingly more micro (including expectations) than macro focus. Big healthcare rally on tap for today following positive results from Phase 3 melanoma trial. Still no credible diplomatic off-ramps for US-Iran conflict with Washington focused on patience/inflicting of economic pain, Iran stepping up attacks on SoH shipping and Gulf neighbors and more concerns about economic spillover effects from surging diesel prices. Pre-market trading update Trading higher +92.2% MRNA trial results in melanoma with MRK; upgrade at Wm Blair +25.5% ARCT sympathy to MRNA +17.3% BNTX sympathy to MRNA +8.2% NYKD.NO shares halted in European trading; sympathy to MRNA +7.9% TEM sympathy to MRNA +7.5% MRK trial results in melanoma with MRNA +6.3% PSNL sympathy to MRNA +5.7% NVAX sympathy to MRNA +3.9% AMLX follow-through, secondary offering +3.0% BAX names new CFO (from SNN) Trading lower -5.6% MREO downgraded at JPMorgan -3.6% SNN CFO steps down for outside opportunity (BAX) -3.3% HLUN.B.DC in European trading; earnings, guidance -1.1% MD downgraded at Jefferies Biotech Trial results: MRNA and MRK announced topline, interim results from phase 3 trial INTerpath-001 evaluating intismeran autogene (mRNA-4157) in combination with Keytruda (pembrolizumab) for melanoma. Trial met its primary endpoint (PFS) - first for an individualized neoantigen therapy (INT) and for a mRNA-based cancer therapy. Data will be shared at an upcoming medical meeting, and with regulatory authorities. (BNTX, NYKD.NO, PSNL, TEM) MRNA upgraded in reaction Earnings: HLUN.B.DC reported Q2 adj EPS DKK1.54 vs consensus DKK1.49 on revenue DKK6.46B vs consensus DKK6.23B, adj EBITDA ahead. Confirms FY revenue outlook and adj EBITDA growth. Regulatory: XSPRAY.SS announced that FDA issued a Complete Response Letter (CRL) for Dasynoc. Reinspection of third party manufacturer remains the gating issue. Company hopes to resubmit NDA this year. Corporate: AMLX announces $350.0M proposed public offering of common stock. Research: MRNA upgraded to outperform from market perform at William Blair (Myles Minter) MREO downgraded to underweight from neutral at JPMorgan (Priyanka Grover) AGMB initiated overweight at Cantor Fitzgerald (Yanni Souroutzidis) AKTS initiated outperform at Wedbush Securities (David Nierengarten), target is $35 or approx. 40% upside. AKTS initiated market outperform at BMO Capital Markets (David Lebowitz), target is $37 or approx. 48% upside. ALNY initiated market outperform at BMO Capital Markets (David Lebowitz), target is $319 or approx. 39% upside. ASND initiated market outperform at BMO Capital Markets (David Lebowitz), target is $319 or approx. 28% upside. BCAX initiated market outperform at BMO Capital Markets (David Lebowitz), target is $35 or approx. 40% upside. BMRN initiated market outperform at BMO Capital Markets (David Lebowitz), target is $98 or approx. 46% upside. CATX initiated market outperform at BMO Capital Markets (David Lebowitz), target is $11 or approx. 243% upside. PRME initiated market outperform at BMO Capital Markets (David Lebowitz), target is $9 or approx. 195% upside. EXEL initiated market perform at BMO Capital Markets (David Lebowitz), target is $54 or approx. 2% upside. IONS initiated market perform at BMO Capital Markets (David Lebowitz), target is $60 or approx. 1% upside. Life Science & MedTech Research: DRIO initiated buy at Alliance Global Partners, target is $12 or approx. 67% upside. RMD initiated neutral at Rothschild & Redburn (Jackson Philips), target is $230 or approx. 5% upside. Services & Hospitals Research: MD downgraded to hold from buy at Jefferies (Jack Slevin), target increased however to $28 from $27 or approx. 5% upside. (FactSet average PT $26; range $21-28) CAH initiated outperform at RBC Capital Markets (Ryan Halsted), target is $276 or approx. 17% upside. COR initiated sector perform at RBC Capital Markets (Ryan Halsted), target is $330 or approx. 4% upside. HCSG initiated outperform at Oppenheimer (Michael Wiederhorn), target is $28 or approx. 28% upside. (FactSet average PT $27; range $24-30) MCK initiated sector perform at RBC Capital Markets (Ryan Halsted), target is $845 or approx. 3% downside. On Deck: Regulatory (cont): EMA CHMP monthly meeting (Aug 17-20, replaced by written procedure) on Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD). Note: Negative FDA Adcomm on 29-Jul. Note x2: Management commented on 13-Aug that extension was possibility, based on BLA amendment and upper limb function indication. on Sun 23-Aug: FDA PDUFA for RARE DTX401 (pariglasgene brecaparvovec) BLA for treatment of glycogen storage disease type IA (GSDIa) Earnings after the close ALVO (call Thu at 8:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AGMB, AKTS, ALNY, ALVO, AMLX, ARCT, ASND, BAX, BCAX, BMRN, BNTX, CAH, CAPR, CATX, COR, DRIO, EXEL, HCSG, HLUN.B.DC, IONS, MCK, MD, MREO, MRK, MRNA, NVAX, NYKD.NO, PRME, PSNL, RARE, RMD, SNN, TEM, XSPRAY.SS...(more)	show story hide story
18-Aug-2026 20:25	White House policy aide Heidi Overton to be named as next FDA Commissioner - Bloomberg, citing a person familiar with the matter See Related StreetAccount comments: 7/8/2026 3:00:55 PM - White House reviewing finalists for FDA Commissioner role -- Stat News Reference Link: bloomberg Reference Link: Bloomberg	show story hide story
18-Aug-2026 16:13	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equites ended mostly higher in Tuesday. Advancers outnumbered decliners nearly 2:1 on the XLV. Healthcare +1.60% vs the S&P 500 (0.69%). Most major healthcare groups ended higher and all outperformed the tape. Pharma was the leading advancer, with the DRG +2.48%, while Medtech was the sole decliner. SMID-cap biotech AMLX +63.8% after announcing topline results from its Phase 3 trial in post-bariatric hypoglycemia (PBH), where it met the primary and all secondary endpoints. VOGX +25.4%, which operates in the same space. PODD +6.0% and CRL (2.5%) bracketed the XLV. Australian drug and vaccinemaker CSL Ltd reported FY results ahead of consensus, and guides a return to sustainable growth in the years ahead. Shares traded +17% higher in Australia on Tuesday. Macro US equities finished lower in Tuesday trading, ending near worst levels. Semi/memory weakness was the big drag on indices today, though not much new in the narrative and atmosphere more rotation than risk-off. Debt issuance, rising CDS spreads, increased capex forecasts continue to hang over AI-linked trade, dovetailing with bubbling worries about rising sovereign debt levels and fiscal deficits. Crowding out from corporate supply related to AI capex boom and Fed uncertainty/credibility played into the worries. US 30Y bond yield hit a post-2007 high yesterday though Treasury yields flipped to modest declines since the morning. Oil prices still in focus though not much evolution in US-Iran conflict and little expectation for near-term diplomatic offramp. Notable Gainers +63.8% AMLX (Amylyx Pharmaceuticals): trial results in PBH +25.4% VOGX (Vogenx, Inc.): sympathy to AMLX +16.0% HAE (Haemonetics): supply agreement with CSL.AU +13.8% OBX (Obsidian Therapeutics): initiation +12.3% EYPT (EyePoint Pharmaceuticals): shares (63%) yesterday; downgrades +9.3% KURA (Kura Oncology): insider buying (CEO) +7.3% NUVB (Nuvation Bio): initiation +6.0% PODD (Insulet): best performer on XLV +0.9% ELVN (Enliven Therapeutics): initiations Notable Decliners -6.7% TWST (Twist Bioscience): worst performer on XBI -2.5% CRL (Charles River Laboratories): worst performer on XLV -0.7% ABCL (AbCellera Biologics): shares +95% MTD Amylyx Pharmaceuticals higher on positive topline results in PBH AMLX announced topline results and that its phase 3 LUCIDITY trial with avexitide in post-bariatric hypoglyclemia (PBH) met the primary endpoint and all secondary endpoints. Company plans to submit NDA for avexitide to FDA by end of 2026. Full data to be presented at a medical meeting. (MBX, VOGX) Quick take: Analysts largely upbeat following the best-case ph3 LUCIDITY readout for Avexitide, which achieved a statistically significant reduction in Level 2/3 hypoglycemic events with clean safety. Several raised price targets, viewing the data as a definitive win, which is seen de-risking regulatory approval ahead of a planned NDA filing at the end of the year and 2027 commercial launch. Notable research in Healthcare today Biotech: EYPT downgraded to sector perform from outperform at RBC Capital Markets (Lisa Walter), target cut to $5 from $37 or approx. 3% upside. EYPT downgraded to neutral from buy at HC Wainwright (Yi Chen). EYPT downgraded to neutral from buy at Chardan Capital (Andreas Argyides), target is $5 or approx. 3% upside. CORT assumed buy at Truist (Srikripa Devarakonda), target increased to $164 from $50 or approx. 40% upside. (FactSet average PT $141; range $50-165) DFTX initiated buy at BofA (Tazeen Ahmad), target is $75 or approx. 66% upside. (FactSet average PT $67; range $52-90) EDIT initiated buy at Ladenburg Thalmann, target is $6 or approx. 111% upside. (FactSet average PT $6; range $1-15) ELVN initiated outperform at William Blair (Andy Hsieh) ELVN initiated overweight at Barclays (Etzer Darout), target is $78 or approx. 31% upside. NUVB initiated overweight at JPMorgan (Priyanka Grover), target is $13 or approx. 101% upside. OBX initiated outperform at LifeSci Capital (Sam Slutsky), target is $43 or approx. 145% upside. RANI initiated buy at Chardan Capital (Andreas Argyrides), target is $6 or approx. 650% upside. SCTX initiated outperform at Leerink Partners (David Risinger), target is $37 or approx. 75% upside. SCTX initiated overweight at Wells Fargo Securities (Yanan Zhu), target is $60 or approx. 183% upside. SCTX initiated buy at Guggenheim (Debjit Chattopadhyay), target is $50 or approx. 136% upside. Managed Care: CVS Wells Fargo analyst Stephen Baxter comments on reserve trends across their Managed Care coverage, and believes that CVS among the strongest positioned in the group. (UNH, HUM, ELV, CI, OSCR, MOH, CNC) Life Science & MedTech: FRNM initiated buy at TD Cowen (Dan Brennan), target is $17 or approx. 31% upside. (FactSet average PT $17; range $17-18) Post-close news Corporate: AMLX announces $350.0M proposed public offering of common stock. On Deck: Aug 15 - 22 Regulatory calendar (cont): EMA CHMP monthly meeting (Aug 17-20, replaced by written procedure) Fri 21-Aug: EMA CHMP opinions for MAA (August 2026) Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD). Note: Negative FDA Adcomm on 29-Jul. Note x2: Management commented on 13-Aug that extension was possibility, based on BLA amendment and upper limb function indication. Sun 23-Aug: FDA PDUFA for RARE DTX401 (pariglasgene brecaparvovec) BLA for treatment of glycogen storage disease type IA (GSDIa) Earnings calendar Wed 19-Aug: after HLUN.B.DC, ALVO This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABCL, AMLX, CI, CNC, CORT, CRL, CVS, DFTX, EDIT, ELV, ELVN, EYPT, FRNM, HAE, HUM, KURA, MBX, MOH, NUVB, OBX, OSCR, PODD, RANI, SCTX, TWST, UNH, VOGX, XNCR...(more)	show story hide story
18-Aug-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare index +1.73% vs the S&P 500 (0.61%). Most major healthcare groups are higher and outperforming the broader tape. Pharma is the leading advancer, with the DRG +2.18%, while biotech is the laggard, with the XBI (0.03%). SMID-cap biotech AMLX +45% after announcing topline results from its Phase 3 trial in post-bariatric hypoglycemia (PBH), where it met the primary and all secondary endpoints. VOGX +15%, which operates in the same space. PODD +4% and MRNA (2%) bracket the XLV. Gainers +45.3% AMLX (Amylyx Pharmaceuticals): trial results in PBH +15.6% HAE (Haemonetics): supply agreement with CSL.AU +14.9% VOGX (Vogenx, Inc.): sympathy to AMLX +10.8% KURA (Kura Oncology): insider buying (CEO); best performer on XBI +7.9% EYPT (EyePoint Pharmaceuticals): shares (63%) yesterday; downgrades +3.9% PODD (Insulet): best performer on XLV +1.1% ELVN (Enliven Therapeutics): initiations +1.0% NUVB (Nuvation Bio): initiation Decliners -4.4% RXRX (Recursion Pharmaceuticals): worst performer on XBI -2.2% MRNA (Moderna): worst performer on XLV -0.7% ABCL (AbCellera Biologics): shares +96% MTD -0.08% OBX (Obsidian Therapeutics): initiation	show story hide story
18-Aug-2026 08:27	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis SMID-cap biotech Amylyx Pharmaceuticals announced topline results from its phase 3 trial in post-bariatric hypoglycemia (PBH), where it met the primary endpoint and all secondary endpoints. Shares of AMLX resumed trading, and are +32% in the pre-market. Recent IPO Vogenx (VOGX) which operates in the same space, actively trading +13% in the pre-market. Australian drug and vaccinemaker CSL Ltd reported FY results ahead of consensus, and guides a return to sustainable growth in the years ahead. Shares traded +17% higher in Australia on Tuesday. Healthcare equities finished mixed but little changed overall yesterday. Sector newsflow was fairly quiet all around, just the typical biotech flow. More of the same expected on Tuesday, the calendar in August lull post-earnings. EMA CHMP operating by written procedures this week. Macro S&P futures are down (0.45%) on Tuesday morning. Very quiet from a headline perspective. Bulk of the focus has been on the global backup in longer-term rates and skepticism about any credible near-term diplomatic off-ramps for the US-Iran conflict. When it comes to rates, fiscal dynamics, crowding out from corporate supply rated to AI capex boom and Fed uncertainty/credibility among the key areas of focus, while higher oil remains in the mix as well. Nothing particularly incremental when it comes to US-Iran, with headlines focused on Trump's recent comments about not seeking extension of 60-day ceasefire and Oman bombing threat, continued ship attacks in SoH and latest Houthi threats in the Red Sea. Pre-market trading update Trading higher +31.5% AMLX trial results in PBH; call at 8ET +13.1% VOGX sympathy to AMLX +17.3% CSL.AU in Australia on Tuesday; earnings +9.1% HAE supply agreement with CSL.AU +6.6% KURA insider buying (CEO) +3.2% NUVB initiation +1.9% ELVN initiations Trading lower -4.5% EYPT follow-through, downgrades -3.5% ABCL follow-through, shares +96% MTD Pharma Earnings: CSL.AU reported FY results including revenue $15.80B vs StreetAccount $15.41B, EBIT $4.62B vs SA $4.46B. Guides FY (June 2027) NPAT +5% y/y CC. FY27 growth driven by Behring and Seqirus and partially offset by challenges in the Vifor business. CSL Seqirus expects to grow revenue LSD in FY27. Notes that immunization rates in the US are expected to decline, but at a slower rate than recent seasons. Biotech Trial results: AMLX announced topline results and that its phase 3 LUCIDITY trial with avexitide in post-bariatric hypoglyclemia (PBH) met the primary endpoint and all secondary endpoints. Company plans to submit NDA for avexitide to FDA by end of 2026. Full data to be presented at a medical meeting. (MBX, VOGX) Conf. call at 8:00ET Research: EYPT downgraded to sector perform from outperform at RBC Capital Markets (Lisa Walter), target cut to $5 from $37 or approx. 3% upside. EYPT downgraded to neutral from buy at HC Wainwright (Yi Chen). EYPT downgraded to neutral from buy at Chardan Capital (Andreas Argyides), target is $5 or approx. 3% upside. CORT assumed buy at Truist (Srikripa Devarakonda), target increased to $164 from $50 or approx. 40% upside. (FactSet average PT $141; range $50-165) DFTX initiated buy at BofA (Tazeen Ahmad), target is $75 or approx. 66% upside. (FactSet average PT $67; range $52-90) EDIT initiated buy at Ladenburg Thalmann, target is $6 or approx. 111% upside. (FactSet average PT $6; range $1-15) ELVN initiated outperform at William Blair (Andy Hsieh) ELVN initiated overweight at Barclays (Etzer Darout), target is $78 or approx. 31% upside. NUVB initiated overweight at JPMorgan (Priyanka Grover), target is $13 or approx. 101% upside. OBX initiated outperform at LifeSci Capital (Sam Slutsky), target is $43 or approx. 145% upside. RANI initiated buy at Chardan Capital (Andreas Argyrides), target is $6 or approx. 650% upside. SCTX initiated outperform at Leerink Partners (David Risinger), target is $37 or approx. 75% upside. SCTX initiated overweight at Wells Fargo Securities (Yanan Zhu), target is $60 or approx. 183% upside. SCTX initiated buy at Guggenheim (Debjit Chattopadhyay), target is $50 or approx. 136% upside. Life Science & MedTech Research: FRNM initiated buy at TD Cowen ( Dan Brennan), target is $17 or approx. 31% upside. (FactSet average PT $17; range $17-18) Managed Care Research: CVS Wells Fargo analyst Stephen Baxter comments on reserve trends across their Managed Care coverage, and believes that CVS among the strongest positioned in the group. (UNH, HUM, ELV, CI, OSCR, MOH, CNC) On Deck: Regulatory (cont): EMA CHMP monthly meeting (Aug 17-20, replaced by written procedure) Earnings calendar on Wed 19-Aug: after HLUN.B.DC, ALVO This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABCL, ALVO, AMLX, CI, CNC, CORT, CSL.AU, CVS, DFTX, EDIT, ELV, ELVN, EYPT, FRNM, HAE, HLUN.B.DC, HUM, KURA, MBX, MOH, NUVB, OBX, OSCR, RANI, SCTX, UNH, VOGX...(more)	show story hide story
17-Aug-2026 16:53	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to little changed overall on Monday. Decliners beat advancers by 2:1 on the XLV. Healthcare (0.21%) vs S&P 500 (0.52%). Major health groups ended widely mixed around the tape on Monday. Sector newsflow was fairly quiet all around, just the typical biotech flow. XBI +1.35% today's leading gainer, followed by the DRG +0.34%. No major biopharma M&A to report on Monday; most impactful clinical readout was the late-stage wet AMD trial from EYPT (67.0%), which lifted up competitors in a crowded field; FDMT +19.3% and OCUL +6.1%. INCY +2.8% and ALGN (5.6%) bracketed the XLV. Managed Care group worst performer top to bottom, between HUM (1.2%) and CNC (4.5%). Latter with a variety of news, including CFO retirement; 13F filings also showed MCOs as a source of investor funds during CQ2. AstraZeneca unmoved by multiple readouts in lung cancer, including one late-stage setback. Friday was the quarterly 13F filing deadline, and brought several notable changes related to Healthcare stocks, but no real significant pre-market movers on Monday morning. AstraZeneca busy with lung cancer updates advancing two separate partnered programs and discontinuing a third wholly-owned program, a bispecific PD-1/CTLA-4. SMID-cap biotech and eye diseases in particular focus on Monday morning. EyePoint announced "confounding" results for the primary endpoint in wet AMD for the first of two pivotal studies with DURAVYU. Macro Higher yields, higher oil no help for stocks in fairly quiet Monday trading. 30Y bond yield hit a fresh post-GFC high with government/corporate supply, fiscal concerns, Fed credibility debate all part of the discussion. Backup coming despite still (relatively) dovish Fed outlook, with market pricing just one-in-three chance of September hike, ~22 bp of hikes through year-end (near lowest level since June). Latest Iran headline noise led crude to its seventh gain in the last eight sessions; newsflow included Iran detaining tankers in SoH, Tehran warning of further escalation in Strait and rejecting ceasefire extension after Monday expiration, Trump threatening Oman. Not much new in other major market narratives. Latest AI updates more positive (including Anthropic revenue growth). Not much corporate newsflow. Notable Gainers +19.3% FDMT (4D Molecular Therapeutics): sympathy to EYPT; best performer on XBI +16.0% ARGX (argenx): trial results in autoimmune myositis +13.0% OABI (OmniAb): license agreement with LLY; updates FY cash outlook +12.0% CAPR (Capricor Therapeutics): follow-through, shares were +58% on Friday; PDUFA is next Saturday +9.8% NBTX (Nanobiotix): on >4X average volume +7.4% PGEN (Precigen): on average volume +6.6% VOGX (Vogenx, Inc.): recent IPO +6.1% OCUL (Ocular Therapeutix): sympathy to EYPT +4.1% RVMD (Revolution Medicines): on average volume +3.0% HCM (Hutchmed): trial results in NSCLC +2.8% INCY (Incyte): best performer on XLV; average volume Notable Decliners -67.0% EYPT (EyePoint Pharmaceuticals): trial results in wet AMD; downgraded at Cantor Fitzgerald -8.5% SION (Sionna Therapeutics): follow-through; worst performer on XBI -8.0% STAA (STAAR Surgical): shares were +8% last week -7.5% IRTC (iRhythm Technologies): on average volume -7.2% CLOV (Clover Health): on average volume -5.6% ALGN (Align Technology): worst performer on XLV; on average volume; shares were +3% on Friday -4.5% CNC (Centene): CFO retirement; reaffirms guidance; Greenlight cuts stake (13F); second-worst on XLV -4.3% ALVO (Alvotech): ahead of earnings (Wed AM) -4.3% SMMT (Summit Therapeutics): sell-side comments on China label / PFS moderated; 52-week low -3.7% OSCR (Oscar Health): shares were +17% last week -3.2% CVS (CVS Health): on average volume -2.6% CI (Cigna Group): on light volume -2.3% REPL (Replimune Group): follow-through, shares were +24% last week EyePoint sharply lower on phase 3 readout in wet AMD EYPT announced topline results from the phase 3 trial LUGANO - first of two pivotal trials for DURAVYU (vorolanib intravitreal insert) for the treatment of wet AMD. Primary endpoint was not achieved in the full dataset, confounded by the asymmetric cohort. Secondary endpoints outperformed, and were called "compelling" and "clinically meaningful". Phase 3 trial LUCIA expected to readout in Q4, with NDA submission planned for H1 of 2027. (OCUL) argenx hits phase 3 trial in autoimmune myositis ARGX announced topline results from the phase 3 trial ALKIVIA evaluating VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) (HALO, ZLAB) in adults with autoimmune myositis. Study met its primary endpoint and demonstrated rapid and sustained treatment benefit. Detailed results will be presented at an upcoming medical meeting. OmniAb raises FY cash outlook following Eli Lilly agreement OABI and LLY announced a global collaboration and license agreement for a new ion channel program - target and modality are undisclosed. Deal terms include up to $370M in milestone payment (R&D and commercial) plus royalties. Upfront payment amount not disclosed, however OmniAb separately raised its FY 2026 cash guidance - company now expects to end FY26 with between $49-53M vs prior $37-41M. AstraZeneca trades flat following phase 3 updates in lung cancer AZN announced it will discontinue the phase 3 trial eVOLVE-Lung02 evaluating PD-1/CTLA-4 bispecific antibody volrustomig chemo combo vs Keytruda chemo combo in mNSCLC. Follows planned review by IDMC, the study unlikely to meet dual primary endpoints. AZN and HCM announced topline results from the phase 3 trial SAFFRON evaluating ORPATHYS (savolitinib) plus Tagrisso (osimertinib) in NSCLC. Study demonstrated stat-sig improvement in PFS and OS versus doublet platinum-based chemotherapy. AZN and Daiichi Sankyo (4568.JP) announced topline results from the phase 3 DESTINY-Lung04 trial evaluating Enhertu versus SOC in HER2 mutant advanced NSCLC. Study demonstrated stat-sig improvement in PFS, and will continue towards secondary enpoints including OS. Centene a leading decliner amidst CFO retirement CNC announced that CFO Drew Asher will step down from the role in December 2026 and retire from the company at the end of 2027. Chris Neczypor, CFO at Lincoln Financial, will become next CFO on 1-Jan-2027. Company reaffirms FY26 financial guidance as per 28-Jul-2026 earnings release. Separately, Greenlight 13F filing shows a (40%) reduced stake during CQ2. Firm had increased stake during each of the prior four quarters. Notable research in Healthcare today Biotech: EYPT downgraded to neutral from overweight at Cantor Fitzgerald (Steve Seedhouse), cites LUGANO missing primary endpoint. IMUX initiated outperform at Wedbush Securities (Martin Fan), target is $45 or approx. 180% upside. (FactSet average PT $42; range $19-85) MedTech: FRNM initiated buy at BTIG (Mark Massaro), target is $17 or approx. 47% upside. FRNM initiated buy at Jefferies (Tycho Peterson), target is $17 or approx. 47% upside. PLSE initiated buy at Needham (Mike Matson), target is $58 or approx. 30% upside. Post-close news Trial results: AMLX schedules call for tomorrow morning to discuss phase 3 LUCIDITY trial results with avexitide in PBH. Call at 8:00ET (MBX, VOGX) Shares trading +14.3% in the after-hours On Deck: Regulatory (cont): EMA CHMP monthly meeting (Aug 17-20, replaced by written procedure) Corporate AMLX call to discuss phase 3 LUCIDITY trial results in PBH (8:00ET) Earnings after the close tomorrow CSL.AU Earnings on Wed 19-Aug afternoon HLUN.B.DC, ALVO This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALGN, ALVO, AMLX, ARGX, AZN, CAPR, CI, CLOV, CNC, CSL.AU, CVS, EYPT, FDMT, FRNM, HALO, HCM, HLUN.B.DC, IMUX, INCY, IRTC, LLY, MBX, NBTX, OABI, OCUL, OSCR, PGEN, PLSE, REPL, RVMD, SION, SMMT, STAA, VOGX, ZLAB...(more)	show story hide story
17-Aug-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.04% vs the S&P 500 (0.16%). Major health groups are all lightly mixed around the tape to begin the week. Newsflow fairly quiet around the sector, mainly just the typical biotech flow. XBI +0.90% leading gainer, followed by the DRG +0.71%. No major biopharma M&A to report; most impactful clinical readout is the late-stage wet AMD trial from EYPT (71%), which is lifting up competitors in a crowded field; FDMT +15% and OCUL +7%. CRL and MRNA +2% leading advancers on the XLV, while CNC (4%) lead decliners; the latter with news including CFO retirement - and MCOs as a source of investor funds during CQ2. AstraZeneca unmoved by multiple readouts in lung cancer, including one late-stage setback. Gainers +18.0% OABI (OmniAb): license agreement with LLY; updates FY cash outlook +17.0% ARGX (argenx): trial results in autoimmune myositis +15.3% FDMT (4D Molecular Therapeutics): sympathy to EYPT; best performer on XBI +6.9% OCUL (Ocular Therapeutix): sympathy to EYPT +5.9% CAPR (Capricor Therapeutics): follow-through, shares were +58% on Friday; PDUFA is next Saturday +3.8% HCM (Hutchmed): trial results in NSCLC +2.0% CRL (Charles River Laboratories): best performer on XLV +2.0% MRNA (Moderna): second-best on XLV +1.9% FULC (Fulcrum Therapeutics): all-stock merger with Slate Medicines Decliners -70.9% EYPT (EyePoint Pharmaceuticals): trial results in wet AMD; downgraded at Cantor Fitzgerald -6.9% STAA (STAAR Surgical): shares were +8% last week -5.6% REPL (Replimune Group): follow-through, shares were +24% last week; worst performer on XBI -4.9% IRTC (iRhythm Technologies): -4.8% SMMT (Summit Therapeutics): sell-side comments on China label / PFS moderated; 52-week low -3.9% CNC (Centene): CFO retirement; reaffirms guidance; Greenlight cuts stake (13F); worst performer on XLV -2.9% ALGN (Align Technology): shares were +3% on Friday -2.6% ZTS (Zoetis): follow-through; 52-week low -2.5% OSCR (Oscar Health): shares were +17% last week -0.6% ELAN (Elanco Animal Health): shares were +7% last week	show story hide story
17-Aug-2026 08:41	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Friday was the quarterly 13F filing deadline, and brought several notable changes related to Healthcare stocks, but no real significant pre-market movers on Monday morning. AstraZeneca busy with lung cancer updates advancing two separate partnered programs and discontinuing a third wholly-owned program, a bispecific PD-1/CTLA-4. ADRs for AZN are little changed in the pre-market. SMID-cap biotech and eye diseases in particular focus on Monday morning. EyePoint announced "confounding" results for the primary endpoint in wet AMD for the first of two pivotal studies with DURAVYU. Shares of EYPT down (65%) in the pre-market; competitor OCUL +15% in reaction. Macro S&P futures are up +0.1% on Monday morning. Busy from a headline perspective but seemingly not much new in terms of narrative. Memory and semis extending their recent outperformance. Weekend AI headlines focused on financing dynamics (including lower NVDA backstop for OpenAI data center and elevated hyperscaler off balance sheet commitments) and some incremental revenue color surrounding Anthropic and OpenAI. Elevated rate backdrop still a big area of discussion, with fiscal and AI-related supply pressures the key drivers. However, recent data have weighed on Fed tightening expectations with market pricing in less than one full rate hike (~22 bp) by year-end. When it comes to the Middle East, reports have focused on heightened efforts by both sides to inflict economic pain, though also some discussion about how covert flows are helping to keep oil prices contained. Earnings still the big bullish talking point for stocks with margins and guidance/revisions among the Q2 standouts. More private credit scrutiny in the financial press, contrasting with the relatively optimistic tone from management teams on Q2 calls. Global growth dynamics also in focus with unexpected slowdown in Japan's Q2 GDP and softer China July activity data. Pre-market trading update Trading higher +17.7% OABI license agreement with LLY; updates FY cash outlook +14.6% OCUL sympathy to EYPT +11.7% ARGX trial results in autoimmune myositis +3.2% HCM trial results in NSCLC +1.6% FULC all-stock merger with Slate Medicines; call at 8ET +0.1% AZN trial results in NSCLC; discontinues bispecific volrustomig Trading lower -65.2% EYPT trial results in wet AMD; call at 8ET -0.3% ELAN shares were +7% last week (low volume) Notable 13F filings in Healthcare - for period ending 30-Jun. ACHC stake decreased by (3%) at Greenlight BDX stake (636K) exited at Starboard BLCO stake (85K) initiated at Third Point BRKR stake (2.9M) initiated at Sachem Head CNC stake decreased by (40%) at Greenlight DHR stake increased by +3% at Third Point DVA stake decreased by (4%) at Berkshire FTRE stake decreased by (36%) at Corvex Management HSIC stake increased by +20% at Greenlight ICLR stake (2.1M) exited at Sachem Head ILMN stake decreased by (36%) at Corvex Management ISRG stake decreased by (7%) at Coatue PFE stake (231K) initiated at Fairholme SHC stake increased by +100% at Greenlight SHC stake increased by +34% at Sachem Head TEVA stake decreased by (1%) at Greenlight UNH stake (90K) exited at Appaloosa VTRS stake increased by +53% at Greenlight WGS stake increased by +48% at Corvex Management Duquesne initiated stakes in TXG, BEAM, DHR, LLY, INSM (calls), GLUE, RLAY, RGEN, RYTM, and TMO. Firm increased stake in INSM, NTRA, PTGX, RVMD; decreased stake in TEVA. Exited stakes in HUM, OPCH, and TWST. Note: ALC stake reported by Pershing Square on 13-Aug. Alcon was not on this 13F filing for period end 30-Jun-2026. Pharma Trial results: AZN announced it will discontinue the phase 3 trial eVOLVE-Lung02 evaluating PD-1/CTLA-4 bispecific antibody volrustomig chemo combo vs Keytruda chemo combo in mNSCLC. Follows planned review by IDMC, the study unlikely to meet dual primary endpoints. AZN and HCM announced topline results from the phase 3 trial SAFFRON evaluating ORPATHYS (savolitinib) plus Tagrisso (osimertinib) in NSCLC. Study demonstrated stat-sig improvement in PFS and OS versus doublet platinum-based chemotherapy. AZN and Daiichi Sankyo (4568.JP) announced topline results from the phase 3 DESTINY-Lung04 trial evaluating Enhertu versus SOC in HER2 mutant advanced NSCLC. Study demonstrated stat-sig improvement in PFS, and will continue towards secondary enpoints including OS. Biotech Trial results: EYPT announced topline results from the phase 3 trial LUGANO - first of two pivotal trials for DURAVYU (vorolanib intravitreal insert) for the treatment of wet AMD. Primary endpoint was not achieved in the full dataset, confounded by the asymmetric cohort. Secondary endpoints outperformed, and were called "compelling" and "clinically meaningful". Phase 3 trial LUCIA expected to readout in Q4, with NDA submission planned for H1 of 2027. (OCUL) Conf. call at 8:00ET ARGX announced topline results from the phase 3 trial ALKIVIA evaluating VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) (HALO, ZLAB) in adults with autoimmune myositis. Study met its primary endpoint and demonstrated rapid and sustained treatment benefit. Detailed results will be presented at an upcoming medical meeting. Collaboration agreement: OABI and LLY announced a global collaboration and license agreement for a new ion channel program - target and modality are undisclosed. Deal terms include up to $370M in milestone payment (R&D and commercial) plus royalties. Upfront payment amount not disclosed, however OmniAb separately raised its FY 2026 cash guidance - company now expects to end FY26 with between $49-53M vs prior $37-41M. Research: IMUX initiated outperform at Wedbush Securities (Martin Fan), target is $45 or approx. 180% upside. (FactSet average PT $42; range $19-85) Life Science & MedTech Research: FRNM initiated buy at BTIG (Mark Massaro), target is $17 or approx. 47% upside. FRNM initiated buy at Jefferies (Tycho Peterson), target is $17 or approx. 47% upside. PLSE initiated buy at Needham (Mike Matson), target is $58 or approx. 30% upside. Managed Care Corporate: CNC announced that CFO Drew Asher will step down from the role in December 2026 and retire from the company at the end of 2027. Chris Neczypor, CFO at Lincoln Financial, will become next CFO on 1-Jan-2027. Company reaffirms FY26 financial guidance as per 28-Jul-2026 earnings release. On Deck: Regulatory EMA CHMP monthly meeting (Aug 17-20, replaced by written procedure) Earnings Tue 18-Aug: after CSL.AU Wed 19-Aug: after HLUN.B.DC, ALVO This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACHC, ALC, ALVO, ARGX, AZN, BDX, BEAM, BLCO, BRKR, CNC, CSL.AU, DHR, DVA, ELAN, EYPT, FRNM, FTRE, FULC, GLUE, HALO, HCM, HLUN.B.DC, HSIC, HUM, ICLR, ILMN, IMUX, INSM, ISRG, LLY, NTRA, OABI, OCUL, OPCH, PFE, PLSE, PTGX, RGEN, RLAY, RVMD, RYTM, SHC, TEVA, TMO, TWST, TXG, UNH, VTRS, WGS, ZLAB...(more)	show story hide story
14-Aug-2026 18:54	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished mixed and lower overall; worst performing sector on Friday. Decliners beat advancers by 2:1 on the XLV. Healthcare (0.60%) vs S&P 500 (0.17%). Major health groups ended lightly mixed around the tape. Early biopharma weakness moderated in the afternoon session, though DRG (1.05%) still turned weekly gain into a small decline. The XBI +0.35% on Friday narrowly avoided a weekly decline. Sector newsflow remained very quiet outside of the small-cap earnings tail. A hopeful regulatory update from CAPR +58.0% perhaps the primary news item. Management believes that FDA is open to company filing a BLA amendment for the upper limb indication in Duchenne. Another key update in SMID-cap biotech: VALN +26.2% on regulatory update for Lyme Disease vaccine. ALGN +2.9% despite soft macroeconomic data, led all gainers on the XLV. Leading decliner was VEEV (3.5%), which partially reversed Thursday's gains on software M&A headlines (PE put). Macro: Fairly quiet finish to what was a relatively quiet week outside of some high-profile macro data. Rate backup one of the more notable stories today. Has come despite some softer consumer data highlighted by a 0.4% decline in July core retail sales. More discussion in the financial press about structural pressures on rates, particularly fiscal and the barrage of AI-related corporate supply. High earnings bar in focus for a second straight session with the pullback in AMAT despite upbeat fundamental/AI takeaways. Oil higher though nothing particularly incremental surrounding the Middle East with the US seemingly embracing the patience dynamic with a heightened focus on inflicting economic pain on Iran. Energy was best performer again today, locking in solid weekly gains. Next week highlighted by July Q retailer reporters, July FOMC minutes (though somewhat stale following key data) and flash PMIs. Last week of August brings NVDA earnings and Fed Chair Warsh's Jackson Hold speech. Michigan preliminary consumer sentiment missed, with both current conditions and expectations indexes lower. Notable Gainers on Friday: +74.9% MDXH - microcap; earnings +58.0% CAPR - best performer on XBI; announced plan to submit amendment to BLA, FDA open to review and potential PDUFA date extension; upgraded at Cantor Fitzgerald +44.3% ETON - earnings +35.7% HTFL - earnings +26.2% VALN - EMA validates MAA for Lyme Disease vaccine (w/PFE) +16.8% NERV - upgraded at Jefferies +9.5% VERA - Wells Fargo comments on FDA review document +9.1% AVAH - follow-through +6.2% CELC - earnings +5.8% DNTH - 13G filing; multi-year highs +5.2% ELAN - Stifel comments on ZTS pricing strategy +3.7% ALMS - earnings +3.4% MOH - shares +9% since Burry comments midweek +2.9% ALGN - best performer on XLV; UMich consumer data Notable Decliners on Friday: -14.0% IPHA - secondary offering priced; business update call -8.9% INBX - earnings; worst performer on XBI -7.4% SPRY - earnings, CSU timeline update -7.3% SKYE - reverse merger with Redx forming Fibrx Therapeutics -5.4% TWST - shares +3% for the week -4.6% SMMT - shares (4%) for the week -3.5% TXG - shares +8% for the week; 9th straight weekly gain -3.5% VEEV - worst performer on XLV; unwinding Thursday gains -2.8% IDXX - follow-through Week in Review: Earnings scorecard: According to FactSet Scorecard, with 93.98% of companies (156 of 166) having reported, 83.77% of the S&P 1500 Health Care (SP567-SPX) have beaten consensus EPS expectations, vs 81.71% last year (Q2 2025), with an average beat of +18.86% vs +8.67% last year. On the topline, 87.66% have beaten sales expectations, vs 82.32% last year (Q2 2025), with an average beat of +2.77% vs +2.56% last year. Healthcare equities outperformed for the week. The S&P 500 Healthcare Index gained +0.98% vs the S&P 500 Index +0.36%. Outperformers: Managed Care, MedTech Underperformers: Services, Pharma, Biotech Major health groups were lightly mixed around the broader tape this week. Relatively quiet week for the markets and the Health sector, as earnings tail populated mostly by small-caps, and conference season offered few updates to change the narrative. Vaccine politics were back in the headlines to start the week, with President Trump signing an Executive Order to split three components of today's Measles, Mumps, Rubella vaccine. On Friday, the CDC reported the highest number of weekly confirmed cases of measles in five months. Molina Healthcare led the MCO group higher following fresh Substack comments by Michael Burry. Year-to-date, Healthcare +7.95% vs the S&P 500 +13.74%. Healthcare seventh out of eleven major sectors in CY26. Energy +37.78% and Consumer Discretionary +0.49% bracket them all. Notable movers for the week: Gainers: ABCL +64.2% - trial results in VMS; secondary offering CAPR +62.6% - earnings; comments on BLA amendment submission; upgrade; best performer on XBI VREX +49.0% - acquired by TDY for $1.1B VALN +34.5% - EMA validates MAA submission for Lyme Disease vaccine OSCR +17.4% - follows (11%) last week LFST +14.6% - 52-week high; new long at Hedgeye ORKA +12.4% - earnings BRKR +8.0% - follows (15%) last week; makes investment in MIMETAS TXG +7.8% - follow-through; higher for 9th straight week; +244% YTD MRNA +7.0% - best performer on XLV; excess mortality vaccine study retracted by BMJ ELAN +7.0% - follows (16%) last week; analyst meeting SOLV +6.8% - 52-week high VEEV +5.8% - sympathy to WDAY headlines RDNT +5.5% - earnings VRTX +2.0% - sympathy to SION; US 1 List at BofA Decliners: SION (87.3%) - trial results Cystic Fibrosis; worst performer on XBI TENX (86.6%) - trial results in PH-HFpEF LQDA (17.5%) - earnings; downgrade HIMS (10.9%) - earnings COGT (10.5%) - earnings DFTX (7.6%) - trial results in GAD NBIX (6.5%) - safety report / STAT article IDXX (6.1%) - Investor Day; worst performer on XLV Week Ahead (Sat - Sun): Aug 15 - 22 Regulatory calendar Mon 17-Aug: EMA CHMP monthly meeting (Aug 17-20, replaced by written procedure) Fri 21-Aug: EMA CHMP opinions for MAA (August 2026) Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD). Note: Negative FDA Adcomm on 29-Jul. Note x2: Management commented on 13-Aug that extension was possibility, based on BLA amendment and upper limb function indication. Sun 23-Aug: FDA PDUFA for RARE DTX401 (pariglasgene brecaparvovec) BLA for treatment of glycogen storage disease type IA (GSDIa) Earnings calendar Tue 18-Aug: after CSL.AU Wed 19-Aug: after HLUN.B.DC, ALVO Related: ABCL, ALGN, ALMS, ALVO, AVAH, BRKR, CAPR, CELC, CSL.AU, DFTX, DNTH, ELAN, ETON, HIMS, HLUN.B.DC, HTFL, IDXX, INBX, IPHA, LFST, LQDA, MDXH, MOH, MRNA, NBIX, NERV, ORKA, OSCR, PFE, RARE, RDNT, SION, SKYE, SMMT, SOLV, SPRY, TENX, TWST, TXG, VALN, VEEV, VERA, VREX, VRTX...(more)	show story hide story
14-Aug-2026 17:44	Notable 13F filings in Healthcare (Q2 2026) ACHC stake decreased by (3%) at Greenlight BDX stake (636K) exited at Starboard BLCO stake (85K) initiated at Third Point BRKR stake (2.9M) initiated at Sachem Head CNC stake decreased by (40%) at Greenlight DHR stake increased by +3% at Third Point DVA stake decreased by (4%) at Berkshire FTRE stake decreased by (36%) at Corvex Management HSIC stake increased by +20% at Greenlight ICLR stake (2.1M) exited at Sachem Head ILMN stake decreased by (36%) at Corvex Management ISRG stake decreased by (7%) at Coatue PFE stake (231K) initiated at Fairholme SHC stake increased by +100% at Greenlight SHC stake increased by +34% at Sachem Head TEVA stake decreased by (1%) at Greenlight UNH stake (90K) exited at Appaloosa VTRS stake increased by +53% at Greenlight WGS stake increased by +48% at Corvex Management Duquenne initiated stakes in TXG, BEAM, DHR, LLY, INSM (calls), GLUE, RLAY, RGEN, RYTM, and TMO. Also increased stake in INSM, NTRA, PTGX, RVMD; decreased stake in TEVA; and exited stakes in HUM, OPCH, and TWST. Note: ALC stake reported by Pershing Square on 13-Aug. Alcon was not on this 13F filing for period end 30-Jun-2026. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ACHC, ALC, BDX, BEAM, BLCO, BRKR, CNC, DHR, DVA, FTRE, GLUE, HSIC, HUM, ICLR, ILMN, INSM, ISRG, LLY, NTRA, OPCH, PFE, PTGX, RGEN, RLAY, RVMD, RYTM, SHC, TEVA, TMO, TWST, TXG, UNH, VTRS, WGS...(more)	show story hide story
14-Aug-2026 15:03	StreetAccount Summary: Notable Drug Events expected for the week of 16-Aug Mon 17-Aug Regulatory meeting: EMA CHMP monthly meeting (replaced by written procedure) (Aug 17-20) Tue 18-Aug Corporate: CSL.AU* (CSL Ltd) earnings call Wed 19-Aug Corporate: HLUN.B.DC (Lundbeck) earnings call Fri 21-Aug Regulatory decisions: EMA CHMP opinions on MAA (August 2026) Sat 22-Aug Regulatory decision: CAPR FDA PDUFA for deramiocel BLA as treatment for cardiomyopathy in patients with Duchenne Muscular Dystrophy (DMD) Note: Negative FDA Adcomm on 29-Jul Note: Management commented on 13-Aug that extension was possibility, based on BLA amendment and upper limb function indication Sun 23-Aug Regulatory decision: RARE FDA PDUFA for DTX401 (pariglasgene brecaparvovec) BLA for treatment of glycogen storage disease type IA (GSDIa) Later during August 2026 Regulatory decisions: XSPRAY.SS (Dasynoc NDA, 25-Aug), ZYME/JAZZ (ZIIHERA sBLA, 25-Aug), GILD (bictegravir+ lenacapavir NDA, 27-Aug), 6446.TT (Besremi sBLA, 30-Aug), PTGX/4502.JP (rusfertide NDA), REGN (garetosmab BLA) Industry meeting with clinical data: European Society of Cardiology (Aug 28-31) Trial results: CGON (Ph3 NMIBC), EYPT (Ph3 wet AMD), LGVN (Ph2 HLHS), TYRA (Ph2 IR NMIBC) Related: 4502.JP, 6446.TT, CAPR, CGON, CSL.AU, EYPT, GILD, HLUN.B.DC, JAZZ, LGVN, PTGX, RARE, REGN, TYRA, XSPRAY.SS, ZYME...(more)	show story hide story
14-Aug-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 healthcare Index (0.73%) vs the S&P 500 (0.12%). Major health groups are lightly mixed around the tape on Friday, and biopharma weakness is giving up weekly gains or extending weekly declines. DRG (1.27%) on the session and now essentially flat WTD. XBI (1.17%) on the session and on track for a (1%) weekly decline. Sector newsflow remains very quiet outside of the small-cap earnings tail. A regulatory update from CAPR +68% perhaps the primary news item. Management believes that FDA is open to company filing a BLA amendment for the upper limb indication in Duchenne. Another key update in SMID-cap biotech: VALN +25% on regulatory update for Lyme Disease vaccine. ALGN +3%, despite consumer sentiment data missed, and VEEV (3%) bracket the XLV. Veeva Systems reversing yesterday's gains on software M&A headlines (PE put). Gainers +84.4% MDXH (MDxHealth): microcap; earnings +67.9% CAPR (Capricor Therapeutics): best performer on XBI; announced plan to submit amendment to BLA, FDA open to review and potential PDUFA date extension; upgraded at Cantor Fitzgerald +33.4% HTFL (Heartflow): earnings +32.4% ETON (Eton Pharmaceuticals): earnings +23.7% VALN (Valneva): EMA validates MAA for Lyme Disease vaccine (w/PFE) +10.2% NERV (Minerva Neurosciences): upgraded at Jefferies +8.8% VERA (Vera Therapeutics): Wells Fargo comments on FDA review document +5.1% AVAH (Aveanna Healthcare Holdings): follow-through +3.7% LQDA (Liquidia): shares remain (17%) WTD +3.4% CELC (Celcuity): earnings +2.7% ALGN (Align Technology): best performer on XLV; UMich consumer data +2.4% MOH (Molina Healthcare): shares +7% WTD (since Burry comments) +2.2% ELAN (Elanco Animal Health): Stifel comments on ZTS pricing strategy +1.9% CNC (Centene): second-best on XLV; sympathy to MOH Decliners -12.0% IPHA (Innate Pharma): secondary offering priced; business update call -6.9% INBX (Inhibrx Biosciences): earnings; worst performer on XBI -6.4% SMMT (Summit Therapeutics): shares (6%) WTD -5.3% SPRY (ARS Pharmaceuticals): earnings, CSU timeline update -4.5% TWST (Twist Bioscience): shares remain +4% WTD -3.2% VEEV (Veeva Systems): worst performer on XLV; unwinding Thursday gains -2.0% TXG (10X Genomics): shares +10% WTD, on track for 9th straight weekly gain	show story hide story
14-Aug-2026 10:30	CDC reports 101 new cases of measles this week First week north of 100 in nearly five months (March 20th), and roughly 2X the trailing five-week average. Year-to-date, CDC has reported 2,566 cases of measles. Earlier this week, President Trump signed an executive order to break the MMR (measles, mumps, rubella) vaccine from a single jab into three separate pediatric visits. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
14-Aug-2026 08:23	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Capricor Therapeutics reported Q2 results, and provided an update on the regulatory review of deramiocel on the earnings call. Subsequent to the negative Adcomm meeting, which focused on the secondary endpoint, company discussed with FDA an amendment to their BLA submission, and FDA expressed an openness to review and possibly extend the PDUFA date beyond August 22nd. Stock upgraded in reaction. Shares of CAPR +98% in the pre-market. Pfizer and Vaccine developer Valneva announced that EMA has validated their MAA submission for Lyme Disease vaccine LB6V. ADRs for VALN trading +30% in the pre-market. Yesterday, Healthcare equities finished mixed to little changed overall. Decliners narrowly outnumbered advancers on the XLV. Healthcare (0.05%) vs S&P 500 +0.65%. Sector newsflow remained very quiet outside of the long tail of SMID-cap biotech earnings, plus a handful of rating changes. Macro S&P futures are little changed on Friday morning. Quiet end to a fairly quiet week outside of the inflation data. OpenAI's reported $40B annual revenue run rate and AMAT earnings/outlook commentary the latest bullish talking points around AI (though latter up against a high bar). FT report also highlighted the price war among the frontier models amid competition from China. Some focus on higher oil amid US preview of new measures intended to cripple Iran economically. Elevated US borrowing rates another area of scrutiny in the financial press despite the move lower in rates this week. BoJ also in the headlines again with Reuters highlighting increased likelihood of a September rate and a potentially faster pace of tightening to follow. Next week looks fairly quiet with retail earnings, July FOMC minutes and flash PMIs the highlights. Last week of August more important given NVDA earnings and Warsh speech at Fed's Jackson Hole conference. Pre-market trading update Trading higher +98.2% CAPR announced plan to submit amendment to BLA, FDA open to review and potential PDUFA date extension; upgraded at Cantor Fitzgerald +30.1% VALN EMA validates MAA for Lyme Disease vaccine (w/PFE) +25.4% HTFL earnings +25.0% ETON earnings +24.2% VERA Wells Fargo comments on FDA review document +10.0% NERV upgraded at Jefferies +3.2% FRNM initiation (low volume) +2.3% BSX on 98K shares +0.1% LNTH FDA approves imaging agent TAUKLARIFY Trading lower -14.3% SPRY earnings, CSU timeline update -12.4% IPHA secondary offering priced; business update call at 8ET -0.1% PFE sympathy to VALN Pharma Regulatory: BMY Post-close on Thursday, the FDA announced it has granted Accelerated Approval (AA) for Zenbexus (iberdomide) in combination with Darzalex Faspro and dexamethasone for adults with r/r multiple myeloma. The PDUFA goal date for the NDA was 17-Aug-2026. Media report / regulatory: Peptide Critic published independent laboratory findings from four sealed vials of research compounds purchased over the counter at a Brooklyn smoke shop -- it could not confirm retatrutide (LLY) or NAD+ in any sample. Biotech Earnings: CAPR reported Q2 results including cash & equivalents $237.9M at 30-Jun - seen as sufficient for the next 12 months. Despite negative outcome for deramiocel Adcomm, Company working towards PDUFA goal date of 22-Aug. On the call: management stated that FDA is 1) open to them submitting an amendment to the BLA and 2) extending the PDUFA goal date. SPRY reported Q2 results including cash & equivalents $143.8M, and with revised cash-based expense plan, expects to reach break-even cash flow by the end of 2027. Regulatory: VLA.FP (VALN) announced that EMA has validated the MAA for Lyme Disease vaccine LB6V (formerly VLA15) (PFE). LNTH announced that FDA approved PET imaging agent Tauklarify for Alzheimer's Disease. The PDUFA goal date for MK-6240 was 16-Aug-2026. Note: Lantheus is pending acquisition by Curium US Research: CAPR upgraded to overweight from neutral at CF (Kristen Kluska), follows earnings call updates on BLA amendment. Target increased to $28 from $3.50 or approx. 565% upside. NERV upgraded to buy from hold at Jefferies (Andrew Tsai), target increased to $10 from $7.50 or approx. 155% upside. ALVO initiated outperform at Evercore ISI (Umer Raffat) KRYS initiated outperform at RBC (Lisa Walter), target is $400 or approx. 22% upside. (FactSet average PT $383; range $284-474) SGP initiated outperform at Raymond James (Christopher Raymond), target is $39 or approx. 55% upside. (FactSet average PT $45; range $37-62) Life Science & MedTech Research: FRNM initiated outperform at Leerink Partners (Puneet Souda), target is $18 or approx. 55% upside. On Deck: Aug 8 - 16 all clear Peek Ahead to the following week (Aug 17-23) EMA CHMP August monthly meeting replaced by written procedure Wed 19-Aug: Piper Sandler MedTech and Diagnostics California Bus Tour Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA (Note: Negative FDA Adcomm last month; optimistic mgmt comments on 13-Aug) Sun 23-Aug: FDA PDUFA for RARE pari-vec BLA This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ALVO, BMY, BSX, CAPR, ETON, FRNM, HTFL, IPHA, KRYS, LLY, LNTH, NERV, PFE, RARE, SGP, SPRY, VALN, VERA, VLA.FP...(more)	show story hide story
13-Aug-2026 17:44	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to little changed overall on Thursday. Decliners narrowly outnumbered advancers on the XLV. Healthcare (0.05%) vs S&P 500 +0.65%. Major health groups ended lightly mixed and all underperformed the broader tape, including Pharma with the DRG +0.15% a leading advancer. MRK +2.0%, PFE +1.9% (insider buying), and ABBV +0.8% (upgrade) all supported the Drug Index, however VEEV +4.6% was Thursday's top gainer on the XLV following some speculative M&A headlines in the software market, broadly lifted the space. MCK (2.5%) bracketed the XLV. Sector newsflow remained very quiet outside of the long tail of SMID-cap biotech earnings, plus a handful of rating changes. Relatively quiet morning with a handful of biotech earnings including Zealand Pharma and Ascendis Pharma reporting. Pfizer disclosed a $1M stock purchase by CEO Albert Bourla. Cullinan Therapeutics reported that a global phase 3 trial in lung cancer hit PFS endpoint at interim analysis. Macro Another quiet, low-volume session though risk-on tone helped drive fairly broad-based gains. Upside tabbed in part to to rate rally that followed cooler July core PPI print (though takeaways mixed including hotter core-core, select items that flow into core PCE). However, market pricing ~34% chance of a September rate hike, little changed from Wednesday, though 24 bp of hikes through year-end, down nearly 4 bp d/d and lowest since mid-June. Latest round of earnings also positive for AI narrative, helped support chip, memory space. Analysts also continue to highlight improving ROI, demand trends that have offset some fears around capex growth, while rising pricing for compute also in focus, as seen in yesterday's CRWV, NBIS results. Oil also weaker (also supported rates) despite little new around US/Iran as diplomacy remains consensus given energy, economic, military dynamics. Other areas of focus include reopening of buyback window, cleaner positioning in some recently extended trades (including memory, Korea), dampened index-level volatility (VIX < 15) but still-elevated single-stock vol. Notable Gainers +34.3% BYSI (BeyondSpring): FDA orphan designation for subsidiary SEED Therapeutics +26.5% OMER (Omeros): earnings +24.8% AVAH (Aveanna Healthcare Holdings): earnings +10.5% CADL (Candel Therapeutics): earnings; best performer on XBI; 52-week high +9.4% MXCT (MaxCyte): earnings +8.4% ACHV (Achieve Life Sciences): initiation; 52-week high +4.6% VEEV (Veeva Systems): software move in sympathy to WDAY headlines; best performer on XLV +4.0% LMRI (Lumexa Imaging Holdings): earnings +3.7% PLSE (Pulse Biosciences): follow-through; +7% WTD on track for 8th weekly gain in last nine +3.6% ZEAL.DC (Zealand Pharma): earnings +3.1% ZTS (Zoetis): FDA grants EUA for Simparica Trio for NWS in dogs Notable Decliners -32.4% OBX (Obsidian Therapeutics): on 19X avg daily volume; recent reverse merger; shares +21% MTD -8.5% LQDA (Liquidia): follow-through, shares down (11%) yesterday -7.9% KOD (Kodiak Sciences): earnings; worst performer on XBI -7.3% SMMT (Summit Therapeutics): follow-through, shares back to even WTD -7.1% BLTE (Belite Bio): earnings -6.7% ZBIO (Zenas BioPharma): earnings -6.6% PHVS (Pharvaris BV): follow-through, shares (2%) WTD -6.3% SEPN (Septerna): follow-through, shares +16% WTD -4.7% PBLS (Parabilis Medicines, Inc.): earnings -4.5% INSM (Insmed): shares (3%) WTD; stock was +33% last week -2.9% CYTK (Cytokinetics): files complaint against BMY seeking judgment the company does not infringe '697 patent -2.5% MCK (McKesson): worst performer on XLV Aveanna Healthcare Holdings shares rise after strong broad-based Q2 results and raised FY26 guidance: AVAH Shares are trading higher after the company delivered better-than-expected Q2 results across revenue, adj. EBITDA, and EPS, driven by robust organic growth across all three business segments. Commentary was somewhat mixed on gross margin performance. Sentiment overall encouraged by the successful repricing of the credit facility and the company raising FY26 revenue and adj. EBITDA guidance, which signals continued positive momentum in its ongoing strategic transformation. During the earnings call, management provided an update on the integration of Family First Homecare, which closed in Q2 and is progressing in line with expectations. The company anticipates ramping up the majority of integration efforts by late 4Q26. Additionally, the firm revised its long-term private duty services organic growth rate upward from 3%-5% to 5%-6% and expects cash flow performance in 2H26 to be broadly in line with the first half of the year Constructive initial takeaways from IDEXX Laboratories Investor Meeting: IDXX Initial sentiment is optimistic, as the company remains steadfast in its organic growth initiatives and continues to leverage its competitive advantages across both U.S. and international markets. The long-term growth trajectory appears intact, with management reiterating forward guidance. A notable bright spot was the announcement of a new equipment offering, MultiCue, with additional details expected to be provided at the 2027 VMX conference. STAAR Surgical lower following Q2 print, inline with July preannounce STAA reported Q2 EPS $0.16 vs year-ago ($0.34), revenue $93.5M vs FactSet $90.6M. In July, company preannounced revenues in excess of $90M. Cullinan Therapeutics higher on lung cancer readout CGEM and partner Otsuka (4578.JP) announced that their global phase 3 trial REZILIENT3 with zipalertinib chemo combo for NSCLC met its primary endpoint for PFS at the planned interim analysis. Trial unblineded, and companies to meet with FDA in pursuit of 1L setting. Notable research in Healthcare today Pharma: ABBV upgraded to outperform at Wolfe Research (Alexandria Hammond) Biotech: BIIB upgraded to outperform at Wolfe Research (Alexandria Hammond) ANNX upgraded to market perform from market underperform at Citizens (Jonathan Wolleben), cites valuation. HCM downgraded to hold from buy at Daiwa (Jing Yang); target cut to $13 from $20, 6% upside (FactSet average target $19; range $12-27) MNPR downgraded to neutral from overweight at Cantor Fitzgerald (Kristen Kluska), target increased however to $119 from $109, 4% upside (FactSet average target $124.75; range $104-145) ACHV initiated overweight at Morgan Stanley (Maxwell Skor), target is $13 or approx. 94% upside. MedTech: SYK downgraded to peer perform from outperform at Wolfe Research (Mike Polark) ABT upgraded to outperform at Wolfe Research (Mike Polark) ALC downgraded to neutral from outperform at BNP Paribas Exane (Hugo Solvet); target cut to $79 from $107, 7% upside (FactSet average target $89; range $62-107) ESTA upgraded to buy from neutral at Citi (Joanne Wuensch), target remains $92, 22% upside (FactSet average target $102; range $92-117). Notes the pullback in shares and the upcoming new product cycle. Post-close news Regulatory: BMY FDA grants Accelerated Approval (AA) for Zenbexus (iberdomide) in combination with Darzalex Faspro and dexamethasone for adults with r/r multiple myeloma. The PDUFA goal date for the NDA was 17-Aug-2026. Media report / regulatory: Peptide Critic published independent laboratory findings from four sealed vials of research compounds purchased over the counter at a Brooklyn smoke shop -- it could not confirm retatrutide (LLY) or NAD+ in any sample. Earnings: CAPR reported Q2 results including cash & equivalents $237.9M at 30-Jun - seen as sufficient for the next 12 months. Despite negative outcome for deramiocel Adcomm, Company working towards PDUFA goal date of 22-Aug. StreetAccount notes market cap at today's close $243.8M Shares trading +61.5% in the after-hours, a move which started during the 16:30ET earnings call. Management said on the call that FDA is 1) open to them submitting an amendment to the BLA and 2) extending the PDUFA goal date. On Deck: Regulatory on Sun 16-Aug: FDA PDUFA for LNTH MK-6240 (F18-florquinitau) NDA, PET-imaging agent targeting Tau in Alzheimer's Disease. Note: Lantheus is pending acquisition by Curium US Peek Ahead to the following week (Aug 17-23) EMA CHMP August monthly meeting replaced by written procedure Wed 19-Aug: Piper Sandler MedTech and Diagnostics California Bus Tour Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA (Note: Negative FDA Adcomm last month) Sun 23-Aug: FDA PDUFA for RARE pari-vec BLA StreetAccount Healthcare Reads Luigi Mangione expected to plead guilty to federal charges in assassination of UnitedHealthcare CEO (13-Aug) NY Post Novo CEO says obesity market won't be winner-take-all battle with Lilly (13-Aug) Reuters Trump's Vaccine Plan Brings Obstacles to Parents, Providers, and Drugmakers (13-Aug) Medpage Today Experts Flag Potential Safety Concerns in New Prader-Willi Drug (13-Aug) Medpage Today What Medicare incentives for AI-based devices mean for tech companies - and hospitals (13-Aug) STAT News COVID Excess Deaths Paper Retracted Over Misinformation (11-Aug) Medpage Today WHO says Trump's latest vaccine policy order is misguided (12-Aug) STAT News Mangione Trial Will Have Anonymous Jurors, More Media Access (11-Aug) Bloomberg Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs (11-Aug) STAT News (Opinion) American Academy of Pediatrics calls Trump vaccine order 'dangerous' (10-Aug) The Hill Cassidy blasts vaccine order, saying Trump has no 'expertise to make these changes' (10-Aug) The Hill This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4578.JP, ABBV, ABT, ACHV, ALC, ANNX, AVAH, BIIB, BLTE, BMY, BYSI, CADL, CAPR, CGEM, CYTK, ESTA, HCM, IDXX, INSM, KOD, LLY, LMRI, LNTH, LQDA, MCK, MNPR, MXCT, NVO, OBX, OMER, PBLS, PHVS, PLSE, RARE, SEPN, SMMT, STAA, SYK, TECH, UNH, VEEV, ZBIO, ZEAL.DC, ZTS...(more)	show story hide story
13-Aug-2026 17:35	CAPR Capricor Therapeutics to submit amendment to BLA for upper limb function - conf call ($4.21) Says continuing to work closely with FDA on review of deramiocel BLA in DMD. Company plans to submit an amendment to the FDA for the upper limb function indication, and says the FDA is open to extending the PDUFA goal date, currently 22-Aug-2026. Shares are trading +61.5% in the after-hours See Related StreetAccount comments: 8/13/2026 4:07:04 PM - Capricor Therapeutics reports Q2 EPS ($0.70) vs FactSet ($0.59) [9 est, ($0.64)-(0.43)] 7/30/2026 9:34:52 AM - Capricor Therapeutics provides update on FDA advisory committee meeting for Deramiocel	show story hide story
13-Aug-2026 16:31	IDXX Constructive initial takeaways from IDEXX Laboratories Investor Meeting: ($566.93) Initial sentiment is optimistic, as the company remains steadfast in its organic growth initiatives and continues to leverage its competitive advantages across both U.S. and international markets. The long-term growth trajectory appears intact, with management reiterating forward guidance. A notable bright spot was the announcement of a new equipment offering, MultiCue, with additional details expected to be provided at the 2027 VMX conference. See Related StreetAccount comments: 8/13/2026 12:55:13 PM - Transcript Intelligence: IDEXX Laboratories Investor Day	show story hide story
13-Aug-2026 12:46	AVAH Aveanna Healthcare Holdings shares rise after strong broad-based Q2 results and raised FY26 guidance: ($10.70 +$1.65) Shares are trading higher after the company delivered better-than-expected Q2 results across revenue, adj. EBITDA, and EPS, driven by robust organic growth across all three business segments. Commentary was somewhat mixed on gross margin performance. Sentiment overall encouraged by the successful repricing of the credit facility and the company raising FY26 revenue and adj. EBITDA guidance, which signals continued positive momentum in its ongoing strategic transformation. During the earnings call, management provided an update on the integration of Family First Homecare, which closed in Q2 and is progressing in line with expectations. The company anticipates ramping up the majority of integration efforts by late 4Q26. Additionally, the firm revised its long-term private duty services organic growth rate upward from 3%-5% to 5%-6% and expects cash flow performance in 2H26 to be broadly in line with the first half of the year. See Related StreetAccount comments: 8/13/2026 7:04:56 AM - StreetAccount Metrics Recap - Aveanna Healthcare Holdings Q2 Earnings 8/13/2026 7:02:53 AM - Aveanna Healthcare Holdings reports Q2 EPS $0.22 ex-items vs FactSet $0.17 [10 est, $0.15-0.18]	show story hide story
13-Aug-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 healthcare Index +0.27% vs the S&P 500 +0.72% Major health groups are all lightly mixed, and all are lagging the broader tape. Pharma the primary source of upside, and ABBV +2%, on an upgrade, leading gainer on the XLV; HCA (2%) leading decliner, with modest moves in between. PFE +1% on the $1M open market purchase by CEO Bourla. Sector newsflow fairly quiet outside of SMID-cap biotech earnings tail, and a handful of rating changes. Gainers +23.0% OMER (Omeros): earnings +16.6% AVAH (Aveanna Healthcare Holdings): earnings +9.9% KURA (Kura Oncology): earnings; best performer on XBI. +3.4% ZEAL.DC (Zealand Pharma): in European trading; earnings +2.5% ESTA (Establishment Labs Holdings): upgraded at Citi +2.1% CGEM (Cullinan Therapeutics): trial results in NSCLC +1.5% PFE (Pfizer): insider buying (CEO) +1.4% ABBV (AbbVie): upgraded at Wolfe Research; best performer on XLV +0.6% OPK (Opko Health): expands strategic relationship with HealthCare Royalty through $125M notes issuance +0.4% BIIB (Biogen): upgraded at Wolfe Research +0.3% CYTK (Cytokinetics): files complaint against Bristol-Myers Squibb seeking judgment the company does not infringe '697 patent +0.3% ABT (Abbott Labs): upgraded at Wolfe Research Decliners -6.2% ZBIO (Zenas BioPharma): earnings; worst performer on XBI. -3.3% STAA (STAAR Surgical): earnings (low volume) -1.5% MCK (McKesson): worst performer on XLV -1.4% SYK (Stryker): downgraded at Wolfe Research; second worst performer on XLV. -0.8% NVO (Novo Nordisk): -0.5% PTCT (PTC Therapeutics): announced acquisition of BLA-stage ST-920, Fabry disease asset from Sangamo. -0.3% ALC (Alcon AG): downgraded at BNP Paribas Exane; Pershing Square letter -0.1% BEAM (Beam Therapeutics):	show story hide story
13-Aug-2026 09:07	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Relatively quiet morning with a handful of biotech earnings including Zealand Pharma and Ascendis Pharma reporting. Pfizer disclosed a $1M stock purchase by CEO Albert Bourla. Cullinan Therapeutics reported that a global phase 3 trial in lung cancer hit PFS endpoint at interim analysis. Shares of CGEM +12% in the pre-market. After market close, PTCT announced the expansion of its rare disease portfolio through the acquisition of BLA-stage ST-920, a Fabry disease asset from Sangamo, drawing favorable analyst commentary. Yesterday, most major health groups ended little changed on the session. Only Managed Care an outlier, with no single catalyst, still saw its best daily move of the week. MRNA +5.1%, following the retraction of critical journal article, and COR (5.9%) bracketed all XLV moves; latter pressured after disclosing an update on its long-term relationship with Walgreens. Sector newsflow remained relatively quiet this week amid the tail-end of Q2 earnings season, and the first brokerage conferences post-earnings. Macro S&P futures up +0.2% on Thursday morning. No big directional drivers in play. Latest batch of tech earnings drove another round of positive takeaways for the AI narrative, though price action mostly weaker (vs the post-earnings rallies on Wednesday). Rates rallying despite some mixed inflation takeaways from July PPI, with core-core a bit hotter, though mixed performance in items that feed into PCE. Rates also helped by oil selloff despite lack of any meaningful incremental developments out of the Middle East. Diplomacy remains consensus given energy, economic and military dynamics. Deal durability skepticism also elevated given Iran's outsized focus on maintaining SoH leverage. Seemingly littler reaction on the macro front to report Japanese government supportive of a near-term rate hike by BoJ. Pre-market trading update Trading higher +19.5% OMER earnings +13.2% CGEM trial results in NSCLC +5.8% AVAH earnings +4.0% BEAM +2.8% ZEAL.DC in European trading; earnings +2.0% ESTA upgraded at Citi +1.6% BIIB upgraded at Wolfe Research +0.9% ABBV upgraded at Wolfe Research +0.3% PFE insider buying (CEO) +0.1% ABT upgraded at Wolfe Research Trading lower -1.6% NVO -0.9% SYK downgraded at Wolfe Research -0.4% STAA earnings (low volume) -0.4% ALC downgraded at BNP Paribas Exane; Pershing Square letter Biotech Trial results: CGEM and partner Otsuka (4578.JP) announced that their global phase 3 trial REZILIENT3 with zipalertinib chemo combo for NSCLC met its primary endpoint for PFS at the planned interim analysis. Trial unblineded, and companies to meet with FDA in pursuit of 1L setting. Earnings: ZEAL.DC reports Q2 net income DKK3.92B vs FactSet DKK3.44B; FY26 financial guidance is unchanged ASND reports Q2 non-IFRS EPS €0.90 vs FactSet €1.50 PBLS reports Q2 net income ($52.5M) vs year-ago ($34.8M) BLTE reports Q2 EPS ($0.70) vs FactSet ($0.78) Corporate: ZEAL.DC and RPRX announced a $100M royalty financing deal related to rusfertide (PTGX, TAK). As previously stated, the PDUFA goal date for polycythemia vera NDA is "in the third quarter of 2026". M&A: PTCT expanding rare disease portfolio with acquisition of BLA-stage ST-920 Fabry disease program from defunct Sangamo Therapeutics. Terms include $100M upfront payment and $110M in contingent milestone payments. Research: ANNX upgraded to market perform from market underperform at Citizens BIIB upgraded to outperform at Wolfe Research HCM downgraded to hold from buy; target cut to $13 from $20, 6% upside (FactSet average target $18.73; range $11.76-26.92) - Daiwa MNPR downgraded to neutral from overweight at Cantor Fitzgerald, target increased however to $119 from $109, 4% upside (FactSet average target $124.75; range $104-145) ACHV initiated overweight at Morgan Stanley Services & Hospitals Earnings: AVAH reported Q2 EPS $0.22 ex-items vs FactSet $0.17 on revenue $670.5M vs FS $638.6M, adj EBITDA $95.4M vs FS $82.0M. Raises FY guidance for revenue and EBITDA. Conf. call at 10:00ET Life Science & MedTech Earnings: STAA reports Q2 EPS $0.16 vs year-ago ($0.34), revenue $93.5M vs FactSet $90.6M Research: ESTA upgraded to buy from neutral at Citi, target remains $92, 22% upside (FactSet average target $102.44; range $92-117) Notes the pullback in shares and the upcoming new product cycle ABT upgraded to outperform at Wolfe Research ALC downgraded to neutral from outperform; target cut to $79 from $107.40, 7% upside (FactSet average target $89.01; range $62-107.40) - BNP Paribas Exane SYK downgraded to peer perform from outperform at Wolfe Research Pharma Insider buy: PFE CEO Albert Bourla disclosed a $1M purchase of stock (38.0K shares), raising his stake by nearly 10% Research: ABBV upgraded to outperform at Wolfe Research On Deck: Aug 8 - 16 Conference calendar (cont.): Canaccord Genuity Growth Conference (Aug 11-13) Corporate calendar Thu 13-Aug: IDXX hosting Investor Day meeting (8:00ET) Regulatory calendar Sun 16-Aug: FDA PDUFA for LNTH MK-6240 (F18-florquinitau) NDA, PET-imaging agent targeting Tau in Alzheimer's Disease. Note: Lantheus is pending acquisition by Curium US Peek Ahead to the following week (Aug 17-23) EMA CHMP August monthly meeting replaced by written procedure Mon 17-Aug: FDA PDUFA for BMY iberdomide NDA Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA Sun 23-Aug: FDA PDUFA for RARE pari-vec BLA This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4578.JP, ABBV, ABT, ACHV, ALC, ANNX, ASND, AVAH, BEAM, BIIB, BLTE, CGEM, ESTA, HCM, MNPR, NVO, OMER, PBLS, PFE, PTCT, PTGX, RPRX, STAA, SYK, TAK, ZEAL.DC...(more)	show story hide story
12-Aug-2026 16:54	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished slightly higher and inline overall on Wednesday. Advancers beat decliners by 2:1 on the XLV. Healthcare +0.23% vs S&P 500 +0.26%. Most major health groups ended little changed on the session. Only Managed Care an outlier, with MOH +5.9%, HUM +4.3%, and CNC +3.4%. XBI +0.84% with no single catalyst, still saw its best daily move of the week. MRNA +5.1%, following the retraction of critical journal article, and COR (5.9%) bracketed all XLV moves; latter pressured after disclosing an update on its long-term relationship with Walgreens. Sector newsflow remained relatively quiet this week amid the tail-end of Q2 earnings season, and the first brokerage conferences post-earnings. In psychedelic drug trial news, DFTX +4.6%, shares closed well off their initial highs, phase 3 results from the VOYAGE study in adults with GAD, achieved its primary endpoint. Efficacy noted as rapid and sustained. NBIX (3.4%) after a group of physicians called attention to the safety of Vykat XR (diazoxide choline) based upon the FDA AERS database records - while acknowledging the known issues with FAERS and no confirmed causation. Macro Stocks saw modest gains in a fairly rangebound, low volume session. Upside tabbed to a couple factors, including in line July CPI that helped keep yields down for the day, pushed September rate hike odds down ~11pp to 40%. Momentum/AI trade a standout on well-received earnings from CRWV, LITE, SMCI and NBIS (South Korean memory stocks rallied overnight on report Temasek to acquire stakes). Not much new when it comes to the Middle East where diplomacy hopes and skepticism remain elevated; at the same time and seemingly most important for the market, kinetic hostilities remain muted. Some other areas of focus include some technical tailwinds (systematics building exposure, deleveraging nearly complete), strong earnings growth and positive revisions, AI-linked credit risks as hyperscaler capex forecasts push higher. Notable Gainers +22.5% SION (Sionna Therapeutics): best performer on XBI; follow-through, shares (88%) WTD +12.4% PYXS (Pyxis Oncology): shares were down (26%) yesterday +11.6% REPL (Replimune Group): follow-through, shares +26% WTD +6.5% SLS (SELLAS Life Sciences Group, Inc.): earnings +6.3% LFST (Lifestance Health Group): shares +11% WTD and +70% YTD +6.3% CMPS (Compass Pathways): sympathy to DFTX +5.9% MOH (Molina Healthcare): rotation, Managed Medicaid outperformance +5.1% MRNA (Moderna): best performer on XLV; BMJ study retraction +4.6% DFTX (Definium Therapeutics): trial results in generalized anxiety disorder +4.3% HUM (Humana): shares were down (3%) yesterday +3.4% CNC (Centene): rotation, Managed Medicaid outperformance Notable Decliners -11.6% EYE (National Vision Holdings): earnings -10.5% LQDA (Liquidia): earnings; downgrade -8.7% GRAL (GRAIL, Inc.): worst performer on XBI; follow-through, shares (1%) WTD -5.9% COR (Cencora): comments on Walgreens volumes, reaffirms FY EPS guidance; worst performer on XLV -5.7% CRDF (Cardiff Oncology): earnings; downgraded at Wm Blair -5.4% LEGN (Legend Biotech): downgraded at Oppenheimer -5.3% VOR (Vor Biopharma): follow-through -4.1% TSHA (Taysha Gene Therapies): earnings -3.4% NBIX (Neurocrine Biosciences): STAT News article on safety of Vykat XR -2.7% IDXX (IDEXX Laboratories): ahead of I-Day (Thursday morning) -2.6% ELAN (Elanco Animal Health): analyst meeting pre-open; shares (3%) YTD Cencora lower after update on Walgreens volume COR disclosed via 8-K on Wednesday that certain Walgreens volume, separate from the prime vendor agreement, began to move away from the company starting 1-Jul-2026. Company reaffirmed FY26 adj EPS outlook. Headlines in SMID-cap biotech DFTX announced topline results from phase 3 VOYAGE study evaluating DT120 ODT in adults with generalized anxiety disorder (GAD). Study met its primary endpoint, with rapid and sustained efficacy changes. NBIX STAT News' Adam Feuerstein writes about the 'Clinician Statement' circulating on Prader-Willi Syndrome treatment Vykat XR. Safety concerns are based upon the FDA AERS database - the physicians and the article acknowledge the shortcomings of FAERS and that the causation has not been proven. Vykat (diazoxide choline) was approved by FDA in March 2025, and sponsor Soleno Therapeutics was acquired by Neurocrine Bio in April 2026. BLTE announced that FDA has accepted for priority review its tinlarebant NDA for Stargardt Disease T1. PDUFA goal date is 12-Feb-2027. Notable research in Healthcare today Pharma: NOVO.B.DC (NVO) downgraded to hold from buy at Berenberg (Kerry Holford), target cut to DKK305 from DKK325 or approx. 1% downside. (FactSet average PT DKK319; range DKK200-453) MRK upgraded to outperform from neutral at Daiwa, target increased to $143 from $120 or approx. 10% upside. (FactSet average PT $138; range $105-155) Biotech: ATAI downgraded to hold from buy at Deutsche Bank (David Hoang), follows company's Q2 results. Target cut to $8 from $12 or approx. 11% upside. (FactSet average PT $9; range $7-16) CRDF downgraded to market perform from outperform at William Blair (Andy Hsieh), follows company's Q2 results. LEGN downgraded to perform from outperform at Oppenheimer (Kostas Biliouris), notes uncertainty around new CEO and pipeline strategy. Target cut to $40 from $75 or approx. 83% upside. (FactSet average PT $50; range $24-78) LQDA downgraded to market perform from outperform at LifeSci Capital (Guarav Maini), target cut to $90 from $101 or approx. 13% upside. (FactSet average PT $92; range $60-130) SMMT upgraded to market perform from underperform at Leerink Partners (Daina Graybosch), target increased to $13 from $12 or approx. 14% downside. (FactSet average PT $30; range $10-41) JSPR initiated overweight at Piper Sandler (Biren Amin), target is $2 or approx. 125% upside. MedTech: ISRG upgraded to outperform from perform at Oppenheimer (Suraj Kalia), notes factors including competitive strength in the US. Target is $500 or approx. 25% upside. (FactSet average PT $479; range $324-685) Post-close news Earnings: STAA reports Q2 EPS $0.16 vs FactSet $0.22 on revenue $93.5M vs FS $90.6M, adj EBITDA $20.0M vs FS $17.1M. Conf. call at 17:30ET Shares trading (5.6%) in the after-hours Insider buy: PFE CEO Albert Bourla disclosed a $1M purchase of stock (38.0K shares), raising his stake by nearly 10%. (Form 4 filing) Shares trading +0.3% in the after-hours Corporate: ZEAL.DC and RPRX announced a $100M royalty financing deal related to rusfertide (PTGX, TAK). As previously stated, the PDUFA goal date for polycythemia vera NDA is "in the third quarter of 2026". On Deck: Conference (cont.): Canaccord Genuity Growth Conference (Aug 11-13) Earnings tomorrow morning ZEAL.DC (call at 8:00ET), AVAH (call at 10:00ET) Corporate IDXX hosting Investor Day meeting (8:00ET) Regulatory on Sun 16-Aug: FDA PDUFA for LNTH MK-6240 (F18-florquinitau) NDA, PET-imaging agent targeting Tau in Alzheimer's Disease. Note: Lantheus is pending acquisition by Curium US. StreetAccount Healthcare Reads COVID Excess Deaths Paper Retracted Over Misinformation (11-Aug) Medpage Today WHO says Trump's latest vaccine policy order is misguided (12-Aug) STAT News Mangione Trial Will Have Anonymous Jurors, More Media Access (11-Aug) Bloomberg Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs (11-Aug) STAT News (Opinion) American Academy of Pediatrics calls Trump vaccine order 'dangerous' (10-Aug) The Hill Cassidy blasts vaccine order, saying Trump has no 'expertise to make these changes' (10-Aug) The Hill This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ATAI, AVAH, BLTE, CMPS, CNC, COR, CRDF, DFTX, ELAN, EYE, GRAL, HUM, IDXX, ISRG, JSPR, LEGN, LFST, LNTH, LQDA, MOH, MRK, MRNA, NBIX, NOVO.B.DC, PFE, PTGX, PYXS, REPL, RPRX, SION, SLS, SMMT, STAA, TAK, TSHA, VOR, ZEAL.DC...(more)	show story hide story
12-Aug-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 healthcare Index (0.14%) vs the S&P 500 +0.21%. Major health groups trading widely mixed around the tape today. Managed Care and Biotech are the leading gainers, however XBI +0.67% with no single catalyst for the best move of the week. MRNA +3% and ZTS (4%) bracket the XLV moves. Sector newsflow remains relatively quiet this week amid the tail-end of Q2 earnings season, and the first brokerage conference post-earnings. Psychedelic drug trial news. DFTX +9% has come down from initial highs - phase 3 results from the VOYAGE study in adults with GAD, achieved its primary endpoint. Efficacy noted as rapid and sustained. Gainers +14.3% SION (Sionna Therapeutics): best performer on XBI; follow-through, shares (89%) WTD +8.7% DFTX (Definium Therapeutics): trial results in generalized anxiety disorder +5.7% SLS (SELLAS Life Sciences Group, Inc.): earnings +4.5% CMPS (Compass Pathways): sympathy to DFTX +3.3% MOH (Molina Healthcare): rotation, Managed Medicaid outperformance +2.6% ABCL (AbCellera Biologics): secondary offering +2.5% MRNA (Moderna): best performer on XLV +2.4% CNC (Centene): ; rotation, Managed Medicaid outperformance +1.8% HUM (Humana): shares were down (3%) yesterday +0.7% SMMT (Summit Therapeutics): upgraded at Leerink; NMPA approval for 1L sqNSCLC Decliners -6.9% VOR (Vor Biopharma): follow-through; worst performer on XBI; follow-through -5.4% TSHA (Taysha Gene Therapies): earnings; worst performer on XBI -4.6% LEGN (Legend Biotech): downgraded at Oppenheimer -4.0% ZTS (Zoetis): worst performer on XLV; shares (42%) YTD -3.9% ALC (Alcon AG): follow-through -3.9% COR (Cencora): second-worst on XLV; shares were +3% yesterday -3.7% ELAN (Elanco Animal Health): shares (3%) YTD -2.4% CRDF (Cardiff Oncology): earnings; downgraded at Wm Blair -2.4% NVO (Novo Nordisk): downgraded at Berenberg -2.3% IDXX (IDEXX Laboratories): ahead of I-Day (Thursday) -2.3% NBIX (Neurocrine Biosciences): STAT News article on safety of Vykat XR	show story hide story
12-Aug-2026 08:17	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Defininum Therapeutics announced topline results from the phase 3 VOYAGE study in adults with GAD, achieving its primary endpoint. Efficacy noted as rapid and sustained. Shares of DFTX have resumed, and are trading +18% in the pre-market. A group of physicians is calling attention to the safety of Vykat XR (diazoxide choline) based upon the FDA AERS database records - while acknowledging the known issues with FAERS and no confirmed causation. Shares of NBIX down (6%) in the pre-market. Tail end of Q2 earnings season, generally small-cap reports left on the calendar. Canaccord Genuity Growth Conference continues (day 2 of 3) and helps to fill the void left in the calendar. Macro S&P futures are up +0.3% on Wednesday morning. Very quiet once again from a headline perspective. Market has been fairly light on narrative since early last week with rally to start August chalked up to cleaner positioning, strong earnings, stable macro and diplomacy hopes. Momentum/AI trade a standout on well-received earnings after the close on Tuesday from CRWV, LITE and SMCI and report overnight that Temasek is planning to acquire stakes in South Korean chipmakers Samsung and SK Hynix. Not much new when it comes to the Middle East where diplomacy hope and skepticism remain elevated at the same time and seemingly most important for the market, kinetic hostilities remain muted. Treasuries firmer into CPI while probability of a September rate hike still stands at ~50%. Pre-market trading update Trading higher +18.0% DFTX trial results in GAD; call at 8ET +3.1% CMPS sympathy to DFTX +3.0% MOH on light volume +2.1% SMMT upgraded at Leerink +1.3% BEAM on 19K shares +0.9% ISRG upgraded at Oppenheimer Trading lower -9.1% ABSI earnings -8.2% TSHA earnings -6.5% CRDF earnings; downgraded at Wm Blair -5.9% NBIX STAT News article on safety of Vykat XR -5.5% ABCL secondary offering -4.2% COR shares were +3% yesterday -2.7% NVO downgraded at Berenberg -2.0% LEGN downgraded at Oppenheimer Pharma Research: NOVO.B.DC (NVO) downgraded to hold from buy at Berenberg (Kerry Holford), target cut to DKK305 from DKK325 or approx. 1% downside. (FactSet average PT DKK319; range DKK200-453) MRK upgraded to outperform from neutral at Daiwa, target increased to $143 from $120 or approx. 10% upside. (FactSet average PT $138; range $105-155) Biotech Trial results: DFTX announced topline results from phase 3 VOYAGE study evaluating DT120 ODT in adults with generalized anxiety disorder (GAD). Study met its primary endpoint, with rapid and sustained efficacy changes. Conf. call at 8:00ET Media report: NBIX STAT News' Adam Feuerstein writes about the 'Clinician Statement' circulating on Prader-Willi Syndrome treatment Vykat XR. Safety concerns are based upon the FDA AERS database - the physicians and the article acknowledge the shortcomings of FAERS and that the causation has not been proven. Vykat (diazoxide choline) was approved by FDA in March 2025, and sponsor Soleno Therapeutics was acquired by Neurocrine Bio in April 2026. IPO priced: VOGX (Vogenx Inc) raised $82M when 6.3M share IPO priced at $13/shr, top-end of the anticipated range. S-1A - clinical-stage biotech focused on small molecule for post-bariatric hypoglycemia (PBH). Twenty-first biotech IPO of CY2026, and 26th overall in Healthcare. Earnings: ABSI reports Q2 results including cash & equivalents sufficient to fund operations into H2 of 2028. MLYS reports Q2 results including cash & equivalents $661.4M at 30-Jun TSHA reports Q2 results including cash & equivalents $455.4M at 30-Jun Regulatory: BLTE announced that FDA has accepted for priority review its tinlarebant NDA for Stargardt Disease T1. PDUFA goal date is 12-Feb-2027. Research: ATAI downgraded to hold from buy at Deutsche Bank (David Hoang), follows company's Q2 results. Target cut to $8 from $12 or approx. 11% upside. (FactSet average PT $9; range $7-16) CRDF downgraded to market perform from outperform at William Blair (Andy Hsieh), follows company's Q2 results. LEGN downgraded to perform from outperform at Oppenheimer (Kostas Biliouris), notes uncertainty around new CEO and pipeline strategy. Target cut to $40 from $75 or approx. 83% upside. (FactSet average PT $50; range $24-78) SMMT upgraded to market perform from underperform at Leerink Partners (Daina Graybosch), target increased to $13 from $12 or approx. 14% downside. (FactSet average PT $30; range $10-41) JSPR initiated overweight at Piper Sandler (Biren Amin), target is $2 or approx. 125% upside. Life Science & MedTech Research: ISRG upgraded to outperform from perform at Oppenheimer (Suraj Kalia), notes factors including competitive strength in the US. Target is $500 or approx. 25% upside. (FactSet average PT $479; range $324-685) On Deck: Conference (cont.): Canaccord Genuity Growth Conference (Aug 11-13) Earnings on Wed 12-Aug: after STAA (call at 17:30ET) Thu 13-Aug: before ZEAL.DC (call at 8:00ET), AVAH (call at 10:00ET) Corporate BIVI hosting investor call to discuss phase 2 SUNRISE-PD trial (16:15ET) on Thu 13-Aug: IDXX hosting Investor Day meeting (8:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABCL, ABSI, ATAI, AVAH, BEAM, BIVI, BLTE, CMPS, COR, CRDF, DFTX, IDXX, ISRG, JSPR, LEGN, MLYS, MOH, MRK, NBIX, NOVO.B.DC, NVO, SMMT, STAA, TSHA, VOGX, ZEAL.DC...(more)	show story hide story
11-Aug-2026 16:46	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to slightly lower and inline overall on Tuesday. Decliners equaled advancers on the XLV by the market close. Healthcare (0.26%) vs S&P 500 (0.32%). Most major health groups ended lower on their averages. MedTech group the primary outlier, shares held onto modest gains for the session with medical devices outperforming. Large-cap device names were led by ALC +2.4% on earnings, a Q2 beat with tariff refund help. Most peers were higher by ~1%. XBI +0.03% finished essentially flat and holds a moderate gain WTD. COR +2.7% and HUM (3.3%) bracketed the XLV, with generally modest moves in between. CAH +1% on earnings but ended off its best levels; distributors among leading gainers on the XLV. Payers were four of the bottom five names on the XLV. HIMS (3.8%) reported Q2 showing topline growth and traction, while margins and profit are not keeping up. Canaccord Genuity Growth Conference (CGGC) helping to fill the post-earnings void, with presentations continuing into Thursday. Earnings calendar winding down for Q2. Alcon reported Q2 EPS beat with tariff impact, sales were just slightly ahead of consensus. Puts and takes, however analysts generally optimistic for H2. Cardinal Health reported fiscal Q4 results including tariff refund impact driving the quarterly beat. Topline was light across all segments. Macro Another very quiet session without much of a narrative. Likely partly of function of waiting game for CPI/PPI over next couple of days given heightened attention/uncertainty surrounding Fed. Market currently pricing in a ~50% probability of a September tightening. However, stocks fell to session lows as oil came off lows, driven by latest hostilities around Gulf shipping disruptions and latest threat from Tehran that Strait of Hormuz to remain closed until demands met (though yields rallying despite some upward oil pressure). Followed several earlier diplomacy headlines, though still a lot of skepticism about the durability of any agreement. AI compute/capex demand theme underpinned by some of the positive takeaways surrounding the NVDA funding headlines out yesterday and data center headlines. Earnings takeaways mixed and while there a few notable tech reporters this week, corporate calendar expected to get more attention next week with shift to July Q reporters. Notable Gainers +47.0% STIM (Neuronetics): earnings +30.7% ALMR (Alamar Biosciences): earnings +22.9% SEPN (Septerna): earnings +17.8% TENX (Tenax Therapeutics): follow-through, shares were (90%) yesterday +13.4% IMMX (Immix Biopharma): best performer on XBI; shares +38% MTD +13.3% SION (Sionna Therapeutics): bounce; shares were (91%) yesterday +7.0% PLSE (Pulse Biosciences): follow-through, stock +223% YTD; presented at Canaccord +5.7% LEGN (Legend Biotech): earnings +4.6% EVH (Evolent Health): upgraded at Citi +2.7% COR (Cencora): sympathy to CAH; best performer on XLV +2.5% MCK (McKesson): sympathy to CAH +2.4% ALC (Alcon AG): earnings +2.2% ELAN (Elanco Animal Health): insider buying - CFO and Director Notable Decliners -26.1% PYXS (Pyxis Oncology): unusual volume, 9X daily average -14.3% BCAX (Bicara Therapeutics, Inc.): earnings; leadership changes; worst performer on XBI -12.6% OLMA (Olema Pharmaceuticals): earnings -10.8% AGL (agilon health): upgraded at Citi -10.7% ACH (Accendra Health): follow-through, downgrades -9.4% DFTX (Definium Therapeutics): on average volume -8.3% BKD (Brookdale Senior Living): earnings -7.8% ALMS (Alumis): trial results from ONWARD3 study -7.2% PACS (PACS Group): below average volume -6.8% COGT (Cogent Biosciences): amended stock sales agreement -5.8% BTSG (BrightSpring Health Services): above average volume -3.8% HIMS (Hims & Hers Health): earnings -3.3% HUM (Humana): worst performer on XLV; shares +46% YTD -3.0% DVA (DaVita): shares (26%) MTD / +57% YTD Alcon higher following Q2 beat; analysts optimistic for H2 ALC reported Q2 core EPS $0.84 vs FactSet $0.75 on revenue $2.78B vs FS $2.76B. Raises FY core EPS growth outlook by 200bps, maintains revenue growth outlook. Cardinal Health higher following fiscal Q4 print, focus on tariff impacts CAH reports fiscal Q4 EPS $2.60 ex-items vs FactSet $2.42 on revenue $63.67B vs FS $65.15B. NG EPS includes tariff refund benefit of $0.31. Topline miss all three segments. Guides FY EPS 42c ahead of FS at the midpoint. Hims & Hers Health lower following mixed Q2, margins lagging despite topline traction HIMS reported Q2 adj EBITDA $60.3M vs FactSet $47.0M on revenue $753.2M vs FS $698.9M. Reports adj. net income ($20.7M) vs year-ago $48.7M. Guides Q3 adj EBITDA range with midpoint 9% below consensus, revenue $100M at the midpoint ahead of FactSet consensus. FY revenue guidance raised by $200M at the midpoints, adj EBITDA outlook lowered by $12.5M at the midpoints. Notable research in Healthcare today Biotech: VRTX added to US 1 List at BofA. HRTX downgraded to neutral from buy at HC Wainwright (Brandon Folkes), follows Q2 results. IPHA upgraded to outperform from market perform at Leerink (Daina Graybosch), notes that financing removes an overhang, target increased to $4 from $3 or approx. 80% upside. (FactSet average PT $6; range $3-8) TENX downgraded to in line from outperform at Evercore ISI (Gavin Clark-Gartner), target cut to $5 from $39 or approx. 262% upside. (FactSet average PT $21; range $4-40) ATHE initiated buy at Craig-Hallum Capital (Adam Vogel), target is $12 or approx. 164% upside. (FactSet average PT $16; range $9-33) VALN initiated buy at TD Cowen (Tara Bancroft), target is $12 or approx. 126% upside. (FactSet average PT $12; range $5-18) MedTech: TKNO upgraded to buy from neutral at BTIG (Mark Massaro), follows Q2 results. Target is $8 or approx. 19% upside. (FactSet average PT $9; range $7-12) Services: AGL upgraded to neutral from sell at Citi (Daniel Grosslight), target increased to $115 from $105 or approx. 19% upside. (FactSet average PT $111; range $31-146) EVH upgraded to buy from neutral at Citi (Daniel Grosslight), target decreased however to $6 from $6.75 or approx. 53% upside. (FactSet average PT $6; range $3-8) ACH downgraded to neutral from buy at Citi (Daniel Grosslight), target cut to $1.50 from $4.50 or approx. 7% upside. (FactSet average PT $2; range $1.50-4.50) ACH downgraded to neutral from outperform at Baird (Eric Coldwell), target cut to $1.50 from $6 or approx. 7% upside. Post-close news Earnings: ABSI reports Q2 results including cash & equivalents sufficient to fund operations into H2 of 2028. Conf. call at 16:30ET Shares trading (12.5%) in the after-hours MLYS reports Q2 results including cash & equivalents $661.4M at 30-Jun Conf. call at 16:30ET Shares trading (4.7%) in the after-hours TSHA reports Q2 results including cash & equivalents $455.4M at 30-Jun Conf. call at 16:30ET Shares trading (5.0) in the after-hours Regulatory: BLTE announced that FDA has accepted for priority review its tinlarebant NDA for Stargardt Disease T1. PDUFA goal date is 12-Feb-2027. Shares trading +1.7% in the after-hours On Deck: Conference (cont.): Canaccord Genuity Growth Conference (Aug 11-13) Syndicate / IPO calendar +VOGX (Vogenx) S-1A - clinical-stage biotech focused on small molecule for post-bariatric hypoglycemia (PBH) Earnings on Wed 12-Aug: after STAA (call at 17:30ET) on Thu 13-Aug: before ZEAL.DC (call at 8:00ET), AVAH (call at 10:00ET) Corporate "week of 10-Aug" DFTX topline data from phase 3 VOYAGE GAD trial on Wed 12-Aug: BIVI hosting investor call to discuss phase 2 SUNRISE-PD trial (16:15ET) on Thu 13-Aug: IDXX hosting Investor Day meeting (8:00ET) StreetAccount Healthcare Reads Mangione Trial Will Have Anonymous Jurors, More Media Access (11-Aug) Bloomberg Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs (11-Aug) STAT News (Opinion) American Academy of Pediatrics calls Trump vaccine order 'dangerous' (10-Aug) The Hill Cassidy blasts vaccine order, saying Trump has no 'expertise to make these changes' (10-Aug) The Hill This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABSI, ACH, AGL, ALC, ALMR, ALMS, ATHE, AVAH, BCAX, BIVI, BKD, BLTE, BTSG, CAH, COGT, COR, DFTX, DVA, ELAN, EVH, HIMS, HRTX, HUM, IDXX, IMMX, IPHA, LEGN, MCK, MLYS, OLMA, PACS, PLSE, PYXS, SEPN, SION, STAA, STIM, TENX, TKNO, TSHA, VALN, VRTX, ZEAL.DC, +VOGX...(more)	show story hide story
11-Aug-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 healthcare Index (0.31%) vs the S&P 500 +0.08%. Most major health groups have turned lower on the averages, although declines are quite moderate everywhere. MedTech group relatively firm and holding onto modest gains - large-cap device names led by ALC +3% on earnings, a Q2 beat with tariff refund help. Peers up +1% to +2% each. XBI is flat on the session with a moderate gain WTD. Distributors leading gainers on the XLV; HSIC +2% on top. CAH +1% on earnings but off best levels, and HUM down (2%) quietly, bracket the XLV. Payers are bottom four names on the XLV. HIMS (2%) reported Q2 showing topline growth and traction, while margins and profit are not keeping up. Gainers +22.2% TENX (Tenax Therapeutics): follow-through, shares were (90%) yesterday +17.7% ALMR (Alamar Biosciences): earnings +12.7% SION (Sionna Therapeutics): best performer on XBI; bounce; shares were (91%) yesterday +10.1% EVH (Evolent Health): upgraded at Citi +5.5% LEGN (Legend Biotech): earnings +2.8% ALC (Alcon AG): earnings +2.5% ELAN (Elanco Animal Health): insider buying (CFO and Director) +2.0% HSIC (Henry Schein): sympathy to CAH; best performer on XLV +2.0% CAH (Cardinal Health): earnings; distributors top three on XLV +1.8% MCK (McKesson): sympathy to CAH; distributors top three on XLV Decliners -12.5% ACH (Accendra Health): follow-through, downgrades -12.1% BCAX (Bicara Therapeutics, Inc.): worst performer on XBI; earnings -11.2% OLMA (Olema Pharmaceuticals): earnings -8.1% ALMS (Alumis): trial results from ONWARD3 study -7.0% BKD (Brookdale Senior Living): earnings -4.7% COGT (Cogent Biosciences): amended stock sales agreement -3.1% BHVN (Biohaven): earnings -2.4% HIMS (Hims & Hers Health): earnings -2.2% AGL (agilon health): upgraded at Citi -2.0% HUM (Humana): worst performer on XLV -1.9% CVS (CVS Health): payers bottom three on XLV -1.8% CI (Cigna Group): payers bottom three on XLV	show story hide story
11-Aug-2026 08:29	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar winding down for Q2. Sector newsflow slowing down as well although conference season begins today with Canaccord Genuity. Hims & Hers Health reported Q2 showing topline growth and traction, while margins and profit are not keeping up. Shares of HIMS down (7%) in the pre-market. Alcon reported Q2 EPS beat with tariff impact, sales were just slightly ahead of consensus. Puts and takes, however analysts generally optimistic for H2. ADRs for ALC +2% in the pre-market. On Tuesday morning Cardinal Health reported fiscal Q4 results including tariff refund impact driving the quarterly beat. Topline was light across all segments. Shares of CAH little changed in the pre-market, ahead of the call. Macro S&P futures are up +0.1% on Tuesday morning. Quiet again ahead of July CPI report on Wednesday. More discussion in the financial press about the importance of this week's inflation prints for September FOMC policy expectations. Market currently pricing in a ~52% probability of a 25 bp rate hike in September and ~30 bp of rate hikes through year-end. Oil higher again as headlines continue highlight the heightened complications surrounding a SoH reopening deal. However, still some semblance of reprieve from the lack of kinetic activity in the region. AI another area of focus with NVDA infrastructure financing push playing into both the compute demand and circular financing narratives. Also more focus on falling enterprise AI costs amid price wars and Chinese open-source competition. Pre-market trading update: Trading higher +6.2% LEGN earnings +5.5% TENX follow-through, downgrade +4.6% EVH upgraded at Citi (low volume) +3.6% BBIO earnings +2.8% BRKR +2.4% ALC earnings +1.3% AGL upgraded at Citi (low volume) +0.3% CAH earnings Trading lower -7.0% HIMS earnings -2.1% BKD earnings -1.4% ACH follow-through, downgrades -1.1% BHVN earnings Biotech Earnings: BBIO reported Q2 results including cash & equivalents $720.2M at 30-Jun, not including $1B preferred equity financing that closed on 1-Jul. Attruby US revenue $222.4M vs consensus $210M (source: Mizuho). BHVN reported Q2 results including cash & equivalents $270.5M at 30-Jun. Research: VRTX added to US 1 List at BofA. HRTX downgraded to neutral from buy at HC Wainwright (Brandon Folkes), follows Q2 results. IPHA upgraded to outperform from market perform at Leerink (Daina Graybosch), notes that financing removes an overhang, target increased to $4 from $3 or approx. 80% upside. (FactSet average PT $6; range $3-8) TENX downgraded to in line from outperform at Evercore ISI (Gavin Clark-Gartner), target cut to $5 from $39 or approx. 262% upside. (FactSet average PT $21; range $4-40) ATHE initiated buy at Craig-Hallum Capital (Adam Vogel), target is $12 or approx. 164% upside. (FactSet average PT $16; range $9-33) VALN initiated buy at TD Cowen (Tara Bancroft), target is $12 or approx. 126% upside. (FactSet average PT $12; range $5-18) Life Science & MedTech Earnings: ALC reported Q2 core EPS $0.84 vs FactSet $0.75 on revenue $2.78B vs FS $2.76B. Raises FY core EPS growth outlook by 200bps, maintains revenue growth outlook. Conf. call at 8:00ET HIMS reported Q2 adj EBITDA $60.3M vs FactSet $47.0M on revenue $753.2M vs FS $698.9M. Reports adj. net income ($20.7M) vs year-ago $48.7M. Guides Q3 adj EBITDA range with midpoint 9% below consensus, revenue $100M at the midpoint ahead of FactSet consensus. FY revenue guidance raised by $200M at the midpoints, adj EBITDA outlook lowered by $12.5M at the midpoints. Research: TKNO upgraded to buy from neutral at BTIG (Mark Massaro), follows Q2 results. Target is $8 or approx. 19% upside. (FactSet average PT $9; range $7-12) Services & Hospitals Earnings: CAH reports fiscal Q4 EPS $2.60 ex-items vs FactSet $2.42 on revenue $63.67B vs FS $65.15B. NG EPS includes tariff refund benefit of $0.31. Topline miss all three segments. Guides FY EPS 42c ahead of FS at the midpoint. Conf. call at 8:30ET BKD reported Q2 adj EBITDA $122.1M vs FactSet $121.3M on revenue $718.6M vs FS $735.6M. Reaffirms FY guidance. Conf. call at 9:00ET Research: AGL upgraded to neutral from sell at Citi (Daniel Grosslight), target increased to $115 from $105 or approx. 19% upside. (FactSet average PT $111; range $31-146) EVH upgraded to buy from neutral at Citi (Daniel Grosslight), target decreased however to $6 from $6.75 or approx. 53% upside. (FactSet average PT $6; range $3-8) ACH downgraded to neutral from buy at Citi (Daniel Grosslight), target cut to $1.50 from $4.50 or approx. 7% upside. (FactSet average PT $2; range $1.50-4.50) ACH downgraded to neutral from outperform at Baird (Eric Coldwell), target cut to $1.50 from $6 or approx. 7% upside. On Deck: Conference Canaccord Genuity Growth Conference (Aug 11-13) Syndicate / IPO calendar Tue 11-Aug (post-close): +VOGX (Vogenx) S-1A - clinical-stage biotech focused on small molecule for post-bariatric hypoglycemia (PBH) Earnings on Wed 12-Aug: after STAA (call at 17:30ET) Corporate "week of 10-Aug" DFTX topline data from phase 3 VOYAGE GAD trial on Wed 12-Aug: BIVI hosting investor call to discuss phase 2 SUNRISE-PD trial (16:15ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACH, AGL, ALC, ATHE, BBIO, BHVN, BIVI, BKD, BRKR, CAH, DFTX, EVH, HIMS, HRTX, IPHA, LEGN, STAA, TENX, TKNO, VALN, VRTX, +VOGX...(more)	show story hide story
10-Aug-2026 17:00	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly higher on Monday. Advancers beat decliners by nearly 4:1 on the XLV. Healthcare +1.68% vs S&P 500 (0.06%). All major health groups ended higher on the averages on Monday. Pharma and MedTech lead all gainers. DRG +1.65% skewed positively by LLY +3.9% which received first European approval for oral weight loss drug Foundayo; GSK (1.5%) an outlier amid MMR vaccine headlines - Trump signed an EO to split the three components of today's Measles, Mumps, Rubella vaccines. VRTX +5.6%, on competitive overhang lift, and CI (1.5%) bracketed movers on the XLV. Sector newsflow heavily concentrated in the SMID-cap biotech space with a slew of clinical readouts which hit the tape on Monday morning. SION (91.2%) proof-of-concept in Cystic Fibrosis failed, and another challenger to Vertex written off. TENX (89.8%) failure in Heart Failure. ABCL +34.8% and SLN +29.1% on the better side with clinical readouts. XBI +0.42% amid the evenly split ETF. SRRK (1.9%) downside despite positive reactions to the BLA update for apitegromab. Ongoing trouble at Catalent Indiana no longer expected to slow down FDA review. Fairly small M&A deals on Monday: VREX +48.8% in a $1.1B deal; JAZZ (0.02%) paying $1.3B for a small molecule for rare epilepsies. Earnings calendar winding down, just a few SMID-cap reports on the tape Monday morning. Axsome Therapeutics Q2 print mixed on SG&A expense. A few more post-close tonight. Macro It was a very quiet Monday session, with little in the headlines to shift broader narrative as market attention focuses on key data later this week. Higher oil, higher yields among headwinds to stocks today. Crude rally driven by latest hawkish updates around US/Iran war, including Iran saying any deal with Oman on Strait of Hormuz would not lead to full reopening, while Trump said in post he's demanding compensation for war. Backup in yields tabbed to factors including supply dynamics, competition from AI financing (FT reported Nvidia working on $500B funding package for AI development), and some reversal of last week's dovish Fed repricing (market sees ~52% chance of September rate hike, up from ~44% Friday). Momentum trade weaker despite Street seemingly more constructive on AI backdrop (solid demand trends, stronger hyperscaler monetization, cleaner positioning). Market somewhat in waiting mode ahead of Wednesday's July core CPI, while other areas of focus Monday include strong Q2 earnings, latest private credit scrutiny, yen weakness as intervention impact fades. Notable Gainers +48.8% VREX (Varex Imaging): acquired by TDY, valued at $1.1B +34.8% ABCL (AbCellera Biologics): trial results in severe Vasomotor Symptoms +29.1% SLN (Silence Therapeutics): earnings; trial results in Polycythemia Vera +28.3% IPHA (Innate Pharma): partnership with SOBI.SS; CMO change +13.3% REPL (Replimune Group): follow-through, secondary offering priced; best performer on XBI +9.9% BFLY (Butterfly Network): follow-through, shares were +24% last week +9.8% LFST (Lifestance Health Group): block trade by Citadel; new long at Hedgeye +8.0% TWST (Twist Bioscience): follow-through, shares were +26% last week +7.9% BMRN (Biomarin Pharmaceutical): on nearly 3X average daily volume +7.7% GRAL (GRAIL, Inc.): shares were +10% on Friday (Adcomm scheduled) +7.4% KMTS (Kestra Medical Technologies): initiation +6.8% RDNT (RadNet): earnings +5.6% VRTX (Vertex Pharmaceuticals): sympathy to SION; best performer on XLV +3.9% LLY (Eli Lilly): Foundayo approved in UK; second-best on XLV +3.8% ISRG (Intuitive Surgical): on low volume; FDA clearance for GI robot system +3.8% AXSM (Axsome Therapeutics): earnings +3.8% RMD (ResMed): on average daily volume Notable Decliners -91.2% SION (Sionna Therapeutics): trial results in Cystic Fibrosis; worst performer on XBI -89.8% TENX (Tenax Therapeutics): trial results in PH-HFpEF -50.0% ACH (Accendra Health): earnings; CEO to retire; Board adopts rights plan -45.1% AIRS (AirSculpt Technologies): earnings -40.0% QTRX (Quanterix): earnings -5.1% MLTX (MoonLake Immunotherapeutics): trial results in Psoriatic Arthritis -4.0% MDLN (Medline): follow-through, shares were (10%) last week -1.9% SRRK (Scholar Rock): regulatory update on Catalent Indiana and second fill-finish -1.4% CI (Cigna Group): worst performer on XLV Notable trial results in SMID-cap biotech SION announces topline results from two programs in Cystic Fibrosis - phase 2A proof-of-concept with SION-719 did not meet its primary endpoint, and phase 1 trial of SION-451 in healthy volunteers led to selection of the preferred dual combo. (VRTX) Downgrades, and one upgrade, in reaction SLN announces that phase 2 SANRECO trial with divesiran in PCV met its primary endpoint and secondary endpoints. Full results will be presented at upcoming medical congress. Company also reports Q2 results. ABCL announced topline results from the phase 2 portion of its phase 1/2 trial with ABCL635 in VMS symptoms. Met the primary endpoints. TENX announces topline results from phase 3 LEVEL trial with TNX-103 in PH-HFpEF. LEVEL did not meet its primary endpoint. Downgraded at Wm Blair in reaction; maintained buy at Canaccord Genuity Earnings in Services & Hospitals RDNT reported Q2 adj EBITDA $99.7M vs FactSet $91.4M on revenue $622.7M vs FS $610.9M, EPS $0.29 vs FS $0.20. Raises FY guidance for Imaging Center, reaffirms Digital Health. Conf. call at 10:30ET SGRY reported Q2 adj EBITDA $125.2M vs FactSet $123.6M on revenue $848.9M vs FS $830.0M, EPS $0.10 ex-items vs FS $0.06. Reaffirms FY guidance. Actio Bio (private) acquired by Jazz Pharma for $1.3B JAZZ and Actio Biosciences (private) announced a definitive agreement for Jazz to acquire Actio for $820M upfront and up to $500M in contingent milestones. Lead asset is ABS-1230 for rare epilepsies. Intuitive Surgical's gastrointestinal robot system cleared by FDA ISRG FDA grants 510(k) clearance to Gastrointestinal robot system IG1000. Decision date 7-Aug-2026. Quick take: BMO Capital Markets analyst Vik Chopra notes PMA approval earlier than the firm expected, and faster than competitor EndoQuest Robotics (private). Wells Fargo analyst Larry Biegelsen says the approval could potentially change the narrative in ISRG given the size of the opportunity. Trump plans to sign EO to split the MMR vaccine - Bloomberg Bloomberg reporting on Monday that President Trump is expected to sign an Executive Order that split the MMR vaccine (Measles, Mumps, Rubella) into three separate shots, to be given at separate medical visits. Report follows a story last week that an EO on vaccines and autism was coming soon. The US FDA-licensed vaccines for MMR are sponsored by Merck (M-M-R II) and GlaxoSmithKline (Priorix). The campaign to split the MMR stems from the Wakefield study (Psychology Today, 20-Oct-2025). Notable research in Healthcare today Biotech: SION upgraded to sector perform from underperform at RBC Capital Markets (Brian Abrahams), follows PrecisION trial readout - and thesis has played out. Target decreased however to $5 from $23 or approx. 21% upside. (FactSet average PT $44; range $5-63) SION downgraded to neutral from outperform at Wedbush Securities (Laura Chico), target cut to $5 from $53 or approx. 19% upside. (FactSet average PT $48; range $7-63) SION downgraded to market perform from market outperform at Citizens (Jonathan Wolleben) SION downgraded to market perform from strong buy at Raymond James (Christopher Raymond) SION downgraded to neutral from buy at Guggenheim Securities (Yatin Suneja) SION downgraded to neutral from buy at BTIG (Kambiz Yazdi) SION downgraded to market perform from outperform at LifeSci Capital (Guarav Maini), target cut to $6 from $60 or approx. 35% upside. SION downgraded to hold at Jones (Debanjana Chatterjee) TENX downgraded to market perform from outperform at William Blair (Matt Phipps), cites LEVEL trial failure. TENX price target cut to $4 from $35 at Canaccord Genuity (Angela Qian), rating remains buy. PTGX upgraded to buy from neutral at Goldman Sachs (Richard Law), notes optimism around pipeline. Target is $186 or approx. 28% upside. (FactSet average PT $159; range $112-225) MPLT downgraded to neutral from buy at UBS (Ashwani Verma), cites recent ZEPHYR results. Target cut to $13 from $52 or approx. 7% upside. (FactSet average PT $32; range $20-52) VRAX downgraded to neutral from buy at B Riley Securities (Anderson Schock), target increased however to $18.90 from $18 or approx. 549% upside. MedTech: KMTS initiated overweight at Morgan Stanley (Robbie Marcus), target is $30 or approx. 14% upside. (FactSet average PT $30; range $28-32) Post-close news Earnings: ALC reports Q2 core EPS $0.84 vs FactSet $0.75 on revenue $2.78B vs FS $2.76B. Raises FY core EPS growth outlook by 200bps, maintains revenue growth outlook. Conf. call tomorrow at 8:00ET ADRs trading +5.9% in the after-hours BBIO reports Q2 results including cash & equivalents $720.2M at 30-Jun, not including $1B preferred equity financing that closed on 1-Jul. Attruby US revenue $222.4M vs consensus $210M (source: Mizuho). Conf. call at 16:30ET Shares trading +0.4% in the after-hours BHVN reports Q2 results including cash & equivalents $270.5M at 30-Jun. Conf. call at 16:30ET Shares trading (5.8%) in the after-hours BKD reports Q2 adj EBITDA $122.1M vs FactSet $121.3M on revenue $718.6M vs FS $735.6M. Reaffirms FY guidance. Conf. call tomorrow at 9:00ET Shares trading +0.4% in the after-hours HIMS reports Q2 adj EBITDA $60.3M vs FactSet $47.0M on revenue $753.2M vs FS $698.9M. Reports adj. net income ($20.7M) vs year-ago $48.7M. Guides Q3 adj EBITDA range with midpoint 9% below consensus, revenue $100M at the midpoint ahead of FactSet consensus. FY revenue guidance raised by $200M at the midpoints, adj EBITDA outlook lowered by $12.5M at the midpoints. Conf. call at 17:00ET Shares trading (3.5%) in the after-hours Research: TENX downgraded to in line from outperform at Evercore ISI (Gavin Clark-Gartner), target cut to $5 from $39 or approx. 262% upside. (FactSet average PT $21; range $4-40) On Deck: Earnings tomorrow morning CAH (call at 8:30ET) Earnings on Wed 12-Aug: after STAA (call at 17:30ET) Corporate "week of 10-Aug" DFTX topline data from phase 3 VOYAGE GAD trial on Wed 12-Aug: BIVI hosting investor call to discuss phase 2 SUNRISE-PD trial (16:15ET) Conference Canaccord Genuity Growth Conference (Aug 11-13) Syndicate / IPO calendar Tue 11-Aug (post-close): +VOGX (Vogenx) S-1A - clinical-stage biotech focused on small molecule for post-bariatric hypoglycemia (PBH) StreetAccount Healthcare Reads We prepared for Ebola - but not this Ebola (10-Aug) STAT News (Opinion) The Trump admin offered sick Medicaid patients a 1-year lifeline. These red states are rejecting it. (9-Aug) Politico The FDA AdComm Reboot: Part 2; Lessons from the Meeting on Replimune's RP1 (7-Aug) FDAlawblog Trump Administration Considers Order on Autism and Vaccines (6-Aug) Bloomberg The FDA AdComm Reboot: Part 1; Lessons from the Meeting on Capricor's Deramiocel (5-Aug) FDAlawblog RFK Jr says Trump wants him to investigate any link between autism and vaccines (2-Aug) The Hill This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABCL, ACH, AIRS, ALC, AXSM, BBIO, BFLY, BHVN, BIVI, BKD, BMRN, CAH, CI, DFTX, GRAL, GSK, HIMS, IPHA, ISRG, JAZZ, KMTS, LFST, LLY, MDLN, MLTX, MPLT, MRK, PTGX, QTRX, RDNT, REPL, RMD, SGRY, SION, SLN, SRRK, STAA, TENX, TWST, VRAX, VREX, VRTX, +VOGX...(more)	show story hide story
10-Aug-2026 14:51	Trump plans to sign EO to split the MMR vaccine - Bloomberg Bloomberg reporting on Monday that President Trump is expected to sign an Executive Order that split the MMR vaccine (Measles, Mumps, Rubella) into three separate shots, to be given at separate medical visits. Report follows a story last week that an EO on vaccines and autism was coming soon. The US FDA-licensed vaccines for MMR are sponsored by Merck (M-M-R II) and GlaxoSmithKline (Priorix). The campaign to split the MMR stems from the Wakefield study (Psychology Today, 20-Oct-2025). For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: GSK, MRK	show story hide story
10-Aug-2026 11:02	StreetAccount Summary - Healthcare Midday Trading Healthcare +is outperforming with the S&P 500 Healthcare Index +0.97% vs the S&P 500 +0.02%. Most major health groups are higher to begin the week, lead by MedTech and Pharma, both mixed to moderately higher overall. Managed Care group has come off its initial highs. VRTX +7%, on competitive overhang lift, and DVA (1%) bracket the XLV. Sector newsflow concentrated in the SMID-cap biotech space with a slew of clinical readouts hitting the tape on Monday morning. SION (92%) proof-of-concept in Cystic Fibrosis failed, and another challenger to Vertex written off. TENX (89%) failure in Heart Failure. SLN +42% and ABCL +34% on the better side with readouts. XBI essentially flat overall amid even breadth across the ETF. SRRK (3%) downside despite positive reactions to the BLA update for apitegromab. Ongoing trouble at Catalent Indiana no longer expected to slow down FDA review. Fairly small M&A deals on Monday: VREX +48% in a $1.1B deal; JAZZ +1% paying $1.3B for a small molecule for rare epilepsies. Gainers +48.4% VREX (Varex Imaging): acquired by TDY for $18.90/shr in cash +41.8% SLN (Silence Therapeutics): earnings; trial results in Polycythemia Vera +33.8% ABCL (AbCellera Biologics): trial results in severe Vasomotor Symptoms +26.6% IPHA (Innate Pharma): partnership with SOBI.SS; CMO change +13.4% LFST (Lifestance Health Group): block trade by Citadel; new long at Hedgeye +11.7% BFLY (Butterfly Network): follow-through, shares were +24% last week +11.1% REPL (Replimune Group): follow-through, secondary offering priced; best performer on XBI +7.9% RDNT (RadNet): earnings +7.7% GRAL (GRAIL, Inc.): shares were +10% on Friday (Adcomm scheduled) +7.1% VRTX (Vertex Pharmaceuticals): sympathy to SION; best performer on XLV +6.7% TWST (Twist Bioscience): follow-through, shares were +26% last week +5.7% KMTS (Kestra Medical Technologies): initiation +2.6% EW (Edwards Lifesciences): second-best on XLV +2.3% PTGX (Protagonist Therapeutics): upgraded at Goldman Sachs +2.3% LLY (Eli Lilly): Foundayo approved in UK +2.1% MPLT (MapLight Therapeutics): downgraded at UBS +1.9% AXSM (Axsome Therapeutics): earnings Decliners -91.8% SION (Sionna Therapeutics): trial results in Cystic Fibrosis; worst performer on XBI -88.9% TENX (Tenax Therapeutics): trial results in PH-HFpEF -50.7% ACH (Accendra Health): earnings; CEO to retire; Board adopts rights plan -42.9% AIRS (AirSculpt Technologies): earnings -36.7% QTRX (Quanterix): earnings -5.9% MLTX (MoonLake Immunotherapeutics): trial results in Psoriatic Arthritis -3.4% MDLN (Medline): follow-through, shares were (10%) last week -2.6% SRRK (Scholar Rock): regulatory update on Catalent Indiana and second fill-finish -1.3% DVA (DaVita): worst performer on XLV -1.1% ZTS (Zoetis): shares were (6%) last week	show story hide story
10-Aug-2026 08:14	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis SMID-cap biotech with a slew of clinical readouts on Monday morning, including Sionna Therapeutics' proof-of-concept in Cystic Fibrosis. Shares of SION (91%), while market leader VRTX +8% in the pre-market. Scholar Rock Therapeutics post-close on Friday provided an update on its BLA for apitegromab, on track for late-September PDUFA goal date with the back-up fill-finish facility after Catalent Indiana site dealt another setback. Shares of SRRK little-changed in the pre-market. Earnings calendar winding down, just a few SMID-cap reports on the tape Monday morning. Axsome Therapeutics Q2 print mixed on SG&A expense, shares of AXSM +3% in the pre-market. Macro S&P futures are up +0.1% on Monday morning. Quiet into another big macro week with July CPI the highlight on Wednesday. Bulk of the weekend discussion revolved around the Middle East. US seems to be shifting its focus to the economic pain it is inflicting on Iran, while Tehran has insisted that while an SoH reopening deal with Oman is close, it is conditional on US permanently ending war, lifting naval blockade, unfreezing assets and paying war reparations. Strong Q2 earnings another area of focus in the press. Also some more discussion about recent signals from Treasury Secretary Bessent aimed at preventing a further backup in long-term rates, along with some renewed scrutiny surrounding private credit. Pre-market trading update Trading higher +49.6% VREX acquired by TDY for $18.90/shr in cash +40.0% SLN earnings; ph2 results in PCV +28.4% ABCL ph2 results in VMS +18.4% IPHA partners with SOBI.SS; CMO change +7.7% VRTX in reaction to SION +4.3% RDNT earnings +3.6% ZTS on 22K shares; shares were (6%) last week +2.9% PTGX upgraded at Goldman Sachs (low volume) +2.9% AXSM earnings +1.4% SRRK regulatory update on Catalent Indiana and second fill-finish (low volume) Trading lower -90.5% SION trial results in CF -85.1% TENX LEVEL trial results in PH-HFpEF -28.9% AIRS earnings -21.8% ACH earnings; CEO to retire; Board adopts rights plan -10.5% MLTX trial results in Psoriatic Arthritis -2.6% RCEL follow-through, ADRs were +64% on Friday; upgrades -2.1% MPLT downgraded at UBS (low volume) -0.8% NVO sympathy to SRRK Biotech Trial results: ABCL announced topline results from the phase 2 portion of its phase 1/2 trial with ABCL635 in VMS symptoms. Met the primary endpoints. Conf. call at 7:30ET SION announces topline results from two programs in Cystic Fibrosis - phase 2A proof-of-concept with SION-719 did not meet its primary endpoint, and phase 1 trial of SION-451 in healthy volunteers led to selection of the preferred dual combo. (VRTX) Conf. call at 8:00ET SLN announces that phase 2 SANRECO trial with divesiran in PCV met its primary endpoint and secondary endpoints. Full results will be presented at upcoming medical congress. Company also reports Q2 results. Conf. call for 8:00ET TENX announces topline results from phase 3 LEVEL trial with TNX-103 in PH-HFpEF. LEVEL did not meet its primary endpoint. Conf. call at 8:00ET Earnings: AXSM reports Q2 EPS ($0.99) vs FactSet ($0.89) on revenue $218.4M vs FS $221.1M. Conf. call at 8:00ET Regulatory: NRXP schedules call for 8:30ET SRRK post-close on Friday announced that FDA review of apitegromab BLA is on track for potential approval by 30-Sep-2026 PDUFA goal date -- review will be based only on the backup/second fill-finish facility, after Catalent Indiana (NVO) notified them of OAI status from the April 2026 site inspection. (REGN) Research: PTGX upgraded to buy from neutral at Goldman Sachs (Richard Law), notes optimism around pipeline. Target is $186 or approx. 28% upside. (FactSet average PT $159; range $112-225) MPLT downgraded to neutral from buy at UBS (Ashwani Verma), cites recent ZEPHYR results. Target cut to $13 from $52 or approx. 7% upside. (FactSet average PT $32; range $20-52) Life Science & MedTech M&A: VREX acquired by TDY for $18.90/shr in cash, transaction value $1.1B. Varex also reports fiscal Q3 financial results. Regulatory: CMS/HHS publish notice with comment period on RAPID coverage pathway. Notice issued post-close on Friday. The FDA first disclosed RAPID as replacement for TCET in April 2026. Services & Hospitals Earnings: RDNT reports Q2 adj EBITDA $99.7M vs FactSet $91.4M on revenue $622.7M vs FS $610.9M, EPS $0.29 vs FS $0.20. Raises FY guidance for Imaging Center, reaffirms Digital Health. Conf. call at 10:30ET SGRY reports Q2 adj EBITDA $125.2M vs FactSet $123.6M on revenue $848.9M vs FS $830.0M, EPS $0.10 ex-items vs FS $0.06. Reaffirms FY guidance. Conf. call at 8:30ET On Deck: Earnings today after ALC (call Tue at 8:00ET), BBIO (call at 16:30ET), BKD (call Tue at 9:00ET), HIMS (call at 17:00ET) Earnings tomorrow Tue 11-Aug: before CAH (call at 8:30ET) Conference on Tue 11-Aug: Canaccord Genuity Growth Conference (Aug 11-13) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABCL, ACH, AIRS, ALC, AXSM, BBIO, BKD, HIMS, IPHA, MLTX, MPLT, NRXP, NVO, PTGX, RCEL, RDNT, REGN, SGRY, SION, SLN, SRRK, TDY, TENX, VREX, VRTX, ZTS...(more)	show story hide story
07-Aug-2026 19:13	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished broadly higher and a modest outperformer overall on Friday. Advancers beat decliners by nearly 4:1 on the XLV. Healthcare +0.78% vs S&P 500 +0.62%. All major health groups ended with gains for the session; most were higher by +1% to +2%. Pharma lagged the tape, the DRG only an inline +0.56% with Animal Health pullback resumed on pricing battle concerns. ZTS (6.0%) biggest decliner on XLV one-day after reporting results. ELAN also down another (8.6%). Managed Care today's leading gainer led by HUM +4.8%, bested only by MRNA +9.9% and VEEV +5.8% on the XLV. Vaccine maker saw its best week in a month. RMD (5.1%) after an inline print. The XBI +1.86% on Friday, green five-straight days, to extend its weekly performance above +7%. SMID-cap earnings again dominate newsflow, as well as the new FDA flexibility that led to Replimune's TUDRIQEV crossing the finish line. IPO streak also continued with two more debuts on the Nasdaq today; returns subpar however for BLSM (flat) and LTGO +1.4%. Macro: Stocks posted solid weekly gains, with a risk-on tone carrying into the weekend amid strong Q2 earnings/guidance, cleaner positioning following July's momentum unwind, solid macro data, and de-escalatory US-Iran headlines. Bad news is good news dynamics also in play following weak July NFP, with September rate-hike odds down 10pp+ to ~44%. Software earnings were another bright spot. Oil logged a sharp weekly decline as expectations for a near-term SoH reopening deal persist. Latest headlines point to Oman-Iran progress, with a US official saying a deal is expected soon and would see the US lift its blockade of Iranian ports. Earnings calendar gets much quieter next week before the shift to the Jul Q reporters though macro in focus with July CPI, PPI and retail sales. Notable Gainers on Friday: +63.6% RCEL - earnings; upgraded at BTIG +21.4% NTRA - earnings; best performer on XBI +21.1% OMDA - earnings +20.2% HALO - earnings; upgraded at Leerink +19.1% TNDM - earnings +11.4% CON - earnings +10.9% ICUI - earnings +10.4% GRDN - earnings +10.1% AGL - shares were down (20%) yesterday +9.9% MRNA - best performer on XLV; shares +8% for the week +9.6% GRAL - FDA formally schedules Adcomm for September; shares were down (15%) yesterday +6.9% GH - shares were down (3%) yesterday +6.2% NTLA - upgraded at Evercore ISI +5.8% VEEV - follow-through, shares +13% for the week +5.1% STRO - initiation +4.8% HUM - shares +50% YTD +3.8% BMRN - earnings Notable Decliners on Friday: -59.8% CVRX - earnings, guidance; downgrades -24.7% QDEL - earnings -17.9% ARDX - earnings; worst performer on XBI -9.2% EBS - follow-through; shares (33%) for the week -8.0% XRAY - earnings -7.0% PGNY - earnings -6.2% REPL - follow-through from FDA approval late Thursday; upgraded at Wedbush -5.7% CYTK - earnings -5.3% ANIP - earnings -5.0% RMD - earnings; worst performer on XLV -5.0% RGNX - downgraded at Barclays Week in Review: Earnings scorecard: According to FactSet Scorecard, with 89.76% of companies (149 of 166) having reported, 85.62% of the S&P 1500 Health Care (SP567-SPX) have beaten consensus EPS expectations, vs 81.71% last year (Q2 2025), with an average beat of +19.03% vs +8.67% last year. On the topline, 87.76% have beaten sales expectations, vs 82.32% last year (Q2 2025), with an average beat of +3.11% vs +2.56% last year. Healthcare equities underperformed for the week. The S&P 500 Healthcare Index gained +1.95% vs the S&P 500 Index +3.58%. Outperformers: Biotech Inline: MedTech Underperformers: Pharma, Services, Managed Care Major health groups were all higher for the week on their averages, although only Biotech group outperformed the wider tape. Earnings calendar remained the primary source of newsflow with over half of the scorecard reporting in the first four days this week. Both EPS and Sales metrics remains well ahead of the year ago quarter. Large-cap pharma earnings briefly overshadowed by a mega-merger that would be the largest pharma combination ever. AZN (4.8%) and BMY (0.9%) each declined comment, and Reuters later sourced a senior exec who stated there are "no discussions". Biopharma M&A continued with radiopharma Curium acquiring LNTH for cash + CVR worth up to $8B combined; CNS drugmakers INDV and SUPN will combine in a $7B+ merger of equals. Outside of Pharma, KKR will acquire CRO Integer Holdings in a $5.7B deal. The streak of IPOs continued in Biotech, with three more Nasdaq launches, totaling almost $900M raised. Regulatory sentiment also took a couple steps forward with FDA approving Moderna' seasonal flu vaccine, the first mRNA-based product in the space. The agency also approved Replimune's RP1 less than a week after the successful Adcom. Year-to-date, Healthcare +6.90% vs the S&P 500 +13.32%. Healthcare seventh out of eleven major sectors in CY26. Energy +28.39% and Telecom +2.03% bracket them all. Notable movers for the week: Gainers: BRVE +66.7% - biotech IPO #18 IOVA +55.8% - earnings, guidance; best performer on XBI CAI +45.1% - earnings INSM +33.0% - earnings, guidance TWST +26.3% - earnings; secondary offering, priced HALO +24.9% - earnings; upgraded at Leerink NTRA +20.3% - earnings HNGE +19.6% - earnings TEM +18.6% - sympathy to PSNL earnings (acquisition pending) PRAX +17.2% - earnings RYTM +16.5% - earnings; trial results in AHO CRL +15.0% - earnings; best performer on XLV VEEV +13.1% - stock closed higher 10 of last 11 days, turns green YTD ACAD +12.9% - earnings EHC +12.7% - earnings SRRK +11.9% - earnings CRSP +11.5% - earnings ICUI +9.5% - earnings MDGL +9.1% - upgraded at Wolfe Research; shares down (14%) last week (earnings) IRTC +9.1% - earnings MRNA +7.9% - FDA approves mFlusiva for adults 50 and older WAT +7.8% - earnings CON +7.6% - earnings BDX +6.8% - earnings HUM +5.8% - shares +50% YTD BSX +5.5% - CEO buys $10M in stock (Form 4) LLY +3.2% - earnings Decliners: EBS (33.0%) - earnings; worst performer on XBI BLLN (32.6%) - earnings DVA (23.5%) - earnings; worst performer on XLV ELAN (16.1%) - earnings / sympathy to ZTS BRKR (15.0%) - earnings PODD (14.6%) - earnings; downgrades OSCR (10.6%) - earnings MDLN (10.3%) - earnings ZTS (6.0%) - earnings / sympathy to ELAN AZN (4.8%) - FT report mega-merger; Reuters report "no discussions" Week Ahead (Sat - Sun): Aug 8 - 16 Earnings calendar Mon 10-Aug: before AXSM, RDNT, SGRY after ALC, BBIO, BKD, HIMS Tue 11-Aug: before CAH Corporate calendar "week of 10-Aug" DFTX topline data from phase 3 VOYAGE GAD trial Mon 10-Aug: NRXP hosting investor call to discuss recent FDA feedback on PF-Ketamine ANDA (8:30ET) Wed 12-Aug: BIVI hosting investor call to discuss phase 2 SUNRISE-PD trial (16:15ET) Thu 13-Aug: IDXX hosting Investor Day meeting (8:00ET) Conference calendar Tue 11-Aug: Canaccord Genuity Growth Conference (Aug 11-13) Regulatory calendar Sun 16-Aug: FDA PDUFA for LNTH MK-6240 (F18-florquinitau) NDA, PET-imaging agent targeting Tau in Alzheimer's Disease. Note: Lantheus is pending acquisition by Curium US Peek Ahead to the following week (Aug 17-23) EMA CHMP August monthly meeting replaced by written procedure Mon 17-Aug: FDA PDUFA for BMY iberdomide NDA Sat 22-Aug: FDA PDUFA for CAPR deramiocel BLA Sun 23-Aug: FDA PDUFA for RARE pari-vec BLA Related: ACAD, AGL, ALC, ANIP, ARDX, AXSM, AZN, BBIO, BDX, BIVI, BKD, BLLN, BMRN, BMY, BRKR, BRVE, BSX, CAH, CAI, CAPR, CON, CRL, CRSP, CVRX, CYTK, DFTX, DVA, EBS, EHC, ELAN, GH, GRAL, GRDN, HALO, HIMS, HNGE, HUM, ICUI, IDXX, INSM, IOVA, IRTC, LLY, LNTH, MDGL, MDLN, MRNA, NRXP, NTLA, NTRA, OMDA, OSCR, PGNY, PODD, PRAX, QDEL, RARE, RCEL, RDNT, REPL, RGNX, RMD, RYTM, SGRY, SRRK, STRO, TEM, TNDM, TWST, VEEV, WAT, XRAY, ZTS...(more)	show story hide story
07-Aug-2026 16:27	CMS publishes notice with comment period on RAPID coverage pathway StreetAccount notes the RAPID pathway was initially reported in April 2026 (see linked comment). Today, the Centers for Medicare & Medicaid Services (CMS) and US Department of Health & Human Services (HHS) issued a notice with comment period which "describes the process we will use to provide national coverage for eligible technologies under the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. The RAPID coverage pathway will provide accelerated Medicare beneficiary access to certain eligible Class II and Class III FDA Breakthrough-designated Devices." Comment period 60 days. Editor's Note: This comment was revised to include a link to the CMS' Fact Sheet. (07-Aug-2026, 16:36 ET) See Related StreetAccount comments: 4/23/2026 9:10:26 AM - FDA pauses TCET pathway and annouces RAPID pathway for medical devices Related: ABT, BSX, EW, HSDT, MDT, SYK, ZBH...(more) Reference Link: CMS-3847-NC Reference Link: Fact Sheet	show story hide story
07-Aug-2026 12:31	StreetAccount Summary: Notable Drug Events expected for the week of 9-Aug Mon 10-Aug Investor call: NRXP to host call to discuss recent FDA feedback on PF-Ketamine ANDA (8:30ET) Trial results: DFTX topline data from phase 3 VOYAGE GAD trial anticipated "the week of 10-Aug" Tue 11-Aug Broker conference: Canaccord Genuity Growth Conference (Aug 11-13) Wed 12-Aug Trial results: BIVI to host call to discuss phase 2 SUNRISE-PD trial in early Parkinson's disease (16:15ET) Sun 16-Aug Regulatory decision: LNTH FDA PDUFA for MK-6240 (F18-florquinitau) NDA, PET-imaging agent targeting Tau in Alzheimer's Disease Note: Lantheus is pending acquisition by Curium US later during August 2026 Regulatory decisions: FDA PDUFAs: BMY (iberdomide NDA, 17-Aug), CAPR (deramiocel BLA, 22-Aug) RARE (pariglasgene brecaparvovec BLA, 23-Aug), XSPRAY.SS (Dasynoc NDA, 25-Aug), ZYME/JAZZ (ZIIHERA sBLA, 25-Aug), GILD (bictegravir+ lenacapavir NDA, 27-Aug), 6446.TT (Besremi sBLA, 30-Aug), PTGX/4502.JP (rusfertide NDA), REGN (garetosmab BLA); EMA CHMP opinions on MAA (21-Aug)Regulatory meeting: EMA CHMP monthly meeting (replaced by written procedure) (Aug 17-20) Industry meeting with clinical data: European Society of Cardiology (Aug 28-31) Trial results: CGON* (Ph3 NMIBC), EYPT (Ph3 wet AMD), TENX (Ph3 PH-HFpEF), LGVN (Ph2 HLHS), TYRA (Ph2 IR NMIBC), SLN (Ph2 PV) Related: 4502.JP, 6446.TT, BIVI, BMY, CAPR, CGON, DFTX, EYPT, GILD, JAZZ, LGVN, LNTH, NRXP, PTGX, RARE, REGN, SLN, TENX, TYRA, XSPRAY.SS, ZYME...(more)	show story hide story
07-Aug-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is inline with the S&P 500 Healthcare Index +0.54% vs the S&P 500 +0.54%. All major health groups are in positive territory on the averages, with most by at least 1%. Managed Care leading, including HUM +4% and CNC +3%, although MRNA +6% today's top gainer on the XLV - shares of the vaccine maker seeing best week in a month. RMD (4%) after an inline print, leading decliner on XLV. The XBI +1.00% extending weekly performance above +6%. SMID-cap earnings again dominate newsflow, as well as the new FDA flexibility that led to Replimmune's TUDRIQEV crossing the finish line. IPO streak also continues with two more debuts on the Nasdaq today; BLSM and LTGO indicating higher. Gainers +48.8% RCEL (AVITA Medical): earnings; upgraded at BTIG +21.6% OMDA (Omada Health, Inc.): earnings +19.9% NTRA (Natera): earnings; best performer on XBI +14.7% HALO (Halozyme Therapeutics): earnings; upgraded at Leerink; second-best on XBI +14.7% AGL (agilon health): shares were down (20%) yesterday +13.5% CON (Concentra Group): earnings +12.9% GRDN (Guardian Pharmacy Services): earnings +11.9% ICUI (ICU Medical): earnings +10.5% TNDM (Tandem Diabetes Care): earnings +6.3% MRNA (Moderna): best performer on XLV; shares +4% WTD +6.0% VEEV (Veeva Systems): follow-through, shares +13% WTD +5.9% GH (Guardant Health): shares were down (3%) yesterday +5.9% NTLA (Intellia Therapeutics): upgraded at Evercore ISI +4.4% BMRN (Biomarin Pharmaceutical): earnings +3.1% CAPR (Capricor Therapeutics): sympathy to REPL +2.7% GRAL (GRAIL, Inc.): shares were down (15%) yesterday +2.7% QURE (uniQure NV): sympathy to REPL +2.5% VTRS (Viatris): shares were down (8%) yesterday Decliners -54.9% CVRX (CVRx, Inc.): earnings, guidance; downgrades -25.0% QDEL (QuidelOrtho): earnings -14.3% ARDX (Ardelyx): earnings; worst performer on XBI -7.9% XRAY (Dentsply Sirona): earnings -6.8% RGNX (REGENXBIO): downgraded at Barclays -6.8% ANIP (ANI Pharmaceuticals): earnings -6.1% CYTK (Cytokinetics): earnings -5.8% PGNY (Progyny): earnings -5.2% REPL (Replimune Group): follow-through from FDA approval late Thursday; upgraded at Wedbush -4.5% RMD (ResMed): earnings; worst performer on XLV	show story hide story
07-Aug-2026 08:34	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight brought the final heavy lifting for the Q2 earnings calendar. Natera beat-and-raise the highlight. Shares of NTRA +16% in the pre-market. Late on Thursday's session the FDA announced approval of Replimmune's TUDRIQEV. Conference call with pricing and launch updates held in the after-hours. Shares of REPL (5%) in the pre-market. Two more Biotech IPOs debut on the Nasdaq today, both upsized and priced overnight. Blossomhill Therapeutics (+BLSM) and Latigo Biotherapeutics (+LTGO) are biotech IPOs #19 and #20. Macro S&P futures are up +0.2% on Friday morning. No big directional drivers as market waits for July NFP this morning and CPI next Wednesday. Another busy night of earnings with well-received results out of the software space, where corporates spent a lot of time talking about AI as a tailwind. Still no interim agreement on opening/reopening SoH and the reported details yesterday of the deal being discussed by Iran and Oman seemed very favorable for Tehran and likely a nonstarter for the US. Stocks on track for big weekly gains on the back of very strong Q2 earnings, cleaner positioning following July momentum unwind (and even some FOMO chatter), solid macro and the (seemingly) de-escalate phase of the escalate to de-escalate narrative surrounding the US-Iran conflict. Pre-market trading update Trading higher +23.7% RCEL earnings; upgraded at BTIG +16.1% NTRA earnings +5.4% HALO earnings; upgraded at Leerink +4.8% BMRN earnings (low volume) +4.1% NTLA upgraded at Evercore ISI +3.5% QURE sympathy to REPL +2.1% ROP.SW in European trading; upgraded at Morgan Stanley +0.7% DVA upgraded at TD Cowen Trading lower -42.4% CVRX earnings, guidance; downgrades -11.3% RMD earnings (low volume) -6.0% ANIP earnings -4.7% REPL follow-through from FDA approval late Thursday; upgraded at Wedbush -3.5% TNDM earnings (low volume) -1.1% RGNX downgraded at Barclays Pharma Research: ROP.SW upgraded to overweight from equal-weight at Morgan Stanley (Sarita Kapila), target increased to CHF410 from CHF295 or approx. 12% upside. (FactSet average PT CHF373; range CHF230-435) Biotech Corporate: REPL issued press release confirming the FDA approval of TUDRIQEV (vuso-vec). Note: FDA announced the approval just prior to the US equity market close. On the call: Priced at $450,000 for a course of therapy for the typical real-world patient. Expects product to ship in approx. 60 days. Cost in line with comparable treatments in advanced melanoma. Slides IPO priced: BLSM (Blossomhill Therapeutics) raised $150M after upsized 9.4M share IPO priced at $16/shr, midpoint of the anticipated range. LTGO (Latigo Biotherapeutics) raised $346M after upsized 19.2M share IPO priced at $18/shr, high-end of the anticipated range. Earnings: BMRN reports Q2 EPS $1.20 vs FactSet $0.95 on revenue $990M vs FS $932.0M. Reaffirms FY revenue guidance; raises FY EPS outlook by 5c at the midpoints. HALO reports Q2 EPS $2.28 ex-items vs FactSet $1.79 on revenue $481.0M vs FS $402.3M. Raises FY guidance top to bottom, including EPS outlook by 82.5c at the midpoints. CYTK reports Q2 results including cash ~$1.7B at 30-Jun. XENE reports Q2 results including cash & equivalents $1.245B at 30-Jun. DFTX reports Q2 results including cash & equivalents $1.1B at 30-Jun. RLAY reports Q2 results including cash & equivalents $910.9M at 30-Jun. DNLI reports Q2 EPS ($0.68) vs FactSet ($0.51) on revenue $3.6M vs FS $2.2M. Comments on positive launch for AVLAYAH for Hunter syndrome. Cash & equivalents $940M at 30-Jun, plus $195M in gross proceeds in July from sale of PRV. Research: AKBA downgraded to market perform from outperform at Leerink Partners (Roanna Ruiz), notes topline trajectory of Vafseo. Target cut to $1 from $3 or approx. 5% upside. (FactSet average PT $4.20; range $3-6) CNTX downgraded to market perform from outperform at LifeSci Capital (Charles Zhu), follows Q2 results. DNA downgraded to hold from buy at TD Cowen (Brendan Smith), follows Q2 results. Target cut to $9 from $12 or approx. 6% upside. HALO upgraded to outperform from market perform at Leerink Partners (David Risinger), target increased to $110 from $83 or approx. 28% upside. (FactSet average PT $91; range $70-105) NTLA upgraded to outperform from in line at Evercore ISI (Jonathan Miller), target is $24 or approx. 114% upside. (FactSet average PT $26; range $8-95) REPL upgraded to outperform from neutral at Wedbush Securities (Robert Driscoll), target increased to $19 from $12 or approx. 48% upside. (FactSet average PT $18; range $12-24) RGNX downgraded to equal weight from overweight at Barclays (Eliana Merle), notes valuation. Target remains $12 or approx. 6% upside. (FactSet average PT $26; range $10-50) Life Science & MedTech Earnings: NTRA reported Q2 EPS ($0.47) vs FactSet ($0.49) on revenue $752.8M vs FS $661.2M. Raises FY revenue outlook by $100M at the midpoints. RMD reported fiscal Q4 EPS $0.295 ex-items vs FactSet $0.29 on revenue $1.46B vs FS $1.46B. GMED reported Q2 EPS $1.34 ex-items vs FactSet $1.10 on revenue $789.6M vs FS $782.9M. Raises FY EPS outlook by 25c at the midpoints, reaffirms revenue outlook. TXG reported Q2 EPS ($0.14) vs FactSet ($0.24) on revenue $151.0M vs FS $146.7M. Raises FY revenue outlook by $7.5M at the midpoints ICUI reported Q2 EPS $2.37 ex-items vs FactSet $1.91 on revenue $547.9M vs FS $533.4M. Raises FY guidance top to bottom. IRTC reported Q2 EPS ($0.01) vs FactSet ($0.04) on revenue $224.2M vs FS $219.3M. Company also announced a settlement agreement with BAX, and the acquisition of privately-held Vital Connect for $287.5M in cash and stock. Research: CVRX downgraded to hold from buy at Craig-Hallum Capital (Chase Knickerbocker), target is $4 or approx. 33% downside. (FactSet average PT $9.60; range $4-14) CVRX downgraded to neutral from overweight at Piper Sandler (Matt O'Brien), cites company's reasons for cutting its FY revenue guidance. RCEL upgraded to buy from neutral at BTIG (Ryan Zimmerman), follows Q2 results. Target is $7 or approx. 47% upside. (FactSet average PT $7; range $4-12) Services & Hospitals Research: DVA upgraded to buy from hold at TD Cowen (Ryan Langston), target increased to $220 from $201 or approx. 21% upside. (FactSet average PT $224; range $170-270) On Deck: Aug 1 - 9 all clear Peek Ahead to next week (Aug 10-16) Mon 10-Aug: Earnings before AXSM, RDNT, SGRY after ALC, BBIO, BKD, HIMS Tue 11-Aug: Earnings before CAH; Canaccord Genuity Growth Conference (Aug 11-13) Thu 13-Aug: IDXX hosting Investor Day meeting (8:00ET) Sun 16-Aug: LNTH FDA PDUFA for MK-6240 NDA (Note: acquisition pending) Mon 17-Aug: BMY FDA PDUFA for iberdomide NDA This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Editor's Note: This comment was revised to correct the pre-market move for ANIP down (6%) not up +6%. (07-Aug-2026, 08:42 ET) Related: AKBA, ALC, ANIP, AXSM, BAX, BBIO, BKD, BLSM, BMRN, BMY, CAH, CNTX, CVRX, CYTK, DFTX, DNA, DNLI, DVA, GMED, HALO, HIMS, ICUI, IDXX, IRTC, LNTH, LTGO, NTLA, NTRA, QURE, RCEL, RDNT, REPL, RGNX, RLAY, RMD, ROP.SW, SGRY, TNDM, TXG, XENE, +BLSM, +LTGO...(more)	show story hide story
06-Aug-2026 17:23	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed, to slightly higher overall on Thursday. At the market close, decliners outnumbered advancers on the XLV. Healthcare +0.14% vs S&P 500 (0.18%). Major health groups ended loosely mixed around the tape and within the band of (1%) to +1% on the averages. Biotech top advancer, commercial-stage SMID-cap updates drove the XBI higher +0.97% and kept the ETF on-track for a 5% weekly gain. Earnings calendar very heavy and the primary driver across the sector. PODD +4.5% to lead the XLV, caught a bid on the back of yesterday's sell-off. VTRS (7.7%) leading decliner on the XLV. MedTech group pressured by LST&D subgroup with specialty diagnostics names down mid- to high-single digits. Recent IPO BLLN (38.9%) following Q2 print roughly inline against hot expectations. GRAL (14.5%) after inline Q2, and disclosing that FDA will hold an Adcom this fall to review Galleri (MCED) PMA. Devices mixed yet relatively firm overall today. With shares down (50%) ytd, BSX +3.3% CEO placed a new $10M bet on his company. Shares of MRNA (4.3%) unable to gain traction from the FDA approval of mFlusiva. Investors flowing into the 18th biotech IPO of the year; BRVE +65.6% on its Nasdaq debut. Earnings calendar includes a handful of large-caps and a raft of SMID-caps reporting. McKesson reported fiscal Q1 beat-and-raise. Becton Dickinson reported fiscal Q3 beat and lifts the low-end of FY outlook. Macro No clear through line for today's pullback, though multiple dynamics still at play. Q2 results still very strong overall (and Street has been very upbeat on revision dynamics), though some scrutiny surrounding semis (high bar the issue) and software results. Geopolitics has been a lingering issue, with oil notably higher today amid reports Iran-Oman deal reopening SoH could bar US and Israeli vessels. But still a lot of skepticism about the possibility of translating anything involving Iranian oversight into a permanent deal. Fed also in focus after FT article suggesting Chair Warsh will continue his light-communication approach despite the market's backlash; article also said Warsh is prepared to raise rates in September if inflation readings come in hotter and market prices in a policy shift. Macro will remain in focus over the near term with NFP tomorrow and more importantly, CPI next Wednesday. Notable Gainers +65.6% BRVE (Braveheart Bio): day one IPO (biotech #18) +43.1% IOVA (Iovance Biotherapeutics): earnings; guidance under review; best performer on XBI +33.9% INSM (Insmed): earnings; guidance raise; second-best on XBI +21.6% CAI (Caris Life Sciences): earnings +16.6% EVH (Evolent Health): earnings +16.0% PRAX (Praxis Precision Medicines): earnings +12.6% CLOV (Clover Health): earnings +12.6% EHC (Encompass Health): earnings +10.0% SRRK (Scholar Rock): earnings +8.7% REPL (Replimune Group): FDA approves Tudriqev (RP1) for advanced melanoma +8.6% ADMA (ADMA Biologics): earnings +6.8% VRDN (Viridian Therapeutics): earnings; shares +16% WTD +6.5% PTGX (Protagonist Therapeutics): follow-through +5.3% SRPT (Sarepta Therapeutics): earnings +5.2% SHC (Sotera Health): earnings +4.5% PODD (Insulet): follow-through, multiple downgrades; best performer on XLV +3.9% ZTS (Zoetis): earnings; downgrade; second-best on XLV; shares even WTD +3.8% BDX (Becton Dickinson): earnings +3.3% BSX (Boston Scientific): CEO Form 4 filing +2.8% LFST (Lifestance Health Group): earnings Notable Decliners -38.9% BLLN (BillionToOne): earnings roughly inline, FY guidance reaffirmed -29.6% EBS (Emergent BioSolutions): earnings; restructuring; worst performer on XBI -19.5% AGL (agilon health): earnings -14.5% GRAL (GRAIL, Inc.): earnings -11.9% OSCR (Oscar Health): earnings -11.0% MIRM (Mirum Pharmaceuticals): earnings -8.2% PRVA (Privia Health Group): earnings -7.9% EXEL (Exelixis): earnings -7.7% VTRS (Viatris): earnings; worst performer on XLV -7.7% ELAN (Elanco Animal Health): follow-through; sympathy to ZTS -5.2% SOLV (Solventum Corp.): earnings; plan to separate business -5.1% MNKD (MannKind): earnings -4.3% MRNA (Moderna): FDA approves mFlusiva -4.2% CNC (Centene): shares were +5% yesterday -3.1% ILMN (Illumina): sympathy to GRAL -2.5% ARQT (Arcutis Biotherapeutics): earnings Earnings in Life Science & MedTech BDX reports fiscal Q3 EPS $3.23 ex-items vs FactSet $3.14 on revenue $4.98B vs FS $4.89B. Lifts the low-end of FY EPS by 10c, midpoint by 5c, and now expects revenue growth toward the high-end of its prior guidance. SOLV reported Q2 EPS $2.55 ex-items vs FactSet $1.90 on revenue $2.21B vs FS $2.15B. Raises FY EPS outlook by 65c at the midpoints. Company also announced plans to separate its HCIT business within the next 12-18 months. Health Information Systems has a run-rate of $1.4B annually, and the market is growing +5-6% annually. QGEN reported Q2 EPS $0.62 ex-items vs FactSet $0.60 on revenue $535M vs FS $527.5M. Reaffirms FY guidance top and bottom lines. BLLN reported Q2 EPS $0.15 vs FactSet $0.18 on revenue $109.4M vs FS $109.2M, adj EBITDA $16.1M vs FS $18.3M. Reaffirms FY revenue outlook. CAI reported Q2 EPS $0.00 vs FactSet $0.01 on revenue $263.7M vs FS $238.1M. Raises FY revenue outlook by $25M at the midpoints. NVST reported Q2 EPS $0.41 ex-items vs FactSet $0.34 on revenue $731M vs FS $716.1M, adj EBITDA $108M vs FS $98.4M. Raises FY guidance top to bottom. GRAL reported Q2 EPS ($2.56) vs FactSet ($2.66) on revenue $44.7M vs FS $42.4M. Adj EBITDA ($90.3M) vs FS ($70.1M) FDA to hold Advisory Committee this fall for Galleri (MCED) PMA Encompass Health sharply higher on Q2 results; volume upside driving positive sentiment EHC reported Q2 adj EBITDA $348M vs FactSet $338.2M on revenue $1.60B vs FS $1.57B, and EPS $1.55 ex-items vs FS $1.48. Raises FY guidance top to bottom. Quick take: Takeaways largely constructive, highlighting strong volumes with SS discharge growth of +2.8% vs +1.6% in Q1 and expectations for approximately +1.8% - the beat comes against noted headwinds from unit closures and occupancy limitations. Guidance also a bright spot, with targets raised beyond the Q2 beat - bullish views suggesting this indicates current momentum is durable and could generate additional EBITDA growth in the back half of the year. On the call at 10:00ET, focus will be on color around current SS volume trends and any additional context around the full year guidance update. Additional earnings in Services MCK reported Q1 EPS $9.93 ex-items vs FactSet $9.56 on revenue $105.38B vs FS $103.88B. Raises FY EPS outlook by 40c at the midpoints. AGL reported Q2 EPS $1.07; unclear if comparable to FactSet $0.14. Reports Q2 revenue $1.50B vs FactSet $1.45B, adj EBITDA $70M vs FS $18.9M. STE reports Q1 EPS $2.59 ex-items vs FactSet $2.49 on revenue $1.49B vs FS $1.49B. Reaffirms FY EPS and revenue growth outlook. Earnings in Managed Care OSCR reported Q2 EPS $1.10 vs FactSet $0.40 on revenue $4.88B vs FS $4.73B. MLR 79.2% vs FactSet 81.2%. Reaffirms revenue outlook, raises OI outlook, and sees improved MLR and SG&A vs prior guidance. CLOV reported Q2 adj EBITDA $40.9M vs FactSet $30.7M on revenue $743.2M vs FS $728.3M. Raises FY guidance top to bottom, including EBITDA by $17.5M at the midpoints. Elanco trades lower for a second day; Zoetis optimistic amid challenging market ZTS reports Q2 EPS $1.87 ex-items vs FactSet $1.85 on revenue $2.5B vs FS $2.50B. US Companion Animal missed in Q2, although International an offset. Lowers FY EPS outlook by 72.5c, and lowers FY revenue guidance by $70M, at the midpoints. Management notes challenges in the marketplace and company's abilities to react and compete. SMID-cap biotech headlines Earnings: INSM reports Q2 EPS ($0.06) vs FactSet ($0.69) on revenue $425.5M vs FS $393.7M. Brinsupri $309.2M vs StreetAccount $276.6M. Raises FY product guidance for Brinsupri to $1.25-1.40B vs at least $1B. Maintains Arikayce outlook. RVMD reported Q2 results including cash & equivalents $3.9B at 30-Jun EXEL reports Q2 EPS $0.91 ex-items vs FactSet $0.85 on revenue $628.7M vs FS $636.4M. Lowers FY revenue guidance by $50M at the midpoints. Quick take: Sentiment somewhat mixed as discussion noted the Cabo miss largely stemmed from slower ramp in NET, as RCC remained solid. Some concern suggested the NET miss could signal a lower opportunity for Cabo in NET - though constructive views focused instead on core Cabo in RCC and feel the NET miss has limited impact; this cohort also sees revised full year guidance as somewhat conservative. Looking ahead, investor focus now on STELLAR-304 in 2H26 and CRC PDUFA on Dec 3. MIRM reported Q2 EPS ($1.06) vs FactSet ($0.74) on revenue $176.2M vs FS $166.3M. Raises FY revenue outlook by $20M at the midpoints. ARQT reported Q2 EPS $0.11 vs FactSet $0.06 on revenue $129.9M vs FS $118.9M. Raises FY revenue guidance by $45M at the midpoints. RCUS reported Q2 results including cash & equivalents $775M at 30-Jun. Runway until at least H2 of 2028. IOVA reported Q2 EPS ($0.11) vs FactSet ($0.13) on revenue $99.3M vs FS $87.8M. FY Amtagvi guidance under review with a revision coming this quarter. MRNA Overnight Moderna announced that FDA approved mFlusiva, its mRNA-based vaccine for seasonal influenza for adults 50 and older. Approval came on-time, and was largely de-risked when the VRBPAC voted unanimously in June to recommend licensure. As expected and in accordance with Moderna's revised BLA strategy, the vaccine submission was granted full approval for adults age 50-64, and accelerated approval for adults 65 and up. Quick take: Analyst sentiment around the flu vaccine is generally upbeat, providing a new commercial opportunity and unlocking the potential for US combo for flu+COVID, however bulls are waiting for the INT data in melanoma later this year as the next major catalyst. As for seasonal flu, discussion centered around the contracting season, with distinct advantages for mRNA and the potential to update quickly for strain mis-match. Management also credited for navigating the FDA with the age split BLA, and see the company well positioned to convert the AA in older adults. Biotech IPO #18 in CY2026 BRVE (Braveheart Bio) priced an upsized IPO above the high-end of its anticipated range. Raised $383M via 21.25M shares at $18/shr. Eighteenth biotech IPO we've tracked in CY2026, and twenty-third overall in the sector. Yesterday, shares of the 17th biotech, ATTO, traded +29% on the Nasdaq debut. BRVE opened at $30.20/shr or +67% FDA approves TUDRIQEV in combination with nivolumab for advanced melanoma REPL Prior to the market close on Thursday, the FDA disclosed it had approved Replimmune's TUDRIQEV (vuso-vec) for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. FDA release Shares of REPL closed higher +8.7% on Thursday Notable research in Healthcare today Pharma: ZTS downgraded to market perform from outperform at William Blair (Brandon Vazquez) MedTech: CRL upgraded to overweight from neutral at JPMorgan (Casey Woodring), target increased to $310 from $180 or approx. 19% upside. (FactSet average PT $251; range $180-300) LMAT upgraded to outperform from market perform at Barrington Research (Michael Petusky), citing valuation. Target is $95 or approx. 20% upside. (FactSet average PT $116; range $94-135) Note: analyst had downgraded one day earlier citing Q2 results. PODD downgraded to market perform from outperform at Leerink Partners (Mike Kratky), target cut to $145 from $247 or approx. 9% upside. (FactSet average PT $180; range $144-275) PODD downgraded to neutral from overweight at JPMorgan (Robbie Marcus), target cut to $152 from $275 or approx. 14% upside. PODD downgraded to neutral from buy at BTIG (Marie Thibault) PODD *downgraded* to equal weight from overweight at Wells Fargo (Larry Biegelsen), target is $144 or approx. 8% upside. PODD downgraded to hold from buy at Truist (Richard Newitter), target cut to $153 from $210 or approx. 15% upside. SN.LN (SNN) downgraded to neutral from overweight at JPMorgan (David Adlington), target cut to 1290p from 1438p or approx. 16% upside. (FactSet average PT 1285p; range 1050-1540p) Post-close news Regulatory: REPL issued press release confirming the FDA approval of TUDRIQEV. Company to hold investor conference call today at 16:30ET. Note: FDA announced the approval just prior to the US equity market close. On the call: Priced at $450,000 for a course of therapy for the typical real-world patient. Expects product to ship in approx. 60 days. Cost in line with comparable treatments in advanced melanoma. Slides Shares trading (11.7%) in the after-hours Earnings: NTRA reports Q2 EPS ($0.47) vs FactSet ($0.49) on revenue $752.8M vs FS $661.2M. Raises FY revenue outlook by $100M at the midpoints. Conf. call at 16:30ET Shares trading +16.8% in the after-hours RMD reports fiscal Q4 EPS $0.295 ex-items vs FactSet $0.29 on revenue $1.46B vs FS $1.46B. Conf. call at 16:30ET ADRs trading (6.2%) in the after-hours BMRN reports Q2 EPS $1.20 vs FactSet $0.95 on revenue $990M vs FS $932.0M. Reaffirms FY revenue guidance; raises FY EPS outlook by 5c at the midpoints. Conf. call at 16:30ET Shares trading +4.1% in the after-hours HALO reports Q2 EPS $2.28 ex-items vs FactSet $1.79 on revenue $481.0M vs FS $402.3M. Raises FY guidance top to bottom, including EPS outlook by 82.5c at the midpoints. Conf. call at 16:30ET Shares trading +4.4% in the after-hours CYTK reports Q2 results including cash ~$1.7B at 30-Jun. Conf. call at 16:30ET Shares trading (1.0%) in the after-hours GMED reports Q2 EPS $1.34 ex-items vs FactSet $1.10 on revenue $789.6M vs FS $782.9M. Raises FY EPS outlook by 25c at the midpoints, reaffirms revenue outlook. Conf. call at 16:30ET Shares trading +1.0% in the after-hours XENE reports Q2 results including cash & equivalents $1.245B at 30-Jun. Conf. call at 16:30ET Shares trading +2.7% in the after-hours DFTX reports Q2 results including cash & equivalents $1.1B at 30-Jun. Conf. call at 16:30ET Shares trading (1.3%) in the after-hours TXG reports Q2 EPS ($0.14) vs FactSet ($0.24) on revenue $151.0M vs FS $146.7M. Raises FY revenue outlook by $7.5M at the midpoints Conf. call at 16:30ET Shares trading (3.5%) in the after-hours RLAY reports Q2 results including cash & equivalents $910.9M at 30-Jun. Shares trading (2.3%) in the after-hours ICUI reports Q2 EPS $2.37 ex-items vs FactSet $1.91 on revenue $547.9M vs FS $533.4M. Raises FY guidance top to bottom. Conf. call at 16:30ET Shares trading UNCH in the after-hours IRTC reports Q2 EPS ($0.01) vs FactSet ($0.04) on revenue $224.2M vs FS $219.3M. Company also announced a settlement agreement with BAX, and the acquisition of privately-held Vital Connect for $287.5M in cash and stock. Conf. call at 16:30ET Shares trading (1.3%) in the after-hours DNLI reports Q2 EPS ($0.68) vs FactSet ($0.51) on revenue $3.6M vs FS $2.2M. Comments on positive launch for AVLAYAH for Hunter syndrome. Cash & equivalents $940M at 30-Jun, plus $195M in gross proceeds in July from sale of PRV. Conf. call at 16:30ET Shares trading +1.5% in the after-hours On Deck: Syndicate / IPO pricing +BLSM (Blossom Hill Therapeutics) +LTGO (Latigo Biotherapeutics) Peek Ahead to next week (Aug 10-16) Conference: Canaccord Genuity Growth Conference (Aug 11-13) Investor Day: IDXX (13-Aug, 8:00ET) FDA PDUFA: LNTH MK-6240 NDA (16-Aug), BMY iberdomide NDA (17-Aug) Earnings: CAH, ALC, BBIO, AXSM, HIMS, RDNT, BKD This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ADMA, AGL, ALC, ARQT, AXSM, BAX, BBIO, BDX, BKD, BLLN, BMRN, BMY, BRVE, BSX, CAH, CAI, CLOV, CNC, CRL, CYTK, DFTX, DNLI, EBS, EHC, ELAN, EVH, EXEL, GMED, GRAL, HALO, HIMS, ICUI, IDXX, ILMN, INSM, IOVA, IRTC, LFST, LMAT, LNTH, MCK, MIRM, MNKD, MRNA, NTRA, NVST, OSCR, PODD, PRAX, PRVA, PTGX, QGEN, RCUS, RDNT, REPL, RLAY, RMD, RVMD, SHC, SN.LN, SOLV, SRPT, SRRK, STE, TXG, VRDN, VTRS, XENE, ZTS, +BLSM, +BRVE, +LTGO...(more)	show story hide story
06-Aug-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 healthcare Index (0.45%) vs the S&P 500 +0.13%. Major health groups are loosely mixed around the tape and (1%) to +1% on the averages. Biotech leading the advancers, commercial-stage SMID-cap updates are driving the XBI higher +1.00% and putting the ETF on-track for a +5% weekly gain. Earnings calendar very heavy and the primary driver across the sector. BDX +4% and SOLV (4%), both on earnings, bracket the XLV, with more modest moves in between. MedTech pressured by LST&D subgroup with specialty diagnostics names down mid- to high-single digits. Recent IPO BLLN (36%) following Q2 print roughly inline against hot expectations. GRAL (13%) after inline Q2, and disclosing that FDA will hold an Adcom this fall to review Galleri (MCED) PMA. Devices relatively firm today. With shares down (50%) ytd, BSX +4% CEO placed a new $10M bet on his company. Muted response, and turning lower intraday, for shares of MRNA (2%) following FDA product approval. Gainers +39.7% IOVA (Iovance Biotherapeutics): earnings; guidance under review; best performer on XBI +33.1% INSM (Insmed): earnings; guidance raise; second-best on XBI +21.3% EVH (Evolent Health): earnings +19.3% CLOV (Clover Health): earnings +16.5% CAI (Caris Life Sciences): earnings +14.1% PRAX (Praxis Precision Medicines): earnings +12.4% EHC (Encompass Health): earnings +8.7% ADMA (ADMA Biologics): earnings +5.5% PACS (PACS Group): follow-through +5.3% SRPT (Sarepta Therapeutics): earnings +5.2% SRRK (Scholar Rock): earnings +5.0% LFST (Lifestance Health Group): earnings +4.1% BDX (Becton Dickinson): earnings; best performer on XLV +3.9% BSX (Boston Scientific): CEO Form 4 filing +1.8% ZTS (Zoetis): earnings, guidance +1.7% ARQT (Arcutis Biotherapeutics): earnings +0.3% PODD (Insulet): follow-through, multiple downgrades Decliners -36.3% BLLN (BillionToOne): earnings roughly inline, FY guidance reaffirmed -32.0% EBS (Emergent BioSolutions): earnings; restructuring; worst performer on XBI -16.1% AGL (agilon health): earnings -12.8% GRAL (GRAIL, Inc.): earnings -11.4% MIRM (Mirum Pharmaceuticals): earnings -10.9% PRVA (Privia Health Group): earnings -9.2% OSCR (Oscar Health): earnings -7.6% ELAN (Elanco Animal Health): follow-through; sympathy to ZTS -6.3% ILMN (Illumina): sympathy to GRAL -6.1% MNKD (MannKind): earnings -4.2% SOLV (Solventum Corp.): earnings; plan to separate business; worst performer on XLV -3.9% STE (STERIS): earnings -2.7% EXEL (Exelixis): earnings -2.0% MRNA (Moderna): FDA approves mFlusiva	show story hide story
06-Aug-2026 09:56	EHC Encompass Health sharply higher on Q2 results; volume upside driving positive sentiment ($122.73 +$11.83) EHC trading up double digits in reaction to Q2 results that included a ~3% adjusted EBITDA beat ($348M vs FactSet $338.2M) - with revenue and EPS also ahead. Full year targets also moved higher; adjusted EBITDA now expected in a range of $1.365B-$1.395B vs prior guidance $1.35B-$1.38B and FactSet $1.37B on revenue $6.41B-$6.49B vs prior guidance $6.375B-$6.47B and FactSet $6.42B. Takeaways largely constructive, highlighting strong volumes with SS discharge growth of +2.8% vs +1.6% in Q1 and expectations for approximately +1.8% - the beat comes against noted headwinds from unit closures and occupancy limitations. Guidance also a bright spot, with targets raised beyond the Q2 beat - bullish views suggesting this indicates current momentum is durable and could generate additional EBITDA growth in the back half of the year. On the call at 10:00ET, focus will be on color around current SS volume trends and any additional context around the full year guidance update. See Related StreetAccount comments: 8/5/2026 4:26:23 PM - Encompass Health reports Q2 adjusted EBITDA $348M vs FactSet $338.2M [12 est, $334.3-341.1M]	show story hide story
06-Aug-2026 08:56	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar includes a handful of large-caps and a raft of SMID-caps reporting. McKesson reported fiscal Q1 beat-and-raise. Shares up +2% on light volume. Becton Dickinson reported fiscal Q3 beat and lifts the low-end of FY outlook. Shares up +2% on light volume early. US FDA approved Moderna's fourth branded vaccine mFlusiva. Shares of MRNA +4% in the pre-market. Boston Scientific CEO Mahoney buys more than $10M worth of his company's stock. Shares were down ~50% YTD. Shares of BSX +2% in the pre-market. Macro S&P futures are up +0.1% on Thursday morning. Very quiet outside of the latest barrage of earnings. Q2 earnings metrics very strong and Street upbeat on revision trends, though a lot of the big themes have already been hashed out and takeaways continue to lean more company specific. However, some scrutiny surrounding tech with the high bar for the memory complex and a number of big decliners in software. Nothing particularly incremental out of the Middle East, where consensus continues to revolve around a near-term deal on SoH that is seen playing into Iran's outsized focus on leverage over transit. Market also in waiting mode for some key July economic data, with NFP out tomorrow and more importantly, CPI out next Wednesday. Pre-market trading update Trading higher +28.3% EVH earnings +26.4% INSM earnings +24.9% IOVA earnings +15.6% CAI earnings +13.3% CLOV earnings +6.5% PRAX earnings +6.4% SRRK earnings +4.3% ARQT earnings +3.6% MRNA FDA approves mFlusiva +3.6% LFST earnings +2.3% BSX CEO Form 4 filing +2.0% BDX earnings (low volume) +0.2% ZTS earnings, guidance Trading lower -25.4% BLLN earnings -15.0% MIRM earnings (low volume) -8.3% EXEL earnings -5.4% AGL earnings -4.7% OSCR earnings -1.9% PODD follow-through, multiple downgrades Pharma Earnings: ZTS reports Q2 EPS $1.87 ex-items vs FactSet $1.85 on revenue $2.5B vs FS $2.50B. US Companion Animal missed in Q2, although International an offset. Lowers FY EPS outlook by 72.5c, and lowers FY revenue guidance by $70M, at the midpoints. Management notes challenges in the marketplace and company's abilities to react and compete. Conf. call at 8:30ET Biotech Regulatory: MRNA Overnight Moderna announced that FDA approved mFlusiva, its mRNA-based vaccine for seasonal influenza for adults 50 and older. Approval came on-time, and was largely de-risked when the VRBPAC voted unanimously in June to recommend licensure. As expected and in accordance with Moderna's revised BLA strategy, the vaccine submission was granted full approval for adults age 50-64, and accelerated approval for adults 65 and up. Quick take: Analyst sentiment around the flu vaccine is generally upbeat, providing a new commercial opportunity and unlocking the potential for US combo for flu+COVID, however bulls are waiting for the INT data in melanoma later this year as the next major catalyst. As for seasonal flu, discussion centered around the contracting season, with distinct advantages for mRNA and the potential to update quickly for strain mis-match. Management also credited for navigating the FDA with the age split BLA, and see the company well positioned to convert the AA in older adults. Earnings: INSM reports Q2 EPS ($0.06) vs FactSet ($0.69) on revenue $425.5M vs FS $393.7M. Brinsupri $309.2M vs StreetAccount $276.6M. Raises FY product guidance for Brinsupri to $1.25-1.40B vs at least $1B. Maintains Arikayce outlook. Conf. call at 8:30ET RVMD reported Q2 results including cash & equivalents $3.9B at 30-Jun EXEL reports Q2 EPS $0.91 ex-items vs FactSet $0.85 on revenue $628.7M vs FS $636.4M. Lowers FY revenue guidance by $50M at the midpoints. Quick take: Sentiment somewhat mixed as discussion noted the Cabo miss largely stemmed from slower ramp in NET, as RCC remained solid. Some concern suggested the NET miss could signal a lower opportunity for Cabo in NET - though constructive views focused instead on core Cabo in RCC and feel the NET miss has limited impact; this cohort also sees revised full year guidance as somewhat conservative. Looking ahead, investor focus now on STELLAR-304 in 2H26 and CRC PDUFA on Dec 3. MIRM reported Q2 EPS ($1.06) vs FactSet ($0.74) on revenue $176.2M vs FS $166.3M. Raises FY revenue outlook by $20M at the midpoints. ARQT reported Q2 EPS $0.11 vs FactSet $0.06 on revenue $129.9M vs FS $118.9M. Raises FY revenue guidance by $45M at the midpoints. RCUS reported Q2 results including cash & equivalents $775M at 30-Jun. Runway until at least H2 of 2028. IPO priced: BRVE (Braveheart Bio) priced an upsized IPO above the high-end of its anticipated range. Raised $383M via 21.25M shares at $18/shr. Eighteenth biotech IPO we've tracked in CY2026, and twenty-third overall in the sector. Life Science & MedTech Insider buying: BSX CEO Michael Mahoney discloses via Form 4 filing a purchase of 208.4K shares, now hold stake of 1.6M shares. Earnings: BDX reports fiscal Q3 EPS $3.23 ex-items vs FactSet $3.14 on revenue $4.98B vs FS $4.89B. Lifts the low-end of FY EPS by 10c, midpoint by 5c, and now expects revenue growth toward the high-end of its prior guidance. Conf. call at 8:00ET SOLV reported Q2 EPS $2.55 ex-items vs FactSet $1.90 on revenue $2.21B vs FS $2.15B. Raises FY EPS outlook by 65c at the midpoints. Company also announced plans to separate its HCIT business within the next 12-18 months. Health Information Systems has a run-rate of $1.4B annually, and the market is growing +5-6% annually. QGEN reported Q2 EPS $0.62 ex-items vs FactSet $0.60 on revenue $535M vs FS $527.5M. Reaffirms FY guidance top and bottom lines. Conf. call at 9:30ET BLLN reported Q2 EPS $0.15 vs FactSet $0.18 on revenue $109.4M vs FS $109.2M, adj EBITDA $16.1M vs FS $18.3M. Reaffirms FY revenue outlook. CAI reported Q2 EPS $0.00 vs FactSet $0.01 on revenue $263.7M vs FS $238.1M. Raises FY revenue outlook by $25M at the midpoints. NVST reported Q2 EPS $0.41 ex-items vs FactSet $0.34 on revenue $731M vs FS $716.1M, adj EBITDA $108M vs FS $98.4M. Raises FY guidance top to bottom. GRAL reported Q2 EPS ($2.56) vs FactSet ($2.66) on revenue $44.7M vs FS $42.4M. Adj EBITDA ($90.3M) vs FS ($70.1M) Research: PODD downgraded to market perform from outperform at Leerink Partners (Mike Kratky), target cut to $145 from $247 or approx. 9% upside. (FactSet average PT $180; range $144-275) PODD downgraded to neutral from overweight at JPMorgan (Robbie Marcus), target cut to $152 from $275 or approx. 14% upside. PODD downgraded to neutral from buy at BTIG (Marie Thibault) PODD *downgraded* to equal weight from overweight at Wells Fargo (Larry Biegelsen), target is $144 or approx. 8% upside. PODD downgraded to hold from buy at Truist (Richard Newitter), target cut to $153 from $210 or approx. 15% upside. SN.LN (SNN) downgraded to neutral from overweight at JPMorgan (David Adlington), target cut to 1290p from 1438p or approx. 16% upside. (FactSet average PT 1285p; range 1050-1540p) CRL upgraded to overweight from neutral at JPMorgan (Casey Woodring), target increased to $310 from $180 or approx. 19% upside. (FactSet average PT $251; range $180-300) LMAT upgraded to outperform from market perform at Barrington Research (Michael Petusky), citing valuation. Target is $95 or approx. 20% upside. (FactSet average PT $116; range $94-135) Note: analyst had downgraded one day earlier citing Q2 results. Managed Care Earnings: OSCR reports Q2 EPS $1.10 vs FactSet $0.40 on revenue $4.88B vs FS $4.73B. MLR 79.2% vs FactSet 81.2%. Reaffirms revenue outlook, raises OI outlook, and sees improved MLR and SG&A vs prior guidance. Conf. call at 8:00ET CLOV reported Q2 adj EBITDA $40.9M vs FactSet $30.7M on revenue $743.2M vs FS $728.3M. Raises FY guidance top to bottom, including EBITDA by $17.5M at the midpoints. Services & Hospitals Earnings: MCK reported Q1 EPS $9.93 ex-items vs FactSet $9.56 on revenue $105.38B vs FS $103.88B. Raises FY EPS outlook by 40c at the midpoints. EHC reported Q2 adj EBITDA $348M vs FactSet $338.2M on revenue $1.60B vs FS $1.57B, and EPS $1.55 ex-items vs FS $1.48. Raises FY guidance top to bottom. Conf. call at 10:00ET AGL reported Q2 EPS $1.07; unclear if comparable to FactSet $0.14. Reports Q2 revenue $1.50B vs FactSet $1.45B, adj EBITDA $70M vs FS $18.9M. STE reports Q1 EPS $2.59 ex-items vs FactSet $2.49 on revenue $1.49B vs FS $1.49B. Reaffirms FY EPS and revenue growth outlook. Conf. call at 9:00ET On Deck: Earnings after the close today NTRA, RMD, GMAB, BMRN, HALO, CYTK, GMED, XENE, DFTX, TXG, CON, RLAY, ICUI, IRTC, DNLI Syndicate / IPO pricing +BLSM (Blossom Hill Therapeutics) +LTGO (Latigo Biotherapeutics) Peek Ahead to next week (Aug 10-16) Conference: Canaccord Genuity Growth Conference (Aug 11-13) Investor Day: IDXX (13-Aug, 8:00ET) FDA PDUFA: LNTH MK-6240 NDA (16-Aug), BMY iberdomide NDA (17-Aug) Earnings: CAH, ALC, BBIO, AXSM, HIMS, RDNT, BKD This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AGL, ARQT, BDX, BLLN, BMRN, BRVE, BSX, CAI, CLOV, CON, CRL, CYTK, DFTX, DNLI, EHC, EVH, EXEL, GMAB, GMED, GRAL, HALO, ICUI, INSM, IOVA, IRTC, LFST, LMAT, MCK, MIRM, MRNA, NTRA, NVST, OSCR, PODD, PRAX, QGEN, RCUS, RLAY, RMD, RVMD, SN.LN, SOLV, SRRK, STE, TXG, XENE, ZTS, +BLSM, +BRVE, +LTGO...(more)	show story hide story
06-Aug-2026 08:05	EXEL Exelixis trading lower on Q2 top-line miss, Cabometyx lower than expected ($56.70) EXEL (5.2%) pre-market following Q2 results, revenue $628.7M vs FactSet $636.4M on Cabometyx sales below - $570.6M vs FactSet $577.7M. Full year guidance also moved lower, revenue now expected $2.500B-2.550B vs prior guidance $2.525B-2.625B and FactSet $2.60B. Sentiment somewhat mixed as discussion noted the Cabo miss largely stemmed from slower ramp in NET, as RCC remained solid. Some concern suggested the NET miss could signal a lower opportunity for Cabo in NET - though constructive views focused instead on core Cabo in RCC and feel the NET miss has limited impact; this cohort also sees revised full year guidance as somewhat conservative. Looking ahead, investor focus now on STELLAR-304 in 2H26 and CRC PDUFA on Dec 3. See Related StreetAccount comments: 8/5/2026 4:28:46 PM - StreetAccount Metrics Recap - Exelixis Q2 Earnings 8/5/2026 4:17:38 PM - Exelixis reports Q2 EPS $0.91 ex-items vs FactSet $0.85 [14 est, $0.77-0.92]	show story hide story
06-Aug-2026 07:54	MRNA Moderna wins approval for US influenza vaccine, and analysts look forward to melanoma catalyst ($56.26) Shares of MRNA +4% in the pre-market Thursday after company announced that FDA approved its mRNA-based vaccine for seasonal influenza for adults 50 and older. Approval came on-time, and was largely de-risked when the VRBPAC voted unanimously in June to recommend licensure. As expected and in accordance with Moderna's revised BLA strategy, the vaccine submission was granted full approval for adults age 50-64, and accelerated approval for adults 65 and up. Analyst sentiment around the flu vaccine is generally upbeat, providing a new commercial opportunity and unlocking the potential for US combo for flu+COVID, however bulls are waiting for the INT data in melanoma later this year as the next major catalyst. As for seasonal flu, discussion centered around the contracting season, with distinct advantages for mRNA and the potential to update quickly for strain mis-match. Management also credited for navigating the FDA with the age split BLA, and see the company well positioned to convert the AA in older adults. See Related StreetAccount comments: 8/5/2026 10:18:30 PM - FDA approves Moderna's mFLUSIVA	show story hide story
05-Aug-2026 17:12	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mostly higher on Wednesday. Advancers beat decliners by 2:1 on the XLV. Healthcare +1.34% vs S&P 500 (0.18%). Most major health groups ended higher on the averages. MedTech a laggard, but primarily skewed lower by PODD (20.1%), biggest decliner on XLV, on a slower growth forecast. Devices weighed by Diabetes Tech declines, but offset by CRO strength. CRL +11.4% top gainer on the XLV behind a Q2 beat-and-raise, including the highest organic growth since Q3 of 2023. LST subgroup lightly mixed. Managed Care and Pharma materially outperformed the wider tape. DRG +1.82%. LLY +4.9% and AMGN +4.6% are standouts on their own respective prints, while AZN +3.7% partially climbed back after new media report refuted the Sunday mega-merger media report. DVA (17.2%) on a Q2 beat, but patient care costs expected to drag on H2 operating income. Earnings calendar in full swing with notable reports from large-cap biotech plus almost every corner of the sector. Last night Amgen and Gilead Sciences with Q2 beat-and-raise prints. Eli Lilly reported strong Q2 sales for diabetes and obesity, and mixed results for key oncology franchise. Volume in Mounjaro and Zepbound the key driver of sales growth. CVS Health reported Q2 beat-and-raise print, with MLR 240bps better than StreetAccount consensus. Insulet Corp reported Q2 beat top and bottom lines, but focus on Omnipod sales growth forecast slower than Q3 consensus, and lowered for FY. "No discussions" between AstraZeneca and Bristol Myers, reports Reuters citing a senior level source. Macro Very busy from a headline perspective but no overriding theme for the day. August risk sentiment has been boosted by overall strength in Q2 earnings, cleaner positioning following July momentum unwind, solid macro data and diplomatic offramp hopes surrounding US-Iran conflict. Mixed takeaways from latest barrage of earnings with AI capex scrutiny, elevated expectations, AI adoption/usage/initiatives and resilient travel demand some of the big themes. Middle East headlines continue to revolve around a near-term deal regarding SoH that is seen playing into Iran's outsized focus on leverage over transit. Economic calendar does not seem to be having much impact with some mixed takeaways from ISM services and a softer ADP private payrolls print. Fedspeak has leaned hawkish but no shift in policy expectations with focus on July NFP Friday, CPI next week and continued reaction function uncertainty. Another heavy earnings day with more than 75% of S&P 500 having now reported. Notable Gainers +28.8% ATTO Attovia Therapeutics): day one IPO (biotech #17) +23.6% AMWL (American Well): earnings +23.0% PRGO (Perrigo Co.): earnings +21.6% GERN (Geron): earnings; best performer on XBI +15.7% TWST (Twist Bioscience): secondary offering, priced +13.7% BVS (Bioventus): earnings +13.6% AGL (agilon health): on heavy volume +12.0% TVTX (Travere Therapeutics): earnings +11.3% CRL (Charles River Laboratories): earnings; best performer on XLV +6.1% ACAD (Acadia Pharmaceuticals): earnings +5.9% FTRE (Fortrea Holdings): sympathy to CRL +5.8% PRCT (PROCEPT BioRobotics): earnings; downgrades +5.5% PGEN (Precigen): earnings +4.8% LLY (Eli Lilly): earnings +4.7% RYTM (Rhythm Pharmaceuticals): follow-through, shares +12% WTD +4.6% ALMR (Alamar Biosciences): minority holder ATTO +4.6% AMGN (Amgen): earnings +4.6% CNC (Centene): on above average volume, shares +8% WTD +3.8% AZN (AstraZeneca): Reuters report on M&A story citing senior source +3.6% COR (Cencora): earnings +3.5% ELV (Elevance Health): on light volume, shares +4% WTD +2.5% ZBH (Zimmer Biomet Holdings): earnings +2.4% ELAN (Elanco Animal Health): earnings +1.9% HNGE (Hinge Health, Inc.): earnings +1.8% PACS (PACS Group): earnings +1.4% ONC (BeOne Medicines): earnings Notable Decliners -25.3% LMAT (LeMaitre Vascular): earnings; downgraded at Barrington -21.0% TYRA (Tyra Biosciences): earning; worst performer on XBI -20.1% PODD (Insulet): earnings; downgraded at Opco; worst performer on XLV -17.2% DVA (DaVita): earnings; second-worst on XLV -5.8% CAPR (Capricor Therapeutics): follow-through, shares +2% WTD -5.3% TMDX (TransMedics Group): earnings -5.1% CVS (CVS Health): earnings -4.2% RXRX (Recursion Pharmaceuticals): earnings -3.4% BMY (Bristol Myers Squibb): Reuters report on M&A story citing senior source -2.6% GILD (Gilead Sciences): earnings Eli Lilly higher on strong incretin volumes in Q2, healthy price competition LLY reports Q2 EPS $8.38 ex-items vs FactSet $6.01 on revenue $22.97B vs FactSet $20.69B. Key product topline beats were Mounjaro, Jardiance, Trulicity, and Zebpound. Foundayo reported $98M in launch quarter sales. Lowers top-end of FY EPS outlook by (50c), raises FY revenue guidance by $2.5B at the midpoints. Quick take: Initial analyst takeaways focus heavily on the incretin volumes which drove Q2 outperformance, with Foundayo numbers viewed as roughly inline. Price competition with Novo Nordisk seen as healthy, with volume growth outweighing concessions. Guidance upgrade was well received, plus UBS posits $50/shr EPS in 2027 (FactSet consensus $45.18). On the 10ET call, analysts seek more color around the Foundayo launch trajectory, early indicators from the Medicare Bridge since 1-July, and any incremental thoughts on business development. AstraZeneca recoups week-to-date losses AZN / BMY Reuters reporting "no discussions" between the two large drugmakers, citing a senior source close to the matter. AZN ADRs were down more than (8%) WTD, BMY shares +1% WTD, since Sunday's FT story. Animal Health trades lower following Elanco beat-and-raise ELAN reported Q2 EPS $0.34 ex-items vs FactSet $0.27 on revenue $1.37B vs FS $1.31B, adj EBITDA $288M vs FS $251.4M. Guides Q3 ahead of consensus. Raises FY EPS outlook by 7c, revenue by $67.5M, at the midpoints. Additional guidance in slides. Earnings in Life Science & MedTech ZBH reported Q2 EPS $2.07 ex-items vs FactSet $2.01 on revenue $2.18B vs FS $2.13B. Organic growth +4.0% vs StreetAccount +2.2%. Raises FY EPS by $0.055 at the midpoints, narrowed and raised FY revenue growth outlook by 90bps at the midpoints. PODD reported Q2 EPS $1.66 ex-items vs FactSet $1.45 on revenue $801.7M vs FS $787.4M. Guides Q3 revenue growth slower than consensus. Lowers FY revenue growth by 100bps, now +20-22% vs prior +21-23%. Stock downgraded in reaction CRL reported Q2 EPS $3.02 ex-items vs FactSet $2.74 on revenue $1.00B vs FS $977.2M. Notes organic revenue growth +0.1% highest since Q3 of 2023. Raises FY EPS outlook by 25c at the midpoints. Narrows FY revenue growth (decline). Earnings in Services and Managed Care CVS reported Q2 EPS $2.58 ex-items vs FactSet $1.85 on revenue $106.10B vs FS $100.03B. MLR 87.4% vs StreetAccount 89.8%. Raises FY EPS outlook by 60c at the midpoints, and CFO guidance to at least $11.5B vs prior at least $9.5B. COR reported fiscal Q3 EPS $4.48 ex-items vs FactSet $4.35 on revenue $84.8B vs FS $84.31B. Raises FY EPS outlook by 5c at the midpoints, reaffirms revenue growth guidance. DVA reported Q2 EPS $4.02 ex-items vs FactSet $3.88 on revenue $3.55B vs FS $3.50B. Repeats FY EPS guidance. MDLN reported Q2 EPS $0.50 ex-items vs FactSet $0.32 on revenue $7.69B vs FS $7.51B, adj EBITDA $1.06B vs FS $798.2M. Results and guidance include tariff refunds. Lowers FY adj EBITDA outlook by $200M, reflecting inflationary pressure from the Middle East conflict and other factors. Raises FY organic sales outlook by 50bps. PACS reported Q2 adj EBITDA $166.8M vs FactSet $147.8M on revenue $1.43B vs FS $1.41B. EPS $0.63 ex-items vs FS $0.54. Raises FY adj EBITDA outlook by $35M, revenue by $100M at the midpoints. Earnings in Biotech AMGN reported Q2 EPS $6.29 ex-items vs FactSet $5.62 on revenue $10.05B vs FS $9.43B. Raises FY EPS outlook by 50c and revenue by $1B, at the midpoints. GILD reported Q2 EPS ($6.75) ex-items vs FactSet ($7.26) on revenue $7.80B vs FS $7.40B. Raises FY EPS outlook by $0.375 and product sales by $50M, at the midpoints. Quick take: Sentiment has been generally positive around the update, suggesting results mitigated some concern around IMS data heading into the release. Commonly highlighted was continued outperformance from the HIV franchise (Biktarvy and PrEP) in the quarter, along with raised full year targets - HIV franchise growth now +9-10% (vs +8% prior). Some questioning around Yeztugo growth trajectory (with full year sales reiterated vs raised), however most viewed results and guidance constructively on the durability of the company's HIV portfolio (with no near-term LOE) and potential for ongoing margin expansion. ONC reported Q2 EPS $2.05 vs FactSet $1.66 on revenue $1.71B vs FS $1.62B. Raises FY revenue outlook by $300M, and NG OI by $250M, at the midpoints. UTHR reported Q2 EPS $7.27 vs FactSet $6.86 on revenue $783.3M vs FS $804.6M. Topline light, spread across three biggest products. Management highlights "strong underlying demand" for Tyvaso DPI (MNKD). TVTX reported Q2 EPS ($0.37) vs FactSet ($0.13) on revenue $169.9M vs FS $157.3M. Highlights continued momentum for Fispari including "promising early launch in FSGS" and continued strength in IgAN. Biotech IPO #17 prices 17M shares at $17/shr Now tracking seventeen biotech IPOs ytd in CY2026, with Attovia Therapeutics (ATTO) raising $289M in today's IPO: 17M shares IPO priced at $17/shr. The clinical-stage biotech is focused on therapeutics for immune-mediated diseases. Initial indications include chronic pruritus, atopic dermatitis (AD), and IBDs ulcerative colitis (UC) and Crohn's (CD). Alamar Biosciences (ALMR) holds more than 5% of capital stock, and is eligible for milestones and royalties under their platform license agreement. Note: Alamar was also a 2026 IPO: Shares have traded +59% since pricing at $17/shr on 17-Apr. Notable research in Healthcare today Biotech: OBX initiated overweight at Piper Sandler (Kelsey Goodwin), target is $42 TKNO initiated buy at Roth Capital (Max Masucci), target is $7 or approx. 27% upside. (FactSet average PT $8.50; range $7-12) MedTech: PODD downgraded to perform from outperform at Oppenheimer (Suraj Kalia), notes forward growth outlook. WAT upgraded to buy from hold at TD Cowen (Dan Brennan), target increased to $475 from $408 or approx. 20% upside. (FactSet average PT $434; range $390-475) PRCT downgraded to market perform from outperform at William Blair (Brandon Vazquez), follows Q2 earnings. PRCT downgraded to equal weight from overweight at Wells Fargo Securities (Nathan Treybeck), target cut to $19 from $34 or approx. 4% upside. (FactSet average PT $25; range $16-37) SN.LN (SNN) downgraded to underweight from equal weight at Barclays (Hassan Al-Wakeel), cites Q2 results. Target cut to 1050p from 1290p or approx. 6% downside. (FactSet average PT 1327p; range 1050-1544p) Managed Care: HUM upgraded to equal weight from underweight at Morgan Stanley (Erin Wright), target increased to $370 from $249 or approx. 2% upside. (FactSet average PT $415; range $280-513) Post-close news Insider buying: BSX CEO Michael Mahoney discloses via Form 4 filing a purchase of 208.4K shares, now hold stake of 1.6M shares. Shares trading +2.3% in the after-hours Corporate: SOLV announced plans to separate its HCIT business within the next 12-18 months. Health Information Systems has a run-rate of $1.4B annually, and the market is growing +5-6% annually. Company also reported Q2 EPS $2.55 ex-items vs FactSet $1.90 on revenue $2.21B vs FS $2.15B. Raises FY EPS outlook by 65c at the midpoints. Shares trading +2.9% in the after-hours Research: PODD downgraded to hold from buy at Truist (Richard Newitter), noting diminished confidence in a near-term sustained recovery. Target cut to $153 from $210 or approx. 15% upside. (FactSet average PT $224; range $150-294) Shares trading UNCH in the after-hours Earnings: MCK reports Q1 EPS $9.93 ex-items vs FactSet $9.56 on revenue $105.38B vs FS $103.88B. Raises FY EPS outlook by 40c at the midpoints. Conf. call at 16:30ET Shares trading +2.6% in the after-hours RVMD reports Q2 results including cash & equivalents $3.9B at 30-Jun Conf. call at 16:30ET Shares trading (1.7%) in the after-hours STE reports Q1 EPS $2.59 ex-items vs FactSet $2.49 on revenue $1.49B vs FS $1.49B. Reaffirms FY EPS and revenue growth outlook. Conf. call Thu at 9:00ET Shares trading +1.0% in the after-hours EXEL reports Q2 EPS $0.91 ex-items vs FactSet $0.85 on revenue $628.7M vs FS $636.4M. Lowers FY revenue guidance by $50M at the midpoints. Conf. call at 16:30ET Shares trading (4.4%) in the after-hours EHC reports Q2 adj EBITDA $348M vs FactSet $338.2M on revenue $1.60B vs FS $1.57B, and EPS $1.55 ex-items vs FS $1.48. Raises FY guidance top to bottom. Conf. call Thu at 10:00ET Shares trading +7.8% in the after-hours QGEN reports Q2 EPS $0.62 ex-items vs FactSet $0.60 on revenue $535M vs FS $527.5M. Reaffirms FY guidance top and bottom lines. Conf. call Thu at 9:30ET ADRs trading (2.0%) in the after-hours MIRM reports Q2 EPS ($1.06) vs FactSet ($0.74) on revenue $176.2M vs FS $166.3M. Raises FY revenue outlook by $20M at the midpoints. Conf. call at 16:30ET Shares trading (20.1%) in the after-hours BLLN reports Q2 EPS $0.15 vs FactSet $0.18 on revenue $109.4M vs FS $109.2M, adj EBITDA $16.1M vs FS $18.3M. Reaffirms FY revenue outlook. Conf. call at 16:30ET Shares trading (22.3%) in the after-hours CAI reports Q2 EPS $0.00 vs FactSet $0.01 on revenue $263.7M vs FS $238.1M. Raises FY revenue outlook by $25M at the midpoints. Conf. call at 16:30ET Shares trading +14.8% in the after-hours NVST reports Q2 EPS $0.41 ex-items vs FactSet $0.34 on revenue $731M vs FS $716.1M, adj EBITDA $108M vs FS $98.4M. Raises FY guidance top to bottom. Conf. call at 17:00ET Shares trading +3.9% in the after-hours ARQT reports Q2 EPS $0.11 vs FactSet $0.06 on revenue $129.9M vs FS $118.9M. Raises FY revenue guidance by $45M at the midpoints. Conf. call at 16:30ET Shares trading +10.2% in the after-hours RCUS reports Q2 results including cash & equivalents $775M at 30-Jun. Runway until at least H2 of 2028. Conf. call at 16:30ET Shares trading +1.0% in the after-hours GRAL reports Q2 EPS ($2.56) vs FactSet ($2.66) on revenue $44.7M vs FS $42.4M. Adj EBITDA ($90.3M) vs FS ($70.1M) Conf. call at 16:30ET Shares trading (9.1%) in the after-hours AGL reports Q2 EPS $1.07; unclear if comparable to FactSet $0.14. Reports Q2 revenue $1.50B vs FactSet $1.45B, adj EBITDA $70M vs FS $18.9M. Conf. call at 16:30ET Shares trading +1.1% in the after-hours On Deck: Regulatory FDA PDUFA today for MRNA mFlusiva (mRNA-1010) BLA Earnings tomorrow Thu 6-Aug: before BDX, ZTS, ROIV, INSM, MRK.GR, VTRS, PRAX, OSCR, IMVT, LNTH, TFX, LGND, SRRK, SHC, LFST, HAE, PRVA after NTRA, RMD, GMAB, BMRN, HALO, CYTK, GMED, XENE, DFTX, TXG, CON, RLAY, ICUI, IRTC, DNLI Syndicate / IPO pricing tonight: +BRVE (Braveheart Bio) StreetAccount Healthcare Reads 'No discussions' over AstraZeneca-Bristol Myers deal, senior source says (5-Aug) Reuters The FDA AdComm Reboot: Part 1; Lessons from the Meeting on Capricor's Deramiocel (5-Aug) FDAlawblog How poor countries are dealing with America's AIDS cuts (3-Aug) The Economist Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea (3-Aug) Fierce Pharma (Opinion) AstraZeneca investors balk at prospect of $400 billion Bristol Myers deal (3-Aug) Reuters After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers (3-Aug) STAT News Kennedy, Oz Contend Fraud Crackdown, Not Skyrocketing Prices, Led Millions To Leave Obamacare (3-Aug) KFF Health News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACAD, AGL, ALMR, AMGN, AMWL, ARQT, ATTO, AZN, BDX, BLLN, BMRN, BMY, BSX, BVS, CAI, CAPR, CNC, CON, COR, CRL, CVS, CYTK, DFTX, DNLI, DVA, EHC, ELAN, ELV, EXEL, FTRE, GERN, GILD, GMAB, GMED, GRAL, HAE, HALO, HNGE, HUM, ICUI, IMVT, INSM, IRTC, LFST, LGND, LLY, LMAT, LNTH, MCK, MDLN, MIRM, MNKD, MRK.GR, MRNA, NTRA, NVST, OBX, ONC, OSCR, PACS, PGEN, PODD, PRAX, PRCT, PRGO, PRVA, QGEN, RCUS, RLAY, RMD, ROIV, RVMD, RXRX, RYTM, SHC, SN.LN, SOLV, SRRK, STE, TFX, TKNO, TMDX, TVTX, TWST, TXG, TYRA, UTHR, VTRS, WAT, XENE, ZBH, ZTS, +BRVE...(more)	show story hide story
05-Aug-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.92% vs the S&P 500 +0.29%. All major health groups are trading higher on the averages, only Pharma and Managed Care are materially outperforming the wider tape. DRG +2.37%. MedTech a laggard, but skewed lower by PODD (18%) on a slower growth forecast. Devices weighed by Diabetes Tech declines, but offset by CRO strength. CRL +11% leading gainer on the XLV behind a Q2 beat-and-raise, including the highest organic growth since Q3 of 2023. LST subgroup lightly mixed. AMGN +5% and LLY +4% standouts on their own respective prints, while AZN +5% climbs back after new media report refutes the Sunday mega-merger report. DVA (19%) faring worst on the XLV as Q2 beat, but patient care costs expected to drag on H2 operating income. Gainers +24.6% AMWL (American Well): earnings +24.1% PRGO (Perrigo Co.): earnings +19.8% GERN (Geron): earnings; best performer on XBI +18.4% BVS (Bioventus): earnings +16.0% TVTX (Travere Therapeutics): earnings +12.2% TWST (Twist Bioscience): secondary offering, priced +11.3% CRL (Charles River Laboratories): earnings; best performer on XLV +11.2% HNGE (Hinge Health, Inc.): earnings +8.4% AGL (agilon health): on good volume +7.4% FTRE (Fortrea Holdings): sympathy to CRL +5.9% AMGN (Amgen): earnings +5.7% PGEN (Precigen): earnings +5.7% ELAN (Elanco Animal Health): earnings +4.8% PRCT (PROCEPT BioRobotics): earnings; downgraded at Wm Blair and Wells Fargo +4.6% ACAD (Acadia Pharmaceuticals): earnings +4.4% AZN (AstraZeneca): Reuters report on M&A story citing senior source +3.6% COR (Cencora): earnings +3.4% LLY (Eli Lilly): earnings +3.3% ZBH (Zimmer Biomet Holdings): earnings +2.4% ONC (BeOne Medicines): earnings +1.7% RYTM (Rhythm Pharmaceuticals): follow-through Decliners -19.3% LMAT (LeMaitre Vascular): earnings; downgraded at Barrington -18.6% DVA (DaVita): earnings; worst performer on XLV -18.1% PODD (Insulet): earnings -15.7% TYRA (Tyra Biosciences): earning; worst performer on XBI -9.5% TMDX (TransMedics Group): earnings -6.1% CVS (CVS Health): earnings -3.9% RXRX (Recursion Pharmaceuticals): earnings -3.4% PACS (PACS Group): earnings -3.2% BMY (Bristol Myers Squibb): Reuters report on M&A story citing senior source -3.1% GILD (Gilead Sciences): earnings	show story hide story
05-Aug-2026 09:48	Biotech IPO #17 prices 17M shares at $17/shr Now tracking seventeen biotech IPOs ytd in CY2026, with Attovia Therapeutics (ATTO) raising $289M in today's IPO: 17M shares IPO priced at $17/shr. The clinical-stage biotech is focused on therapeutics for immune-mediated diseases. Initial indications include chronic pruritus, atopic dermatitis (AD), and IBDs ulcerative colitis (UC) and Crohn's (CD). Alamar Biosciences (ALMR) holds more than 5% of capital stock, and is eligible for milestones and royalties under their platform license agreement. Note: Alamar was also a 2026 IPO: Shares have traded +59% since pricing at $17/shr on 17-Apr. ATTO is scheduled to begin trading at 10:20ET on the Nasdaq. For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: ALMR, ATTO	show story hide story
05-Aug-2026 08:52	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis "No discussions" between AstraZeneca and Bristol Myers, reports Reuters citing a senior level source. ADRs for AZN +6%, BMY (1%) in the pre-market. Earnings calendar in full swing with notable reports from large-cap biotech plus almost every corner of the sector. Last night Amgen and Gilead Sciences with Q2 beat-and-raise prints, shares of AMGN and GILD both little changed in the pre-market. Eli Lilly reported strong Q2 sales for diabetes and obesity, and mixed results for key oncology franchise. Volume in Mounjaro and Zepbound the key driver of sales growth. Shares of LLY +5% in the pre-market. CVS Health reported Q2 beat-and-raise print, with MLR 240bps better than StreetAccount consensus. Shares of CVS +3% in the pre-market Insulet Corp reported Q2 beat top and bottom lines, but focus on Omnipod sales growth forecast slower than Q3 consensus, and lowered for FY. Shares of PODD (14%) in the pre-market. Macro S&P futures are up +0.5% on Wednesday morning. Path of least resistance has been higher this week on the back of very strong Q2 earnings, cleaner positioning following July momentum unwind/deleveraging, positive macro surprise momentum and latest bout of diplomatic optimism surrounding the Middle East that has weighed on oil and yields. Busy night of earnings with SPCX hit by capex concerns and AMD under pressure with takeaways focused on very elevated expectations into the print. Middle East the other areas of focus. Headlines continue to suggest an interim deal to open the SoH is imminent, though Houthis said they attacked a Saudi tanker in the Read Sea. Pre-market trading update Trading higher +13.3% TVTX earnings +10.2% PRGO earnings +8.5% CRL earnings +7.5% BCRX earnings +6.9% PGEN earnings +6.4% ELAN earnings +6.0% AZN Reuters report on M&A story citing senior source +5.2% LLY earnings +3.3% CVS earnings +3.3% ZBH earnings +3.2% COR earnings +2.2% ONC earnings +0.4% AMGN earnings +0.2% GILD earnings Trading lower -14.3% PODD earnings -8.4% TMDX earnings -8.2% RXRX earnings -6.9% PRCT earnings; downgraded at Wm Blair and Wells Fargo -5.7% DVA earnings -1.8% HNGE earnings -1.6% BMY Reuters report on M&A story citing senior source Pharma M&A / media report: AZN / BMY Reuters reporting "no discussions" between the two large drugmakers, citing a senior source close to the matter. AZN ADRs were down more than (8%) WTD, BMY shares +1% WTD, since Sunday's FT story. Earnings: LLY reports Q2 EPS $8.38 ex-items vs FactSet $6.01 on revenue $22.97B vs FactSet $20.69B. Key product topline beats were Mounjaro, Jardiance, Trulicity, and Zebpound. Foundayo reported $98M in launch quarter sales. Lowers top-end of FY EPS outlook by (50c), raises FY revenue guidance by $2.5B at the midpoints. Conf. call at 10:00ET Quick take: Initial analyst takeaways focus heavily on the incretin volumes which drove Q2 outperformance, with Foundayo numbers viewed as roughly inline. Price competition with Novo Nordisk seen as healthy, with volume growth outweighing concessions. Guidance upgrade was well received, plus UBS posits $50/shr EPS in 2027 (FactSet consensus $45.18). On the 10ET call, analysts seek more color around the Foundayo launch trajectory, early indicators from the Medicare Bridge since 1-July, and any incremental thoughts on business development. ELAN reports Q2 EPS $0.34 ex-items vs FactSet $0.27 on revenue $1.37B vs FS $1.31B, adj EBITDA $288M vs FS $251.4M. Guides Q3 ahead of consensus. Raises FY EPS outlook by 7c, revenue by $67.5M, at the midpoints. Additional guidance in slides. Conf. call at 8:00ET Biotech Earnings: AMGN reported Q2 EPS $6.29 ex-items vs FactSet $5.62 on revenue $10.05B vs FS $9.43B. Raises FY EPS outlook by 50c and revenue by $1B, at the midpoints. GILD reported Q2 EPS ($6.75) ex-items vs FactSet ($7.26) on revenue $7.80B vs FS $7.40B. Raises FY EPS outlook by $0.375 and product sales by $50M, at the midpoints. Quick take: Sentiment has been generally positive around the update, suggesting results mitigated some concern around IMS data heading into the release. Commonly highlighted was continued outperformance from the HIV franchise (Biktarvy and PrEP) in the quarter, along with raised full year targets - HIV franchise growth now +9-10% (vs +8% prior). Some questioning around Yeztugo growth trajectory (with full year sales reiterated vs raised), however most viewed results and guidance constructively on the durability of the company's HIV portfolio (with no near-term LOE) and potential for ongoing margin expansion. ONC reports Q2 EPS $2.05 vs FactSet $1.66 on revenue $1.71B vs FS $1.62B. Raises FY revenue outlook by $300M, and NG OI by $250M, at the midpoints. Conf. call at 8:00ET UTHR reports Q2 EPS $7.27 vs FactSet $6.86 on revenue $783.3M vs FS $804.6M. Topline light, spread across three biggest products. Management highlights "strong underlying demand" for Tyvaso DPI (MNKD). Conf. call at 9:00ET TVTX reported Q2 EPS ($0.37) vs FactSet ($0.13) on revenue $169.9M vs FS $157.3M. Highlights continued momentum for Fispari including "promising early launch in FSGS" and continued strength in IgAN. Life Science & MedTech Earnings: ZBH reports Q2 EPS $2.07 ex-items vs FactSet $2.01 on revenue $2.18B vs FS $2.13B. Organic growth +4.0% vs StreetAccount +2.2%. Raises FY EPS by $0.055 at the midpoints, narrowed and raised FY revenue growth outlook by 90bps at the midpoints. Conf. call at 8:30ET PODD reports Q2 EPS $1.66 ex-items vs FactSet $1.45 on revenue $801.7M vs FS $787.4M. Guides Q3 revenue growth slower than consensus. Lowers FY revenue growth by 100bps, now +20-22% vs prior +21-23%. Conf. call at 8:00ET CRL reports Q2 EPS $3.02 ex-items vs FactSet $2.74 on revenue $1.00B vs FS $977.2M. Notes organic revenue growth +0.1% highest since Q3 of 2023. Raises FY EPS outlook by 25c at the midpoints. Narrows FY revenue growth (decline). Conf. call at 9:00ET Research: WAT upgraded to buy from hold at TD Cowen (Dan Brennan), target increased to $475 from $408 or approx. 20% upside. (FactSet average PT $434; range $390-475) PRCT downgraded to market perform from outperform at William Blair (Brandon Vazquez), follows Q2 earnings. PRCT downgraded to equal weight from overweight at Wells Fargo Securities (Nathan Treybeck), target cut to $19 from $34 or approx. 4% upside. (FactSet average PT $25; range $16-37) SN.LN (SNN) downgraded to underweight from equal weight at Barclays (Hassan Al-Wakeel), cites Q2 results. Target cut to 1050p from 1290p or approx. 6% downside. (FactSet average PT 1327p; range 1050-1544p) Services & Hospitals and Managed Care Earnings: CVS reports Q2 EPS $2.58 ex-items vs FactSet $1.85 on revenue $106.10B vs FS $100.03B. MLR 87.4% vs StreetAccount 89.8%. Raises FY EPS outlook by 60c at the midpoints, and CFO guidance to at least $11.5B vs prior at least $9.5B. Conf. call at 8:00ET COR reports fiscal Q3 EPS $4.48 ex-items vs FactSet $4.35 on revenue $84.8B vs FS $84.31B. Raises FY EPS outlook by 5c at the midpoints, reaffirms revenue growth guidance. Conf. call at 8:30ET DVA reported Q2 EPS $4.02 ex-items vs FactSet $3.88 on revenue $3.55B vs FS $3.50B. Repeats FY EPS guidance. MDLN reports Q2 EPS $0.50 ex-items vs FactSet $0.32 on revenue $7.69B vs FS $7.51B, adj EBITDA $1.06B vs FS $798.2M. Results and guidance include tariff refunds. Lowers FY adj EBITDA outlook by $200M, reflecting inflationary pressure from the Middle East conflict and other factors. Raises FY organic sales outlook by 50bps. Conf. call at 9:30ET Research: HUM upgraded to equal weight from underweight at Morgan Stanley (Erin Wright), target increased to $370 from $249 or approx. 2% upside. (FactSet average PT $415; range $280-513) On Deck: Regulatory FDA PDUFA for MRNA mFlusiva (mRNA-1010) BLA Corporate NAMS hosting Investor Day meeting (9:00ET) Earnings after the close MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL Earnings tomorrow Thu 6-Aug: before BDX, ZTS, ROIV, INSM, MRK.GR, VTRS, PRAX, OSCR, IMVT, LNTH, TFX, LGND, SRRK, SHC, LFST, HAE, PRVA after NTRA, RMD, GMAB, BMRN, HALO, CYTK, GMED, XENE, DFTX, TXG, CON, RLAY, ICUI, IRTC, DNLI This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: AMGN, ARQT, AZN, BCRX, BDX, BLLN, BMRN, BMY, CAI, CON, COR, CRL, CVS, CYTK, DFTX, DNLI, DVA, EHC, ELAN, EXEL, GILD, GMAB, GMED, GRAL, HAE, HALO, HNGE, HUM, ICUI, IMVT, INSM, IRTC, LFST, LGND, LLY, LNTH, MCK, MDLN, MIRM, MNKD, MRK.GR, MRNA, NAMS, NTRA, NVO, NVST, ONC, OSCR, PGEN, PODD, PRAX, PRCT, PRGO, PRVA, QGEN, RCUS, RLAY, RMD, ROIV, RVMD, RXRX, SHC, SN.LN, SOLV, SRRK, STE, TFX, TMDX, TVTX, TXG, UTHR, VTRS, WAT, XENE, ZBH, ZTS...(more)	show story hide story
05-Aug-2026 08:41	LLY Eli Lilly higher on strong incretin volumes in Q2, healthy price competition ($1115.68) Shares of LLY +4.7% early following Q2 EPS $8.38 ex-items vs FactSet $6.01 on revenue $22.97B vs FactSet $20.69B. Key product topline beats were Mounjaro, Jardiance, Trulicity, and Zebpound. Foundayo reported $98M in launch quarter sales. Lowers top-end of FY EPS outlook by (50c), raises FY revenue guidance by $2.5B at the midpoints. Initial analyst takeaways focus heavily on the incretin volumes which drove Q2 outperformance, with Foundayo numbers viewed as roughly inline. Price competition with Novo Nordisk seen as healthy, with volume growth outweighing concessions. Guidance upgrade was well received, plus UBS posits $50/shr EPS in 2027 (FactSet consensus $45.18). On the 10ET call, analysts seek more color around the Foundayo launch trajectory, early indicators from the Medicare Bridge since 1-July, and any incremental thoughts on business development. See Related StreetAccount comments: 8/5/2026 6:52:09 AM - Eli Lilly reports Q2 EPS $8.38 ex-items vs FactSet $6.01 [16 est, $5.28-6.62]	show story hide story
05-Aug-2026 07:58	GILD Gilead Sciences Q2 beat and raise on continued outperformance in HIV ($135.25) GILD shares little changed following Q2 results that included EPS ($6.75) ex-items vs FactSet ($7.26) on revenue ahead at $7.80B vs FactSet $7.40B. FY guidance also raised, now expecting EPS $ (0.65) - $(0.30) vs prior guidance $(1.05) to $(0.65) and FactSet ($0.75) on product sales $30.10 - $30.40B vs prior guidance $30.00B to $30.40B. Sentiment has been generally positive around the update, suggesting results mitigated some concern around IMS data heading into the release. Commonly highlighted was continued outperformance from the HIV franchise (Biktarvy and PrEP) in the quarter, along with raised full year targets - HIV franchise growth now +9-10% (vs +8% prior). Some questioning around Yeztugo growth trajectory (with full year sales reiterated vs raised), however most viewed results and guidance constructively on the durability of the company's HIV portfolio (with no near-term LOE) and potential for ongoing margin expansion. See Related StreetAccount comments: 8/4/2026 4:47:21 PM - Gilead Sciences provides updated FY2026 guidance - Earnings Slides 8/4/2026 4:06:50 PM - Gilead Sciences reports Q2 EPS ($6.75) ex-items vs FactSet ($7.26) [20 est, ($7.93)-(6.40)] 8/3/2026 11:02:48 AM - StreetAccount Consensus Metrics Preview - Gilead Sciences Q2 Earnings	show story hide story
04-Aug-2026 16:36	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished evenly mixed overall on Tuesday. By the closing bell, advancers equaled decliners on the XLV. Healthcare (0.14%) vs S&P 500 +1.79%. Most major health groups red on the averages, with only Biotech outperforming the wider tape. XBI +3.10% with highly positive breadth across the ETF. Not one contributor stood out, although IgAN data from Otsuka seen as reading across to JBIO +11.5%, CLYM +6.4%, and VERA (7.1%). VRTX +1.7% with earnings, also has eyes on a catalyst in the space later this year. WAT +5.7% and RVTY (3.3%), both on earnings, bracketed the XLV. MedTech group mixed to positive. Downside today primarily from Payers and Providers, including HUM (3.3%). CI (2.8%) was downgraded at Jefferies citing various headwinds, including PBM economics amid a legislative push. UNH (1.9%) and CVS (0.9%). Earnings calendar today's primary source of direction however. Dialysis names weak after FMS (5.0%) investors question LT growth outlook; DVA (2.4%) reports tonight. Overnight earnings calendar was fairly light. Vertex Pharma the highlight but just inline and all eyes on the pipeline, specifically the Fall 2026 PDUFA. Earnings calendar this morning loaded with large-cap pharma and life science names, plus many more. Merck and Pfizer each with uneventful Q2 prints, sales outlook raised at both. M&A in August off to strong start in Healthcare, though the mega-merger speculation in pharma remains just that. Macro Geopolitics a focus today after morning's comments from Treasury Secretary Bessent that a deal on reopening the SoH could come today or tomorrow; Qatar also said mediators have been making progress. Despite lack of specificity and Tehran's denial of direct talks yesterday, oil came under pressure and helped push yields down. Today also saw a renewed momentum rally, coming after a more mixed performance Monday (outshined by hyperscalers in the forefront). Cleaner positioning continues to get a lot of attention. Also some focus today on memory supply crunch and strength in optical stocks on headline US drafting ban on Chinese data center components. Earnings another bright spot for the broader AI compute/capex boom narrative. Mixed takeaways from the latest flurry of earnings but overall Q2 earnings sentiment remains very upbeat. Notable Gainers +27.1% ORIC (Oric Pharmaceuticals): earnings; best performer on XBI +25.2% UFPT (UFP Technologies): earnings +23.0% INSP (Inspire Medical Systems): earnings; upgraded at Oppenheimer +11.5% JBIO (Jade Biosciences): sympathy to Otsuka IGAN data +10.2% COGT (Cogent Biosciences): unusual volume +9.4% BEAM (Beam Therapeutics): earnings +8.9% HRMY (Harmony Biosciences): earnings +5.7% WAT (Waters): earnings; best performer on XLV +5.3% MDGL (Madrigal Pharmaceuticals): upgraded at Wolfe Research +4.5% WGS (GeneDx Holdings): earnings +3.6% IDXX (IDEXX Laboratories): earnings +3.0% HSIC (Henry Schein): earnings Notable Decliners -38.1% AHCO (AdaptHealth): earnings -21.8% BRKR (Bruker): earnings -16.3% CLPT (Clearpoint Neuro): earnings -8.2% BHC (Bausch Health Cos.): shares were +50% since earnings 29-Jul -7.1% ALHC (Alignment Healthcare): follow-through -7.1% VERA (Vera Therapeutics): sympathy to Otsuka IGAN data; worst performer on XBI -6.0% NVO (Novo Nordisk): earnings, guidance -5.9% MD (Pediatrix Medical Group): earnings -5.2% SNN (Smith & Nephew): earnings -4.9% FMS (Fresenius Medical Care): earnings -4.6% CERT (Certara): earnings -3.5% RVTY (Revvity): earnings; worst performer on XLV -2.9% CI (Cigna Group): downgraded at Jefferies -2.8% IBRX (ImmunityBio): earnings -2.4% DVA (DaVita): sympathy to FMS; ahead of earnings tonight Earnings in Life Science & MedTech IDXX reports Q2 EPS $4.27 vs FactSet $3.94 on revenue $1.22B vs FS $1.20B. Raises FY EPS guidance by $0.14 and revenue by $5M at the midpoints. WAT reports Q2 EPS $3.05 ex-items vs FactSet $3.01 on revenue $1.65B vs FS $1.62B. CC organic growth +9.0% vs FS +7.0%. Guides Q3 bracketing consensus despite organic growth again ahead. Raises FY EPS by 5c at the midpoints, revenue mildly higher as well. SN.LN (SNN) reports H1 EPS $0.48 ex-items vs consensus $0.47 on sales $3.10B vs consensus $3.14B. Q2 sales growth +1.6% widely missed consensus, however guides H2 growth +5.0-5.5%. Quick take: Analyst reaction is broadly negative, with the sizeable Q2/H1 sales miss and FY26 organic sales guidance cut to ~4% from ~6% the key disappointment. While a downgrade was expected, the magnitude of the cut was worse than anticipated and below consensus of ~5%. The ~3% trading profit beat and reiterated ~8% organic trading profit guidance are seen as unlikely to offset the weaker top line, particularly as they are supported by tariff refunds and an additional $50M of cost savings. RVTY reports Q2 EPS $1.41, including tariff related refunds vs FactSet $1.21, on revenue $730M vs FS $703.0M. Raises FY EPS outlook by $0.10 at the midpoints, revenue by $20M at the midpoints. BRKR reports Q2 EPS $0.49 ex-items vs FactSet $0.38 on revenue $838.5M vs FS $853.6M. Updates FY guidance for FX and tax only. INSP reported Q2 EPS $0.14 ex-items vs FactSet ($0.24) on revenue $200.6M vs FS $194.7M. Raises FY EPS outlook by 25c at the midpoints, revenue by 5M at the midpoints. Stock upgraded in reaction Earnings in Pharma MRK reports Q2 non-GAAP EPS ($0.13) vs FactSet ($0.27) on revenue $16.61B vs FS $16.37B. NG EPS includes one-time charge of $9.0B or $3.62/shr related to the acquisition of Cidara and $5.7B / $2.31/shr related to Terns. Raises FY revenue outlook by $400M at the midpoints. Relatively uneventful quarter of sales for key products, including a modest beat for Keytruda, Gardasil, and Winrevair. Quick Take: Commentary is constructive on momentum across key launch products, with reacceleration in Winrevair and the topline beat primarily attributed to stronger-than-expected sales of Keytruda Qlex, Welireg, Bridion, and Ohtuvayre, which offset weakness in Keytruda IV and Vaxneuvance. However, some view the beat-and-raise as lower quality given the reliance on legacy products facing LOE pressures, with focus remaining on multiple pipeline catalysts expected in 2H26 and 2027. PFE reports Q2 EPS $0.77 ex-items vs FactSet $0.68 on revenue $15.03B vs FS $14.40B. Reaffirms FY EPS outlook and raises revenue outlook by $500M at the midpoints. Eliquis and Ibrance drove the topline beat; Prevnar a little light. Conf. call at 10:00ET BAYN.GR reports Q2 Core EPS €0.95 vs consensus €0.73 on sales €10.87B vs consensus €10.68B. Confirms FY guidance. Quick take: Analysts question however if this was a clean beat given some one-offs. Elsewhere, Bayer's top line helped partly by Pharmaceuticals (including Nubeqa and Karendia beats, whilst Eylea saw a miss on generic pressures). Bayer confirmed its currency-adjusted FY guidance with modest upward tweaks on FX, and flagged a material reduction in expected net debt to €29-30B from €32-33B following the previously announced €3.0B Apollo LARC deal. UBS says its fast take is positive; firm notes following recent SCOTUS ruling many investors on sidelines were looking for 2Q operating reassurance. Thinks the 2% sales (Kerendia, Nubeqa, Crop) & 10% Core EBITDA beat (Crop cost savings, glyphosate price) should be supportive. Earnings in Biotech VRTX reported Q2 EPS $4.73 vs FactSet $4.74 on revenue $3.33B vs FS $3.23B. Raises FY revenue outlook by $125M at the midpoints. Guidance does not incorporate pending acquisition of Crinetics Pharma (CRNX). Quick take: Initial commentary is mixed, with some highlighting moderating Q2 growth and viewing the topline revenue guidance increase as underwhelming. However, others remain constructive on the durability of the CF franchise, launch readiness for new products, the strategic rationale of the Crinetics acquisition, and continued momentum across Journavx/Casgevy, supporting confidence in the company's broader revenue diversification strategy. Investor attention remains centered on the 11/30 povetacicept PDUFA, along with additional clinical catalysts expected in 2H. BNTX reports Q2 results including revenue €105.6M vs FactSet €157.8M, and adj EPS €2.22. Cuts FY revenue outlook by €400M at the midpoints due to the COVID-19 vaccine market softer than anticipated globally. JAZZ reported Q2 EPS $5.71 ex-items vs FactSet $6.18 on revenue $1.21B vs FS $1.11B. Raises FY revenue outlook by $300M at the midpoints. CRSP reported Q2 results including cash & equivalents $2.36B as of 30-Jun. Casgevy $76M (sales reported by Vertex) +151% y/y growth. Dialysis stocks weak following Fresenius Medical print FME.GR (FMS) reports Q2 EPS €0.81 vs consensus €0.68 on revenue €4.86B vs consensus €4.79B. Quick take: Initial analyst takeaways highlight strong Q2 performance with +1% revenue beat, +4.9% organic growth with adjusted operating profit +10% above consensus. Point out positives as Care Delivery, TDAPA, favourable rate effects and lower implicit price concessions. Flags sequential deterioration with negative same market treatment growth (0.4%), in the US (0.9%), which is below expectations and likely due to clinic closure programme resulting in patient number decline of (1%). Say this will raise questions on the long-term growth outlook Henry Schein higher following Q2 beat-and-raise HSIC reports Q2 EPS $1.27 ex-items vs FactSet $1.24 on revenue $3.46B vs FS $3.37B. Raises FY EPS outlook by 4c at the midpoints, revenue growth upped by 100bps at the midpoints. Notable research in Healthcare today Biotech: MDGL upgraded to outperform from peer perform at Wolfe Research (Andy Chen), target is $605 or approx. 26% upside. (FactSet average PT $678; range $543-962) REPL upgraded to outperform from market perform at Leerink Partners (Daina Graybosch). Believes FDA approval likely despite FDA action delay. Target increased to $17 from $11 or approx. 43% upside. (FactSet average PT $14; range $11-17) ACHV initiated outperform at LifeSci Capital (Patrick Dolezal), target is $17 or approx. 169% upside. (FactSet average PT $14; range $9-21) FTH initiated buy at Jones (Boris Peaker), target is $55 or approx. 101% upside. (FactSet average PT $55; range $50-60) YARW initiated outperform at LifeSci Capital (Rami Katkhuda and Sam Slutsky), target is $56 or approx. 67% upside. MedTech: INSP upgraded to outperform from perform at Oppenheimer (Suraj Kalia), follows Q2 results. Target is $85 or approx. 63% upside. (FactSet average PT $58; range $39-75) Managed Care: CI downgraded to hold from buy at Jefferies (David Windley), cites increasing headwinds. Target cut to $307 from $336 or approx. 9% upside. (FactSet average PT $342; range $297-400) Post-close news Earnings: AMGN reports Q2 EPS $6.29 ex-items vs FactSet $5.62 on revenue $10.05B vs FS $9.43B. Raises FY EPS outlook by 50c and revenue by $1B, at the midpoints. Conf. call at 16:30ET Shares trading UNCH in the after-hours GILD reports Q2 EPS ($6.75) ex-items vs FactSet ($7.26) on revenue $7.80B vs FS $7.40B. Raises FY EPS outlook by $0.375 and product sales by $50M, at the midpoints. Conf. call at 16:30ET Shares trading UNCH in the after-hours DVA reports Q2 EPS $4.02 ex-items vs FactSet $3.88 on revenue $3.55B vs FS $3.50B. Repeats FY EPS guidance. Conf. call at 17:00ET Shares trading (5.0%) in the after-hours TVTX reports Q2 EPS ($0.37) vs FactSet ($0.13) on revenue $169.9M vs FS $157.3M. Highlights continued momentum for Fispari including "promising early launch in FSGS" and continued strength in IgAN. Conf. call at 16:30ET Shares trading +12.5% in the after-hours On Deck: Regulatory FDA PDUFA on Wed 5-Aug for MRNA mFlusiva (mRNA-1010) BLA Corporate NAMS hosting Investor Day meeting (9:00ET) Earnings tomorrow: before LLY, CVS, COR, ONC, SDZ.SW, MDLN, FRE.GR, RPRX, UTHR, ZBH, ELAN, PODD, CRL, KYMR, LIVN after MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACHV, AHCO, ALHC, AMGN, ARQT, BAYN.GR, BEAM, BHC, BLLN, BNTX, BRKR, CAI, CERT, CI, CLPT, COGT, COR, CRL, CRNX, CRSP, CVS, DVA, EHC, ELAN, EXEL, FME.GR, FMS, FRE.GR, FTH, GILD, GRAL, HRMY, HSIC, IBRX, IDXX, INSP, JAZZ, JBIO, KYMR, LIVN, LLY, MCK, MD, MDGL, MDLN, MIRM, MRK, MRNA, NAMS, NVO, NVST, ONC, ORIC, PFE, PODD, QGEN, RCUS, REPL, RPRX, RVMD, RVTY, SDZ.SW, SN.LN, SNN, SOLV, STE, TVTX, UFPT, UTHR, VERA, VRTX, WAT, WGS, YARW, ZBH...(more)	show story hide story
04-Aug-2026 13:49	StreetAccount Sector Summary: Healthcare Monthly Recap - July 2026 Month in Review: Healthcare equities outperformed for the month of July 2026. The S&P 500 Healthcare Index added +2.24% vs the S&P 500 Index down (0.13%). Third straight month of gains for Healthcare, and second straight month of outperformance. Outperformers: MedTech, Services Underperformers: Biotech, Managed Care, Pharma Most major health group returns were widely split for the month, either up MSD or down MSD. Pharma group the exception with DRG down (1.11%) including large-cap drugmakers even more widely split in July, between BMY +13%, on earnings, and AZN (11%), on trial results. Q2 earnings were the primary source of newsflow in July, and were off to an ominous beginning with a negative preannouncement by HCA, which pinned volume softness on HIX enrollment declines after the expiry of ACA subsidies. Medical device subgroup traded weaker on this headline, including and through the report by ISRG which echoed concerns around procedure volumes due to the ACA changes. From there forward, sentiment and commentary from peers (both hospitals and device makers) was surprisingly resilient and supported some of the best gains in July. Biopharma M&A continued with several high-premium deals, and the XBI topped $160 for the first time since February 2021, before cooling off in the back half of the month. XBI fell more than (7%) in July, coming after its best month in years during June. Top 5 on the XLV: +23.9% DXCM, +22.7% BAX, +22.3% REGN, +21.6% IQV, +16.5% ABT Bottom 5 on the XLV: -21.7% MRNA, -11.2% ISRG, -8.4% HUM, -6.1% BIIB, -5.0% WST Year-to-date, Healthcare +4.86% vs the S&P 500 +9.41%. Healthcare seventh out of eleven major sectors in CY26. Energy +32.77% and Consumer Discretionary (0.31%) bracket them all. Two IPOs in July, twenty-one YTD 2026: versus three in July 2025 / twenty YTD 2025 cumulatively raised $6.39B YTD vs $2.55B YTD 2025 APMD +56.3% - raised $192M - Biotech SCTX +29.9% - raised $129M - Biotech Notable movers for the month: Gainers: FBRX +260.5% - acquired by ARGX for $2.2B CRNX +123.2% - acquired by VRTX for $10.0B TRAX +118.9% - sympathy to FBRX and TEVA; best performer on XBI AVTR +39.2% - stock higher 11 straight weeks (including earnings 29-Jul) THC +36.2% - earnings CORT +31.7% - earnings DXCM +23.9% - sympathy to ABT (diabetes tech); earnings; best performer on XLV BAX +22.7% - earnings (concluding best one-week gain and third-best month of all time) MMSI +22.6% - earnings; best month since April 2020 REGN +22.3% - earnings; best week in nearly four years IQV +21.6% - earnings MMED +20.7% - sympathy to ABT (diabetes tech) GKOS +19.3% - earnings ILMN +16.6% - earnings; stock higher four straight months ABT +16.5% - earnings; best month since April 2020 TMO +14.5% - earnings; stock higher six straight weeks BMY +13.3% - earnings; 52-week high UHS +13.3% - Medicare proposed rules for HH, OP, ASC; downgrade; earnings Decliners: CAPR (84.0%) - FDA briefing docs / Adcom; worst performer on XBI IONS (34.7%) - trial results in ATTR-CM with AZN; Roche discontinued HD program; Biogen presented CELIA at AAIC; downgraded at Wolfe ALNY (31.7%) - sympathy to AZN trial results in ATTR-CM TEM (24.3%) - acquired PSNL for $1.5B; earnings; fifth double-digit % month in CY2026 MRNA (21.7%) - follows +48% in prior month; worst performer on XLV HIMS (19.9%) - sixth double-digit % month in CY2026; FDA panel recommends peptides for compounding; FTC lawsuit RDY (18.2%) - semaglutide supply issues; downgrades IBRX (18.1%) - shares remain +262% YTD; UAE MAA for Anktiva CELC (17.4%) - FDA approved REVTORPYK; launch readiness questioned CRSP (12.0%) - gene editing weakness with XBI (7.10%) ending six-month win streak ISRG (11.2%) - earnings/procedure growth (comments on HIX/uninsured) AZN (10.5%) - trial results in ATTR-CM w/IONS Related: ABT, ALNY, APMD, ARGX, AVTR, AZN, BAX, BIIB, BMY, CAPR, CELC, CORT, CRNX, CRSP, DXCM, FBRX, GKOS, HIMS, HUM, IBRX, ILMN, IONS, IQV, ISRG, MMED, MMSI, MRNA, PSNL, RDY, REGN, SCTX, TEM, TEVA, THC, TMO, TRAX, UHS, VRTX, WST...(more)	show story hide story
04-Aug-2026 11:05	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 healthcare Index (0.43%) vs the S&P 500 +1.21%. Most major health groups lower on the averages, only Biotech slightly outperforming the wider tape. XBI +1.13% with highly positive breadth across the ETF. Not one contributor standing apart, though IgAN data from Otsuka reading across to JBIO +6% and VERA (4%). VRTX +2% with earnings, also has eyes on its own catalyst in the space later this year. WAT +4% and RVTY (4%), both on earnings, bracket the XLV. MedTech group flat overall. Downside today primarily from Payers and Providers. HUM (3%). CI (3%) downgraded at Jefferies citing various headwinds, including PBM economics amid a legislative push. UNH (2%) and CVS (1%). Earnings calendar a primary source of direction however. Dialysis names weak after FMS (6%) investors question LT growth outlook; DVA (2%). Gainers +19.5% INSP (Inspire Medical Systems): earnings; upgraded at Oppenheimer +12.8% ORIC (Oric Pharmaceuticals): earnings; best performer on XBI +11.5% HRMY (Harmony Biosciences): earnings +7.5% COGT (Cogent Biosciences): on average volume +6.2% JBIO (Jade Biosciences): sympathy to Otsuka IGAN data +4.1% WAT (Waters): earnings; best performer on XLV +3.8% IDXX (IDEXX Laboratories): earnings +3.6% BEAM (Beam Therapeutics): earnings +3.3% HSIC (Henry Schein): earnings +3.3% MDGL (Madrigal Pharmaceuticals): upgraded at Wolfe Research +1.6% BAYN.GR (Bayer AG): earnings +1.6% VRTX (Vertex Pharmaceuticals): earnings +0.6% MRK (Merck): earnings +0.6% REPL (Replimune Group): upgraded at Leerink Partners +0.1% RYTM (Rhythm Pharmaceuticals): earnings Decliners -41.3% AHCO (AdaptHealth): earnings -19.9% CLPT (Clearpoint Neuro): earnings -17.4% BRKR (Bruker): earnings -9.4% CERT (Certara): earnings -6.6% FMS (Fresenius Medical Care): earnings -5.7% SNN (Smith & Nephew): earnings -5.1% IBRX (ImmunityBio): earnings; worst performer on XBI -4.3% MD (Pediatrix Medical Group): earnings -4.1% VERA (Vera Therapeutics): sympathy to Otsuka IGAN data -3.9% RVTY (Revvity): earnings; worst performer on XLV -2.9% CI (Cigna Group): downgraded at Jefferies -2.6% WGS (GeneDx Holdings): earnings -2.1% DVA (DaVita): sympathy to FMS -0.5% PFE (Pfizer): earnings	show story hide story
04-Aug-2026 08:58	MRK Merck delivers a Q2 beat-and-raise; pipeline remains key focus ($127.77) MRK reported Q2 non-GAAP EPS at a smaller loss than FactSet with revenue ahead. Raised FY revenue outlook. Commentary is constructive on momentum across key launch products, with reacceleration in Winrevair and the topline beat primarily attributed to stronger-than-expected sales of Keytruda Qlex, Welireg, Bridion, and Ohtuvayre, which offset weakness in Keytruda IV and Vaxneuvance. However, some view the beat-and-raise as lower quality given the reliance on legacy products facing LOE pressures, with focus remaining on multiple pipeline catalysts expected in 2H26 and 2027. See Related StreetAccount comments: 8/4/2026 6:36:19 AM - StreetAccount Metrics Recap - Merck Q2 Earnings 8/4/2026 6:34:52 AM - Merck reports Q2 non-GAAP EPS ($0.13) vs FactSet ($0.27) [17 est, ($0.40)-(0.21)]	show story hide story
04-Aug-2026 08:27	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight earnings calendar was fairly light. Vertex Pharma the highlight but just inline and all eyes on the pipeline, specifically the Fall 2026 PDUFA. Shares of VRTX down (1%) in the pre-market. Earnings calendar this morning loaded with large-cap pharma and life science names, plus many more. Merck and Pfizer each with uneventful Q2 prints, sales outlook raised at both. Muted gains for both MRK and PFE in the pre-market, ahead of their respective calls 9ET and 10ET. M&A in August off to strong start in Healthcare, though the mega-merger speculation in pharma remains just that. Macro S&P futures are up +0.35% on Tuesday morning, near best levels. Big development this morning has been reversal in oil to the downside following comments from Treasury Secretary Bessent that US could reach a deal with Iran to open SoH as soon as Wednesday. However, Iran has repeatedly said it is only in talks with Oman and any deal would involve it gaining more leverage over transit. Earnings takeaways mixed, though results from some of the higher-profile names (CAT, MCD, PLTR, ON) have been well received and overall sentiment surrounding Q2 earnings season remains very upbeat. Cleaner positioning following outsized July momentum unwind another bullish talking point. Solid macro backdrop has also been in focus this week with the four-year high in ISM manufacturing. AI as the key US economic growth tailwind also discussed in the financial press. Other AI headlines have revolved around open-weight model proliferation, US-China tensions (US reportedly drafting ban on Chinese data center devices) and memory supply crunch. Pre-market trading update Trading higher +14.6% INSP earnings; upgraded at Oppenheimer +13.5% WGS earnings +5.2% REPL upgraded at Leerink Partners +5.0% BAYN.GR in European trading; earnings +4.0% IDXX earnings +3.2% HRMY earnings +1.7% MDGL upgraded at Wolfe Research +1.3% MRK earnings +0.2% RYTM earnings +0.2% HSIC earnings Trading lower -29.4% AHCO earnings -24.2% CERT earnings -14.0% CLPT earnings -14.1% MD earnings -12.1% BRKR earnings -5.3% FMS earnings -4.7% SNN earnings -2.9% DVA sympathy to FMS -1.8% IBRX earnings -1.1% WAT earnings -0.9% CI downgraded at Jefferies -0.6% VRTX earnings -0.1% PFE earnings Pharma Earnings: BAYN.GR reports Q2 Core EPS €0.95 vs consensus €0.73 on sales €10.87B vs consensus €10.68B. Confirms FY guidance. Quick take: Analysts question however if this was a clean beat given some one-offs. Elsewhere, Bayer's top line helped partly by Pharmaceuticals (including Nubeqa and Karendia beats, whilst Eylea saw a miss on generic pressures). Bayer confirmed its currency-adjusted FY guidance with modest upward tweaks on FX, and flagged a material reduction in expected net debt to €29-30B from €32-33B following the previously announced €3.0B Apollo LARC deal. UBS says its fast take is positive; firm notes following recent SCOTUS ruling many investors on sidelines were looking for 2Q operating reassurance. Thinks the 2% sales (Kerendia, Nubeqa, Crop) & 10% Core EBITDA beat (Crop cost savings, glyphosate price) should be supportive. Conf. call at 8:00ET PFE reports Q2 EPS $0.77 ex-items vs FactSet $0.68 on revenue $15.03B vs FS $14.40B. Reaffirms FY EPS outlook and raises revenue outlook by $500M at the midpoints. Eliquis and Ibrance drove the topline beat; Prevnar a little light. Conf. call at 10:00ET MRK reports Q2 non-GAAP EPS ($0.13) vs FactSet ($0.27) on revenue $16.61B vs FS $16.37B. NG EPS includes one-time charge of $9.0B or $3.62/shr related to the acquisition of Cidara and $5.7B / $2.31/shr related to Terns. Raises FY revenue outlook by $400M at the midpoints. Relatively uneventful quarter of sales for key products, including a modest beat for Keytruda, Gardasil, and Winrevair. Conf. call at 9:00ET Biotech Earnings: VRTX reported Q2 EPS $4.73 vs FactSet $4.74 on revenue $3.33B vs FS $3.23B. Raises FY revenue outlook by $125M at the midpoints. Guidance does not incorporate pending acquisition of Crinetics Pharma (CRNX). Quick take: Initial commentary is mixed, with some highlighting moderating Q2 growth and viewing the topline revenue guidance increase as underwhelming. However, others remain constructive on the durability of the CF franchise, launch readiness for new products, the strategic rationale of the Crinetics acquisition, and continued momentum across Journavx/Casgevy, supporting confidence in the company's broader revenue diversification strategy. Investor attention remains centered on the 11/30 povetacicept PDUFA, along with additional clinical catalysts expected in 2H. BNTX reports Q2 results including revenue €105.6M vs FactSet €157.8M, and adj EPS €2.22. Cuts FY revenue outlook by €400M at the midpoints due to the COVID-19 vaccine market softer than anticipated globally. Conf. call at 8:00ET JAZZ reported Q2 EPS $5.71 ex-items vs FactSet $6.18 on revenue $1.21B vs FS $1.11B. Raises FY revenue outlook by $300M at the midpoints. CRSP reported Q2 results including cash & equivalents $2.36B as of 30-Jun. Casgevy $76M (sales reported by Vertex) +151% y/y growth. Research: MDGL upgraded to outperform from peer perform at Wolfe Research (Andy Chen), target is $605 or approx. 26% upside. (FactSet average PT $678; range $543-962) REPL upgraded to outperform from market perform at Leerink Partners (Daina Graybosch). Believes FDA approval likely despite FDA action delay. Target increased to $17 from $11 or approx. 43% upside. (FactSet average PT $14; range $11-17) ACHV initiated outperform at LifeSci Capital (Patrick Dolezal), target is $17 or approx. 169% upside. (FactSet average PT $14; range $9-21) FTH initiated buy at Jones (Boris Peaker), target is $55 or approx. 101% upside. (FactSet average PT $55; range $50-60) YARW initiated outperform at LifeSci Capital (Rami Katkhuda and Sam Slutsky), target is $56 or approx. 67% upside. Life Science & MedTech Earnings: IDXX reports Q2 EPS $4.27 vs FactSet $3.94 on revenue $1.22B vs FS $1.20B. Raises FY EPS guidance by $0.14 and revenue by $5M at the midpoints. Conf. call at 8:30ET WAT reports Q2 EPS $3.05 ex-items vs FactSet $3.01 on revenue $1.65B vs FS $1.62B. CC organic growth +9.0% vs FS +7.0%. Guides Q3 bracketing consensus despite organic growth again ahead. Raises FY EPS by 5c at the midpoints, revenue mildly higher as well. Conf. call at 8:00ET SN.LN (SNN) reports H1 EPS $0.48 ex-items vs consensus $0.47 on sales $3.10B vs consensus $3.14B. Q2 sales growth +1.6% widely missed consensus, however guides H2 growth +5.0-5.5%. Quick take: Analyst reaction is broadly negative, with the sizeable Q2/H1 sales miss and FY26 organic sales guidance cut to ~4% from ~6% the key disappointment. While a downgrade was expected, the magnitude of the cut was worse than anticipated and below consensus of ~5%. The ~3% trading profit beat and reiterated ~8% organic trading profit guidance are seen as unlikely to offset the weaker top line, particularly as they are supported by tariff refunds and an additional $50M of cost savings. Conf. call at 6:30ET RVTY reports Q2 EPS $1.41, including tariff related refunds vs FactSet $1.21, on revenue $730M vs FS $703.0M. Raises FY EPS outlook by $0.10 at the midpoints, revenue by $20M at the midpoints. Conf. call at 7:30ET BRKR reports Q2 EPS $0.49 ex-items vs FactSet $0.38 on revenue $838.5M vs FS $853.6M. Updates FY guidance for FX and tax only. Conf. call at 9:00ET INSP reported Q2 EPS $0.14 ex-items vs FactSet ($0.24) on revenue $200.6M vs FS $194.7M. Raises FY EPS outlook by 25c at the midpoints, revenue by 5M at the midpoints. Stock upgraded in reaction Research: INSP upgraded to outperform from perform at Oppenheimer (Suraj Kalia), follows Q2 results. Target is $85 or approx. 63% upside. (FactSet average PT $58; range $39-75) Services & Hospitals Earnings: FME.GR (FMS) reports Q2 EPS €0.81 vs consensus €0.68 on revenue €4.86B vs consensus €4.79B. Quick take: Initial analyst takeaways highlight strong Q2 performance with +1% revenue beat, +4.9% organic growth with adjusted operating profit +10% above consensus. Point out positives as Care Delivery, TDAPA, favourable rate effects and lower implicit price concessions. Flags sequential deterioration with negative same market treatment growth (0.4%), in the US (0.9%), which is below expectations and likely due to clinic closure programme resulting in patient number decline of (1%). Say this will raise questions on the long-term growth outlook Conf. call at 8:00ET HSIC reports Q2 EPS $1.27 ex-items vs FactSet $1.24 on revenue $3.46B vs FS $3.37B. Raises FY EPS outlook by 4c at the midpoints, revenue growth upped by 100bps at the midpoints. Conf. call at 8:00ET Managed Care Research: CI downgraded to hold from buy at Jefferies (David Windley), cites increasing headwinds. Target cut to $307 from $336 or approx. 9% upside. (FactSet average PT $342; range $297-400) On Deck: Regulatory on Wed 5-Aug: FDA PDUFA for MRNA mFlusiva (mRNA-1010) BLA Earnings after the close today: AMGN (call at 16:30ET), GILD (call at 16:30ET), DVA (call at 17:00ET), ARWR (call at 16:30ET), BIO (call at 17:00ET), PACS (call Wed at 11:30ET), TVTX (call at 16:30ET), ACAD (call at 16:30ET), HNGE (call at 16:30ET) Earnings on Wed 5-Aug: before LLY, NVO, CVS, COR, ONC, SDZ.SW, MDLN, FRE.GR, RPRX, UTHR, ZBH, ELAN, PODD, CRL, KYMR, LIVN after MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL Corporate on Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACAD, ACHV, AHCO, AMGN, ARQT, ARWR, BAYN.GR, BIO, BLLN, BNTX, BRKR, CAI, CERT, CI, CLPT, COR, CRL, CRNX, CRSP, CVS, DVA, EHC, ELAN, EXEL, FME.GR, FMS, FRE.GR, FTH, GILD, GRAL, HNGE, HRMY, HSIC, IBRX, IDXX, INSP, JAZZ, KYMR, LIVN, LLY, MCK, MD, MDGL, MDLN, MIRM, MRK, MRNA, NAMS, NVO, NVST, ONC, PACS, PFE, PODD, QGEN, RCUS, REPL, RPRX, RVMD, RVTY, RYTM, SDZ.SW, SN.LN, SNN, SOLV, STE, TVTX, UTHR, VRTX, WAT, WGS, YARW, ZBH...(more)	show story hide story
04-Aug-2026 07:48	VRTX Vertex Pharmaceuticals posts a mixed Q2; Street remains focused on pipeline ($470.72) VRTX shares (1.7%) premarket after reporting reported Q2 EPS a penny below FactSet but with revenue ahead. Raised FY revenue guidance at the midpoint, excluding any contribution from the pending Crinetics acquisition. Initial commentary is mixed, with some highlighting moderating Q2 growth and viewing the topline revenue guidance increase as underwhelming. However, others remain constructive on the durability of the CF franchise, launch readiness for new products, the strategic rationale of the Crinetics acquisition, and continued momentum across Journavx/Casgevy, supporting confidence in the company's broader revenue diversification strategy. Investor attention remains centered on the 11/30 povetacicept PDUFA, along with additional clinical catalysts expected in 2H. See Related StreetAccount comments: 8/3/2026 4:05:32 PM - StreetAccount Metrics Recap - Vertex Pharmaceuticals Q2 Earnings 8/3/2026 4:05:21 PM - Vertex Pharmaceuticals reports Q2 EPS $4.73 vs FactSet $4.74 [24 est, $3.99-5.17]	show story hide story
03-Aug-2026 16:43	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to slightly lower overall on Monday. Advancers beat decliners by 2:1 on the XLV. Healthcare (0.17%) vs S&P 500 +1.48%. Little changed from the morning, as most major health groups end higher for the session. Pharma was the exception, large drugmakers mostly red (1%) to (2%), however the DRG (1.84%) remained skewed lower by AZN (6.9%) as investors reacted to the mega-merger headlines. BMY +0.2% finished at neither highs nor lows of the day. M&A dominated sector newsflow today, beginning with the potential for the largest pharma merger ever, if the media reports come to fruition. XBI +0.20% or essentially flat. Read-through for biotech cautious, as deal would remove one potential acquirer. BAX +7.4%, picking up where it left off last week, and MCK (3.4%) bracketed the XLV. MRNA +0.6% ahead of an imminent FDA decision on its influenza vaccine. Earnings calendar picks up tonight with VRTX (1.3%), followed by multiple large-cap drugmakers Tuesday morning. M&A Monday: FT reported on Sunday that AstraZeneca has held talks with Bristol Myers Squibb - for a combined company worth around $400B. Actual biopharma M&A on the tape too, with radiopharmaceutical Curium acquiring LNTH +1.6% for cash plus CVR valued at up to $8B combined. CNS drugmakers INDV (6.6%) and Supernus Pharma +3.1% will combine in a merger of equals, the combined company will have revenues approx. $2.2B. Supernus' CEO will lead the combined company. Outside of pharma, ITGR +2.7% confirmed Friday's media report - KKR will acquire the CRO for $127/shr or $5.7B deal. Macro August started up with a risk-on session, helped by several tailwinds. Most Mag 7 names rallied sharply while some cyclical pockets fared well; momentum clawed off an early session selloff in the wake of last week's big rally. Market seemed to largely look past a day of conflicting headlines about the US-Iran conflict (Trump said attacks called off for negotiations, Iran said no negotiations ongoing), though continued escalate/deescalate cycle supportive of market's view that a return to broader kinetic action is unlikely. Today's lower oil also weighed on rates amid a continued flurry of Fed credibility concern/policy uncertainty headlines. Highest ISM manufacturing print in four years supportive of the solid macro narrative. Earnings still a big bullish talking point for stocks with the latest sell-side strategist commentary highlighting the strong Q2 metrics. Also a busy day of M&A headlines. Notable Gainers +12.1% SLS (SELLAS Life Sciences Group, Inc.): best performer on XBI; shares +198% YTD +11.0% HIMS (Hims & Hers Health): shares were down (20%) in July +10.4% TWST (Twist Bioscience): earnings; second-best on XBI +9.5% CDNA (CareDx): upgraded at Craig-Hallum +7.4% BAX (Baxter International): best performer on XLV; shares were +17% last week +7.2% ALNY (Alnylam Pharmaceuticals): upgraded at Raymond James +6.3% REPL (Replimune Group): follow-through, on >2X average volume; PDUFA was Sunday +6.2% ISRG (Intuitive Surgical): FDA 510(k) clearance for DV5 +4.8% SYK (Stryker): Medicare extends CJR-X model +3.6% BSX (Boston Scientific): Medicare extends CJR-X model +3.2% ZBH (Zimmer Biomet Holdings): Medicare extends CJR-X model +3.2% EW (Edwards Lifesciences): Medicare extends CJR-X model +3.1% SUPN (Supernus Pharmaceuticals): to merge with INDV; earnings +2.7% ITGR (Integer Holdings): confirms acquisition by KKR for $127/shr Notable Decliners -11.3% TGTX (TG Therapeutics): earnings; worst performer on XBI -8.4% KRYS (Krystal Biotech): earnings -7.4% SOBI.SS (Swedish Orphan Biovitrum): CEO to step down for outside opportunity -6.9% AZN (AstraZeneca): media report - in talks with BMY; takeaways -6.6% INDV (Indivior Pharmaceuticals): to merge with SUPN; earnings -3.4% MCK (McKesson): worst performer on XLV -2.7% DVA (DaVita): sympathy to FMS; second-worst on XLV -2.4% LLY (Eli Lilly): reports on Wednesday AstraZeneca in talks with Bristol Myers Squibb - media reports On Sunday afternoon, CNBC reported on the potential merger of big pharma companies AstraZeneca (AZN.LN) and Bristol Myers Squibb (BMY), as first reported by FT. Merger would value combined company at roughly $400B. Discussions have taken place over the last few months. According to FactSet data, market cap as of Friday's close: AZN $263B, BMY $133B Takeaways: Analysts highlighted the media reports but view a potential transaction as highly unlikely. While a deal could secure value for BMY investors ahead of key Ph3 readouts, the strategic rationale for AZN is seen as weak. Some pointed to AZN's strong standalone 2030 financial targets, noting that an acquisition would yield limited synergies, while also compounding its exposure to upcoming LOEs. Furthermore, any formal announcement would trigger intense US and UK antitrust and political scrutiny regarding overlapping oncology portfolios and the combined entity's final domicile. Actual M&A in biopharma LNTH and Curium (private) announced announced a definitive agreement under which Curium US will acquire all outstanding shares of LNTH for $102.50 in cash, plus a CVR worth up to $12/shr, for total value of up to $8.0B. Total value represents a 38% premium to the unaffected 60-day VWAP. INDV and SUPN announced a definitive agreement to combine in an all-stock merger of equals, with approx. $2.2B in combined annual revenues. Expect to realize $125M of annual cost synergies. Supernus CEO Jack Khattar will become CEO of the combined company. INDV stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing of the merger. Both companies also reported Q2 earnings; both beat-and-raised. According to FactSet data, market cap at Friday's close: INDV $4.8B, SUPN $2.5B KKR takes Integer Holdings private in $5.7B deal ITGR and KKR confirm Friday media report - companies agreed on a definitive agreement for an all-cash transaction at $127/shr or total value of around $5.7B. Medicare extends CJR model as expected, althrough slightly delayed Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028 (vs proposed 1-Oct-2027) Gilead Sciences wins favorable ruling at California Supreme Court CA Supreme Court ruled 6-1 in favor of the HIV drugmaker, the TDF litigation put to rest a multi-decade legal overhang. Federal litigation was settled in 2024, but California went to trial, and lower courts had held Gilead Sciences (GILD) negligent for delaying development of a newer drug with fewer side effects than TDF. Notable research in Healthcare today Pharma: JNJ removed from the US Conviction List at Goldman Sachs. Biotech: ALNY upgraded to strong buy from outperform at Raymond James (Martin Auster), target is $420 or approx. 104% upside. (FactSet average PT $388; range $23-536) ADIL initiated buy at Alliance Global Partners, target is $11 or approx. 229% upside. (FactSet average PT $17; range $6-42) CLYM initiated outperform at RBC Capital Markets (Nevin Varghese), target is $23 or approx. 93% upside. (FactSet average PT $21; range $15-35) PYXS initiated overweight at Wells Fargo Securities (Derek Archila), target is $12 or approx. 353% upside. (FactSet average PT $7; range $5-8) YARW initiated buy at BTIG (Julian Harrison), target is $58 or approx. 66% upside. MedTech: CDNA upgraded to buy at Craig-Hallum Capital (Bill Bonello), notes confidence in near-term and long-term drivers of growth. Target increased to $64 from $35 or approx. 46% upside. (FactSet average PT $44; range $35-50) Managed Care: ALHC downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $19 from $22 or approx. 28% upside (FactSet average PT $24; range $16-30) CI downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $320 from $350 or approx. 15% upside (FactSet average PT $342; range $297-400) Post-close news Earnings: VRTX reports Q2 EPS $4.73 vs FactSet $4.74 on revenue $3.33B vs FS $3.23B. Raises FY revenue outlook by $125M at the midpoints. Guidance does not incorporate pending acquisition of Crinetics Pharma (CRNX). Conf. call at 16:30ET Shares trading (0.3%) in the after-hours JAZZ reports Q2 EPS $5.71 ex-items vs FactSet $6.18 on revenue $1.21B vs FS $1.11B. Raises FY revenue outlook by $300M at the midpoints. Conf. call at 16:30ET Shares trading+4.4% in the after-hours CRSP reports Q2 results including cash & equivalents $2.36B as of 30-Jun. Casgevy $76M (sales reported by Vertex) +151% y/y growth. Shares trading +2.5% in the after-hours On Deck: Regulatory Sun 2-Aug: FDA PDUFA for REPL TUDRIQEV (vusolimogene oderparepvec-wtpg) BLA on Wed 5-Aug: FDA PDUFA for MRNA mFlusiva (mRNA-1010) BLA Earnings tomorrow before BAYN.GR (call at 8:00ET), MRK (call at 9:00ET), PFE (call at 10:00ET), IDXX (call at 8:30ET), WAT (call at 8:00ET), BNTX, SNN (call at 6:30ET), FMS (call at 8:00ET), RVTY (call at 7:30ET), HSIC (call at 8:00ET), BRKR (call at 9:00ET), RYTM (call at 8:00ET) after AMGN (call at 16:30ET), GILD (call at 16:30ET), DVA (call at 17:00ET), ARWR (call at 16:30ET), BIO (call at 17:00ET), PACS (call Wed at 11:30ET), TVTX (call at 16:30ET), ACAD (call at 16:30ET), HNGE (call at 16:30ET) Earnings on Wed 5-Aug: before LLY, NVO, CVS, COR, ONC, SDZ.SW, MDLN, FRE.GR, RPRX, UTHR, ZBH, ELAN, PODD, CRL, KYMR, LIVN after MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL Corporate on Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) StreetAccount Healthcare Reads How poor countries are dealing with America's AIDS cuts (3-Aug) The Economist Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea (3-Aug) Fierce Pharma (Opinion) AstraZeneca investors balk at prospect of $400 billion Bristol Myers deal (3-Aug) Reuters After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers (3-Aug) STAT News Kennedy, Oz Contend Fraud Crackdown, Not Skyrocketing Prices, Led Millions To Leave Obamacare (3-Aug) KFF Health News This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACAD, ADIL, ALHC, ALNY, AMGN, ARQT, ARWR, AZN, AZN.LN, BAX, BAYN.GR, BIO, BLLN, BMY, BNTX, BRKR, BSX, CAI, CDNA, CI, CLYM, COR, CRL, CRNX, CRSP, CVS, DVA, EHC, ELAN, EW, EXEL, FMS, FRE.GR, GILD, GRAL, HIMS, HNGE, HSIC, IDXX, INDV, ISRG, ITGR, JAZZ, JNJ, KRYS, KYMR, LIVN, LLY, LNTH, MCK, MDLN, MIRM, MRK, MRNA, NAMS, NVO, NVST, ONC, PACS, PFE, PODD, PYXS, QGEN, RCUS, REPL, RPRX, RVMD, RVTY, RYTM, SDZ.SW, SLS, SNN, SOBI.SS, SOLV, STE, SUPN, SYK, TGTX, TVTX, TWST, UTHR, VRTX, WAT, YARW, ZBH...(more)	show story hide story
03-Aug-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (0.40%) vs the S&P 500 +1.14%. Most major health groups higher to begin the week. Pharma the exception, large drugmakers mostly red (1%) to (2%), however the DRG (2.50%) is skewed lower by AZN (9%) as investors react to the mega-merger headlines. BMY down (2%) flipping the pre-market MSD gains. M&A dominates the sector newsflow today, beginning with the potential for the largest pharma merger ever, if the media reports come to fruition. XBI essentially flat. Read-through for biotech cautious, as deal would remove one potential acquirer. MRNA +5%, ahead of an FDA decision on its influenza vaccine, and LLY (2%) bracket the XLV. Earnings calendar picks up tonight with VRTX (2%), followed by multiple large-cap drugmakers Tuesday morning. Gainers +10.0% SUPN (Supernus Pharmaceuticals): to merge with INDV; earnings +9.4% CDNA (CareDx): upgraded at Craig-Hallum; best performer on XBI +9.1% HIMS (Hims & Hers Health): shares were down (20%) in July +5.6% MRNA (Moderna): best performer on XLV; ahead of PDUFA on Wednesday +5.2% TWST (Twist Bioscience): earnings +4.9% ALNY (Alnylam Pharmaceuticals): upgraded at Raymond James +4.8% BAX (Baxter International): shares were +17% last week +4.7% ISRG (Intuitive Surgical): FDA 510(k) clearance for DV5 +2.6% ITGR (Integer Holdings): confirms acquisition by KKR for $127/shr +2.5% LNTH (Lantheus Holdings): acquired by Curium for cash + CVR Decliners -8.8% TGTX (TG Therapeutics): earnings; worst performer on XBI -8.7% AZN (AstraZeneca): media report - in talks with BMY; takeaways -7.6% KRYS (Krystal Biotech): earnings -7.1% SOBI.SS (Swedish Orphan Biovitrum): CEO to step down for outside opportunity -5.1% INDV (Indivior Pharmaceuticals): to merge with SUPN; earnings -2.8% LLY (Eli Lilly): worst performer on XLV -1.4% BMY (Bristol Myers Squibb): media report - AZN merger talks; takeaways	show story hide story
03-Aug-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis M&A Monday with the potential for the largest pharma merger ever, if the media reports come to fruition. FT reported on Sunday that AstraZeneca has held talks with Bristol Myers Squibb - for a combined company worth around $400B. Shares of BMY +4% in the pre-market; AZN (6%) in the pre-market. Actual biopharma M&A on the tape too, with radiopharmaceutical Curium acquiring Lantheus for cash plus CVR valued at up to $8.0B combined. Shares of LNTH +3% in the pre-market. CNS drugmakers Indivior ($4.8B) and Supernus Pharma ($2.5B) will combine in a merger of equals, the combined company will have revenues approx. $2.2B. Supernus' CEO will lead the combined company. Shares of INDV +3% and SUPN +15% in the pre-market. Integer Holdings confirms the media report on Friday, KKR will acquire the CRO for $127/shr or $5.7B deal. Shares of ITGR +3% in the pre-market. Macro S&P futures are up +0.5% on Monday morning. Risk sentiment underpinned by renewed traction surrounding escalate to de-escalate narrative as Trump said over the weekend he called off a potential attack on Iran to allow for more talks, which he noted will take place on Monday. Also reports Iran and Oman nearing a deal regarding a new SoH route. Pretty quiet outside of geopolitics. Strength of Q2 earnings season and positive revisions the big theme in recent strategist commentary. Open-weight still the big story in AI with focus on new Qwen3.8-Max model. Fed credibility another high-profile theme with Musalem flagging signaling from bond market. US and Japan confirmed joint intervention to support yen and warned more could be in the pipeline. Big M&A in the weekend headlines with report about potential tie-up in pharma. Pre-market trading update Trading higher +15.4% SUPN to merge with INDV; earnings +4.9% CDNA upgraded at Craig-Hallum +4.1% BMY media report - AZN merger talks; takeaways +3.0% INDV to merge with SUPN; earnings +2.9% LNTH acquired by Curium for cash + CVR +2.7% ITGR confirms acquisition by KKR for $127/shr +2.7% VEEV Wells Fargo comments on impact from AZN-BMY Trading lower -7.9% KRYS earnings -7.2% TWST earnings -6.4% SOBI.SS in European trading; CEO to step down for outside opportunity -6.1% AZN media report - in talks with BMY; takeaways -5.5% TGTX earnings -2.5% REPL follow-through; PDUFA was Sunday -2.3% ABVX sympathy to pharma M&A headlines Pharma M&A: AstraZeneca in talks with Bristol Myers Squibb - media reports On Sunday afternoon, CNBC reported on the potential merger of big pharma companies AstraZeneca (AZN.LN) and Bristol Myers Squibb (BMY), as first reported by FT. Merger would value combined company at roughly $400B. Discussions have taken place over the last few months. According to FactSet data, market cap as of Friday's close: AZN $263B, BMY $133B Takeaways: Analysts highlighted the media reports but view a potential transaction as highly unlikely. While a deal could secure value for BMY investors ahead of key Ph3 readouts, the strategic rationale for AZN is seen as weak. Some pointed to AZN's strong standalone 2030 financial targets, noting that an acquisition would yield limited synergies, while also compounding its exposure to upcoming LOEs. Furthermore, any formal announcement would trigger intense US and UK antitrust and political scrutiny regarding overlapping oncology portfolios and the combined entity's final domicile. Regulatory: NOVN.SW (NVS) FDA approves Pluvicto sNDA for metastatic hormone-sensitive prostate cancer (mHSPC). PDUFA was expected during H2 of 2026. Research: JNJ removed from the US Conviction List at Goldman Sachs. Biotech M&A: LNTH and Curium (private) announced announced a definitive agreement under which Curium US will acquire all outstanding shares of LNTH for $102.50 in cash, plus a CVR worth up to $12/shr, for total value of up to $8.0B. Total value represents a 38% premium to the unaffected 60-day VWAP. INDV and SUPN announced a definitive agreement to combine in an all-stock merger of equals, with approx. $2.2B in combined annual revenues. Expect to realize $125M of annual cost synergies. Supernus CEO Jack Khattar will become CEO of the combined company. INDV stockholders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing of the merger. Both companies also reported Q2 earnings; both beat-and-raised. According to FactSet data, market cap at Friday's close: INDV $4.8B, SUPN $2.5B Conf. call at 8:30ET Research: ALNY upgraded to strong buy from outperform at Raymond James (Martin Auster), target is $420 or approx. 104% upside. (FactSet average PT $388; range $23-536) ADIL initiated buy at Alliance Global Partners, target is $11 or approx. 229% upside. (FactSet average PT $17; range $6-42) CLYM initiated outperform at RBC Capital Markets (Nevin Varghese), target is $23 or approx. 93% upside. (FactSet average PT $21; range $15-35) PYXS initiated overweight at Wells Fargo Securities (Derek Archila), target is $12 or approx. 353% upside. (FactSet average PT $7; range $5-8) YARW initiated buy at BTIG (Julian Harrison), target is $58 or approx. 66% upside. Life Science & MedTech M&A: ITGR and KKR confirm Friday media report - companies agreed on a definitive agreement for an all-cash transaction at $127/shr or total value of around $5.7B. Regulatory: Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028. Research: CDNA upgraded to buy at Craig-Hallum Capital (Bill Bonello), notes confidence in near-term and long-term drivers of growth. Target increased to $64 from $35 or approx. 46% upside. (FactSet average PT $44; range $35-50) Services & Hospitals Regulatory: Post-close on Friday, the CMS finalized IPPS and LTCH rule for FY2027, rates +2.3% vs +2.4% proposed. CMS also extended CJR Model nationwide, now called CJR-X, and effective 1-Jan-2028. Managed Care Research: ALHC downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $19 from $22 or approx. 28% upside (FactSet average PT $24; range $16-30) CI downgraded to outperform from strong buy at Raymond James (Parker Snure), target cut to $320 from $350 or approx. 15% upside (FactSet average PT $342; range $297-400) On Deck: Regulatory Sun 2-Aug: FDA PDUFA for REPL vuso-vec BLA on Wed 5-Aug: FDA PDUFA for MRNA mFlusiva BLA Corporate JNJ hosting business update call to discuss recent FDA approval of OTTAVA Robotic Surgery System (8:00ET) MRK hosting business update call post-International AIDS Conference (8:00ET) on Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) Earnings after the close today: VRTX (call at 16:30ET), JAZZ (call at 16:30ET) Earnings tomorrow Tue 4-Aug: before BAYN.GR, MRK, PFE, IDXX, WAT, BNTX, SNN, FMS, RVTY, HSIC, BRKR, RYTM after AMGN, GILD, DVA, ARWR, BIO, PACS, TVTX, ACAD, HNGE This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABVX, ACAD, ADIL, ALHC, ALNY, AMGN, ARWR, AZN, AZN.LN, BAYN.GR, BIO, BMY, BNTX, BRKR, CDNA, CI, CLYM, DVA, FMS, GILD, HNGE, HSIC, IDXX, INDV, ITGR, JAZZ, JNJ, KRYS, LNTH, MRK, MRNA, NAMS, NOVN.SW, PACS, PFE, PYXS, REPL, RVTY, RYTM, SNN, SOBI.SS, SUPN, TGTX, TVTX, TWST, VRTX, WAT, YARW...(more)	show story hide story
02-Aug-2026 16:46	AstraZeneca in talks with Bristol Myers Squibb - media reports CNBC reporting on the potential merger of big pharma companies AstraZeneca (AZN.LN) and Bristol Myers Squibb (BMY), as first reported on Sunday by FT. Merger would value combined company at roughly $400B. Discussions have taken place over the last few months. According to FactSet data, market cap as of Friday's close: AZN $263B, BMY $133B For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: AZN.LN, BMY	show story hide story
31-Jul-2026 21:36	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished mixed and moderately lower overall on Friday. At the close, decliners just outnumbered advancers on the XLV, breadth significantly improved from the morning session. Healthcare (0.55%) vs S&P 500 +0.70%. All major health groups lagged the wider tape, and most ended red on the session. Services group today's relative performer, including UHS +3.2% among top performers on the XLV. Declines moderated in the afternoon session, only the XBI (2.94%) significantly lower on the day, followed by DRG (0.95%). Biotech returns were market-cap agnostic. Daily double for REPL +107.0% on favorable FDA Adcom outcome. DRG (1.65%) with NVO (8.8%) on late-stage setback for IL-6 program with read-across negative into SMID-cap biotech. Large-cap drugmakers end mixed on the session, including ABBV (2.5%) following the Q2 print. A pair of medical device names bracketed the XLV on respective earnings updates, DXCM +12.0% and SYK (6.4%). TNDM +2.6% but other diabetes tech names unable to keep pace. Stryker's soft outlook reading across cautiously to LC ortho peers. Hospitals were the only notable pockets of strength today. Macro: Lots of moving pieces to end a busy week. Momentum better again on the back of a big Thursday bounce, though not a one-way trade despite latest flurry of deleveraging done/cleaner positioning chatter. Hyperscaler capex ROI momentum in focus for a second straight session with the blowout AWS results (and AI/chip business momentum) from AMZN. However, also a flurry of big earnings decliners today, including AAPL on softer Sep Q guidance chalked up to supply chain and input cost pressures. Renewed backup in yields the other big story, though no one specific catalyst (FOMC dissent details, more Warsh credibility headlines, BoJ and yen intervention dynamics, higher oil). Combination of momentum outperformance and higher yields may be acting as overhangs on the broadening out trade (with technicals also recently flagged). Today marks month-end (momentum unwind the big story for July) and August represents one of the worst months from a seasonal perspective (though buybacks pick up throughout the month). Next week brings another big week of earnings (~14% of S&P 500 market cap) and high-profile July macro data. Notable Gainers on Friday: +107.0% REPL (Replimune Group): FDA panel recommends vuso-vec; upgrade; best performer on XBI +56.3% APMD (Apnimed): day one IPO (biotech) +20.2% ITGR (Integer Holdings): media report, in talks to be acquired by KKR +14.7% CDNA (CareDx): earnings +13.4% IRWD (Ironwood Pharmaceuticals): sympathy to AbbVie (Linzess); best one-day return in six months +12.0% DXCM (Dexcom): earnings; best performer on XLV +6.3% GH (Guardant Health): earnings Notable Decliners on Friday: -72.6% KPTI (Karyopharm Therapeutics): trial results in endometrial cancer; downgrades -63.6% BIOA (BioAge Labs): sympathy to NVO -46.7% MYGN (Myriad Genetics): earnings; worst performer on XBI -27.2% GLUE (Monte Rosa Therapeutics): sympathy to NVO -22.5% VCYT (Veracyte): earnings -20.2% ALHC (Alignment Healthcare): earnings -13.2% IOVA (Iovance Biotherapeutics): sympathy to REPL -10.1% NBIX (Neurocrine Biosciences): earnings -9.9% PTCT (PTC Therapeutics): earnings -8.8% NVO (Novo Nordisk): trial results with IL-6 in MACE reductions -6.4% SYK (Stryker): earnings; worst performer on XLV -5.4% MRNA (Moderna): earnings Week in Review: Earnings scorecard: According to FactSet Scorecard, with 35.54% of companies (59 of 166) having reported, 94.92% of the S&P 1500 Health Care (SP567-SPX) have beaten consensus EPS expectations, vs 81.71% last year (Q2 2025), with an average beat of +12.67% vs +8.67% last year. On the topline, 93.22% have beaten sales expectations, vs 82.32% last year (Q2 2025), with an average beat of +2.94% vs +2.56% last year. Healthcare equities underperformed for the week. The S&P 500 Healthcare Index essentially flat (0.01%) vs the S&P 500 Index higher +1.05%. Outperformers: MedTech, Services Underperformers: Managed Care, Biotech, Pharma Major health groups were widely mixed around the tape this week. Earnings calendar the primary source of newsflow with key reports from all corners of the sector. Strong earnings combined with upgraded outlooks lifted most equipment stocks, despite the setup from HCA's recent warning. Obesity duopoly weighed by Cigna commentary on GLP-1s, and Novo Nordisk diversification strategy took a hit after ZEUS trial failure. JNJ proposed a $5.5B settlement to resolve MDL talc litigation. FDA Adcoms are back - and the REPL case a good reminder why. The same committee agreed with FDA on the CAPR case. Biotech returns driven more this week by earnings than M&A. Year-to-date, Healthcare +4.86% vs the S&P 500 +9.41%. Healthcare seventh out of eleven major sectors in CY26. Energy +32.77% and Consumer Discretionary (0.31%) bracket them all. Notable movers for the week: Gainers: TRAX +24.0% - best performer on XBI; follow-through, shares +119% for the month AVTR +20.5% - earnings; upgraded at Jefferies CORT +20.1% - earnings; Lifyorli launch KNSA +18.3% - earnings; raised guidance for Arcalyst BAX +16.8% - earnings; upgraded at Citi; best performer on XLV DXCM +16.6% - earnings; raised guidance REGN +16.3% - earnings; Dupixent beat REPL +15.5% - FDA briefing documents (negative); FDA Adcom (positive) MMSI +14.4% - earnings; raised guidance TEVA +13.6% - earnings; sympathy to ALVO site inspection IQV +13.0% - earnings; raised guidance GEHC +12.3% - earnings; reaffirmed GH +10.0% - earnings SOLV +9.5% - assumed buy at UBS (upgrade) THC +9.3% - follows +20% prior week; sympathy to UHS RGEN +6.9% - earnings Decliners: CAPR (80.5%) - FDA briefing documents / FDA Adcom (negative); worst performer on XBI ALNY (24.4%) - earnings; lowers guidance for Amvuttra ALHC (23.6%) - earnings; guidance VCYT (18.2%) - earnings LEGN (16.5%) - CEO steps down to pursue outside opportunity MDGL (14.2%) - earnings HUM (6.5%) - earnings; 3 upgrades & 1 downgrade; worst performer on XLV WAY (6.2%) - earnings; CFO departs for personal reasons Week Ahead (Sat - Sun): Aug 1 - 9 Regulatory calendar Sun 2-Aug: FDA PDUFA for REPL vuso-vec BLA Wed 5-Aug: FDA PDUFA for MRNA mFlusiva BLA Corporate calendar Mon 3-Aug: JNJ hosting business update call to discuss recent FDA approval of OTTAVA Robotic Surgery System (8:00ET); MRK hosting business update call post-International AIDS Conference (8:00ET) Wed 5-Aug: NAMS hosting Investor Day meeting (9:00ET) Earnings calendar Mon 3-Aug: before 4523.JP, KRYS, TGTX, TWST after VRTX, JAZZ Tue 4-Aug: before BAYN.GR, MRK, PFE, IDXX, WAT, BNTX, SNN, FMS, RVTY, HSIC, BRKR, RYTM, INDV after AMGN, GILD, DVA, ARWR, BIO, PACS, TVTX, ACAD, HNGE Wed 5-Aug: before LLY, NVO, CVS, COR, ONC, SDZ.SW, MDLN, FRE.GR, RPRX, UTHR, ZBH, ELAN, PODD, CRL, KYMR, LIVN after MCK, RVMD, STE, SOLV, EXEL, EHC, QGEN, MIRM, BLLN, CAI, NVST, ARQT, RCUS, GRAL Thu 6-Aug: before BDX, ZTS, ROIV, INSM, MRK.GR, VTRS, PRAX, OSCR, IMVT, LNTH, TFX, LGND, SRRK, SHC, LFST, HAE, ITGR, PRVA after NTRA, RMD, GMAB, BMRN, HALO, CYTK, GMED, XENE, DFTX, TXG, CON, RLAY, ICUI, IRTC, DNLI Conference calendar n/a Syndicate calendar / potential IPO pricing n/a Related: 4523.JP, ABBV, ACAD, ALHC, ALNY, ALVO, AMGN, APMD, ARQT, ARWR, AVTR, BAX, BAYN.GR, BDX, BIO, BIOA, BLLN, BMRN, BNTX, BRKR, CAI, CAPR, CDNA, CON, COR, CORT, CRL, CVS, CYTK, DFTX, DNLI, DVA, DXCM, EHC, ELAN, EXEL, FMS, FRE.GR, GEHC, GH, GILD, GLUE, GMAB, GMED, GRAL, HAE, HALO, HNGE, HSIC, HUM, ICUI, IDXX, IMVT, INDV, INSM, IOVA, IQV, IRTC, IRWD, ITGR, JAZZ, JNJ, KNSA, KPTI, KRYS, KYMR, LEGN, LFST, LGND, LIVN, LLY, LNTH, MCK, MDGL, MDLN, MIRM, MMSI, MRK, MRK.GR, MRNA, MYGN, NAMS, NBIX, NTRA, NVO, NVST, ONC, OSCR, PACS, PFE, PODD, PRAX, PRVA, PTCT, QGEN, RCUS, REGN, REPL, RGEN, RLAY, RMD, ROIV, RPRX, RVMD, RVTY, RYTM, SDZ.SW, SHC, SNN, SOLV, SRRK, STE, SYK, TEVA, TFX, TGTX, THC, TRAX, TVTX, TWST, TXG, UHS, UTHR, VCYT, VRTX, VTRS, WAT, WAY, XENE, ZBH, ZTS...(more)	show story hide story
31-Jul-2026 16:27	CMS finalizes FY27 rule for IPPS and LTCH; rates +2.3% vs proposed +2.4%; expands CJR model CMS issued the final rule that updates Medicare payment policies and rates for inpatient and long-term care hospitals under the Medicare hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital Prospective Payment System (LTCH PPS) for FY2027. The final rule expands the Comprehensive Care for Joint Replacement (CJR) Model, which produced strong evidence of cost savings while maintaining quality of care. The expanded model, called CJR-X, is designed to improve care for Original Medicare patients undergoing hip, knee, and ankle replacements (also called lower extremity joint replacements) performed in inpatient and hospital outpatient settings. CJR-X will be mandatory nationwide and begin on January 1, 2028. CMS is updating the IPPS payment rates by +2.3%, or $2.9B y/y This reflects a projected FY 2027 hospital market basket percentage increase of +3.2%, reduced by a (0.9%) productivity adjustment. StreetAccount notes that the April proposal was for an increase of +2.4% CMS is updating the LTCH standard payment rate by +2.3%, or $54M y/y This reflects a projected LTCH PPS market basket percentage increase of +3.2%, reduced by a (0.9%) productivity adjustment. StreetAccount notes that the April proposal was for an increase of +2.4% CMS estimates that the CJR-X model in this final rule would result in saving the Medicare program $725M across 5 performance years. See Related StreetAccount comments: 4/10/2026 5:21:41 PM - CMS proposes FY27 rule for IPPS and LTCH; rates +2.4% each; nationwide expansion of CJR Model Related: ATRC, BSX, CARL, CYH, ELV, EW, HCA, HUM, JNJ, MDT, SIBN, SN.LN, SYK, THC, UHS, UNH, ZBH...(more) Reference Link: CMS-1849-F and CMS-0062-F (2704pp) Reference Link: Fact Sheet Reference Link: CJR-X press release	show story hide story
31-Jul-2026 12:48	StreetAccount Summary: Notable Drug Events expected for the week of 2-Aug Sun 2-Aug Regulatory decision: REPL FDA PDUFA for vuso-vec (formerly RP1) for advanced melanoma Note: Positive Adcom vote on 30-Jul Mon 3-Aug Corporate update: MRK to discuss updates at International AIDS Conference (8:00ET) VRTX earnings call (16:30ET) Tue 4-Aug Corporate updates: MRK earnings call (9:00ET) PFE earnings call (10:00ET) AMGN earnings call (16:30ET) GILD earnings call (16:30ET) Wed 5-Aug Regulatory decision: MRNA FDA PDUFA for mFlusiva vaccine in seasonal influenza Note: Positive Adcom vote on 18-Jun Corporate update: NAMS hosting Investor Day meeting (9:00ET) NVO earnings call (7:00ET) LLY earnings call (10:00ET) later during August 2026 Regulatory decisions: FDA PDUFAs: LNTH (MK-6240 NDA, 16-Aug), BMY (iberdomide NDA, 17-Aug), RARE (pariglasgene brecaparvovec BLA, 23-Aug), XSPRAY.SS (Dasynoc NDA, 25-Aug), ZYME/JAZZ (ZIIHERA sBLA, 25-Aug), GILD (bictegravir+ lenacapavir NDA, 27-Aug), 6446.TT (Besremi sBLA, 30-Aug), PTGX/4502.JP (rusfertide NDA), REGN (garetosmab BLA); EMA CHMP opinions on MAA (21-Aug) Regulatory meeting: EMA CHMP monthly meeting (replaced by written procedure) (Aug 17-20) Industry meeting with clinical data: European Society of Cardiology (Aug 28-31) Trial results: TENX* (Ph3 PH-HFpEF), LGVN (Ph2 HLHS), TYRA (Ph2 IR NMIBC), SLN (Ph2 PV) Related: 4502.JP, 6446.TT, AMGN, BMY, GILD, JAZZ, LGVN, LLY, LNTH, MRK, MRNA, NAMS, NVO, PFE, PTGX, RARE, REGN, REPL, SLN, TENX, TYRA, VRTX, XSPRAY.SS, ZYME...(more)	show story hide story
31-Jul-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (1.12%) vs the S&P 500 +0.15%. All major health groups are red for the session, most by (1%) to (3%). XBI (2.68%) market-cap agnostic and despite REPL +99% on FDA Adcom outcome. DRG (1.65%) with NVO (9%) clinical setback for IL-6 program reads across negative into SMID-cap biotech. Large-cap drugmakers are mostly red including ABBV (2%) following the Q2 print. Pair of Medical Device names bracket the XLV on earnings updates, DXCM +10% and SYK (8%). DexCom not helping Diabetes Tech stocks, all are down as much as (6%) today. Stryker's soft outlook reading across cautiously to LC ortho peers. No real pockets of respite today; closest may be a pair of diagnostic gainers on earnings, CDNA +12% and GH +7%. Awaiting launch of biotech APMD into the red tape. Looking ahead to next week, earnings calendar remains loaded with LC biopharma and distributors. Gainers +99.2% REPL (Replimune Group): FDA panel recommends vuso-vec; upgrade; best performer on XBI +13.0% CDNA (CareDx): earnings +10.2% DXCM (Dexcom): earnings; best performer on XLV +7.0% GH (Guardant Health): earnings +4.3% QURE (uniQure NV): sympathy to REPL +2.6% PSNL (Personalis): sympathy to TEM +0.8% MTD (Mettler-Toledo International): earnings +0.2% MRNA (Moderna): earnings Decliners -66.3% KPTI (Karyopharm Therapeutics): trial results in endometrial cancer; downgrades -59.5% BIOA (BioAge Labs): sympathy to NVO -41.9% MYGN (Myriad Genetics): earnings; worst performer on XBI -29.4% GLUE (Monte Rosa Therapeutics): sympathy to NVO -25.9% VCYT (Veracyte): earnings -16.3% ALHC (Alignment Healthcare): earnings -9.3% IOVA (Iovance Biotherapeutics): sympathy to REPL -8.7% NBIX (Neurocrine Biosciences): earnings -8.5% NVO (Novo Nordisk): trial results with IL-6 in MACE reductions -7.6% SYK (Stryker): earnings; worst performer on XLV -7.4% PTCT (PTC Therapeutics): earnings -3.2% SNN (Smith & Nephew): sympathy to SYK -3.1% INCY (Incyte): follow-through -3.0% ZBH (Zimmer Biomet Holdings): sympathy to SYK -2.9% TEM (Tempus AI): earnings -2.2% BAX (Baxter International): upgraded at Citi -2.0% ABBV (AbbVie): earnings -1.1% ABVX (Abivax): regulatory alignment with FDA -0.9% IMNM (Immunome): Wedbush comments, reiterate OP	show story hide story
31-Jul-2026 08:45	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Overnight the largest slate of earnings reports yet for Q2 earnings season. Stryker beat in Q2 but outlook narrow & raise less than expected. Shares of SYK (6%) in the pre-market. DexCom beat in Q2 driven by margins ahead of consensus. Shares of DXCM +7% in the pre-market. Pre-open on Friday, Moderna reported Q2 results generally inline, and company maintained FY guidance. Focus on mFlusiva upcoming PDUFA and a return to growth. Interim analysis of norovirus trial did not meet stat criteria, will enroll next cohort. Shares of MRNA (3%) in the pre-market. Novo Nordisk announced that a large CVOT evaluating IL-6 inhibitor for the reduction of MACE failed to achieve a benefit. HR 0.99 or 1% reduction in risk. ADRs down (8%) in the pre-market. Biotechs including GLUE and BIOA lower in reaction. Biggest surprise came from FDA advisory committee reviewing Replimmune's vuso-vec for melanoma. The 10-3 positive vote challenged FDA staff. Shares of REPL +135% after being halted during Thursday's meeting. Another Biotech IPO priced, #16 of CY2026. Apnimed with its drug treatment for obstructive sleep apnea, raised $192M in an upsized offering. Macro S&P futures are up +0.2% on Friday morning, off best levels. Momentum bounce has continued today with more discussion about deleveraging largely done and support for the fundamental compute/capex demand narrative from hyperscaler earnings with AMZN delivering better-than-expected 37% AWS growth and positive capex ROI commentary. While AAPL a notable post-earnings laggard, takeaways largely focused on supply constraints, input pressures and a high bar, as demand backdrop healthy. Very quiet elsewhere, including when it comes to the Middle East. BoJ left rates unchanged as expected, while China July PMIs came in softer with both manufacturing and services falling back into contraction. Pre-market trading update Trading higher +132.2% REPL FDA panel recommends vuso-vec; upgrade +11.5% CDNA earnings +7.8% GH earnings +7.3% DXCM earnings +6.2% QURE sympathy to REPL +5.8% PSNL sympathy to TEM +3.9% IMNM Wedbush comments, reiterate OP +3.8% ABVX regulatory alignment with FDA +2.5% BAX upgraded at Citi +1.5% TEM earnings Trading lower -70.6% KPTI trial results in endometrial cancer; downgrades -60.6% BIOA sympathy to NVO -31.1% GLUE sympathy to NVO -15.5% ALHC earnings -11.3% VCYT earnings -8.0% NVO trial results with IL-6 in MACE reductions -6.2% SYK earnings -4.5% IOVA sympathy to REPL -3.6% MRNA earnings -3.6% MCK on 56K shares Pharma Trial results: NOVO.B.DC (NVO) announced topline results from the phase 3 CVOT trial (ZEUS) evaluating IL-6 inhibitor ziltivekimab for MACE risk reduction in people with ASCVD, CKD, and inflammation. The study enrolled over 6,300 people and reported a hazard ratio of 0.99. Two other trials, HERMES and ARTEMIS are ongoing. Earnings: ABBV reports Q2 EPS $3.65 vs FactSet $3.60 on revenue $16.99B vs FS $16.78B. Updates FY outlook to reflect Apogee acquisition, partially offset by outperformance: Lowers EPS outlook by $0.04 at the midpoints. Conf. call at 9:00ET Biotech Earnings: MRNA reports Q2 EPS ($1.97) vs FactSet ($2.03) on revenue $145M vs FS $102.9M. Cash & equivalents $6.9B at 30-Jun. Maintains FY revenue growth outlook of +10% y/y. Focus on next leg of growth; PDUFA for mFlusiva in August, follows positive Adcom in June. Interim analysis of norovirus vaccine trial did not reach statistical criteria, preparing to enroll next cohort. Conf. call at 8:00ET NBIX reported Q2 EPS $1.39 vs FactSet $1.66 on revenue $959M vs FactSet $891.2M. Ingrezza sales $716M. Raises FY guidance for Ingrezza sales by $100M at the midpoints. PTCT reported Q2 EPS $0.92 vs FactSet $0.24 on revenue $360.5M vs FactSet $298.6M. Cash & equivalents $2.229B at 30-Jun. Raises FY revenue outlook by $100M at the midpoints. Regulatory: REPL Post-close on Thursday, FDA CTGTAC voted 10-3 in support of the efficacy data for vuso-vec (formerly RP1) BLA for melanoma. Shares were halted on Thursday, and were down (44%) WTD. Stock upgraded in reaction. Trial results: KPTI announced topline results from its phase 3 XPORT-EC-042 trial evaluating selinexor in recurrent endometrial cancer. The trial did not meet its primary endpoint of PFS. The results do not affect other potential indications. Stock downgaded in reaction IPO priced: APMD (Apnimed) priced an upsized Nasdaq IPO at the top-end of expected price range, 12M shares at $16/shr or $192M before the shoe. S-1A. Sole product candidate in the clinic: AD109 (Oxnimbi) for obstructive sleep apnea (OSA). Research: REPL upgraded to overweight from neutral at Cantor Fitzgerald (Li Watsek), follows Adcom vote to support RP1. KPTI downgraded to neutral from outperform at Baird (Colleen Kusy), target cut to $3 from $15 or approx. 57% downside. (FactSet average PT $13; range $3-24) KPTI downgraded to neutral from buy at HC Wainwright (Robert Burns), citing trial results. Target cut to $3 from $13 or approx. 57% downside. (FactSet average PT $13; range $3-24) CAPR downgraded to hold from buy at Jones (Catherine Novack), cites recent Adcom vote. 4516.JP downgraded to neutral from buy at Mizuho Securities (Hiroshi Tanaka), target cut to ¥3650 from ¥6600 or approx. 4% upside. (FactSet average PT ¥4626; range ¥2600-8600) Life Science & MedTech Earnings: SYK reports Q2 EPS $3.69 ex-items vs FactSet $3.49 on revenue $6.59B vs FS $6.58B. Raises low-end of FY EPS guidance range, midpoint higher by 2.5c. Narrows FY organic net sales growth outlook. DXCM reports Q2 EPS $0.70 ex-items vs FactSet $0.61 on revenue $1.31B vs FS $1.29B. FY guidance tweaked slightly higher at the midpoints. ILMN reports Q2 EPS $1.31 ex-items vs FactSet $1.23 on revenue $1.16B vs FS $1.13B. Raises FY EPS guidance by $0.125 at the midpoints, revenue by $50M at the midpoints. GH reports Q2 EPS ($0.42) ex-items vs FactSet ($0.76) on revenue $335.0M vs FS $314.2M, adj EBITDA ($55.9M) vs FS ($50.2M). FY revenue outlook by $40M at the midpoints. MTD reports Q2 EPS $11.46 ex-items vs FactSet $10.80 on revenue $1.03B vs FS $1.03B. Guides Q3 EPS bracketing consensus. Raises FY revenue growth to +4% to +5% vs prior +4%. Conf. call at 7:30ET TEM reports Q2 EPS ($0.04) ex-items vs FactSet ($0.14) on revenue $382.5M vs FS $379.7M, adj EBITDA $8.0M vs FS $8.4M. MMSI reports Q2 EPS $1.19 ex-items vs FactSet $0.96 on revenue $418.8M vs FS $405.2M. Raises FY guidance by $0.22 at the midpoints, revenue by $14M at the midpoints. VCYT reports Q2 EPS $0.54 ex-items vs FactSet $0.43 on revenue $150.3M vs FS $144.6M, adj EBITDA $44.0M vs FS $37.3M. Raises FY revenue outlook $6M at the midpoints, reaffirms FY EBITDA outlook. Research: BAX upgraded to neutral from sell at Citi (Joanne Wuensch), follows Q2 results. Target increased to $28 from $17 or approx. 5% upside. (FactSet average PT $27; range $19-32) Services & Hospitals Earnings: BTSG reports Q2 adj EBITDA $206M vs FactSet $194.7M on revenue $3.87B vs FS $3.66B, EPS $0.45 ex-items vs FS $0.40. Raises FY EBITDA guidance $22.5M at the midpoints, revenue guidance by $187.5M at the midpoints. Conf. call at 8:30ET Regulatory: CMS finalized Hospice PPS rate for FY2027, an increase of +2.3% vs +2.4% proposed. CMS finalized Inpatient Rehabilitation Facility (IRF) PPS rate for FY2027, an increase of +2.3% vs +2.4% proposed. Managed Care Earnings: ALHC reported Q2 EPS $0.17 vs FactSet $0.13 on revenue $1.34B vs FS $1.31B, adj EBITDA $68.1M vs FS $57.7M. Guides Q3 revenue light at the midpoint, adj EBITDA below consensus. Raises FY guidance for revenue and adj EBITDA. On Deck: Calendar for this week is all clear. Peek Ahead to next week (Aug 3-9) Overview: A very busy week of large-cap earnings reports (LLY, MRK, AMGN, NVO, GILD, PFE, CVS, VRTX, MCK, COR, and many more); JNJ hosting investor call on 3-Aug to discuss recent FDA approval of OTTAVA Robotic Surgical System; FDA PDUFA for MRNA seasonal influenza vaccine "mFlusiva" on 5-Aug (unanimously recommended by VRBPAC on 18-Jun). This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4516.JP, ABBV, ABVX, ALHC, AMGN, APMD, BAX, BIOA, BTSG, CAPR, CDNA, COR, CVS, DXCM, GH, GILD, GLUE, ILMN, IMNM, IOVA, JNJ, KPTI, LLY, MCK, MMSI, MRK, MRNA, MTD, NBIX, NOVO.B.DC, NVO, PFE, PSNL, PTCT, QURE, REPL, SYK, TEM, VCYT, VRTX...(more)	show story hide story
30-Jul-2026 17:35	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished broadly lower on Thursday. Decliners beat advancers by 4:1 on the XLV. Healthcare (1.65%) vs S&P 500 +1.66%. Most major health groups ended red on the session; Biotech widely mixed with earnings updates, but small-caps caught a bid to drive XBI gains. Breadth positive on the XBI +2.40% on the session / and green WTD. ALNY (28.3%) after guidance reset underpins the ETF. Decliners are led today by Pharma with the DRG (2.38%). SNY (4.4%) dragged the Drug Index lower despite a Q2 beat-and-raise; new CEO emphasizes need for disciplined BD and M&A focus to return to growth. LLY (4.5%), lower on Cigna comments on GLP-1s, and JNJ (3.7%) also down for the session. Outlier was BMY +2.8% on Q2 viewed strong operationally. BAX +8.0%, on earnings, and LLY bracketed the XLV. Earnings calendar heaviest yet for the Q2 season. Broad range of reports across the sector and market caps. TDOC (28.3%) with a mixed Q2 last night, noted a cash pay decline beyond internal assumptions. SMID-cap biotechs volatile on launch / sales updates. Alnylam Pharma trims FY outlook for Amvuttra in the second-line setting after another quarter under the belt. CORT +27.3% reported strong initial quarter sales for Lifyorli. CFO told investors that inventory was not a big factor either. Baxter margins handily beat consensus, topline also widely beat. CMS published final PPS rules for IPF and SNF, both matching their respective proposed growth rates of +2.3% and +2.4%. FDA panel voted 9-3 against the one voting question - evidence of efficacy in the treatment of cardiomyopathy in DMD patients. Shares of CAPR resumed, trading down another (36.2%). CTGTAC turns attention to Replimmune's BLA today. Shares of REPL are halted throughout the meeting. Vote planned post-close. Huge slate of earnings tonight, and a few more tomorrow morning. Macro Momentum bounce the big story. Played into recent talk around unwind largely exhausted, oversold conditions, though biggest focus on hedge fund Situational Awareness, which suffered heavy losses from AI trade selloff. Firm exited all public investments, which helped ease fears around technical/leverage issues, disorderly unwind. Also plenty of support for the fundamental compute/capex narrative from the earnings calendar (though not a new dynamic). Big tech earnings takeaways mixed, including when it comes to AI capex ROI/monetization debate. Still a lot of focus on the Fed/Warsh, though rates have stabilized after long-end was hit yesterday on reaction fund uncertainty and inflation credibility dynamics. Economic calendar largely a non-factor today ahead of high-profile data next week. Middle East also seems to be on the backburner with lots of moving pieces, including potential for an extended/heightened wave of US attacks, expansion (recent explosion in Egypt), diplomatic efforts, and a pickup in SoH transit. Notable Gainers +27.3% CORT (Corcept Therapeutics): earnings +14.1% TRAX (First Tracks Biotherapeutics Inc): best performer on XBI; on avg volume; shares +134% MTD +12.6% SMTI (Sanara MedTech): acquired by MDGX for $35/shr +12.1% GRAL (GRAIL, Inc.): diagnostics outperforming, turn weekly declines around; second-best on XBI +9.1% IBRX (ImmunityBio): MAA in UAE +8.0% BAX (Baxter International): earnings; best performer on XLV +6.3% MRNA (Moderna): shares +96% YTD +6.2% REGN (Regeneron): earnings +5.7% GH (Guardant Health): diagnostics outperforming, turn weekly declines around +4.2% GKOS (Glaukos): earnings +2.8% BMY (Bristol Myers Squibb): earnings Notable Decliners -36.2% CAPR (Capricor Therapeutics): FDA panel vote against; downgrades; worst performer on XBI -28.3% TDOC (Teladoc Health): earnings -28.3% ALNY (Alnylam Pharmaceuticals): earnings, guidance; second-worst on XBI -14.6% WAY (Waystar Holding): earnings -10.4% OMCL (Omnicell): earnings -9.8% MDGL (Madrigal Pharmaceuticals): earnings -4.5% LLY (Eli Lilly): worst performer on XLV; sympathy to Cigna comments on GLP-1 -4.4% SNY (Sanofi): earnings; comments on BD and M&A -3.9% IQV (IQVIA Holdings): shares remain +14% WTD -3.7% ALGN (Align Technology): earnings -3.7% JNJ (Johnson & Johnson): shares turn red WTD -3.1% AMRX (Amneal Pharmaceuticals): earnings -3.1% VEEV (Veeva Systems): shares remain +8% WTD -3.0% CI (Cigna Group): earnings -2.9% PODD (Insulet): shares remain +1% WTD -2.7% GEHC (GE HealthCare Technologies): shares remain +15% WTD -1.7% BBIO (BridgeBio Pharma): sympathy to ALNY -1.0% VKTX (Viking Therapeutics): earnings Baxter higher following Q2 beat-and-raise BAX reports EPS $0.56 ex-items vs FactSet $0.37 on revenue $2.96B vs FS $2.80B. Margins beat handily. Raises FY EPS guidance by $0.10 at the midpoints, revenue growth guidance now +3-4% vs prior flat to +1%. Additional earnings in MedTech ICLR reported Q2 EPS $2.56 ex-items vs FactSet $2.55 on revenue $2.06B vs FS $2.00B, adj EBITDA $327.2M vs FS $322.3M. Reaffirms FY26 guidance top and bottom. ALGN reported Q2 EPS $2.64 ex-items vs FactSet $2.62 on revenue $1.06B vs FS $1.05B. Aligner volume increased 7.4% y/y to 691.8K cases. GKOS reported Q2 EPS ($0.31) vs FactSet ($0.21) on revenue $185.6M vs FS $150.9M. Raises FY revenue outlook by $62.5M at the midpoints. WAY reported Q2 NG EPS $0.43 vs FactSet $0.40 on revenue $319.7M vs FactSet $316.2M, adj EBITDA $136.7M vs FS $131.1M. Raises FY26 EPS guidance by 2c, adj EBITDA by $5M, and the low-end of revenue guidance. ADPT reported Q2 EPS ($0.25) vs FactSet ($0.13) on revenue $71.6M vs FS $65.4M. Raises FY26 outlook for MRD business revenue by $8M. Cigna lower following Q2 beat-and-raise; highlights declining coverage for GLP-1s CI reports Q2 EPS $7.78 ex-items vs FactSet $7.60 on revenue $71.67B vs FS $70.14B. MLR 84.5% vs StreetAccount 85.0%. Raises FY26 EPS outlook, and now expects FY MLR down 100bps to 83.7%. On the call: "Additionally, in the second quarter, we observed moderating GLP-1 growth as coverage levels slightly declined and utilization growth slowed from elevated levels experienced in prior periods. We expect this trend to continue throughout the remainder of the year, and it is contemplated in our full-year outlook." (LLY, NVO) Bristol Myers higher following Q2 beat-and-raise, pipeline updates BMY reports Q2 EPS $2.04 vs FactSet $1.60 on revenue $12.97B vs FS $11.74B. Raises FY26 EPS guidance by $0.675 at the midpoints, and revenue by $2.75B at the midpoints. Quick Take: Takeaways caution that the beat was largely driven by the legacy portfolio, led by Eliquis, with the majority of the guidance increase also attributable to legacy products approaching or already facing loss of exclusivity. Delays to the LIBREXIA-AF readout and the ADEPT study in AD psychosis were largely anticipated, though they are seen as adding uncertainty around the pipeline and tempering what was otherwise viewed as a strong quarter operationally. Additional earnings in Pharma SNY reports Q2 business EPS €2.09 vs consensus €1.90 on net sales €11.60B vs consensus €10.85B. Raises FY26 sales outlook to around 10% CER vs prior HSD. TAK reports Q1 net income attributable ¥113.20B vs FactSet ¥73.25B on revenue ¥1.220T vs FactSet ¥1.150T. Maintains FY (Mar 27) guidance. AMRX reports Q2 EPS $0.30 ex-items vs FactSet $0.22 on revenue $796.2M vs FS $768.2M, adj EBITDA $206.5M vs FS $177.4M. Raises FY26 EPS guidance by $0.01, revenue by $50M, and adj EBITDA by $10M at the midpoints. Corcept Therapeutics higher on Q2 results, strong launch quarter for Lifyorli CORT reports Q2 EPS $0.36 on revenue $256.1M vs FactSet $221.1M Quick Take: A strong Lifyorli launch prompted many to materially increase their PT, noting a potentially underappreciated commercial opportunity for the drug. Commentary is also constructive on the strong rebound in Korlym sales, with demand continuing to strengthen. The Dec 2026 PDUFA for relacorilant in Cushing's syndrome remains the next key catalyst, with views mixed on the outcome as some expect approval, while others see risk of a potential CRL. Additional earnings in Biotech REGN reports Q2 EPS $14.29 ex-items vs FactSet $10.16 on revenue $4.29B vs FS $3.82B. Sanofi collaboration products drove the beat. Dupixent sales (recorded by Sanofi) beat by nearly 11%. Narrows FY expense guidance, raises FY gross margin guide by 100bps. ALNY reports Q2 GAAP EPS $1.21 vs FactSet $1.63 on revenue $1.29B vs FS $1.32B. Lowers FY net product guidance by $200M at the midpoints, after demand normalized for Amvuttra in 2L segment. MDGL reports Q2 EPS ($1.99) s FactSet ($2.68) on revenue $364.2M vs FS $352.1M. Cash & equivalents $838.9M as of 30-Jun. Notes milestone of 50,000 patients on Rezdiffra achieved this month. Building out MASH pipeline. VKTX reports Q2 results including cash & equivalents $502M at 30-Jun. Labcorp higher folllowing Q2 beat-and-raise LH reports Q2 EPS $4.99 ex-items vs FactSet $4.78 on revenue $3.73B vs FS $3.71B. Raises FY EPS outlook by $0.45 at the midpoints, revenue outlook by $45M at the midpoints. Notable research in Healthcare today Biotech: CAPR downgraded at Cantor Fitzgerald, HC Wainwright, Ladenburg Thalmann, Oppenheimer, Piper Sandler. LONA upgraded to market outperform from market perform at Citizens (Jason Butler), cites factors including pipeline expansion. Target os $18 or approx. 156% upside. QURE upgraded to outperform at Wolfe Research (Rudy Li), target is $65 or approx. 62% upside. (FactSet average PT $66; range $37-95) ACTU initiated buy at Rodman & Renshaw (Michael King), target is $6 or approx. 456% upside. (FactSet average PT $10l range $5-15) ALNY resumed outperform at Bernstein (Jeffrey Walch), target is $429 or approx. 50% upside (FactSet average PT $437; range $285-551) BIIB resumed outperform at Bernstein (Jeffrey Walch), target is $236 or approx. 13% upside. CTNM initiated outpeform at LifeSci Capital (Guarav Maini), target is $24 or approx. 67% upside. (FactSet average PT $22; range $16-28) IMVT resumed market perform at Bernstein (Jeffrey Walch), target is $37 or approx. 4% downside. KYMR initiated hold at Deutsche Bank (David Hoang), target is $120 or approx. 14% upside. (FactSet average PT $127; range $97-155) REGN resumed market perform at Bernstein (Jeffrey Walch), target is $753 or approx. 8% upside. ROIV resumed outperform at Bernstein (Jeffrey Walch), target is $41 or approx. 25% upside. VRTX resumed outperform at Bernstein (Jeffrey Walch), target is $608 or approx. 26% upside. MedTech: BIO assumed neutral at Citi (Daniel Grosslight), target remains $300 or approx. 7% downside. MDLN assumed buy at Citi (Daniel Grosslight), target remains $55 or approx. 38% upside. RVTY assumed buy at Citi (Daniel Grosslight), target remains $135 or approx. 21% upside. Services: OPCH downgraded to hold from buy at Deutsche Bank (Pito Chickering), follows Q2 results. Target cut to $24 from $26 (FactSet average PT $28; range $22-39) Managed Care: HUM downgraded to market perform from outperform at Raymond James (Parker Snure) HUM upgraded to outperform from market perform at Leerink Partners (Whit Mayo), notes valuation. Target increased to $513 from $255 or approx. 40% upside. HUM upgraded to overweight at Piper Sandler (Jessica Tassan). Target increased to $463 from $254 or approx. 27% upside. Post-close news Regulatory: REPL FDA panel (CTGTAC) votes 10-3 in support of the efficacy data for vuso-vec (RP1) BLA for melanoma. Shares remain halted, and were down (44%) WTD CMS finalized Hospice PPS rate for FY2027, an increase of +2.3% vs +2.4% proposed. CMS finalized Inpatient Rehabilitation Facility (IRF) PPS rate for FY2027, an increase of +2.3% vs +2.4% proposed. Earnings: SYK reports Q2 EPS $3.69 ex-items vs FactSet $3.49 on revenue $6.59B vs FS $6.58B. Raises low-end of FY EPS guidance range, midpoint higher by 2.5c. Narrows FY organic net sales growth outlook. Conf. call at 16:30ET Shares trading (8.6%) in the after-hours DXCM reports Q2 EPS $0.70 ex-items vs FactSet $0.61 on revenue $1.31B vs FS $1.29B. FY guidance tweaked slightly higher at the midpoints. Conf. call at 16:30ET Shares trading +7.3% in the after-hours ILMN reports Q2 EPS $1.31 ex-items vs FactSet $1.23 on revenue $1.16B vs FS $1.13B. Raises FY EPS guidance by $0.125 at the midpoints, revenue by $50M at the midpoints. Conf. call at 16:30ET Shares trading (2.5%) in the after-hours GH reports Q2 EPS ($0.42) ex-items vs FactSet ($0.76) on revenue $335.0M vs FS $314.2M, adj EBITDA ($55.9M) vs FS ($50.2M). FY revenue outlook by $40M at the midpoints. Conf. calll at 16:30ET Shares trading +7.8% in the after-hours NBIX reports Q2 EPS $1.39 vs FactSet $1.66 on revenue $959M vs FactSet $891.2M. Ingrezza sales $716M. Raises FY guidance for Ingrezza sales by $100M at the midpoints. Conf. calll at 16:30ET Shares trading UNCH in the after-hours TEM reports Q2 EPS ($0.04) ex-items vs FactSet ($0.14) on revenue $382.5M vs FS $379.7M, adj EBITDA $8.0M vs FS $8.4M. Conf. calll at 16:30ET Shares trading (2.7%) in the after-hours PTCT reports Q2 EPS $0.92 vs FactSet $0.24 on revenue $360.5M vs FactSet $298.6M. Cash & equivalents $2.229B at 30-Jun. Raises FY revenue outlook by $100M at the midpoints. Conf. calll at 16:30ET Shares trading (0.1%) in the after-hours MMSI reports Q2 EPS $1.19 ex-items vs FactSet $0.96 on revenue $418.8M vs FS $405.2M. Raises FY guidance by $0.22 at the midpoints, revenue by $14M at the midpoints. Conf. calll at 16:30ET Shares trading +4.4% in the after-hours ALHC reports Q2 EPS $0.17 vs FactSet $0.13 on revenue $1.34B vs FS $1.31B, adj EBITDA $68.1M vs FS $57.7M. Guides Q3 revenue light at the midpoint, adj EBITDA below consensus. Raises FY guidance for revenue and adj EBITDA. Conf. calll at 17:00ET Shares trading (14.3%) in the after-hours VCYT reports Q2 EPS $0.54 ex-items vs FactSet $0.43 on revenue $150.3M vs FS $144.6M, adj EBITDA $44.0M vs FS $37.3M. Raises FY revenue outlook $6M at the midpoints, reaffirms FY EBITDA outlook. Conf. calll at 16:30ET Shares trading (7.7%) in the after-hours MTD reports Q2 EPS $11.46 ex-items vs FactSet $10.80 on revenue $1.03B vs FS $1.03B. Guides Q3 EPS bracketing consensus. Raises FY revenue growth to +4% to +5% vs prior +4%. Conf. call tomorrow at 7:30ET Shares trading +4.1% in the after-hours On Deck: Earnings tomorrow morning ABBV (call at 9:00ET), MRNA (call at 8:00ET), BTSG (call at 8:30ET) Syndicate / IPO pricing tonight +APMD (Apnimed) potential pricing of IPO - S-1A - Sole product candidate in the clinic: AD109 (Oxnimbi) for obstructive sleep apnea (OSA). Peek Ahead to next week (Aug 3-9) Overview: A very busy week of large-cap earnings reports (LLY, MRK, AMGN, NVO, GILD, PFE, CVS, VRTX, MCK, COR, and many more); JNJ hosting investor call on 3-Aug to discuss recent FDA approval of OTTAVA Robotic Surgical System; FDA PDUFA for MRNA seasonal influenza vaccine "mFlusiva" on 5-Aug (unanimously recommended by VRBPAC on 18-Jun). This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABBV, ACTU, ADPT, ALGN, ALHC, ALNY, AMRX, BAX, BBIO, BIIB, BIO, BMY, BTSG, CAPR, CI, COR, CORT, CTNM, CVS, DXCM, GEHC, GH, GILD, GKOS, GRAL, HUM, IBRX, ICLR, ILMN, IMVT, IQV, JNJ, KYMR, LH, LLY, LONA, MCK, MDGL, MDLN, MMSI, MRK, MRNA, MTD, NBIX, NVO, OMCL, OPCH, PFE, PODD, PTCT, QURE, REGN, REPL, ROIV, RVTY, SMTI, SNY, SYK, TAK, TDOC, TEM, TRAX, VCYT, VEEV, VKTX, VRTX, WAY, +APMD...(more)	show story hide story
30-Jul-2026 16:55	CMS finalizes FY2027 payment and policy changes for Hospices; rates +2.3% vs +2.4% proposed CMS issued a final rule (CMS-1851-F) that would update Medicare hospice payments and the aggregate cap amount for fiscal year (FY) 2027 under existing statutory and regulatory requirements. For FY 2027, CMS updated the hospice payment rate by +2.3% (an estimated increase of $755M in payments from FY 2026). This figure results from the finalized +3.2% inpatient hospital market basket percentage increase reduced, as required by law, by a finalized (0.9%) productivity adjustment. StreetAccount notes the final rate increase for FY26 was +2.6% vs +2.4% proposed. See Related StreetAccount comments: 4/2/2026 5:13:34 PM - CMS proposes FY2027 payment and policy changes for Hospices; rates +2.4% Related: ADUS, AVAH, CHE, EHC, PNTG, UNH...(more) Reference Link: CMS-1851-F (160pp) Reference Link: Fact Sheet	show story hide story
30-Jul-2026 16:50	CMS finalizes FY2027 payment and policy changes for Inpatient Rehabilitation Facility (IRF); rates +2.3% vs +2.4% proposed CMS issued a final rule that updates Medicare payment policies and rates for inpatient rehabilitation facilities under the Inpatient Rehabilitation Facilities (IRF) Prospective Payment System (PPS) and the IRF Quality Reporting Program (QRP) for fiscal year (FY) 2027. For FY 2027, CMS finalized an update to the IRF PPS payment rates of +2.3% based on an IRF market basket update of +3.2%, less a (0.9%) productivity adjustment. CMS estimates the final technical rate setting changes would result in an estimated increase in IRF payments of $340M for FY 2027. StreetAccount notes the final rate increase for FY26 was +2.6% vs +2.6% proposed. See Related StreetAccount comments: 4/2/2026 4:27:18 PM - CMS proposes FY2027 payment and policy changes for Inpatient Rehabilitation Facility (IRF); rates +2.4% Related: CYH, EHC, HCA, THC Reference Link: Fact Sheet Reference Link: CMS-1845-F (137pp)	show story hide story
30-Jul-2026 11:04	StreetAccount Summary - Healthcare Midday Trading Healthcare is underperforming with the S&P 500 Healthcare Index (2.41%) vs the S&P 500 +0.94%. Most major health groups are red on the session; Biotech widely mixed with earnings updates, but small-caps are catching a bid to keep the XBI afloat. Breadth actually positive on the XBI +0.76%. ALNY (27%) after guidance reset underpins the ETF. Decliners are led today by Pharma with the DRG (3.00%). SNY (7%) dragging down the Drug Index despite the Q2 beat-and-raise; new CEO emphasizes need for disciplined BD and M&A focus to return to growth. LLY and JNJ also down (4%) on the session. Outlier is BMY +1% on Q2 viewed strong operationally. BAX +16%, also on earnings, and VEEV (5%) bracket the XLV. Gainers +29.1% CORT (Corcept Therapeutics): earnings +15.8% BAX (Baxter International): earnings; best performer on XLV +14.2% TRAX (First Tracks Biotherapeutics Inc): best performer on XBI; on avg volume; shares +134% MTD +12.0% SMTI (Sanara MedTech): acquired by MDGX for $35/shr +9.0% GRAL (GRAIL, Inc.): diagnostics outperforming, turn weekly declines around; second-best on XBI +7.3% GH (Guardant Health): diagnostics outperforming, turn weekly declines around +5.7% IBRX (ImmunityBio): MAA in UAE +5.6% GKOS (Glaukos): earnings +1.9% REGN (Regeneron): earnings +1.6% BMY (Bristol Myers Squibb): earnings Decliners -51.5% CAPR (Capricor Therapeutics): FDA panel vote against; downgrades; worst performer on XBI -27.6% TDOC (Teladoc Health): earnings -26.1% ALNY (Alnylam Pharmaceuticals): earnings, guidance; second-worst on XBI -15.7% WAY (Waystar Holding): earnings -12.8% MDGL (Madrigal Pharmaceuticals): earnings -9.9% OMCL (Omnicell): earnings -6.7% SNY (Sanofi): earnings -5.2% VEEV (Veeva Systems): worst performer on XLV; shares remain +6% WTD -4.9% IQV (IQVIA Holdings): shares remain +13% WTD -4.7% GEHC (GE HealthCare Technologies): shares remain +13% WTD -4.5% PODD (Insulet): shares back to even WTD -4.2% AMRX (Amneal Pharmaceuticals): earnings -3.7% LLY (Eli Lilly): shares turn red WTD -3.7% VKTX (Viking Therapeutics): earnings -3.5% JNJ (Johnson & Johnson): shares turn red WTD -3.1% ALGN (Align Technology): earnings -3.1% CI (Cigna Group): earnings -2.2% BBIO (BridgeBio Pharma): sympathy to ALNY	show story hide story
30-Jul-2026 09:12	BMY Bristol Myers Squibb posts Q2 beat; pipeline delays temper enthusiasm ($63.10) BMY shares pressured despite reporting Q2 EPS ahead of FactSet expectations, with revenue also above consensus, driven by upside across both its growth and legacy portfolios. The company also raised its FY26 EPS and revenue guidance. Takeaways caution that the beat was largely driven by the legacy portfolio, led by Eliquis, with the majority of the guidance increase also attributable to legacy products approaching or already facing loss of exclusivity. Delays to the LIBREXIA-AF readout and the ADEPT study in AD psychosis were largely anticipated, though they are seen as adding uncertainty around the pipeline and tempering what was otherwise viewed as a strong quarter operationally. See Related StreetAccount comments: 7/30/2026 7:12:46 AM - StreetAccount Metrics Recap - Bristol Myers Squibb Q2 Earnings 7/30/2026 7:02:35 AM - Bristol Myers Squibb reports Q2 EPS $2.04 vs FactSet $1.60 [23 est, $1.48-1.68]	show story hide story
30-Jul-2026 08:50	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar heaviest yet for the Q2 season. Broad range of reports across the sector and market caps. Teladoc with a mixed Q2 last night, noted a cash pay decline beyond internal assumptions. Shares of TDOC (21%) in the pre-market. SMID-cap biotechs volatile on launch / sales updates. Alnylam Pharma trims FY outlook for Amvuttra in the second-line setting after another quarter under the belt. Shares of ALNY (23%) in the pre-market. Corcept Therapeutics reported strong initial quarter sales for Lifyorli. CFO told investors that inventory was not a big factor either. Share of CORT +18% in the pre-market. Baxter margins handily beat consensus, topline also widely beat. Shares of BAX +15% in the pre-market. FDA panel voted 9-3 against the one voting question - evidence of efficacy in the treatment of cardiomyopathy in DMD patients. Shares of CAPR resumed, trading down another (55%). CTGTAC turns attention to Replimmune's BLA today. Shares of REPL are halted ahead of the meeting. CMS published final PPS rules for IPF and SNF, both matching their respective proposed growth rates of +2.3% and +2.4%. Macro S&P futures are up +0.7% on Thursday morning, near best levels. Market dealing with a number of moving pieces. Big tech earnings takeaways mixed, including when it comes to AI capex ROI/monetization debate. Elsewhere, Fed continues to get a lot of attention in terms of the upward post-FOMC pressure on longer-term yields related to reaction function uncertainty. Middle East another area of focus. US launched retaliatory strikes on Iran though also headlines about the two sides still talking and a pickup in SoH traffic. When it comes to momentum unwind, recent focus has been on much cleaner positioning and oversold conditions, though also uncertainty surrounding de-leveraging/pain trade dynamics and the recent traction behind some of the more cautious leaning inputs for the fundamental narrative. Pre-market trading update Trading higher +17.5% CORT earnings +15.1% BAX earnings +10.4% SMTI acquired by MDGX for $35/shr +8.0% GKOS earnings (low volume) +6.7% IBRX MAA in UAE +5.8% AMRX earnings +2.8% REGN earnings +1.4% BMY earnings +0.1% VKTX earnings (low volume) +0.0% REPL shares halted for FDA Adcom today Trading lower -55.4% CAPR shares remain halted; FDA panel vote against; downgrades -22.5% ALNY earnings -20.7% TDOC earnings -5.3% ALGN earnings -4.2% CI earnings -3.4% SNY earnings -1.0% OPCH follow-through; downgraded at Deutsche Bank -0.6% LEGN follow-through -0.4% HUM follow-through; downgraded at Raymond James, upgraded at Evercore Pharma Earnings: BMY reports Q2 EPS $2.04 vs FactSet $1.60 on revenue $12.97B vs FS $11.74B. Raises FY26 EPS guidance by $0.675 at the midpoints, and revenue by $2.75B at the midpoints. Conf. call at 8:15ET SNY reports Q2 business EPS €2.09 vs consensus €1.90 on net sales €11.60B vs consensus €10.85B. Raises FY26 sales outlook to around 10% CER vs prior HSD. Conf. call at 7:00ET TAK reports Q1 net income attributable ¥113.20B vs FactSet ¥73.25B on revenue ¥1.220T vs FactSet ¥1.150T. Maintains FY (Mar 27) guidance. Conf. call at 6:00ET AMRX reports Q2 EPS $0.30 ex-items vs FactSet $0.22 on revenue $796.2M vs FS $768.2M, adj EBITDA $206.5M vs FS $177.4M. Raises FY26 EPS guidance by $0.01, revenue by $50M, and adj EBITDA by $10M at the midpoints. Conf. call at 8:30ET Biotech Regulatory: CAPR Post-close on Wednesday, FDA panel voted 9-3 against for the one voting question, evidence of efficacy for the treatment of cardiomyopathy in DMD patients. (4516.JP) Earnings: REGN reports Q2 EPS $14.29 ex-items vs FactSet $10.16 on revenue $4.29B vs FS $3.82B. Sanofi collaboration products drove the beat. Dupixent sales (recorded by Sanofi) beat by nearly 11%. Narrows FY expense guidance, raises FY gross margin guide by 100bps. Conf. call at 8:30ET ALNY reports Q2 GAAP EPS $1.21 vs FactSet $1.63 on revenue $1.29B vs FS $1.32B. Lowers FY net product guidance by $200M at the midpoints, after demand normalized for Amvuttra in 2L segment. Conf. call at 8:30ET MDGL reports Q2 EPS ($1.99) s FactSet ($2.68) on revenue $364.2M vs FS $352.1M. Cash & equivalents $838.9M as of 30-Jun. Notes milestone of 50,000 patients on Rezdiffra achieved this month. Building out MASH pipeline. Conf. call at 8:00ET CORT reports Q2 EPS $0.36 on revenue $256.1M vs FactSet $221.1M Quick Take: A strong Lifyorli launch prompted many to materially increase their PT, noting a potentially underappreciated commercial opportunity for the drug. Commentary is also constructive on the strong rebound in Korlym sales, with demand continuing to strengthen. The Dec 2026 PDUFA for relacorilant in Cushing's syndrome remains the next key catalyst, with views mixed on the outcome as some expect approval, while others see risk of a potential CRL. VKTX reports Q2 results including cash & equivalents $502M at 30-Jun. Research: CAPR downgraded at Cantor Fitzgerald, HC Wainwright, Ladenburg Thalmann, Oppenheimer, Piper Sandler. LONA upgraded to market outperform from market perform at Citizens (Jason Butler), cites factors including pipeline expansion. Target os $18 or approx. 156% upside. QURE upgraded to outperform at Wolfe Research (Rudy Li), target is $65 or approx. 62% upside. (FactSet average PT $66; range $37-95) ACTU initiated buy at Rodman & Renshaw (Michael King), target is $6 or approx. 456% upside. (FactSet average PT $10l range $5-15) ALNY resumed outperform at Bernstein (Jeffrey Walch), target is $429 or approx. 50% upside (FactSet average PT $437; range $285-551) BIIB resumed outperform at Bernstein (Jeffrey Walch), target is $236 or approx. 13% upside. CTNM initiated outpeform at LifeSci Capital (Guarav Maini), target is $24 or approx. 67% upside. (FactSet average PT $22; range $16-28) IMVT resumed market perform at Bernstein (Jeffrey Walch), target is $37 or approx. 4% downside. KYMR initiated hold at Deutsche Bank (David Hoang), target is $120 or approx. 14% upside. (FactSet average PT $127; range $97-155) REGN resumed market perform at Bernstein (Jeffrey Walch), target is $753 or approx. 8% upside. ROIV resumed outperform at Bernstein (Jeffrey Walch), target is $41 or approx. 25% upside. VRTX resumed outperform at Bernstein (Jeffrey Walch), target is $608 or approx. 26% upside. Life Science & MedTech Earnings: BAX reports EPS $0.56 ex-items vs FactSet $0.37 on revenue $2.96B vs FS $2.80B. Margins beat handily. Raises FY EPS guidance by $0.10 at the midpoints, revenue growth guidance now +3-4% vs prior flat to +1%. Conf. call at 8:30ET ICLR reported Q2 EPS $2.56 ex-items vs FactSet $2.55 on revenue $2.06B vs FS $2.00B, adj EBITDA $327.2M vs FS $322.3M. Reaffirms FY26 guidance top and bottom. Conf. call at 8:00ET ALGN reported Q2 EPS $2.64 ex-items vs FactSet $2.62 on revenue $1.06B vs FS $1.05B. Aligner volume increased 7.4% y/y to 691.8K cases. GKOS reported Q2 EPS ($0.31) vs FactSet ($0.21) on revenue $185.6M vs FS $150.9M. Raises FY revenue outlook by $62.5M at the midpoints. WAY reported Q2 NG EPS $0.43 vs FactSet $0.40 on revenue $319.7M vs FactSet $316.2M, adj EBITDA $136.7M vs FS $131.1M. Raises FY26 EPS guidance by 2c, adj EBITDA by $5M, and the low-end of revenue guidance. ADPT reported Q2 EPS ($0.25) vs FactSet ($0.13) on revenue $71.6M vs FS $65.4M. Raises FY26 outlook for MRD business revenue by $8M. M&A: SMTI acquired by MDXG for $35/shr in cash and stock, or total enterprise value $350M. Services & Hospitals Regulatory: CMS finalizes Skilled Nursing Facility (SNF) PPS rate for FY2027, an increase of +2.4% vs +2.4% as proposed. CMS finalizes Inpatient Psychiatric Facility (IPF) PPS rate for FY2027, and increase of +2.3% vs +2.3% as proposed. Earnings: LH reports Q2 EPS $4.99 ex-items vs FactSet $4.78 on revenue $3.73B vs FS $3.71B. Raises FY EPS outlook by $0.45 at the midpoints, revenue outlook by $45M at the midpoints. Conf. call at 9:00ET Research: OPCH downgraded to hold from buy at Deutsche Bank (Pito Chickering), follows Q2 results. Target cut to $24 from $26 (FactSet average PT $28; range $22-39) Managed Care Earnings: CI reports Q2 EPS $7.78 ex-items vs FactSet $7.60 on revenue $71.67B vs FS $70.14B. MLR 84.5% vs StreetAccount 85.0%. Raises FY26 EPS outlook, and now expects FY MLR down 100bps to 83.7%. Conf. call at 8:30ET Research: HUM downgraded to market perform from outperform at Raymond James (Parker Snure) HUM upgraded to outperform from market perform at Leerink Partners (Whit Mayo), notes valuation. Target increased to $513 from $255 or approx. 40% upside. On Deck: Regulatory FDA Adcom: CTGTAC to review REPL vusolimogene oderparepvec (RP1) for advanced melanoma Shares are halted Earnings after the close today SYK (call at 16:30ET), DXCM (call at 16:30ET), ILMN (call at 16:30ET), MTD (call Fri at 7:30ET), GH (call at 16:30ET), NBIX (call at 16:30ET), TEM (call at 16:30ET), PTCT (call at 16:30ET), MMSI (call at 16:30ET), ALHC (call at 17:00ET), VCYT (call at 16:30ET) Earnings tomorrow Fri 31-Jul: before ABBV (call at 9:00ET), MRNA (call at 8:00ET), BTSG (call at 8:30ET) Syndicate / IPO pricing post-close +APMD (Apnimed) potential pricing of IPO - S-1A - Sole product candidate in the clinic: AD109 (Oxnimbi) for obstructive sleep apnea (OSA). This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4516.JP, ABBV, ACTU, ADPT, ALGN, ALHC, ALNY, AMRX, BAX, BIIB, BMY, BTSG, CAPR, CI, CORT, CTNM, DXCM, GH, GKOS, HUM, IBRX, ICLR, ILMN, IMVT, KYMR, LEGN, LH, LONA, MDGL, MDXG, MMSI, MRNA, MTD, NBIX, OPCH, PTCT, QURE, REGN, REPL, ROIV, SMTI, SNY, SYK, TAK, TDOC, TEM, VCYT, VKTX, VRTX, WAY, +APMD...(more)	show story hide story
30-Jul-2026 07:43	CORT Corcept Therapeutics higher following a strong Lifyorli launch ($92.95) CORT shares +20.2% premarket after reporting Q2 EPS above FactSet consensus, with revenue well ahead of expectations. Raised FY26 revenue guidance. A strong Lifyorli launch prompted many to materially increase their PT, noting a potentially underappreciated commercial opportunity for the drug. Commentary is also constructive on the strong rebound in Korlym sales, with demand continuing to strengthen. The Dec 2026 PDUFA for relacorilant in Cushing's syndrome remains the next key catalyst, with views mixed on the outcome as some expect approval, while others see risk of a potential CRL. See Related StreetAccount comments: 7/29/2026 4:10:49 PM - Corcept Therapeutics reports Q2 EPS $0.36 vs year-ago $0.29	show story hide story
29-Jul-2026 17:20	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed to moderately lower overall on Wednesday. At the market close, decliners narrowly outnumbered advancers on the XLV. Healthcare (0.61%) vs S&P 500 (1.52%). Most major health groups ended lower for the session. Not surprising that earnings were the primary source of newsflow, with the market turning over on the FOMC headlines in the final hours. MedTech was today's leading advancer; Managed Care the leading decliner. GEHC +12.2% and HUM (6.0%) both on earnings, consistently bracketed the XLV with many more moderate moves in between - including BSX (0.0%) after recovering from its worst levels of the morning. Investors digest management comments on H2 growth and a lack of visibility for 2027. SMID-cap biotech remained a drag with the XBI (1.25%) ending around session lows. Shares of CAPR, down (67%) WTD were halted throughout today's Adcom. Patient representative Buddy with another poignant line of questioning. Panel voted post-close. HIMS (14.7%) hit by another negative headline - yet another FTC lawsuit, which management called baseless. Earnings calendar ramp the primary focus. Last night, Acadia Healthcare reported a Q2 beat with only the low-end of FY guidance raised. Today, Boston Scientific with a Q2 beat, but attention is on the H2 outlook with lowered FY guidance as WATCHMAN and EP issues addressed by management on the call. Healthcare coming off a strong performance on Tuesday with just one modest decliner on the XLV, beneficiary of the market rotation away from AI. Sector broadly outperforming WTD, with the exception of Biotech, the FDA Advisory Committee stocks dragging on the XBI. Macro Stocks lower in very choppy post-FOMC trading a lot of Fed-related moving pieces. Chair Warsh press conference offered very few takeaways, though both stock and bond market volatility may reflect uncertainty around Fed's reaction function, lack of forward guidance. Treasuries rallied at front-end (market now pricing ~28 bp of hikes through year-end, down from 41 bp just before decision) though long-end sold off sharply. Early economist reads said three dissents more than expected, and that increasingly hawkish composition could put pressure on Warsh in meetings ahead, though markets still pricing ~53% chance of September hike, little changed from pre-meeting. Momentum ultimately lower in choppy trading; came after SKHY miss, another weak SK session overnight. Other areas of focus included lack of rotational/broadening move to offset momentum weakness, HF deleveraging/degrossing and much cleaner positioning in AI/tech trade, and ramp in US/Iran tensions (overnight US-Iran attacks, Trump threats to hit Iran hard after last night's "surprise" attacks, oil rally). Latest earnings takeaways focused on mixed tech/AI ecosystem commentary and high bar (BE, KLAC, NXPI), more cautious staples results, and weak household/capital goods/building materials updates. In addition, MSFT and META report after the close. Notable Gainers +22.0% MPLT (MapLight Therapeutics): best performer on XBI; insider purchase; follow-through, off 52-week low, shares remain (58%) WTD +15.8% AVTR (Avantor): earnings +14.0% NEO (NeoGenomics): earnings +13.9% ALVO (Alvotech): update on FDA inspection +12.2% GEHC (GE HealthCare Technologies): earnings; best performer on XLV +9.6% TEVA (Teva Pharmaceutical): earnings; sympathy to ALVO +9.3% QURE (uniQure NV): earnings; second-best on XBI +8.1% MASS (908 Devices): initiation +6.5% OPCH (Option Care Health): earnings +5.3% XRAY (Dentsply Sirona): sell-side comments on ADA dental survey +5.2% NVST (Envista Holdings): sell-side comments on ADA dental survey; shares on track for second-best daily gain in 2026 +3.3% VEEV (Veeva Systems): second-best on XLV; shares higher fourth straight day +2.6% ALGN (Align Technology): sell-side comments on ADA dental survey +1.8% BIIB (Biogen): earnings Notable Decliners -17.3% OPK (Opko Health): follow-through, shares were +34% yesterday -16.5% IART (Integra LifeSciences Holdings): earnings -16.3% ACHC (Acadia Healthcare): earnings -14.7% HIMS (Hims & Hers Health): FTC lawsuit over data/privacy -6.3% IRWD (Ironwood Pharmaceuticals): worst performer on XBI; stock lower 12 of last 15 sessions -6.0% HUM (Humana): earnings; worst performer on XLV -4.3% ALKS (Alkermes): follow-through, shares were (4%) yesterday -4.0% OCGN (Ocugen): despite RMAT designation -3.3% CNC (Centene): follow-through; sympathy to HUM -3.1% CVS (CVS Health): sympathy to HUM -2.5% ELV (Elevance Health): sympathy to HUM -2.3% IONS (Ionis Pharmaceuticals): earnings -1.4% FTRE (Fortrea Holdings): earnings Humana trades lower after MLR seen underwhelming HUM reports Q2 EPS $7.61 ex-items vs FactSet $7.26 on revenue $40.87B vs FS $40.57B. MLR 91.1% matching StreetAccount consensus. Reaffirms FY EPS guidance, MA membership growth, and MLR guide. Stock upgraded at BofA and Evercore, in reaction Boston Scientific volatile following downbeat call tone BSX reports Q2 EPS $0.86 ex-items vs FactSet $0.83 on revenue $5.44B vs FS $5.36B. Organic growth ahead of StreetAccount consensus, driven by CV beat. Margins slightly ahead too. Guides Q3 EPS and revenue growth below consensus. Lowers FY26 EPS outlook by 9.5c at the midpoints, and lowers revenue growth outlook to +5.5-6.5% or (175) bps at the midpoints. On the call: On the guidance reduction: One, US WATCHMAN has slowed sharply and unexpectedly; and Two, US EP competition greater than anticipated. WATCHMAN global growth flat to LSD, with H2 declining mid- to high-single digits y/y in the US. EP global growth seen flat to up LSD, flat in the US. Expects US EP performance to improve in H2 of 2027. Additional earnings in MedTech GEHC reports Q2 EPS $1.13 ex-items vs FactSet $1.04 on revenue $5.30B as reported on 23-Jul. Reaffirms FY26 guidance top to bottom. AVTR reports Q2 EPS $0.21 ex-items vs FactSet $0.19 on revenue $1.69B vs FS $1.61B. Raises low-end of FY26 EPS guidance by 3c, and at the midpoint by 1.5c. Now expects organic revenue (0.5%) to +0.5% vs prior (2.5%) to (0.5%). BLCO reports Q2 EPS $0.15 ex-items vs FactSet $0.15 on revenue $1.39B vs FS $1.37B. Raises FY26 revenue outlook by the $20M outperformance in Q2; also notes softer FX tailwind. Teva Pharma higher despite mixed Q2 print; focus on growth TEVA reports Q2 EPS $0.02 ex-items vs FactSet $0.05 on revenue $4.14B vs FS $4.02B, adj EBITDA $474M vs FS $424.4M. Reaffirms FY26 EPS and adj EBITDA outlook. Revenue guide tweaks higher. Two additional indications for TL1a duvakitug - HS and FSCD (ROIV, SYRE, ABSI) Earnings in Biotech BIIB reports Q2 $3.60 ex-items vs FactSet $2.94 on revenue $2.74B vs FS $2.46B. Raises FY26 EPS guidance by 60c at the midpoints. Now expects revenue growth MSD vs prior MSD decline and FS +1.7% IONS reports Q2 EPS ($0.69) vs FactSet ($1.08) on revenue $268M vs FS $189.1M. Announces CSO Bennett to retire. Earnings in Services OPCH reports Q2 adj EBITDA $117.5M vs FactSet $113.2M on revenue $1.44B vs FS $1.42B, EPS $0.45 ex-items vs FS $0.43. Reaffirms FY26 revenue guide, but lowers high-end of FY26 adj EBITDA outlook by $10M, and raises low-end of EPS guide by 3c. ACHC reported Q2 EPS $0.38 ex-items vs FactSet $0.35 on revenue $865.8M vs FS $844.2M. Raises low-end of FY26 guidance top to bottom; EPS midpoint up $0.05/shr. CHE reported Q2 EPS $6.06 ex-items vs FactSet $5.60 on revenue $673.3M vs FS $665.0M. Raises FY26 EPS guidance by $1.00/shr. Notable research in Healthcare today Biotech: 4516.JP (Nippon Shinyaku) initiated underperform at BofA (Koichi Mamegano), target is ¥2800 or approx. 21% downside. (FactSet average PT ¥4625; range ¥2600-8600) MedTech: AVTR upgraded to hold from underperform at Jefferies (Tycho Peterson), follows Q2 results. Target increased to $13 from $7 or approx. 9% downside. (FactSet average PT $12; range $7-19) LNTH downgraded to hold from buy at Brookline Capital Markets (Kemp Dolliver), target remains $105 or approx. 2% upside. (FactSet average PT $113; range $98-129) MASS initiated buy at Roth Capital (Max Masucci), target is $11 or approx. 56% upside. Managed Care: HUM upgraded to buy from neutral at BofA (Kevin Fischbeck), target increased to $500 from $410 or approx. 29% upside. (FactSet average PT $352; range $195-502) HUM upgraded to outperform from in line at Evercore ISI (Elizabeth Anderson), cites improved LT outlook and upside from Stars. Target increased to $480 from $430 or approx. 32% upside. (FactSet average PT $356; range $195-502) Post-close news Regulatory: CAPR FDA panel votes 9-3 against for the one voting question, evidence of efficacy for the treatment of cardiomyopathy in DMD patients. (4516.JP) Shares of CAPR remain halted CMS finalizes Skilled Nursing Facility (SNF) PPS rate for FY2027, an increase of +2.4% vs +2.4% as proposed. CMS finalizes Inpatient Psychiatric Facility (IPF) PPS rate for FY2027, and increase of +2.3% vs +2.3% as proposed. M&A: SMTI acquired by MDXG for $35/shr in cash and stock, or total enterprise value $350M. Shares trading +7.6% in the after-hours Earnings: ICLR reports Q2 EPS $2.56 ex-items vs FactSet $2.55 on revenue $2.06B vs FS $2.00B, adj EBITDA $327.2M vs FS $322.3M. Reaffirms FY26 guidance top and bottom. Conf. call tomorrow at 8:00ET Shares trading +3.9% in the after-hours ALGN reports Q2 EPS $2.64 ex-items vs FactSet $2.62 on revenue $1.06B vs FS $1.05B. Aligner volume increased 7.4% y/y to 691.8K cases. Conf. call at 16:30ET Shares trading (9.6%) in the after-hours CORT reports Q2 EPS $0.36 on revenue $256.1M vs FactSet $221.1M Conf. call at 17:00ET Shares trading +18.4% in the after-hours GKOS reports Q2 EPS ($0.31) vs FactSet ($0.21) on revenue $185.6M vs FS $150.9M. Raises FY revenue outlook by $62.5M at the midpoints. Conf. call at 17:00ET Shares trading +7.3% in the after-hours VKTX reports Q2 results including cash & equivalents $502M at 30-Jun. Conf. call at 16:30ET Shares trading +1.1% in the after-hours WAY reports Q2 NG EPS $0.43 vs FactSet $0.40 on revenue $319.7M vs FactSet $316.2M, adj EBITDA $136.7M vs FS $131.1M. Raises FY26 EPS guidance by 2c, adj EBITDA by $5M, and the low-end of revenue guidance. Conf. call at 16:30ET Shares trading (4.7%) in the after-hours ADPT reports Q2 EPS ($0.25) vs FactSet ($0.13) on revenue $71.6M vs FS $65.4M. Raises FY26 outlook for MRD business revenue by $8M. Conf. call at 16:30ET Shares trading +0.1% in the after-hours Research: QURE upgraded to outperform at Wolfe Research (Rudy Li), target is $65 or approx. 62% upside. (FactSet average PT $66; range $37-95) On Deck: Regulatory FDA Adcom: CTGTAC to review REPL vusolimogene oderparepvec (RP1) for advanced melanoma Earnings tomorrow: before BMY (call at 8:15ET), SNY (call at 7:00ET), CI (call at 8:30ET), REGN (call at 8:30ET), TAK (call at 6:00ET), ALNY (call at 8:30ET), LH (call at 9:00ET), MDGL (call at 8:00ET), BAX (call at 8:30ET), AMRX (call at 8:30ET) after SYK (call at 16:30ET), DXCM (call at 16:30ET), ILMN (call at 16:30ET), MTD (call Fri at 7:30ET), GH (call at 16:30ET), NBIX (call at 16:30ET), TEM (call at 16:30ET), PTCT (call at 16:30ET), MMSI (call at 16:30ET), ALHC (call at 17:00ET), VCYT (call at 16:30ET) Syndicate / potential IPO pricing post-close Thursday +APMD (Apnimed) potential pricing of IPO - S-1A - Sole product candidate in the clinic: AD109 (Oxnimbi) for obstructive sleep apnea (OSA). This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4516.JP, ABSI, ACHC, ADPT, ALGN, ALHC, ALKS, ALNY, ALVO, AMRX, AVTR, BAX, BIIB, BLCO, BMY, BSX, CAPR, CHE, CI, CNC, CORT, CSU, CTRE, CVS, CYH, DXCM, ELV, ENSG, FTRE, GEHC, GH, GKOS, HCA, HIMS, HUM, IART, ICLR, ILMN, IONS, IRWD, LH, LNTH, LTC, MASS, MDGL, MDXG, MMSI, MPLT, MTD, NBIX, NEO, NHC, NHI, NVST, OCGN, OPCH, OPK, PTCT, QURE, REGN, REPL, ROIV, SBRA, SMTI, SNY, SYK, SYRE, TAK, TEM, TEVA, THC, UHS, VCYT, VEEV, VKTX, WAY, XRAY, +APMD...(more)	show story hide story
29-Jul-2026 16:37	CMS finalizes FY2027 payment and policy changes for Skilled Nursing Facilities (SNF); rates +2.4% vs +2.4% proposed CMS issued the final rule that updates Medicare payment policies and rates for skilled nursing facilities under the Skilled Nursing Facility (SNF) Prospective Payment System (PPS) for fiscal year (FY) 2027. For FY 2027, CMS finalized updating SNF PPS rates by +2.4% based on the final SNF market basket of 3.3%, reduced by a (0.9%) productivity adjustment, for an estimated increase of $882.74M in aggregate payments to SNFs. StreetAccount notes the proposed rate increase in April was also +2.4%. For FY2026, the CMS finalized +3.2% vs proposed +2.8%. See Related StreetAccount comments: 4/2/2026 5:36:20 PM - CMS proposes FY2027 payment and policy changes for Skilled Nursing Facilities (SNF); rates +2.4% Related: CSU, CTRE, ENSG, LTC, NHC, NHI, SBRA...(more) Reference Link: Fact Sheet Reference Link: CMS-1843-F	show story hide story
29-Jul-2026 16:32	CMS finalizes FY2027 payment and policy changes for Inpatient Psychiatric Facility (IPF); rates +2.3% vs +2.3% proposed CMS issued a final rule to update Medicare payment policies and rates for Inpatient Psychiatric Facilities (IPFs) under the IPF Prospective Payment System (PPS) (CMS-1847-F) for fiscal year (FY) 2027. For FY 2027, CMS is updating the IPF PPS payment rates by +2.3%. based on the 2021-based IPF market basket increase of 3.2% less a (0.9%) productivity adjustment. Additionally, CMS is updating the outlier threshold so that estimated outlier payments remain at 2% of total IPF PPS payments. The overall economic impact of this final rule is an estimated $60M in increased payments to IPFs during FY 2027. StreetAccount notes the proposed rate increase in April was also +2.3%. For FY2026, the CMS finalized +2.4% vs proposed +2.4%. See Related StreetAccount comments: 4/2/2026 5:40:16 PM - CMS proposes FY2027 payment and policy changes for Inpatient Psychiatric Facilities (IPF); rates +2.3% Related: ACHC, CYH, HCA, THC, UHS Reference Link: Fact Sheet Reference Link: CMS-1847-F	show story hide story
29-Jul-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.11% vs the S&P 500 (0.76%). Major health groups are loosely mixed on the session. Not surprising that earnings calendar the primary source of newsflow. MedTech leading advancer; Biotech and Managed Care are leading decliners. GEHC +12% and HUM (7%) bracket the XLV with more moderate moves in between, including BSX (flat) recovering from worst pre-market levels. Investors digesting management comments on H2 growth and a lack of visibility for 2027. SMID-cap biotech remains a drag with the XBI (1.65%). BIIB +4% an outlier with evidence of sales growth coming from outside core MS. Gainers +21.3% MPLT (MapLight Therapeutics): best performer on XBI; follow-through, off 52-week low, (59%) WTD +17.4% NEO (NeoGenomics): earnings +13.9% ALVO (Alvotech): update on FDA inspection +12.6% AVTR (Avantor): earnings +11.9% GEHC (GE HealthCare Technologies): earnings; best performer on XLV +9.8% MASS (908 Devices): initiation +8.7% TEVA (Teva Pharmaceutical): earnings; sympathy to ALVO +6.4% NVST (Envista Holdings): sell-side comments on ADA dental survey; shares on track for second-best daily gain in 2026 +6.3% OPCH (Option Care Health): earnings +6.2% QURE (uniQure NV): earnings; second-best on XBI +4.9% AXGN (AxoGen): earnings; minority stake in Trace Bio with RoFR +4.6% BIIB (Biogen): earnings; second-best on XLV +3.2% XRAY (Dentsply Sirona): sell-side comments on ADA dental survey +2.6% ALGN (Align Technology): sell-side comments on ADA dental survey +0.7% FTRE (Fortrea Holdings): earnings +0.0% CAPR (Capricor Therapeutics): shares halted during FDA Adcom; down (67%) WTD Decliners -14.5% OPK (Opko Health): follow-through, shares were +34% yesterday -12.5% ACHC (Acadia Healthcare): earnings -10.0% IART (Integra LifeSciences Holdings): earnings -6.5% HUM (Humana): earnings; worst performer on XLV -5.6% REPL (Replimune Group): worst performer on XBI; follow-through; shares (48%) WTD -0.3% BSX (Boston Scientific): earnings; mgmt comments on H2 outlook	show story hide story
29-Jul-2026 08:44	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar ramping again, with key reports in all major groups. Wednesday morning brings reports in Large-cap MedTech, Diversified MCO, Large-cap Biotech, LifeSci, and Specialty Pharma. Last night, Acadia Healthcare reported a Q2 beat with only the low-end of FY guidance raised. Shares of ACHC +1% in the pre-market, coming back in from early declines. Boston Scientific with a Q2 beat, but attention is on the H2 outlook with lowered FY guidance as WATCHMAN and EP issues addressed by management on the call. Shares of BSX (7%) in the pre-market. Healthcare coming off a strong performance on Tuesday with just one modest decliner on the XLV, beneficiary of the market rotation away from AI. Sector broadly outperforming WTD, with the exception of Biotech, the FDA Advisory Committee stocks dragging on the XBI. Shares of Capricor Therapeutics, down (67%) WTD, halted ahead of today's Adcom meeting. Macro S&P futures are down (0.1%) on Wednesday morning, coming off best levels. AI trade showing some signs of stabilization despite SKHY miss and a ~6% pullback in South Korea's Kospi overnight. However, more discussion about the HF meaningful deleveraging and de-grossing that has taken place and much cleaner positioning. Equities back to ignoring geopolitics despite the bounce in oil and higher yields following renewed kinetic activities in the Middle East, including Iranian attacks on three oil tankers in the Middle East. Lower oil/yields had seemed to provide some additional support for the broadening out/rotation trade over the last couple of sessions. Big pickup in earnings activity overnight with some of the usual (positive) suspects in focus from a thematic perspective, including AI compute/capex boom and consumer resilience. Today's focus will be on the Fed, particularly with the elevated uncertainty into the meeting (despite fairly widespread expectations for a hawkish hold). In addition, MSFT and META report after the close Pre-market trading update Trading higher +10.7% NEO earnings +10.1% GEHC earnings +9.6% AVTR earnings +6.2% QURE earnings +6.0% TEVA earnings +4.6% OPCH earnings +3.4% ROIV sympathy to TEVA comments on TL1A +3.1% FTRE earnings +1.0% ABSI sympathy to TEVA comments on TL1A +0.6% ACHC earnings (low volume) Trading lower -6.6% BSX earnings; mgmt comments on H2 outlook -3.8% HUM earnings -1.9% SYRE sympathy to TEVA comments on TL1A -0.8% CLOV sympathy to HUM (low volume) Pharma Earnings: TEVA reports Q2 EPS $0.02 ex-items vs FactSet $0.05 on revenue $4.14B vs FS $4.02B, adj EBITDA $474M vs FS $424.4M. Reaffirms FY26 EPS and adj EBITDA outlook. Revenue guide tweaks higher. Two additional indications for TL1a duvakitug - HS and FSCD (ROIV, SYRE, ABSI) Conf. call at 8:00ET Regulatory: VTRS announced FDA approval of Gwyn Lo once-weekly contraceptive patch with low-dose estrogen. PDUFA goal date for the MR-100A-01 NDA was Thursday 30-Jul. Biotech Earnings: BIIB reports Q2 $3.60 ex-items vs FactSet $2.94 on revenue $2.74B vs FS $2.46B. Raises FY26 EPS guidance by 60c at the midpoints. Now expects revenue growth MSD vs prior MSD decline and FS +1.7% Conf. call at 8:30ET IONS reports Q2 EPS ($0.69) vs FactSet ($1.08) on revenue $268M vs FS $189.1M. Announces CSO Bennett to retire. Conf. call at 8:30ET Life Science & MedTech Earnings: BSX reports Q2 EPS $0.86 ex-items vs FactSet $0.83 on revenue $5.44B vs FS $5.36B. Organic growth ahead of StreetAccount consensus, driven by CV beat. Margins slightly ahead too. Guides Q3 EPS and revenue growth below consensus. Lowers FY26 EPS outlook by 9.5c at the midpoints, and lowers revenue growth outlook to +5.5-6.5% or (175) bps at the midpoints. Conf. call at 8:00ET On the call: On the guidance reduction: One, US WATCHMAN has slowed sharply and unexpectedly; and Two, US EP competition greater than anticipated. WATCHMAN global growth flat to LSD, with H2 declining mid- to high-single digits y/y in the US. EP global growth seen flat to up LSD, flat in the US. Expects US EP performance to improve in H2 of 2027. GEHC reports Q2EPS $1.13 ex-items vs FactSet $1.04 on revenue $5.30B as reported on 23-Jul. Reaffirms FY26 guidance top to bottom. Conf. call at 8:30ET AVTR reports Q2 EPS $0.21 ex-items vs FactSet $0.19 on revenue $1.69B vs FS $1.61B. Raises low-end of FY26 EPS guidance by 3c, and at the midpoint by 1.5c. Now expects organic revenue (0.5%) to +0.5% vs prior (2.5%) to (0.5%). Conf. call at 8:00ET BLCO reports Q2 EPS $0.15 ex-items vs FactSet $0.15 on revenue $1.39B vs FS $1.37B. Raises FY26 revenue outlook by the $20M outperformance in Q2; also notes softer FX tailwind. Conf. call at 8:00ET Research: LNTH downgraded to hold from buy at Brookline Capital Markets (Kemp Dolliver), target remains $105 or approx. 2% upside. (FactSet average PT $113; range $98-129) MASS initiated buy at Roth Capital (Max Masucci), target is $11 or approx. 56% upside. Services & Hospitals Earnings: OPCH reports Q2 adj EBITDA $117.5M vs FactSet $113.2M on revenue $1.44B vs FS $1.42B, EPS $0.45 ex-items vs FS $0.43. Reaffirms FY26 revenue guide, but lowers high-end of FY26 adj EBITDA outlook by $10M, and raises low-end of EPS guide by 3c. Conf. call at 8:30ET ACHC reported Q2 EPS $0.38 ex-items vs FactSet $0.35 on revenue $865.8M vs FS $844.2M. Raises low-end of FY26 guidance top to bottom; EPS midpoint up $0.05/shr. Conf. call at 9:00ET CHE reported Q2 EPS $6.06 ex-items vs FactSet $5.60 on revenue $673.3M vs FS $665.0M. Raises FY26 EPS guidance by $1.00/shr. Conf. call at 10:00ET Managed Care Earnings: HUM reports Q2 EPS $7.61 ex-items vs FactSet $7.26 on revenue $40.87B vs FS $40.57B. MLR 91.1% matching StreetAccount consensus. Reaffirms FY EPS guidance, MA membership growth, and MLR guide. Conf. call at 8:00ET On Deck: Conference (cont.): BTIG Biotechnology Conference (Jul 28-29) Regulatory FDA Adcom: CTGTAC to review CAPR deramiocel BLA for CM in DMD (4516.JP) Share of CAPR halted today on Thu 30-Jul: FDA Adcom: CTGTAC to review REPL vusolimogene oderparepvec (RP1) for advanced melanoma Earnings after the close today ICLR (call Thu at 8:00ET), ALGN (call at 16:30ET), CORT (call at 17:00ET), GKOS (call at 16:30ET), VKTX (call at 16:30ET), WAY (call at 16:30ET), ADPT (call at 16:30ET) Earnings tomorrow Thu 30-Jul: before BMY (call at 8:15ET), SNY (call at 7:00ET), CI (call at 8:30ET), REGN (call at 8:30ET), TAK (call at 6:00ET), ALNY (call at 8:30ET), LH (call at 9:00ET), MDGL (call at 8:00ET), BAX (call at 8:30ET), AMRX (call at 8:30ET) after SYK (call at 16:30ET), DXCM (call at 16:30ET), ILMN (call at 16:30ET), MTD (call Fri at 7:30ET), GH (call at 16:30ET), NBIX (call at 16:30ET), TEM (call at 16:30ET), PTCT (call at 16:30ET), MMSI (call at 16:30ET), ALHC (call at 17:00ET), VCYT (call at 16:30ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ABSI, ACHC, ADPT, ALGN, ALHC, ALNY, AMRX, AVTR, BAX, BIIB, BLCO, BMY, BSX, CHE, CI, CLOV, CORT, DXCM, FTRE, GEHC, GH, GKOS, HUM, ICLR, ILMN, IONS, LH, LNTH, MASS, MDGL, MMSI, MTD, NBIX, NEO, OPCH, PTCT, QURE, REGN, REPL, ROIV, SNY, SYK, SYRE, TAK, TEM, TEVA, VCYT, VKTX, VTRS, WAY...(more)	show story hide story
28-Jul-2026 16:57	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished as best performing sector on Tuesday. Just one modest decliner on the XLV; CNC (0.3%) nearly recovered from its early fall. Healthcare +2.33% vs S&P 500 +0.21%. Busy day of newsflow. Most major health groups higher by +2% to 3% on the session, led by Services, and followed by MedTech, Pharma and Managed Care. Diversified MCOs widely outperformed their Medicaid peers amid broader market rotation away from AI and into value pockets. CNC almost fully recovered from morning lows, lone decliner on the XLV following today's Q2 beat-and-raise, before shares tumbled as much as (9%) on Medicaid membership comments. Universal Health higher on earnings, while peers HCA +7.3% and THC +7.9% nearly doubled UHS +4.3%. Biotech the only declining group. REPL (38.0%), negative briefing docs, and CAPR (6.1%) day-two digestion of briefing docs, weighed on the XBI (0.54%). Large-cap biotech rallied however, INCY +9.3%, on earnings related updates. AMGN +4.5% a top-4 session this year. IQV +13.9% however lead all gainers on the XLV following its Q2 print, another beat-and-raise quarter for the CRO subgroup. Takeaways encouraged by booking trends; peers all rallied in reaction. Medical devices also fared well today. UBS out with bullish research coverage in the space with multiple upgrades, including a double upgrade for ZBH +4.0%. Large-cap pharma was led by SNY +3.5% and GSK +3.3%, the latter on a Q2 beat-and-reffirm; JNJ +0.3% positive, but a notable laggard relative to the DRG +1.71%, on the promise of talc resolution. Earnings calendar ramping again, with key reports in all major groups. Tuesday morning brings reports in Pharma, Biotech, LifeSci/CRO, and Managed Medicaid. Last night, Universal Health Systems reported a mixed Q2 with forward guidance raised on the topline but lowered on the bottom line. Ahead of Wednesday's report, Boston Scientific disclosed a global restructuring plan, with substantial amount of savings to be reinvested in strategic growth initiatives. JNJ announced a proposed resolution of remaining MDL litigation (talc) with a $5.5B commitment. Macro Tuesday's price action defined by sizable rotation/broadening move, as another big momentum drag offset by upside from select Big Tech, pockets of cyclicals. Momentum selloff continues to reflect fears around AI capex/ROI, open-weight/China competition, circularity. Not much new around the narrative Tuesday, though increased equity/debt supply, rising CDS rates, cautious signaling from SPCX post-IPO performance (though shares stabilizing today), and technical factors among latest areas of scrutiny, while GLW/AMKR/CARR post-earnings selloffs adding to extremely high bar narrative. Some dovish updates around Iran a tailwind to risk sentiment, including reports mediators believe they are nearing breakthrough for deal. Market also somewhat in waiting mode ahead of this week's Mag 7 earnings (META, MSFT Wednesday, AAPL, AMZN Thursday), Wednesday's FOMC decision. Rate rally driven by latest fall in oil prices, but several economist previews continue to note a Fed hike not off the table (and some outright calls for hikes) despite some easing war risks. Notable Gainers +33.9% OPK (Opko Health): earnings +25.3% KNSA (Kiniksa Pharmaceuticals): earnings +14.2% RGEN (Repligen Corp.): earnings +12.3% IQV (IQVIA Holdings): earnings; 52-week high; best performer on XLV +11.5% MPLT (MapLight Therapeutics): follow-through; downgraded at Morgan Stanley; best performer on XBI +10.7% OSCR (Oscar Health): sympathy to CNC +10.4% PRLD (Prelude Therapeutics): sympathy to INCY +9.9% INCY (Incyte): earnings; second-best on XLV and the XBI +8.4% FTRE (Fortrea Holdings): sympathy to IQV +7.4% ATEC (Alphatec Holdings): initiated at UBS +7.3% PLSE (Pulse Biosciences): sympathy to BSX +6.8% ICLR (ICON plc): sympathy to IQV +6.2% SOLV (Solventum Corp.): initiation at UBS (upgrade) +5.7% THC (Tenet Healthcare): sympathy to UHS +5.6% HCA (HCA Healthcare): sympathy to UHS +5.5% CRL (Charles River Laboratories): sympathy to IQV; 52-week high +4.2% BAX (Baxter International): initiation at UBS +4.2% ZBH (Zimmer Biomet Holdings): initiation at UBS (double upgrade) +4.0% AMGN (Amgen): 52-week high +3.6% BDX (Becton Dickinson): initiation at UBS +3.4% GSK (GSK Plc): earnings +3.2% MDT (Medtronic): initiation at UBS (upgrade) +2.9% UHS (Universal Health Services): earnings +2.3% ISRG (Intuitive Surgical): shares were +6% yesterday +2.1% GOSS (Gossamer Bio): follow-through; upgraded at Leerink +1.7% ELV (Elevance Health): sympathy to CNC +1.4% DHR (Danaher): sympathy to RGEN +0.5% JNJ (Johnson & Johnson): talc settlement proposal Notable Decliners -38.0% REPL (Replimune Group): FDA publishes briefing documents for VO; worst performer on XBI -15.1% OTLK (Outlook Therapeutics): on >2X average daily volume; shares (39%) since FDA approval of Lytenava -8.3% KURA (Kura Oncology): follow-through; second-worst on XBI -6.9% SLS (SELLAS Life Sciences Group, Inc.): update on arbitration; guides cash EOQ2 -6.3% PRAX (Praxis Precision Medicines): on average volume; shares even YTD -6.1% CAPR (Capricor Therapeutics): follow-through; Adcom tomorrow -5.0% LNTH (Lantheus Holdings): media report, Curium in talks to acquire -4.2% SMMT (Summit Therapeutics): 52-week low -4.2% ALKS (Alkermes): earnings -3.0% HIMS (Hims & Hers Health): follow-through -0.3% CNC (Centene): earnings; Medicaid membership guidance; lone decliner on XLV -0.1% SYRE (Spyre Therapeutics): downgraded at Wolfe Research Earnings in LifeSci / CRO subgroup IQV reported Q2 EPS $3.15 ex-items vs FactSet $3.03 on revenue $4.37B vs FactSet $4.30B, and adj EBITDA $994M vs FactSet $964.5M. Raises FY26 EPS guidance by $0.10, revenue by $125M, adj EBITDA by $25M, all at the midpoints. RGEN reported Q2 EPS $0.54 ex-items vs FactSet $0.45 on revenue $204.1M vs FS $201.6M. Raises FY26 guidance top and bottom, and organic revenue growth outlook by 100bps at the midpoints. Centene shares give back gains after Medicaid membership update CNC reports Q2 EPS $2.51 ex-items vs FactSet $1.08 on revenue $53.58B vs FS $47.64B. Q2 HBR 89.6% vs StreetAccount 91.2%. Raises FY26 financial guidance, and lowers FY HBR outlook by 40bps at the midpoints. Quick take: The magnitude of the guidance increase exceeds most investors' expectations, reinforcing confidence that the earnings recovery is sustainable. Q2 upside is attributed to Medicaid, driven by improved expense management, normalizing acuity trends, and favorable rate increases, while commentary on margin recovery remains constructive. However, some point out that the commercial MLR beat is driven in part by a one-time Marketplace risk adjustment true-up. On the call: "we expect full year Medicaid membership to be down (8%) to (9%) .. versus our prior view of being down (6%)" Hospitals higher following UHS print UHS reported Q2 adj EBITDA $677.9M vs StreetAccount $681.2M, EPS $5.98, on revenue $4.64B vs FS $4.58B. Lowers FY26 adj EBITDA outlook by $51.5M, raises revenue by $28.5M, and lowers EPS by $0.615 - all at the midpoints. Quick take: Sentiment muted on what is being generally described as a modest EBITDA miss, driven by weakness in Acute. Discussion noted new facilities (including Cedar Hill) weighed on results - though Acute SS metrics relatively strong in the period. Lowered FY guidance also weighing on shares, as drag from Q2 headwinds, along with lower volume assumptions in both segments resulting in lowered targets for EPS and adjusted EBITDA. On the call at 9:00 ET, investors will be listening for additional commentary around volume assumptions for H2 and trajectory of EBITDA growth, with some suggesting new lowered targets still appear aggressive given Q2 new facility drag and lower volume expectations. GSK leads the DRG higher on Q2 beat-and-reffirm GSK reported Q2 Core EPS 50.5p vs consensus 47.1p on revenue £8.41B vs consensus £8.24B. Reaffirms FY26 guidance and five-year sales outlook. Boston Scientific provides update before the Q2 print BSX discloses via 8-K a new global restructuring plan, to initiate in 2026 and complete by the end of 2029. Company expects a substantial amount of the savings to be reinvested in strategic growth initiatives. Company scheduled to report Q2 earnings on Wednesday morning; call at 8:00ET SMID-cap biotech headlines ALKS reported Q2 EPS $0.00 vs FactSet ($0.03) on revenue $496.0M vs FS $457.4M. Lowers FY26 outlook for net income, and revenue below consensus at the midpoint. INCY reported Q2 EPS $3.09 ex-items on revenue $1.67B vs FactSet $1.50B. Reports net sales $1.49B vs FS $1.28B. Raises FY26 net sales guidance. Discontinues development of '0058, instead will prioritize a program partnered with PRLD. REPL FDA published briefing documents ahead of Thursday Adcom for VO. Agency tone remains negative on efficacy and safety. Notable research in Healthcare today Biotech: CAPR downgraded to neutral from buy at Alliance Global Partners (Matthew Venezia), target cut to $7 from $51. GOSS upgraded to outperform from market perform at Leerink Partners (Joseph Schwartz), target remains $1 or approx. 400% upside. MPLT downgraded to equal-weight from overweight at Morgan Stanley (Sean Laaman), target cut to $21 from $34 or approx. 112% upside. (FactSet average PT $32; range $20-52) SYRE downgraded to peer perform from outperform at Wolfe Research (Andy Chen) BNTC initiated outperform at Wedbush Securities FTH initiated outperform at Oppenheimer (Jay Olson), target is $60 or approx. 129% upside. MDCX initiated buy at AGP RAPP initiated outperform at William Blair TENX initiated buy at Canaccord Genuity MedTech: PODD assumed neutral at UBS (Patrick Wood), prior rating was buy. Analyst also assumes coverage of BBNX, DXCM, and TNDM and initiated coverage on MMED with a buy rating, target is $25 or approx. 41% upside. UBS analyst Patrick Wood initiates coverage on seven names in medical devices (4 buy, 3 neutral) and assumes coverage on another twelve (9 buy, 2 neutral, 1 sell (INSP) UBS analyst Patrick Wood initiates coverage on six names in the vision subgroup (2 buy, 3 neutral, 1 sell (STAA). Services: FME.GR (FMS) downgraded to underperform from neutral at BNP Paribas Exane (Hugo Solvet), target increased to €35 from €34.50 or approx. 20% downside. (FactSet average PT €42; range €31-59) PGNY downgraded to equal weight from overweight at Barclays (Peter Warendorf), target increased however to $34 from $27 or approx. 8% upside. (FactSet average PT $34; range $27-40) Post-close news Earnings: ACHC reports Q2 EPS $0.38 ex-items vs FactSet $0.35 on revenue $865.8M vs FS $844.2M. Raises low-end of FY26 guidance top to bottom; EPS midpoint up $0.05/shr. Conf. call tomorrow at 9:00ET Shares trading (2.1%) in the after-hours CHE reports Q2 EPS $6.06 ex-items vs FactSet $5.60 on revenue $673.3M vs FS $665.0M. Raises FY26 EPS guidance by $1.00/shr. Conf. call tomorrow at 10:00ET Shares trading +1.5% in the after-hours On Deck: Conference (cont.): BTIG Biotechnology Conference (Jul 28-29) Earnings tomorrow before BSX (call at 8:00ET), HUM (call at 8:00ET), TEVA (call at 8:00ET), BIIB (call at 8:30ET), GEHC (call at 8:30ET), IONS (call at 8:30ET), AVTR (call at 8:00ET), BLCO (call at 8:00ET), OPCH (call at 8:30ET) after ICLR (call Thu at 8:00ET), ALGN (call at 16:30ET), CORT (call at 17:00ET), GKOS (call at 16:30ET), VKTX (call at 6:30ET), WAY (call at 16:30ET), ADPT (call at 16:30ET) Regulatory FDA Adcom: CTGTAC to review CAPR deramiocel BLA for CM in DMD This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACHC, ADPT, ALGN, ALKS, AMGN, ATEC, AVTR, BAX, BBNX, BDX, BIIB, BLCO, BNTC, BSX, CAPR, CHE, CNC, CORT, CRL, DHR, DXCM, ELV, FME.GR, FTH, FTRE, GEHC, GKOS, GOSS, GSK, HCA, HIMS, HUM, ICLR, INCY, INSP, IONS, IQV, ISRG, JNJ, KNSA, KURA, LNTH, MDCX, MDT, MPLT, OPCH, OPK, OSCR, OTLK, PGNY, PLSE, PODD, PRAX, PRLD, RAPP, REPL, RGEN, SLS, SMMT, SOLV, STAA, SYRE, TENX, TEVA, THC, TNDM, UHS, VKTX, WAY, ZBH...(more)	show story hide story
28-Jul-2026 11:00	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +2.52% vs the S&P 500 (0.05%). Major health groups widely mixed on their averages. Upside coming from Services and Pharma, followed by MedTech. UHS +2% on earnings, while peers HCA and THC up twice as much +4%. Managed Care skewed lower by CNC (9%), leading decliner on the XLV after Q2 beat-and-raise, shares tumbling on Medicaid membership comments. Diversified MCOs trading mixed to flattish. Biotech the other key decliner. REPL (31%), negative briefing docs, and CAPR (15%) day two post-docs, weighing on the XBI (1.68%). Large-cap biotech rallying however, AMGN and INCY +5%, the latter on earnings related updates. IQV +12% leading all gainers on the XLV following its Q2 print, another beat-and-raise quarter for the CRO subgroup. Medical devices also faring better today. UBS with bullish research coverage in the space with multiple upgrades and a double upgrade for ZBH +6%. Pharma led by GSK +5% on the Q2 beat-and-reffirm; JNJ +2% higher on the promise of talc resolution, though broader DRG is up similarly. Gainers +32.3% OPK (Opko Health): earnings +19.8% PRLD (Prelude Therapeutics): sympathy to INCY +13.4% RGEN (Repligen Corp.): earnings +12.6% IQV (IQVIA Holdings): earnings; 52-week high; best performer on XLV +7.6% GOSS (Gossamer Bio): follow-through; upgraded at Leerink +6.7% SOLV (Solventum Corp.): initiation at UBS (upgrade); second-best on XLV +5.6% CRL (Charles River Laboratories): sympathy to IQV; 52-week high +5.4% INCY (Incyte): earnings; best performer on XBI +5.2% ZBH (Zimmer Biomet Holdings): initiation at UBS (double upgrade) +5.2% GSK (GSK Plc): earnings +5.0% BAX (Baxter International): initiation at UBS +5.0% BDX (Becton Dickinson): initiation at UBS +5.0% AMGN (Amgen): 52-week high; second-best on XBI +4.9% MDT (Medtronic): initiation at UBS (upgrade) +3.3% ISRG (Intuitive Surgical): shares were +6% yesterday +2.5% JNJ (Johnson & Johnson): talc settlement proposal +2.1% UHS (Universal Health Services): earnings +1.9% DHR (Danaher): sympathy to RGEN Decliners -31.0% REPL (Replimune Group): FDA publishes briefing documents for VO; worst performer on XBI -15.8% OTLK (Outlook Therapeutics): on heavy volume -15.2% CAPR (Capricor Therapeutics): follow-through; second-worst on XBI -11.8% SLS (SELLAS Life Sciences Group, Inc.): update on arbitration; guides cash EOQ2 -8.6% CNC (Centene): earnings; Medicaid membership guidance; worst performer on XLV -7.6% HIMS (Hims & Hers Health): follow-through -6.0% LNTH (Lantheus Holdings): media report, Curium in talks to acquire -5.9% MOH (Molina Healthcare): sympathy to CNC -5.8% SYRE (Spyre Therapeutics): downgraded at Wolfe Research -5.6% PRAX (Praxis Precision Medicines): shares just +1% YTD -3.9% MRNA (Moderna): second-worst on XLV -3.5% ALKS (Alkermes): earnings -0.9% ELV (Elevance Health): sympathy to CNC	show story hide story
28-Jul-2026 09:42	CNC Centene shares reverse course after comments on Medicaid membership ($59.92 -$4.16) Conference call excerpt: "We did consider we did continue to see attrition in our Medicaid membership end in Q2 with 12.1 million members, and we expect some states to continue to trim Medicaid rolls leading up to any OB3 implementation in 2027. So for now, we are holding the incremental 50 basis point benefit of the rate improvement to account for a little higher membership attrition in the back half of the year, including the associated acuity impact. To be more specific, we expect full year Medicaid membership to be down (8%) to (9%) .. versus our prior view of being down (6%)." Trading update: CNC (7.5%), MOH (3.6%) See Related StreetAccount comments: 7/28/2026 8:26:04 AM - Centene higher following a Q2 beat/raise Related: MOH	show story hide story
28-Jul-2026 09:22	FDA publishes draft product-specific guidance for certain generic peptide products, including top-selling GLP1s FDA published 17 revised, draft PSG for peptide products that address obesity, type 2 diabetes, osteoporosis, and macular degeneration. The products are: Calcitonin salmon (CALCIMAR, NDA 017769) (SNY) Calcitonin salmon (MIACALCIN, NDA 017808) (VTRS) Dasiglucagon hydrochloride (ZEGALOGUE, NDA 214231) (NVO, ZEAL.DC) Glucagon (BAQSIMI , NDA 210134) (LLY) Glucagon (GLUCAGON, NDA 020928) (LLY) Glucagon (GVOKE, NDA 212097) (XERS) Liraglutide (Victoza , NDA 022341) (NVO) Liraglutide (Saxenda , NDA 206321) (NVO) Pegcetacoplan (SYFOVRE , NDA 217171) (BIIB) Pegcetacoplan (EMPAVELI , NDA 215014) (BIIB) Semaglutide (Ozempic , NDA 209637) (NVO) Semaglutide (WEGOVY , NDA 215256) (NVO) Teriparatide (FORTEO , NDA 021318) (LLY) Teriparatide (TERIPARATIDE, NDA 218771) (ALVO) Tirzepatide (MOUNJARO , NDA 215866) (LLY) Tirzepatide (ZEPBOUND , NDA 217806) (LLY) Vosoritide (VOXZOGO , NDA 214938) (BMRN) Related: ALVO, BIIB, BMRN, LLY, NVO, SNY, VTRS, XERS, ZEAL.DC...(more) Reference Link	show story hide story
28-Jul-2026 08:59	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar ramping again, with key reports in all major groups. Tuesday morning brings reports in Pharma, Biotech, LifeSci/CRO, and Managed Medicaid. Shares mostly little changed in reaction however. Last night, Universal Health Systems reported a mixed Q2 with forward guidance raised on the topline but lowered on the bottom line. Shares of UHS (3%) in the pre-market. Ahead of Wednesday's report, Boston Scientific disclosed a global restructuring plan, with substantial amount of savings to be reinvested in strategic growth initiatives. Shares of BSX +1% in the pre-market. JNJ announced a proposed resolution of remaining MDL litigation (talc) with a $5.5B commitment. Share of JNJ +2% in the pre-market. Macro S&P futures are little changed on Tuesday morning, however Nasdaq futures down (0.8%). Big story continues to revolve around momentum weakness with the AI trade under scrutiny. Blame has been attributed to both technical and (often intertwined) fundamental factors. When it comes to latter, recent focus has been on elevated hyperscaler capex, circular financing, widening credit spreads, open-model momentum and China competition. However, some cushion from a broadening out trade that has been helped thus far this week by lower oil and bond yields. Oil pullback a function of recent pause in kinetic hostilities in the Middle East that has put some hope back around the escalate to de-escalate narrative (diplomatic efforts focused on reopening SoH). Quiet elsewhere as market continues to look ahead to FOMC on Wednesday afternoon, MSFT and META after the close on Wednesday and AAPL and AMZN after the close on Thursday. Pre-market trading update Trading higher +36.9% GOSS follow-through; upgraded at Leerink +21.9% PRLD sympathy to INCY +11.2% IQV earnings +10.1% ALT trial results in alcohol use disorder (AUD); call at 8ET +7.2% OPK earnings +5.3% RGEN earnings (low volume) +2.4% ISRG shares were +6% yesterday +2.0% JNJ talc settlement proposal +1.6% GSK earnings +1.3% CNC earnings Trading lower -20.8% REPL FDA publishes briefing documents for VO -5.2% ALKS earnings -4.9% INSP initiation -3.9% LNTH media report, Curium in talks to acquire -3.8% PHG follow-through -3.3% UHS earnings -3.3% PGNY downgrade -2.3% OTLK on heavy volume -1.3% STAA initiation -0.7% INCY earnings Pharma Earnings: GSK reports Q2 Core EPS 50.5p vs consensus 47.1p on revenue £8.41B vs consensus £8.24B. Reaffirms FY26 guidance and five-year sales outlook. Conf. call at 9:00ET Litigation: JNJ announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms in the MDL. The proposed resolution includes payments of $5.5B, bringing "finality to this meritless 15-year litigation". Biotech Earnings: ALKS reports Q2 EPS $0.00 vs FactSet ($0.03) on revenue $496.0M vs FS $457.4M. Lowers FY26 outlook for net income, and revenue below consensus at the midpoint. INCY reports Q2 EPS $3.09 ex-items on revenue $1.67B vs FactSet $1.50B. Reports net sales $1.49B vs FS $1.28B. Raises FY26 net sales guidance. Discontinues development of '0058, instead will prioritize a program partnered with PRLD. Regulatory: REPL FDA publishes briefing documents ahead of Thursday Adcom for VO. Agency tone remains negative on efficacy and safety. Research: CAPR downgraded to neutral from buy at Alliance Global Partners (Matthew Venezia), target cut to $7 from $51. GOSS upgraded to outperform from market perform at Leerink Partners (Joseph Schwartz), target remains $1 or approx. 400% upside. MPLT downgraded to equal-weight from overweight at Morgan Stanley (Sean Laaman), target cut to $21 from $34 or approx. 112% upside. (FactSet average PT $32; range $20-52) SYRE downgraded to peer perform from outperform at Wolfe Research (Andy Chen) BNTC initiated outperform at Wedbush Securities FTH initiated outperform at Oppenheimer (Jay Olson), target is $60 or approx. 129% upside. MDCX initiated buy at AGP RAPP initiated outperform at William Blair TENX initiated buy at Canaccord Genuity Life Science & MedTech Earnings: IQV reports Q2 EPS $3.15 ex-items vs FactSet $3.03 on revenue $4.37B vs FactSet $4.30B, and adj EBITDA $994M vs FactSet $964.5M. Raises FY26 EPS guidance by $0.10, revenue by $125M, adj EBITDA by $25M, all at the midpoints. Conf. call at 9:00ET RGEN reports Q2 EPS $0.54 ex-items vs FactSet $0.45 on revenue $204.1M vs FS $201.6M. Raises FY26 guidance top and bottom, and organic revenue growth outlook by 100bps at the midpoints. Conf. call at 8:00ET Corporate: BSX discloses via 8-K a new global restructuring plan, to initiate in 2026 and complete by the end of 2029. Company expects a substantial amount of the savings to be reinvested in strategic growth initiatives. Research: PODD assumed neutral at UBS (Patrick Wood), prior rating was buy. Analyst also assumes coverage of BBNX, DXCM, and TNDM and initiated coverage on MMED with a buy rating, target is $25 or approx. 41% upside. UBS analyst Patrick Wood initiates coverage on seven names in medical devices (4 buy, 3 neutral) and assumes coverage on another twelve (9 buy, 2 neutral, 1 sell (INSP) UBS analyst Patrick Wood initiates coverage on six names in the vision subgroup (2 buy, 3 neutral, 1 sell (STAA). Services & Hospitals Earnings: UHS reported Q2 adj EBITDA $677.9M vs StreetAccount $681.2M, EPS $5.98, on revenue $4.64B vs FS $4.58B. Lowers FY26 adj EBITDA outlook by $51.5M, raises revenue by $28.5M, and lowers EPS by $0.615 - all at the midpoints. Conference call at 9:00ET Quick take: Sentiment muted on what is being generally described as a modest EBITDA miss, driven by weakness in Acute. Discussion noted new facilities (including Cedar Hill) weighed on results - though Acute SS metrics relatively strong in the period. Lowered FY guidance also weighing on shares, as drag from Q2 headwinds, along with lower volume assumptions in both segments resulting in lowered targets for EPS, revenue and adjusted EBITDA. On the call at 9:00 ET, investors will be listening for additional commentary around volume assumptions for H2 and trajectory of EBITDA growth, with some suggesting new lowered targets still appear aggressive given Q2 new facility drag and lower volume expectations. Research: FME.GR (FMS) downgraded to underperform from neutral at BNP Paribas Exane (Hugo Solvet), target increased to €35 from €34.50 or approx. 20% downside. (FactSet average PT €42; range €31-59) PGNY downgraded to equal weight from overweight at Barclays (Peter Warendorf), target increased however to $34 from $27 or approx. 8% upside. (FactSet average PT $34; range $27-40) Managed Care Earnings: CNC reports Q2 Q2 EPS $2.51 ex-items vs FactSet $1.08 on revenue $53.58B vs FS $47.64B. Q2 HBR 89.6% vs StreetAccount 91.2%. Raises FY26 financial guidance, and lowers FY HBR outlook by 40bps at the midpoints. Conf. call at 8:30ET Quick take: The magnitude of the guidance increase exceeds most investors' expectations, reinforcing confidence that the earnings recovery is sustainable. Q2 upside is attributed to Medicaid, driven by improved expense management, normalizing acuity trends, and favorable rate increases, while commentary on margin recovery remains constructive. However, some point out that the commercial MLR beat is driven in part by a one-time Marketplace risk adjustment true-up. On Deck: Earnings after the close today CHE (call Wed at 10:00ET), ACHC (call Wed at 9:00ET Earnings tomorrow Wed 29-Jul: before BSX (call at 8:00ET), HUM (call at 8:00ET), TEVA (call at 8:00ET), BIIB (call at 8:30ET), GEHC (call at 8:30ET), IONS (call at 8:30ET), AVTR (call at 8:00ET), BLCO (call at 8:00ET), OPCH (call at 8:30ET) after ICLR (call Thu at 8:00ET), ALGN (call at 16:30ET), CORT (call at 17:00ET), GKOS (call at 16:30ET), VKTX (call at 16:30ET), WAY (call at 16:30ET), ADPT (call at 16:30ET) Conference BTIG Biotechnology Conference (Jul 28-29) Regulatory on Wed 29-Jul: FDA Adcom: CTGTAC to review CAPR deramiocel BLA for CM in DMD on Thu 30-Jul: FDA Adcom: CTGTAC to review REPL vusolimogene oderparepvec (RP1) for advanced melanoma This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: ACHC, ADPT, ALGN, ALKS, ALT, AVTR, BBNX, BIIB, BLCO, BNTC, BSX, CAPR, CHE, CNC, CORT, DXCM, FME.GR, FTH, GEHC, GKOS, GOSS, GSK, HUM, ICLR, INCY, INSP, IONS, IQV, ISRG, JNJ, LNTH, MDCX, MPLT, OPCH, OPK, OTLK, PGNY, PHG, PODD, PRLD, RAPP, REPL, RGEN, STAA, SYRE, TENX, TEVA, TNDM, UHS, VKTX, WAY...(more)	show story hide story
28-Jul-2026 08:33	UHS Universal Health Services trading lower on Q2 results / weaker than expected adjusted EBITDA ($159.31) UHS (3.4%) pre-market following last night's Q2 release that included EPS $5.98 vs year-ago $5.43; though softer adjusted EBITDA of $677.9M ex-items vs StreetAccount $681.2M weighing on shares. Management also lowered FY guidance targets, now expecting EPS $22.28-23.65 ex-items vs prior guidance $22.64-24.52 on adjusted EBITDA net of NCI $2.610-2.717B vs prior guidance $2.641-2.789B and FactSet $2.70B. Sentiment muted on what is being generally described as a modest EBITDA miss, driven by weakness in Acute. Discussion noted new facilities (including Cedar Hill) weighed on results - though Acute SS metrics relatively strong in the period. Lowered FY guidance also weighing on shares, as drag from Q2 headwinds, along with lower volume assumptions in both segments resulting in lowered targets for EPS and adjusted EBITDA. On the call at 9:00 ET, investors will be listening for additional commentary around volume assumptions for H2 and trajectory of EBITDA growth, with some suggesting new lowered targets still appear aggressive given Q2 new facility drag and lower volume expectations.	show story hide story
28-Jul-2026 08:26	CNC Centene higher following a Q2 beat/raise ($64.08) CNC shares +1.9% premarket after reporting Q2 EPS ahead of FactSet with revenue also ahead and MLR of 89.6% better than SA 91.2%. The company also raised FY26 EPS and revenue guidance. The magnitude of the guidance increase exceeds most investors' expectations, reinforcing confidence that the earnings recovery is sustainable. Q2 upside is attributed to Medicaid, driven by improved expense management, normalizing acuity trends, and favorable rate increases, while commentary on margin recovery remains constructive. However, some point out that the commercial MLR beat is driven in part by a one-time Marketplace risk adjustment true-up. See Related StreetAccount comments: 7/28/2026 6:20:08 AM - StreetAccount Metrics Recap - Centene Q2 Earnings 7/28/2026 6:19:49 AM - Centene reports Q2 EPS $2.51 ex-items vs FactSet $1.08 [20 est, $0.41-1.94]	show story hide story
27-Jul-2026 17:02	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished moderately higher overall on Monday. Advancers beat decliners by nearly 4:1 on the XLV. Healthcare +0.52% vs S&P 500 +0.02%. Moderate gains for almost all major health groups for the session. Managed Care dispatched some early morning softness to finish flat and just inline. ISRG +5.7%, shares remain lower (10%) MTD, and RVTY (2.2%) bracketed the XLV. MedTech the relative outperformer, with Medical devices catching a bid amidst today's risk-on trade. LST names unable to gain much traction, traded more mixed. Biotech ended essentially flat on a choppy session marked by high-premium M&A and fresh FDA insight into a hotly debated drug application. CAPR (64.5%) after FDA briefing documents. FBRX +39.6% acquired by ARGX (%) for around $2.2B. Positive read-across for TRAX +18.3%, shares now +121% YTD. AZN +0.2% the key earnings report on the tape this morning; muted response to a roughly inline print and guidance just maintained. A late-stage clinical failure for AstraZeneca's Ultomiris seen as benefitting OMER +15.8%. Relatively quiet weekend for sector newsflow, with Monday morning M&A returning to Biotech group. Argenx paying $2.2B to acquire Forte Biosciences. Earnings calendar this week ramps significantly, but slowly with only AstraZeneca on the tape Monday morning. Q2 results were mixed, with oncology drug sales light, and company just reaffirmed FY guidance. Regulatory calendar this week highlighted by back to back FDA Adcoms in Biotech. Briefing materials were published Monday morning for Capricor Therapeutics. FDA tone remains negative on efficacy, benefit-risk assessment. Macro Risk sentiment bolstered by pause in kinetic hostilities in the Middle East. Followed some of the dampened traction/hope last week surrounding the escalate to de-escalate narrative. However, still a lot skepticism when it comes to sustainable diplomatic offramps. Oil selloff and lower yield backdrop supportive of the broadening out trade, with select consumer groups, pockets of cyclicals among best performers. Semis under pressure again despite continued support for the AI compute/capex narrative. However, latest headlines \also played into some concerns surrounding circular financing and China competition. Former followed another ramp in scrutiny surrounding elevated hyperscaler capex sustainability. Pretty quiet elsewhere ahead of a big macro and micro week. FOMC the macro highlight on Wednesday with latest flurry of previews highlighting expectations for a hawkish hold. Roughly 35% of S&P market cap reports this week, including four of the Mag 7 names. Notable Gainers +46.6% GOSS (Gossamer Bio): strategic and regulatory updates in PAH +39.6% FBRX (Forte Biosciences): acquired by ARGX for $2.2B in cash +18.3% TRAX (First Tracks Biotherapeutics Inc): sympathy to FBRX; best performer on XBI +15.8% OMER (Omeros): sympathy to AZN trial results +8.0% ZBIO (Zenas BioPharma): second-best performer on XBI +7.7% HIMS (Hims & Hers Health): follow-through, shares down (15%) last week +5.7% ISRG (Intuitive Surgical): risk-on trade, Medical devices rebound; best performer on XLV +5.0% MMED (MiniMed Group): risk-on trade, Medical devices rebound +4.4% VEEV (Veeva Systems): risk-on trade; second-best on XLV +4.4% THC (Tenet Healthcare): on average volume; shares up +20% last week +4.2% BAX (Baxter International): risk-on trade, Medical equipment rebound +4.0% RMD (ResMed): risk-on trade, Medical devices rebound; smpathy to PHG +3.9% RYTM (Rhythm Pharmaceuticals): initiation +2.8% BSX (Boston Scientific): risk-on trade, Medical devices rebound +2.6% DXCM (Dexcom): risk-on trade, Medical devices rebound Notable Decliners -72.9% MPLT (MapLight Therapeutics): trial results in schizophrenia; worst performer on XBI -64.5% CAPR (Capricor Therapeutics): FDA publishes briefing documents ahead of Wed Adcom -24.2% OTLK (Outlook Therapeutics): follow-through; upgraded at BTIG -13.3% LEGN (Legend Biotech): CEO steps dowped down effective 24-Jul -12.4% SCTX (Scribe Therapeutics, Inc.): day two biotech IPO -11.0% REPL (Replimune Group): sympathy to CAPR; ahead of briefing docs tomorrow / Adcom Thursday -5.8% ACHC (Acadia Healthcare): on above average volume -5.3% ASTH (Astrana Health): on below average volume -4.4% CORT (Corcept Therapeutics): downgraded at Wolfe Research -4.4% PHG (Koninklijke Philips): earnings (early release) -4.1% TWST (Twist Bioscience): on below average volume -2.2% RVTY (Revvity): worst performer on XLV -2.1% HUM (Humana): rotation, MCO unwind AstraZeneca slightly higher following Q2 print AZN reports Q2 core EPS $2.63 vs consensus $2.48 on revenue $15.38B vs consensus $15.39B. Maintains FY26 financial guidance. Quick take: A few analysts point out that while there were no updates on key H2 catalysts (namely AVANZAR and SERENA-4) it was confirmed that there should be no delays there. DNB Carnegie says pipeline momentum in the coming 18 months looks strong, including those two key oncology read-outs - both having a sales potential >$5B. Overall, the Q2 results and guidance reiteration mean limited changes to consensus forecasts at this stage. Koninklijke Philips lower on Q2 print; focus on tariff refund PHIA.NA (PHG) results were scheduled for Tuesday morning, but were released early on Monday afternoon. Q2 EPS €0.49 ex-items vs consensus €0.33 on revenue €4.36B vs €4.31B. Raises FY26 EBITDA marginby 100bps to reflect tariff refund benefit. ADRs subsequently halted lower on the NYSE, and resumed lower. Guardant Health lower following Freenome's FDA clearance FRNM FDA approved PMA for SimpleScreen CRC. Decision date 24-Jul-2026. Freenome announces it will received $100M milestone payment from Abbott (ABT) under their existing commercial agreement. (GH) SMID-cap Biotech headlines FBRX acquired by ARGX.BB (ARGX) for $77/shr in cash, or total equity value of $2.2B. CAPR FDA publishes briefing materials ahead of Wednesday's Adcom for deramiocel for CM in DMD Reviewers reiterate the negative stance from the prior CRL - the benefit-risk assessment appears unfavorable in the absence of evidence of effectiveness. Panel to vote on the evidence from Study HOPE-3. LEGN disclosed that CEO Ying Huang stepped down effective 24-July. Aan Bash named interim CEO and the company has begun a comprehensive search process for a permanent successor. SRPT announced that Michael Severino has been appointed CEO effective 28-Jul. Previous CEO at Tessera Therapeutics, and a former exec at AbbVie. The retirement of Doug Ingram was announced in February 2026. FDA approved first NDSRI for treatment of ADHD in adults and children 4578.JP FDA approved first NDSRI, Otsuka's SIMTRIYO (centanafadine), for the treatment of ADHD in adults and pediatric patients. Otsuka expects SIMTRIYO will be available later this year following scheduling by the U.S. DEA. (SUPN) Notable research in Healthcare today Biotech: CAPR downgraded to neutral from buy at B Riley Securities (Madison El-Saadi), target cut to $10 from $63 or approx. 56% upside. CORT downgraded to underperform from peer perform at Wolfe Research (Kalpit Patel) OTLK upgraded to buy from neutral at BTIG (Julian Harrison) notes positive labeling outcome with today's FDA approval of Lytenava, target is $4 or approx. 184% upside. CMPS initiated equal weight at Wells Fargo Securities (Benjamin Burnett), target is $13 or approx. % upside. DFTX initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $68 or approx. 58% upside. GHRS initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $44 or approx. 61% upside. HELP initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $16 or approx. 110% upside. MDGL initiated overweight at Wells Fargo Securities (Sadia Rahman), target is $685 or approx. 26% upside. PLYX initiated buy at Lucid Capital Markets (Dev Prasad), target is $7 or approx. 241% upside. PMN initiated buy at Chardan Capital (Keay Nakae), target is $20 or approx. 64% upside. RYTM initiated overweight at JPMorgan (Priyanka Grover), target is $145 or approx. 42% upside. SMMT transferred buy at Clear Street, rating and $31 PT unchanged. Analyst is Mara Goldstein. MedTech: PROF upgraded to strong buy from outperform at Raymond James (Michael Freeman), target remains $11 or approx. 41% upside. COCH initiated buy at Lucid Capital Markets (Alex Nowak), target is $2 or approx. 203% upside. Post-close news Corporate: BSX discloses via 8-K a new global restructuring plan, to initiate in 2026 and complete by the end of 2029. Company expects a substantial amount of the savings to be reinvested in strategic growth initiatives. Shares trading (0.7%) in the after-hours Earnings: UHS reports Q2 adj EBITDA $677.9M vs StreetAccount $681.2M, EPS $5.98, on revenue $4.64B vs FS $4.58B. Lowers FY26 adj EBITDA outlook by $51.5M, raises revenue by $28.5M, and lowers EPS by $0.615 - all at the midpoints Conference call tomorrow at 9:00ET Shares trading (3.5%) in the after-hours On Deck: Earnings tomorrow: before GSK (call at 9:00ET), IQV (call at 9:00ET), CNC (call at 8:30ET), INCY (call at 8:00ET), ALKS (call at 8:00ET), RGEN (call at 8:00ET) after CHE (call Wed at 10:00ET), ACHC (call Wed at 9:00ET) Earnings on Wed 29-Jul: before BSX (call at 8:00ET), HUM (call at 8:00ET), TEVA (call at 8:00ET), BIIB (call at 8:30ET), GEHC (call at 8:30ET), IONS (call at 8:30ET), AVTR (call at 8:00ET), BLCO (call at 8:00ET), OPCH (call at 8:30ET) after ICLR (call Thu at 8:00ET), ALGN (call at 16:30ET), CORT (call at 17:00ET), GKOS (call at 16:30ET), VKTX (call at 16:30ET), WAY (call at 16:30ET), ADPT (call at 16:30ET) Conference BTIG Biotechnology Conference (Jul 28-29) Regulatory FDA briefing documents ahead of Thu Adcom (REPL) on Wed 29-Jul: FDA Adcom: CTGTAC to review CAPR deramiocel BLA for CM in DMD on Thu 30-Jul: FDA Adcom: CTGTAC to review REPL vusolimogene oderparepvec (RP1) for advanced melanoma This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4578.JP, ABT, ACHC, ADPT, ALGN, ALKS, ARGX.BB, ASTH, AVTR, AZN, BAX, BIIB, BLCO, BSX, CAPR, CHE, CMPS, CNC, COCH, CORT, DFTX, DXCM, FBRX, FRNM, GEHC, GH, GHRS, GKOS, GOSS, GSK, HELP, HIMS, HUM, ICLR, INCY, IONS, IQV, ISRG, LEGN, MDGL, MMED, MPLT, OMER, OPCH, OTLK, PHG, PHIA.NA, PLYX, PMN, PROF, REPL, RGEN, RMD, RVTY, RYTM, SCTX, SMMT, SRPT, SUPN, TEVA, THC, TRAX, TWST, UHS, VEEV, VKTX, WAY, ZBIO...(more)	show story hide story
27-Jul-2026 11:01	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.98% vs the S&P 500 +0.13%. Most major health groups are higher by 1% to begin the week. Managed Care softness a function of the risk-on rotation and unwind of recent momentum. Pharma and MedTech leading all gainers. ISRG +5%, shares were down (15%) MTD, and HUM (2%) bracket the XLV. Biotech in choppy trading, XBI +0.55% but off best levels of the morning. More high-premium M&A, and FDA insight into a highly debated drug are in focus. ARGX (2%) buying FBRX +40% for around $2.2B. Read-across for TRAX +20%; shares now +121% YTD. CAPR (66%) after FDA briefing documents. AZN +2% the key earnings report on the tape; muted response to a roughly inline print and guidance just maintained. Late-stage clinical failure for AstraZeneca's Ultomiris seen benefitting OMER +12%. Gainers +39.5% FBRX (Forte Biosciences): acquired by ARGX for $2.2B in cash +19.5% TRAX (First Tracks Biotherapeutics Inc): sympathy to FBRX; best performer on XBI +11.7% OMER (Omeros): sympathy to AZN trial results +8.7% GOSS (Gossamer Bio): strategic and regulatory updates in PAH +6.1% ZBIO (Zenas BioPharma): second-best performer on XBI +5.5% ISRG (Intuitive Surgical): risk-on trade, Medical devices rebound; best performer on XLV +4.7% VEEV (Veeva Systems): risk-on trade; second-best on XLV +4.4% BSX (Boston Scientific): risk-on trade, Medical devices rebound +4.2% BAX (Baxter International): risk-on trade, Medical equipment rebound +4.0% DXCM (Dexcom): risk-on trade, Medical devices rebound +2.6% SRPT (Sarepta Therapeutics): appoints new CEO +2.1% ABT (Abbott Labs): commercial partner with FRNM +2.0% AZN (AstraZeneca): earnings +0.9% LQDA (Liquidia): shares were +8% last week Decliners -66.4% CAPR (Capricor Therapeutics): FDA publishes briefing documents ahead of Wed Adcom; worst performer on XBI -62.3% MPLT (MapLight Therapeutics): trial results in schizophrenia -20.6% OTLK (Outlook Therapeutics): follow-through; upgraded at BTIG -13.2% REPL (Replimune Group): sympathy to CAPR; ahead of briefing docs tomorrow / Adcom Thursday -13.1% LEGN (Legend Biotech): CEO steps dowped down effective 24-Jul -4.3% CORT (Corcept Therapeutics): downgraded at Wolfe Research -2.2% GH (Guardant Health): read-across from FRNM -2.0% HUM (Humana): rotation, MCO unwind; worst performer on XLV -1.0% CVS (CVS Health): rotation, MCO unwind -0.8% UNH (UnitedHealth Group): rotation, MCO unwind -0.5% FRNM (Freenome): FDA approves PMA for SimpleScreen CRC	show story hide story
27-Jul-2026 08:50	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Relatively quiet weekend for sector newsflow, with Monday morning M&A returning to Biotech group. Argenx paying $2.2B to acquire Forte Biosciences. Shares of FBRX +40% in the pre-market. Earnings calendar this week ramps significantly, but slowly with only AstraZeneca on the tape Monday morning. Q2 results were mixed, with oncology drug sales light, and company just reaffirmed FY guidance. ADRs for AZN up +1% in the pre-market. Regulatory calendar this week highlighted by back to back FDA Adcoms in Biotech. Briefing materials were published Monday morning for Capricor Therapeutics. Shares of CAPR down (60%) as FDA tone remains negative on efficacy, benefit-risk assessment. Macro S&P futures are up +0.9% on Monday morning. Oil down, yields down, stocks up. Market supported by recent pause in hostilities in the Middle East. Headlines have highlighted some semblance of traction behind Omani-led diplomacy efforts, along with US concerns about the effectiveness of additional bombing around the SoH and dwindling munitions. AI also in the headlines with reports about a NVDA backstop for an OpenAI data center lease supportive of both the compute/capex demand and circularity scrutiny narratives. Also more discussion about corporate push to rein in AI costs, including via increased use of open-source models. Memory another big story amid the 466% surge in China's CXMT following its IPO and the push by AAPL (and pushback by MU) for White House approval to utilize China chips. Weekend headlines also continued to focus on the heightened uncertainty surrounding the Fed into this week's policy decision. Pre-market trading update Trading higher +39.6% FBRX acquired by ARGX for $2.2B in cash +26.1% GOSS microcap biotech; strategic and regulatory updates in PAH +13.4% OMER +7.6% FRNM FDA approves PMA for SimpleScreen CRC +7.0% SRPT appoints new CEO +5.7% LQDA shares were +8% last week +2.5% KURA trial results in ccRCC +2.0% GH read-across from FRNM (low volume) +1.8% OTLK follow-through; upgraded at BTIG +1.1% AZN earnings +0.9% ABT commerical partner with FRNM Trading lower -60.9% CAPR FDA publishes briefing documents ahead of Wed Adcom -6.6% LEGN CEO steps dowped down effective 24-Jul -4.2% CORT downgraded at Wolfe Research Pharma Earnings: AZN reports Q2 core EPS $2.63 vs consensus $2.48 on revenue $15.38B vs consensus $15.39B. Maintains FY26 financial guidance. Conf. call at 6:45ET Quick take: A few analysts point out that while there were no updates on key H2 catalysts (namely AVANZAR and SERENA-4) it was confirmed that there should be no delays there. DNB Carnegie says pipeline momentum in the coming 18 months looks strong, including those two key oncology read-outs - both having a sales potential >$5B. Overall, the Q2 results and guidance reiteration mean limited changes to consensus forecasts at this stage. Regulatory: 4578.JP FDA approved first NDSRI, Otsuka's SIMTRIYO (centanafadine), for the treatment of ADHD in adults and pediatric patients. Otsuka expects SIMTRIYO will be available later this year following scheduling by the U.S. DEA. (SUPN) Biotech M&A: FBRX acquired by ARGX.BB (ARGX) for $77/shr in cash, or total equity value of $2.2B. Conf. call at 8:00ET Regulatory: CAPR FDA publishes briefing materials ahead of Wednesday's Adcom for deramiocel for CM in DMD Reviewers reiterate the negative stance from the prior CRL - the benefit-risk assessment appears unfavorable in the absence of evidence of effectiveness. Panel to vote on the evidence from Study HOPE-3. Corporate: LEGN disclosed that CEO Ying Huang stepped down effective 24-July. Aan Bash named interim CEO and the company has begun a comprehensive search process for a permanent successor. SRPT announced that Michael Severino has been appointed CEO effective 28-Jul. Previous CEO at Tessera Therapeutics, and a former exec at AbbVie. The retirement of Doug Ingram was announced in February 2026. Research: OTLK upgraded to buy from neutral at BTIG (Julian Harrison) notes positive labeling outcome with today's FDA approval of Lytenava, target is $4 or approx. 184% upside. CORT downgraded to underperform from peer perform at Wolfe Research (Kalpit Patel) CMPS initiated equal weight at Wells Fargo Securities (Benjamin Burnett), target is $13 or approx. % upside. DFTX initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $68 or approx. 58% upside. GHRS initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $44 or approx. 61% upside. HELP initiated overweight at Wells Fargo Securities (Benjamin Burnett), target is $16 or approx. 110% upside. MDGL initiated overweight at Wells Fargo Securities (Sadia Rahman), target is $685 or approx. 26% upside. PLYX initiated buy at Lucid Capital Markets (Dev Prasad), target is $7 or approx. 241% upside. PMN initiated buy at Chardan Capital (Keay Nakae), target is $20 or approx. 64% upside. RYTM initiated overweight at JPMorgan (Priyanka Grover), target is $145 or approx. 42% upside. SMMT transferred buy at Clear Street, rating and $31 PT unchanged. Analyst is Mara Goldstein. Life Science & MedTech Regulatory: FRNM FDA approved PMA for SimpleScreen CRC. Decision date 24-Jul-2026. Freenome announces it will received $100M milestone payment from Abbott (ABT) under their existing commercial agreement. (GH) Research: COCH initiated buy at Lucid Capital Markets (Alex Nowak), target is $2 or approx. 203% upside. On Deck: Earnings after the close today UHS (call on Tue at 9:00ET) Earnings on Tue 28-Jul: before GSK, IQV, CNC, INCY, ALKS,RGEN after CHE, ACHC Regulatory on Tue 28-Jul: FDA briefing documents ahead of Wed Adcom (REPL) on Wed 29-Jul: FDA Adcom: CTGTAC to review CAPR deramiocel BLA for CM in DMD Conference on Tue 28-Jul: BTIG Biotechnology Conference (Jul 28-29) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4578.JP, ABT, ACHC, ALKS, ARGX.BB, AZN, CAPR, CHE, CMPS, CNC, COCH, CORT, DFTX, FBRX, FRNM, GH, GHRS, GOSS, GSK, HELP, INCY, IQV, KURA, LEGN, LQDA, MDGL, OMER, OTLK, PLYX, PMN, REPL, RGEN, RYTM, SMMT, SRPT, SUPN, UHS...(more)	show story hide story
25-Jul-2026 13:55	4578.JP FDA approves first NDSRI, SIMTRIYO (centanafadine), for the treatment of ADHD in adults and pediatric patients (¥11155) Otsuka announced that the FDA has granted approval of SIMTRIYO (centanafadine), a once-daily extended-release capsule for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older weighing at least 20kg. As the first and only approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), SIMTRIYO introduces a new treatment approach for patients and healthcare professionals managing this complex and highly individualized condition. By inhibiting the reuptake of norepinephrine, dopamine, and serotonin, SIMTRIYO increases the availability of these neurotransmitters in pathways involved in attention and behavioral regulation. Otsuka expects SIMTRIYO will be available later this year following scheduling by the U.S. DEA. The full label, including BOXED WARNING, is available at the link below. StreetAccount notes the approval was on the PDUFA goal date 24-Jul-2026. The boxed warning reflects the dual drug classes - both the class-wide CNS stimulant warning (abuse and addiction), and the class-wide non-stimulant warning (suicidal ideation risk). Reference Link: Press release See Related StreetAccount comments: 7/17/2026 2:45:02 PM - StreetAccount Summary: Notable Drug Events expected for the week of 19-Jul 1/26/2026 7:12:55 PM - FDA accepts for priority review NDA for Otsuka Pharmaceutical's Centanafadine for treatment of ADHD Reference Link: Approved Label	show story hide story
24-Jul-2026 21:43	StreetAccount Sector Summary - Healthcare Weekly Recap Friday synopsis: Healthcare equities finished loosely mixed yet higher overall on Friday. Advancers beat decliners by nearly 2:1 on the XLV. Healthcare +0.64% vs S&P 500 +0.05%. Most major health groups ended flat to higher on the session. Services group remained today's primary supplier of upside with Hospital earnings updates broadly lifting providers, and also helping to shore up rattled sentiment in HCIT and medical devices. Big headline was THC +17.2% print which Leerink called a "masterpiece"; HCA +1.5% print was inline with the ten-day old preannounce. VEEV +3.7% and WST (7.7%) bracketed the XLV. MedTech group was split on the session - devices higher in sympathy with the hospitals, while LST trimmed weekly gains. Biotech joined the pullback in Life Science. MRNA (5.2%) volatile once again. XBI (1.15%) extended its weekly decline to (2.45%). Non-earnings / regulatory headlines: Measles cases YTD in the US have passed the 2025 total; EMA CHMP recommended twelve (12) medicines for approval at the July 2026 meeting ( including one biosimilar and three generics); and MAHA heavy panel tells the FDA how consumers want their peptides. FDA PCAC on Friday recommended two more peptides for inclusion on the compounding list, and narrowly voted against a third, affirming support for 6 of 7 overall. Macro: Rotational dynamics in play in Friday trading. Momentum the big drag as semis, memory both sold off, though offset by upside across select cyclicals/broadening trade. Not much specific behind move though some chatter around still-extended semis positioning, upcoming China's CXMT IPO. Latest Iran updates mixed with reports Trump meeting with advisers today to decide whether to intensity campaign against Iran, offsetting latest diplomatic optimism after reports Pakistan exploring ways to push for talks. However, oil down Friday, possibly signaling easing war-related risk backdrop (Houthi attacks in Red Sea seemingly quieter), while softer crude also a bit of a tailwind to rates Friday. Other areas of focus included renewed tariff threats including Trump threat of tariffs on EU over US tech company fines (though markets mostly playing down broader tariff risk), hawkish Fed into next week's July FOMC meeting (market pricing 42 bp of hikes through year-end, near YTD high), dampened Mag 7 sentiment, rising bond volatility, AI-linked debt concerns. Notable Gainers on Friday: +44.3% SCTX (Scribe Therapeutics, Inc.): biotech IPO (gene editing) +17.2% THC (Tenet Healthcare): earnings; upbeat takeaways +11.1% ORIC (Oric Pharmaceuticals): Cantor Fitzgerald comments on rinzi; best performer on XBI +6.4% OTLK (Outlook Therapeutics): FDA approves Lytevana BLA for wet AMD +6.2% MNKD (MannKind): FDA approves Furoscix sNDA; private placement $50M +4.8% STTK (Shattuck Labs): initiation +3.7% VEEV (Veeva Systems): HCIT sympathy to hospitals; best performer on XLV +3.5% SYK (Stryker): devices sympathy to hospitals +3.4% BAX (Baxter International): medical equipment sympathy to hospitals +3.4% SGRY (Surgery Partners): sympathy to hospitals +3.0% UHS (Universal Health Services): sympthy to hospitals Notable Decliners on Friday: -23.9% ZVRA (Zevra Therapeutics): EMA CHMP negative opinion -14.2% HIMS (Hims & Hers Health): amid Day 2 of compounding Adcom; shares end the week down (15%) -8.8% SMMT (Summit Therapeutics): earnings; stock sales agreement; worst performer on XBI -7.7% WST (West Pharmaceutical Services): worst performer on XLV; follow-through, shares (8%) for the week -6.5% CELC (Celcuity): shares (7%) for the week, follows (18%) last week -5.6% LEGN (Legend Biotech): downgraded at UBS -5.2% MRNA (Moderna): EMA CHMP opinions; shares +83% YTD -3.0% NAMS (NewAmsterdam Pharma): partner Menarini EMA CHMP positive opinion Week in Review: Earnings scorecard: According to FactSet Scorecard, with 8.43% of companies (14 of 166) having reported, 92.86% of the S&P 1500 Health Care (SP567-SPX) have beaten consensus EPS expectations, vs 81.71% last year (Q2 2025), with an average beat of +10.29% vs +8.67% last year. On the topline, 92.86% have beaten sales expectations, vs 82.32% last year (Q2 2025), with an average beat of +1.28% vs +2.56% last year. Healthcare equities outperformed for the week. The S&P 500 Healthcare Index gained +0.83% vs the S&P 500 Index down (0.61%). Outperformers: Pharma, Services Underperformers: Managed Care, Biotech, MedTech Major health groups were mixed for the week. Earnings calendar the primary driver, and the Services group home of the best- and worst-received prints, especially given the setup by HCA's negative preannounce earlier this month. CYH (17%) inline Q2 but lowered FY guidance, while THC +20% reported HIX headwinds better than feared to finish the week. Molina Healthcare (12%) with a mixed print, dragged on both Medicaid- and Marketplace-levered payers. Medical device stocks came under pressure again on the latest hospital prints. LifeSci earnings widely mixed for the week between TMO +7% and DHR (6%). Pharma group buoyed by the JNJ MedTech regulatory win, as Ottava gained clearance in the US. Eli Lilly also reported more registrational data for its triple G agonist, but the submission timeline slipped into Q1 of 2027. President Trump announced that the honeymoon is ending for generic drugs, with 100% tariffs to begin in two years, 1-Aug-2028, rising to 200% on 1-Aug-2029. Major measles milestone this week as YTD cases in 2026 have surpassed the total from 2025. MAHA endorsed peptides took a step towards FDA legitimacy on a panel stacked with Kennedy appointees. Fairly quiet week in Biotech as the XBI dipped (2.45%), a third straight weekly decline, but ended with its first IPO in five weeks. Year-to-date, Healthcare up +4.87% vs the S&P 500 up +8.28%. Healthcare eighth out of eleven major sectors in CY26. Energy +33.02% and Consumer Discretionary (7.96%) bracket them all. Notable movers for the week: Gainers: SCTX +44.3% - biotech IPO #15 of CY26 THC +19.6% - earnings ARWR +15.2% - trial results in sHTG MEDP +11.8% - earnings DGX +8.2% - earnings TMO +6.7% - earnings ARGX +6.7% - earnings A +5.4% - sympathy to TMO JNJ +4.1% - FDA clearance for OTTAVA robotic system LLY +1.4% - trial results for GGG; submission timing slips to Q1 2027 Decliners: TEM (18.6%) - acquired PSNL for $1.5B; stock lower 11 of last 14 days HNGE (14.7%) - shares remain +60% YTD vs XLV +5% HIMS (14.5%) - volatile amid FDA Adcom on peptides MRNA (12.5%) - shares (23%) MTD MOH (12.3%) - earnings RGEN (10.4%) - sympathy to DHR WST (8.4%) - earnings DXCM (6.7%) - weakness in Diabetes Tech space; selected for TEMPO pilot RDY (6.4%) - Trump Tariffs on generic drugs; earnings; downgrades DHR (6.0%) - earnings Week Ahead (Sat - Sun): Jul 25 - Aug 2 Earnings calendar Mon 27-Jul: before AZN after UHS Tue 28-Jul: before GSK, IQV, CNC, INCY, ALKS,RGEN after CHE, ACHC Wed 29-Jul: before BSX, HUM, TEVA, BIIB, GEHC, IONS, AVTR, BLCO, OPCH after ICLR, ALGN, CORT. GKOS, VKTX, WAY, ADPT Thu 30-Jul: before BMY, SNY, CI, REGN, TAK, ALNY, LH, MDGL, BAX, AMRX after SYK, DXCM, ILMN, MTD, GH, NBIX, TEM, PTCT, MMSI, ALHC, VCYT Fri 31-Jul: before ABBV, MRNA, BTSG Corporate calendar Mon 27-Jul: KURA Investor Call to discuss phase 1 data for darlifarnib + cabozantinib in ccRCC (call 8:00ET) Regulatory calendar Mon 27-Jul: FDA briefing documents ahead of Wed Adcom (CAPR) Tue 28-Jul: FDA briefing documents ahead of Wed Adcom (REPL) Wed 29-Jul: FDA Adcom: CTGTAC to review CAPR deramiocel BLA for CM in DMD Thu 30-Jul: FDA Adcom: CTGTAC to review REPL vusolimogene oderparepvec (RP1) for advanced melanoma; FDA PDUFA for VTRS NDA for MR-101A-01 (contraceptive) Conference calendar Tue 28-Jul: BTIG Biotechnology Conference (Jul 28-29)	show story hide story
24-Jul-2026 14:28	StreetAccount Summary: Notable Drug Events expected for the week of 26-Jul Mon 27-Jul Trial results: KURA Ph1 data for darlifarnib + cabozantinib in ccRCC (call 8:00ET) Corporate update: AZN.LN (AZN) earnings call (3:00ET) FDA briefing materials: CAPR CTGTAC to publish materials ahead of the 29-Jul meeting for deramiocel BLA Tue 28-Jul FDA briefing materials: REPL CTGTAC to publish materials ahead of the 30-Jul meeting for vusolimogene oderparepvec BLA Wed 29-Jul Regulatory decisions: NRXP FDA GDUFA for KETAFREE ANDA in suicidal ideation in depression, including bipolar depression Regulatory meeting: CAPR FDA Adcom (CTGTAC) to review deramiocel BLA Thu 30-Jul Regulatory decision: VTRS FDA PDUFA for MR-100A-01 NDA for contraception Regulatory meeting: REPL FDA Adcom (CTGTAC) review vusolimogene oderparepvec BLA Fri 31-Jul Corporate update: ABBV earnings call (9:00ET) also expected July 2026 Trial results: NTHI (Ph2 IDH-mutant glioma), EVMN (Ph 2 AD) Related: ABBV, AZN.LN, CAPR, EVMN, KURA, NRXP, NTHI, REPL, VTRS...(more)	show story hide story
24-Jul-2026 11:14	CDC reports 58 new cases of measles this week, YTD total exceeds 2025 As of 23-Jul, the CDC says 2,318 confirmed cases of measles reported YTD vs 2,260 as of 16-Jul. New cases totaled 58, doubling the cases reported the prior week, and +24% ahead of the trailing four-week average. In under seven months, the US has more confirmed cases than in all of 2025 (2,318 vs 2,289). For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
24-Jul-2026 11:07	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +0.65% vs the S&P 500 +0.25%. Most major health groups are split on the session. Services group source of the upside with Hospital earnings updates broadly lifting providers. THC +21% print which Leerink called a "masterpiece"; HCA +3% print inline with preannounce. UHS +6% and MRNA (5%) bracket the XLV. Breadth on the XLV is narrowing, with Biotech joining the pullback in Life Science, and Payers soft in reaction to the hospitals. XBI (1.33%) extending weekly decline to around (3%). Gainers +20.9% THC (Tenet Healthcare): earnings; call at 1130ET +7.4% SGRY (Surgery Partners): sympathy to THC and HCA +6.0% ARDT (Ardent Health): sympathy to THC and HCA +5.8% UHS (Universal Health Services): sympthy to THC and HCA; best performer on XLV +5.6% ORIC (Oric Pharmaceuticals): Cantor Fitzgerald comments on rinzi; best performer on XBI +4.3% MNKD (MannKind): FDA approves Furoscix sNDA; private placement $50M +3.3% NKTR (Nektar Therapeutics): sympathy to SAN.FP discontinuation +3.2% EHC (Encompass Health): sympathy to THC and HCA +3.2% BAX (Baxter International): second-best on XLV +2.7% EW (Edwards Lifesciences): earnings; upgraded at Leerink +2.7% HCA (HCA Healthcare): earnings +0.5% NAMS (NewAmsterdam Pharma): partner Menarini EMA CHMP positive opinion Decliners -22.0% ZVRA (Zevra Therapeutics): EMA CHMP negative opinion -8.7% SMMT (Summit Therapeutics): earnings; stock sales agreement; worst performer on XBI -4.9% MRNA (Moderna): EMA CHMP opinions; worst performer on XLV; shares +84% YTD -4.1% WST (West Pharmaceutical Services): follow-through, shares (5%) WTD -3.5% LEGN (Legend Biotech): downgraded at UBS -1.8% STTK (Shattuck Labs): initiation -1.4% GEHC (GE HealthCare Technologies): preannounce; CFO departure -0.2% SNY (Sanofi): update on amlitelimab program (discontinuation of OX40 for AD)	show story hide story
24-Jul-2026 08:44	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar building with strong prints from Edwards Lifesciences and Tenet Healthcare overnight. Shares of EW +7% and THC +16% in the pre-market. HCA reports full Q2 results pre-open; shares are down around (4%) since the preannounce ten days ago. EMA CHMP recommended twelve (12) medicines for approval at the July 2026 meeting ( including one biosimilar and three generics). FDA PCAC continues into Day 2. Yesterday, the panel recommended the first four peptides for inclusion on the compounding list. Three more peptides scheduled for today. Macro S&P futures are up +0.2% on Friday morning. Market trying to bounce on a fairly quiet headline day. Mag 7 outperforming after falling nearly 5% in prior session in what was biggest one-day decline since "Liberation Day". Oil on the defensive despite report that Iran rejected a recent ceasefire proposal from the US, while US conducted a 13th consecutive wave of strikes on Iran on Friday. Oil pullback seems to be helping yields stabilize. Recent bond yield backup and accompanying pickup in Fed tightening expectations has been another overhang on risk sentiment. Not much from the earnings calendar as the focus shifts to next week's peak week that features four of the Mag 7 names. Trump's new tariffs have received a lot of headlines but were widely telegraphed and don't seem to be much of an issue for markets at this point. Pre-market trading update Trading higher +17.1% THC earnings; call at 1130ET +6.8% EW earnings; upgraded at Leerink +6.4% NKTR sympathy to SAN.FP discontinuation +5.9% MNKD FDA approves Furoscix sNDA; private placement $50M; call at 9ET +2.2% NAMS EMA CHMP positive opinion +1.5% HCA earnings; call at 10ET +1.3% STTK initiation +0.9% GEHC preannounce; CFO departure Trading lower -5.2% SMMT earnings; stock sales agreement -1.6% SNY update on amlitelimab program (discontinuation of OX40 for AD) -0.4% LEGN downgraded at UBS EMA CHMP publishes summary of opinions for July 2026 meeting Summary here. EMA recommends twelve (12) new medicines for approval (including one biosimilar and three generics), and extension of therapeutic indication for another eight (8). CHMP issued three (3) negative opinions for MAA. Positive opinions for MAA include: LIB Therapeutics (private) / Everest (1952.HK) Lyrokaul (lerodalcibep) Menarini (private) / NewAmsterdam (NAMS) Evlarco (obicetrapib / ezetimibe) Menarini (private) / NewAmsterdam (NAMS) Ubeslo (obicetrapib) Roche (ROP.SW) Susvimo (rabinizumab) Janssen (JNJ) / Protagonist (PTGX) Icotyde (icotrokinra) Glaxosmithkline (GSK) Lynavoy (linerixibat) Minoryx (private) Nezglyal (leriglitazone) Shionogi (4507.JP) Zokovea (ensitrelvir) Plus one biosimilar and three generics Also gave positive opinion to update the composition of COVID-19 vaccines Bimervax (HIPRA), Comirnaty (PFE / BNTX), Nuvaxovid (NVAX) and Spikevax (MRNA). Extensions of indication were recommended for: Enhertu (4568.JP / AZN), Jivi (BAYN.GR), Piqray (NOVN.SW), Repatha (AMGN), Riltrava Aerosphere (AZN), Rinvoq (ABBV), Trixeo Aerosphere (AZN), and Trodelvy (GILD) Negative opinions for MAA include: Proveca (private) KemSu (sufentanil / ketamine) ZVRA Meplyffa (arimoclomol citrate) CATS Consultants' (private) Qezzaqar (catequentinib) Re-examination of application: OMER Yartemlea (narsoplimab) MAAT.FP Xervyteg (allogeneic faecal microbiota, pooled) Withdrawal of application: Adienne (private) Azacitidine Adienne (azacitidine) SAN.FP / REGN Dupixent (dupilumab) AZN Imfinzi (durvalumab) Pharma Trial results: SAN.FP announced the discontinuation of further development of OX40 mAb amlitelimab in atopic dermatitis (AD). Decides not to submit regulatory applications, citing totality of the efficacy and safety data to date. (APGE, KYMR, NKTR, REGN) Biotech Regulatory: MNKD announced that FDA approved Furoscix ReadyFlow sNDA, an at-home treatment option designed to help adults with heart failure or chronic kidney disease address edema earlier. Company also announced a private placement ($50M) - plans to use to fund the $45M CVR payment triggered by approval. Conf. call at 9:00ET Earnings: SMMT reported Q2 results including cash & equivalents $690.7M at 30-Jun. Expects HARMONi-3 events for final PFS in squamous NSCLC to be reached in H2 of 2026; interim analysis of OS planned. Filed a common stock sales agreement for up to $380M Research: LEGN downgraded to neutral from buy at UBS (Ashwani Verma), citing competition for Carvykti. Target cut to $28 from $49 or approx. 19% upside. (FactSet average PT $54; range $27-86) STTK initiated overweight at JPMorgan (Brian Cheng), target is $10 or approx. 41% upside. (FactSet average PT $16; range $11-18) IPO priced: SCTX Scribe Therapeutics Inc 8.6M share IPO priced at $15/shr, or $129M raise before the shoe. Lead candidate is a CRISPR-based gene editing agent for lowering LDL-C Twentieth healthcare IPO we've tracked in 2026, and the fifteenth biotech IPO. Average YTD return for Biotech IPOs +64%, skewed by MANE. Median YTD return +9%. Scheduled to begin trading on Nasdaq at 10:20ET Life Science & MedTech Earnings: EW reported Q2 EPS $0.78 vs FactSet $0.74 on revenue $1.74B vs FS $1.70B. Raises FY26 sales growth guidance to +10-11% from +9-11%; Reaffirms FY26 EPS guidance Stock upgraded in reaction Corporate / management change / preannounce: GEHC announced that CFO Jay Saccaro will step down for an opportunity outside of the medtech industry. Companny also announces preliminary Q2 revenue $5.30B vs FactSet $5.26B, guides Q2 EPS ahead of prior expectation, and reaffirms FY26 financial guidance. Research: EW upgraded to outperform from market perform at Leerink Partners (Mike Kratky), target increased to $101 from $87 or approx. 20% upside. (FactSet average PT $101; range $85-110) RBC Capital Markets transfers coverage on seventeen stocks in large-cap medical device space. Analyst is Kendall Au. Outperform ratings on 13; sector perform on 4. Services & Hospitals Earnings: HCA reports Q2 adj EBITDA $4.03B, inline with 14-Jul preannouncement. Repeats FY26 financial guidance (lowered on 14-Jul). Conf. call at 10:00ET THC reported Q2 adj EBITDA $1.30B vs FactSet $1.14B on revenue $5.63B vs FS $5.43B. Raises FY26 guidance from top to bottom lines Quick Take: Commentary on the Q2 print is broadly positive, with the beat attributed to improved pricing and strong hospital expense management. EBITDA exceeded expectations even excluding the benefit from the out-of-period prior-year Medicaid DPP, while HIX headwinds came in better than feared following unfavorable peer reports. Guidance commentary is also constructive, with the magnitude of the guidance raise seen as signaling continued underlying momentum. On the call, focus will be on the DPP benefit, utilization trends, payer mix, and the durability of recent expense performance. Conf. call at 11:30ET On Deck: Regulatory (cont.): FDA advisory committee (Day 2 of 2): Compounding Drugs to discuss peptides (Jul 24 8:00-16:15ET) FDA PDUFA today for Otsuka (4578.JP) in ADHD Peek Ahead to next week (Jul 27 - Aug 2) Overview: FDA advisory committee meetings for CAPR and REPL; FDA PDUFA goal dates for MNKD and OTLK. Earnings volume ramps significantly in the third week of the Q2 season, including: AZN, UHS, CNC, GSK, BSX, HUM, BIIB, GEHC, TEVA, ALGN, BMY, CI, REGN, SNY, SYK, MTD, DXCM, ILMN, GH, ABBV, MRNA This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 1952.HK, 4507.JP, 4568.JP, 4578.JP, ABBV, ALGN, AMGN, APGE, AZN, BAYN.GR, BIIB, BMY, BNTX, BSX, CI, CNC, DXCM, EW, GEHC, GH, GILD, GSK, HCA, HUM, ILMN, JNJ, KYMR, LEGN, MAAT.FP, MNKD, MRNA, MTD, NAMS, NKTR, NOVN.SW, NVAX, OMER, OTLK, PFE, PTGX, REGN, ROP.SW, SAN.FP, SCTX, SMMT, SNY, STTK, SYK, TEVA, THC, UHS, ZVRA...(more)	show story hide story
24-Jul-2026 07:55	EMA CHMP publishes summary of opinions for July 2026 meeting Summary here. EMA recommends twelve (12) new medicines for approval (including one biosimilar and three generics), and extension of therapeutic indication for another eight (8). CHMP issued three (3) negative opinions for MAA. Positive opinions for MAA include: LIB Therapeutics (private) / Everest (1952.HK) Lyrokaul (lerodalcibep) Menarini (private) / NewAmsterdam (NAMS) Evlarco (obicetrapib / ezetimibe) Menarini (private) / NewAmsterdam (NAMS) Ubeslo (obicetrapib) Roche (ROP.SW) Susvimo (rabinizumab) Janssen (JNJ) / Protagonist (PTGX) Icotyde (icotrokinra) Glaxosmithkline (GSK) Lynavoy (linerixibat) Minoryx (private) Nezglyal (leriglitazone) Shionogi (4507.JP) Zokovea (ensitrelvir) Plus one biosimilar and three generics Also gave positive opinion to update the composition of COVID-19 vaccines Bimervax (HIPRA), Comirnaty (PFE / BNTX), Nuvaxovid (NVAX) and Spikevax (MRNA). Extensions of indication were recommended for: Enhertu (4568.JP / AZN), Jivi (BAYN.GR), Piqray (NOVN.SW), Repatha (AMGN), Riltrava Aerosphere (AZN), Rinvoq (ABBV), Trixeo Aerosphere (AZN), and Trodelvy (GILD) Negative opinions for MAA include: Proveca (private) KemSu (sufentanil / ketamine) ZVRA Meplyffa (arimoclomol citrate) CATS Consultants' (private) Qezzaqar (catequentinib) Re-examination of application: OMER Yartemlea (narsoplimab) MAAT.FP Xervyteg (allogeneic faecal microbiota, pooled) Withdrawal of application: Adienne (private) Azacitidine Adienne (azacitidine) SAN.FP / REGN Dupixent (dupilumab) AZN Imfinzi (durvalumab) For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page. Related: 1952.HK, 4507.JP, 4568.JP, ABBV, AMGN, AZN, BAYN.GR, BNTX, GILD, GSK, JNJ, MAAT.FP, MRNA, NAMS, NOVN.SW, NVAX, OMER, PFE, PTGX, REGN, ROP.SW, SAN.FP, ZVRA...(more)	show story hide story
24-Jul-2026 07:42	THC Tenet Healthcare rallies following a beat/raise as expense discipline offsets HIX concerns ($199.02) THC shares +16.1% premarket after reporting Q2 adj EBITDA well ahead of FactSet with revenue also ahead. Raised FY26 guidance from top to bottom lines. Commentary on the Q2 print is broadly positive, with the beat attributed to improved pricing and strong hospital expense management. EBITDA exceeded expectations even excluding the benefit from the out-of-period prior-year Medicaid DPP, while HIX headwinds came in better than feared following unfavorable peer reports. Guidance commentary is also constructive, with the magnitude of the guidance raise seen as signaling continued underlying momentum. On the call, focus will be on the DPP benefit, utilization trends, payer mix, and the durability of recent expense performance. See Related StreetAccount comments: 7/23/2026 4:10:58 PM - StreetAccount Metrics Recap - Tenet Healthcare Q2 Earnings 7/23/2026 4:09:27 PM - Tenet Healthcare reports Q2 adjusted EBITDA $1.30B vs FactSet $1.14B [19 est, $1.05-1.23B]	show story hide story
23-Jul-2026 17:00	StreetAccount Sector Summary - Healthcare Post-Market Synopsis Healthcare equities finished mixed yet stronger overall on Thursday. Advancers beat decliners by nearly 2:1 on the XLV. Healthcare +1.29% vs S&P 500 (1.21%). Most major health groups ended higher on the averages, led by Pharma and MedTech. DRG +1.32% with major drugmakers (1%) to +2%. Managed Care group was today's key decliner after a mixed print by MOH (9.7%) dragged on Medicaid and Marketplace levered payers. Earnings calendar ramped quickly overnight and pre-open Thursday, and remained the primary driver across the sector. TMO +8.7% / DGX +8.6%, both on earnings, and CNC (3.3%), in sympathy to Molina's earnings, bracketed the XLV. Medical device stocks also under pressure again on the latest hospital print; CYH (13.7%). ALGN and ISRG were down (2.5%) each. Several Life Science prints on the tape, including TMO providing some renewed optimism to the space; CRO MEDP +14.7% also surprised with a rebound in bookings during Q2. Obesity drug names faring better today, with LLY +2.0% on new data from its triple G agonist. Positive efficacy data overshadowing bearish noise on CV and timing slip. Day One of the FDA Pharmacy Compounding Adcom discussed the regulation of peptides; first of seven votes to recommend BPC-157 lifted shares of HIMS to session highs; stock closed up +3.3%. Earnings calendar ramp brought a first look at the CRO space, and secondary reports in Managed Medicaid and Hospitals. Heavyweight slate of LST&D reports also on Thursday. CRO Medpace Holdings delivered a strong Q2 beat-and-raise with a big rebound for bookings. Eli Lilly reported more pivotal readouts from the GGG agonist program for retatrutide. Efficacy data support BLA submissions in obesity, knee OA pain, and OSA. Timeline slipped however from 2026 into Q1 of 2027. Edwards Lifesciences headlines the earnings calendar tonight. HCA reports full Q2 results on Friday morning; shares down ~(4%) since preannounce nine days ago. FDA PCAC continues into Day 2 on Friday. Macro Earnings was one of the big drivers of today's drop, with GOOGL and TSLA both down sharply after their reports. Capex a notable overhang on the former though remains a positive for the AI infrastructure narrative; however, some mix for momentum group today (sems/semicaps down while memory and energy AI infrastructure hold up better). Geopolitics today's other major theme. Pressure from rising oil making it difficult to ignore the Mideast conflict; while investors still looking for a diplomatic solution vs major escalation, that off-ramp is not yet in sight. Lot of headline volatility today with market processing Red Sea tanker attacks by Houthi militants and Trump hinting he could be close to restarting major combat operations. Oil prices influencing today's higher Treasury yields as well (along with fiscal and corporate supply), while also some renewed discussion about potential for heightened bond volatility (negative for risk assets) from Fed's shift away from forward guidance. Notable Gainers +28.4% NVCR (Novocure): earnings +14.7% MEDP (Medpace Holdings): earnings; raised FY guidance +8.7% TMO (Thermo Fisher Scientific): earnings; best performer on XLV +8.6% DGX (Quest Diagnostics): earnings, guidance; second-best on XLV +8.6% ARGX (argenx): earnings +6.3% PALI (Palisade Bio): initiation +5.4% TGTX (TG Therapeutics): best performer on XBI; on average volume; shares +86% YTD +5.1% ROP.SW (Roche Holding): earnings +4.9% CAPR (Capricor Therapeutics): above average volume; upcoming Adcom +4.8% CRL (Charles River Laboratories): sympathy to MEDP +3.7% RDY (Dr. Reddy's Laboratories): ADRs were (9%) yesterday +3.4% IONS (Ionis Pharmaceuticals): shares remain (30%) MTD/YTD +3.4% LH (Labcorp Holdings): sympathy to DGX +3.3% HIMS (Hims & Hers Health): amid FDA panel on peptides; first vote positive +3.1% RVMD (Revolution Medicines): regulatory update +2.0% LLY (Eli Lilly): trial results in obesity/T2D; BLA timeline slipped Notable Decliners -16.7% EVH (Evolent Health): downgraded at Citi -16.4% AGL (agilon health): downgraded at Citi -13.7% CYH (Community Health Systems): earnings; lowered FY guidance -9.7% MOH (Molina Healthcare): earnings, guidance -6.5% IMMX (Immix Biopharma): worst performer on XBI; shares +68% YTD -4.1% XRAY (Dentsply Sirona): dental weakness on provider sympathy -3.3% CNC (Centene): sympathy to MOH; worst performer on XLV -2.5% ISRG (Intuitive Surgical): sympathy to CYH; shares down (17%) MTD -2.4% ALGN (Align Technology): dental weakness on provider sympathy CROs trade higher in reaction to Medpace outlook MEDP reported Q2 EPS $4.25 vs FactSet $3.98 on revenue $707.3M vs FS $689.5M. Raises FY26 financial guidance top to bottom. Net book-to-bill ratio of 1.13x Quick take: Takeaways largely constructive around the update, with the Q2 bookings rebound following a weaker Q1 (on elevated cancellations) commonly flagged. Notes suggesting the meaningful improvement likely stemming from an improved cancellation rate vs prior quarters - and should help mitigate concern around the company's competitive position. On the call this morning (9:00 ET), focus will be on the composition of revenue and bookings in Q2 and any forward look into bookings, cancellation rates and margin trajectory to support the FY guidance raise. Earnings in Life Science Tools TMO reports Q2 EPS $6.03 ex-items vs FactSet $5.72 on revenue $11.99B vs FS $11.71B. On the call: Guided Q3 EPS $0.35-40 higher than Q2, implying range ahead of FactSet consensus. Raises FY26 outlook on top and bottom lines. SRT3.GR reports H1 EPS €2.49 on revenue €1.81B and confirms FY26 guidance, including sales growth 5-9% cc at the group level. WST reports Q2 EPS $2.37 ex-items vs FactSet $2.08 on revenue $872.3M vs FS $840.0M. Guides Q3 ahead of consensus. Raises FY26 EPS outlook by $0.375 at the midpoints, revenue by $35M at the midpoints. Another hospital profit warning; Community Health comments on payor mix headwinds CYH reported Q2 adj EBITDA $330M vs FactSet $326.7M on revenue $2.83B vs FS $2.89B. Lowers FY26 financial guidance top to bottom. Medicaid and Marketplace headwinds an overhang for Molina Healthcare MOH reported Q2 EPS $1.51 ex-items vs FactSet $1.39 on revenue $10.87B vs FS $10.83B. Consolidated MCR 92.2% vs SA 92.5%. Quick Take: Initial negative share reaction is attributed to worse-than-expected Marketplace headwinds, with margin pressure driven by an unfavorable acuity mix and prior-year risk adjustment. Discussion also points to elevated expectations following the stock's strong YTD performance, with the modest guidance raise falling short of investor expectations. The Marketplace business is viewed as a continued near-term overhang; however, commentary is constructive on Medicaid cost trend stabilization, strength in Medicare, and improving free cash flow. Quest Diagnostics higher on Q2 beat-and-raise DGX reports Q2 EPS $3.12 ex-items vs FactSet $2.82 on revenue $3.04B vs FS $2.97B. Raises FY26 EPS outlook by $0.42 at the midpoints, revenue outlook by $160M at the midpoints. Quick Take: Results are seen as alleviating concerns around a potential volume slowdown, with momentum viewed as a combination of company-specific and broader market factors. Margin came in softer than expected, with pressure attributed to an unfavorable mix. Commentary on guidance is constructive and seen as signaling underlying operational upside potential. Roche higher following H1 print and reaffirm ROP.SW reports H1 core EPS CHF10.85 vs consensus CHF10.17 on revenue CHF30.36 vs consensus CHF30.27B. Topline beat driven by pharma segment, with diagnostics a hair light of consensus. Repeats FY26 sales growth MSD CER, and core EPS in the HSD range. Eli Lilly higher on GGG update LLY announced topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating triple G agonist retatrutide in obesity. Management comments: "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea." Work on the CMC data package ongoing; BLA submission now planned for Q1 of 2027 versus prior 2026. Note that TRIUMPH-1 was toplined in May 2026 and presented at ADA in June. FDA panel recommends two peptides for inclusion on bulk compounding list Two-day FDA Advisory Committee reviewing the current restrictions on compounding of peptides. Reuters writes that Hims & Hers Health (HIMS) stands to benefit from the potential loosening of FDA restrictions. STAT News says to expect peptide enthusiasts to clash with FDA staff who stand in the way. The expert panel itself may also be divided by idealogy. Pharmacy Compounding Advisory Committee (PCAC) to meet 23-Jul (8:00-18:20ET) and 24-Jul (8:00-16:15ET) with votes taken throughout the meeting. (Votes) First of seven peptides discussed by the FDA's PCAC, with votes following product-specific discussion. The evaluated use of BPC-157 is for Ulcerative Colitis. PCAC voted 8 yes, 6 no, 1 abstain. Leerink analyst Michael Cherny notes that '157 is not only first on the panel's agenda, but also one of the most commercially viable of the seven. Firm maintains market perform rating on HIMS. Second of seven: Panel voted: 8 Yes, 6 No, 1 Abstain Full question: Should KPV (free base) be placed on the 503A bulks list? Note: same vote for KPV acetate Meeting ongoing. The PCAC to vote on five additional peptides over the next day and a half. Notable research in Healthcare today Biotech: AGMB initiated buy at B Riley Securities (William Wood), target is $34 or approx. 193% upside. (FactSet average PT $33; range $27-36) PALI initiated outperform at Oppenheimer (Leland Gershell), target is $8 or approx. 321% upside. (FactSet average PT $11; range $5-25) MedTech: AGL downgraded to sell from neutral at Citi (Daniel Grosslight), citing valuation on YTD runup, target increased however to $105 from $80 or approx. 12% downside. (FactSet average PT $72; range $22-141) EVH downgraded to neutral from buy at Citi (Daniel Grosslight), citing low visibility given membership changes for HIX and Medicaid. Target increased however to $6.75 from $5.50 or approx. 21% upside. (FactSet average PT $6; range $3-8) Post-close news Corporate / CFO transition / Preannounce: GEHC announced that CFO Jay Saccaro will step down for an opportunity outside of the medtech industry. Companny also announces preliminary Q2 revenue $5.30B vs FactSet $5.26B, guides Q2 EPS ahead of prior expectation, and reaffirms FY26 financial guidance. Shares trading +1.0% in the after-hours Earnings: EW reports Q2 EPS $0.78 vs FactSet $0.74 on revenue $1.74B vs FS $1.70B. Raises FY26 sales growth guidance to +10-11% from +9-11%; Reaffirms FY26 EPS guidance Conf. call at 17:00ET Shares trading +7.0% in the after-hours THC reports Q2 adj EBITDA $1.30B vs FactSet $1.14B on revenue $5.63B vs FS $5.43B. Raises FY26 guidance from top to bottom lines Conf. call tomorrow at 11:30ET Shares trading +14.6% in the after-hours SMMT reports Q2 results including cash & equivalents $690.7M at 30-Jun. Expects HARMONi-3 events for final PFS in squamous NSCLC to be reached in H2 of 2026; interim analysis of OS planned. Filed a common stock sales agreement for up to $380M Conf. call at 16:30ET Shares trading (4.4%) in the after-hours On Deck: Regulatory (cont.): FDA advisory committee (Day 2 of 2): Compounding Drugs to discuss peptides (Jul 24 8:00-16:15ET) on Friday: EMA CHMP opinions for MAA (July) on Friday: FDA PDUFA for Otsuka (4578.JP) in ADHD on Sun 26-Jul: FDA PDUFA for MannKind (MNKD) Furoscix autoinjector Earnings before the open HCA (call at 10:00ET) Peek Ahead to next week (Jul 27 - Aug 2) Overview: FDA advisory committee meetings for CAPR and REPL; FDA PDUFA goal dates for MNKD and OTLK. Earnings volume ramps significantly in the third week of the Q2 season, including: AZN, UHS, CNC, GSK, BSX, HUM, BIIB, TEVA, ALGN, BMY, CI, REGN, SNY, SYK, MTD, DXCM, ILMN, GH, ABBV, MRNA This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4578.JP, AGL, AGMB, ALGN, ARGX, CAPR, CNC, CRL, CYH, DGX, EVH, EW, GEHC, HCA, HIMS, IMMX, IONS, ISRG, LH, LLY, MEDP, MNKD, MOH, NVCR, PALI, RDY, ROP.SW, RVMD, SMMT, SRT3.GR, TGTX, THC, TMO, WST, XRAY...(more)	show story hide story
23-Jul-2026 15:06	FDA panel recommends a second peptide for inclusion on bulk compounding list Panel voted: 8 Yes, 6 No, 1 Abstain Full question: Should KPV (free base) be placed on the 503A bulks list? Meeting ongoing. The PCAC to vote on five additional peptides over the next day and a half. Trading update: Shares of HIMS +4.4% have been volatile amid the meeting today. See Related StreetAccount comments: 7/23/2026 12:46:31 PM - Hims & Hers Health trading higher; Adcom votes to place BPC-157 peptide on allowed pharmacy compounding list - Reuters 7/23/2026 9:17:29 AM - HIMS trading lower in the pre-market; two-day peptides Adcom underway Related: HIMS	show story hide story
23-Jul-2026 11:08	StreetAccount Summary - Healthcare Midday Trading Healthcare is outperforming with the S&P 500 Healthcare Index +1.36% vs the S&P 500 (1.40%). Most major health groups are higher on the averages. Managed Care the key decliner, last night's print by MOH (13%) dragging on Medicaid and Marketplace levered payers. Earnings calendar ramped quickly overnight and this morning, and remains the primary driver across the sector. TMO/ DGX +9%, both on earnings, and ISRG (3%) / ALGN (3%) bracket the XLV. Medical device stocks pressured again on the latest hospital print; CYH (8%). CNC also (3%) in sympathy to Molina's earnings. Several Life Science prints on the tape, including TMO providing some renewed optimism to the space; CRO MEDP +14% also surprised with a rebound in bookings during Q2. Obesity drug names faring better today, with LLY +2% higher on new data from its triple G agonist. Positive efficacy data overshadowing bearish noise on CV and timing slip. Gainers +26.3% NVCR (Novocure): earnings +15.3% PALI (Palisade Bio): initiation +14.4% MEDP (Medpace Holdings): earnings +10.2% TMO (Thermo Fisher Scientific): earnings; best performer on XLV +10.0% DGX (Quest Diagnostics): earnings +5.8% IONS (Ionis Pharmaceuticals): best performer on XBI +5.3% ROP.SW (Roche Holding): earnings +5.0% RVMD (Revolution Medicines): regulatory update +4.5% LH (Labcorp Holdings): sympathy to DGX +3.7% CRL (Charles River Laboratories): sympathy to MEDP +2.8% RDY (Dr. Reddy's Laboratories): ADRs were (9%) yesterday +1.6% LLY (Eli Lilly): trial results in obesity/T2D; BLA timeline slipped +0.8% HIMS (Hims & Hers Health): amid FDA panel on peptides Decliners -14.1% EVH (Evolent Health): downgraded at Citi -12.4% AGL (agilon health): downgraded at Citi -12.3% MOH (Molina Healthcare): earnings -7.5% CYH (Community Health Systems): earnings -3.5% SPRY (ARS Pharmaceuticals): worst performer on XBI; 52-week low -3.1% ALGN (Align Technology): worst performer on XLV; devices weaker on hospital print -2.9% ISRG (Intuitive Surgical): sympathy to CYH; shares down (17%) MTD -2.9% CNC (Centene): sympathy to MOH -0.7% SRT3.GR (Sartorius): earnings -0.3% WST (West Pharmaceutical Services): earnings	show story hide story
23-Jul-2026 10:08	DGX Quest Diagnostics higher following a Q2 beat/raise ($209.83) DGX shares +10.6% after reporting a Q2 top/bottom-line beat and raising FY26 EPS and revenue outlook. Results are seen as alleviating concerns around a potential volume slowdown, with momentum viewed as a combination of company-specific and broader market factors. Margin came in softer than expected, with pressure attributed to an unfavorable mix. Commentary on guidance is constructive and seen as signaling underlying operational upside potential.	show story hide story
23-Jul-2026 09:17	HIMS HIMS trading lower in the pre-market; two-day peptides Adcom underway HIMS trading (2%) lower at start of two-day FDA Advisory Committee reviewing the current restrictions on compounding of peptides. Reuters writes that Hims & Hers Health (HIMS) stands to benefit from the potential loosening of FDA restrictions. STAT News says to expect peptide enthusiasts to clash with FDA staff who stand in the way. The expert panel itself may also be divided by idealogy. Pharmacy Compounding Advisory Committee (PCAC) to meet 23-Jul (8:00-18:20ET) and 24-Jul (8:00-16:15ET) with votes taken throughout the meeting. (Votes) For the latest updates on this story and all top news, please visit the Healthcare Today's Top News page.	show story hide story
23-Jul-2026 08:37	StreetAccount Sector Summary - Healthcare Pre-Market Synopsis Earnings calendar ramping up across the sector with a first look at the CRO space, and secondary reports in Managed Medicaid and Hospitals overnight. A big slate of LST&D reports on Thursday morning. CRO Medpace Holdings delivered a strong Q2 beat-and-raise with a big rebound for bookings. Shares of MEDP +17% higher in the pre-market (low volume). Eli Lilly reported more pivotal readouts from the GGG agonist program for retatrutide. Efficacy data support BLA submissions in obesity, knee OA pain, and OSA. Timeline slipped however from 2026 into Q1 of 2027. Shares down (1%) in the pre-market. Today, FDA advisory committee opens two-day meeting to discuss the compounding of peptides. Edwards Lifesciences headlines the earnings calendar tonight. Macro S&P futures are down (0.6%) on Thursday morning, near pre-market lows. Mag 7 a drag following results from GOOGL and TSLA. However, continued hyperscaler capex ramp a positive for the AI infrastructure trade with momentum outperforming again (and some firms suggesting bounce has more room to run given cleaner positioning). Higher oil the other big area of focus as diplomatic off-ramp hopes dissipate, headlines hint at further escalation and Red Sea dynamics add to energy supply concerns. Higher oil a factor behind higher yields (along with fiscal and corporate supply), while also some renewed discussion about potential for heightened bond volatility (negative for risk assets) from Fed's shift away from forward guidance. Pre-market trading update Trading higher +16.9% MEDP earnings (low volume) +15.6% NVCR earnings +8.2% DGX earnings +6.2% WST earnings +4.7% TMO earnings +2.8% RDY ADRs were (9%) yesterday +2.5% ROP.SW in European trading; earnings Trading lower -12.4% CYH earnings -6.7% MOH earnings -5.0% EVH downgraded at Citi -4.7% AGL downgraded at Citi -3.7% CNC sympathy to MOH -2.4% SRT3.GR in European trading; earnings -0.8% LLY trial results in obesity/T2D; BLA timeline slipped Pharma Earnings: ROP.SW reports H1 core EPS CHF10.85 vs consensus CHF10.17 on revenue CHF30.36 vs consensus CHF30.27B. Topline beat driven by pharma segment, with diagnostics a hair light of consensus. Repeats FY26 sales growth MSD CER, and core EPS in the HSD range. Conf. call at 8:00ET Trial results: LLY announced topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating triple G agonist retatrutide in obesity. Management comments: "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea." Work on the CMC data package ongoing; BLA submission now planned for Q1 of 2027 versus prior 2026. Note that TRIUMPH-1 was toplined in May 2026 and presented at ADA in June. Regulatory: PFE announced that FDA has accepted for priority review its sNDA for Talzenna plus Xtandi combo in mCSPC. PDUFA goal date in Q4 of 2026. Biotech Regulatory: RVMD announced that FDA has accepted for review its daraxonrasib NDA for 2L mPDAC, completing the rolling submission. Company previously confirmed that the NDA was filed utilizing a Commissioner's National Priority Review Voucher (CNPV), suggesting that total review time could be as short as 1-2 months. (RPRX) Life Science & MedTech Earnings: WST reports Q2 EPS $2.37 ex-items vs FactSet $2.08 on revenue $872.3M vs FS $840.0M. Guides Q3 ahead of consensus. Raises FY26 EPS outlook by $0.375 at the midpoints, revenue by $35M at he midpoints. Conf. call at 8:00ET TMO reports Q2 EPS $6.03 ex-items vs FactSet $5.72 on revenue $11.99B vs FS $11.71B. Conf. call at 8:30ET - Guides on the call. SRT3.GR reports H1 EPS €2.49 on revenue €1.81B and confirms FY26 guidance, including sales growth 5-9% cc at the group level. Conf. call at 7:00ET MEDP reported Q2 EPS $4.25 vs FactSet $3.98 on revenue $707.3M vs FS $689.5M. Raises FY26 financial guidance top to bottom. net book-to-bill ratio of 1.13x Conf. call at 9:00ET Quick take: Takeaways largely constructive around the update, with the Q2 bookings rebound following a weaker Q1 (on elevated cancellations) commonly flagged. Notes suggesting the meaningful improvement likely stemming from an improved cancellation rate vs prior quarters - and should help mitigate concern around the company's competitive position. On the call this morning (9:00 ET), focus will be on the composition of revenue and bookings in Q2 and any forward look into bookings, cancellation rates and margin trajectory to support the FY guidance raise. Research: AGL downgraded to sell from neutral at Citi (Daniel Grosslight), citing valuation on YTD runup, target increased however to $105 from $80 or approx. 12% downside. (FactSet average PT $72; range $22-141) EVH downgraded to neutral from buy at Citi (Daniel Grosslight), citing low visibility given membership changes for HIX and Medicaid. Target increased however to $6.75 from $5.50 or approx. 21% upside. (FactSet average PT $6; range $3-8) Services & Hospitals Earnings: DGX reports Q2 EPS $3.12 ex-items vs FactSet $2.82 on revenue $3.04B vs FS $2.97B. Raises FY26 EPS outlook by $0.42 at the midpoints, revenue outlook by $160M at the midpoints. Conf. call at 8:30ET CYH reported Q2 adj EBITDA $330M vs FactSet $326.7M on revenue $2.83B vs FS $2.89B. Lowers FY26 financial guidance top to bottom. Conf. call at 11:00ET Managed Care Earnings: MOH reported Q2 EPS $1.51 ex-items vs FactSet $1.39 on revenue $10.87B vs FS $10.83B. Consolidated MCR 92.2% vs SA 92.5%. Quick Take: Initial negative share reaction is attributed to worse-than-expected Marketplace headwinds, with margin pressure driven by an unfavorable acuity mix and prior-year risk adjustment. Discussion also points to elevated expectations following the stock's strong YTD performance, with the modest guidance raise falling short of investor expectations. The Marketplace business is viewed as a continued near-term overhang; however, commentary is constructive on Medicaid cost trend stabilization, strength in Medicare, and improving free cash flow. Conf. call at 8:00ET On Deck: Regulatory (cont.): EMA CHMP monthly meeting (Jul 20-23) FDA advisory committee: Compounding Drugs to discuss peptides (Jul 23, 8:00-18:20ET) and (Jul 24 8:00-16:15ET) on Fri 24-Jul: EMA CHMP opinions for MAA (July); FDA PDUFA for Otsuka (4578.JP) in ADHD on Sun 26-Jul: FDA PDUFA for MannKind (MNKD) Furoscix autoinjector Earnings after the close today EW (call at 17:00ET), SMMT (call at 16:30ET) Earnings on Fri 24-Jul morning HCA (call at 10:00ET), THC (call at 11:30ET) This summary (along with intraday updates) can also be found on the Healthcare Today's Top News page. Related: 4578.JP, AGL, CNC, CYH, DGX, EVH, EW, HCA, LLY, MEDP, MNKD, MOH, NVCR, PFE, RDY, ROP.SW, RPRX, RVMD, SMMT, SRT3.GR, THC, TMO, WST...(more)	show story hide story
23-Jul-2026 08:08	MEDP Medpace Holdings trading higher on Q2 beat and raise, strong booking rebound highlighted ($528.12) MEDP trading sharply higher in reaction to Q2 results that included revenue, EBTIDA and EPS all ahead with net new business wins +28.2% y/y. FY27 guidance targets raised to FY revenue in a range of $2.805-$2.885B vs prior guidance $2.755-$2.855B and EPS EPS of $17.25-$17.95 vs prior guidance $16.68-$17.50. Takeaways largely constructive around the update, with the Q2 bookings rebound following a weaker Q1 (on elevated cancellations) commonly flagged. Notes suggesting the meaningful improvement likely stemming from an improved cancellation rate vs prior quarters - and should help mitigate concern around the company's competitive position. On the call this morning (9:00 ET), focus will be on the composition of revenue and bookings in Q2 and any forward look into bookings, cancellation rates and margin trajectory to support the FY guidance raise. See Related StreetAccount comments: 7/22/2026 4:23:46 PM - Medpace Holdings reports Q2 EPS $4.25 vs FactSet $3.98 [10 est, $3.71-4.10] 4/22/2026 4:18:33 PM - Medpace Holdings reports Q1 GAAP EPS $4.28 vs FactSet $3.92 [10 est, $3.60-4.16]	show story hide story
23-Jul-2026 07:57	MOH Molina Healthcare shares lower despite a Q2 beat as marketplace headwinds weigh ($221.74) MOH shares (7.8%) despite reporting Q2 adjusted EPS above FactSet, with revenue also ahead and a consolidated MCR of 92.2% vs SA 92.5%. The company also raised FY EPS guidance. Initial negative share reaction is attributed to worse-than-expected Marketplace headwinds, with margin pressure driven by an unfavorable acuity mix and prior-year risk adjustment. Discussion also points to elevated expectations following the stock's strong YTD performance, with the modest guidance raise falling short of investor expectations. The Marketplace business is viewed as a continued near-term overhang; however, commentary is constructive on Medicaid cost trend stabilization, strength in Medicare, and improving free cash flow. See Related StreetAccount comments: 7/22/2026 4:24:04 PM - StreetAccount Metrics Recap - Molina Healthcare Q2 Earnings 7/22/2026 4:18:27 PM - Molina Healthcare reports Q2 EPS $1.51 ex-items vs FactSet $1.39 [19 est, $0.98-2.04]	show story hide story

Download StreetAccount for iOS from the App Store.
All times are in (UTC-05:00) Eastern Time (US & Canada) unless otherwise specified.
Copyright ©2026 FactSet Research Systems Inc.

Terms and Conditions Disclaimer Sitemap Privacy Policy Careers

Week \| Month \| Quarter
Start:
End:
Enter dates in mm/dd/yyyy format